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Treatment Repurposing is the application of a treatment to diseases or symptoms of interest other than the 
disease(s) or symptom(s) for which the treatment was developed (and used) initially.  It includes, but goes 
well beyond, Drug Repurposing.  The present monograph uses Literature-Related Discovery (LRD) to 
identify treatments that could be repurposed for diseases of interest. 
The LRD methodology for identifying candidate repurposable treatments is presented in detail, and 
illustrative examples are provided from a recent monograph on prevention and treatment of Alzheimer's 
Disease [Kostoff et al, 2018].  The present monograph also contains an extensive Bibliography of the core 
Treatment Repurposing literature, as well as two novel taxonomies of this literature.  One taxonomy uses 
text clustering to display the myriad categories (and their relationships) in this Treatment Repurposing 













Chapter 1 - Introduction and Background 
1A. Overview 
 Literature-Related Discovery (LRD) is a systematic approach to bridging unconnected disciplines 
based on text mining procedures [Kostoff et al, 2008a; Kostoff et al, 2008b; Kostoff, 2012].  In the LRD 
context, discovery is linking two or more literature concepts that have heretofore not been linked (i.e., 
disjoint), in order to produce novel, interesting, plausible, and intelligible knowledge. 
 In the medical arena, LRD can be used for identifying potentially new treatments for a disease 
(aka Treatment Repurposing), identifying potentially new contributing factors for a disease, identifying 
new biomarkers for a disease, etc.  By 'new', we mean previously non-existent in the core biomedical 
literature for the disease of interest. 
 The present monograph presents a detailed description of LRD-based Treatment Repurposing 
(which includes Drug Repurposing, but goes well beyond drugs to include any type of treatment).  It 
contains illustrative examples of Treatment Repurposing from a recent study on preventing and 
reversing Alzheimer's Disease (AD) [Kostoff et al, 2018], as well as an algorithm for generating 
voluminous Treatment Repurposing (see Appendix 1).   
1B. Structure of Treatment Repurposing Literature 
 Treatment Repurposing (hereafter abbreviated as TR) is the application of a treatment to diseases 
or symptoms of interest other than the disease(s) or symptom(s) for which the treatment was developed 
(and used) initially.  A number of comprehensive reviews of one component of TR, drug 
repurposing/repositioning, have been published recently [Xue et al, 2018; March-Vila et al, 2017; Yella et 
al, 2018; Karaman and Sippl, 2018; Sahu and Kharkar, 2016]. As shown in these reviews, as well as 
many other more narrowly-focused documents, there are myriad possible categorizations for the TR 
literature.  
 For example, some TR papers are: 
*disease-focused [Abbruzzese et al, 2017; Abbasi, 2016];  
*drug focused [Albinana et al, 2017; Ahmad et al, 2018];  
*biomarker-focused [Amar et al, 2015; Kim et al, 2018; Ohmichi et al, 2018]; 
*prediction methodology-focused, etc.   
 The prediction methodology category includes, but is not limited to, the following sub-categories:  
*text-mining [Abrams et al, 2015; Kuusisto et al, 2017; Tari and Patel, 2014; Brown and Patel, 2017; 
Jang et al, 2017; Yang et al, 2017];  
*machine learning [Ekins et al, 2015; Huang et al, 2016; Jamal et al, 2015; Nath, Kumari, and Chaube, 
2018];  
 




*network-based [Alaimo et al, 2015; Azmi et al, 2013; Berenstein et al, 2016; Bourdakou, Athanasiadis, 
and Spyrou, 2016; Carson and Lu, 2015; Cheng et al, 2018; Fukuoka, Takei, and Ogawa, 2013];  
*semantics [Cheng at al, 2014; Cohen et al, 2012; Liang, Sun, and Tao, 2015; Mullen et al, 2016; Qu et 
al, 2009];  
*ligand-binding/ligand-protein docking/binding-site focused [Wang et al, 2017; Huang et al, 2017; Dash 
et al, 2018; Di Muzio, Toti, and Polticelli, 2017]; Chartier, Adriansen, and Najmanovich, 2016; Di 
Domizio et al, 2014];  
*protein targeting [Huang et al, 2018; Li et al, 2018];  
*transcriptional signature-focused [Iorio et al, 2010; Iorio et al, 2015].   
 The LRD approach of TR is in the text mining sub-category of prediction methodology-focused 
approaches.  LRD-TR identifies treatments from the biomedical literature that alter combinations of 
markers (mainly biomarkers) in directions required to reverse target diseases of interest (see Appendix 1 
for details).   
 A less subjective perspective on the structure of the TR literature is offered by text clustering.  
Appendix 2 contains a hierarchical taxonomy of the TR literature obtained with the CLUTO text 
clustering software [CLUTO, 2018]. This unique taxonomy presents the higher-level and most detailed 
categories that constitute the core TR biomedical literature.  Additionally, the actual display of the 
taxonomy links to the titles of papers in the most detailed categories, in order to present the full spectrum 
of sub-themes contained within each of these detailed categories.  Chapter 4 contains a more extensive 
Bibliography of TR (mainly drug repurposing) papers, with complete references.   
1C. Structure of Monograph 
 Chapter 1, the Introduction and Background, is followed by Chapter 2, Methodology, Results, 
and Conclusions.  Chapter 3 contains the text References and Appendices: 
*Appendix 1 is the TR query; 
*Appendix 2 contains  the CLUTO text mining-based core TR literature taxonomy; 
*Appendix 3 contains the VP factor analysis-based core TR literature taxonomy; 
*Appendix 4 contains markers from the AD study, and their directions of change as a result of treatments 
or contributing factors. 
Chapter 4 contains the core TR literature (mainly drug repurposing) Bibliography, with full references. 
 




Chapter 2 - Methodology, Results, and Conclusions 
2A. Overview of LRD-TR Methodology 
 Treatments of disease or causes of disease (contributing factors to disease) result in changes to 
myriad markers in the body, including, but not limited to:  
*general biomarkers (e.g., neuroinflammation, neurodegeneration, DNA damage, mitochondrial 
dysfunction, oxidative stress, neurotransmission dysfunction; olfactory dysfunction, glutamate uptake, 
glucose homeostasis, etc);  
*specific biomarkers (e.g., ATP, B12, B6, BACE-1, Bax, Bcl-2, BDNF, c-AMP, caspase, folate, GLP-1, 
GSK-3, etc);  
*symptoms (e.g., insomnia, ataxia, dysphagia, etc);  
*performance (e.g., memory, learning, cognition, etc);  
*behaviors (e.g., apathy, depression, anxiety, aggression, agitation, etc); 
*others.   
 Appendix 4 contains extensive examples of myriad markers from the AD study, and the 
directions in which they changed in association with the presence/imposition of AD contributing factors 
or the provision of AD treatments.  
 The TR discovery approach of the present monograph consists of a two-stage process: 
 Stage 1: identify critical markers associated with a disease of interest, and identify how the values 
of those markers change 1) when contributing factors to disease are operable and 2) when treatments are 
operable.  
 Stage 2: search the non-disease-of-interest literature for potential treatments that will change the 
markers of interest in the desired direction. 
2B. Specific Methodology Adapted from AD Study [Kostoff et al, 2018] 
Stage 1 
2B-1A. Identify critical markers and their directions of change associated with existing AD contributing 
factors 
 The first step in Stage 1 of the AD study (and in a subsequent chronic disease reversal study 
being performed presently) was to 1) identify existing contributing factors (causes) to AD and 2) identify 
markers (mainly biomarkers) whose changes from the norm were associated with the AD contributing 
factors.  A number of approaches were used to identify these existing AD contributing factors and their 
associated markers, since no one approach was fully comprehensive. 
 
 




2B-1A1. Visual Inspection 
 A Visual Inspection approach was used initially for the AD study.  It started by generating a 
database of millions of abstract phrases parsed from ~100,000 records that constituted the total AD core 
Medline literature.  Then, tens of thousands of the highest frequency phrases were inspected visually, and  
those that appeared to be contributing factors to AD were selected.  During this process, and in the 
subsequent confirmatory process that validated the selection of AD contributing factors, a number of non-
biomedical terms were identified that were closely associated with the existing AD contributing factors 
(shown in section 1A2).  These non-biomedical terms could then be (and were) used as 'linking terms', to 
target lower frequency phrases (among the millions of abstract phrases) that had high probability of 
being/including existing AD contributing factors.  
2B-1A2. Linking Term 
 A number of linking term approaches were used to target records or phrases with high 
probability of containing existing AD contributing factors.  These included: 
*MeSH Qualifiers associated strongly with contributing factors (e.g., adverse effects, toxicity, 
pathogenicity, poisoning);   
*Relatively unambiguous MeSH Headings associated strongly with contributing factors (e.g., "Drug-
Related Side Effects AND Adverse Reactions"; Abnormalities, Drug Induced; Air Pollutants, 
Occupational; Amphetamine Related Disorders; Carcinogens; Chemical Warfare Agents; Chemically-
Induced Disorders, etc);  
*Text terms associated strongly with contributing factors (e.g., -induced; caused by; induced by; -
contaminated; exposure to; exposure(s) [at end of phrase]; exposed to; poisoning [at end]; -exposed [at 
end]; -related; -associated; -infected; abuse*; toxicity).  
These linking terms were especially valuable for accessing low-frequency existing AD contributing 
factors not accessible from visual inspection of the high-frequency phrases. 
2B-1A3. Dot Product 
 A dot product approach was used to identify phrases that had high probability of being existing 
AD contributing factors.  External lists of toxic substances generated by Federal government 
organizations, state regulatory agencies, and other major organizations were aggregated.  The final list of 
toxic substances was intersected with the full list of millions of abstract phrases in the core AD literature, 
to identify additional existing AD contributing factors. 
 The total number of existing AD contributing factors identified by the above approaches (from 
the premier biomedical literature and validated)  numbered about 400-600, depending on how the existing 
AD contributing factors were aggregated.  In all the approaches to identifying existing AD contributing 
factors shown above, the initial existing AD contributing factors selected were confirmed and validated 
by detailed reading of the relevant abstracts.   
 




 During the confirmation and validation process, one or (usually) more record abstracts containing 
the candidate existing AD contributing factor term was read, and other relevant data in the abstract were 
recorded.  These data included biomarkers, symptoms, and behaviors impacted by the existing AD 
contributing factor(s), and the directions in which these markers were moved (increased, decreased, etc).  
In some/many of these records, one or more existing AD treatment(s) were also identified, as well as the 
myriad markers associated with the existing AD treatments and the directions of change these markers 
experienced as a result of the existing AD treatment(s).  These treatment-related data were also recorded. 
2B-1B. Identify critical markers and their directions of change associated with existing AD treatments 
 The  second step in Stage 1 of the AD study (and in a subsequent chronic disease reversal study 
being performed presently) was to 1) identify existing AD treatments and 2) identify markers (mainly 
biomarkers) whose changes from the norm were associated with the existing AD treatments.  A number 
of approaches were used to identify these existing AD treatments and their associated markers, since no 
one approach was fully comprehensive.   
2B-1B1. Visual Inspection 
 A Visual Inspection approach (actually part of the visual inspection approach described in 
section 1A1) was used, which consisted of reading the thousands of high frequency abstract phrases in the 
core AD literature, and selecting those that appeared to be treatments for AD.  During this process, and in 
the subsequent confirmatory process that validated the selection of existing AD treatments, a number of 
non-biomedical terms were identified that were closely associated with the existing AD treatments 
(shown in 1B2).  These non-biomedical terms could then be (and were) used as 'linking terms', to target 
phrases (among the millions of abstract phrases) that had high probability of being/including existing AD 
treatments. 
2B-1B2. Linking Term 
 A number of linking term approaches were used to target records with high probability of 
containing existing AD treatments.  These included: 
*MeSH Qualifiers associated strongly with treatments (e.g., diet therapy, drug therapy, prevention & 
control, therapeutic use, therapy, etc);   
*Relatively unambiguous MeSH Headings associated strongly with treatments (e.g., Treatment 
Outcome, Neuroprotective Agents, Nootropic Agents, Plant Extracts, Phytotherapy, Dietary Supplements, 
Drugs, Chinese Herbal, etc);  
*Text terms associated strongly with treatments (treat*, therap*, prevent*, protect*, improv*, reduc*, 
attenuat*, ameliorat*, enhanc*,  revers*, promot*, alleviat*, inhibit*, remov*, suppress*, mitigat*, 
restor*, lower*, preserv*, regenerat*, rescu*, slow*).  
 These linking terms were especially valuable for accessing existing low-frequency AD treatments 
not accessible from visual inspection of the high-frequency phrases.  Some of these linking terms had 
higher efficiencies of identifying the treatment consequences of interest than others.  Terms like prevent*, 
protect*, improv*, restor*, alleviat*, ameliorat*, mitigat*, etc, almost always gave the desired AD 
 




markers and the direction in which they changed as a result of treatment.  Terms like decreas*and 
increas* (used initially, then abandoned), reduc*, slow*, etc, could go either way.  The former group of 
terms had the 'sense' of improvement, while the latter group of terms reflected change (positive or 
negative), and may or may not have reflected improvement.   
 The total number of existing AD treatments identified by the above approaches (from the premier 
biomedical literature and validated) numbered about 600-700, depending on how the existing AD 
treatments were aggregated.  In all the approaches to identifying existing AD treatments shown above, the 
initial existing AD treatments selected were confirmed and validated by detailed reading of the relevant 
abstracts.   
 During the confirmation and validation process, one or (usually) more record abstracts containing 
the candidate existing AD treatment term was read, and other relevant data in the abstract were recorded.  
These data included biomarkers, symptoms, and behaviors impacted by the treatment(s), and the 
directions in which these markers were moved (increased, decreased, etc) associated with the treatment.  
In some/many of these records, one or more existing AD contributing factor(s) were also identified, as 
well as the myriad markers associated with the existing AD contributing factor(s) and the directions of 
change these markers experienced associated with the existing AD contributing factor(s).  These 
contributing factor-related data were also recorded. 
2B-1C. Identify critical markers and their directions of change not identified in 2B-1A or 2B-1B 
 The  third step in Stage 1 of the AD study (and in a subsequent chronic disease reversal study 
being performed presently) was to identify existing AD markers of interest. 
2B-1C1. Visual Inspection 
 During the Visual Inspection process used to identify the higher-frequency existing AD 
contributing factors and treatments, the higher-frequency existing AD markers were also recorded.  
During this process, and in the subsequent confirmatory process that validated the selection of existing 
AD markers, a number of non-biomedical terms were identified that were closely associated with the 
existing AD markers.  These non-biomedical terms could then be used as 'linking terms', to target phrases 
(among the millions of abstract phrases) that had high probability of being/including existing AD 
markers.   
 For the most part, these marker 'linking terms' were included in the combined list of linking terms 
used to identify existing low-frequency AD contributing factors and treatments (see sections 1A2 and 1B2 
for the contributing factor linking terms and the treatment linking terms, respectively).  The existing low-
frequency AD markers had been identified as part of the AD low-frequency contributing factor and 
treatment identification process. 
 In reality, the existing AD contributing factors and existing AD treatments identified in 1A, 1B, 
1C, 2A, 2B above served effectively as linking terms to the existing AD markers in their own right. 
 A total of about 250 major and semi-major existing AD biomarkers, symptoms, behaviors, etc, 
were identified, of which about 200 were specific existing AD biomarkers.  This number of existing AD 
markers was deemed sufficient to meet the study objectives and constraints; no other methods were used 
 




to identify additional existing AD markers.  One of these constraints was to identify only those existing 
markers whose values were altered due to the effects of existing AD contributing factors or existing AD 
treatments.  This was achieved by extracting only those markers related to existing AD contributing 
factors and existing AD treatments.   
 If any of the readers have applications where markers beyond those co-occurring with 
contributing factors or treatments would be required, then some of the techniques listed in sections 2B-1A 
and 2B-1B above could be used to generate these additional markers.  One obvious example would be to 
use the relatively unambiguous MeSH Heading 'Biomarkers' as an effective linking term for identifying 
existing markers.  The MeSH Heading 'Biomarkers' would contain biomarkers in myriad contexts, some 
of which may not be associated with contributing factors or treatments in the articles. 
 It should be noted that  
*additional linking term approaches and text linking terms could have been identified;  
*linking term patterns (combinations of linking terms) could have been identified for greater precision in 
predicting high probability existing AD biomarker phrases;  
*not all linking terms identified were used;  
*not all existing AD markers appeared in text in proximity to the identified linking terms, or to the 
identified contributing factors and treatments;  
*software limitations on extracted phrase length excluded those existing AD markers not in very close 
proximity to the identified linking terms.   
 An expanded study could have easily overcome these limitations, and possibly doubled the 
number of existing AD biomarkers identified.  The present ongoing new chronic disease study is 
exploiting these lessons from the AD study, and many more existing markers have been identified.   
Stage 2: search the non-disease-of-interest literature for potential treatments that will change the markers 
of interest in the desired direction. 
 Text mining of the AD biomedical literature (especially records focused on treatments and 
contributing factors) identified the critical markers associated with AD, and identified the directions in 
which these critical markers needed to change for potential AD alleviation/reversal [Kostoff et al, 2018; 
also, see Appendix 4 of the present document].  For example, critical general biomarkers for AD and their 
desired directions of change included 'reduce oxidative stress', 'alleviate mitochondrial dysfunction', 
'prevent apoptosis', etc.  Critical specific biomarkers for AD and their desired directions of change 
included 'reduce BACE1', 'increase Bcl-2', 'enhance ADAM10', etc. 
 From these markers and their desired directions of change for effective treatment of AD, a query 
was developed to 1) identify potential AD treatments from 2) treatments used in the non-AD literature 
(see Appendix 1 for query details).  The non-AD biomedical literature was then searched for records 
including one or more of these AD markers that moved in desired directions as a result of treatments (e.g., 
 




reduced Abeta; increased Bcl-2; reduced tau hyperphosphorylation; restricted NFKappaB signaling; 
reduced inflammation; reduced oxidative stress; enhanced Nrf2, etc).   
 Searching for records that had a threshold of including at least one of these desired marker 
alterations produced a voluminous retrieval.  To keep the records retrieved at a manageable level, the 
requirement that a record in the non-AD literature must contain at least two AD markers  (that moved in 
the appropriate direction in conjunction with a treatment) to be retrieved was imposed.  Even then, the 
retrieval was voluminous, indicating the wealth of potential AD treatment repurposing possible from an 
expanded well-resourced study. 
 As a practical matter, combinations of the more fundamental and less AD-specific linking phrases 
were used for the treatment repurposing query.  The general form of the query was 1) combinations of the 
markers and their desired directions of change followed by 2) negation of records that contained existing 
AD treatments.  These existing AD treatments had been obtained in the first part of the AD study [Kostoff 
et al, 2018]. 
 As an example of the query format: 
(((increas* OR enhanc* OR restor*) NEAR/3 "norepinephrine") AND ((increas* OR enhanc* OR 
restor*) NEAR/3 "Nrf2")) 
NOT  
((alzheimer* OR dementia OR "mild cognitive impairment") OR {existing AD treatments}).   
 While terms such as 'reduce Abeta' or 'reduce tau phosphorylation' may be efficient for extracting 
existing AD treatments from the AD literature, they are very inefficient, either in isolation or especially in 
combination, for AD treatment repurposing from the non-AD literature.  It is difficult to imagine people 
doing research in reducing Abeta or reducing tau hyperphosphorylation (much less doing research in 
both) not emphasizing the AD/dementia applications in their publications. 
 Finally, there are no restrictions on the numbers of treatments that could be repurposed for any 
disease of interest.  For example, assume that a patient has been diagnosed with a specific disease, 
characterized by three abnormal biomarker values.  The query could be applied to identify/discover 1) one 
treatment that would bring all three of the biomarkers back to normal, or 2)  one treatment that would 
bring two of the biomarkers back to normal and one treatment that would bring the third biomarker back 
to normal, or 3) three treatments, each of which would bring one of the biomarkers back to normal.  
Obviously, the  repurposed treatments in 2) and 3) would have to be compatible, but the technique offers 
a wide variety of options.  
2C. Results 
 Appendix 1 contains the details of the actual query used to identify potential repurposed 
treatments for AD.  Since the treatment repurposing described in the AD study was a proof-of-principle 
demonstration of the latest incarnation of our LRDI approach, only a few examples were provided for 
illustrative purposes.  These examples were based on using combinations of two biomarkers only in the 
query, and are contained in the following table:  
 




Table 2C-1: Illustrative LRD-TR Results from AD Study 
EXAMPLES OF POTENTIAL REPURPOSED AD TREATMENTS 
 
• Fortunellin protects against high fructose-induced diabetic heart injury in mice by suppressing 
inflammation and oxidative stress via AMPK/Nrf-2 pathway regulation [] 
 
• Protective effects of sarains on H2O2-induced mitochondrial dysfunction and oxidative stress; 
improving mitochondrial function and decreasing reactive oxygen species levels; ability to block the 
mPTP and to enhance the Nrf2 pathway [] 
 
• Carboxyamidotriazole alleviates muscle atrophy in tumor-bearing mice by inhibiting NF-kappaB 
and activating SIRT1; CAI restricted the NF-kappaB signaling, downregulated the level of TNF-
alpha in muscle and both TNF-alpha and IL-6 levels in serum, directly stimulated SIRT1 activity in 
vitro, and increased SIRT1 content in muscle [] 
 
• Protective effects and mechanism of meretrix meretrix oligopeptides (MMO) against nonalcoholic 
fatty liver disease; MMO inhibited the activation of cell death-related pathways, based on reduced p-
JNK, Bax expression, tumor necrosis factor-alpha, caspase-9, and caspase-3 activity in the NAFLD 
model cells, and Bcl-2 expression was enhanced in the NAFLD model cells [] 
 
• Extract from Periostracum cicadae inhibits oxidative stress and inflammation induced by Ultraviolet 
B Irradiation; decreased reactive oxygen species (ROS) production. The extract attenuates the 
expression of interleukin-6 (IL-6), matrix metalloproteinase-2 (MMP-2), and MMP-9 in UVB-
treated HaCaT cells. Also, P. cicadae abrogated UVB-induced activation of NF-kappaB, p53, and 




Note that while the query was limited to combinations of two biomarkers only as selection criteria, the 
actual numbers of biomarkers in the retrieved records that moved in the desired directions for healing 
were typically greater (sometimes much greater) than two. 
2D. Validation of TR Candidates 
 The final step involved in converting an existing treatment in the non-AD literature to a 
repurposed AD treatment is validation that the potential AD treatment has not been associated with AD 
application in the literature.  Each candidate potential AD repurposed treatment retrieved using the query 
in Appendix 1 was subject to this validation before becoming a potential AD repurposed treatment.  The 
candidate potential AD repurposed treatment was intersected with the core AD literature, and was 
validated only after this intersection showed orthogonality.   
 For example, the candidate potential AD repurposed treatment "fortunellin" was retrieved 
because it satisfied the desired query general biomarker combination of reducing inflammation and 
oxidative stress.  Fortunellin also had the additional specific biomarkers-based benefits of reducing the 
pro-inflammatory cytokines and the expression of p-IkappaB kinase alpha, p-IkappaBalpha, and p-
nuclear factor-kappaB, while significantly enhancing superoxide dismutase, catalase, heme oxygenase-
 




1and p-AMP-activated protein kinase.  Fortunellin was intersected with the core AD biomedical 
literature retrieval terms (alzheimer* OR dementia OR "mild cognitive impairment"), and no records were 
retrieved, demonstrating that fortunellin could not be found in the core AD literature.  Fortunellin was 
therefore validated as a potential AD repurposed treatment (LRD Discovery). 
2E. Conclusions 
 The LRD-TR approach has evolved from its initial structure in 2008 [Kostoff et al, 2008a, 2008b] 
to the more advanced and targeted process described in the present monograph.  It has the capability to 
generate voluminous TR results for any disease or symptom of interest; the only limitations are study 
resources. 
 The same generic process can be applied to identifying contributing factors to a symptom or 
disease of interest that have not been existent previously in the core biomedical literature of that disease 
or symptom of interest, but have been existent in the core biomedical literature of other diseases or 
symptoms.  The same extrapolation process can be used for myriad markers as well. 
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3B. Appendix 1 - Query for Identifying Potential AD Repurposed Treatments  
 The most general form of the TR query can incorporate any number of biomarkers and other 
markers of interest.  For AD, a two biomarker query was deemed adequate for demonstration purposes.  
The generic form of the two biomarker AD treatment repurposing query is  
(A and B) not (C or D), where 
A is a biomarker and its associated desired direction of change 
B is another biomarker and its associated direction of change 
C is the query used to retrieve the AD core literature 
D is a list of existing AD treatments identified in the initial part of the AD study 
 Thus, the combination (A and B) retrieves ALL records from the biomedical literature that 
contain potential AD treatments based on the two desired characteristics A and B, while (C or D) 
subtracts those records associated with the AD core literature.  The remainder is non-AD records with 
substances that could be candidate repurposed AD treatments, based on the requirement that A and B 
must be present. 
 Twenty of the more than 200 biomarkers identified in the AD study (through text mining 
techniques) were selected for the query.  The query was run in Thompson-Reuters-Medline, since its 
search engine allows for proximity searching (e.g., [direction] within three words of [biomarker], or 
[direction] near/3 [biomarker]).  In modular form, each query term is shown as follows: 
 #1 - (reduc* OR decreas* OR prevent* OR attenuat* OR suppress* OR  alleviat* OR ameliorat*) 
near/3 "oxidative stress" 
 #2 - (reduc* OR decreas* OR prevent* OR attenuat* OR suppress* OR  alleviat* OR ameliorat*) 
near/3 "apoptosis" 
 #3 - ((protect* OR improv* OR enhanc* OR restor* OR preserv*) near/3 "mitochondrial 
function") OR  ((reduc* OR decreas* OR prevent* OR attenuat* OR suppress* OR  alleviat* OR 
ameliorat*) near/3 "mitochondrial dysfunction") 
 #4 - (inhibit* OR reduc* OR attenuat* OR decreas*) near/3 "BACE1" 
 #5 - (modulat* OR attenuat* OR reduc* OR inhibit* OR decreas*) near/3 "gamma-secretase" 
 #6 - (enhanc* OR increas* OR improv* OR protect*) near/3 "autophagy" 
 #7 - (attenuat* OR reduc* OR prevent* OR inhibit*) near/3 ("caspase*  activ*" OR "caspase* 
express*") 
 #8 - (increas* OR restor* OR enhanc*) near/3 "Bcl-2" 
 #9 - (attenuat* OR reduc* OR inhibit* OR decreas* OR prevent*) near/3 "NF-kappaB" 
 




 #10 - (increas* OR enhanc* OR restor*) near/3 "ADAM10" 
 #11 - (increas* OR restor* OR enhanc*) near/3 "CREB" 
 #12 - (inhibit* OR decreas* OR reduc* OR attenuat*) near/3 "GSK-3" 
 #13 - (increas* OR enhanc* OR restor*) near/3 "GLP-1" 
 #14 - (increas* OR enhanc* OR restor*) near/3 "ABCA1" 
 #15 - (increas* OR enhanc* OR restor*) near/3 "norepinephrine" 
 #16 - (increas* OR enhanc* OR restor*) near/3 "Nrf2" 
 #17 - (increas* OR enhanc* OR restor*) near/3 "seladin-1" 
 #18 - (increas* OR enhanc* OR restor*) near/3 "LRP1" 
 #19 - (increas* OR enhanc* OR restor*) near/3 "SIRT1" 
 #20 - (attenuat* OR reduc* OR inhibit* OR decreas*) near/3 "beclin1" 
NOT ((#21 - alzheimer* OR dementia OR "mild cognitive impairment") [Core AD Literature]  
 OR  
Existing AD Treatments 
 #22 - ("donepezil" OR "memantine" OR "Rivastigmine" OR "galantamine" OR "Tacrine" OR 
"hormone replacement therapy" OR "vitamin E" OR "risperidone" OR "Curcumin" OR "melatonin" OR 
"docosahexaenoic" OR "olanzapine" OR "walking" OR "nicotine" OR "folate" OR "17 beta-estradiol" 
OR "physostigmine" OR "lithium" OR "vitamin B-12" OR "neurotrophin" OR "quetiapine" OR "omega-3 
fatty acid" OR "Haloperidol" OR "huperzine" OR "psychotherapy" OR "music therapy" OR 
"occupational therapy" OR "acupuncture" OR "social interaction" OR "resveratrol" OR "polyunsaturated 
fatty acids" OR "neural stem cells" OR "transcranial magnetic stimulation" OR "vitamin D" OR 
"selegiline" OR "piracetam" OR "citalopram" OR "Testosterone" OR "folic acid" OR "vitamin C" OR 
"muscarinic agonist" OR "clioquinol" OR "ibuprofen" OR "Nimodipine" OR "simvastatin" OR 
"Carbamazepine" OR "electroconvulsive therapy" OR "rapamycin" OR "clozapine" OR "caffeine" OR 
"cannabinoid" OR "extract EGb 761" OR "tetrahydroaminoacridine" OR "alpha tocopherol" OR "ECT" 
OR "leisure activity" OR "Ginseng" OR "Mediterranean diet" OR "acetyl-L-carnitine" OR "metrifonate" 
OR "Aricept" OR "Bapineuzumab" OR "mesenchymal stem cells" OR "trazodone" OR "Cerebrolysin" 
OR "Epigallocatechin-3-gallate" OR "humanin" OR "reminiscence therapy" OR "B vitamin" OR 
"sertraline" OR "solanezumab" OR "Ginsenoside" OR "aerobic exercise" OR "pioglitazone" OR 
"Retinoic acid" OR "deep brain stimulation" OR "indomethacin" OR "leptin" OR "aromatherapy" OR 
"Cognitive Stimulation Therapy" OR "insulin therapy" OR "Intravenous immunoglobulin" OR "L-
deprenyl" OR "turmeric" OR "galanin" OR "selenium" OR "treadmill" OR "coffee" OR "DHEA" OR 
"progesterone" OR "Atorvastatin" OR "massage" OR "electroacupuncture" OR "fluoxetine" OR "memory 
training" OR "phosphatidylserine" OR "rosiglitazone" OR "phosphatidylcholine" OR "semagacestat" OR 
 




"Green tea" OR "nicotinamide" OR "physical therapy" OR "Aripiprazole" OR "rTMS" OR "bright light 
therapy" OR "quercetin" OR "fish oil" OR "phenserine" OR "S-adenosylmethionine" OR "saponin" OR 
"alpha lipoic acid" OR "amylin" OR "environmental enrichment" OR "Propentofylline" OR "social 
activity" OR "vitamin B-6" OR "cobalamin" OR "flurbiprofen" OR "methylene blue" OR "metformin" 
OR "rasagiline" OR "Group Therapy" OR "catechin" OR "coumarin" OR "lipoic acid" OR "lovastatin" 
OR "berberine" OR "ferulic acid" OR "small interfering RNA" OR "cognitive behavioral therapy" OR 
"DNA vaccine" OR "Reminyl" OR "velnacrine" OR "bexarotene" OR "carotenoid" OR "Citicoline" OR 
"desferrioxamine" OR "Huperzia serrata" OR "Liraglutide" OR "Thiamine" OR "morphine" OR "N-
acetylcysteine" OR "amantadine" OR "ascorbic acid" OR "caloric restriction" OR "Dimebon" OR 
"erythropoietin" OR "genistein" OR "grape" OR "lamotrigine" OR "red wine" OR "behavioral therapy" 
OR "curcuminoid" OR "medroxyprogesterone" OR "methylphenidate" OR "pravastatin" OR "scyllo-
inositol" OR "Xanomeline" OR "divalproex" OR "gabapentin" OR "lavender" OR "levetiracetam" OR 
"raloxifene" OR "transcranial direct current stimulation" OR "validation therapy" OR "ziprasidone" OR 
"arecoline" OR "idebenone" OR "ladostigil" OR "minocycline" OR "nicergoline" OR "PBT2" OR 
"perindopril" OR "soy" OR "Chondroitin sulfate" OR "etanercept" OR "hydergine" OR "piperidine" OR 
"sodium valproate" OR "sulfonamide" OR "animal-assisted therapy" OR "clonazepam" OR "Cognex" OR 
"deferoxamine" OR "multisensory stimulation" OR "allopregnanolone" OR "buspirone" OR "clonidine" 
OR "coenzyme Q10" OR "cyclophilin" OR "fluvoxamine" OR "garlic" OR "Imipramine" OR 
"tarenflurbil" OR "transcutaneous electrical nerve stimulation" OR "AF102B" OR "anthocyanin" OR 
"citrus" OR "embryonic stem cell" OR "escitalopram" OR "Higher education level" OR "Alpha2 
macroglobulin" OR "Amaryllidaceae" OR "aminoguanidine" OR "art therapy" OR "benzothiazole" OR 
"Caffeic acid" OR "doxycycline" OR "Eptastigmine" OR "exendin-4" OR "gelsolin" OR "Icariin" OR 
"M30" OR "resistance training" OR "Tai Chi" OR "tanshinone" OR "Vinpocetine" OR "Yizhi" OR 
"Bacopa" OR "bisdemethoxycurcumin" OR "cocoa" OR "Colostrinin" OR "gantenerumab" OR 
"Geniposide" OR "hydrogen sulfide" OR "moxibustion" OR "oxiracetam" OR "Reality orientation 
therapy" OR "rifampicin" OR "strength training" OR "9-Amino-1,2,3,4-tetrahydroacridine" OR 
"apigenin" OR "cinnamon" OR "cognitive therapy" OR "D-cycloserine" OR "propargylamine" OR 
"rosmarinic acid" OR "telmisartan" OR "topiramate" OR "Tramiprosate" OR "blueberry" OR "Fortasyn" 
OR "hyperforin" OR "Kampo" OR "mirtazapine" OR "N-benzylpiperidine" OR "Panax notoginseng" OR 
"Salvia miltiorrhiza" OR "Taurine" OR "yoga" OR "aniracetam" OR "CHF5074" OR "colostrum" OR 
"dantrolene" OR "Ghrelin" OR "grape seed" OR "hyperbaric oxygen" OR "linopirdine" OR "oleic acid" 
OR "propranolol" OR "pyridostigmine" OR "retinoid*" OR "saffron" OR "trehalose" OR "AF150" OR 
"captopril" OR "Crocus sativus" OR "demethoxycurcumin" OR "H2S" OR "latrepirdine" OR "lycopene" 
OR "piperazine" OR "Polygala tenuifolia" OR "ramelteon" OR "Riluzole" OR "tiapride" OR "beer" OR 
"clomipramine" OR "dance therapy" OR "Doll therapy" OR "gold nanoparticles" OR "Huannao Yicong" 
OR "lentiviral vectors" OR "Luteolin" OR "memoquin" OR "Nefiracetam" OR "pitavastatin" OR 
"pomegranate" OR "Puerarin" OR "scFv antibody" OR "zolpidem" OR "acupressure" OR "AF267B" OR 
"anandamide" OR "apomorphine" OR "ASS234" OR "Curcuma longa" OR "dihydrotestosterone" OR 
"glatiramer acetate" OR "horticultural therapy" OR "ketogenic diet" OR "L-3-n-butylphthalide" OR 
"losartan" OR "rutin" OR "tea polyphenols" OR "Zingiber" OR "7,8-dihydroxyflavone" OR 
"Aducanumab" OR "aged garlic extract" OR "amiridin" OR "apocynin" OR "baicalein" OR "Centella 
asiatica" OR "Danshen" OR "edaravone" OR "focused ultrasound" OR "HP 029" OR "Huprine" OR 
"milieu therapy" OR "natural origin" OR "paeoniflorin" OR "R-flurbiprofen" OR "retinoic acid receptor" 
OR "Selenate" OR "single-chain antibody" OR "Withania somnifera" OR "Acori graminei" OR "akatinol" 
 




OR "beta-asarone" OR "cotinine" OR "cryptotanshinone" OR "cyproterone" OR "dronabinol" OR 
"ganstigmine" OR "laser therapy" OR "Lavandula angustifolia" OR "naringenin" OR "Noopept" OR 
"oleocanthal" OR "pepper" OR "pet therapy" OR "ponezumab" OR "Pyritinol" OR "Rehmannia 
glutinosa" OR "Salidroside" OR "Salvianolic acid" OR "silymarin" OR "T0901317" OR 
"Tauroursodeoxycholic acid" OR "thalidomide" OR "triflusal" OR "Triptolide" OR "valsartan" OR 
"AMPK activation" OR "Colivelin" OR "fullerene*" OR "gastrodin" OR "hesperidin" OR "JWH-133" 
OR "Naftidrofuryl" OR "naringin" OR "neuroglobin" OR "nobiletin" OR "Oleuropein aglycone" OR 
"sodium butyrate" OR "talsaclidine" OR "Tannic acid" OR "Tetrahydrohyperforin" OR "Tiaoxin" OR 
"Uncaria rhynchophylla" OR "4-Phenylbutyrate" OR "asiatic acid" OR "benzylpiperidine" OR 
"Capsaicin" OR "Carnosic acid" OR "Catalpol" OR "D609" OR "Danggui-Shaoyao-San" OR 
"dihydroergotoxine" OR "ellagic acid" OR "fingolimod" OR "FLZ" OR "glycosaminoglycan polysulfate" 
OR "granulocyte colony-stimulating factor" OR "graphene" OR "IKKbeta" OR "mifepristone" OR 
"osthole" OR "protocatechuic acid" OR "Qingxin Kaiqiao" OR "rhynchophylline" OR "S14G-HN" OR 
"Selenomethionine" OR "Sodium selenate" OR "umbilical cord blood cells" OR "vagus nerve 
stimulation" OR "Wuzi Yanzong" OR "Xanthoceras" OR "xanthoceraside" OR "Xiusanzhen" OR "yi-
gan" OR "Abeta12-28P" OR "carvedilol" OR "Choto-san" OR "cyclandelate" OR 
"cytidinediphosphocholine" OR "ebselen" OR "fucoidan" OR "H-89" OR "Hericium erinaceus mycelia" 
OR "JTP-4819" OR "L-theanine" OR "low molecular weight heparin" OR "Namaste Care" OR "Naoling" 
OR "neotrofin" OR "Noninvasive Brain Stimulation" OR "Oligonol" OR "red mold" OR "retinoid x 
receptor alpha" OR "S-allyl-l-cysteine" OR "Scutellaria baicalensis" OR "spatial training" OR 
"SuHeXiang" OR "Tolfenamic acid" OR "Tong Luo Jiu Nao" OR "touch intervention" OR "Valeriana 
amurensis" OR "15-deoxy-Delta(12,14)-PGJ(2)" OR "17-AAG" OR "4-O-methylhonokiol" OR "alpha-
Mangostin" OR "Anatabine" OR "angiotensin-(1-7)" OR "Arundic acid" OR "bee venom" OR "betaine" 
OR "Cinnamomum" OR "coconut" OR "coptisine" OR "corticotropin-releasing factor receptor" OR 
"Cranberry" OR "diallyl disulfide" OR "Emblica officinalis" OR "Fucoxanthin" OR "Fuzhisan" OR 
"Gamma-hydroxybutyrate" OR "intermittent fasting" OR "isorhynchophylline" OR "Isradipine" OR 
"morin" OR "neural stem cell transplantation" OR "neuritin" OR "Nicotinamide mononucleotide" OR 
"pifithrin-alpha" OR "PQCA" OR "s-Ethyl cysteine" OR "s-propyl cysteine" OR "scFv-h3D6" OR 
"sulforaphane" OR "synj1" OR "tamibarotene" OR "targretin" OR "tenuifolin" OR "Tetrandrine" OR 
"Thymoquinone" OR "tropisetron" OR "vildagliptin" OR "3,6'-dithiothalidomide" OR "4% figs" OR "6-
shogaol" OR "A-887755" OR "Activated protein C" OR "AF151" OR "Agmatine" OR 
"aminopyridazines" OR "apple juice concentrate" OR "arachidonic acid ARA" OR "AVP-786" OR 
"benfotiamine" OR "BMP9 administration" OR "BMS-299897" OR "compound-1" OR "CREB-binding 
protein CBP" OR "crocetin" OR "cyclophilin A." OR "Cystatin B deletion" OR "dasatinib" OR "delta-9-
tetrahydrocannabinol" OR "derivative of benzothiazole aniline" OR "diazoxide" OR "Dl-PHPB" OR 
"Drp1 inhibitors" OR "Enoxaparin" OR "ergothioneine" OR "Fbx2" OR "glycyrrhizic acid" OR 
"Gossypium herbaceam" OR "Human amniotic epithelial cells" OR "hunger" OR "Hydroxysafflor 
yellow" OR "ICI 118,551" OR "IL-33" OR "ILEI" OR "indirubin-3'-monoxime" OR "iododiflunisal" OR 
"isoliquiritigenin" OR "L803-mts" OR "linagliptin" OR "Memogain" OR "Meserine" OR "mithramycin" 
OR "MMP9 gene" OR "Ophiopogon japonicus" OR "PEI-conjugated R8-Abeta(25-35)" OR 
"phloroglucinol" OR "PLD2 ablation" OR "protein-iPSCs" OR "rexinoid*" OR "RNS60" OR "Safflower 
yellow" OR "salubrinal" OR "saxagliptin" OR "Sendai virus" OR "single-walled carbon nanotubes" OR 
"Smart Soup" OR "sodium benzoate" OR "sulfomucopolysaccharide" OR "T-817MA" OR 
"tetrathiomolybdate" OR "WAY-100635" OR "WIN55212-2" OR "2-methyl-5-(3-{4-[(S)-
 




methylsulfinyl]phenyl}-1-benzofuran-5-yl" OR "2-phenylethynyl-butyltellurium" OR "2S -neoeriocitrin" 
OR "3,4-dihydroxyphenylethanol" OR "3-alpha-akebonoic acid" OR "40 Hz light-flickering regime" OR 
"AA3E2" OR "AAD-2004" OR "AAV-p75ECD" OR "Abeta-HBc VLPs" OR "ACAT1 gene ablation" 
OR "acetate extract of Centipedegrass" OR "Activase rt-PA" OR "activation-inhibitory Lactobacillus 
pentosus" OR "AD-35" OR "adipose-derived stem cell-conditioned medium" OR "allicin" OR "alpha-
chymotrypcin" OR "alpha-tocopherol quinine" OR "alpha-Zearalanol" OR "Anhydroexfoliamycin" OR 
"anthoxanthin" OR "anti-dementia effects of s-limonene" OR "anti-TLR2 antibody" OR "arctigenin" OR 
"AS2030680" OR "AS2674723" OR "ASP5736" OR "AVP-923" OR "beta-caryophyllene" OR "Bis(9)-(-
)-nor-meptazinol" OR "BMS-289948" OR "BMS-708,163" OR "BRET-Qdot-emitted NIR" OR 
"butyrolactone" OR "C-30-27" OR "Cardiotrophin-1" OR "Cassia obtusifolia" OR "catechin hydrate" OR 
"chitosan oligosaccharides" OR "chloroquine derivatives" OR "chronic intranasal treatment" OR 
"ciproxifan" OR "collagen VI" OR "Cudrania cochinchinensis" OR "cyclophilin B" OR "Cyperus 
rotundus" OR "cytosine-guanosine-containing DNA oligodeoxynucleotides" OR "DA-JC4" OR 
"Dalesconol B" OR "Daucosterol palmitate" OR "DcR3" OR "Dehydroevodiamine" OR "deleting Nogo" 
OR "Dendrobium Nobile Lindl" OR "deoxyschisandrin" OR "dexamethasone exposure during 
pregnancy" OR "Dietary niacin" OR "Dihydromyricetin" OR "dipotassium N-stearoyltyrosinate" OR 
"dynorphin A-(1-13)" OR "dZip1 inhibition" OR "ephrinB1/Fc" OR "Eugenia jambolana" OR 
"EUK1001" OR "exogenous Abeta fibrillar seeds" OR "fenugreek seed powder" OR "Fructus mume" OR 
"Fumanjian" OR "Gami-Chunghyuldan" OR "genetic deletion of 12/15LO" OR "Genetic deletion of 
eIF2alpha" OR "Gfa2-VIVIT" OR "GSM-2" OR "Harpagoside" OR "hemizygous deletion of Synj1" OR 
"high potassium intakes" OR "hunger-inducing drug" OR "HX630" OR "hypericin" OR "IL-1R blocking 
Ab" OR "illite" OR "Inhibition of GIVA-PLA(2)" OR "Interleukin-34" OR "iso-alpha-acids" OR "JC-
124" OR "JM6" OR "Jujuboside" OR "K6Abeta1-30[E18E19]" OR "kallikrein 7" OR "Kamikihi-to" OR 
"kappacarrageenanderived pentasaccharide" OR "L-NNNBP" OR "laminin 1" OR "Lentiviral ABN" OR 
"low-intensity pulsed LIP ultrasound" OR "LX2343" OR "Magnesium sulfate treatment" OR "maltolyl p-
coumarate" OR "Marapuama" OR "MER5101" OR "MOG45D" OR "MS-275" OR "murine pathogen-
free" OR "MW01-2-069A-SRM" OR "MW01-2-151SRM" OR "N-butylidenephthalide" OR "NButGT" 
OR "Neuropep-1" OR "ninjin'yoeito" OR "NRG1" OR "P. frutescens extract" OR "P11-hEGF" OR 
"Paeng-Jo-Yeon-Nyeon-Baek-Ja-In-Hwan" OR "Pantethine" OR "pBri-peptide-based 
immunomodulation" OR "PD146176" OR "pentamidine" OR "peoniflorin" OR "pharmacological inducer 
of HO-1" OR "PHF13" OR "Pleurotus ostreatus" OR "PP-3copy-Abeta1-6-loop123" OR "pratensein" OR 
"proteolytic nanobodies" OR "Pterocarpus marsupium" OR "pulsed ultrasound" OR "Qifu-Yin" OR 
"recombinant brain-targeted neprilysin ASN12" OR "reduced InsP3R1 expression" OR "reduction in 
mTOR signaling" OR "Reduction of exosome secretion" OR "repeated cognitive enrichment" OR 
"replace the endogenous apoE" OR "Rhizophora mucronata" OR "RP-1" OR "S1 peptide" OR 
"Saengshik" OR "Salvia sahendica" OR "Satureja bachtiarica" OR "scanning ultrasound" OR 
"Schisantherin B" OR "selenofuranoside" OR "Shengmai" OR "shRNA in the dentate" OR "Sia 
hydroxamate" OR "skeletal analogues of gambierol" OR "ST09" OR "SUN11602" OR "TAK-070" OR 
"tangeretin" OR "TAT-BDNF peptide" OR "TAT-haFGF" OR "tenascin-C-deficient" OR "TG101209" 
OR "TNFSF10 neutralizing antibody" OR "Tongmai Yizhi Decoction" OR "Transplantation of neural 
progenitor" OR "tri-lithium pyrroloquinoline quinone" OR "tricyclodecan-9-xanthogenate" OR 
"unmethylated DNA CpG motif" OR "Wen-Dan-Tang" OR "Y-29794" OR "yonkenafil" OR "Zataria 
multiflora Boiss" OR "zinc/copper chelators")) 
 




 The final query actually entered into the search engine was: 
(#1 AND (#2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 
OR #15 OR #16 OR #17 OR #18 OR #19 OR #20)) NOT (#21 OR #22) 
(#2 AND (#3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR 
#15 OR #16 OR #17 OR #18 OR #19 OR #20)) NOT (#21 OR #22) 
(#3 AND (#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR 
#16 OR #17 OR #18 OR #19 OR #20)) NOT (#21 OR #22) 
(#4 AND (#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR 
#17 OR #18 OR #19 OR #20)) NOT (#21 OR #22) 
(#5 AND (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 
OR #18 OR #19 OR #20)) NOT (#21 OR #22) 
(#6 AND (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 
OR #19 OR #20)) NOT (#21 OR #22) 
#7 AND (#8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 
OR #20)) NOT (#21 OR #22) 
(#8 AND (#9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR 
#20)) NOT (#21 OR #22) 
(#9 AND (#10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20)) 
NOT (#21 OR #22) 
(#10 AND (#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20)) NOT (#21 
OR #22) 
(#11 AND (#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20)) NOT (#21 OR #22) 
(#12 AND (#13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20)) NOT (#21 OR #22) 
(#13 AND (#14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20)) NOT (#21 OR #22) 
(#14 AND (#15 OR #16 OR #17 OR #18 OR #19 OR #20)) NOT (#21 OR #22) 
(#15 AND (#16 OR #17 OR #18 OR #19 OR #20)) NOT (#21 OR #22) 
(#16 AND (#17 OR #18 OR #19 OR #20)) NOT (#21 OR #22) 
(#17 AND (#18 OR #19 OR #20)) NOT (#21 OR #22) 
(#18 AND (#19 OR #20)) NOT (#21 OR #22) 
(#19 AND (#20)) NOT (#21 OR #22)  
 




3B. Appendix 2 - TR Literature Taxonomy based on Text Clustering 
A2-1. Overview of TR text clustering literature taxonomy 
 The 2890 Medline records that constitute the core TR (mainly drug repurposing) literature were 
sub-divided into a 32 cluster hierarchical taxonomy using the CLUTO text clustering software [CLUTO, 
2018].  Both the top-level aggregated clusters in the taxonomy (Table A2-1) and the 32 elemental clusters 
(the lowest and most detailed level of the taxonomy-Table A2-2) will be presented in the following 
sections.   
 The 32 elemental cluster presentation will include the titles of records assigned to each cluster by 
the algorithm.  The version of CLUTO used for this analysis does not include fuzzy clustering, so each 
record is assigned to one cluster only.  A number of the records contained multiple themes, and could 
have been assigned to more than one cluster.  Nevertheless, the taxonomy does provide a unique and 
interesting perspective on the structure of the TR literature. 
 The themes of the clusters shown in Tables A2-1 and A2-2 are, of necessity, very broad.  The 
titles are provided for each of the 32 elemental clusters shown in Table A2-2 to provide the full spectrum 
of sub-themes within each elemental cluster, and allow the interested reader to identify specific sub-
themes of personal interest within the cluster.  The full reference for each title is provided in Chapter 4, 








 Before the details of the 32 'leaf' (lowest level) clusters are presented, a high-level (top three 
levels) view of the TR text clustering taxonomy is shown in Table A2-1. 
Table A2-1: TOP-LEVEL TR TEXT CLUSTERING TAXONOMY  
(number of records in each cluster shown in parenthesis ()) 
SECOND LEVEL THIRD LEVEL FOURTH LEVEL 
Cluster 58 (1096) 
Drug repurposing 
prediction 
Cluster 51 (439) - Gene 
expression; protein 
interaction network 




Cluster 41 (246) - Gene 
expression; genome 
wide association 
Cluster 56 (657) - 
Drug-target interaction 








Cluster 61 (1793) 
Disease treatment 




Cluster 7 (114) - Drug-
resistant tuberculosis  
Cluster 57 (455) - 
Viral/bacterial 
infections; parasites 





Cluster 52 (590) - 
Cancer treatment 




 The first bifurcated level of the hierarchical taxonomy shows two definite thrust areas: Methods 
for drug repurposing prediction (Cluster 58),  and disease treatments that resulted from drug repositioning 
(Cluster 61).  The next two levels of the hierarchy are self-explanatory. 








Table A2-2: LOWEST LEVEL TR TEXT CLUSTERING TAXONOMY 
(number of records in each cluster shown in parenthesis (); this number is hyperlinked to the actual record 
titles) 
FOURTH LEVEL LOWEST LEVEL (LEAF CLUSTERS) 




Cluster 4 (47) - drug-disease associations 
Cluster 18 (146) - network-based prediction, 
especially protein interaction networks 




Cluster 16 (65) - genome-wide associations 
Cluster 21 (181) - gene expression, especially 
gene expression signatures and gene expression 
profiles 




Cluster 13 (100) - drug-target interaction 
prediction 
Cluster 22 (176) - ligand binding-sites, protein-
ligand interactions, and protein-protein 
interactions 




Cluster 9 (37) - rare diseases 
Cluster 20 (91) - computational drug 
repositioning 
Cluster 26 (86) - marketing aspects of drug 
repurposing 
Cluster 29 (167) - drug development and 
discovery 
Cluster 7 (114) - Drug-
resistant tuberculosis 
Cluster 7 (114) - drug-resistant tuberculosis 
Cluster 57 (455) - 
Viral/bacterial 
infections; parasites 
Cluster 1 (41) - antiviral treatments for viral 
infections, especially Ebola virus 
Cluster 0 (21) - antiviral treatments for viral 
infections, especially Zika virus 
Cluster 15 (80) - antiviral treatments for other 
viral infections, especially dengue virus, hepatitis 
B virus, chikungunya virus, human 
immunodeficiency virus, japanese encephalitis 
virus, rift valley fever virus, human 
cytomegalovirus, respiratory syncytial virus, west 
nile virus 
Cluster 14 (62) - treatments for parasites, 
especially trypanosoma cruzi, african 
trypanosomiasi, trypanosoma brucei, leishmania 
amazonensi 
Cluster 19 (93) - treatments for parasites, 
especially plasmodium falciparum, schistosoma 
mansoni, toxoplasma gondii 
Cluster 6 (45) - antifungal treatments 
Cluster 17 (113) - antimicrobial and antibiotic 
treatments for infections 
 




Cluster 52 (590) - 
Cancer treatment 
Cluster 23 (93) - repurposing kinase inhibitors, 
especially for treatment of acute myeloid 
leukemia 
Cluster 12 (59) - ovarian cancer treatments, 
especially niclosamide 
 
Cluster 27 (160) - treatments that destroy cancer 
cells 
Cluster 25 (171) - anti-cancer treatments 
Cluster 5 (41) - treatments for pancreatic cancer, 
especially Metformin 
 
Cluster 11 (66) - breast cancer treatments 
Cluster 55 (634) - 
Neurodegenerative 
disease treatment 
Cluster 2 (48) - Alzheimer's Disease treatments 
Cluster 8 (30) - neurodegenerative disease 
treatments, especially Parkinson's Disease 
Cluster 24 (117) - treatments for brain disease, 
especially stroke 
Cluster 3 (33) - drug repurposing patent 
applications 
Cluster 10 (46) - glioblastoma treatments 
Cluster 31 (151) - anti-inflammatory treatments 
Cluster 28 (97) - treatments for addiction 
disorders (especially alcohol use) and chronic 
pain 
Cluster 30 (112) - cancer treatments, especially 
metronomic chemotherapy 
 
 The details of each of the leaf clusters in which the eight fourth level categories have been sub-
divided (by the CLUTO text clustering algorithm) will now be presented in some detail.  In the 
presentation structure, each fourth-level cluster (shown in both tables above) will be followed by its 
constituent leaf clusters.  For each leaf cluster, there will be a summary of its biomedical thrust, followed 
by the titles of the records in the leaf cluster.  These record titles in each cluster are hyperlinked to the 
corresponding cluster number shown in Table A2-2.  To obtain the full reference for any title(s) of 
interest, the reader needs to search the Bibliography references in Chapter 4. 
 




A2-2. Details of leaf clusters 
 The first time a leaf cluster is presented, its number will be followed by the number of records 
contained within the cluster, in parentheses.  For example, in section A2-2a, 'Cluster 4 (47)' means the 
leaf Cluster #4 contains 47 records. 
A2-2a. Leaf clusters under Cluster 35 
 There are two leaf clusters under Cluster 35: Cluster 4 (47) and Cluster 18 (146).   
*Cluster 4 focuses on drug-disease associations;  
*Cluster 18 focuses on network-based prediction, especially using protein interaction networks. 
 




A2-2a1. Cluster 4 record titles 
1. Predicting drug-disease associations and their therapeutic function based on the drug-disease 
association bipartite network. 
2. Inferring drug-disease associations from integration of chemical, genomic and phenotype data using 
network propagation. 
3. DR2DI: a powerful computational tool for predicting novel drug-disease associations. 
4. Inferring drug-disease associations based on known protein complexes. 
5. Prediction of new drug indications based on clinical data and network modularity. 
6. Drug Repositioning by Integrating Known Disease-Gene and Drug-Target Associations in a Semi-
supervised Learning Model. 
7. Network-based inference methods for drug repositioning. 
8. Computational drug repositioning using low-rank matrix approximation and randomized algorithms. 
9. Systematic drug repositioning for a wide range of diseases with integrative analyses of phenotypic and 
molecular data. 
10. A miRNA-driven inference model to construct potential drug-disease associations for drug 
repositioning. 
11. Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm. 
12. LRSSL: predict and interpret drug-disease associations based on data integration using sparse 
subspace learning. 
13. Predicting drug-disease interactions by semi-supervised graph cut algorithm and three-layer data 
integration. 
14. Towards drug repositioning: a unified computational framework for integrating multiple aspects of 
drug similarity and disease similarity. 
15. Matrix Factorization-Based Prediction of Novel Drug Indications by Integrating Genomic Space. 
16. Scoring multiple features to predict drug disease associations using information fusion and 
aggregation. 
17. Drug-disease association and drug-repositioning predictions in complex diseases using causal 
inference-probabilistic matrix factorization. 
18. Linking PharmGKB to phenotype studies and animal models of disease for drug repurposing. 
19. Inferring disease association using clinical factors in a combinatorial manner and their use in drug 
repositioning. 
 




20. The extraction of drug-disease correlations based on module distance in incomplete human 
interactome. 
21. Inferring new indications for approved drugs via random walk on drug-disease heterogenous 
networks. 
22. Predicting Potential Drugs for Breast Cancer based on miRNA and Tissue Specificity. 
23. Compensating for literature annotation bias when predicting novel drug-disease relationships through 
Medical Subject Heading Over-representation Profile (MeSHOP) similarity. 
24. Computational drug repurposing to predict approved and novel drug-disease associations. 
25. An Integrated Data Driven Approach to Drug Repositioning Using Gene-Disease Associations. 
26. Network-based in silico drug efficacy screening. 
27. DrPOCS: Drug repositioning based on projection onto convex sets. 
28. Prediction of Novel Drugs and Diseases for Hepatocellular Carcinoma Based on Multi-Source 
Simulated Annealing Based Random Walk. 
29. Drug repositioning based on triangularly balanced structure for tissue-specific diseases in incomplete 
interactome. 
30. Drug repositioning by kernel-based integration of molecular structure, molecular activity, and 
phenotype data. 
31. Heter-LP: A heterogeneous label propagation algorithm and its application in drug repositioning. 
32. Identification of associations between small molecule drugs and miRNAs based on functional 
similarity. 
33. Prediction of Novel Drugs for Hepatocellular Carcinoma Based on Multi-Source Random Walk. 
34. On the Integration of In Silico Drug Design Methods for Drug Repurposing. 
35. Prediction of Non-coding RNAs as Drug Targets. 
36. Large-scale extraction of accurate drug-disease treatment pairs from biomedical literature for drug 
repurposing. 
37. ANTENNA, a Multi-Rank, Multi-Layered Recommender System for Inferring Reliable Drug-Gene-
Disease Associations: Repurposing Diazoxide as a Targeted Anti-Cancer Therapy. 
38. Inferring novel indications of approved drugs via a learning method with local and global consistency. 
39. Identification association of drug-disease by using functional gene module for breast cancer. 
40. miREFRWR: a novel disease-related microRNA-environmental factor interactions prediction method. 
 




41. Network-based approach to prediction and population-based validation of in silico drug repurposing. 
42. Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for 
myasthenia gravis. 
43. Deciphering miRNA transcription factor feed-forward loops to identify drug repurposing candidates 
for cystic fibrosis. 
44. Drug voyager: a computational platform for exploring unintended drug action. 
45. Systematical analysis of lncRNA-mRNA competing endogenous RNA network in breast cancer 
subtypes. 
46. Linking molecular feature space and disease terms for the immunosuppressive drug rapamycin. 








A2-2a2. Cluster 18 record titles 
1. Building a drug-target network and its applications. 
2. Prediction of novel drug indications using network driven biological data prioritization and integration. 
3. Network-based prediction and knowledge mining of disease genes. 
4. Human pathway-based disease network. 
5. VisANT 4.0: Integrative network platform to connect genes, drugs, diseases and therapies. 
6. DrugNet: network-based drug-disease prioritization by integrating heterogeneous data. 
7. Drug target prediction and repositioning using an integrated network-based approach. 
8. Computational drug repositioning through heterogeneous network clustering. 
9. Fusing literature and full network data improves disease similarity computation. 
10. Network approaches to drug discovery. 
11. Discovering gene re-ranking efficiency and conserved gene-gene relationships derived from gene co-
expression network analysis on breast cancer data. 
12. Network mirroring for drug repositioning. 
13. A Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles 
Using Pathway-Drug Network. 
14. Drug repositioning by integrating target information through a heterogeneous network model. 
15. Drug repositioning using disease associated biological processes and network analysis of drug targets. 
16. Ariadne's ChemEffect and Pathway Studio knowledge base. 
17. Mining integrated semantic networks for drug repositioning opportunities. 
18. GUILDify: a web server for phenotypic characterization of genes through biological data integration 
and network-based prioritization algorithms. 
19. DNetDB: The human disease network database based on dysfunctional regulation mechanism. 
20. Towards building a disease-phenotype knowledge base: extracting disease-manifestation relationship 
from literature. 
21. Systematic integration of biomedical knowledge prioritizes drugs for repurposing. 
22. Network-based machine learning and graph theory algorithms for precision oncology. 
23. Drug Repositioning Through Network Pharmacology. 
 




24. Prediction of drugs having opposite effects on disease genes in a directed network. 
25. Human disease-drug network based on genomic expression profiles. 
26. Construction of drug network based on side effects and its application for drug repositioning. 
27. A comparative study of disease genes and drug targets in the human protein interactome. 
28. A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target 
Therapies in Triple Negative Breast Cancer. 
29. The human disease network in terms of dysfunctional regulatory mechanisms. 
30. Learning disease relationships from clinical drug trials. 
31. Computational drug repositioning with random walk on a heterogeneous network. 
32. DiseaseConnect: a comprehensive web server for mechanism-based disease-disease connections. 
33. Advanced systems biology methods in drug discovery and translational biomedicine. 
34. A review of network-based approaches to drug repositioning. 
35. dRiskKB: a large-scale disease-disease risk relationship knowledge base constructed from biomedical 
text. 
36. Inferring novel disease indications for known drugs by semantically linking drug action and disease 
mechanism relationships. 
37. Literature-based discovery of new candidates for drug repurposing. 
38. Constructing Disease Similarity Networks Based on Disease Module Theory. 
39. Rectifying cancer drug discovery through network pharmacology. 
40. Network-based drug repositioning. 
41. Informed walks: whispering hints to gene hunters inside networks' jungle. 
42. DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-
based drug repurposing. 
43. Unveiling the role of network and systems biology in drug discovery. 
44. Generating Gene Ontology-Disease Inferences to Explore Mechanisms of Human Disease at the 
Comparative Toxicogenomics Database. 
45. Rational drug repositioning guided by an integrated pharmacological network of protein, disease and 
drug. 
46. Disease classification: from phenotypic similarity to integrative genomics and beyond. 
 




47. Network-based drug ranking and repositioning with respect to DrugBank therapeutic categories. 
48. ProphTools: general prioritization tools for heterogeneous biological networks. 
49. A two-step drug repositioning method based on a protein-protein interaction network of genes shared 
by two diseases and the similarity of drugs. 
50. SemFunSim: a new method for measuring disease similarity by integrating semantic and gene 
functional association. 
51. Generation and application of drug indication inference models using typed network motif 
comparison analysis. 
52. Identifying aberrant pathways through integrated analysis of knowledge in pharmacogenomics. 
53. A network-based drug repositioning infrastructure for precision cancer medicine through targeting 
significantly mutated genes in the human cancer genomes. 
54. Drug repositioning through incomplete bi-cliques in an integrated drug-target-disease network. 
55. A disease similarity matrix based on the uniqueness of shared genes. 
56. Cancer based pharmacogenomics network supported with scientific evidences: from the view of drug 
repurposing. 
57. COMPUTING THERAPY FOR PRECISION MEDICINE: COLLABORATIVE FILTERING 
INTEGRATES AND PREDICTS MULTI-ENTITY INTERACTIONS. 
58. Diffusion mapping of drug targets on disease signaling network elements reveals drug combination 
strategies. 
59. Large-scale data-driven integrative framework for extracting essential targets and processes from 
disease-associated gene data sets. 
60. Pathway-based drug repositioning using causal inference. 
61. Data integration to prioritize drugs using genomics and curated data. 
62. Pathway and network-based strategies to translate genetic discoveries into effective therapies. 
63. Co-expression Network Approach Reveals Functional Similarities among Diseases Affecting Human 
Skeletal Muscle. 
64. Proximal Pathway Enrichment Analysis for Targeting Comorbid Diseases via Network 
Endopharmacology. 
65. A systems-level analysis of drug-target-disease associations for drug repositioning. 
66. Biomolecular Network Controllability With Drug Binding Information. 
 




67. Network insights into the genes regulated by hepatocyte nuclear factor 4 in response to drug induced 
perturbations: a review. 
68. Network and matrix analysis of the respiratory disease interactome. 
69. Network biology concepts in complex disease comorbidities. 
70. Network-Based Drug Discovery: Coupling Network Pharmacology with Phenotypic Screening for 
Neuronal Excitability. 
71. PISTON: Predicting drug indications and side effects using topic modeling and natural language 
processing. 
72. Computational Drug Repurposing: Current Trends. 
73. Toward creation of a cancer drug toxicity knowledge base: automatically extracting cancer drug-side 
effect relationships from the literature. 
74. Systematic drug repositioning based on clinical side-effects. 
75. Convergent downstream candidate mechanisms of independent intergenic polymorphisms between 
co-classified diseases implicate epistasis among noncoding elements. 
76. Comparing a knowledge-driven approach to a supervised machine learning approach in large-scale 
extraction of drug-side effect relationships from free-text biomedical literature. 
77. Large-scale automatic extraction of side effects associated with targeted anticancer drugs from full-
text oncological articles. 
78. Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New 
Platform for Computer-Aided Drug Repurposing. 
79. Inferring new drug indications using the complementarity between clinical disease signatures and 
drug effects. 
80. A two-tiered unsupervised clustering approach for drug repositioning through heterogeneous data 
integration. 
81. Combined Analysis of Phenotypic and Target-Based Screening in Assay Networks. 
82. RANKS: a flexible tool for node label ranking and classification in biological networks. 
83. Semantic Web Ontology and Data Integration: a Case Study in Aiding Psychiatric Drug Repurposing. 
84. MTGO: PPI Network Analysis Via Topological and Functional Module Identification. 
85. A framework for the targeted selection of herbs with similar efficacy by exploiting drug repositioning 
technique and curated biomedical knowledge. 
86. Community-driven roadmap for integrated disease maps. 
 




87. Pharmacodynamics and Systems Pharmacology Approaches to Repurposing Drugs in the Wake of 
Global Health Burden. 
88. Prediction of drug gene associations via ontological profile similarity with application to drug 
repositioning. 
89. Network-based drug repositioning: A novel strategy for discovering potential antidepressants and 
their mode of action. 
90. Semantic Web Ontology and Data Integration: a Case Study in Aiding Psychiatric Drug Repurposing. 
91. Drug repurposing by integrated literature mining and drug-gene-disease triangulation. 
92. DeCoST: A New Approach in Drug Repurposing From Control System Theory. 
93. Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System. 
94. Identifying Candidates for Breast Cancer Using Interactions of Chemicals and Proteins. 
95. Complex-disease networks of trait-associated single-nucleotide polymorphisms (SNPs) unveiled by 
information theory. 
96. Automatic construction of a large-scale and accurate drug-side-effect association knowledge base 
from biomedical literature. 
97. A bidirectional drug repositioning approach for Parkinson's disease through network-based inference. 
98. Discovering discovery patterns with Predication-based Semantic Indexing. 
99. A systematic analysis of FDA-approved anticancer drugs. 
100. Computational Study of Drugs by Integrating Omics Data with Kernel Methods. 
101. Network medicine in disease analysis and therapeutics. 
102. Combining automatic table classification and relationship extraction in extracting anticancer drug-
side effect pairs from full-text articles. 
103. Finding complex biological relationships in recent PubMed articles using Bio-LDA. 
104. Literature-based prediction of novel drug indications considering relationships between entities. 
105. The pain interactome: connecting pain-specific protein interactions. 
106. DenguePredict: An Integrated Drug Repositioning Approach towards Drug Discovery for Dengue. 
107. MeSHDD: Literature-based drug-drug similarity for drug repositioning. 
108. DSviaDRM: an R package for estimating disease similarity via dysfunctional regulation mechanism. 
 




109. Chemotext: A Publicly Available Web Server for Mining Drug-Target-Disease Relationships in 
PubMed. 
110. Chemical-induced disease extraction via recurrent piecewise convolutional neural networks. 
111. Integrative network modeling approaches to personalized cancer medicine. 
112. Large-scale integration of heterogeneous pharmacogenomic data for identifying drug mechanism of 
action. 
113. Integrative Cancer Pharmacogenomics to Infer Large-Scale Drug Taxonomy. 
114. Uncovering novel repositioning opportunities using the Open Targets platform. 
115. Changing Trends in Computational Drug Repositioning. 
116. MediSyn: uncertainty-aware visualization of multiple biomedical datasets to support drug treatment 
selection. 
117. Inflammatory pathway network-based drug repositioning and molecular phenomics. 
118. Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine 
Approach. 
119. Drug repurposing: a better approach for infectious disease drug discovery? 
120. Computational methods and opportunities for phosphorylation network medicine. 
121. DESM: portal for microbial knowledge exploration systems. 
122. Exploring the pharmacogenomics knowledge base (PharmGKB) for repositioning breast cancer 
drugs by leveraging Web ontology language (OWL) and cheminformatics approaches. 
123. Multi-aspect candidates for repositioning: data fusion methods using heterogeneous information 
sources. 
124. Drug knowledge bases and their applications in biomedical informatics research. 
125. Medical concept normalization in social media posts with recurrent neural networks. 
126. Using predicate and provenance information from a knowledge graph for drug efficacy screening. 
127. DrugMap Central: an on-line query and visualization tool to facilitate drug repositioning studies. 
128. Automated QuantMap for rapid quantitative molecular network topology analysis. 
129. Network-assisted prediction of potential drugs for addiction. 
130. Neighbours of cancer-related proteins have key influence on pathogenesis and could increase the 
drug target space for anticancer therapies. 
 




131. 'RE:fine drugs': an interactive dashboard to access drug repurposing opportunities. 
132. Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders. 
133. A physarum-inspired prize-collecting steiner tree approach to identify subnetworks for drug 
repositioning. 
134. Graph theory enables drug repurposing--how a mathematical model can drive the discovery of 
hidden mechanisms of action. 
135. A phenome-guided drug repositioning through a latent variable model. 
136. Drug repositioning for prostate cancer: using a data-driven approach to gain new insights. 
137. Investigating drug repositioning opportunities in FDA drug labels through topic modeling. 
138. Early repositioning through compound set enrichment analysis: a knowledge-recycling strategy. 
139. A Simple Text Mining Approach for Ranking Pairwise Associations in Biomedical Applications. 
140. Correction: A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-
Target Therapies in Triple Negative Breast Cancer. 
141. Linking biochemical pathways and networks to adverse drug reactions. 
142. Big Data Mining and Adverse Event Pattern Analysis in Clinical Drug Trials. 
143. A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth 
muscle relaxation to direct neuroprotection. 
144. Information exploration system for sickle cell disease and repurposing of hydroxyfasudil. 
145. A systems pharmacology-oriented discovery of a new therapeutic use of the TCM formula 
Liuweiwuling for liver failure. 
146. Neuroprotective Drug for Nerve Trauma Revealed Using Artificial Intelligence. 
  
 





A2-2b. Leaf clusters under Cluster 41 
 There are two leaf clusters under Cluster 41: Cluster 16 (65) and Cluster 21 (181).   
*Cluster 16 focuses on genome-wide associations;  








A2-2b1. Cluster 16 record titles 
1. Genome-wide association studies of cancer: current insights and future perspectives. 
2. Use of genome-wide association studies for drug repositioning. 
3. From the era of genome analysis to the era of genomic drug discovery: a pioneering example of 
rheumatoid arthritis. 
4. Genetics of rheumatoid arthritis contributes to biology and drug discovery. 
5. Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry. 
6. [GWAS of Rheumatoid Arthritis and Drug Discovery]. 
7. GWAS and drug targets. 
8. Drug enrichment and discovery from schizophrenia genome-wide association results: an analysis and 
visualisation approach. 
9. Identification of novel therapeutics for complex diseases from genome-wide association data. 
10. A meta-analysis of reflux genome-wide association studies in 6750 Northern Europeans from the 
general population. 
11. Connecting genetics and gene expression data for target prioritisation and drug repositioning. 
12. Use of genome-wide association studies for cancer research and drug repositioning. 
13. Learning Opportunities for Drug Repositioning via GWAS and PheWAS Findings. 
14. Symposium 2-1The autoimmunome: Similarities and differences among genetic susceptibility to 
common immune-related diseases. 
15. Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities 
in schizophrenia. 
16. Enhancing the Promise of Drug Repositioning through Genetics. 
17. New pathogenic insights into rheumatoid arthritis. 
18. Schizophrenia interactome with 504 novel protein-protein interactions. 
19. A genomics-based systems approach towards drug repositioning for rheumatoid arthritis. 
20. Update on the genetic architecture of rheumatoid arthritis. 
21. The druggable genome and support for target identification and validation in drug development. 
22. Computational drug repositioning: from data to therapeutics. 
 




23. Future Directions of Genomics Research in Rheumatic Diseases. 
24. Approaches for establishing the function of regulatory genetic variants involved in disease. 
25. Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic. 
26. Phenome-wide association studies: a new method for functional genomics in humans. 
27. Novel therapeutics for coronary artery disease from genome-wide association study data. 
28. Genome-wide association analyses for lung function and chronic obstructive pulmonary disease 
identify new loci and potential druggable targets. 
29. Novel putative drugs and key initiating genes for neurodegenerative disease determined using 
network-based genetic integrative analysis. 
30. Molecular mechanisms underlying variations in lung function: a systems genetics analysis. 
31. Revisiting Antipsychotic Drug Actions Through Gene Networks Associated With Schizophrenia. 
32. Identification of ST3AGL4, MFHAS1, CSNK2A2 and CD226 as loci associated with systemic lupus 
erythematosus (SLE) and evaluation of SLE genetics in drug repositioning. 
33. Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. 
34. The emergence of genome-based drug repositioning. 
35. Mood, stress and longevity: convergence on ANK3. 
36. Genetic and molecular aspects of hypertension. 
37. Functional genomics of pain in analgesic drug development and therapy. 
38. Human CCL3L1 copy number variation, gene expression, and the role of the CCL3L1-CCR5 axis in 
lung function. 
39. Systems Pharmacology-Based Approach of Connecting Disease Genes in Genome-Wide Association 
Studies with Traditional Chinese Medicine. 
40. Sequence Analysis of Drug Target Genes with Suicidal Behavior in Bipolar Disorder Patients. 
41. Opportunities for drug repositioning from phenome-wide association studies. 
42. Translating Mendelian and complex inheritance of Alzheimer's disease genes for predicting unique 
personal genome variants. 
43. Drug repositioning for diabetes based on 'omics' data mining. 
44. Computational functional genomics-based approaches in analgesic drug discovery and repurposing. 
 




45. Explore Small Molecule-induced Genome-wide Transcriptional Profiles for Novel Inflammatory 
Bowel Disease Drug. 
46. What do the genetic association data say about the high risk of suicide in people with depression? A 
novel network-based approach to find common molecular basis for depression and suicidal behavior and 
related therapeutic targets. 
47. A perspective on genomic-guided anthelmintic discovery and repurposing using Haemonchus 
contortus. 
48. Drug Repositioning in Inflammatory Bowel Disease Based on Genetic Information. 
49. A phenome-wide association study of a lipoprotein-associated phospholipase A2 loss-of-function 
variant in 90 000 Chinese adults. 
50. Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning 
targets for IBD and other autoimmune diseases. 
51. Repositioning of drugs using open-access data portal DTome: A test case with probenecid (Review). 
52. A machine-learned computational functional genomics-based approach to drug classification. 
53. Precision medicine for suicidality: from universality to subtypes and personalization. 
54. Omics studies: their use in diagnosis and reclassification of SLE and other systemic autoimmune 
diseases. 
55. Calcium channel blockers as drug repurposing candidates for gestational diabetes: Mining large scale 
genomic and electronic health records data to repurpose medications. 
56. ZikaVR: An Integrated Zika Virus Resource for Genomics, Proteomics, Phylogenetic and Therapeutic 
Analysis. 
57. Towards precision medicine-based therapies for glioblastoma: interrogating human disease genomics 
and mouse phenotypes. 
58. Drug repurposing for glioblastoma based on molecular subtypes. 
59. Personalized Proteomics for Precision Health: Identifying Biomarkers of Vitreoretinal Disease. 
60. Drug repositioning in SLE: crowd-sourcing, literature-mining and Big Data analysis. 
61. Repurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic medical records. 
62. Opportunities for Web-based Drug Repositioning: Searching for Potential Antihypertensive Agents 
with Hypotension Adverse Events. 
63. Systems pharmacology of adverse event mitigation by drug combinations. 
64. Simvastatin offers new prospects for the treatment of Duchenne muscular dystrophy. 
 




65. A second look: Efforts to repurpose old drugs against Zika cast a wide net. 
  
 




A2-2b2. Cluster 21 record titles 
1. Connectivity mapping using a combined gene signature from multiple colorectal cancer datasets 
identified candidate drugs including existing chemotherapies. 
2. Drug similarity search based on combined signatures in gene expression profiles. 
3. Finding the targets of a drug by integration of gene expression data with a protein interaction network. 
4. Discovery of the neuroprotective effects of alvespimycin by computational prioritization of potential 
anti-Parkinson agents. 
5. Harnessing the biological complexity of Big Data from LINCS gene expression signatures. 
6. New drug candidates for treatment of atypical meningiomas: An integrated approach using gene 
expression signatures for drug repurposing. 
7. Gene-Set Local Hierarchical Clustering (GSLHC)--A Gene Set-Based Approach for Characterizing 
Bioactive Compounds in Terms of Biological Functional Groups. 
8. ADEPTUS: a discovery tool for disease prediction, enrichment and network analysis based on profiles 
from many diseases. 
9. Statistically controlled identification of differentially expressed genes in one-to-one cell line 
comparisons of the CMAP database for drug repositioning. 
10. A novel computational approach for drug repurposing using systems biology. 
11. Cogena, a novel tool for co-expressed gene-set enrichment analysis, applied to drug repositioning and 
drug mode of action discovery. 
12. MD-Miner: a network-based approach for personalized drug repositioning. 
13. Utilizing Cancer - Functional Gene Set - Compound Networks to Identify Putative Drugs for Breast 
Cancer. 
14. Revisiting Connectivity Map from a gene co-expression network analysis. 
15. DeSigN: connecting gene expression with therapeutics for drug repurposing and development. 
16. Drug repositioning for orphan genetic diseases through Conserved Anticoexpressed Gene Clusters 
(CAGCs). 
17. Drug repositioning: a machine-learning approach through data integration. 
18. A Computational Systems Biology Approach for Identifying Candidate Drugs for Repositioning for 
Cardiovascular Disease. 
19. Network-based analysis of transcriptional profiles from chemical perturbations experiments. 
 




20. DIGEP-Pred: web service for in silico prediction of drug-induced gene expression profiles based on 
structural formula. 
21. Multi-target drug repositioning by bipartite block-wise sparse multi-task learning. 
22. Integrating Clinical Phenotype and Gene Expression Data to Prioritize Novel Drug Uses. 
23. DrugSig: A resource for computational drug repositioning utilizing gene expression signatures. 
24. From gene networks to drugs: systems pharmacology approaches for AUD. 
25. Master Regulators Connectivity Map: A Transcription Factors-Centered Approach to Drug 
Repositioning. 
26. Repositioning drugs by targeting network modules: a Parkinson's disease case study. 
27. Transcriptional data: a new gateway to drug repositioning? 
28. Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer 
cell lines and pathway mechanisms of resistance. 
29. A computational method for drug repositioning using publicly available gene expression data. 
30. Identifying prognostic features by bottom-up approach and correlating to drug repositioning. 
31. Functional Module Connectivity Map (FMCM): a framework for searching repurposed drug 
compounds for systems treatment of cancer and an application to colorectal adenocarcinoma. 
32. GeneExpressionSignature: an R package for discovering functional connections using gene expression 
signatures. 
33. Drug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for 
Drug Repositioning in Cancer Therapy. 
34. Gene Vector Analysis (Geneva): a unified method to detect differentially-regulated gene sets and 
similar microarray experiments. 
35. Personalised drug repositioning for Clear Cell Renal Cell Carcinoma using gene expression. 
36. Pathway-based Bayesian inference of drug-disease interactions. 
37. DvD: An R/Cytoscape pipeline for drug repurposing using public repositories of gene expression 
data. 
38. Improved anticancer drug response prediction in cell lines using matrix factorization with similarity 
regularization. 
39. Drug-Path: a database for drug-induced pathways. 
40. Drug Repurposing Using Deep Embeddings of Gene Expression Profiles. 
 




41. Prioritizing therapeutics for lung cancer: an integrative meta-analysis of cancer gene signatures and 
chemogenomic data. 
42. A cross-species analysis method to analyze animal models' similarity to human's disease state. 
43. GDA, a web-based tool for Genomics and Drugs integrated analysis. 
44. cudaMap: a GPU accelerated program for gene expression connectivity mapping. 
45. Integrating systems biology sources illuminates drug action. 
46. Identification of small molecules enhancing autophagic function from drug network analysis. 
47. DSigDB: drug signatures database for gene set analysis. 
48. Support for phosphoinositol 3 kinase and mTOR inhibitors as treatment for lupus using in-silico drug-
repurposing analysis. 
49. Drug Repositioning through Systematic Mining of Gene Coexpression Networks in Cancer. 
50. Linking drug target and pathway activation for effective therapy using multi-task learning. 
51. Systematic Identification and Assessment of Therapeutic Targets for Breast Cancer Based on 
Genome-Wide RNA Interference Transcriptomes. 
52. Discovery of drug mode of action and drug repositioning from transcriptional responses. 
53. Cell-specific prediction and application of drug-induced gene expression profiles. 
54. Connection Map for Compounds (CMC): A Server for Combinatorial Drug Toxicity and Efficacy 
Analysis. 
55. Integrated analysis of numerous heterogeneous gene expression profiles for detecting robust disease-
specific biomarkers and proposing drug targets. 
56. Synergistic drug combinations from electronic health records and gene expression. 
57. Transcriptomic-Guided Drug Repositioning Supported by a New Bioinformatics Search Tool: 
geneXpharma. 
58. Drug repositioning framework by incorporating functional information. 
59. Designing Dietary Recommendations Using System Level Interactomics Analysis and Network-
Based Inference. 
60. BRCA-Monet: a breast cancer specific drug treatment mode-of-action network for treatment effective 
prediction using large scale microarray database. 
61. The use of a gene expression signature and connectivity map to repurpose drugs for bipolar disorder. 
 




62. Drug-repurposing identified the combination of Trolox C and Cytisine for the treatment of type 2 
diabetes. 
63. An integrated network platform for contextual prioritization of drugs and pathways. 
64. Discovery and preclinical validation of drug indications using compendia of public gene expression 
data. 
65. Using gene expression signatures to identify novel treatment strategies in gulf war illness. 
66. Probabilistic drug connectivity mapping. 
67. An integrative approach using real-world data to identify alternative therapeutic uses of existing 
drugs. 
68. Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug 
combinations. 
69. DMAP: a connectivity map database to enable identification of novel drug repositioning candidates. 
70. PREDICT: a method for inferring novel drug indications with application to personalized medicine. 
71. A network based approach to drug repositioning identifies plausible candidates for breast cancer and 
prostate cancer. 
72. ksRepo: a generalized platform for computational drug repositioning. 
73. Systematic drug safety evaluation based on public genomic expression (Connectivity Map) data: 
myocardial and infectious adverse reactions as application cases. 
74. Transcriptomic Analysis of the Host Response and Innate Resilience to Enterotoxigenic Escherichia 
coli Infection in Humans. 
75. Identification of common biological pathways and drug targets across multiple respiratory viruses 
based on human host gene expression analysis. 
76. Elucidating the modes of action for bioactive compounds in a cell-specific manner by large-scale 
chemically-induced transcriptomics. 
77. A Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and 
Repositioning Predictions. 
78. CellFateScout - a bioinformatics tool for elucidating small molecule signaling pathways that drive 
cells in a specific direction. 
79. A Large-Scale Gene Expression Intensity-Based Similarity Metric for Drug Repositioning. 
80. Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and 
prostate cancer. 
 




81. Exploring the molecular mechanisms of Traditional Chinese Medicine components using gene 
expression signatures and connectivity map. 
82. Introduction: Cancer Gene Networks. 
83. Bioinformatics methods in drug repurposing for Alzheimer's disease. 
84. Gene expression-based drug repurposing to target aging. 
85. Application of Atlas of Cancer Signalling Network in preclinical studies. 
86. gene2drug: a computational tool for pathway-based rational drug repositioning. 
87. Using Big Data to Discover Diagnostics and Therapeutics forGastrointestinal and Liver Diseases. 
88. NetwoRx: connecting drugs to networks and phenotypes in Saccharomyces cerevisiae. 
89. Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular 
carcinoma. 
90. Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional 
Signatures. 
91. PATIENT-SPECIFIC DATA FUSION FOR CANCER STRATIFICATION AND PERSONALISED 
TREATMENT. 
92. Classifying cancer genome aberrations by their mutually exclusive effects on transcription. 
93. Comparing structural and transcriptional drug networks reveals signatures of drug activity and toxicity 
in transcriptional responses. 
94. Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of 
dyslipidemia. 
95. Objective assessment of cancer genes for drug discovery. 
96. EMUDRA: Ensemble of Multiple Drug Repositioning Approaches to improve prediction accuracy. 
97. Mantra 2.0: an online collaborative resource for drug mode of action and repurposing by network 
analysis. 
98. Drug Targeting and Biomarkers in Head and Neck Cancers: Insights from Systems Biology Analyses. 
99. Prediction of anti-cancer drug response by kernelized multi-task learning. 
100. High-throughput screening for the identification of new therapeutic options for metastatic 
pheochromocytoma and paraganglioma. 
101. Computational identification of multi-omic correlates of anticancer therapeutic response. 
 




102. Signatures for drug repositioning. 
103. [Identification of key pathways and drug repurposing for anaplastic thyroid carcinoma by integrated 
bioinformatics analysis]. 
104. A Biologically-Based Computational Approach to Drug Repurposing for Anthrax Infection. 
105. A cellular genetics approach identifies gene-drug interactions and pinpoints drug toxicity pathway 
nodes. 
106. Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical 
properties. 
107. Identify potential drugs for cardiovascular diseases caused by stress-induced genes in vascular 
smooth muscle cells. 
108. Deciphering cellular biological processes to clinical application: a new perspective for Talpha1 
treatment targeting multiple diseases. 
109. Cancer Drug Response Profile scan (CDRscan): A Deep Learning Model That Predicts Drug 
Effectiveness from Cancer Genomic Signature. 
110. A subpathway-based method of drug reposition for polycystic ovary syndrome. 
111. Mining the transcriptome for rare disease therapies: a comparison of the efficiencies of two data 
mining approaches and a targeted cell-based drug screen. 
112. EHFPI: a database and analysis resource of essential host factors for pathogenic infection. 
113. In search for geroprotectors: in silico screening and in vitro validation of signalome-level mimetics 
of young healthy state. 
114. Drug repositioning discovery for early- and late-stage non-small-cell lung cancer. 
115. Exploration of the Anti-Inflammatory Drug Space Through Network Pharmacology: Applications 
for Drug Repurposing. 
116. Pathway analysis for drug repositioning based on public database mining. 
117. Rational drug repurposing using sscMap analysis in a HOX-TALE model of leukemia. 
118. Predicting High-Impact Pharmacological Targets by Integrating Transcriptome and Text-Mining 
Features. 
119. Integrative bioinformatic analyses of an oncogenomic profile reveal the biology of endometrial 
cancer and guide drug discovery. 
120. Computational approaches for drug repositioning and combination therapy design. 
 




121. Systems Biology-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap 
Insertional Mutagenesis. 
122. Drug discovery in the age of systems biology: the rise of computational approaches for data 
integration. 
123. Text Mining and Data Modeling of Karyotypes to aid in Drug Repurposing Efforts. 
124. Bioinformatics: Novel Insights from Genomic Information. 
125. Nucleosome Repositioning: A Novel Mechanism for Nicotine- and Cocaine-Induced Epigenetic 
Changes. 
126. Drug repositioning for schizophrenia and depression/anxiety disorders: A machine learning approach 
leveraging expression data. 
127. Systems biological understanding of the regulatory network and the possible therapeutic strategies 
for vascular calcification. 
128. Context-specific functional module based drug efficacy prediction. 
129. Antiviral effects of inhibiting host gene expression. 
130. The functional therapeutic chemical classification system. 
131. Drug repurposing in idiopathic pulmonary fibrosis filtered by a bioinformatics-derived composite 
score. 
132. Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug 
Repurposing Using Transcriptomic Data. 
133. Systematic discovery of drug action mechanisms by an integrated chemical genomics approach: 
identification of functional disparities between azacytidine and decitabine. 
134. A computational method for clinically relevant cancer stratification and driver mutation module 
discovery using personal genomics profiles. 
135. Integrative omics analyses broaden treatment targets in human cancer. 
136. Computational repositioning and preclinical validation of mifepristone for human vestibular 
schwannoma. 
137. NMR spectroscopy-based metabolic profiling of drug-induced changes in vitro can discriminate 
between pharmacological classes. 
138. Significance and suppression of redundant IL17 responses in acute allograft rejection by 
bioinformatics based drug repositioning of fenofibrate. 
 




139. Drug repositioning for non-small cell lung cancer by using machine learning algorithms and 
topological graph theory. 
140. Mining Exosomal Genes for Pancreatic Cancer Targets. 
141. Drug repurposing and therapeutic anti-microRNA predictions for inhibition of oxidized low-density 
lipoprotein-induced vascular smooth muscle cell-associated diseases. 
142. A chemical-genetic interaction map of small molecules using high-throughput imaging in cancer 
cells. 
143. Molecular property diagnostic suite for diabetes mellitus (MPDSDM): An integrated web portal for 
drug discovery and drug repurposing. 
144. Discovery of novel therapeutic properties of drugs from transcriptional responses based on multi-
label classification. 
145. Radiation protective effects of baclofen predicted by a computational drug repurposing strategy. 
146. Bioinformatic and biological avenues for understanding alcohol use disorder. 
147. Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. 
148. A Computational Workflow Translates a 58-Gene Signature to a Formalin-Fixed, Paraffin-
Embedded Sample-Based Companion Diagnostic for Personalized Treatment of the BRAF-Mutation-Like 
Subtype of Colorectal Cancers. 
149. Clobetasol and Halcinonide Act as Smoothened Agonists to Promote Myelin Gene Expression and 
RxRgamma Receptor Activation. 
150. Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems 
chemical biology analysis. 
151. Exploration and analysis of drug modes of action through feature integration. 
152. Predicting and characterizing selective multiple drug treatments for metabolic diseases and cancer. 
153. Transcriptomic profiling of human hippocampal progenitor cells treated with antidepressants and its 
application in drug repositioning. 
154. Neuroblastoma, a Paradigm for Big Data Science in Pediatric Oncology. 
155. siRNA Genome Screening Approaches to Therapeutic Drug Repositioning. 
156. Integrated Computational Analysis of Genes Associated with Human Hereditary Insensitivity to 
Pain. A Drug Repurposing Perspective. 
157. Myotonic dystrophy: candidate small molecule therapeutics. 
158. Drug-target based cross-sectional analysis of olfactory drug effects. 
 




159. Systems approach to the pharmacological actions of HDAC inhibitors reveals EP300 activities and 
convergent mechanisms of regulation in diabetes. 
160. Advances in epilepsy gene discovery and implications for epilepsy diagnosis and treatment. 
161. IMPACT web portal: oncology database integrating molecular profiles with actionable therapeutics. 
162. Combined analysis of gene expression and genome binding profiles identified potential therapeutic 
targets of ciclopirox in Ewing sarcoma. 
163. RDF SKETCH MAPS - KNOWLEDGE COMPLEXITY REDUCTION FOR PRECISION 
MEDICINE ANALYTICS. 
164. From the Viewpoint of Drug Metabolism Research. 
165. A structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 
ATPase. 
166. Personalizing Chinese medicine by integrating molecular features of diseases and herb ingredient 
information: application to acute myeloid leukemia. 
167. Drug repurposing for aging research using model organisms. 
168. A profound computational study to prioritize the disease-causing mutations in PRPS1 gene. 
169. High-Throughput Flow Cytometry Drug Combination Discovery with Novel Synergy Analysis 
Software, SynScreen. 
170. A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors. 
171. Integrative clinical transcriptomics analyses for new therapeutic intervention strategies: a psoriasis 
case study. 
172. Identification of Atorvastatin for Moderate toSevere Hidradenitis through Drug Repositioning Using 
Public Gene ExpressionDatasets. 
173. Drug Synergy Slows Aging and Improves Healthspan through IGF and SREBP Lipid Signaling. 
174. Olfactory drug effects approached from human-derived data. 
175. The prescribable drugs with efficacy in experimental epilepsies (PDE3) database for drug 
repurposing research in epilepsy. 
176. A network pharmacology approach reveals new candidate caloric restriction mimetics in C. elegans. 
177. A curated C. difficile strain 630 metabolic network: prediction of essential targets and inhibitors. 
178. Registered report: Discovery and preclinical validation of drug indications using compendia of 
public gene expression data. 
 




179. Mining mouse behavior for patterns predicting psychiatric drug classification. 
180. Identification of Alpha-Adrenergic Agonists asPotential Therapeutic Agents for Dermatomyositis 
through Drug-Repurposing Using Public Expression Datasets. 
181. Mixed outcomes for computational predictions. 
  
 




A2-2c. Leaf clusters under Cluster 48 
 There are two leaf clusters under Cluster 48: Cluster 13 (100) and Cluster 22 (176).   
*Cluster 13 focuses on drug-target interaction prediction;  
*Cluster 22 focuses on ligand binding-sites, protein-ligand interactions, and protein-protein interactions. 
  
 




A2-2c1. Cluster 13 record titles 
1. Drug-Target Interactions: Prediction Methods and Applications. 
2. Some Remarks on Prediction of Drug-Target Interaction with Network Models. 
3. Recent advances in the machine learning-based drug-target interaction prediction. 
4. Prediction of drug-target interaction by label propagation with mutual interaction information derived 
from heterogeneous network. 
5. Toward more realistic drug-target interaction predictions. 
6. Deep-Learning-Based Drug-Target Interaction Prediction. 
7. Link prediction in drug-target interactions network using similarity indices. 
8. Predicting Drug-Target Interactions With Multi-Information Fusion. 
9. Computational Prediction of Drug?Target Interactions Using Chemical, Biological, and Network 
Features. 
10. Computational Discovery of Putative Leads for Drug Repositioning through Drug-Target Interaction 
Prediction. 
11. Prediction of Human Drug Targets and Their Interactions Using Machine Learning Methods: Current 
and Future Perspectives. 
12. A network integration approach for drug-target interaction prediction and computational drug 
repositioning from heterogeneous information. 
13. Predicting drug-target interactions using restricted Boltzmann machines. 
14. Mining significant substructure pairs for interpreting polypharmacology in drug-target network. 
15. Predicting Drug-Target Interactions via Within-Score and Between-Score. 
16. Drug-target interaction prediction by integrating multiview network data. 
17. SELF-BLM: Prediction of drug-target interactions via self-training SVM. 
18. A computational approach to finding novel targets for existing drugs. 
19. Prediction of drug-target interactions for drug repositioning only based on genomic expression 
similarity. 
20. Drug-target interaction prediction: A Bayesian ranking approach. 
21. Drug-target interaction prediction by integrating chemical, genomic, functional and pharmacological 
data. 
 




22. Drug target prediction using adverse event report systems: a pharmacogenomic approach. 
23. Predicting drug-target interaction for new drugs using enhanced similarity measures and super-target 
clustering. 
24. Global optimization-based inference of chemogenomic features from drug-target interactions. 
25. Recommendation Techniques for Drug-Target Interaction Prediction and Drug Repositioning. 
26. SDTNBI: an integrated network and chemoinformatics tool for systematic prediction of drug-target 
interactions and drug repositioning. 
27. Large-Scale Prediction of Drug-Target Interaction: a Data-Centric Review. 
28. Screening drug-target interactions with positive-unlabeled learning. 
29. MPGraph: multi-view penalised graph clustering for predicting drug-target interactions. 
30. Prediction of drug-target interactions and drug repositioning via network-based inference. 
31. Computational-experimental approach to drug-target interaction mapping: A case study on kinase 
inhibitors. 
32. RepTB: a gene ontology based drug repurposing approach for tuberculosis. 
33. Drug-Target Networks. 
34. Polypharmacological Drug-target Inference for Chemogenomics. 
35. An improved approach for predicting drug-target interaction: proteochemometrics to molecular 
docking. 
36. Prediction of polypharmacological profiles of drugs by the integration of chemical, side effect, and 
therapeutic space. 
37. DT-Web: a web-based application for drug-target interaction and drug combination prediction 
through domain-tuned network-based inference. 
38. Predicting drug-target interactions using probabilistic matrix factorization. 
39. Open-source chemogenomic data-driven algorithms for predicting drug-target interactions. 
40. Improved prediction of drug-target interactions using regularized least squares integrating with kernel 
fusion technique. 
41. Large-Scale Off-Target Identification Using Fast and Accurate Dual Regularized One-Class 
Collaborative Filtering and Its Application to Drug Repurposing. 
42. Updates on drug-target network; facilitating polypharmacology and data integration by growth of 
DrugBank database. 
 




43. A simple mathematical approach to the analysis of polypharmacology and polyspecificity data. 
44. Identification of drug candidates and repurposing opportunities through compound-target interaction 
networks. 
45. Design of a tripartite network for the prediction of drug targets. 
46. BalestraWeb: efficient online evaluation of drug-target interactions. 
47. Computational Drug Target Screening through Protein Interaction Profiles. 
48. Clustering drug-drug interaction networks with energy model layouts: community analysis and drug 
repurposing. 
49. Drug Target Commons 2.0: a community platform for systematic analysis of drug-target interaction 
profiles. 
50. Analysis of A Drug Target-based Classification System using Molecular Descriptors. 
51. Predicting new indications for approved drugs using a proteochemometric method. 
52. Leveraging 3D chemical similarity, target and phenotypic data in the identification of drug-protein 
and drug-adverse effect associations. 
53. A New Method for Computational Drug Repositioning Using Drug Pairwise Similarity. 
54. Target-Based Drug Repositioning Using Large-Scale Chemical-Protein Interactome Data. 
55. The role of drug profiles as similarity metrics: applications to repurposing, adverse effects detection 
and drug-drug interactions. 
56. Network predicting drug's anatomical therapeutic chemical code. 
57. Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target 
Interactions. 
58. Drug repositioning by applying 'expression profiles' generated by integrating chemical structure 
similarity and gene semantic similarity. 
59. Drug repurposing based on drug-drug interaction. 
60. A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case. 
61. Mouse model phenotypes provide information about human drug targets. 
62. A Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases. 
63. Similarity-based prediction for Anatomical Therapeutic Chemical classification of drugs by 
integrating multiple data sources. 
 




64. Prediction of chemical-protein interactions network with weighted network-based inference method. 
65. C-SPADE: a web-tool for interactive analysis and visualization of drug screening experiments 
through compound-specific bioactivity dendrograms. 
66. In silico prediction of chemical mechanism of action via an improved network-based inference 
method. 
67. Large-scale Direct Targeting for Drug Repositioning and Discovery. 
68. Drug target central. 
69. Many approved drugs have bioactive analogs with different target annotations. 
70. Drug target prediction by multi-view low rank embedding. 
71. Prediction of drug indications based on chemical interactions and chemical similarities. 
72. Prediction of drug's Anatomical Therapeutic Chemical (ATC) code by integrating drug-domain 
network. 
73. REPRODUCIBLE DRUG REPURPOSING: WHEN SIMILARITY DOES NOT SUFFICE. 
74. A hybrid method for prediction and repositioning of drug Anatomical Therapeutic Chemical classes. 
75. Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching. 
76. Logical comparison over RDF resources in bio-informatics. 
77. Drug Repositioning Strategies for the Identification of Novel Therapies for Rheumatic Autoimmune 
Inflammatory Diseases. 
78. Predicting anatomic therapeutic chemical classification codes using tiered learning. 
79. Extracting drug-enzyme relation from literature as evidence for drug drug interaction. 
80. Relating anatomical therapeutic indications by the ensemble similarity of drug sets. 
81. In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against 
multiple life stages of Schistosoma mansoni. 
82. Realizing drug repositioning by adapting a recommendation system to handle the process. 
83. Concept-based semi-automatic classification of drugs. 
84. Exploring drug-target interaction networks of illicit drugs. 
85. Large-Scale Prediction of Beneficial Drug Combinations Using Drug Efficacy and Target Profiles. 
86. Drug Repurposing by Simulating Flow Through Protein-Protein Interaction Networks. 
 




87. Drug repositioning using in silico compound profiling. 
88. Target-similarity search using Plasmodium falciparum proteome identifies approved drugs with anti-
malarial activity and their possible targets. 
89. IDMap: facilitating the detection of potential leads with therapeutic targets. 
90. Clustering based drug-drug interaction networks for possible repositioning of drugs against EGFR 
mutations: Clustering based DDI networks for EGFR mutations. 
91. DrugBank 5.0: a major update to the DrugBank database for 2018. 
92. From malaria to cancer: Computational drug repositioning of amodiaquine using PLIP interaction 
patterns. 
93. Defining the Schistosoma haematobium kinome enables the prediction of essential kinases as anti-
schistosome drug targets. 
94. Genetic screens for the control of influenza virus replication: from meta-analysis to drug discovery. 
95. Protein localization vector propagation: a method for improving the accuracy of drug repositioning. 
96. Computational drug repositioning for peripheral arterial disease: prediction of anti-inflammatory and 
pro-angiogenic therapeutics. 
97. Predict drug permeability to blood-brain-barrier from clinical phenotypes: drug side effects and drug 
indications. 
98. Interaction and localization diversities of global and local hubs in human protein-protein interaction 
networks. 
99. Correction: Large-Scale Off-Target Identification Using Fast and Accurate Dual Regularized One-
Class Collaborative Filtering and Its Application to Drug Repurposing. 
100. US science: The Obama experiment. 
  
 




A2-2c2. Cluster 22 record titles 
1. eModel-BDB: a database of comparative structure models of drug-target interactions from the Binding 
Database. 
2. Polypharmacology rescored: protein-ligand interaction profiles for remote binding site similarity 
assessment. 
3. SMAP-WS: a parallel web service for structural proteome-wide ligand-binding site comparison. 
4. eMatchSite: sequence order-independent structure alignments of ligand binding pockets in protein 
models. 
5. Virtual target screening: validation using kinase inhibitors. 
6. ProBiS-ligands: a web server for prediction of ligands by examination of protein binding sites. 
7. Characterizing the pocketome of Mycobacterium tuberculosis and application in rationalizing 
polypharmacological target selection. 
8. Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key. 
9. Protein-ligand-based pharmacophores: generation and utility assessment in computational ligand 
profiling. 
10. Binding site matching in rational drug design: algorithms and applications. 
11. Identify drug repurposing candidates by mining the protein data bank. 
12. Reverse Screening Methods to Search for the Protein Targets of Chemopreventive Compounds. 
13. Large-scale detection of drug off-targets: hypotheses for drug repurposing and understanding side-
effects. 
14. Assessing protein kinase target similarity: Comparing sequence, structure, and cheminformatics 
approaches. 
15. Comparative assessment of strategies to identify similar ligand-binding pockets in proteins. 
16. BioGPS: The Music for the Chemo- and Bioinformatics Walzer. 
17. High-Throughput parallel blind Virtual Screening using BINDSURF. 
18. SPILLO-PBSS: detecting hidden binding sites within protein 3D-structures through a flexible 
structure-based approach. 
19. In Silico target fishing: addressing a "Big Data" problem by ligand-based similarity rankings with data 
fusion. 
20. BioGPS: navigating biological space to predict polypharmacology, off-targeting, and selectivity. 
 




21. Predicting targeted polypharmacology for drug repositioning and multi- target drug discovery. 
22. An integrated structure- and system-based framework to identify new targets of metabolites and 
known drugs. 
23. Detection of Binding Site Molecular Interaction Field Similarities. 
24. TargetHunter: an in silico target identification tool for predicting therapeutic potential of small 
organic molecules based on chemogenomic database. 
25. Structure Investigation, Enrichment Analysis and Structure-based Repurposing of FDA-approved 
Drugs as Inhibitors of BET-BRD4. 
26. Local Alignment of Ligand Binding Sites in Proteins for Polypharmacology and Drug Repositioning. 
27. Chemical-protein interactome and its application in off-target identification. 
28. Homopharma: a new concept for exploring the molecular binding mechanisms and drug repurposing. 
29. Computational profiling of bioactive compounds using a target-dependent composite workflow. 
30. A large-scale computational approach to drug repositioning. 
31. Docking-based inverse virtual screening: methods, applications, and challenges. 
32. From laptop to benchtop to bedside: structure-based drug design on protein targets. 
33. TarPred: a web application for predicting therapeutic and side effect targets of chemical compounds. 
34. RepurposeVS: A Drug Repurposing-Focused Computational Method for Accurate Drug-Target 
Signature Predictions. 
35. Exploring polypharmacology using a ROCS-based target fishing approach. 
36. Structural analysis of protein tyrosine phosphatase 1B reveals potentially druggable allosteric binding 
sites. 
37. What is the potential of structure-based target prediction methods? 
38. Proteome-scale docking: myth and reality. 
39. Exploring Polypharmacology in Drug Discovery and Repurposing Using the CANDO Platform. 
40. Old friends in new guise: repositioning of known drugs with structural bioinformatics. 
41. PDID: database of molecular-level putative protein-drug interactions in the structural human 
proteome. 
42. ChemMapper: a versatile web server for exploring pharmacology and chemical structure association 
based on molecular 3D similarity method. 
 




43. Bioinformatics and Drug Discovery. 
44. Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate 
Synthase Case. 
45. Drugs Polypharmacology by In Silico Methods: New Opportunities in Drug Discovery. 
46. The CARLSBAD database: a confederated database of chemical bioactivities. 
47. SPIDR: small-molecule peptide-influenced drug repurposing. 
48. PROMISCUOUS: a database for network-based drug-repositioning. 
49. Implications of the small number of distinct ligand binding pockets in proteins for drug discovery, 
evolution and biochemical function. 
50. Application of the 4D fingerprint method with a robust scoring function for scaffold-hopping and 
drug repurposing strategies. 
51. Uncovering Drug Mechanism of Action by Proteome Wide- Identification of Drug-Binding Proteins. 
52. Characterizing protein domain associations by Small-molecule ligand binding. 
53. A machine learning-based method to improve docking scoring functions and its application to drug 
repurposing. 
54. Docking of a novel DNA methyltransferase inhibitor identified from high-throughput screening: 
insights to unveil inhibitors in chemical databases. 
55. Anti-infectious drug repurposing using an integrated chemical genomics and structural systems 
biology approach. 
56. Prediction of off-target drug effects through data fusion. 
57. MOST: most-similar ligand based approach to target prediction. 
58. Detecting drug promiscuity using Gaussian ensemble screening. 
59. Reverse docking: a powerful tool for drug repositioning and drug rescue. 
60. A combined systems and structural modeling approach repositions antibiotics for Mycoplasma 
genitalium. 
61. Incorporating Protein Dynamics Through Ensemble Docking in Machine Learning Models to Predict 
Drug Binding. 
62. Review and comparative assessment of similarity-based methods for prediction of drug-protein 
interactions in the druggable human proteome. 
 




63. A drug target slim: using gene ontology and gene ontology annotations to navigate protein-ligand 
target space in ChEMBL. 
64. Comprehensive prediction of drug-protein interactions and side effects for the human proteome. 
65. Methods to Profile the Macromolecular Targets of Small Compounds. 
66. A novel multi-modal drug repurposing approach for identification of potent ACK1 inhibitors. 
67. GES polypharmacology fingerprints: a novel approach for drug repositioning. 
68. A review of MED-SuMo applications. 
69. Orphan receptor ligand discovery by pickpocketing pharmacological neighbors. 
70. Explicit Drug Re-positioning: Predicting Novel Drug-Target Interactions of the Shelved Molecules 
with QM/MM Based Approaches. 
71. The purchasable chemical space: a detailed picture. 
72. Tools for in silico target fishing. 
73. Enhancing the Enrichment of Pharmacophore-Based Target Prediction for the Polypharmacological 
Profiles of Drugs. 
74. Advances in the Development of Shape Similarity Methods and Their Application in Drug Discovery. 
75. Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective. 
76. Using reverse docking for target identification and its applications for drug discovery. 
77. Finding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-
based systems biology approach. 
78. CANDO and the infinite drug discovery frontier. 
79. Exploring the anti-proliferative activity of Pelargonium sidoides DC with in silico target identification 
and network pharmacology. 
80. Molecular Connectivity Predefines Polypharmacology: Aliphatic Rings, Chirality, and sp3 Centers 
Enhance Target Selectivity. 
81. Checking the STEP-Associated Trafficking and Internalization of Glutamate Receptors for Reduced 
Cognitive Deficits: A Machine Learning Approach-Based Cheminformatics Study and Its Application for 
Drug Repurposing. 
82. Discovery of Novel Liver-Stage Antimalarials through Quantum Similarity. 
83. Systematic Prioritization of Druggable Mutations in 5000 Genomes Across 16 Cancer Types Using a 
Structural Genomics-based Approach. 
 




84. Data Sets Representative of the Structures and Experimental Properties of FDA-Approved Drugs. 
85. DPDR-CPI, a server that predicts Drug Positioning and Drug Repositioning via Chemical-Protein 
Interactome. 
86. Exploring the associations between drug side-effects and therapeutic indications. 
87. Human enterovirus 71 protein interaction network prompts antiviral drug repositioning. 
88. Network measures for chemical library design. 
89. Development of a Sigma-2 Receptor affinity filter through a Monte Carlo based QSAR analysis. 
90. Target Fishing by Cross-Docking to Explain Polypharmacological Effects. 
91. Discovery of Surface Target Proteins Linking Drugs, Molecular Markers, Gene Regulation, Protein 
Networks, and Disease by Using a Web-Based Platform Targets-search. 
92. Assessing relative bioactivity of chemical substances using quantitative molecular network topology 
analysis. 
93. Reactions of model proteins with aurothiomalate, a clinically established gold(I) drug: The 
comparison with auranofin. 
94. Exploring the relationship between drug side-effects and therapeutic indications. 
95. FDA approved drugs complexed to their targets: evaluating pose prediction accuracy of docking 
protocols. 
96. The Mu.Ta.Lig. Chemotheca: A Community-Populated Molecular Database for Multi-Target Ligands 
Identification and Compound-Repurposing. 
97. Identifying the macromolecular targets of de novo-designed chemical entities through self-organizing 
map consensus. 
98. Cyclotides as Tools in Chemical Biology. 
99. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking 
(MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-
6/GP130 interface. 
100. Polypharmacology: challenges and opportunities in drug discovery. 
101. Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems 
Pharmacology. 
102. IsoMIF Finder: online detection of binding site molecular interaction field similarities. 
103. Recognizing drug targets using evolutionary information: implications for repurposing FDA-
approved drugs against Mycobacterium tuberculosis H37Rv. 
 




104. High-throughput identification of off-targets for the mechanistic study of severe adverse drug 
reactions induced by analgesics. 
105. Can sodium/hydrogen exchange inhibitors be repositioned for treating attention deficit hyperactivity 
disorder? An in silico approach. 
106. Exploiting large-scale drug-protein interaction information for computational drug repurposing. 
107. Visual Analysis of Biological Activity Data with Scaffold Hunter. 
108. The bitter pill: clinical drugs that activate the human bitter taste receptor TAS2R14. 
109. A potential target of Tanshinone IIA for acute promyelocytic leukemia revealed by inverse docking 
and drug repurposing. 
110. [Research advance in the drug target prediction based on chemoinformatics]. 
111. DockingApp: a user friendly interface for facilitated docking simulations with AutoDock Vina. 
112. Targeting the off-targets: a computational bioinformatics approach to understanding the 
polypharmacology of nelfinavir. 
113. DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the 
chemical-protein interactome. 
114. Identification of cisapride as new inhibitor of putrescine uptake in Trypanosoma cruzi by combined 
ligand- and structure-based virtual screening. 
115. Mapping Protein Targets of Bioactive Small Molecules Using Lipid-Based Chemical Proteomics. 
116. Structure based investigation on the binding interaction of transport proteins in leishmaniasis: 
insights from molecular simulation. 
117. Computational tools for polypharmacology and repurposing. 
118. Beyond Channel Activity: Protein-Protein Interactions Involving Viroporins. 
119. Pharmacological use of a novel scaffold, anomeric N,N-diarylamino tetrahydropyran: molecular 
similarity search, chemocentric target profiling, and experimental evidence. 
120. Prediction of chemical-protein interactions: multitarget-QSAR versus computational chemogenomic 
methods. 
121. Multiscale modelling of relationships between protein classes and drug behavior across all diseases 
using the CANDO platform. 
122. In Silico Receptorome Screening of Antipsychotic Drugs. 
123. Benchmarking human protein complexes to investigate drug-related systems and evaluate predicted 
protein complexes. 
 




124. Insights from pharmacological similarity of epigenetic targets in epipolypharmacology. 
125. Accidental interaction between PDZ domains and diclofenac revealed by NMR-assisted virtual 
screening. 
126. Compound promiscuity: what can we learn from current data? 
127. SWEETLEAD: an in silico database of approved drugs, regulated chemicals, and herbal isolates for 
computer-aided drug discovery. 
128. Steroids-specific target library for steroids target prediction. 
129. DeCAF-Discrimination, Comparison, Alignment Tool for 2D PHarmacophores. 
130. POAP: A GNU parallel based multithreaded pipeline of open babel and AutoDock suite for boosted 
high throughput virtual screening. 
131. Cascade Ligand- and Structure-Based Virtual Screening to Identify New Trypanocidal Compounds 
Inhibiting Putrescine Uptake. 
132. Multivariate analysis in the identification of biological targets for designed molecular structures: the 
BIOTA protocol. 
133. How Reliable Are Ligand-Centric Methods for Target Fishing? 
134. Catecholamine receptors: prototypes for GPCR-based drug discovery. 
135. New opportunities for kinase drug repurposing and target discovery. 
136. Activity-Based Protein Profiling for the Study of Parasite Biology. 
137. Heme Oxygenase Database (HemeOxDB) and QSAR Analysis of Isoform?1 Inhibitors. 
138. Prediction of structure of human WNT-CRD (FZD) complex for computational drug repurposing. 
139. Macromolecular target prediction by self-organizing feature maps. 
140. A quality alert and call for improved curation of public chemistry databases. 
141. [Adverse Effect Predictions Based on Computational Toxicology Techniques and Large-scale 
Databases]. 
142. Insights into the Modulation of Dopamine Transporter Function by Amphetamine, Orphenadrine, 
and Cocaine Binding. 
143. Microbial protein targets: towards understanding and intervention. 
144. Hit Recycling: Discovery of a Potent Carbonic Anhydrase Inhibitor by in Silico Target Fishing. 
 




145. Pharmacophore-based screening and drug repurposing exemplified on glycogen synthase kinase-3 
inhibitors. 
146. A rapid and affordable screening platform for membrane protein trafficking. 
147. How good are publicly available web services that predict bioactivity profiles for drug repurposing? 
148. A chemo-centric view of human health and disease. 
149. Drug repurposing: mining protozoan proteomes for targets of known bioactive compounds. 
150. Identification of FDA-approved drugs that computationally bind to MDM2. 
151. Identification of Potential Therapeutics to Conquer Drug Resistance in Salmonella typhimurium: 
Drug Repurposing Strategy. 
152. Correction to "Machine learning-based method to improve docking scoring functions and its 
application to drug repurposing". 
153. Drug Side Effect Profiles as Molecular Descriptors for Predictive Modeling of Target Bioactivity. 
154. Many drugs contain unique scaffolds with varying structural relationships to scaffolds of currently 
available bioactive compounds. 
155. Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking 
(MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and 
activator of transcription 3 (STAT3). 
156. A tool to utilize adverse effect profiles to identify brain-active medications for repurposing. 
157. Structural analysis of dihydrofolate reductases enables rationalization of antifolate binding affinities 
and suggests repurposing possibilities. 
158. Molecular Topology and other Promiscuity Determinants as Predictors of Therapeutic Class- A 
Theoretical Framework to guide Drug Repositioning? 
159. Repurposing of Potent Drug Candidates for Multiparasite Targeting. 
160. Virtual screening and repositioning of inconclusive molecules of beta-lactamase Bioassays-A data 
mining approach. 
161. HEDD: the human epigenetic drug database. 
162. G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many 
Drugs? 
163. Substrate-driven mapping of the degradome by comparison of sequence logos. 
164. DRABAL: novel method to mine large high-throughput screening assays using Bayesian active 
learning. 
 




165. Repurposed FDA-approved drugs targeting genes influencing aging can extend lifespan and 
healthspan in rotifers. 
166. Quantification of quaternary structure stability in aggregation-prone proteins under physiological 
conditions: the transthyretin case. 
167. Design of efficient computational workflows for in silico drug repurposing. 
168. Repurposing FDA-approved drugs for anti-aging therapies. 
169. Computational Drug Repositioning by Target Hopping: A Use Case in Chagas Disease. 
170. Repositioning organohalogen drugs: a case study for identification of potent B-Raf V600E inhibitors 
via docking and bioassay. 
171. Database of Optimized Proteomic Quantitative Methods for Human Drug Disposition-Related 
Proteins for Applications in Physiologically Based Pharmacokinetic Modeling. 
172. Drug repositioning for enzyme modulator based on human metabolite-likeness. 
173. Understanding organellar protein folding capacities and assessing their pharmacological modulation 
by small molecules. 
174. MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that 
Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia. 
175. Anticonvulsant activity of artificial sweeteners: a structural link between sweet-taste receptor T1R3 
and brain glutamate receptors. 
176. Predicting unintended effects of drugs based on off-target tissue effects.  
 




A2-2d. Leaf clusters under Cluster 49 
 There are four leaf clusters under Cluster 49: Cluster 9 (37), Cluster 20 (91), Cluster 26 (86), and 
Cluster 29 (167).   
*Cluster 9 focuses on rare diseases;  
*Cluster 20 focuses on computational drug repositioning;  
*Cluster 26 focuses on marketing aspects of drug repurposing;  
*Cluster 29 focuses on drug development and discovery. 
  
 




A2-2d1. Cluster 9 record titles 
1. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan 
diseases. 
2. Computational drug repositioning for rare diseases in the era of precision medicine. 
3. Rare Diseases: Drug Discovery and Informatics Resource. 
4. Trends of Clinical Trials for Drug Development in Rare Diseases. 
5. Large-scale computational drug repositioning to find treatments for rare diseases. 
6. Collaboration for rare disease drug discovery research. 
7. Drug discovery and development for rare genetic disorders. 
8. Repositioning 'old' drugs to treat rare diseases: arguing from the mechanism of action. 
9. Potential Reuse of Oncology Drugs in the Treatment of Rare Diseases. 
10. High-content drug screening for rare diseases. 
11. In silico repositioning of approved drugs for rare and neglected diseases. 
12. eRepo-ORP: Exploring the Opportunity Space to Combat Orphan Diseases with Existing Drugs. 
13. The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to 
foster orphan drug development. 
14. Finding promiscuous old drugs for new uses. 
15. Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French 
medical pharmacology. 
16. Drug repositioning for orphan diseases. 
17. Repositioning Drugs for Rare Immune Diseases: Hopes and Challenges for a Precision Medicine. 
18. A generalizable pre-clinical research approach for orphan disease therapy. 
19. [Possible framework and best practices in the future for prescriptions outside market authorization 
indications for rare diseases?]. 
20. Incentives to Repurpose Existing Drugs for Orphan Indications. 
21. Transcriptomic RNAseq drug screen in cerebrocortical cultures: toward novel neurogenetic disease 
therapies. 
22. Personalized drug discovery: HCA approach optimized for rare diseases at Tel Aviv University. 
 




23. The roles of academia, rare diseases, and repurposing in the development of the most transformative 
drugs. 
24. Affordable orphan drugs: a role for not-for-profit organizations. 
25. Shining a light in the black box of orphan drug pricing. 
26. Drug repositioning can accelerate discovery of pharmacological chaperones. 
27. Concept Modeling-based Drug Repositioning. 
28. NFFinder: an online bioinformatics tool for searching similar transcriptomics experiments in the 
context of drug repositioning. 
29. The Power of Rare: An Opportunity to Repurpose an Old Drug for Mitochondrial Cardiomyopathy. 
30. New Therapeutic Uses for Existing Drugs. 
31. Drug repositioning in sarcomas and other rare tumors. 
32. The Molecular Revolution in Cutaneous Biology: Emerging Landscape in Genomic Dermatology: 
New Mechanistic Ideas, Gene Editing, and Therapeutic Breakthroughs. 
33. Infectious diseases. Drug developers finally take aim at a neglected disease. 
34. [What's new in dermatology?]. 
35. [Baclofen: Innovative treatment or French controversy?]. 
36. Biomedicine. NIH's secondhand shop for tried-and-tested drugs. 
37. NIH gambles on recycled drugs. 
  
 




A2-2d2. Cluster 20 record titles 
1. Drug repositioning: identifying and developing new uses for existing drugs. 
2. Computational and experimental advances in drug repositioning for accelerated therapeutic 
stratification. 
3. Computational drug repositioning for cancer therapeutics. 
4. Exploiting drug-disease relationships for computational drug repositioning. 
5. Drug repositioning from the combined evaluation of phenotypic and target-based screening. 
6. A Review of Computational Drug Repositioning Approaches. 
7. Computational Drug Repositioning: A Lateral Approach to Traditional Drug Discovery? 
8. A survey of current trends in computational drug repositioning. 
9. Challenges and opportunities of drug repositioning. 
10. Review of Drug Repositioning Approaches and Resources. 
11. High-throughput drug repositioning for the discovery of new treatments for Chagas disease. 
12. Drug repositioning: re-investigating existing drugs for new therapeutic indications. 
13. A review of validation strategies for computational drug repositioning. 
14. Toward better drug repositioning: prioritizing and integrating existing methods into efficient 
pipelines. 
15. Recent advances in drug repositioning for the discovery of new anticancer drugs. 
16. In vitro screening for drug repositioning. 
17. In silico drug repositioning: what we need to know. 
18. The value of drug repositioning in the current pharmaceutical market. 
19. Serological biochemical markers of surrogate efficacy and safety as a novel approach to drug 
repositioning. 
20. Mining drug-disease relationships as a complement to medical genetics-based drug repositioning: 
Where a recommendation system meets genome-wide association studies. 
21. Drug repositioning approaches to parasitic diseases: a medicinal chemistry perspective. 
22. Back to the future - Is the drug repositioning concept applicable to vaccines? 
23. Computational and Practical Aspects of Drug Repositioning. 
 




24. Drug repositioning, a new alternative in infectious diseases. 
25. Novel insight into drug repositioning: Methylthiouracil as a case in point. 
26. In Silico Chemogenomics Drug Repositioning Strategies for Neglected Tropical Diseases. 
27. Drug repositioning summit: finding new routes to success. 
28. Drug repositioning for personalized medicine. 
29. Systematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, 
biological and epidemiological factors influencing drug repositioning. 
30. An integrated dataset for in silico drug discovery. 
31. In vivo phenotypic screening: clinical proof of concept for a drug repositioning approach. 
32. Drug combination therapy increases successful drug repositioning. 
33. Online structure-based screening of purchasable approved drugs and natural compounds: retrospective 
examples of drug repositioning on cancer targets. 
34. A standard database for drug repositioning. 
35. Drug repositioning by structure-based virtual screening. 
36. Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning. 
37. Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario. 
38. Leveraging Population-Based Clinical Quantitative Phenotyping for Drug Repositioning. 
39. Identification of anti-melanogenic natural compounds from Galega officinalis and further drug 
repositioning. 
40. Neglected Tropical Protozoan Diseases: Drug Repositioning as a Rational Option. 
41. Reply to Rational drug repositioning by medical genetics. 
42. Rational drug repositioning by medical genetics. 
43. Drug repositioning: playing dirty to kill pain. 
44. Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine 
and saquinavir. 
45. DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on 
patient survival information. 
46. Pharmacological approach for drug repositioning against cardiorenal diseases. 
 




47. Drug repositioning for treatment of movement disorders: from serendipity to rational discovery 
strategies. 
48. Laying in silico pipelines for drug repositioning: a paradigm in ensemble analysis for 
neurodegenerative diseases. 
49. [Drug Repositioning Research Utilizing a Large-scale Medical Claims Database to Improve Survival 
Rates after Cardiopulmonary Arrest]. 
50. Nonprofit disease groups earmark grants for drug repositioning. 
51. Drug repositioning and repurposing: terminology and definitions in literature. 
52. A Network-Biology Informed Computational Drug Repositioning Strategy to Target Disease Risk 
Trajectories and Comorbidities of Peripheral Artery Disease. 
53. Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds. 
54. Editorial: Drug Repositioning: Current Advances and Future Perspectives. 
55. Baseline Regularization for Computational Drug Repositioning with Longitudinal Observational 
Data. 
56. The Importance of Bioactivation in Computer-Guided Drug Repositioning. Why the Parent Drug is 
Not Always Enough. 
57. Drug Repositioning and Off-Label Use-Finding the Balance and Understanding the Differences: 
Interview with David Cavalla, MA, PhD, Founder, Numedicus. 
58. Computational Drug Repositioning Using Continuous Self-Controlled Case Series. 
59. Systematic evaluation of drug-disease relationships to identify leads for novel drug uses. 
60. Systematic drug repositioning through mining adverse event data in ClinicalTrials.gov. 
61. Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases. 
62. Challenges in secondary analysis of high throughput screening data. 
63. Drug screening: Drug repositioning needs a rethink. 
64. Drug Signature-based Finding of Additional Clinical Use of LC28-0126 for Neutrophilic Bronchial 
Asthma. 
65. A Practical Guide for Exploring Opportunities of Repurposing Drugs for CNS Diseases in Systems 
Biology. 
66. Genomics-enabled drug repositioning and repurposing: insights from an IOM Roundtable activity. 
67. Pioneering government-sponsored drug repositioning collaborations: progress and learning. 
 




68. Correction to: Realizing drug repositioning by adapting a recommendation system to handle the 
process. 
69. The CTSA Pharmaceutical Assets Portal - a public-private partnership model for drug repositioning. 
70. PhenoPredict: A disease phenome-wide drug repositioning approach towards schizophrenia drug 
discovery. 
71. Applications and implications of heparin and protamine in tissue engineering and regenerative 
medicine. 
72. Application of drug repositioning strategy to TOFISOPAM. 
73. Therapeutic drug repositioning using personalized proteomics of liquid biopsies. 
74. Recycling side-effects into clinical markers for drug repositioning. 
75. Phenytoin repositioned in wound healing: clinical experience spanning 60 years. 
76. New therapeutic bearings for repositioned drugs. 
77. Mefloquine neurotoxicity and gap junction blockade: critical insights in drug repositioning. 
78. [Drug repositioning in neuro-oncology-targeting GSK3beta for glioblastoma]. 
79. Computational repositioning and experimental validation of approved drugs for HIF-prolyl 
hydroxylase inhibition. 
80. Overcoming Obstacles to Drug Repositioning in Japan. 
81. Medical genetic inspirations for anticancer drug repurposing. 
82. Exploiting drug repositioning and the brain microenvironment to treat brain metastases. 
83. [Discovering L-type calcium channels inhibitors of antihypertensive drugs based on drug 
repositioning]. 
84. The Immunogenetics of Psoriasis and Implications for Drug Repositioning. 
85. Measuring cognitive effects: cognition in drug development and repositioning. 
86. Interview with Farid Khan, PhD. 
87. Interview with Raul Insa, MD, PhD. 
88. Encouraging New Uses for Old Drugs. 
89. Correction: In Silico Repositioning-Chemogenomics Strategy Identifies New Drugs with Potential 
Activity against Multiple Life Stages of Schistosoma mansoni. 
90. Current Progress in Bioinformatics 2016. 
 




91. Make better, safer biomaterials. 
  
 




A2-2d3. Cluster 26 record titles 
1. The year's new drugs and biologics--2006. 
2. The year's new drugs and biologics--2007. 
3. Editorial: Old Drugs Learn New Tricks: Advances and Applications for Drug Repurposing. 
4. The Year's New Drugs & Biologics - 2009. 
5. The year's new drugs & biologics - 2008. 
6. Scientific advice - is drug repurposing missing a trick? 
7. Filling the gap in CNS drug development: evaluation of the role of drug repurposing. 
8. Repurposing medicinal compounds for blood cancer treatment. 
9. Challenges and Benefits of Repurposing Products for Use during a Radiation Public Health 
Emergency: Lessons Learned from Biological Threats and other Disease Treatments. 
10. Drug repurposing from the perspective of pharmaceutical companies. 
11. Drug reformulations and repositioning in the pharmaceutical industry and their impact on market 
access: regulatory implications. 
12. Editorial: computational methods for drug repurposing. 
13. Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: 
reassessment of nomenclature. 
14. The promise of genomics-based drug repurposing. 
15. Regulatory pitfalls and opportunities when repurposing for inhalation therapy. 
16. Drug Repurposing as An Efficient Strategy In Drug Development - Example Of Cns Area. 
17. Purposeful learning with drug repurposing. 
18. Challenges and Benefits of Repurposing Licensed/Approved/Cleared Products for a Radiation 
Indication. 
19. Drug repurposing in pharmaceutical industry and its impact on market access: market access 
implications. 
20. Overcoming Drug Development Bottlenecks With Repurposing: Old drugs learn new tricks. 
21. [Development of new indications for old products: difficulties and search for solutions]. 
22. Lost interest for existing compounds: New boosts. 
 




23. Teaching old drugs new tricks. 
24. Can you teach old drugs new tricks? 
25. Extensions of indication throughout the drug product lifecycle: a quantitative analysis. 
26. Industrial perspective of gastroretentive drug delivery systems: physicochemical, biopharmaceutical, 
technological and regulatory consideration. 
27. Drug repurposing and adverse event prediction using high-throughput literature analysis. 
28. Drug repurposing in oncology--patient and health systems opportunities. 
29. Systematic drug repurposing through text mining. 
30. Drug repurposing in pediatrics and pediatric hematology oncology. 
31. Overcoming the legal and regulatory barriers to drug repurposing. 
32. Expanding the scope of drug repurposing in pediatrics: the Children's Pharmacy Collaborative. 
33. Wish-fulfilling jewel pills: Tibetan medicines from exclusivity to ubiquity. 
34. Teaching Old Drugs New Tricks: Repositioning Pharmaceuticals for Bench to Bedside Success. 
35. Using Social Media Data to Identify Potential Candidates for Drug Repurposing: A Feasibility Study. 
36. Biocomputing drug repurposing toward targeted therapies. 
37. Drug Repurposing for the Development of Novel Analgesics. 
38. Retrospective clinical analysis for drug rescue: for new indications or stratified patient groups. 
39. Medication Repurposing in Pediatric Patients: Teaching Old Drugs New Tricks. 
40. Regulatory exclusivities for medicinal products for human use in the EU. 
41. Molecular Docking for Identification of Potential Targets for Drug Repurposing. 
42. Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead. 
43. Drug repurposing and the medicinal chemist. 
44. How Much Nonclinical Safety Data Are Required for a Clinical Study in Ophthalmology? 
45. The Rescue and Repurposing of Pharmaceuticals: Augmenting the Drug Development Paradigm. 
46. A Special Focus on Drug Repurposing, Rescue, and Repositioning. 
47. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of 
supplemental indications. 
 




48. The promise and challenges of drug repurposing in psychiatry. 
49. Hangover free! The social and material trajectories of PartySmart. 
50. Drug repurposing programmes get lift off. 
51. [Dutch Medicines Act also applicable to repurposing]. 
52. Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. 
Part I. 
53. [New indications for existing drugs; repurposing in psychiatry and addiction medicine]. 
54. APT drug R&D: the right active ingredient in the right presentation for the right therapeutic use. 
55. Changes on the Horizon for Drug Repurposing, Rescue, and Repositioning at ASSAY. 
56. Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. 
Part II. 
57. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for 
children and adolescents with cancer. 
58. Why Do Promising Therapies Stall in Development and How Can We Move Them Forward? 
59. Drug repurposing a reality: from computers to the clinic. 
60. Editorial (Thematic Issue: Drug Reprofiling: An Alternative Path to Drug Discovery). 
61. A bibliometric review of drug repurposing. 
62. Mendelian randomization: a novel approach for the prediction of adverse drug events and drug 
repurposing opportunities. 
63. EDITORIAL: Repurposing Niacin as Antiplatelet Drug? 
64. Formalizing drug indications on the road to therapeutic intent. 
65. Pimping up Drugs Recovered, Superannuated and Under Exploited Drugs - An Introduction to the 
Basics of Drug Reprofiling. 
66. NCATS launches drug repurposing program. 
67. Inventing new therapies without reinventing the wheel: the power of drug repurposing. 
68. Editorial: Computational and Experimental Approaches in Multi-target Pharmacology. 
69. Creating New Economic Incentives for Repurposing Generic Drugs for Unsolved Diseases Using 
Social Finance. 
70. Hard Drug Repurposing for Precision Oncology: The Missing Link? 
 




71. Recent European legal developments on second medical uses and dosage regimes. 
72. Drug repurposing and beyond: the fundamental role of pharmacology. 
73. Supplementary protection certificates on reformulations and new uses after Neurim: where do we go 
from here? 
74. Second act: Drug repurposing gets a boost as academic researchers join the search for novel uses of 
existing drugs. 
75. Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic 
potential. 
76. Busting the billion-dollar myth: how to slash the cost of drug development. 
77. Drug Repurposing and Artificial Intelligence: From Liaison to Marriage. 
78. Finding Hsp90 inhibitors by drug repurposing: the power of chemical genetics. 
79. Drug repurposing to target proteostasis and prevent neurodegeneration: accelerating translational 
efforts. 
80. New Formulations of Old Analgesics and Repurposing of Old Drugs as "New" Analgesics. 
81. The Drug Repurposing Hub: a next-generation drug library and information resource. 
82. New Indications and a Sense of (Re)purpose. 
83. Integrative cancer pharmacogenomics to establish drug mechanism of action: drug repurposing. 
84. [Exception drugs status: specific characteristics and the role in the proper use of drugs]. 
85. Could repurposing existing drugs be an efficient protective method against microbial biologic threats? 
86. Advocating for mutually beneficial access to shelved compounds. 
  
 




A2-2d4. Cluster 29 record titles 
1. A Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery 
and the Advancement of Personalized Medicine. 
2.  [Identification of a molecular mechanism for actions of existing medicines and its application for drug 
development]. 
3. Drug discovery in a multidimensional world: systems, patterns, and networks. 
4. Drug discovery and development focusing on existing medicines: drug re-profiling strategy. 
5. Contributions from emerging transcriptomics technologies and computational strategies for drug 
discovery. 
6. Drug repurposing: translational pharmacology, chemistry, computers and the clinic. 
7. Quality by design (QbD) approach of pharmacogenomics in drug designing and formulation 
development for optimization of drug delivery systems. 
8. High-field MRS in clinical drug development. 
9. An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs. 
10. Bioinformatics in translational drug discovery. 
11. Use of big data in drug development for precision medicine. 
12. The University of New Mexico Center for Molecular Discovery. 
13. Harnessing Polypharmacology with Computer-Aided Drug Design and Systems Biology. 
14. Drug discovery in academia. 
15. Systems chemical biology and the Semantic Web: what they mean for the future of drug discovery 
research. 
16. In silico methods to address polypharmacology: current status, applications and future perspectives. 
17. Renovation as innovation: is repurposing the future of drug discovery research? 
18. Computational polypharmacology: a new paradigm for drug discovery. 
19. Applications of chemogenomic library screening in drug discovery. 
20. Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery. 
21. Target repurposing for neglected diseases. 
22. Advancing cancer drug discovery towards more agile development of targeted combination therapies. 
 




23. Expediting the Design, Discovery and Development of Anticancer Drugs using Computational 
Approaches. 
24. Reverse pharmacognosy: another way to harness the generosity of nature. 
25. Integrative methods for analyzing big data in precision medicine. 
26. The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development. 
27. Genomic medicine: a decade of successes, challenges, and opportunities. 
28. The opportunities of mining historical and collective data in drug discovery. 
29. The prince and the pauper. A tale of anticancer targeted agents. 
30. Drug discovery for neglected tropical diseases at the Sandler Center. 
31. Computational approaches for innovative antiepileptic drug discovery. 
32. Chemical & RNAi screening at MSKCC: a collaborative platform to discover & repurpose drugs to 
fight disease. 
33. Recent trends and future prospects in computational GPCR drug discovery: from virtual screening to 
polypharmacology. 
34. Systems biology-embedded target validation: improving efficacy in drug discovery. 
35. Revisiting Repurposing. 
36. Multitasking models for quantitative structure-biological effect relationships: current status and future 
perspectives to speed up drug discovery. 
37. New sources of drugs for hematologic malignancies. 
38. Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and 
Drug Administration-Approved Drugs. 
39. Structure based drug discovery for designing leads for the non-toxic metabolic targets in multi drug 
resistant Mycobacterium tuberculosis. 
40. The polypharmacology of natural products. 
41. Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances. 
42. Biocomputational resources useful for drug discovery against compartmentalized targets. 
43. Mining small-molecule screens to repurpose drugs. 
44. Web-based drug repurposing tools: a survey. 
45. Shifting from the single to the multitarget paradigm in drug discovery. 
 




46. Systems medicine: evolution of systems biology from bench to bedside. 
47. In silico methods for drug repurposing and pharmacology. 
48. Genomes, structural biology and drug discovery: combating the impacts of mutations in genetic 
disease and antibiotic resistance. 
49. Repurposing High-Throughput Image Assays Enables Biological Activity Prediction for Drug 
Discovery. 
50. Back to the Roots: Prediction of Biologically Active Natural Products from Ayurveda Traditional 
Medicine. 
51. Individualized network-based drug repositioning infrastructure for precision oncology in the panomics 
era. 
52. Pharmacology and Clinical Drug Candidates in Redox Medicine. 
53. Drug repurposing in chemical genomics: can we learn from the past to improve the future? 
54. The ReFRAME library as a comprehensive drug repurposing library and its application to the 
treatment of cryptosporidiosis. 
55. Polypharmacology in Precision Oncology: Current Applications and Future Prospects. 
56. Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and 
applying the lessons across diseases. 
57. Pharmacogenomics to Revive Drug Development in Cardiovascular Disease. 
58. New horizons for old drugs and drug leads. 
59. The Repurposing of Old Drugs or Unsuccessful Lead Compounds by in Silico Approaches: New 
Advances and Perspectives. 
60. Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics. 
61. Modern Approaches for the Discovery of Anti-Infectious Drugs for the Treatment of Neglected 
Diseases. 
62. Connections in pharmacology: innovation serving translational medicine. 
63. Process Pharmacology: A Pharmacological Data Science Approach to Drug Development and 
Therapy. 
64. Phosphoproteomics in drug discovery. 
65. Recent Advances and Emerging Applications in Text and Data Mining for Biomedical Discovery. 
66. An integrated drug development approach applying topological descriptors. 
 




67. Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang 
Wan as a case study. 
68. Cheaper faster drug development validated by the repositioning of drugs against neglected tropical 
diseases. 
69. Rational application of drug promiscuity in medicinal chemistry. 
70. Polypharmacology - foe or friend? 
71. Scaffold Repurposing of Old Drugs Towards New Cancer Drug Discovery. 
72. Transplantomics: Toward Precision Medicine in Transplantation Research. 
73. PubChem applications in drug discovery: a bibliometric analysis. 
74. Third-generation sequencing techniques and applications to drug discovery. 
75. Polypharmacology in Drug Development: A Minireview of Current Technologies. 
76. Getting the most out of PubChem for virtual screening. 
77. Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia. 
78. Drug repurposing: far beyond new targets for old drugs. 
79. Drug Repurposing from an Academic Perspective. 
80. Recent Advances in the Development of Pharmaceutical Agents for Metabolic Disorders: A 
Computational Perspective. 
81. Surveying Recent Themes in Translational Bioinformatics: Big Data in EHRs, Omics for Drugs, and 
Personal Genomics. 
82. The use of transcriptomic biomarkers for personalized medicine. 
83. Phenotypic screening of the Prestwick library for treatment of Parkinson's tremor symptoms using a 
humanized quantitative systems pharmacology platform. 
84. Complementary new approaches enable repositioning of failed drug candidates. 
85. IBM Watson: How Cognitive Computing Can Be Applied to Big Data Challenges in Life Sciences 
Research. 
86. Discovery and development of DNA methyltransferase inhibitors using in silico approaches. 
87. Use of Computational Functional Genomics in Drug Discovery and Repurposing for Analgesic 
Indications. 
88. Insights into respiratory disease through bioinformatics. 
 




89. Drug discovery and repurposing at Memorial Sloan Kettering Cancer Center: chemical biology drives 
translational medicine. 
90. Repurposing Drugs to Target the Diabetes Epidemic. 
91. Chapter 7: Pharmacogenomics. 
92. Pharmacogenomic approaches to lipid-regulating trials. 
93. CancerHSP: anticancer herbs database of systems pharmacology. 
94. Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders. 
95. Exploring the epigenetic drug discovery landscape. 
96. Turning omics data into therapeutic insights. 
97. e-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design. 
98. Identifying Novel Cancer Therapies Using Chemical Genetics and Zebrafish. 
99. Literature mining, ontologies and information visualization for drug repurposing. 
100. Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a 
medicinal chemist perspective. 
101. Assessment of berberine as a multi-target antimicrobial: a multi-omics study for drug discovery and 
repositioning. 
102. Schistosomiasis: from drug deployment to drug development. 
103. PregOMICS-Leveraging systems biology and bioinformatics for drug repurposing in maternal-child 
health. 
104. Nuclear matrix, nuclear envelope and premature aging syndromes in a translational research 
perspective. 
105. beta3-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in 
a repositioning clinical drug development project. 
106. In silico frameworks for systematic pre-clinical screening of potential anti-leukemia therapeutics. 
107. High-throughput analysis of behavior for drug discovery. 
108. Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of 
Neuroendocrine Prostate Cancer. 
109. Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All? 
110. Repurposing strategies for tropical disease drug discovery. 
 




111. Drug target identification in protozoan parasites. 
112. Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease. 
113. Genetics and pharmacology of longevity: the road to therapeutics for healthy aging. 
114. Beyond new chemical entities: advancing drug development based on functional versatility of 
antibodies. 
115. The thiol-polyamine metabolism of Trypanosoma cruzi: molecular targets and drug repurposing 
strategies. 
116. Reprint of: Highthroughtput analysis of behavior for drug discovery. 
117. Opportunities and challenges provided by cloud repositories for bioinformatics-enabled drug 
discovery. 
118. Pathogenesis of thrombosis: cellular and pharmacogenetic contributions. 
119. Predicting New Target Conditions for Drug Retesting Using Temporal Patterns in Clinical Trials: A 
Proof of Concept. 
120. KCa 3.1-a microglial target ready for drug repurposing? 
121. New approach to generating insights for aging research based on literature mining and knowledge 
integration. 
122. Discovery of New Potential Anti-Infective Compounds Based on Carbonic Anhydrase Inhibitors by 
Rational Target-Focused Repurposing Approaches. 
123. Toward a Reasoned Classification of Diseases Using Physico-Chemical Based Phenotypes. 
124. Recent advances in technologies for developing drugs against Chlamydia pneumoniae. 
125. Repurposing metformin: an old drug with new tricks in its binding pockets. 
126. Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly 
Accessible Panel of Assays. 
127. Therapeutic Approaches to Prion Diseases. 
128. Challenges and recommendations for obtaining chemical structures of industry-provided repurposing 
candidates. 
129. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs 
enabling repurposing and chemical genomics. 
130. fMRI in analgesic drug discovery. 
131. Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis? 
 




132. Literature Based Discovery: Models, methods, and trends. 
133. Drugs in clinical development for the treatment of amyotrophic lateral sclerosis. 
134. Using genetics to inform new therapeutics for diabetes. 
135. Computational Multitarget Drug Design. 
136. Managing Bardet-Biedl Syndrome-Now and in the Future. 
137. Therapeutic Manipulation of Ageing: Repurposing Old Dogs and Discovering New Tricks. 
138. Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art. 
139. Clinical neuroscience of addiction: similarities and differences between alcohol and other drugs. 
140. The Repurposing Drugs in Oncology (ReDO) Project. 
141. Epigenetic drugs: from chemistry via biology to medicine and back. 
142. Repurposing available drugs for neurodevelopmental disorders: The fragile X experience. 
143. When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a 
New Indication in the Absence of Preclinical Efficacy Data. 
144. Beyond multiple mechanisms and a unique drug: Defective autophagy as pivotal player in cerebral 
cavernous malformation pathogenesis and implications for targeted therapies. 
145. Drug discovery. Repurposing with a difference. 
146. Drug discovery for the treatment of substance use disorders: novel targets, repurposing, and the need 
for new paradigms. 
147. Designer Drugs 2.0. 
148. Mendelian randomisation in cardiovascular research: an introduction for clinicians. 
149. Repositioning the substrate activity screening (SAS) approach as a fragment-based method for 
identification of weak binders. 
150. Discontinued anxiolytic drugs (2009 - 2014). 
151. Antifungal drug discovery: something old and something new. 
152. Identifying new antiepileptic drugs through genomics-based drug repurposing. 
153. Looking Back, Looking Forward at Halogen Bonding in Drug Discovery. 
154. Help luck along to find psychiatric medicines. 
 




155. Computer-Aided Identification of Anticonvulsant Effect of Natural Nonnutritive Sweeteners 
Stevioside and Rebaudioside A. 
156. Old friends in new guise: exploiting privileged structures for scaffold re-evolution/refining. 
157. How will insights from genetics translate to clinical practice in inflammatory bowel disease? 
158. Is there a relationship between sweet taste and seizures? Anticonvulsant and proconvulsant effects of 
non-nutritive sweeteners. 
159. Exploring old drugs for the treatment of hematological malignancies. 
160. Lithium Pharmacogenetics: Where Do We Stand? 
161. The genome of Onchocerca volvulus, agent of river blindness. 
162. Psilocybin: Good Trip or Bad Trip. 
163. The Second Insubria Autumn School on Neuroimmune Pharmacology: Repurposing Established 
Drugs for Novel Indications. 
164. Pharmacologic Treatment of Polycystic Ovary Syndrome: Alternate and Future Paths. 
165. The rise of translational bioinformatics. 
166. Use of venlafaxine in psychiatric disorders and climacteric syndrome: is a therapeutic bridge? 
167. Mental health: depression needs large human-genetics studies.  
 




A2-2e. Leaf clusters under Cluster 7 
 *Cluster 7 (114) is a leaf cluster, and focuses on treatments for drug-resistant tuberculosis. 
A2-2e1. Cluster 7 record titles 
1. Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio. 
2. Clinical management of adults and children with multidrug-resistant and extensively drug-resistant 
tuberculosis. 
3. Repurposing and Revival of the Drugs: A New Approach to Combat the Drug Resistant Tuberculosis. 
4. The potential role of trimethoprim-sulfamethoxazole in the treatment of drug-resistant tuberculosis. 
5. Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment. 
6. Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease. 
7. Pipeline of drugs for related diseases: tuberculosis. 
8. null 
9. New anti-tuberculosis drugs and regimens: 2015 update. 
10. Tuberculosis: From an incurable scourge to a curable disease - journey over a millennium. 
11. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-
TB regimen and bedaquiline for all with MDR-TB? 
12. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and 
rational design. 
13. The challenge of new drug discovery for tuberculosis. 
14. New drugs and perspectives for new anti-tuberculosis regimens. 
15. Repurposing-a ray of hope in tackling extensively drug resistance in tuberculosis. 
16. New Antituberculosis Drugs: From Clinical Trial to Programmatic Use. 
17. Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants 
of resistance and implications for personalized care. 
18. Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-
Bechamp Debates. 
19. An optimized background regimen for treatment of active tuberculosis with the next-generation 
benzothiazinone Macozinone (PBTZ169). 
20. Meropenem-clavulanate for drug-resistant tuberculosis: a follow-up of relapse-free cases. 
 




21. New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis. 
22. New Approaches to the Treatment of Tuberculosis. 
23. Is repositioning of drugs a viable alternative in the treatment of tuberculosis? 
24. Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-
infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill. 
25. Rising to the challenge: new therapies for tuberculosis. 
26. Totally drug-resistant tuberculosis and adjunct therapies. 
27. Advances in the development of new tuberculosis drugs and treatment regimens. 
28. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, 
extensively drug-resistant, and incurable tuberculosis. 
29. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-
directed therapies. 
30. Recent developments in genomics, bioinformatics and drug discovery to combat emerging drug-
resistant tuberculosis. 
31. New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based 
Recommendations. 
32. Management of drug-resistant TB in patients with HIV co-infection. 
33. Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015. 
34. Turning the tide against tuberculosis. 
35. Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, 
and biomarkers. 
36. Current therapies for the treatment of multidrug-resistant tuberculosis in children in India. 
37. New drugs and regimens for tuberculosis. 
38. Neuroleptic drugs in the treatment of tuberculosis: Minimal inhibitory concentrations of different 
phenothiazines against Mycobacterium tuberculosis. 
39. New drugs for the treatment of Mycobacterium tuberculosis infection. 
40. Bis-biguanide dihydrochloride inhibits intracellular replication of M. tuberculosis and controls 
infection in mice. 
41. Methodological considerations in clinical trials for new MDR-TB treatment regimens. 
 




42. Current status of pharmacokinetic and safety studies of multidrug-resistant tuberculosis treatment in 
children. 
43. In Vitro Activity and MIC of Sitafloxacin against Multidrug-Resistant and Extensively Drug-
Resistant Mycobacterium tuberculosis Isolated in Thailand. 
44. Drug repositioning in the treatment of malaria and TB. 
45. Pros and cons of the tuberculosis drugome approach--an empirical analysis. 
46. Treatment of drug-resistant tuberculosis among people living with HIV. 
47. Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-
approved phosphodiesterase inhibitors in the mouse model. 
48. Interplay of DDP4 and IP-10 as a Potential Mechanism for Cell Recruitment to Tuberculosis Lesions. 
49. Aerosolized gentamicin reduces the burden of tuberculosis in a murine model. 
50. Mycobacterium tuberculosis... Can we beat it? Report from a Euroscicon conference 2013. 
51. Exploring the potential of adjunct therapy in tuberculosis. 
52. Mode of Action of Clofazimine and Combination Therapy with Benzothiazinones against 
Mycobacterium tuberculosis. 
53. Docking-based virtual screening of known drugs against murE of Mycobacterium tuberculosis 
towards repurposing for TB. 
54. Mefloquine and its oxazolidine derivative compound are active against drug-resistant Mycobacterium 
tuberculosis strains and in a murine model of tuberculosis infection. 
55. Recent therapeutic approaches for the management of tuberculosis: Challenges and opportunities. 
56. Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South 
Africa: a retrospective cohort study. 
57. The role of moxifloxacin in tuberculosis therapy. 
58. Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations? 
59. Tackling tuberculosis: Insights from an international TB Summit in London. 
60. Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in 
children. 
61. Recent Developments and Future Opportunities in the Treatment of Tuberculosis in Children. 
62. Translating the Tuberculosis Research Agenda: Much Accomplished, but Much More to Be Done. 
 




63. Tuberculosis: An Inorganic Medicinal Chemistry Perspective. 
64. Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines. 
65. Advancing host-directed therapy for tuberculosis. 
66. Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs. 
67. The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis. 
68. Antitubercular activity of disulfiram, an antialcoholism drug, against multidrug- and extensively drug-
resistant Mycobacterium tuberculosis isolates. 
69. Bioinformatics approach to prioritize known drugs towards repurposing for tuberculosis. 
70. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review. 
71. Newer patents in antimycobacterial therapy. 
72. Performance of the GenoType MTBDRsl assay for the detection second-line anti-tuberculosis drug 
resistance. 
73. Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine 
tuberculosis. 
74. [New drugs against multidrug-resistant tuberculosis]. 
75. Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat 
multi-drug and extensively drug resistant tuberculosis. 
76. Priming the tuberculosis drug pipeline: new antimycobacterial targets and agents. 
77. Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in 
enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis. 
78. Inhibiting Mycobacterium tuberculosis within and without. 
79. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant 
tuberculosis: analysis of published guidance and meta-analysis of cohort studies. 
80. Meta-analysis of human gene expression in response to Mycobacterium tuberculosis infection reveals 
potential therapeutic targets. 
81. Statistical considerations for pediatric multidrug-resistant tuberculosis efficacy trials. 
82. Bedaquiline and Repurposed Drugs for Fluoroquinolone-Resistant MDR-TB: How Much Better Are 
They? 
83. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. 
 




84. Estimated generic prices for novel treatments for drug-resistant tuberculosis. 
85. Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. 
86. Sharpening nature's tools for efficient tuberculosis control: A review of the potential role and 
development of host-directed therapies and strategies for targeted respiratory delivery. 
87. Design and synthesis of novel anti-tuberculosis agents from the celecoxib pharmacophore. 
88. Old Drugs and New Targets as an Outlook for the Treatment of Tuberculosis. 
89. Targeting intracellular p-aminobenzoic acid production potentiates the anti-tubercular action of 
antifolates. 
90. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and 
bedaquiline. 
91. Pharmacologically active metabolites, combination screening and target identification-driven drug 
repositioning in antituberculosis drug discovery. 
92. An allosteric inhibitor of Mycobacterium tuberculosis ArgJ: Implications to a novel combinatorial 
therapy. 
93. Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic 
killing of Mycobacterium tuberculosis through inositol depletion. 
94. Novel Pharmacological Activity of Artesunate and Artemisinin: Their Potential as Anti-Tubercular 
Agents. 
95. Interaction of Mycobacterium tuberculosis Virulence Factor RipA with Chaperone MoxR1 Is 
Required for Transport through the TAT Secretion System. 
96. Identifying and Tackling Emergent Vulnerability in Drug-Resistant Mycobacteria. 
97. Loperamide Restricts Intracellular Growth of Mycobacterium tuberculosis in Lung Macrophages. 
98. Zafirlukast inhibits complexation of Lsr2 with DNA and growth of Mycobacterium tuberculosis. 
99. Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model 
of Tuberculosis. 
100. Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine 
kinase inhibitors as host-directed antimicrobials. 
101. Synthetic lethality reveals mechanisms of Mycobacterium tuberculosis resistance to beta-lactams. 
102. Evaluation of anti-tubercular activity of linolenic acid and conjugated-linoleic acid as effective 
inhibitors against Mycobacterium tuberculosis. 
 




103. Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of 
tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners. 
104. Three-dimensional models of Mycobacterium tuberculosis proteins Rv1555, Rv1554 and their 
docking analyses with sildenafil, tadalafil, vardenafil drugs, suggest interference with quinol binding 
likely to affect protein's function. 
105. The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with 
rifampicin, targeting RNA polymerase. 
106. Resistance to Thiacetazone Derivatives Active against Mycobacterium abscessus Involves Mutations 
in the MmpL5 Transcriptional Repressor MAB_4384. 
107. The trials and tribulations of repurposing metformin and other generic drugs for tuberculosis. 
108. Synthesis and SAR evaluation of novel thioridazine derivatives active against drug-resistant 
tuberculosis. 
109. Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent 
antitubercular agents. 
110. The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis. 
111. High-throughput screening for daunorubicin-mediated drug resistance identifies mometasone furoate 
as a novel ABCB1-reversal agent. 
112. Synthesis and in vitro investigation of halogenated 1,3-bis(4-nitrophenyl)triazenide salts as 
antitubercular compounds. 
113. We need a global system to help identify new uses for existing drugs. 
114. New cures sought from old drugs.  
 




A2-2f. Leaf clusters under Cluster 57 
 There are seven leaf clusters under Cluster 57: Cluster 1 (41), Cluster 0 (21), Cluster 15 (80), 
Cluster 14 (62), Cluster 19 (93), Cluster 6 (45), and Cluster 17 (113).   
*Cluster 1 focuses on antiviral treatments for viral infections, especially Ebola virus; 
*Cluster 0 focuses on antiviral treatments for viral infections, especially Zika virus; 
*Cluster 15 focuses on antiviral treatments for other viral infections, especially dengue virus, hepatitis B 
virus, chikungunya virus, human immunodeficiency  virus, japanese encephalitis virus, rift valley fever 
virus, human cytomegalovirus, respiratory syncytial virus, west nile virus. 
*Cluster 14 focuses on treatments for parasites, especially trypanosoma cruzi, african trypanosomiasi, 
trypanosoma brucei, leishmania amazonensi.  
*Cluster 19 focuses on treatments for parasites, especially plasmodium falciparum, schistosoma mansoni, 
toxoplasma gondii. 
*Cluster 6 focuses on antifungal treatments 
*Cluster 17 focuses on antimicrobial and antibiotic treatments for infections. 
  
 




A2-2f1. Cluster 1 record titles 
1. Ebola virus: A gap in drug design and discovery - experimental and computational perspective. 
2. Teicoplanin inhibits Ebola pseudovirus infection in cell culture. 
3. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of 
approved drugs. 
4. Ebola therapy: Developing new drugs or repurposing old ones? 
5. Ibuprofen as a template molecule for drug design against Ebola virus. 
6. Repurposed therapeutic agents targeting the Ebola virus: a protocol for a systematic review. 
7. A Systematic Review of Computational Drug Discovery, Development, and Repurposing for Ebola 
Virus Disease Treatment. 
8. Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus. 
9. Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA 
virus infection. 
10. Improving attrition rates in Ebola virus drug discovery. 
11. Will There Be a Cure for Ebola? 
12. In Vitro and In Vivo Activity of Amiodarone Against Ebola Virus. 
13. Combating Ebola with Repurposed Therapeutics Using the CANDO Platform. 
14. Drug repurposing to target Ebola virus replication and virulence using structural systems 
pharmacology. 
15. Hyperimmune serum from healthy vaccinated individuals for Ebola virus disease? 
16. FDA approved drugs as potential Ebola treatments. 
17. A response adaptive randomization platform trial for efficient evaluation of Ebola virus treatments: A 
model for pandemic response. 
18. A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus 
activity. 
19. Antiviral Screening of Multiple Compounds against Ebola Virus. 
20. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. 
21. Against the clock towards new Ebola virus therapies. 
22. Did Ebola survivors use plant medicines, and if so, which ones? 
 




23. High-throughput drug screening using the Ebola virus transcription- and replication-competent virus-
like particle system. 
24. Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review. 
25. Screening of FDA-Approved Drugs for Treatment of Emerging Pathogens. 
26. Drug repurposing for Ebola virus disease: principles of consideration and the Animal Rule. 
27. [Integrating clinical research into epidemic response: the field perspective in the Ebola experience]. 
28. Synergistic drug combination effectively blocks Ebola virus infection. 
29. Rethinking the development of Ebola treatments. 
30. Infectious diseases. Debate erupts on 'repurposed' drugs for Ebola. 
31. Machine learning models identify molecules active against the Ebola virus in vitro. 
32. Evaluation of Ebola Virus Inhibitors for Drug Repurposing. 
33. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome 
coronavirus infection. 
34. Current treatment options and the role of peptides as potential therapeutic components for Middle East 
Respiratory Syndrome (MERS): A review. 
35. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. 
36. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus 
and Middle East Respiratory Syndrome Coronavirus Fusion. 
37. Alternative screening approaches for discovery of Middle East respiratory syndrome coronavirus 
inhibitors. 
38. Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic 
Options and Potential Targets for Novel Therapies. 
39. Treatment With Lopinavir/Ritonavir or Interferon-beta1b Improves Outcome of MERS-CoV Infection 
in a Nonhuman Primate Model of Common Marmoset. 
40. Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis 
C virus drugs against human corona viruses. 
41. Repurposing potential of 1st generation H1-specific antihistamines as anti-filovirus therapeutics. 
  
 




A2-2f2. Cluster 0 record titles 
1. A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. 
2. Drug Repurposing: New Treatments for Zika Virus Infection? 
3. Chloroquine, a FDA-approved Drug, Prevents Zika Virus Infection and its Associated Congenital 
Microcephaly in Mice. 
4. Pediatric Drug Nitazoxanide: A Potential Choice for Control of Zika. 
5. The A-Z of Zika drug discovery. 
6. The antimalarial drug amodiaquine possesses anti-ZIKA virus activities. 
7. Advances in Developing Therapies to Combat Zika Virus: Current Knowledge and Future 
Perspectives. 
8. Repurposing of the anti-malaria drug chloroquine for Zika Virus treatment and prophylaxis. 
9. Host-Directed Antivirals: A Realistic Alternative to Fight Zika Virus. 
10. Recent trends in ZikV research: A step away from cure. 
11. Repurposing drugs for use against Zika virus infection. 
12. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a 
drug repurposing screen. 
13. Novel antiviral activity and mechanism of bromocriptine as a Zika virus NS2B-NS3 protease 
inhibitor. 
14. 2,8-bis(trifluoromethyl)quinoline analogs show improved anti-Zika virus activity, compared to 
mefloquine. 
15. Cell-line dependent antiviral activity of sofosbuvir against Zika virus. 
16. Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells. 
17. Can an FDA-Approved Alzheimer's Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika 
Virus? 
18. Stem Cell Hydrogel, Jump-Starting Zika Drug Discovery, and Engineering RNA Recognition. 
19. Repurposing Drugs to Treat Zika. 
20. Novel strategies for discovering inhibitors of Dengue and Zika fever. 
21. Cases of babies in Brazil born with thalidomide defects. 
  
 




A2-2f3. Cluster 15 record titles 
1. N-Desmethylclozapine, Fluoxetine, and Salmeterol Inhibit Postentry Stages of the Dengue Virus Life 
Cycle. 
2. Drug repurposing approaches to fight Dengue virus infection and related diseases. 
3. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. 
4. Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B 
Virus Infection. 
5. Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication. 
6. Drug repurposing of quinine as antiviral against dengue virus infection. 
7. Meeting report: 28th International Conference on Antiviral Research in Rome, Italy. 
8. Repurposing of prochlorperazine for use against dengue virus infection. 
9. Drug repurposing of minocycline against dengue virus infection. 
10. Repurposed FDA-Approved drug sorafenib reduces replication of Venezuelan equine encephalitis 
virus and other alphaviruses. 
11. Drug Repurposing for Viral Infectious Diseases: How Far Are We? 
12. Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for 
Drug Repurposing in Infectious Viral Diseases. 
13. A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, 
West Nile and Chikungunya viruses. 
14. Screening of FDA-Approved Drugs for Inhibitors of Japanese Encephalitis Virus Infection. 
15. Natural Products as Promising Therapeutics for Treatment of Influenza Disease. 
16. Use of attenuated paramyxoviruses for cancer therapy. 
17. H7N9 and other pathogenic avian influenza viruses elicit a three-pronged transcriptomic signature that 
is reminiscent of 1918 influenza virus and is associated with lethal outcome in mice. 
18. Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy. 
19. Molecular Basis for the Selective Inhibition of Respiratory Syncytial Virus RNA Polymerase by 2'-
Fluoro-4'-Chloromethyl-Cytidine Triphosphate. 
20. Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library. 
21. High-content assay to identify inhibitors of dengue virus infection. 
 




22. Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of HBV Infection. 
23. The HIV integrase inhibitor raltegravir inhibits felid alphaherpesvirus 1 (FeHV-1) replication by 
targeting both DNA replication and late gene expression. 
24. Drug Repurposing Approach Identifies Inhibitors of the Prototypic Viral Transcription Factor IE2 that 
Block Human Cytomegalovirus Replication. 
25. Direct-acting antivirals and host-targeting strategies to combat enterovirus infections. 
26. Dengue Antiviral Development: A Continuing Journey. 
27. Current Strategies for Inhibition of Chikungunya Infection. 
28. Hyphenated 3D-QSAR statistical model-drug repurposing analysis for the identification of potent 
neuraminidase inhibitor. 
29. Use of minocycline in viral infections. 
30. Identification of FDA-approved drugs that target hepatitis B virus transcription. 
31. Kinome Profiling Identifies Druggable Targets for Novel Human Cytomegalovirus (HCMV) 
Antivirals. 
32. Repurposing the clinically approved calcium antagonist manidipine dihydrochloride as a new early 
inhibitor of human cytomegalovirus targeting the Immediate-Early 2 (IE2) protein. 
33. West Nile virus drug discovery. 
34. A dual drug regimen synergistically blocks human parainfluenza virus infection. 
35. Antiviral activity of cationic amphiphilic drugs. 
36. Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for 
hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity. 
37. Identification of Retinoic Acid Receptor Agonists as Potent Hepatitis B Virus Inhibitors via a Drug 
Repurposing Screen. 
38. Antiviral activity of doxycycline against vesicular stomatitis virus in vitro. 
39. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C 
virus infection. 
40. Identification of resveratrol analogs as potent anti-dengue agents using a cell-based assay. 
41. Metformin inhibits hepatitis B virus protein production and replication in human hepatoma cells. 
42. The combination effects of licl and the active leflunomide metabolite, A771726, on viral-induced 
interleukin 6 production and EV-A71 replication. 
 




43. Phosphorylation of Single Stranded RNA Virus Proteins and Potential for Novel Therapeutic 
Strategies. 
44. Identification of KX2-391 as an inhibitor of HBV transcription by a recombinant HBV-based 
screening assay. 
45. Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of 
influenza A virus. 
46. Antiviral activity of micafungin against enterovirus 71. 
47. Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment. 
48. Transcriptomic characterization of the novel avian-origin influenza A (H7N9) virus: specific host 
response and responses intermediate between avian (H5N1 and H7N7) and human (H3N2) viruses and 
implications for treatment options. 
49. Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection. 
50. Management and Treatment of Dengue and Chikungunya - Natural Products to the Rescue. 
51. Enterovirus replication: go with the (counter)flow. 
52. Computer-Aided Structure Based Drug Design Approaches for the Discovery of New Anti-CHIKV 
Agents. 
53. Antiviral activity of gemcitabine against human rhinovirus invitro and invivo. 
54. Inhibition of Rift Valley fever virus replication and perturbation of nucleocapsid-RNA interactions by 
suramin. 
55. Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs. 
56. Treating Influenza Infection, From Now and Into the Future. 
57. Drug Repurposing Identifies Inhibitors of Oseltamivir-Resistant Influenza Viruses. 
58. New developments in flavivirus drug discovery. 
59. Inhibitors for the hepatitis C virus RNA polymerase explored by SAR with advanced machine 
learning methods. 
60. [Open Sesame: regulation of hepatitis C virus entry into hepatocytes]. 
61. Hydroxyurea inhibits parvovirus B19 replication in erythroid progenitor cells. 
62. Developing a dengue vaccine: progress and future challenges. 
63. Exploiting drug repositioning for discovery of a novel HIV combination therapy. 
 




64. Sorafenib Impedes Rift Valley Fever Virus Egress by Inhibiting Valosin-Containing Protein Function 
in the Cellular Secretory Pathway. 
65. Evaluation of Crimean-Congo hemorrhagic fever virus in vitro inhibition by chloroquine and 
chlorpromazine, two FDA approved molecules. 
66. Identification of potential anti-hepatitis C virus agents targeting non structural protein 5B using 
computational techniques. 
67. Investigational drugs in early development for treating dengue infection. 
68. Using HIV drugs to target human papilloma virus. 
69. [L-Lysine-alpha-Oxidase in vitro Activity in Experiments on Models of Viruses Sindbis, Forest-
Spring Encephalitis, Western Nile, Tyaginya and Dhori]. 
70. LEDGIN-mediated Inhibition of Integrase-LEDGF/p75 Interaction Reduces Reactivation of Residual 
Latent HIV. 
71. Rhinovirus - From bench to bedside. 
72. Artemisinin analogues as potent inhibitors of in vitro hepatitis C virus replication. 
73. Fighting viruses with antibiotics: an overlooked path. 
74. Pentosan Polysulfate: a Novel Glycosaminoglycan-Like Molecule for Effective Treatment of 
Alphavirus-Induced Cartilage Destruction and Inflammatory Disease. 
75. Repurposing of HDAC inhibitors toward anti-hepatitis C virus drug discovery: teaching an old dog 
new tricks. 
76. Pharmacophore anchor models of flaviviral NS3 proteases lead to drug repurposing for DENV 
infection. 
77. Repurposing of rutin for the inhibition of norovirus replication. 
78. Drug Repurposing: Tolfenamic Acid Inactivates PrbP, a Transcriptional Accessory Protein in 
Liberibacter asiaticus. 
79. Analysis and assay of oseltamivir-resistant mutants of influenza neuraminidase via direct observation 
of drug unbinding and rebinding in simulation. 
80. Old and new uses of surfactant. 
  
 




A2-2f4. Cluster 14 record titles 
1. Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma 
cruzi. 
2. Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review. 
3. In vitro and in vivo studies of the antiparasitic activity of sterol 14alpha-demethylase (CYP51) 
inhibitor VNI against drug-resistant strains of Trypanosoma cruzi. 
4. In vitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania 
amazonensis. 
5. Optimization of Physicochemical Properties for 4-Anilinoquinoline Inhibitors of Plasmodium 
falciparum Proliferation. 
6. Novel cruzipain inhibitors for the chemotherapy of chronic Chagas disease. 
7. Discovery of novel polyamine analogs with anti-protozoal activity by computer guided drug 
repositioning. 
8. Stairway to Heaven or Hell? Perspectives and Limitations of Chagas Disease Chemotherapy. 
9. Pyrazinoates as antiparasitic agents against Trypanosoma cruzi. 
10. Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, 
lapatinib-derived lead compound for trypanosomiasis. 
11. Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma 
cruzi Hit-Discovery Screening Cascade. 
12. The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug 
discovery via target repurposing. 
13. Discovery of a Carbazole-Derived Lead Drug for Human African Trypanosomiasis. 
14. Benznidazole/Itraconazole Combination Treatment Enhances Anti-Trypanosoma cruzi Activity in 
Experimental Chagas Disease. 
15. The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new 
opportunity for drug repurposing. 
16. Repurposing of the Open Access Malaria Box for Kinetoplastid Diseases Identifies Novel Active 
Scaffolds against Trypanosomatids. 
17. Drug repurposing strategy against Trypanosoma cruzi infection: In vitro and in vivo assessment of the 
activity of metronidazole in mono- and combined therapy. 
 




18. Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual 
Screening, In Vitro and In Vivo Studies. 
19. Therapeutical approaches under investigation for treatment of Chagas disease. 
20. The Oral Antimalarial Drug Tafenoquine Shows Activity against Trypanosoma brucei. 
21. Repurposing Strategy of Atorvastatin against Trypanosoma cruzi: In Vitro Monotherapy and 
Combined Therapy with Benznidazole Exhibit Synergistic Trypanocidal Activity. 
22. Repurposing of Human Kinase Inhibitors in Neglected Protozoan Diseases. 
23. New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine 
kinase inhibitor drugs. 
24. Trypanocidal Effect of Isotretinoin through the Inhibition of Polyamine and Amino Acid Transporters 
in Trypanosoma cruzi. 
25. Activity of anti-cancer protein kinase inhibitors against Leishmania spp. 
26. Cruzain inhibitors: efforts made, current leads and a structural outlook of new hits. 
27. Novel lead compounds in pre-clinical development against African sleeping sickness. 
28. Repurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and evaluation 
of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors. 
29. Polypharmacology in the treatment of Chagas disease. 
30. Recent developments in rationally designed multitarget antiprotozoan agents. 
31. Synthesis and in vitro evaluation of Ca2+ channel blockers 1,4-dihydropyridines analogues against 
Trypanosoma cruzi and Leishmania amazonensis: SAR analysis. 
32. Ketanserin, an antidepressant, exerts its antileishmanial action via inhibition of 3-hydroxy-3-
methylglutaryl coenzyme A reductase (HMGR) enzyme of Leishmania donovani. 
33. Imidazolium salts as innovative agents against Leishmania amazonensis. 
34. Ibandronate metal complexes: solution behavior and antiparasitic activity. 
35. The antifungal compound butenafine eliminates promastigote and amastigote forms of Leishmania 
(Leishmania) amazonensis and Leishmania (Viannia) braziliensis. 
36. 2-acylamino-5-nitro-1,3-thiazoles: preparation and in vitro bioevaluation against four neglected 
protozoan parasites. 
37. Antileishmanial Activity of Ezetimibe: Inhibition of Sterol Biosynthesis, In Vitro Synergy with 
Azoles, and Efficacy in Experimental Cutaneous Leishmaniasis. 
 




38. Identification of levothyroxine antichagasic activity through computer-aided drug repurposing. 
39. Application of computer-aided drug repurposing in the search of new cruzipain inhibitors: discovery 
of amiodarone and bromocriptine inhibitory effects. 
40. Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the 
human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei. 
41. Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of 
human African trypanosomiasis. 
42. Activity of imidazole compounds on Leishmania (L.) infantum chagasi: reactive oxygen species 
induced by econazole. 
43. Nanoliposomal Buparvaquone Immunomodulates Leishmania infantum-Infected Macrophages and Is 
Highly Effective in a Murine Model. 
44. Leishmaniasis treatment: update of possibilities for drug repurposing. 
45. In vitro additive interaction between ketoconazole and antimony against intramacrophage Leishmania 
(Leishmania) amazonensis amastigotes. 
46. In vitro leishmanicidal effects of the anti-fungal drug natamycin are mediated through disruption of 
calcium homeostasis and mitochondrial dysfunction. 
47. An invitro and invivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi 
predicted by a computational drug repositioning method. 
48. Nelfinavir and lopinavir impair Trypanosoma cruzi trypomastigote infection in mammalian host cells 
and show anti-amastigote activity. 
49. Engineering Synergistically Active and Bioavailable Cost-effective Medicines for Neglected Tropical 
Diseases; The Role of Excipients. 
50. Drug repurposing for Leishmania. Molecular basis of the leishmanicidal activity of the antidepressant 
sertraline. 
51. In silico drug re-purposing against African sleeping sickness using GlcNAc-PI de-N-acetylase as an 
experimental target. 
52. Development of a semi-automated image-based high-throughput drug screening system. 
53. CYP51 as drug targets for fungi and protozoan parasites: past, present and future. 
54. Histamine H1-receptor antagonists against Leishmania (L.) infantum: an in vitro and in vivo 
evaluation using phosphatidylserine-liposomes. 
55. Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical 
Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis. 
 




56. Development of anti-fungal pesticides from protein kinase inhibitor-based anticancer agents. 
57. CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM). 
58. Repurposing N,N'-bis-(arylamidino)-1,4-piperazinedicarboxamidines: An unexpected class of potent 
inhibitors of cholinesterases. 
59. Treatment of Disseminated Leishmaniasis With Liposomal Amphotericin B. 
60. Is the pharmaceutical industry's preoccupation with the monotherapy drug model stifling the 
development of effective new drug therapies? 
61. Repurposing an old anti-fungal drug as a Hedgehog inhibitor. 
62. Low-Income Countries And Repurposed Drugs. 
  
 




A2-2f5. Cluster 19 record titles 
1. A class of tricyclic compounds blocking malaria parasite oocyst development and transmission. 
2. Antimalarial activity of novel 4-cyano-3-methylisoquinoline inhibitors against Plasmodium falciparum: 
design, synthesis and biological evaluation. 
3. Efficacy of Synriam, a new antimalarial combination of OZ277 and piperaquine, against different 
developmental stages of Schistosoma mansoni. 
4. Expanding the Antimalarial Drug Arsenal-Now, But How? 
5. Repurposing drugs to target the malaria parasite unfolding protein response. 
6. Antimalarials in the treatment of schistosomiasis. 
7. Chemical signatures and new drug targets for gametocytocidal drug development. 
8. Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni. 
9. Screening a repurposing library, the Medicines for Malaria Venture Stasis Box, against Schistosoma 
mansoni. 
10. Small molecule inhibition of apicomplexan FtsH1 disrupts plastid biogenesis in human pathogens. 
11. Drug repurposing and human parasitic protozoan diseases. 
12. Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma mansoni. 
13. Controlling schistosomiasis with praziquantel: How much longer without a viable alternative? 
14. New leads for drug repurposing against malaria. 
15. In vitro and in vivo antischistosomal activity of ferroquine derivatives. 
16. Repositioning: the fast track to new anti-malarial medicines? 
17. Approved oncology drugs lack in vivo activity against Trichuris muris despite in vitro activity. 
18. Miltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A 
Preclinical Study. 
19. Exploring anti-malarial potential of FDA approved drugs: an in silico approach. 
20. Auranofin is highly efficacious against Toxoplasma gondii in vitro and in an in vivo experimental 
model of acute toxoplasmosis. 
21. Drug Repurposing Screening Identifies Novel Compounds That Effectively Inhibit Toxoplasma 
gondii Growth. 
 




22. Treatment of Schistosoma mansoni with miltefosine in vitro enhances serological recognition of 
defined worm surface antigens. 
23. Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives. 
24. Drug Repurposing for Schistosomiasis: Combinations of Drugs or Biomolecules. 
25. High-throughput screen of drug repurposing library identifies inhibitors of Sarcocystis neurona 
growth. 
26. Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by 
medium-throughput phenotypic screening. 
27. Screening of chemical compound libraries identified new anti-Toxoplasma gondii agents. 
28. High-Throughput Screening of Entamoeba Identifies Compounds Which Target Both Life Cycle 
Stages and Which Are Effective Against Metronidazole Resistant Parasites. 
29. Review of Experimental Compounds Demonstrating Anti-Toxoplasma Activity. 
30. The Glucose Transporter PfHT1 Is an Antimalarial Target of the HIV Protease Inhibitor Lopinavir. 
31. Miltefosine lipid nanocapsules: Intersection of drug repurposing and nanotechnology for single dose 
oral treatment of pre-patent schistosomiasis mansoni. 
32. Repositioning of chlorambucil as a potential anti-schistosomal agent. 
33. Distinct effects of HIV protease inhibitors and ERAD inhibitors on zygote to ookinete transition of 
the malaria parasite. 
34. Ion channels and drug transporters as targets for anthelmintics. 
35. Cryo-EM structure of the Plasmodium falciparum 80S ribosome bound to the anti-protozoan drug 
emetine. 
36. Activity of mefloquine and mefloquine derivatives against Echinococcus multilocularis. 
37. Identification of Cryptosporidium parvum active chemical series by Repurposing the open access 
malaria box. 
38. A systematic and prospectively validated approach for identifying synergistic drug combinations 
against malaria. 
39. Viability Screen of LOPAC1280 Reveals Phosphorylation Inhibitor Auranofin as a Potent Inhibitor of 
Blastocystis Subtype 1, 4, and 7 Isolates. 
40. Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis. 
41. Repurposing of antiparasitic drugs: the hydroxy-naphthoquinone buparvaquone inhibits vertical 
transmission in the pregnant neosporosis mouse model. 
 




42. Sertraline, Paroxetine, and Chlorpromazine Are Rapidly Acting Anthelmintic Drugs Capable of 
Clinical Repurposing. 
43. Antischistosomal agents: state of art and perspectives. 
44. Re-positioning protein-kinase inhibitors against schistosomiasis. 
45. Investigating antimalarial drug interactions of emetine dihydrochloride hydrate using CalcuSyn-based 
interactivity calculations. 
46. Repurposing pharma assets: an accelerated mechanism for strengthening the schistosomiasis drug 
development pipeline. 
47. Evaluation of methylene blue, pyrimethamine and its combination on an in vitro Neospora caninum 
model. 
48. Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity. 
49. Toward organometallic antischistosomal drug candidates. 
50. Drug repositioning as a route to anti-malarial drug discovery: preliminary investigation of the in vitro 
anti-malarial efficacy of emetine dihydrochloride hydrate. 
51. The potential of quinoline derivatives for the treatment of Toxoplasma gondii infection. 
52. Repurposing drugs for the treatment and control of helminth infections. 
53. Road towards new antimalarials - overview of the strategies and their chemical progress. 
54. Anthelmintics - from discovery to resistance. 
55. Phase I Clinical Trial Results of Auranofin, a Novel Antiparasitic Agent. 
56. A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia. 
57. In vitro activity of immunosuppressive drugs against Plasmodium falciparum. 
58. A repurposing strategy for Hsp90 inhibitors demonstrates their potency against filarial nematodes. 
59. Auranofin inactivates Trichomonas vaginalis thioredoxin reductase and is effective against 
trichomonads in vitro and in vivo. 
60. Screening of the Open Source Malaria Box Reveals an Early Lead Compound for the Treatment of 
Alveolar Echinococcosis. 
61. Adverse neuropsychiatric effects of antimalarial drugs. 
62. Synergic in vitro combinations of artemisinin, pyrimethamine and methylene blue against Neospora 
caninum. 
 




63. Arylpyrrole and fipronil analogues that inhibit the motility and/or development of Haemonchus 
contortus in vitro. 
64. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for 
cryptosporidiosis. 
65. Nanotechnology as a potential therapeutic alternative for schistosomiasis. 
66. In vitro effects of new artemisinin derivatives in Neospora caninum-infected human fibroblasts. 
67. Methylene blue inhibits lumefantrine-resistant Plasmodium berghei. 
68. Gefitinib inhibits the growth of Toxoplasma gondii in HeLa cells. 
69. Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and 
isoprenoid synthesis that block Cryptosporidium parvum growth. 
70. Drug repositioning for novel antitrichomonas from known antiprotozoan drugs using hierarchical 
screening. 
71. Oral treatments of Echinococcus multilocularis-infected mice with the antimalarial drug mefloquine 
that potentially interacts with parasite ferritin and cystatin. 
72. Repositioning of an existing drug for the neglected tropical disease Onchocerciasis. 
73. Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in 
HIV/AIDS. 
74. Artemisinin derivatives: a patent review (2006 - present). 
75. Drug repositioning and pharmacophore identification in the discovery of hookworm MIF inhibitors. 
76. Repurposing of approved drugs from the human pharmacopoeia to target Wolbachia endosymbionts 
of onchocerciasis and lymphatic filariasis. 
77. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic 
manifestations from malaria to multifarious diseases. 
78. Treatment of Cryptosporidium: What We Know, Gaps, and the Way Forward. 
79. Chloroquine: An Old Drug with New Perspective Against Giardiasis. 
80. Repositioning of DHFR Inhibitors. 
81. Modeling of Plasmodium falciparum Telomerase Reverse Transcriptase Ternary Complex: 
Repurposing of Nucleoside Analog Inhibitors. 
82. Repurposing isoxazoline veterinary drugs for control of vector-borne human diseases. 
 




83. Preclinical drug evaluation system in the Plasmodium knowlesi baboon model of malaria: the 
methotrexate study. 
84. Structural basis for inactivation of Giardia lamblia carbamate kinase by disulfiram. 
85. Short communication: Nitazoxanide inhibits HIV viral replication in monocyte-derived macrophages. 
86. A novel cell-based high-throughput screen for inhibitors of HIV-1 gene expression and budding 
identifies the cardiac glycosides. 
87. Ivermectin: repurposing an old drug to complement malaria vector control. 
88. Microplate fluorescence protease assays test the inhibition of select North American snake venoms' 
activities with an anti-proteinase library. 
89. Drug repurposing: An approach to tackle drug resistance in S. typhimurium. 
90. Laboratory testing of clinically approved drugs against Balamuthia mandrillaris. 
91. Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma. 
92. Prospects for Moxidectin as a New Oral Treatment for Human Scabies. 
93. Considerations in the repurposing of mefloquine for prevention and treatment of osteoporosis. 
  
 




A2-2f6. Cluster 6 record titles 
1. Novel Antifungal Compounds Discovered in Medicines for Malaria Venture's Malaria Box. 
2. High-throughput screening of a collection of known pharmacologically active small compounds for 
identification of Candida albicans biofilm inhibitors. 
3. Strategies in the discovery of novel antifungal scaffolds. 
4. Antifungals. 
5. Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans. 
6. Antifungal application of nonantifungal drugs. 
7. Antifungal adjuvants: Preserving and extending the antifungal arsenal. 
8. Screening a Repurposing Library for Inhibitors of Multidrug-Resistant Candida auris Identifies Ebselen 
as a Repositionable Candidate for Antifungal Drug Development. 
9. Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi. 
10. Virtual screening and drug repositioning as strategies for the discovery of new antifungal inhibitors of 
oxidosqualene cyclase. 
11. Repurposing antipsychotic drugs into antifungal agents: Synergistic combinations of azoles and 
bromperidol derivatives in the treatment of various fungal infections. 
12. Repurposing Approach Identifies Auranofin with Broad Spectrum Antifungal Activity That Targets 
Mia40-Erv1 Pathway. 
13. The triphenylethylenes, a novel class of antifungals. 
14. Reversal of Azole Resistance in Candida albicans by Sulfa Antibacterial Drugs. 
15. Candidiasis and the impact of flow cytometry on antifungal drug discovery. 
16. Quinacrine inhibits Candida albicans growth and filamentation at neutral pH. 
17. Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida 
albicans biofilms. 
18. Antifungal Phenothiazines: Optimization, Characterization of Mechanism, and Modulation of 
Neuroreceptor Activity. 
19. In vitro analysis of finasteride activity against Candida albicans urinary biofilm formation and 
filamentation. 
20. Anticancer Drugs as Antibiofilm Agents in Candida albicans: Potential Targets. 
 




21. Antifungal amphiphilic kanamycins: new life for an old drug. 
22. The anti-Aspergillus drug pipeline: Is the glass half full or empty? 
23. Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans. 
24. Antifungal properties of the anti-hypertensive drug: aliskiren. 
25. Cancer drugs inhibit morphogenesis in the human fungal pathogen, Candida albicans. 
26. Tricyclic antidepressants inhibit Candida albicans growth and biofilm formation. 
27. Newer patents in antimycotic therapy. 
28. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. 
29. The Anti-helminthic Compound Mebendazole Has Multiple Antifungal Effects against Cryptococcus 
neoformans. 
30. How promising are combinatorial drug strategies in combating Candida albicans biofilms? 
31. Rapid identification of antifungal compounds against Exserohilum rostratum using high throughput 
drug repurposing screens. 
32. Artemisinins, new miconazole potentiators resulting in increased activity against Candida albicans 
biofilms. 
33. Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis. 
34. A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common 
structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis. 
35. Drugs currently under investigation for the treatment of invasive candidiasis. 
36. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and 
synergize with fluconazole in vivo. 
37. Repositioning of Endonuclear Receptors Binders as Potential Antibacterial and Antifungal Agents. 
Eptyloxim: A Potential and Novel Gyrase B and Cytochrome Cyp51 Inhibitor. 
38. Can repurposing of existing drugs provide more effective therapies for invasive fungal infections? 
39. Topical delivery of ebselen encapsulated in biopolymeric nanocapsules: drug repurposing enhanced 
antifungal activity. 
40. Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of 
bacterial infections: a puzzling paradox or a logical consequence of their mode of action? 
41. Toward improved anti-cryptococcal drugs: Novel molecules and repurposed drugs. 
 




42. New applications for known drugs: Human glycogen synthase kinase 3 inhibitors as modulators of 
Aspergillus fumigatus growth. 
43. Atorvastatin as a promising anticryptococcal agent. 
44. Fluoxetine and thioridazine inhibit efflux and attenuate crystalline biofilm formation by Proteus 
mirabilis. 
45. The Repurposing of Anti-Psychotic Drugs, Quetiapine and Olanzapine, as Anti-Cryptococcus Drugs. 
  
 




A2-2f7. Cluster 17 record titles 
1. Repurposing Non-Antimicrobial Drugs and Clinical Molecules to Treat Bacterial Infections. 
2. Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections. 
3. Repurposing auranofin for the treatment of cutaneous staphylococcal infections. 
4. Repurposing of Anticancer Drugs for the Treatment of Bacterial Infections. 
5. Innovative approaches to treat Staphylococcus aureus biofilm-related infections. 
6. Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus. 
7. Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus. 
8. Drug repurposing for the treatment of staphylococcal infections. 
9. Repurposing Ivacaftor for treatment of Staphylococcus aureus infections. 
10. In vitro antibacterial effects of statins against bacterial pathogens causing skin infections. 
11. Repurposing Clinical Molecule Ebselen to Combat Drug Resistant Pathogens. 
12. Screening a Commercial Library of Pharmacologically Active Small Molecules against 
Staphylococcus aureus Biofilms. 
13. Repurposing celecoxib as a topical antimicrobial agent. 
14. Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent. 
15. Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial 
pathogens. 
16. Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void? 
17. In Vitro Screening of an FDA-Approved Library Against ESKAPE Pathogens. 
18. Repurposing of nucleoside- and nucleobase-derivative drugs as antibiotics and biofilm inhibitors. 
19. In vitro antimicrobial activity of monensin against common clinical isolates associated with canine 
otitis externa. 
20. Repurposing FDA-approved drugs to combat drug-resistant Acinetobacter baumannii. 
21. Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe 
staphylococcal infections. 
22. Repurposing the anticancer drug mitomycin C for the treatment of persistent Acinetobacter baumannii 
infections. 
 




23. Drug repurposing: a new front in the war against Staphylococcus aureus. 
24. Statins and Antimicrobial Effects: Simvastatin as a Potential Drug against Staphylococcus aureus 
Biofilm. 
25. Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing Against 
Polymyxin-Resistant Multidrug-Resistant Gram-Negative Pathogens. 
26. The Immunomodulatory Drug Glatiramer Acetate is Also an Effective Antimicrobial Agent that Kills 
Gram-negative Bacteria. 
27. Recent Drug-Repurposing-Driven Advances in the Discovery of Novel Antibiotics. 
28. Screening a repurposing library for potentiators of antibiotics against Staphylococcus aureus biofilms. 
29. New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria. 
30. Inhibition of Fosfomycin Resistance Protein FosA by Phosphonoformate (Foscarnet) in Multidrug-
Resistant Gram-Negative Pathogens. 
31. Pathogenicity phenomena in three model systems: from network mining to emerging system-level 
properties. 
32. Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, 
Escherichia coli, and Klebsiella pneumoniae. 
33. Triclosan Is an Aminoglycoside Adjuvant for Eradication of Pseudomonas aeruginosa Biofilms. 
34. Repurposing niclosamide as a versatile antimicrobial surface coating against device-associated, 
hospital-acquired bacterial infections. 
35. Non-anti-infective effects of antimicrobials and their clinical applications: a review. 
36. Host-directed antimicrobial drugs with broad-spectrum efficacy against intracellular bacterial 
pathogens. 
37. Repurposing screens identify rifamycins as potential broad-spectrum therapy for multidrug-resistant 
Acinetobacter baumannii and select agent microorganisms. 
38. Combination therapy: the propitious rationale for drug development. 
39. Host response to respiratory bacterial pathogens as identified by integrated analysis of human gene 
expression data. 
40. An FDA-Drug Library Screen for Compounds with Bioactivities against Meticillin-Resistant 
Staphylococcus aureus (MRSA). 
41. New frontiers for anti-biofilm drug development. 
 




42. Identification of Agents Active against Methicillin-Resistant Staphylococcus aureus USA300 from a 
Clinical Compound Library. 
43. Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections. 
44. Repurposing of gallium-based drugs for antibacterial therapy. 
45. Resistance-resistant antibiotics. 
46. From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" 
Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators. 
47. Statins: antimicrobial resistance breakers or makers? 
48. Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa 
pathogenicity. 
49. Is There Potential for Repurposing Statins as Novel Antimicrobials? 
50. Antimicrobial Activity of Gallium Compounds on ESKAPE Pathogens. 
51. Extensive impact of non-antibiotic drugs on human gut bacteria. 
52. Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant 
Enterobacteriaceae infections. 
53. Raloxifene attenuates Pseudomonas aeruginosa pyocyanin production and virulence. 
54. Strategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant 
bacterial infections. 
55. Tedizolid Activity Against Clinical Mycobacterium abscessus Complex Isolates-An in vitro 
Characterization Study. 
56. In-house chemical library repurposing: A case example for Pseudomonas aeruginosa antibiofilm 
activity and quorum sensing inhibition. 
57. Identification and Validation of an Antivirulence Agent Targeting HlyU-Regulated Virulence in 
Vibrio vulnificus. 
58. Repurposing Toremifene for Treatment of Oral Bacterial Infections. 
59. Auranofin and its Analogues Show Potent Antimicrobial Activity Covering Multiresistant Pathogens: 
Structure-Activity Relationships. 
60. Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant 
Acinetobacter baumannii. 
61. Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium 
abscessus and Mycobacterium chelonae. 
 




62. Evaluating New Compounds to Treat Burkholderia pseudomallei Infections. 
63. In vitro activity of the antiasthmatic drug zafirlukast against the oral pathogens Porphyromonas 
gingivalis and Streptococcus mutans. 
64. Repurposing the Nonsteroidal Anti-inflammatory Drug Diflunisal as an Osteoprotective, 
Antivirulence Therapy for Staphylococcus aureus Osteomyelitis. 
65. Comparative analysis of methicillin-sensitive and resistant Staphylococcus aureus exposed to emodin 
based on proteomic profiling. 
66. Role of acid responsive genes in the susceptibility of Escherichia coli to ciclopirox. 
67. New Antimicrobial Approaches: Reuse of Old Drugs. 
68. Identification of novel drug targets in bovine respiratory disease: an essential step in applying 
biotechnologic techniques to develop more effective therapeutic treatments. 
69. Alternative clinical indications for novel antibiotics licensed for skin and soft tissue infection? 
70. Real-Time High-Throughput Drug and Synergy Testing for Multidrug-Resistant Bacterial Infection: 
A Case Report. 
71. Prospects for Anti-Biofilm Pharmaceuticals. 
72. Combating Multidrug-Resistant Pathogens with Host-Directed Nonantibiotic Therapeutics. 
73. Ribavirin suppresses bacterial virulence by targeting LysR-type transcriptional regulators. 
74. Drug Repositioning to Alleviate Systemic Inflammatory Response Syndrome Caused by Gram-
Negative Bacterial Outer Membrane Vesicles. 
75. Repurposing of Existing Statin drugs for treatment of Microbial Infections: How much Promising? 
76. Combating Intracellular Pathogens with Repurposed Host-Targeted Drugs. 
77. Skin and Soft Tissue Infections Due to Nontuberculous Mycobacteria. 
78. Repositioning of Memantine as a Potential Novel Therapeutic Agent against Meningitic E. coli-
Induced Pathogenicities through Disease-Associated Alpha7 Cholinergic Pathway and RNA Sequencing-
Based Transcriptome Analysis of Host Inflammatory Responses. 
79. Drug repurposing screens and synergistic drug-combinations for infectious diseases. 
80. A Drug Repositioning Approach Reveals that Streptococcus mutans Is Susceptible to a Diverse Range 
of Established Antimicrobials and Nonantibiotics. 
81. Editorial: Alternative Therapeutics against MDR Bacteria - "Fighting the Epidemic of Antibiotic 
Resistance". 
 




82. Antibacterial effects of antiretrovirals, potential implications for microbiome studies in HIV. 
83. A drug-repositioning screening identifies pentetic acid as a potential therapeutic agent for suppressing 
the elastase-mediated virulence of Pseudomonas aeruginosa. 
84. Mode of action and resistance studies unveil new roles for tropodithietic acid as an anticancer agent 
and the gamma-glutamyl cycle as a proton sink. 
85. Lytic activity of the staphylolytic Twort phage endolysin CHAP domain is enhanced by the SH3b cell 
wall binding domain. 
86. [Reinstating cloxacilin for empiric antibiotic in late-onset sepsis]. 
87. Characterization of a Francisella tularensis-Caenorhabditis elegans Pathosystem for the Evaluation of 
Therapeutic Compounds. 
88. Bedaquiline Inhibits the ATP Synthase in Mycobacterium abscessus and Is Effective in Infected 
Zebrafish. 
89. Inhibition of adenovirus infection by mifepristone. 
90. Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic 
protease in mycobacteria. 
91. Analysis of drug binding pockets and repurposing opportunities for twelve essential enzymes of 
ESKAPE pathogens. 
92. Protein kinase C-delta inhibitor, Rottlerin inhibits growth and survival of mycobacteria exclusively 
through Shikimate kinase. 
93. New antibacterial, non-genotoxic materials, derived from the functionalization of the anti-thyroid 
drug methimazole with silver ions. 
94. Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori. 
95. Antidepressants, antimicrobials or both? Gut microbiota dysbiosis in depression and possible 
implications of the antimicrobial effects of antidepressant drugs for antidepressant effectiveness. 
96. L-Captopril and its derivatives as potential inhibitors of microbial enzyme DapE: A combined 
approach of drug repurposing and similarity screening. 
97. Toward Repositioning Niclosamide for Antivirulence Therapy of Pseudomonas aeruginosa Lung 
Infections: Development of Inhalable Formulations through Nanosuspension Technology. 
98. Screening of a Drug Library Identifies Inhibitors of Cell Intoxication by CNF1. 
99. SCMBYK: prediction and characterization of bacterial tyrosine-kinases based on propensity scores of 
dipeptides. 
 




100. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning 
in local therapy of lung infections. 
101. [Nonantibiotic properties of macrolides and their role in modulation of the inflammatory reaction]. 
102. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide 
analogue drug exposure. 
103. Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA 
Efflux Pump Inhibitors. 
104. Potential repurposing of known drugs as potent bacterial beta-glucuronidase inhibitors. 
105. Structural Basis of Metallo-beta-Lactamase Inhibition by Captopril Stereoisomers. 
106. HIV reverse transcriptase: structural interpretation of drug resistant genetic variants from India. 
107. Antibiotic shortages: effective alternatives in the face of a growing problem. 
108. Exposure Matching of Pediatric Anti-infective Drugs: Review of Drugs Submitted to the Food and 
Drug Administration for Pediatric Approval. 
109. In Vitro and Intracellular Activity of Imipenem Combined with Rifabutin and Avibactam against 
Mycobacterium abscessus. 
110. Repurposing an old drug: aztreonam as a new treatment strategy for gonorrhoea. 
111. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 
reverse transcriptase. 
112. L-Lysine-alpha-Oxidase: Acidovorax citrulli Bacterium Inhibitor. 
113. Rapid Recovery of Clofazimine-Loaded Nanoparticles with Long-Term Storage Stability as Anti-
Cryptosporidium Therapy.  
 





A2-2g. Leaf clusters under Cluster 52 
 There are six leaf clusters under Cluster 52: Cluster 23 (93), Cluster 12 (59), Cluster 27 (160), 
Cluster 25 (171), Cluster 5 (41), Cluster 11 (66). 
*Cluster 23 focuses on repurposing kinase inhibitors, especially for treatment of acute myeloid leukemia 
*Cluster 12 focuses on ovarian cancer treatments, especially niclosamide 
*Cluster 27 focuses on treatments that destroy cancer cells 
*Cluster 25 focuses on anti-cancer treatments 
*Cluster 5 focuses on treatments for pancreatic cancer, especially Metformin 
*Cluster 11 focuses on breast cancer treatments 
  
 




A2-2g1. Cluster 23 record titles 
1. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and 
discovery of potential new DDK inhibitor scaffolds. 
2. K-Map: connecting kinases with therapeutics for drug repurposing and development. 
3. Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3beta and 
Activates WNT Signaling. 
4. Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) 
pseudokinase in cancer cells. 
5. Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480. 
6. Kinase Inhibitor Screening in Myeloid Malignancies. 
7. Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction with 
Dbf4 by the Fragment Complementation and Drug Repositioning Approach. 
8. A novel application of furazolidone: anti-leukemic activity in acute myeloid leukemia. 
9. Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer 
resistance to EGFR therapy. 
10. One reporter for in-cell activity profiling of majority of protein kinase oncogenes. 
11. Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer. 
12. Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with 
FLT3/ITD leukemia. 
13. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints. 
14. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute 
myeloid leukemia. 
15. Multi-pathway cellular analysis of compound selectivity. 
16. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. 
17. Monocyte-macrophage differentiation of acute myeloid leukemia cell lines by small molecules 
identified through interrogation of the Connectivity Map database. 
18. High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-
ALL. 
19. Repositioning of bromocriptine for treatment of acute myeloid leukemia. 
 




20. Redox modulation of adjacent thiols in VLA-4 by AS101 converts myeloid leukemia cells from a 
drug-resistant to drug-sensitive state. 
21. In silico drug repurposing of FDA-approved drugs to predict new inhibitors for drug resistant T315I 
mutant and wild-type BCR-ABL1: A virtual screening and molecular dynamics study. 
22. Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid 
leukemia. 
23. Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank 
database for allosteric Bcr-Abl inhibitors. 
24. Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA 
Metabolic Pathway Regulated by DCPS. 
25. Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human 
Nonsmall Cell Lung Cancer. 
26. In silico identification of potent small molecule inhibitors targeting epidermal growth factor receptor 
1. 
27. Chemogenomic Landscape of RUNX1-mutated AML Reveals Importance of RUNX1 Allele Dosage 
in Genetics and Glucocorticoid Sensitivity. 
28. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. 
29. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute 
lymphoblastic leukemia. 
30. A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast 
Differentiation In Vitro. 
31. Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1. 
32. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia. 
33. Valproic acid in the complex therapy of malignant tumors. 
34. Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies 
and in vivo effects. 
35. In silico identification of novel kinase inhibitors targeting wild-type and T315I mutant ABL1 from 
FDA-approved drugs. 
36. Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal 
tumor. 
37. The protein kinase 2 inhibitor CX-4945 regulates osteoclast and osteoblast differentiation in vitro. 
 




38. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids 
to inhibitors of B-cell receptor signaling. 
39. PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase 
inhibitors by inducing autophagy. 
40. A screen for Fli-1 transcriptional modulators identifies PKC agonists that induce erythroid to 
megakaryocytic differentiation and suppress leukemogenesis. 
41. Repurposing anticancer drugs for targeting necroptosis. 
42. Virtual Screening against Phosphoglycerate Kinase 1 in Quest of Novel Apoptosis Inhibitors. 
43. Bisphosphonates inactivate human EGFRs to exert antitumor actions. 
44. Upgrading gemcitabine with recycled kinase inhibitors. 
45. Inhibition of EGFR Signaling Protects from Mucormycosis. 
46. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute 
lymphoblastic leukemia and synergistically works with dasatinib. 
47. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug 
resistance of lung cancer. 
48. Cyclic AMP efflux inhibitors as potential therapeutic agents for leukemia. 
49. Drug-Repositioning Screens Identify Triamterene as a Selective Drug for the Treatment of DNA 
Mismatch Repair Deficient Cells. 
50. Structure-based repurposing of FDA-approved drugs as inhibitors of NEDD8-activating enzyme. 
51. Drug repurposing for gastrointestinal stromal tumor. 
52. Discovery of Novel SPAK Inhibitors That Block WNK Kinase Signaling to Cation Chloride 
Transporters. 
53. Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma 
treatment. 
54. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma 
Therapy. 
55. Selective human inhibitors of ATR and ATM render Leishmania major promastigotes sensitive to 
oxidative damage. 
56. Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through 
Akt/mTOR suppression. 
57. FDA-approved drugs selected using virtual screening bind specifically to G-quadruplex DNA. 
 




58. Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-
induced lytic activation. 
59. Fluvastatin activates sirtuin 6 to regulate sterol regulatory element-binding proteins and AMP-
activated protein kinase in HepG2 cells. 
60. Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally 
activated FGFR3 signaling in achondroplasia. 
61. Copper is required for oncogenic BRAF signalling and tumorigenesis. 
62. Molecular therapeutic strategies for FGFR3 gene-related skeletal dysplasia. 
63. 5-azacytidine inhibits nonsense-mediated decay in a MYC-dependent fashion. 
64. Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for 
gastrointestinal stromal tumor. 
65. A protein folding molecular imaging biosensor monitors the effects of drugs that restore mutant p53 
structure and its downstream function in glioblastoma cells. 
66. Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake 
in Lung Cancer. 
67. Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues. 
68. Repurposing existing drugs for new AMPK activators as a strategy to extend lifespan: a computer-
aided drug discovery study. 
69. A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase 
Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy. 
70. In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma. 
71. Molecular docking studies on thirteen fluoroquinolines with human topoisomerase II a and b. 
72. Discovery of alkyl bis(oxy)dibenzimidamide derivatives as novel protein arginine methyltransferase 1 
(PRMT1) inhibitors. 
73. Repurposing the antihelmintic mebendazole as a hedgehog inhibitor. 
74. A comprehensive approach to identifying repurposed drugs to treat SCN8A epilepsy. 
75. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from 
enhanced docking approach and molecular dynamics analyses. 
76. A Dual Readout Assay Based on Fluorescence Polarization and Time-Resolved Fluorescence 
Resonance Energy Transfer to Screen for RSK1 Inhibitors. 
77. Identification of FDA-approved drugs as novel allosteric inhibitors of human executioner caspases. 
 




78. Identification of toxin inhibitors using a magnetic nanosensor-based assay. 
79. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical 
activity against chronic lymphocytic leukemia. 
80. A small molecule screen identifies an inhibitor of DNA repair inducing the degradation of TFIIH and 
the chemosensitization of tumor cells to platinum. 
81. Identification of novel small-molecule inhibitors targeting menin-MLL interaction, repurposing the 
antidiarrheal loperamide. 
82. Unveiling anticancer potential of glibenclamide: Its synergistic cytotoxicity with doxorubicin on 
cancer cells. 
83. Response to hydralazine-valproate in a patient with mycosis fungoides. 
84. Cooperative recognition of T:T mismatch by echinomycin causes structural distortions in DNA 
duplex. 
85. Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer 
Chemotherapeutic. 
86. Toward drug repurposing in epigenetics: olsalazine as a hypomethylating compound active in a 
cellular context. 
87. Selected drugs with reported secondary cell-differentiating capacity prime latent HIV-1 infection for 
reactivation. 
88. Thermal profiling reveals phenylalanine hydroxylase as an off-target of panobinostat. 
89. Inhibition of Peroxidase Activity of Cytochrome c: De Novo Compound Discovery and Validation. 
90. Drug repurposing identifies therapeutic agents for gastrointestinal stromal tumors. 
91. Butamben derivatives enhance BMP-2-stimulated commitment of C2C12 cells into osteoblasts with 
induction of voltage-gated potassium channel expression. 
92. PP2A Controls Genome Integrity by Integrating Nutrient-Sensing and Metabolic Pathways with the 
DNA Damage Response. 
93. Cell reprogramming for skeletal dysplasia drug repositioning. 
  
 




A2-2g2. Cluster 12 record titles 
1. A Blockade of IGF Signaling Sensitizes Human Ovarian Cancer Cells to the Anthelmintic 
Niclosamide-Induced Anti-Proliferative and Anticancer Activities. 
2. Niclosamide and its analogs are potent inhibitors of Wnt/beta-catenin, mTOR and STAT3 signaling in 
ovarian cancer. 
3. Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells. 
4. Bithionol inhibits ovarian cancer cell growth in vitro - studies on mechanism(s) of action. 
5. Metformin and epithelial ovarian cancer therapeutics. 
6. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma 
in vitro and in vivo. 
7. Ormeloxifene efficiently inhibits ovarian cancer growth. 
8. A new niclosamide derivatives-B17 can inhibit urological cancers growth through apoptosis-related 
pathway. 
9. Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via 
oxidative stress-mediated mTOR inhibition. 
10. Assessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer. 
11. Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and 
Ovarian Carcinoma in Mouse Models. 
12. Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent 
drug candidates for cancer treatment. 
13. A Small-molecule Kinase Inhibitor, CEP-1347, Inhibits Survivin Expression and Sensitizes Ovarian 
Cancer Stem Cells to Paclitaxel. 
14. Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian 
cancer cells. 
15. Licofelone Enhances the Efficacy of Paclitaxel in Ovarian Cancer by Reversing Drug Resistance and 
Tumor Stem-like Properties. 
16. Drug Repurposing of the Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia. 
17. Discovering drugs to overcome chemoresistance in ovarian cancers based on the cancer genome atlas 
tumor transcriptome profile. 
18. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and 
noncanonical Wnt signaling pathway. 
 




19. The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells 
by Targeting Multiple Signal Pathways. 
20. Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian 
Cancer. 
21. Niclosamide enhances ROS-mediated cell death through c-Jun activation. 
22. Niclosamide, a Drug with Many (Re)purposes. 
23. Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell 
Cancer Cells. 
24. Niclosamide Induces Epiboly Delay During Early Zebrafish Embryogenesis. 
25. Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer. 
26. Valproic Acid Promotes Apoptosis and Cisplatin Sensitivity Through Downregulation of H19 
Noncoding RNA in Ovarian A2780 Cells. 
27. Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by 
inhibiting Wnt/beta-catenin signaling. 
28. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces 
Growth of Hepatocellular Carcinoma Cells InVitro and in Mice by Inhibiting Cell Division Cycle 37 
Signaling. 
29. Disulfiram/copper causes redox-related proteotoxicity and concomitant heat shock response in ovarian 
cancer cells that is augmented by auranofin-mediated thioredoxin inhibition. 
30. Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein 
phosphatase 2A in non-small cell lung cancer cells. 
31. Antibiotic drug rifabutin is effective against lung cancer cells by targeting the eIF4E-beta-catenin 
axis. 
32. Pyrvinium Sensitizes Clear Cell Renal Cell Carcinoma Response to Chemotherapy Via Casein Kinase 
1alpha-Dependent Inhibition of Wnt/beta-Catenin. 
33. beta-catenin and PI3Kdelta inhibition expands precursor Th17 cells with heightened stemness and 
antitumor activity. 
34. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. 
35. Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft 
model. 
36. In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian 
cancer. 
 




37. Antiviral Drug Ribavirin Targets Thyroid Cancer Cells by Inhibiting the eIF4E-beta-Catenin Axis. 
38. A convenient synthesis of lubeluzole and its enantiomer: evaluation as chemosensitizing agents on 
human ovarian adenocarcinoma and lung carcinoma cells. 
39. Doxycycline inhibits proliferation and induces apoptosis of both human papillomavirus positive and 
negative cervical cancer cell lines. 
40. Antimalarial drug mefloquine inhibits nuclear factor kappa B signaling and induces apoptosis in 
colorectal cancer cells. 
41. Inhibition of mTOR/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in 
oral tongue squamous cell carcinoma. 
42. Identification of Chemical Inhibitors of beta-Catenin-Driven Liver Tumorigenesis in Zebrafish. 
43. Repositioning of anti-viral drugs as therapy for cervical cancer. 
44. Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of 
action. 
45. A Novel High Content Imaging-Based Screen Identifies the Anti-Helminthic Niclosamide as an 
Inhibitor of Lysosome Anterograde Trafficking and Prostate Cancer Cell Invasion. 
46. Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian 
tumor cells. 
47. Doxycycline is an NF-kappaB inhibitor that induces apoptotic cell death in malignant T-cells. 
48. Repurposing the anti-malarial drug dihydroartemisinin suppresses metastasis of non-small-cell lung 
cancer via inhibiting NF-kappaB/GLUT1 axis. 
49. Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer. 
50. Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of 
interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma. 
51. Effects of digitoxin on cell migration in ovarian cancer inflammatory microenvironment. 
52. Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase 
Inhibition for Peritoneal Carcinomatosis. 
53. Ribavirin as a tri-targeted antitumor repositioned drug. 
54. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent 
pathways among FDA-approved compounds. 
55. Repurposing disulfiram for cancer therapy via targeted nanotechnology through enhanced tumor mass 
penetration and disassembly. 
 




56. Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-kappaB 
signaling. 
57. Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc 
adenomas are downregulated in response to tumor suppression by Clotam. 
58. Repurposing the FDA-approved pinworm drug pyrvinium as a novel chemotherapeutic agent for 
intestinal polyposis. 








A2-2g3. Cluster 27 record titles 
1. Delineation of biological and molecular mechanisms underlying the diverse anticancer activities of 
mycophenolic acid. 
2. Transcriptomic changes induced by mycophenolic acid in gastric cancer cells. 
3. Therapeutic Effect of Quinacrine, an Antiprotozoan Drug, by Selective Suppression of p-CHK1/2 in 
p53-Negative Malignant Cancers. 
4. A novel anti-cancer role of beta-apopicropodophyllin against non-small cell lung cancer cells. 
5. Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from 
pathophysiology to treatment. 
6. TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) 
Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin. 
7. Drug Repurposing Screening Identifies Tioconazole as an ATG4 Inhibitor that Suppresses Autophagy 
and Sensitizes Cancer Cells to Chemotherapy. 
8. New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer 
cell line panels. 
9. New derivatives of the antimalarial drug Pyrimethamine in the control of melanoma tumor growth: an 
in vitro and in vivo study. 
10. The combination astemizole-gefitinib as a potential therapy for human lung cancer. 
11. The antiparasitic drug, potassium antimony tartrate, inhibits tumor angiogenesis and tumor growth in 
nonsmall-cell lung cancer. 
12. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces 
endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. 
13. Proton pump inhibitor ilaprazole suppresses cancer growth by targeting T-cell-originated protein 
kinase. 
14. Repurposing of phentolamine as a potential anticancer agent against human castration-resistant 
prostate cancer: A central role on microtubule stabilization and mitochondrial apoptosis pathway. 
15. The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-
associated fibroblasts. 
16. Screening of a composite library of clinically used drugs and well-characterized pharmacological 
compounds for cystathionine beta-synthase inhibition identifies benserazide as a drug potentially suitable 
for repurposing for the experimental therapy of colon cancer. 
17. Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy. 
 




18. The aryl hydrocarbon receptor is required for induction of p21cip1/waf1 expression and growth 
inhibition by SU5416 in hepatoma cells. 
19. Eritoran Suppresses Colon Cancer by Altering a Functional Balance in Toll-like Receptors That Bind 
Lipopolysaccharide. 
20. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell 
lung cancer cells. 
21. Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2. 
22. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell 
carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis. 
23. Identification of repurposed small molecule drugs for chordoma therapy. 
24. Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with 
Repurposing Potential. 
25. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon 
cancer. 
26. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-
induced ferroptosis. 
27. Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination 
with erlotinib in pancreatic cancer cells. 
28. Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple 
opportunities for drug repurposing. 
29. CLC-Pred: A freely available web-service for in silico prediction of human cell line cytotoxicity for 
drug-like compounds. 
30. Repositioning of amprenavir as a novel extracellular signal-regulated kinase-2 inhibitor and apoptosis 
inducer in MCF-7 human breast cancer. 
31. Antibiotic drug levofloxacin inhibits proliferation and induces apoptosis of lung cancer cells through 
inducing mitochondrial dysfunction and oxidative damage. 
32. Glutamate release inhibitor, Riluzole, inhibited proliferation of human hepatocellular carcinoma cells 
by elevated ROS production. 
33. Parainfluenza Virus Infection Sensitizes Cancer Cells to DNA-Damaging Agents: Implications for 
Oncolytic Virus Therapy. 
34. p73 as a pharmaceutical target for cancer therapy. 
 




35. Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity 
in thyroid cancer cells: opportunities for repurposing. 
36. Verteporfin inhibits gastric cancer cell growth by suppressing adhesion molecule FAT1. 
37. Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivity. 
38. Repositioning of difluorinated propanediones as inhibitors of histone methyltransferases and their 
biological evaluation in human leukemic cell lines. 
39. Tigecycline targets nonsmall cell lung cancer through inhibition of mitochondrial function. 
40. The Antiarrhythmic Drug, Amiodarone, Decreases AKT Activity and Sensitizes Human Acute 
Myeloid Leukemia Cells to Apoptosis by ABT-263. 
41. Autophagy Induced by Naftopidil Inhibits Apoptosis of Human Gastric Cancer Cells. 
42. Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by 
artesunate. 
43. Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer. 
44. Drug Repurposing Approach Identifies a Synergistic Drug Combination of an Antifungal Agent and 
an Experimental Organometallic Drug for Melanoma Treatment. 
45. Pharmacological targeting of p38 MAP-Kinase 6 (MAP2K6) inhibits the growth of esophageal 
adenocarcinoma. 
46. Identification of thiazolo[5,4-d]pyrimidine derivatives as potent antiproliferative agents through the 
drug repurposing strategy. 
47. Autophagy in HIV-induced T cell death. 
48. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in 
cancer cell lines. 
49. Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT 
Pathways. 
50. Four clinically utilized drugs were identified and validated for treatment of adrenocortical cancer 
using quantitative high-throughput screening. 
51. In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a 
Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug. 
52. Acute oxidant damage promoted on cancer cells by amitriptyline in comparison with some common 
chemotherapeutic drugs. 
 




53. Repurposing itraconazole to the benefit of skin cancer treatment: A combined azole-DDAB 
nanoencapsulation strategy. 
54. Targeting Phosphatidylinositol 4-Kinase IIIalpha for Radiosensitization: A Potential Model of Drug 
Repositioning Using an Anti-Hepatitis C Viral Agent. 
55. Anticancer Properties of Fenofibrate: A Repurposing Use. 
56. Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing. 
57. A tumor deconstruction platform identifies definitive end points in the evaluation of drug responses. 
58. Repositioning "old" drugs for new causes: identifying new inhibitors of prostate cancer cell migration 
and invasion. 
59. Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes 
differentiation of head and neck squamous cell carcinoma (HNSCC). 
60. Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new 
potential strategy for identification of anti-cancer therapeutics in B-cell malignancies. 
61. Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt/mTOR and inducing 
oxidative stress. 
62. P-gp Inhibition by the Anti-psychotic Drug Pimozide Increases Apoptosis, as well as Expression of 
pRb and pH2AX in Highly Drug-resistant KBV20C Cells. 
63. Luteolin Impacts on the DNA Damage Pathway in Oral Squamous Cell Carcinoma. 
64. Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in 
adrenocortical carcinoma and has biomarkers of response. 
65. Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a 
Candidate for Treatment of Colorectal Cancer. 
66. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling. 
67. Multiple effects of digoxin on subsets of cancer-associated genes through the alternative splicing 
pathway. 
68. High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitor. 
69. Emerging roles of Myc in stem cell biology and novel tumor therapies. 
70. Induction of DNA damage and apoptosis in human leukemia cells by efavirenz. 
71. From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy. 
72. Identifying candidate agents for lung adenocarcinoma by walking the human interactome. 
 




73. Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T-cell 
leukemia cells. 
74. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung 
cancer and other neuroendocrine tumors. 
75. Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial 
agent. 
76. In silico prediction and in vitro and in vivo validation of acaricide fluazuron as a potential inhibitor of 
FGFR3 and a candidate anticancer drug for bladder carcinoma. 
77. Ex vivo drug sensitivity testing as a means for drug repurposing in esophageal adenocarcinoma. 
78. Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do? 
79. Therapeutic Effect of Repurposed Temsirolimus in Lung Adenocarcinoma Model. 
80. The antimalarial amodiaquine causes autophagic-lysosomal and proliferative blockade sensitizing 
human melanoma cells to starvation- and chemotherapy-induced cell death. 
81. Repositioning of anti-cancer drug candidate, AZD7762, to an anti-allergic drug suppressing IgE-
mediated mast cells and allergic responses via the inhibition of Lyn and Fyn. 
82. Tumor deconstruction as a tool for advanced drug screening and repositioning. 
83. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer. 
84. Expression Profiling Identifies Bezafibrate as Potential Therapeutic Drug for Lung Adenocarcinoma. 
85. N-bromotaurine surrogates for loss of antiproliferative response and enhances cisplatin efficacy in 
cancer cells with impaired glucocorticoid receptor. 
86. In vitro and in vivo study of hydralazine, a potential anti-angiogenic agent. 
87. Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung 
Cancer. 
88. Increasing procaspase 8 expression using repurposed drugs to induce HIV infected cell death in ex 
vivo patient cells. 
89. Revisiting old drugs as novel agents for retinoblastoma: in vitro and in vivo antitumor activity of 
cardenolides. 
90. Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC/BCL2 
double-hit B cell lymphoma. 
91. Pharmacological exploitation of the phenothiazine antipsychotics to develop novel antitumor agents-A 
drug repurposing strategy. 
 




92. Biotin-targeted Pluronic() P123/F127 mixed micelles delivering niclosamide: A repositioning strategy 
to treat drug-resistant lung cancer cells. 
93. The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in 
hepatocellular carcinoma. 
94. PPARgamma agonists promote differentiation of cancer stem cells by restraining YAP transcriptional 
activity. 
95. Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas. 
96. Concise Review: Cell Surface N-Linked Glycoproteins as Potential Stem Cell Markers and Drug 
Targets. 
97. Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing. 
98. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. 
99. Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive 
melanoma: a strategy for repurposing a phase I clinical trial drug. 
100. Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1. 
101. Repurposed drug screen identifies cardiac glycosides as inhibitors of TGF-beta-induced cancer-
associated fibroblast differentiation. 
102. Concise Review: Cell Surface N-Linked Glycoproteins as Potential Stem Cell Markers and Drug 
Targets. 
103. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon 
Cancer Epigenome. 
104. Possible targets on carcinoma for bMAb retargeting of lymphocyte or drug cytotoxicity. 
105. Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of 
human fatty acid synthase. 
106. Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: a crucial 
role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation. 
107. Piperazine-based Alpha-1 AR Blocker, Naftopidil, Selectively Suppresses Malignant Human 
Bladder Cells via Induction of Apoptosis. 
108. Vitamin K and hepatocellular carcinoma: The basic and clinic. 
109. Identification of a new pharmacological activity of the phenylpiperazine derivative naftopidil: 
tubulin-binding drug. 
 




110. Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and 
displayed synergistic lethality with piperlongumine in gastric cancer. 
111. High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A 
drug repurposing strategy for advanced cancer. 
112. Albendazole as a promising molecule for tumor control. 
113. Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer 
associated fibroblasts (CAFs) by synergistic induction of apoptosis. 
114. Drug Repositioning of Proton Pump Inhibitors for Enhanced Efficacy and Safety of Cancer 
Chemotherapy. 
115. Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic 
pontine glioma. 
116. HMG-CoA Reductase Inhibition Delays DNA Repair and Promotes Senescence After Tumor 
Irradiation. 
117. The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell 
carcinoma. 
118. Aging-related Repositioned Drugs, Donepezil and Sildenafil Citrate, Increase Apoptosis of Anti-
mitotic Drug-resistant KBV20C Cells Through Different Molecular Mechanisms. 
119. Highly Halaven-resistant KBV20C Cancer Cells Can Be Sensitized by Co-treatment with 
Fluphenazine. 
120. The human immunodeficiency virus protease inhibitor ritonavir is potentially active against 
urological malignancies. 
121. FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model. 
122. Synthesis and biological evaluation of thiabendazole derivatives as anti-angiogenesis and vascular 
disrupting agents. 
123. Phenotypic identification of the redox dye methylene blue as an antagonist of heat shock response 
gene expression in metastatic melanoma cells. 
124. Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate 
cancer cells. 
125. Fenofibrate Suppresses Oral Tumorigenesis via Reprogramming Metabolic Processes: Potential 
Drug Repurposing for Oral Cancer. 
126. Computational repositioning and preclinical validation of pentamidine for renal cell cancer. 
 




127. The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory 
NRASQ61K melanoma. 
128. Prevention of skin carcinogenesis by the beta-blocker carvedilol. 
129. Ferroquine, the next generation antimalarial drug, has antitumor activity. 
130. Comparative oncology approach to drug repurposing in osteosarcoma. 
131. The EYA tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromarone. 
132. Quinacrine in endometrial cancer: Repurposing an old antimalarial drug. 
133. Reprofiling using a zebrafish melanoma model reveals drugs cooperating with targeted therapeutics. 
134. Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning. 
135. New HSP27 inhibitors efficiently suppress drug resistance development in cancer cells. 
136. Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in 
colorectal cancer: Invitro and invivo study. 
137. A statin-regulated microRNA represses human c-Myc expression and function. 
138. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the 
bone marrow microenvironment. 
139. Replication Study: Discovery and preclinical validation of drug indications using compendia of 
public gene expression data. 
140. Stromal microenvironment in type VII collagen-deficient skin: The ground for squamous cell 
carcinoma development. 
141. Auranofin: repurposing an old drug for a golden new age. 
142. Repurposing cephalosporin antibiotics as pro-senescent radiosensitizers. 
143. Discovery of rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer. 
144. The Hippo pathway in normal development and cancer. 
145. Activation of PP2A by perphenazine induces apoptosis in T-ALL. 
146. Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis 
of fatty acids. 
147. Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of 
retinoblastoma protein in renal cell carcinoma. 
148. Repurposing of Drugs Targeting YAP-TEAD Functions. 
 




149. Homology modelling and molecular docking of MDR1 with chemotherapeutic agents in non-small 
cell lung cancer. 
150. Clomipramine kills Trypanosoma brucei by apoptosis. 
151. Autophagy Modulation in Disease Therapy: Where Do We Stand? 
152. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer. 
153. Novel spirobicyclic artemisinin analogues (artemalogues): Synthesis and antitumor activities. 
154. Ibrutinib repurposing: from B-cell malignancies to solid tumors. 
155. Drug repurposing using high-throughput screening identifies a promising drug combination to treat 
adrenocortical carcinoma. 
156. Repurposing Vitamin D as an Anticancer Drug. 
157. Molecular mimicry-based repositioning of nutlin-3 to anti-apoptotic Bcl-2 family proteins. 
158. Selective inhibition of host cell signaling for rotavirus antivirals: PI3K/Akt/mTOR-mediated 
rotavirus pathogenesis. 
159. [Role of bioinformatics in research and development of antipsychotic agents]. 
160. Chlorambucil in indolent mantle cell lymphoma--just another old drug for a new disease? 
  
 




A2-2g4. Cluster 25 record titles 
1. Repurposing Tecfidera for cancer. 
2. Drug repurposing in cancer. 
3. Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug 
development. 
4. Revisiting Non-Cancer Drugs for Cancer Therapy. 
5. Cancer Prevention and Interception: A New Era for Chemopreventive Approaches. 
6. A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. 
7. The potential to treat lung cancer via inhalation of repurposed drugs. 
8. Drug Repurposing in the Development of Anticancer Agents. 
9. Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell 
migration and invasion and is inhibited by statins. 
10. Drug Repositioning for Effective Prostate Cancer Treatment. 
11. Drug Repurposing for Cancer Therapy. 
12. Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-
cancer activity. 
13. Targeting ADAM17 Sheddase Activity in Cancer. 
14. Repurposing Drugs in Oncology (ReDO)-nitroglycerin as an anti-cancer agent. 
15. Molecular pathways: trafficking of metabolic resources in the tumor microenvironment. 
16. Potential anti-cancer drugs commonly used for other indications. 
17. Repositioning of drugs for intervention in tumor progression and metastasis: Old drugs for new 
targets. 
18. Drug Repurposing in Anticancer Reagent Development. 
19. Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells. 
20. Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent. 
21. Cancer drug discovery by repurposing: teaching new tricks to old dogs. 
22. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover 
Potentially Targetable Cancer Cell Dependencies. 
 




23. [Chemoprevention of colorectal cancer for broad clinical use in the future]. 
24. Glipizide suppresses prostate cancer progression in the TRAMP model by inhibiting angiogenesis. 
25. The impact of transcription on metabolism in prostate and breast cancers. 
26. Cell line modeling for systems medicine in cancers (review). 
27. Repositioning approved drugs for the treatment of problematic cancers using a screening approach. 
28. Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent. 
29. Repurposing Drugs for Cancer Prevention. 
30. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer 
treatment. 
31. CONCORD biomarker prediction for novel drug introduction to different cancer types. 
32. Transforming Cancer Prevention through Precision Medicine and Immune-oncology. 
33. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. 
34. Repositioning of proton pump inhibitors in cancer therapy. 
35. Combining genomic and network characteristics for extended capability in predicting synergistic 
drugs for cancer. 
36. Misfolded proteins: from little villains to little helpers in the fight against cancer. 
37. A current perspective on the oncopreventive and oncolytic properties of selective serotonin reuptake 
inhibitors. 
38. Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent. 
39. Identification of driver copy number alterations in diverse cancer types and application in drug 
repositioning. 
40. [Metabolic Competition in Tumor Microenvironment]. 
41. Patient derived organoids to model rare prostate cancer phenotypes. 
42. Tumor progression: the neuronal input. 
43. Memantine induces apoptosis and inhibits cell cycle progression in LNCaP prostate cancer cells. 
44. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer 
Treatment. 
45. Novel drug candidates for the treatment of metastatic colorectal cancer through global inverse gene-
expression profiling. 
 




46. Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs. 
47. Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake. 
48. Metformin for Prevention and Treatment of Colon Cancer: A Reappraisal of Experimental and 
Clinical Data. 
49. From drug response profiling to target addiction scoring in cancer cell models. 
50. Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform. 
51. Repurposing of FDA-approved drugs against cancer - focus on metastasis. 
52. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. 
53. Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent. 
54. The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance 
in cancer cell lines. 
55. Identification of an old antibiotic clofoctol as a novel activator of unfolded protein response pathways 
and an inhibitor of prostate cancer. 
56. Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of 
Opportunity for Ovarian Cancer Chemoprevention. 
57. Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via 
MACC1. 
58. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. 
59. Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia 
Patients. 
60. Anti-cancer potential of a novel SERM ormeloxifene. 
61. The mortality reducing effect of aspirin in colorectal cancer patients: Interpreting the evidence. 
62. Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent. 
63. Repurposing itraconazole as an anticancer agent. 
64. The Emerging Facets of Non-Cancerous Warburg Effect. 
65. Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New 
Again. 
66. Personalization of cancer treatment using predictive simulation. 
67. Repurposing Drugs in Oncology: Next Steps. 
 




68. Identification of Small-Molecule Inhibitors of Human Golgi Mannosidase via a Drug Repositioning 
Screen. 
69. Discovery and validation of the antimetastatic activity of citalopram in colorectal cancer. 
70. The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate 
cancer. 
71. The Concept of Hormesis in Cancer Therapy - Is Less More? 
72. Possibility as an anti-cancer drug of astemizole: Evaluation of arrhythmogenicity by the chronic 
atrioventricular block canine model. 
73. Repurposing psychiatric drugs as anti-cancer agents. 
74. Targeting ion channels for cancer therapy by repurposing the approved drugs. 
75. Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved 
Therapies and Emerging Concepts. 
76. Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and 
therapeutic opportunities. 
77. Designing novel therapies against sarcomas in the era of personalized medicine and economic crisis. 
78. Role of ion channels in natural killer cell function towards cancer. 
79. Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from 
Chemorefractory Neoplasia. 
80. Discovery and development of Seliciclib. How systems biology approaches can lead to better drug 
performance. 
81. In Silico-Based Repositioning of Phosphinothricin as a Novel Technetium-99m Imaging Probe with 
Potential Anti-Cancer Activity. 
82. Challenges and perspective of drug repurposing strategies in early phase clinical trials. 
83. Repurposing and Rescuing of Mibefradil, an Antihypertensive, for Cancer: A Case Study. 
84. Could cancer drugs be repurposed for use in Parkinson's and Alzheimer's? 
85. Old-School Chemotherapy in Immunotherapeutic Combination in Cancer, A Low-cost Drug 
Repurposed. 
86. The Architecture and Function of Monoclonal Antibody-Functionalized Mesoporous Silica 
Nanoparticles Loaded with Mifepristone: Repurposing Abortifacient for Cancer Metastatic 
Chemoprevention. 
 




87. A chemical genomics approach to drug reprofiling in oncology: Antipsychotic drug risperidone as a 
potential adenocarcinoma treatment. 
88. The Amide Local Anesthetic Lidocaine in Cancer Surgery-Potential Antimetastatic Effects and 
Preservation of Immune Cell Function? A Narrative Review. 
89. A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor. 
90. Repositioning therapy for thyroid cancer: new insights on established medications. 
91. Immune Cell Metabolism in Tumor Microenvironment. 
92. A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent Cancers. 
93. Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents. 
94. Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from 
nature and drug repurposing. 
95. Cancer Drug Development Using Drosophila as an in vivo Tool: From Bedside to Bench and Back. 
96. Seek and destroy: relating cancer drivers to therapies. 
97. S100A4 in Cancer Metastasis: Wnt Signaling-Driven Interventions for Metastasis Restriction. 
98. The wisdom of crowds and the repurposing of artesunate as an anticancer drug. 
99. Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer. 
100. An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer. 
101. Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy. 
102. Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins. 
103. Mouse hospital and co-clinical trial project--from bench to bedside. 
104. Insights into the Link Between Obesity and Cancer. 
105. Drug Repurposing for Terminal-Stage Cancer Patients. 
106. Reprofiling of Troglitazone Towards More Active and Less Toxic Derivatives: A New Hope for 
Cancer Treatment? 
107. Pharmacological targeting of ion channels for cancer therapy: In vivo evidences. 
108. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate 
cancer invivo. 
109. The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. 
 




110. Some leopards can change their spots: potential repositioning of stem cell reprogramming 
compounds as anti-cancer agents. 
111. Molecular-targeted nanotherapies in cancer: enabling treatment specificity. 
112. Repurposing drugs in your medicine cabinet: untapped opportunities for cancer therapy? 
113. Systematic dissection of dysregulated transcription factor-miRNA feed-forward loops across tumor 
types. 
114. CaV channels and cancer: canonical functions indicate benefits of repurposed drugs as cancer 
therapeutics. 
115. The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod. 
116. Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent. 
117. Anti-malarials are anti-cancers and vice versa - one arrow two sparrows. 
118. Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells. 
119. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from 
rational design, nature and old drug reposition. 
120. Idiopathic pulmonary fibrosis and cancer: do they really look similar? 
121. Drug repurposing for the treatment of glioblastoma multiforme. 
122. Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism. 
123. Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and 
redox capacity. 
124. Repurposing itraconazole for the treatment of cancer. 
125. SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for 
colorectal cancer. 
126. Role of TGFbeta in regulation of the tumor microenvironment and drug delivery (review). 
127. Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy. 
128. [Paradigms, doses and controversies in cancer therapy]. 
129. Copper Complexes in Cancer Therapy. 
130. Cancer: fundamentals behind pH targeting and the double-edged approach. 
131. Anticancer and Immunogenic Properties of Cardiac Glycosides. 
132. Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review. 
 




133. Drug Repurposing of Metabolic Agents in Malignant Glioma. 
134. New use for old drugs? Prospective targets of chloroquines in cancer therapy. 
135. Chemoprevention agents for melanoma: a path forward into phase 3 clinical trials. 
136. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly 
Guided Targeted Therapy. 
137. Study finds possible role for aspirin as treatment for colon cancer. 
138. Low-dose salinomycin induces anti-leukemic responses in AML and MLL. 
139. Repurposing apoptosis-inducing cancer drugs to treat schistosomiasis. 
140. Metabolic reprogramming in clear cell renal cell carcinoma. 
141. Drug Repositioning Meets Precision in Glioblastoma. 
142. Teaching an old dog new tricks: drug repositioning in small cell lung cancer. 
143. Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target 
energy metabolism for cancer treatment. 
144. Repurposing Cationic Amphiphilic Antihistamines for Cancer Treatment. 
145. Revisiting nomenclature for the description of prostate cancer androgen-responsiveness. 
146. Perioperative therapies - Enhancing the impact of cancer surgery with repurposed drugs. 
147. Trimodal Therapy: Combining Hyperthermia with Repurposed Bexarotene and Ultrasound for 
Treating Liver Cancer. 
148. Radiation-Drug Combinations to Improve Clinical Outcomes and Reduce Normal Tissue Toxicities: 
Current Challenges and New Approaches: Report of the Symposium Held at the 63rd Annual Meeting of 
the Radiation Research Society, 15-18 October 2017; Cancun, Mexico. 
149. A screening cascade to identify ERbeta ligands. 
150. Hyaluronan-Derived Swelling of Solid Tumors, the Contribution of Collagen and Cancer Cells, and 
Implications for Cancer Therapy. 
151. Repositioning compounds from cancer drug discovery to IPF: PI3K inhibition. 
152. Case Report: Propranolol increases the therapeutic response to temozolomide in a patient with 
metastatic paraganglioma. 
153. Appraisal of mechanisms of radioprotection and therapeutic approaches of radiation 
countermeasures. 
 




154. Mitochondrial dysfunction and potential anticancer therapy. 
155. Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing. 
156. Nanomedicine for prostate cancer using nanoemulsion: A review. 
157. The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the 
treatment of haematologic malignancy. 
158. Targeting STAT1 in Both Cancer and Insulin Resistance Diseases. 
159. Summary of the 45th annual meeting on women's cancers. 
160. Drug repositioning from bench to bedside: tumour remission by the antihelmintic drug mebendazole 
in refractory metastatic colon cancer. 
161. Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy. 
162. Repurposing cancer drugs to treat neurological diseases - Src inhibitors as examples. 
163. Chloroquine-containing compounds: a patent review (2010 - 2014). 
164. Marketed drugs used for the management of hypercholesterolemia as anticancer armament. 
165. Cell Metabolism Clinical and Translational Reports. 
166. The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in 
hepatocellular carcinoma. 
167. Cancer immunotherapy without frontiers: 2nd Annual Immuno-Oncology Meeting of the Centro de 
Investigacion de Cancer en Sonora (CICS), Ciudad Obregon, Sonora Mexico, Dec 2-4, 2016. 
168. Does the oncology community have a rejection bias when it comes to repurposed drugs? 
169. Nonprofit drugs as the salvation of the world's healthcare systems: the case of Antabuse (disulfiram). 
170. Repurposing approved and abandoned drugs for the treatment and prevention of cancer through 
public-private partnership. 
171. Clarithromycin as a "repurposing drug" against MALT lymphoma. 
  
 




A2-2g5. Cluster 5 record titles 
1. Modified Metformin as a More Potent Anticancer Drug: Mitochondrial Inhibition, Redox Signaling, 
Antiproliferative Effects and Future EPR Studies. 
2. No association between metformin use and survival in patients with pancreatic cancer: An 
observational cohort study. 
3. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled 
phase 2 trial. 
4. Mitochondria-targeted metformins: anti-tumour and redox signalling mechanisms. 
5. Model-based unsupervised learning informs metformin-induced cell-migration inhibition through an 
AMPK-independent mechanism in breast cancer. 
6. Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic 
cancer prevention and treatment. 
7. Old drug, new trick: repurposing metformin for gynecologic cancers? 
8. Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery. 
9. Metformin directly acts on mitochondria to alter cellular bioenergetics. 
10. Repurposing metformin for the prevention of cancer and cancer recurrence. 
11. Metformin as a geroprotector: experimental and clinical evidence. 
12. Metformin: its emerging role in oncology. 
13. MATE2 Expression Is Associated with Cancer Cell Response to Metformin. 
14. [New perspectives for metformin in cancer therapy]. 
15. Metformin use and gynecological cancers: A novel treatment option emerging from drug 
repositioning. 
16. Metformin for non-small cell lung cancer patients: Opportunities and pitfalls. 
17. Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and 
Radiosensitizing Effects in Pancreatic Cancer Cells. 
18. Metformin Use in Relation With Survival Outcomes of Patients With Renal Cell Carcinoma. 
19. Metformin repositioning as antitumoral agent: selective antiproliferative effects in human 
glioblastoma stem cells, via inhibition of CLIC1-mediated ion current. 
20. Prediction of Candidate Drugs for Treating Pancreatic Cancer by Using a Combined Approach. 
 




21. The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer. 
22. One-carbon metabolism: an aging-cancer crossroad for the gerosuppressant metformin. 
23. Validating drug repurposing signals using electronic health records: a case study of metformin 
associated with reduced cancer mortality. 
24. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow 
Tumor Growth in Mice. 
25. Use of metformin and survival of patients with high-grade glioma. 
26. Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a 
phase II trial. 
27. Repurposing old drugs to chemoprevention: the case of metformin. 
28. A drug-repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6-
thioguanine as an effective therapeutic agent for TPMT-low cancer cells. 
29. A selective mitochondrial-targeted chlorambucil with remarkable cytotoxicity in breast and pancreatic 
cancers. 
30. A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing 
disulfiram. 
31. Blocking IL-6/GP130 signaling inhibits cell viability/proliferation, glycolysis, and colony forming 
activity in human pancreatic cancer cells. 
32. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity 
and Metastasis. 
33. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy. 
34. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma. 
35. Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs). 
36. Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-
mutated or IDH2-mutated solid tumours. 
37. Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as 
adjuncts to therapy. 
38. Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective. 
39. A therapy for FXS? 
40. Metastasis and chemoresistance in CD133 expressing pancreatic cancer cells are dependent on their 
lipid raft integrity. 
 












A2-2g6. Cluster 11 record titles 
1. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast 
cancer. 
2. PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness. 
3. The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit 
epithelial-to-mesenchymal transition and augment capecitabine efficacy. 
4. Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of 
sensitivity. 
5. Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) 
polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast 
cancer cells. 
6. Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer. 
7. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant 
mammary tissues of MMTV-erbB-2 transgenic mice. 
8. FoxO3a Mediates the Inhibitory Effects of the Antiepileptic Drug Lamotrigine on Breast Cancer 
Growth. 
9. Pathway-Based Drug Repositioning for Breast Cancer Molecular Subtypes. 
10. Existing drugs and their application in drug discovery targeting cancer stem cells. 
11. Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes. 
12. Inhibitors of Cancer Stem Cells. 
13. The CARMA3-Bcl10-MALT1 Signalosome Drives NFkappaB Activation and Promotes 
Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer. 
14. The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo. 
15. Metformin and propranolol combination prevents cancer progression and metastasis in different breast 
cancer models. 
16. Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote 
metastasis. 
17. Novel modeling of cancer cell signaling pathways enables systematic drug repositioning for distinct 
breast cancer metastases. 
18. Cytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted 
therapeutics. 
 




19. Repositioning of antibiotic levofloxacin as a mitochondrial biogenesis inhibitor to target breast 
cancer. 
20. Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched 
for stem cell-like properties. 
21. [Cancer stem cells as the therapeutic target of tomorrow]. 
22. Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in 
ER+ breast cancer. 
23. Integration of a prognostic gene module with a drug sensitivity module to identify drugs that could be 
repurposed for breast cancer therapy. 
24. Propranolol and breast cancer-a work in progress. 
25. Emerging nanotherapeutic strategies in breast cancer. 
26. Aripiprazole, an Antipsychotic and Partial Dopamine Agonist, Inhibits Cancer Stem Cells and 
Reverses Chemoresistance. 
27. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent 
activity against breast cancer. 
28. Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common 
therapies. 
29. New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate. 
30. An Integrative Drug Repurposing Pipeline: Switching Viral Drugs to Breast Cancer. 
31. Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality. 
32. Mucuna pruriens (L.) DC chemo sensitize human breast cancer cells via downregulation of prolactin-
mediated JAK2/STAT5A signaling. 
33. Doxycycline and therapeutic targeting of the DNA damage response in cancer cells: old drug, new 
purpose. 
34. Imidazole Antifungal Drugs Inhibit the Cell Proliferation and Invasion of Human Breast Cancer Cells. 
35. Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. 
36. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast 
cancer growth and metastasis. 
37. The heterogeneity of cancer stem-like cells at the invasive front. 
38. Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015). 
 




39. The Tissue-Reconstructing Ability of Colon CSCs Is Enhanced by FK506 and Suppressed by GSK3 
Inhibition. 
40. The sodium channel-blocking antiepileptic drug phenytoin inhibits breast tumour growth and 
metastasis. 
41. Targeting cancer stem cells with dietary phytochemical - Repositioned drug combinations. 
42. PEGylated chitosan nanoparticles potentiate repurposing of ormeloxifene in breast cancer therapy. 
43. Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem 
cells. 
44. Use of monoclonal antibody-IRDye800CW bioconjugates in the resection of breast cancer. 
45. Chk1 as a new therapeutic target in triple-negative breast cancer. 
46. Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-
like cancer cells. 
47. Targeting of embryonic annexin A2 expressed on ovarian and breast cancer by the novel monoclonal 
antibody 2448. 
48. Inhibition of PI4K IIIalpha radiosensitizes in human tumor xenograft and immune-competent 
syngeneic murine tumor model. 
49. Carglumic acid promotes apoptosis and suppresses cancer cell proliferation in vitro and in vivo. 
50. Therapeutic potential for phenytoin: targeting Na(v)1.5 sodium channels to reduce migration and 
invasion in metastatic breast cancer. 
51. Repositioning of Anti-parasitic Drugs in Cyclodextrin Inclusion Complexes for Treatment of Triple-
Negative Breast Cancer. 
52. Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the 
proliferative expansion of stem-like cancer cells (CSCs). 
53. Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast 
cancer. 
54. Inhibition of Wnt signalling and breast tumour growth by the multi-purpose drug suramin through 
suppression of heterotrimeric G proteins and Wnt endocytosis. 
55. Targeting epithelial-mesenchymal plasticity in cancer: clinical and preclinical advances in therapy and 
monitoring. 
56. Virtual screening-driven repositioning of etoposide as CD44 antagonist in breast cancer cells. 
 




57. Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for 
Overcoming Tamoxifen Resistance in ER-positive Breast Cancer. 
58. Folate Receptor-Targeted Polymeric Micellar Nanocarriers for Delivery of Orlistat as a Repurposed 
Drug against Triple-Negative Breast Cancer. 
59. Voltage-gated sodium channels and metastatic disease. 
60. [Novel strategies of ovarian cancer treatment]. 
61. Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor  
62. Optimized acriflavine-loaded lipid nanocapsules as a safe and effective delivery system to treat breast 
cancer. 
63. Olanzapine, an Atypical Antipsychotic, Inhibits Survivin Expression and Sensitizes Cancer Cells to 
Chemotherapeutic Agents. 
64. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing 
tumour blood vessels. 
65. Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the 
EIS regimen. 
66. Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs.  
 




A2-2h. Leaf clusters under Cluster 55 
 There are eight leaf clusters under Cluster 55: Cluster 2 (48), Cluster 8 (30), Cluster 24 (117), 
Cluster 3 (33), Cluster 10 (46), Cluster 31 (151), Cluster 28 (97), Cluster 30 (112). 
*Cluster 2 focuses on Alzheimer's Disease treatments 
*Cluster 8 focuses on neurodegenerative disease treatments, especially Parkinson's Disease 
*Cluster 24 focuses on treatments for brain disease, especially stroke 
*Cluster 3 focuses on drug repurposing patent applications 
*Cluster 10 focuses on glioblastoma treatments 
*Cluster 31 focuses on anti-inflammatory treatments 
*Cluster 28 focuses on treatments for addiction disorders (especially alcohol use) and chronic pain 
*Cluster 30 focuses on cancer treatments, especially metronomic chemotherapy 
  
 




A2-2h1. Cluster 2 record titles 
1. Emerging amyloid and tau targeting treatments for Alzheimer's disease. 
2. Alzheimer's Disease (AD) therapeutics - 1: Repeated clinical failures continue to question the amyloid 
hypothesis of AD and the current understanding of AD causality. 
3. Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease. 
4. Discovering new treatments for Alzheimer's disease by repurposing approved medications. 
5. [A review of drugs for treatment of Alzheimer's disease in clinical trials: main trends]. 
6. Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets. 
7. Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease. 
8. A review: treatment of Alzheimer's disease discovered in repurposed agents. 
9. Approved drugs are to be studied for use in Alzheimer's disease. 
10. Cyclin dependent kinase 5: A novel avenue for Alzheimer's disease. 
11. Potential repurposing of oncology drugs for the treatment of Alzheimer's disease. 
12. Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory 
Defects. 
13. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease. 
14. Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining. 
15. Medical genetics-based drug repurposing for Alzheimer's disease. 
16. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease. 
17. Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends. 
18. Clozapine Improves Memory Impairment and Reduces Abeta Level in the Tg-APPswe/PS1dE9 
Mouse Model of Alzheimer's Disease. 
19. Metabolic Dysfunction in Alzheimer's Disease: From Basic Neurobiology to Clinical Approaches. 
20. The Coming of Age of the Angiotensin Hypothesis in Alzheimer's Disease: Progress Toward Disease 
Prevention and Treatment? 
21. Recent progress in repositioning Alzheimer's disease drugs based on a multitarget strategy. 
22. Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with 
Lewy bodies. 
 




23. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. 
24. Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's Disease. 
25. Molecular investigations of protriptyline as a multi-target directed ligand in Alzheimer's disease. 
26. Do Cancer Drugs Counteract Neurodegeneration? Repurposing forAlzheimer's Disease. 
27. Is a potential Alzheimer's therapy already in use for other conditions? Can medications for 
hypertension, diabetes and acne help with the symptoms? 
28. Drug repositioning for Alzheimer's disease. 
29. T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's 
Disease. 
30. [Alzheimer disease: the temptation coming from off-label use]. 
31. Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological 
Proteins Related to the Alzheimer's Disease. 
32. Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future 
Perspectives. 
33. Research and development of anti-Alzheimer's disease drugs: an update from the perspective of 
technology flows. 
34. Advanced Assay Monitoring APP-Carboxyl-Terminal Fragments as Markers of APP Processing in 
Alzheimer Disease Mouse Models. 
35. In silico repurposing of antipsychotic drugs for Alzheimer's disease. 
36. iPSC-Based Compound Screening and InVitro Trials Identify a Synergistic Anti-amyloid beta 
Combination for Alzheimer's Disease. 
37. Exploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A 
convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation. 
38. Drug repositioning in Alzheimer's disease. 
39. AlzhCPI: A knowledge base for predicting chemical-protein interactions towards Alzheimer's disease. 
40. Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target 
Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment 
of Alzheimer's Disease. 
41. One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug. 
42. Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and 
pharmacological intervention. 
 




43. Alzheimer's disease master regulators analysis: search for potential molecular targets and drug 
repositioning candidates. 
44. Epigenetic Drug Repositioning for Alzheimer's Disease Based on Epigenetic Targets in Human 
Interactome. 
45. Tacrine-deferiprone hybrids as multi-target-directed metal chelators against Alzheimer's disease: a 
two-in-one drug. 
46. Value added medicines: what value repurposed medicines might bring to society? 
47. Application of molecular framework-based data-mining method in the search for beta-secretase 1 
inhibitors through drug repurposing. 
48. The case of galantamine: repurposing and late blooming of a cholinergic drug. 
  
 




A2-2h2. Cluster 8 record titles 
1. Drug Repurposing in Parkinson's Disease. 
2. Repurposed drugs for use in Parkinson's disease. 
3. Advances in drug development for Parkinson's disease: present status. 
4. Recent Advances in Drug Repurposing for Parkinson's Disease. 
5. Cell specificity dictates similarities in gene expression in multiple sclerosis, Parkinson's disease, and 
Alzheimer's disease. 
6. Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using 
screening of multiple prospective new treatments. 
7. Combining Human Disease Genetics and Mouse Model Phenotypes towards Drug Repositioning for 
Parkinson's disease. 
8. Old wines in new bottles: Repurposing opportunities for Parkinson's disease. 
9. Validating the Predicted Effect of Astemizole and Ketoconazole Using a Drosophila Model of 
Parkinson's Disease. 
10. Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease. 
11. Biomarker repurposing: Therapeutic drug monitoring of serum theophylline offers a potential 
diagnostic biomarker of Parkinson's disease. 
12. Old Drugs as New Treatments for Neurodegenerative Diseases. 
13. The Linked Clinical Trials Initiative (LCT) for Parkinson's disease. 
14. In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-
melanoma drug, for Parkinson's disease. 
15. Exenatide and the treatment of patients with Parkinson's disease. 
16. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug 
development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis. 
17. CNS repurposing - Potential new uses for old drugs: Examples of screens for Alzheimer's disease, 
Parkinson's disease and spasticity. 
18. Repurposing of Copper(II)-chelating Drugs for the Treatment of Neurodegenerative Diseases. 
19. Using Drugs as Molecular Probes: AComputational Chemical Biology Approach in 
Neurodegenerative Diseases. 
20. Overcoming obstacles to repurposing for neurodegenerative disease. 
 




21. From stroke to neurodegenerative diseases: The multi-target neuroprotective effects of 3-n-
butylphthalide and its derivatives. 
22. Neurodegenerative disease: Halting neurodegeneration - are repurposed drugs the answer? 
23. Exploiting the therapeutic potential of ready-to-use drugs: Repurposing antibiotics against amyloid 
aggregation in neurodegenerative diseases. 
24. Neurotrophin strategies for neuroprotection: are they sufficient? 
25. Can commonly prescribed drugs be repurposed for the prevention or treatment of Alzheimer's and 
other neurodegenerative diseases? Protocol for an observational cohort study in the UK Clinical Practice 
Research Datalink. 
26. Six psychotropics for pre-symptomatic & early Alzheimer's (MCI), Parkinson's, and Huntington's 
disease modification. 
27. Intelligent and effective informatic deconvolution of "Big Data" and its future impact on the 
quantitative nature of neurodegenerative disease therapy. 
28. Approaches for discovering anti-prion compounds: lessons learned and challenges ahead. 
29. Repackaging FDA-approved drugs for degenerative diseases: promises and challenges. 
30. Drugs in search of diseases. 
  
 




A2-2h3. Cluster 24 record titles 
1. Advanced neuroprotection for brain ischemia: an alternative approach to minimize stroke damage. 
2. Minocycline repurposing in critical illness: focus on stroke. 
3. Drug repurposing for vascular protection after acute ischemic stroke. 
4. Drug repurposing for immune modulation in acute ischemic stroke. 
5. Poly(ADP-ribose) polymerase is not involved in the neuroprotection exerted by azithromycin against 
ischemic stroke in mice. 
6. Mmp-9 inhibition: a therapeutic strategy in ischemic stroke. 
7. Drug repurposing for drug development in stroke. 
8. A Combination of Three Repurposed Drugs Administered at Reperfusion as a Promising Therapy for 
Postischemic Brain Injury. 
9. Azithromycin protects mice against ischemic stroke injury by promoting macrophage transition 
towards M2 phenotype. 
10. Stroke is one of the most common and undertreated diseases in the world, and ischemic stroke makes 
up more than 85% of all strokes. Introduction. 
11. Clinical validation of blood/brain glutamate grabbing in acute ischemic stroke. 
12. Activation of RXR/PPARgamma underlies neuroprotection by bexarotene in ischemic stroke. 
13. Dexpramipexole improves bioenergetics and outcome in experimental stroke. 
14. Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential 
interventions. 
15. Development of a stretch-induced neurotrauma model for medium-throughput screening in vitro: 
identification of rifampicin as a neuroprotectant. 
16. Senicapoc: Repurposing a Drug to Target Microglia KCa3.1 in Stroke. 
17. Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and 
with GABAA potentiating activity for use in dementia. 
18. Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute 
ischemic stroke: minocycline. 
19. Parkinson's Disease, Diabetes and Cognitive Impairment. 
20. Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's 
disease. 
 




21. Post-ischemic treatment with azithromycin protects ganglion cells against retinal ischemia/reperfusion 
injury in the rat. 
22. Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute 
ischemic stroke: minocycline. 
23. Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. 
24. Fast, non-competitive and reversible inhibition of NMDA-activated currents by 2-BFI confers 
neuroprotection. 
25. alpha-Methyl-alpha-phenylsuccinimide ameliorates neurodegeneration in a C. elegans model of TDP-
43 proteinopathy. 
26. Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy. 
27. Repurposed drugs targeting eIF2?-P-mediated translational repression prevent neurodegeneration in 
mice. 
28. Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models. 
29. Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's 
disease pathology. 
30. Potential repositioning of exemestane as a neuroprotective agent for Parkinson's disease. 
31. Repurposing and repositioning neurosteroids in the treatment of traumatic brain injury: A report from 
the trenches. 
32. Sulforaphane Prevents Neuronal Apoptosis and Memory Impairment in Diabetic Rats. 
33. Hippocampal Neurophysiologic Changes after Mild Traumatic Brain Injury and Potential 
Neuromodulation Treatment Approaches. 
34. Drug repurposing for drug development in stroke. 
35. Metformin treatment ameliorates diabetes-associated decline in hippocampal neurogenesis and 
memory via phosphorylation of insulin receptor substrate 1. 
36. Utility of Induced Pluripotent Stem Cells for the Study and Treatment of Genetic Diseases: Focus on 
Childhood Neurological Disorders. 
37. High-Throughput Screening forIdentification of Blood-Brain Barrier Integrity Enhancers: A Drug 
Repurposing Opportunity to Rectify Vascular Amyloid Toxicity. 
38. A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials. 
39. Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease. 
40. Modeling Niemann Pick type C1 using human embryonic and induced pluripotent stem cells. 
 




41. Human Pluripotent Stem Cell-derived Cortical Neurons for High Throughput Medication Screening in 
Autism: A Proof of Concept Study in SHANK3 Haploinsufficiency Syndrome. 
42. Neuroprotective and immunomodulatory effects of raloxifene in the myenteric plexus of a mouse 
model of Parkinson's disease. 
43. Tetracycline repurposing in neurodegeneration: focus on Parkinson's disease. 
44. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system 
availability of AZD0530 (saracatinib) in Alzheimer's disease. 
45. Platelet Hyperreactivity in Diabetes: Focus on GPVI Signaling-Are Useful Drugs Already Available? 
46. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-
expression and improves myelination, axonal and functional parameters in models of CMT1A 
neuropathy. 
47. Targeting cyclin D3/CDK6 activity for treatment of Parkinson's disease. 
48. Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation. 
49. The proton-pump inhibitor lansoprazole enhances amyloid beta production. 
50. Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease. 
51. Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs. 
52. Folic Acid Exerts Post-Ischemic Neuroprotection In Vitro Through HIF-1alpha Stabilization. 
53. Preclinical Evidence Supporting Early Initiation of Citalopram Treatment in Machado-Joseph 
Disease. 
54. CK2 inhibition confers functional protection to young and aging axons against ischemia by 
differentially regulating the CDK5 and AKT signaling pathways. 
55. Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. 
56. Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine. 
57. Retinal Neuroprotective Effects of Flibanserin, an FDA-Approved Dual Serotonin Receptor Agonist-
Antagonist. 
58. Cell-based screening identifies paroxetine as an inhibitor of diabetic endothelial dysfunction. 
59. Myelination induction by a histamine H3 receptor antagonist in a mouse model of preterm white 
matter injury. 
60. Rationale for an experimental treatment of retinitis pigmentosa: 140-month test of hypothesis with 
one patient. 
 




61. Novel Tadalafil Derivatives Ameliorates Scopolamine-Induced Cognitive Impairment in Mice via 
Inhibition of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5). 
62. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. 
63. Isogenic FUS-eGFP iPSC Reporter Lines Enable Quantification of FUS Stress Granule Pathology that 
Is Rescued by Drugs Inducing Autophagy. 
64. Systemic hemin therapy attenuates blood-brain barrier disruption after intracerebral hemorrhage. 
65. DPP-4 inhibitors promote proliferation and migration of rat brain microvascular endothelial cells 
under hypoxic/high-glucose conditions, potentially through the SIRT1/HIF-1/VEGF pathway. 
66. Stem cells in pediatric cardiology. 
67. Candesartan stimulates reparative angiogenesis in ischemic retinopathy model: role of 
hemeoxygenase-1 (HO-1). 
68. Quantitative high-throughput screening identifies cytoprotective molecules that enhance SUMO 
conjugation via the inhibition of SUMO-specific protease (SENP)2. 
69. Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent. 
70. Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced 
depression model via improving hippocampal neural plasticity. 
71. Modeling cerebrovascular pathophysiology in amyloid-beta metabolism using neural-crest-derived 
smooth muscle cells. 
72. Spironolactone is an antagonist of NRG1-ERBB4 signaling and schizophrenia-relevant 
endophenotypes in mice. 
73. Inhibition of ACE Retards Tau Hyperphosphorylation and Signs of Neuronal Degeneration in Aged 
Rats Subjected to Chronic Mild Stress. 
74. Protein Kinases and Parkinson's Disease. 
75. Neuron-specific regulation of class I PI3K catalytic subunits and their dysfunction in brain disorders. 
76. The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced 
apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes. 
77. Repurposing HAMI3379 to Block GPR17 and Promote Rodent and Human Oligodendrocyte 
Differentiation. 
78. Effects of Benzothiazolamines on Voltage-Gated Sodium Channels. 
79. Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved 
outcomes in spinal muscular atrophy patient-derived fibroblasts. 
 




80. Reduction of amyloid-beta deposition and attenuation of memory deficits by tolfenamic acid. 
81. Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-Joseph 
Disease. 
82. Minocycline attenuates mechanical allodynia and expression of spinal NMDA receptor 1 subunit in 
rat neuropathic pain model. 
83. Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-beta. 
84. Development of Molecular Therapies for Venous Malformations. 
85. SUMOylation in brain ischemia: Patterns, targets, and translational implications. 
86. Stress-Activated Kinase Mitogen-Activated Kinase Kinase-7 Governs Epigenetics of Cardiac 
Repolarization for Arrhythmia Prevention. 
87. Fine-tuning PERK signaling for neuroprotection. 
88. Small Molecules in Development for the Treatment of Spinal Muscular Atrophy. 
89. Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial 
infarction. 
90. Tamoxifen Provides Structural and Functional Rescue in Murine Models of Photoreceptor 
Degeneration. 
91. Nutrients, neurogenesis and brain ageing: From disease mechanisms to therapeutic opportunities. 
92. Drug Repurposing for Duchenne Muscular Dystrophy: The Monoamine Oxidase B Inhibitor 
Safinamide Ameliorates the Pathological Phenotype in mdx Mice and in Myogenic Cultures From DMD 
Patients. 
93. Clobetasol promotes remyelination in a mouse model of neuromyelitis optica. 
94. Neutrophil Infiltration and Matrix Metalloproteinase-9 in Lacunar Infarction. 
95. Rescue of cell death and inflammation of a mouse model of complex 1-mediated vision loss by 
repurposed drug molecules. 
96. Interferons in Traumatic Brain and Spinal Cord Injury: Current Evidence for Translational 
Application. 
97. Ebselen inhibits the activity of acetylcholinesterase globular isoform G4 in vitro and attenuates 
scopolamine-induced amnesia in mice. 
98. Treating the dysfunctional placenta. 
99. Amino acid conjugated chitosan nanoparticles for the brain targeting of a model dipeptidyl peptidase-
4 inhibitor. 
 




100. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated 
cellular toxicity. 
101. Prevention of Epilepsy: Issues and Innovations. 
102. Screening and personalizing nootropic drugs and cognitive modulator regimens in silico. 
103. ERK and ROCK functionally interact in a signaling network that is compensationally upregulated in 
Spinal Muscular Atrophy. 
104. The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer's 
disease amyloid-beta peptides. 
105. Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion 
injury and for treating heart failure. 
106. Mechanistic insights into epigenetic modulation of ethanol consumption. 
107. A Drug Screen using Human iPSC-Derived Hepatocyte-like Cells Reveals Cardiac Glycosides as a 
Potential Treatment for Hypercholesterolemia. 
108. alpha2-Adrenergic blockade rescues hypoglossal motor defense against obstructive sleep apnea. 
109. Interactions of Selective Serotonin Reuptake Inhibitors with beta-Amyloid. 
110. A review of contemporary options for medical management of hemangiomas, other vascular tumors, 
and vascular malformations. 
111. Oral administration of erythromycin decreases RNA toxicity in myotonic dystrophy. 
112. Mitochondrial protein sorting as a therapeutic target for ATP synthase disorders. 
113. Pharmacokinetic and protein binding profile of peptidomimetic DPP-4 inhibitor - Teneligliptin in 
rats using liquid chromatography-tandem mass spectrometry. 
114. Repurposing the Selective Oestrogen Receptor Modulator Tamoxifen for the Treatment of Duchenne 
Muscular Dystrophy. 
115. Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease. 
116. Do traditional anti-seizure drugs have a future? A review of potential anti-seizure drugs in clinical 
development. 
117. Diabetes Drug Receives New Indication. 
  
 




A2-2h4. Cluster 3 record titles 
1. Drug Repurposing Patent Applications July-September 2015. 
2. Drug Repurposing Patent Applications April-June 2015. 
3. Drug Repurposing Patent Applications April-June 2016. 
4. Drug Repurposing Patent Applications July-September 2016. 
5. Drug Repurposing Patent Applications January-March 2017. 
6. Drug Repurposing Patent Applications October-December 2016. 
7. Drug Repurposing Patent Applications January-March 2018. 
8. Drug Repurposing Patent Applications October-December 2017. 
9. Second medical use in Turkey. 
10. Drug repurposing and the prior art patents of competitors. 
11. Sources and Targets for Drug Repurposing: Landscaping Transitions in Therapeutic Space. 
12. Use patents can be useful: the case of rescued drugs. 
13. Patent review. 
14. Patent review. 
15. Computational Approaches for Translational Oncology: Concepts and Patents. 
16. A perspective on second medical indication patents in Brazil. 
17. What are the risks of second medical use and dosing regimens in pharmaceutical patenting? 
18. Therapeutic compositions and uses of alpha1-antitrypsin: a patent review (2012 - 2015). 
19. The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs 
for multiple sclerosis? 
20. Tecfidera(): an approach for repurposing. 
21. Computational biology: future challenges for the patenting of repurposed drugs. 
22. New drugs or alternative therapy to blurring the symptoms of fibromyalgia-a patent review. 
23. Predictive methods in drug repurposing: gold mine or just a bigger haystack? 
24. Drug Repositioning in the Mirror of Patenting: Surveying and Mining Uncharted Territory. 
25. Patent cliff mitigation strategies: giving new life to blockbusters. 
 




26. Future perspectives for cryptococcosis treatment. 
27. Finding new uses for existing medications. 
28. Second medical use claims and 'skinny' labels: clear guidance at last? 
29. Enforceability of second medical use claims in the UK. 
30. Repurposing of drugs for dermatologic applications: five key medications. 
31. [Modern disease-modifying antirheumatic drugs]. 
32. Drug repurposing for neuroregeneration in multiple sclerosis. 








A2-2h5. Cluster 10 record titles 
1. Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and 
over-rides resistance to temozolomide. 
2. Evidence for the efficacy of disulfiram and copper combination in glioblastoma multiforme - A propos 
of a case. 
3. Drug Repositioning in Glioblastoma: A Pathway Perspective. 
4. Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference? 
5. Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by 
repurposing disulfiram. 
6. Inhibition of Radiation and Temozolomide-Induced Invadopodia Activity in Glioma Cells Using FDA-
Approved Drugs. 
7. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide 
targeting de novo DNA synthesis, irrespective of molecular subtype. 
8. Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell 
agent using public gene expression data. 
9. Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug. 
10. Bacoside A Induces Tumor Cell Death in Human Glioblastoma Cell Lines through Catastrophic 
Macropinocytosis. 
11. Case-specific potentiation of glioblastoma drugs by pterostilbene. 
12. Identification of repaglinide as a therapeutic drug for glioblastoma multiforme. 
13. Biological basis and clinical study of glycogen synthase kinase- 3beta-targeted therapy by drug 
repositioning for glioblastoma. 
14. Proscillaridin A exerts anti-tumor effects through GSK3beta activation and alteration of microtubule 
dynamics in glioblastoma. 
15. Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin 
polymerization. 
16. Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide. 
17. Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme. 
18. Repurposing drugs for glioblastoma: From bench to bedside. 
19. Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase 
(MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage. 
 




20. Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine 
for the treatment of malignant glioma. 
21. Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic. 
22. Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine 
uptake through system Xc-, leading to glutathione depletion. 
23. Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma. 
24. The anti-hypertensive drug prazosin inhibits glioblastoma growth via the PKCdelta-dependent 
inhibition of the AKT pathway. 
25. Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity 
to provide new treatment options for glioblastoma. 
26. Repositioning of the antipsychotic trifluoperazine: Synthesis, biological evaluation and in silico study 
of trifluoperazine analogs as anti-glioblastoma agents. 
27. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of 
survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated 
Improvement of Glioblastoma Care. 
28. Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of 
cytochrome c oxidase bearing the COX4-1 regulatory subunit. 
29. A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by 
Combining a Spontaneously Emulsifying Component with a Polymer Carrier. 
30. Disulfiram's Anticancer Activity: Evidence and Mechanisms. 
31. Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma? 
32. Adaptive mitochondrial reprogramming and resistance to PI3K therapy. 
33. Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma invivo. 
34. Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed Drugs Elicits 
Cell-Lethal Autophagy and Therapeutic Benefit. 
35. Improving contrast enhancement in magnetic resonance imaging using 5-aminolevulinic acid-induced 
protoporphyrin IX for high-grade gliomas. 
36. Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an 
active anticancer agent. 
37. Modulating the metabolism by trimetazidine enhances myoblast differentiation and promotes 
myogenesis in cachectic tumor-bearing c26 mice. 
 




38. Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells. 
39. Posttranslational Regulation of O(6)-Methylguanine-DNA Methyltransferase (MGMT) and New 
Opportunities for Treatment of Brain Cancers. 
40. Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its 
Anticancer Activity. 
41. Establishing a Preclinical Multidisciplinary Board for Brain Tumors. 
42. Nanoscale Reaction Vessels Designed for Synthesis of Copper-Drug Complexes Suitable for 
Preclinical Development. 
43. Glioma: Repurposed drugs combined to amplify autophagy. 
44. Elesclomol restores mitochondrial function in genetic models of copper deficiency. 
45. Angiotensin II type 1 receptor blockers increase tolerance of cells to copper and cisplatin. 








A2-2h6. Cluster 31 record titles 
1. Ameliorative effect of methylthiouracil on TGFBIp-induced septic responses. 
2. Anti-inflammatory effects of methylthiouracil in vitro and in vivo. 
3. Repurposing an orally available drug for the treatment of geographic atrophy. 
4. Suppressive effects of methylthiouracil on polyphosphate-mediated vascular inflammatory responses. 
5. Anti-inflammatory effects of dabrafenib in vitro and in vivo. 
6. Repositioning drugs for inflammatory disease - fishing for new anti-inflammatory agents. 
7. Antiseptic effects of dabrafenib on TGFBIp-induced septic responses. 
8. beta-Caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and 
metabolic dysregulation in mice. 
9. Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption. 
10. Repositioning of 2,4-dichlorophenoxy acetic acid as a potential anti-inflammatory agent: in silico and 
pharmaceutical formulation study. 
11. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis. 
12. 4-Acetoxyphenol Prevents RPE Oxidative Stress-Induced Necrosis by Functioning as an NRF2 
Stabilizer. 
13. Methylthiouracil, a new treatment option for sepsis. 
14. Fibrosis in systemic sclerosis: common and unique pathobiology. 
15. A Zebrafish Drug-Repurposing Screen Reveals sGC-Dependent and sGC-Independent Pro-
Inflammatory Activities of Nitric Oxide. 
16. Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. 
17. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. 
18. Toll-Like Receptor-4 Signaling Drives Persistent Fibroblast Activation and Prevents Fibrosis 
Resolution in Scleroderma. 
19. ACTH: The forgotten therapy. 
20. Immunomodulatory tetracyclines shape the intestinal inflammatory response inducing mucosal 
healing and resolution. 
21. 3, 5, 3'-Triiodothyroacetic acid (TRIAC) is an anti-inflammatory drug that targets toll-like receptor 2. 
 




22. Propofol post-conditioning alleviates hepatic ischaemia reperfusion injury via BRG1-mediated 
Nrf2/HO-1 transcriptional activation in human and mice. 
23. Adrenergic regulation of innate immunity: a review. 
24. Fishing Anti-Inflammatories from Known Drugs: In Silico Repurposing, Design, Synthesis and 
Biological Evaluation of Bisacodyl Analogues. 
25. Identification and validation of uterine stimulant methylergometrine as a potential inhibitor of 
caspase-1 activation. 
26. Identification of Iguratimod as an Inhibitor of Macrophage Migration Inhibitory Factor (MIF) with 
Steroid-sparing Potential. 
27. Suppressive effects of dabrafenibon endothelial protein C receptor shedding. 
28. Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in 
cystic fibrosis. 
29. Glybenclamide: an antidiabetic with in vivo antithrombotic activity. 
30. The possible repositioning of an oral anti-arthritic drug, auranofin, for Nrf2-activating therapy: The 
demonstration of Nrf2-dependent anti-oxidative action using a zebrafish model. 
31. Lansoprazole Upregulates Polyubiquitination of the TNF Receptor-Associated Factor 6 and Facilitates 
Runx2-mediated Osteoblastogenesis. 
32. Repurposing Thioridazine (TDZ) as an anti-inflammatory agent. 
33. Functional genetics-directed identification of novel pharmacological inhibitors of FAS- and TNF-
dependent apoptosis that protect mice from acute liver failure. 
34. Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft 
Rejection: Therapeutic Implications of IL-6 Receptor Blockade. 
35. Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in 
Parkinson's Disease. 
36. Ibuprofen and diclofenac treatments reduce proliferation of pancreatic acinar cells upon inflammatory 
injury and mitogenic stimulation. 
37. A signalome screening approach in the autoinflammatory disease TNF receptor associated periodic 
syndrome (TRAPS) highlights the anti-inflammatory properties of drugs for repurposing. 
38. Drug-Repositioning Screening for Keap1-Nrf2 Binding Inhibitors using Fluorescence Correlation 
Spectroscopy. 
39. Repurposing Treprostinil for Enhancing Hematopoietic Progenitor Cell Transplantation. 
 




40. Characterization of drug-induced transcriptional modules: towards drug repositioning and functional 
understanding. 
41. Repurposing ospemifene for potentiating an antigen-specific immune response. 
42. Activation of MyD88-dependent TLR1/2 signaling by misfolded alpha-synuclein, a protein linked to 
neurodegenerative disorders. 
43. Bromide supplementation exacerbated the renal dysfunction, injury and fibrosis in a mouse model of 
Alport syndrome. 
44. Fenofibrate Attenuates Neutrophilic Inflammation in Airway Epithelia: Potential Drug Repurposing 
for Cystic Fibrosis. 
45. Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the 
early phase after heart transplantation in rats. 
46. Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the 
Receptor Activator of NF-kappaB Ligand Pathway. 
47. Repositioning of molsidomine for its efficacy in diabetes induced erectile dysfunction in rats: In 
silico, in vitro and in vivo approach. 
48. Repositioning of Tak-475 In Mevalonate Kinase Disease: Translating Theory Into Practice. 
49. Repurposing a novel parathyroid hormone analogue to treat hypoparathyroidism. 
50. Dopaminergic Regulation of Innate Immunity: a Review. 
51. Adjuvant potential of selegiline in attenuating organ dysfunction in septic rats with peritonitis. 
52. An in vitro test system for compounds that modulate human inflammatory macrophage polarization. 
53. Glycogen phosphorylase inhibition improves beta cell function. 
54. Histamine-2 receptor antagonist famotidine modulates cardiac stem cell characteristics in 
hypertensive heart disease. 
55. Inhibition of effector antigen-specific T cells by intradermal administration of heme oxygenase-1 
inducers. 
56. The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory 
responses and accelerates wound healing in a murine model of third-degree burn injury. 
57. The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-
enhanced platelet function. 
58. Old drugs with new skills: fenoprofen as an allosteric enhancer at melanocortin receptor 3. 
 




59. Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in 
Cystic Fibrosis. 
60. Repurposing an Osteoporosis Drug for beta Cell Regeneration in Diabetic Patients. 
61. Treatment of experimental autoimmune uveoretinitis with peroxisome proliferator-activated receptor 
alpha agonist fenofibrate. 
62. Rebamipide, an Amino Acid Analog of 2(1H)-Quinolinone, Inhibits the Formation of Human 
Osteoclasts. 
63. Colonic delivery of celecoxib is a potential pharmaceutical strategy for repositioning the selective 
COX-2 inhibitor as an anti-colitic agent. 
64. Oxidative stress during acetaminophen hepatotoxicity: Sources, pathophysiological role and 
therapeutic potential. 
65. Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of 
tauopathy. 
66. Repurposing Lesogaberan to Promote Human Islet Cell Survival and beta-Cell Replication. 
67. Identification of Non-Electrophilic Nrf2 Activators from Approved Drugs. 
68. Rifampin inhibits Toll-like receptor 4 signaling by targeting myeloid differentiation protein 2 and 
attenuates neuropathic pain. 
69. Tegaserod mimics the neurostimulatory glycan polysialic acid and promotes nervous system repair. 
70. Molecular Characterization of GABA-A Receptor Subunit Diversity within Major Peripheral Organs 
and Their Plasticity in Response to Early Life Psychosocial Stress. 
71. Repurposing an old drug for a new use: glybenclamide exerts antiplatelet activity by interacting with 
the thromboxane A(2) receptor. 
72. Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review 
(2008-present). 
73. Targeting Abl kinases to regulate vascular leak during sepsis and acute respiratory distress syndrome. 
74. Inhibition of the insulin-like growth factor system is a potential therapy for rheumatoid arthritis. 
75. Repositioning Potential of PAK4 to Osteoclastic Bone Resorption. 
76. Exploring novel pharmacotherapeutic applications and repurposing potential of sodium glucose 
CoTransporter 2 inhibitors. 
77. Repurposing matrine for the treatment of hepatosteatosis and associated disorders in glucose 
homeostasis in mice. 
 




78. Mitigation of carbon tetrachloride-induced hepatic injury by methylene blue, a repurposed drug, is 
mediated by dual inhibition of GSK3beta downstream of PKA. 
79. Evaluation of a systems biology approach to identify pharmacological correctors of the mutant CFTR 
chloride channel. 
80. Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in 
Clinical Situations. 
81. Fragmin/protamine microparticle carriers as a drug repositioning strategy for cell transplantation. 
82. Repurposing of Aspirin and Ibuprofen as Candidate Anti-Cryptococcus Drugs. 
83. Drug Repositioning for Preeclampsia Therapeutics by In Vitro Screening: Phosphodiesterase-5 
Inhibitor Vardenafil Restores Endothelial Dysfunction via Induction of Placental Growth Factor. 
84. Novel Therapeutics Identification for Fibrosis in Renal Allograft Using Integrative Informatics 
Approach. 
85. High-throughput screening for modulators of ACVR1 transcription: discovery of potential 
therapeutics for fibrodysplasia ossificans progressiva. 
86. Repurposing the anti-malarial drug, quinacrine: new anti-colitis properties. 
87. A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of 
hydrocephalus. 
88. Fenoprofen -- an old drug rediscovered as a biased allosteric enhancer for melanocortin receptors. 
89. Inflammation-dependent cerebrospinal fluid hypersecretion by the choroid plexus epithelium in 
posthemorrhagic hydrocephalus. 
90. Hemin activation of innate cellular response blocks human immunodeficiency virus type-1-induced 
osteoclastogenesis. 
91. Thiopurine Drugs Repositioned as Tyrosinase Inhibitors. 
92. Repositioning Clofazimine as a Macrophage-Targeting Photoacoustic Contrast Agent. 
93. Repurposing doxycycline for synucleinopathies: remodelling of alpha-synuclein oligomers towards 
non-toxic parallel beta-sheet structured species. 
94. The Horizon of a Therapy for Rare Genetic Diseases: A "Druggable" Future for Fibrodysplasia 
Ossificans Progressiva. 
95. Therapeutic Approaches to Type I Interferonopathies. 
 




96. Structural re-positioning, in silico molecular modelling, oxidative degradation, and biological 
screening of linagliptin as adenosine 3 receptor (ADORA3) modulators targeting hepatocellular 
carcinoma. 
97. The chaperone activity of 4PBA ameliorates the skeletal phenotype of Chihuahua, a zebrafish model 
for dominant osteogenesis imperfecta. 
98. Anti-obesogenic and hypolipidemic effects of a glucagon-like peptide-1 receptor agonist derived from 
the saliva of the Gila monster. 
99. Investigating Drug Repositioning Approach to Design Novel Prodrugs for Colon-specific Release of 
Fexofenadine for Ulcerative Colitis. 
100. Alendronate inhalation ameliorates elastase-induced pulmonary emphysema in mice by induction of 
apoptosis of alveolar macrophages. 
101. Carbamazepine alone and in combination with doxycycline attenuates isoproterenol-induced cardiac 
hypertrophy. 
102. Repositioning of Thiourea-Containing Drugs as Tyrosinase Inhibitors. 
103. Prilocaine hydrochloride protects zebrafish from lethal effects of ionizing radiation: role of 
hematopoietic cell expansion. 
104. Personalized Proteomics in Proliferative Vitreoretinopathy Implicate Hematopoietic Cell 
Recruitment and mTOR as a Therapeutic Target. 
105. Structure-based repurposing of FDA-approved drugs as TNF-alpha inhibitors. 
106. New culture medium concepts for cell transplantation. 
107. Captopril mitigates splenomegaly and myelofibrosis in the Gata1low murine model of myelofibrosis. 
108. Newly Identified Targets of Aspirin and Its Primary Metabolite, Salicylic Acid. 
109. Drug-Mediated Regulation of Glycosaminoglycan Biosynthesis. 
110. The polysialic acid mimetics idarubicin and irinotecan stimulate neuronal survival and neurite 
outgrowth and signal via protein kinase C. 
111. Calcineurin-NFAT signalling in myeloid leucocytes: new prospects and pitfalls in 
immunosuppressive therapy. 
112. [Doxycycline or how to create new with the old?]. 
113. GDC-0879, a BRAFV600E Inhibitor, Protects Kidney Podocytes from Death. 
114. Tezosentan inhibits uptake of proinflammatory endothelin-1 in stenotic aortic valves. 
 




115. Chloroquine upregulates TRAIL/TRAILR2 expression and potentiates doxorubicin anti-tumor 
activity in thioacetamide-induced hepatocellular carcinoma model. 
116. Pluripotent Stem Cell Platforms for Drug Discovery. 
117. A common rejection module (CRM) for acute rejection across multiple organs identifies novel 
therapeutics for organ transplantation. 
118. Tyrosinase inhibitors: a patent review (2011-2015). 
119. Alternative molecular formats and therapeutic applications for bispecific antibodies. 
120. Liraglutide modulates gut microbiota and reduces NAFLD in obese mice. 
121. Promethazine Hydrochloride Inhibits Ectopic Fat Cell Formation in Skeletal Muscle. 
122. Metabolic switch during adipogenesis: From branched chain amino acid catabolism to lipid 
synthesis. 
123. Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. 
124. Clinical dosage of meclozine promotes longitudinal bone growth, bone volume, and trabecular bone 
quality in transgenic mice with achondroplasia. 
125. Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-beta-N-
acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease. 
126. Lethal action of the nitrothiazolyl-salicylamide derivative nitazoxanide via induction of oxidative 
stress in Leishmania (L.) infantum. 
127. Valproic acid mediates miR-124 to down-regulate a novel protein target, GNAI1. 
128. IL-4 as a Repurposed Biological Drug for Myocardial Infarction through Augmentation of 
Reparative Cardiac Macrophages: Proof-of-Concept Data in Mice. 
129. YAP/TAZ Are Mechanoregulators of TGF-beta-Smad Signaling and Renal Fibrogenesis. 
130. Targeting transcriptional control of soluble guanylyl cyclase via NOTCH for prevention of 
cardiovascular disease. 
131. A Topical Zinc Ionophore Blocks Tumorigenic Progression in UV-exposed SKH-1 High-risk Mouse 
Skin. 
132. Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity. 
133. Neural Crossroads in the Hematopoietic Stem Cell Niche. 
134. Developmental toxicity of auranofin in zebrafish embryos. 
 




135. Sympathoadrenergic modulation of hematopoiesis: a review of available evidence and of therapeutic 
perspectives. 
136. In silico model of the human ClC-Kb chloride channel: pore mapping, biostructural pathology and 
drug screening. 
137. Identification of the antiarrhythmic drugs amiodarone and lorcainide as potent H3 histamine receptor 
inverse agonists. 
138. Tetracycline hydrochloride: A potential clinical drug for radioprotection. 
139. SIRT1 activation by methylene blue, a repurposed drug, leads to AMPK-mediated inhibition of 
steatosis and steatohepatitis. 
140. In vitro biological evaluation of glyburide as potential inhibitor of collagenases. 
141. Drug repurposing: In-vitro anti-glycation properties of 18 common drugs. 
142. Structural Basis of Antisickling Effects of Selected FDA Approved Drugs: A Drug Repurposing 
Study. 
143. Diclofenac Identified as a Kynurenine 3-Monooxygenase Binder and Inhibitor by Molecular 
Similarity Techniques. 
144. Identification of raloxifene as a novel CB2 inverse agonist. 
145. Repurposing an established drug: an emerging role for methylene blue in L-DOPA-induced 
dyskinesia. 
146. Repurposing miltefosine for the treatment of immune-mediated disease? 
147. Drug repurposing: Ibrutinib exhibits immunosuppressive potential in organ transplantation. 
148. Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related 
Macular Degeneration. 
149. Structural basis for the hepatoprotective effects of antihypertensive 1,4-dihydropyridine drugs. 
150. In silico prediction of new inhibitors for the nucleotide pool sanitizing enzyme, MTH1, using drug 
repurposing. 
151. Deal watch: IL-2 focus switches to stimulating Tregs. 
  
 




A2-2h7. Cluster 28 record titles 
1. More Treatments on Deck for Alcohol Use Disorder. 
2. Medications for alcohol use disorders: An overview. 
3. New pharmacological treatment strategies for relapse prevention. 
4. New steps for treating alcohol use disorder. 
5. Therapeutic Strategies for the Treatment of Alcoholic Hepatitis. 
6. Delivering drugs to the lungs: The history of repurposing in the treatment of respiratory diseases. 
7. Medication discovery for addiction: translating the dopamine D3 receptor hypothesis. 
8. Buspirone Counteracts MK-801-Induced Schizophrenia-Like Phenotypes through Dopamine D3 
Receptor Blockade. 
9. Neuropathic Pain Creates an Enduring Prefrontal Cortex Dysfunction Corrected by the Type II 
Diabetic Drug Metformin But Not by Gabapentin. 
10. Capsaicin: Current Understanding of Its Mechanisms and Therapy of Pain and Other Pre-Clinical and 
Clinical Uses. 
11. Oral delivery of ivermectin using a fast dissolving oral film: Implications for repurposing ivermectin 
as a pharmacotherapy for alcohol use disorder. 
12. Investigational drug therapies in phase I and phase II clinical trials for alcohol use disorders. 
13. EMA401: an old antagonist of the AT2R for a new indication in neuropathic pain. 
14. The neuroimmune transcriptome and alcohol dependence: potential for targeted therapies. 
15. Microglial role in the development of chronic pain. 
16. Ketamine for treatment-resistant unipolar depression: current evidence. 
17. Repurposed drugs for the treatment of schizophrenia and bipolar disorders. 
18. Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction. 
19. Effects of the nicotinic agonist varenicline on the performance of tasks of cognition in aged and 
middle-aged rhesus and pigtail monkeys. 
20. Antifibrotic Therapies: Where Are We Now? 
21. Drug repurposing and emerging adjunctive treatments for schizophrenia. 
22. Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas. 
 




23. The effects of buspirone on occupancy of dopamine receptors and the rat gambling task. 
24. Drug repurposing to treat asthma and allergic disorders: Progress and prospects. 
25. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. 
26. Targeting CYP2J to reduce paclitaxel-induced peripheral neuropathic pain. 
27. What We Know About the Pathogenesis of Idiopathic Pulmonary Fibrosis. 
28. Repurposing drugs as inhaled therapies in asthma. 
29. Topical phenytoin for the treatment of neuropathic pain. 
30. Identification of Nitazoxanide as a Group I Metabotropic Glutamate Receptor Negative Modulator for 
the Treatment of Neuropathic Pain: An In Silico Drug Repositioning Study. 
31. Effects of lorcaserin and buspirone, administered alone and as a mixture, on cocaine self-
administration in male and female rhesus monkeys. 
32. Ketamine: repurposing and redefining a multifaceted drug. 
33. Preclinical development of moxidectin as a novel therapeutic for alcohol use disorder. 
34. Drug repurposing may generate novel approaches to treating depression. 
35. Inhalation of repurposed drugs to treat pulmonary hypertension. 
36. Inhaled mannitol in patients with cystic fibrosis: A randomised open-label dose response trial. 
37. Symptomatic thinking: the current state of Phase III and IV clinical trials for cognition in 
schizophrenia. 
38. Low Dose Loxapine: Neuromotor Side Effects and Tolerability in Autism Spectrum Disorders. 
39. Repurposing Pentoxifylline for the Treatment of Fibrosis: An Overview. 
40. The Significance of Hypothiocyanite Production via the Pendrin/DUOX/Peroxidase Pathway in the 
Pathogenesis of Asthma. 
41. Benign Paroxysmal Positional Vertigo Following Sinus Floor Elevation in Patient with Antecedents 
of Vertigo. 
42. Where do we stand in the field of anti-abuse drug discovery? 
43. Sphingolipids as targets for inhalation treatment of cystic fibrosis. 
44. Efficacy of SRM-IV Vestibular Function Diagnosis and Treatment System in Treating Benign 
Paroxysmal Positional Vertigo. 
45. Larval zebrafish model for FDA-approved drug repositioning for tobacco dependence treatment. 
 




46. Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective drugs. 
47. Repurposing Drugs for Cognition in Schizophrenia. 
48. New drug candidates for depression - a nationwide population-based study. 
49. How to study sex differences in addiction using animal models. 
50. [Comparison of simple canalith repositioning treatment and medication therapeutic alliance in the 
management of canalithiasis associated with benign paroxysmal positional vertigo of the horizontal 
semicircular canal]. 
51. The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-
beta1. 
52. Repurposing steroidogenesis inhibitors for the therapy of neuropsychiatric disorders: Promises and 
caveats. 
53. Genetic Mechanisms of Asthma and the Implications for Drug Repositioning. 
54. Pediatric psychopharmacology: too much or too little? 
55. Subanaesthetic dose of ketamine in intractable asthma. 
56. Treatments: In the waiting room. 
57. Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics. 
58. Neuropathy: A name for their pain. 
59. Fragile Histidine Triad (FHIT), a Novel Modifier Gene in Pulmonary Arterial Hypertension. 
60. [Experience of Vasonat usage in treatment of patients with chronic toxic hepatitis]. 
61. A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future 
Research. 
62. N-acetylcysteine prevents stress-induced anxiety behavior in zebrafish. 
63. Loxapine add-on for adolescents and adults with autism spectrum disorders and irritability. 
64. The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment 
of psychiatric disorders. 
65. Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in 
Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and 
Blocking LTB4 Biosynthesis. 
66. Evaluation of safety and efficacy of brain targeted chitosan nanoparticles of minocycline. 
 




67. For peace and pain: the medical legitimisation of Afghanistan's poppy crop. 
68. [The assessment of sequential treatment for subjective and objective benign paroxysmal positional 
vertigo]. 
69. Dopamine antagonists for treatment resistance in autism spectrum disorders: review and focus on 
BDNF stimulators loxapine and amitriptyline. 
70. Repurposing buspirone for drug addiction treatment. 
71. Orally inhaled migraine therapy: Where are we now? 
72. Metformin in Idiopathic Pulmonary Fibrosis "Seeking the Holy-Grail through Drug-Repositioning". 
73. Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current 
perspectives. 
74. Exploration of alpha1-antitrypsin treatment protocol for islet transplantation: dosing plan and route of 
administration. 
75. Repurposed drugs in metabolic disorders. 
76. Advances in intravesical therapy for urinary tract disorders. 
77. Repositioning Microtubule Stabilizing Drugs for Brain Disorders. 
78. The behavioural profile of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol in 
humans. 
79. [Effects of canalith repositioning procedures with anti-vertigo drugs on benign paroxysmal positional 
vertigo]. 
80. A Critical Review of Repurposing Apomorphine for Smoking Cessation. 
81. Repurposing Resveratrol and Fluconazole To Modulate Human Cytochrome P450-Mediated 
Arachidonic Acid Metabolism. 
82. Repurposing an old drug: A low-cost allergy medication provides new hope for hepatitis C patients. 
83. Drug delivery for the treatment of endometriosis and uterine fibroids. 
84. Metabolome analysis of effect of aspirin on Drosophila lifespan extension. 
85. Microsomal cytochrome P450 as a target for drug discovery and repurposing. 
86. Can anti-obesity drugs be repurposed to treat cocaine addiction? 
87. [LIRAGUTIDE AT A DOSE OF 3.0 MG (SAXENDA): NEW INDICATION FOR THE 
TREATMENT OF OBESITY]. 
 




88. Continuous Suprascapular Nerve Block With a Perineural Catheter for Reverse Shoulder Arthroplasty 
Rescue Analgesia in a Patient With Severe Chronic Obstructive Pulmonary Disease. 
89. JAK Inhibitors for Treatment of AlopeciaAreata. 
90. [Utilization of veno-venous bypass in orthotopic liver transplantation]. 
91. Old and new applications of non-anticoagulant heparin. 
92. Examining the potential preventative effects of minocycline prescribed for acne on the incidence of 
severe mental illnesses: A historical cohort study. 
93. Identification of circadian clock modulators from existing drugs. 
94. Repositioning of dexamethasone intravitreal implant (Ozurdex) migrated into the anterior chamber. 
95. The potential for repositioning antithyroid agents as antiasthma drugs. 
96. [To dare trying a diuretic in autism treatment]. 
97. [T stands for testosterone: do you have enough of it?]. 
  
 




A2-2h8. Cluster 30 record titles 
1. Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan. 
2. Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and 
Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study. 
3. Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic 
and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai. 
4. Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning 
in oncology, 27-28 May, 2016, Rosario, Argentina. 
5. Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete 
response of a relapsing metastatic angiosarcoma. 
6. Preliminary evaluation of children treated with metronomic chemotherapy and valproic acid in a low-
income country: Metro-Mali-02. 
7. The poor design of clinical trials of statins in oncology may explain their failure - Lessons for drug 
repurposing. 
8. Statins in conditions other than hypocholesterolemic effects for chronic subdural hematoma therapy, 
old drug, new tricks? 
9. Has the time come for metronomics in low-income and middle-income countries? 
10. Metronomics: towards personalized chemotherapy? 
11. Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients. 
12. Sustained Complete Response to Metronomic Chemotherapy in a Child with Refractory Atypical 
Teratoid Rhabdoid Tumor: A Case Report. 
13. The role of statins in inflammatory vasculitides. 
14. Emerging drugs for primary progressive multiple sclerosis. 
15. Repurposing of statins via inhalation to treat lung inflammatory conditions. 
16. Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis. 
17. Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-
Lindau disease. 
18. Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm 
phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three 
neuroprotective drugs in secondary progressive multiple sclerosis. 
19. Innovations in asthma therapy: is there a role for inhaled statins? 
 




20. Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study. 
21. Development of therapies for autoimmune disease at Stanford: a tale of multiple shots and one goal. 
22. Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot 
investigating propranolol administration in patients receiving hematopoietic cell transplantation. 
23. Are biologic treatments a potential approach to wear- and corrosion-related problems? 
24. Simvastatin Therapy for Drug Repositioning to Reduce the Risk of Prostate Cancer Mortality in 
Patients With Hyperlipidemia. 
25. A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from 
baseline in CMTNS and ONLS scales after one year of treatment. 
26. Hydroquinidine Prevents Life-Threatening Arrhythmic Events in Patients With ShortQTSyndrome. 
27. Statin: new life for an old drug. 
28. Drug Repurposing Screen Identifies Foxo1-Dependent Angiopoietin-2 Regulation in Sepsis. 
29. Evaluation of multiday analgesia with etoricoxib in a double-blind, randomized controlled trial using 
the postoperative third-molar extraction dental pain model. 
30. METFORMIN: NONGLYCEMIC EFFECTS AND POTENTIAL NOVEL INDICATIONS. 
31. Insights from Second-Line Treatments for Idiopathic Dilated Cardiomyopathy. 
32. Current and future immunotherapy targets in autoimmune neurology. 
33. High-dose methotrexate with leucovorin rescue: For monumentally severe CNS inflammatory 
syndromes. 
34. Erythropoietin, a novel repurposed drug: an innovative treatment for wound healing in patients with 
diabetes mellitus. 
35. Repurposing Medications for Hospice/Palliative Care Symptom Control Is No Longer Sufficient: A 
Manifesto for Change. 
36. From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic 
Small Cell Lung Cancer (SCLC). 
37. Drug repurposing in kidney disease. 
38. Metronomics: Intrinsic Anakoinosis Modulator? 
39. Topical mevastatin promotes wound healing by inhibiting the transcription factor c-Myc via the 
glucocorticoid receptor and the long non-coding RNA Gas5. 
40. Novel Therapeutic Approaches to Allosensitization and Antibody-Medicated Rejection. 
 




41. Old drugs, new uses. 
42. Drug repurposing in malignant pleural mesothelioma: a breath of fresh air? 
43. Histone Deacetylase Inhibitors and Diabetic Kidney Disease. 
44. Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis. 
45. Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for 
secondary progressive multiple sclerosis. 
46. Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical 
reports. 
47. Paradoxical strategy for treating chronic diseases where the therapeutic effect is derived from 
compensatory response rather than drug effect. 
48. [Fumaric acid as therapeutic agent for multiple sclerosis]. 
49. Systemic amyloidosis: novel therapies and role of biomarkers. 
50. Current issues concerning drug development for pediatric hematologic malignancies. 
51. Designing drugs that combat kidney damage. 
52. Novel therapeutic approaches for chronic kidney disease due to glomerular disorders. 
53. Repurposing of approved cardiovascular drugs. 
54. Antidepressants in the Treatment of Functional Dyspepsia: A Systematic Review and Meta-Analysis. 
55. Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, 
and Neurological Diseases: A Mini-Review. 
56. Metformin - The Drug for the Treatment of Autoimmune Diseases; A New Use of a Known Anti-
Diabetic Drug. 
57. Understanding and Treating Glioblastoma. 
58. Topical isopropyl unoprostone for retinitis pigmentosa: microperimetric results of the phase 2 clinical 
study. 
59. Evaluating a novel treatment for coronary artery inflammation in acute Kawasaki disease: A Phase 
I/IIa trial of atorvastatin. 
60. beta2-Adrenoceptor agonists as novel, safe and potentially effective therapies for Amyotrophic lateral 
sclerosis (ALS). 
61. Nutraceuticals and "repurposed" drugs of phytochemical origin in prevention and interception of 
chronic degenerative disease and cancer. 
 




62. Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in 
dermatology. 
63. Non-diabetic clinical applications of insulin. 
64. [Possibilities and limits of topical hydrocortisone therapy. Experiences in general practice]. 
65. [Possibilities of the use of parenteral form of alpha- and beta-adrenoblocker for the treatment of 
hypertensive crises at prehospital stage]. 
66. Oleanolic acid derivatives for pharmaceutical use: a patent review. 
67. Therapeutic compounds for Cushing's syndrome: a patent review (2012-2016). 
68. Repurposing Valproate, Enteral Clonidine, and Phenobarbital for Comfort in Adult ICU Patients: A 
Literature Review with Practical Considerations. 
69. Nilotinib - Differentiating the Hope fromtheHype. 
70. Repurposing of sodium channel antagonists as potential new anti-myotonic drugs. 
71. A multicenter, randomized, placebo-controlled trial for cilostazol in patients with mild cognitive 
impairment: The COMCID study protocol. 
72. Pathology assessment is necessary to validate translational endpoints in preclinical aging studies. 
73. Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD. 
74. New developments in the management of neurogenic orthostatic hypotension. 
75. Balance and circumstance: The renin angiotensin system in wound healing and fibrosis. 
76. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian 
randomisation analysis. 
77. Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic 
review and meta-analysis. 
78. Symptomatic therapy in multiple sclerosis: Big pharma should do more - NO. 
79. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. 
Preliminary results of a phase-II trial. 
80. Perhexiline maleate in the treatment of fibrodysplasia ossificans progressiva: an open-labeled clinical 
trial. 
81. Molecular therapies for inherited epidermolysis bullosa. 
82. Serendipity: How the search for meaning of serum uric acid might lead to the repurposing of an old 
drug in patients with cardiovascular disease. 
 




83. [Pulmonary amniotic fluid embolism syndrome: case report and literature review]. 
84. Multiple sclerosis: Repurposing dopaminergic drugs for MS--the evidence mounts. 
85. Multicentric study of monitoring alarms in the adult intensive care unit (ICU): a descriptive analysis. 
86. Repurposing an Old Drug for a New Epidemic: Ursodeoxycholic Acid to Prevent Recurrent 
Clostridioides difficile Infection. 
87. Repositioning Bevacizumab: A Promising Therapeutic Strategy for Cartilage Regeneration. 
88. Vinblastine as a second rescue for the treatment of canine multicentric lymphoma in 39 cases (2005 to 
2014). 
89. [Effects of nutrition intervention for pressure ulcer patients--healing rate and speed of wound size and 
nutrition--]. 
90. ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for a single-arm 
feasibility trial. 
91. Vinorelbine rescue therapy for dogs with primary urinary bladder carcinoma. 
92. Current Care and Investigational Therapies in Achondroplasia. 
93. Quantitative determination of sulfisoxazole and its three N-acetylated metabolites using HPLC-
MS/MS, and the saturable pharmacokinetics of sulfisoxazole in mice. 
94. Application of Pharmacokinetics and Pharmacodynamics in Product Life Cycle Management. A Case 
Study with a Carbidopa-Levodopa Extended-Release Formulation. 
95. Comparing treatments for age-related macular degeneration: safety, effectiveness and cost. 
96. [The Management of the Vertiginous Patient]. 
97. Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005 - 2013). 
98. Medical marijuana in the workplace: challenges and management options for occupational physicians. 
99. Oral Paracetamol for Patent Ductus Arteriosus Rescue Closure. 
100. Molecular determinants of high-affinity drug binding to HERG channels. 
101. Non-contraceptive health benefits of intrauterine hormonal systems. 
102. Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease. 
103. Drug rediscovery to prevent off-label prescription reduces health care costs: the case of tioguanine in 
the Netherlands. 
104. Nanocarrier for poorly water-soluble anticancer drugs--barriers of translation and solutions. 
 




105. Use of dilutional ultrasound monitoring to detect changes in recirculation during venovenous 
extracorporeal membrane oxygenation in swine. 
106. Repurposing drugs to treat neurological diseases. 
107. [Anti-VEGF: one drug for different conditions?]. 
108. Practice variation in the management of intrapartum fetal distress in The Netherlands and the 
Western world. 
109. Inhibition of Cholesterol Esterification in the Adrenal Gland by ATR101/PD132301-2, A Promising 
Case of Drug Repurposing. 
110. Deserves a hearing? A case report of remitting tinnitus with N-acetyl cysteine. 
111. Reporting unexpected benefit through the yellow card system. 
112. Eco-pharma of approved drug focused on mitochondria fission. 
 




3B. Appendix 3 - TR Literature Taxonomy based on Factor Analysis 
A3-1. Overview of TR literature taxonomy based on Factor Analysis 
 The previous appendix provided one perspective (text clustering) on the taxonomic structure of 
the TR literature.  The CLUTO text clustering software incorporates all phrases (minus stop-words), and 
uses one selected algorithm to generate a hierarchical taxonomy.  Another approach our group has used in 
the past to generate literature taxonomies is Factor Analysis.  Here, only pre-selected phrases are used.   
 The present appendix contains the results of a 37 factor study.  A factor matrix that identifies the 
main theme of each factor (and shows the key phrases that determine each theme) is presented.  
Additionally, the titles of the records associated with each of the key phrases in the 37 themes is presented 
as well (similar to what was done in Appendix 2 for each factor). 
A3-2. Results of Factor Analysis 
 Figure A3-1 (in a companion file on this site) shows the factor matrix containing the 37 factors.  
Column B contains the factor themes and the key phrases that determined the theme of each factor.  The 
line containing the number of each factor and its theme is highlighted in orange.  Thus, this line for Factor 
1 is: "1. IN VITRO EXPERIMENTS OF REPURPOSED DRUG CANDIDATES ON CANCER CELL LINES". 
 The key phrases that determine the main theme of each factor are listed under the orange line.  
Thus, for Factor 1, the key phrases include "cancer, cancer cells, cancer cell lines, cell lines, apoptosis, 
anticancer, tumor, cancers, cancer treatment, cell line, cancer cell line".   
 How is the order of these phrases determined; what makes them key phrases?  The answer lies in 
the numbers contained in the appropriate column to the right of Column B.  The heading for each column 
to the right of Column B is the factor number.  The cells in each column are the factor loadings, 
weightings that determine the importance of each phrase to the central factor theme.  The weightings are 
ordered by decreasing absolute value. 
 Thus, for Factor 1, the theme is determined mainly by the top phrases colored in medium green, 
with some input from the next group of phrases colored light green.  Any remaining non-colored phrases 
provide confirmatory examples. 
 The weightings for any factor range from positive in value to negative.  Typically, one 'tail' of this 
spectrum is large (at least one weighting has absval>0.3) and the other is small (absval<0.2).  The 'tail' 
containing the large absval weighting determines the theme of the factor.  In a few cases, both 'tails' will 
have at least one weighting absval>0.3. In these cases, the factor is split into two themes.  In the present 
case, Factors 5, 8, and 11 have A and B components.   
 While many broad thematic categories were possible, four appeared to be dominant.  These 
included: Repurposing Prediction Methodologies (PRED), Diseases (DISEASE), Biomarker Targets 
(BIOTARG), and Drug Types (DRUG).  Figure A3-2 lists all the 37 factor themes, and Figure A3-3 
shows the factor numbers under each major category.  Note that some factors have been assigned to 
multiple categories in Figure A3-3. 
 




Figure A3-2: FACTOR THEMES 
(each factor hyperlinked to associated record titles) 
1. In Vitro Experiments of Repurposed Drug Candidates on Cancer Cell Lines 
2. Gene Expression Signatures for Predicting Repurposed Drugs 
3. Antiviral Protease Inhibitors for Cancer Therapy 
4. Neurodegenerative Diseases Biomarkers for Repurposing Targets 
5a. Antifungal Applications of Non-Antifungal Drugs 
5b. Network-Based Approaches to Drug Repositioning 
6. Antimicrobial Applications of Repurposed Drugs 
7. Repurposed Drugs or Antifungal Applications 
8a. Use of Cellular Signatures Library to Provide Gene Expression Profiles for Drug Repurposing 
Prediction 
8b. Ligand-Based Target Inference 
9. Binding Site Analysis for Drug Repurposing 
10. Antiinflammatory Applications for Repurposed Drugs 
11a. Biomarkers for Repurposed Drug-Enhanced Apoptosis of Cancer Cells 
11b. Repurposed Drugs for Oxidative Stress Reduction 
12. Repurposed Drugs that Increase or Decrease ROS for Different Applications 
13. Similarity Searching of Ligand-Target Sets for Drug Repurposing 
14. AMPK Activation for Cancer Treatment, Emphasizing Anti-Diabetic Drug Metformin 
15. Repurposing of Cholesterol-Lowering Drugs for Chronic and Infectious Diseases 
16. Similarity-Based Methods for Drug Repurposing 
17. Machine Learning-Based Drug Repurposing Prediction 
18. Tyrosine Kinase Inhibitors Repurposed for Cancer Treatment 
19. Chemical Structure Similarity for Repurposing Prediction 
20. Network-Based Inference for Predicting Drug-Target Interaction 
21. Drug Repurposing for Viral Diseases 
22. Drug Repurposing for Anti-Parasitic Applications 
23. Phosphodiesterase Inhibitors Repurposed from Predicitions of Drug Response Signatures 
24. Inhibiting NF-KappaB Signaling for Cancer and Inflammation Treatment 
25. Repurposing Based on Comprehensive Multi-Metric Similarity Measures 
26. Genome-Wide Association-Based Networks for Repurposing 
27. Drug Repurposing for Brain Cancer 
28. Repurposing Anthelmintic Drugs for Cancer Treatment 
29. Drug Repurposing for Neurodegenerative Diseases 
30. Repurposed Drugs Targeting Glutamate Receptors 
31. Repurposing Drugs that Target Oxidative and Inflammation Biomarkers VEGF, HO-1, iNOS, Nrf2 
32. Computational Drug Repositioning Based on Similarity Networks 
33. Repurposing Antipsychotic Drugs 









Figure A3-3: MAIN TAXONOMY CATEGORIES FROM FACTOR ANALYSIS 
CATEGORY PRED DISEASE BIOTARG DRUG 
FACTOR # 2, 5B, 8A, 8B, 9, 
13, 16, 17, 19, 20, 
23, 25, 26, 32, 34 
CANCER 
1, 3, 11A, 14, 18, 




5A, 6, 7, 15, 21, 22 
 
4, 10, 11A, 11B, 
12, 14, 15, 18, 23, 
24, 30, 31 
3, 14, 18, 23, 33 
 
A3-3.  Factor Theme Summary 
 Figures A3-2 and A3-3 show the following broad characteristics of the TR literature.  The main 
diseases studied are cancer (by far), neurodegenerative, and infectious.  The main biomarker targets 
studied focus on oxidative stress and inflammatory metrics.  While drugs of many ifferent classes have 
been researched for repurposing, the main drug classes as emphasized in Figure A3-2 are Inhibitors of 
myriad signaling pathways. 
 Finally, the main repurposing prediction methodologies studied focus on networks, similarity, 
machine learning, gene expression signatures, genome-wide associations, ligand-target interactions, and 
binding site analyses. 
  
 




A3-4. Factor Theme Record Titles 
 In Figure A3-1, key phrases are listed under each factor.  The remainder of the present section 
contains the titles for each record associated with those phrases listed in Figure A3-1.  This listing allows 
the reader to examine the full spectrum of concepts that underlie each factor, and to retrieve the full 
record (from the full references provided in Chapter 4) for more detail.  The presentation format is factor 
number/factor theme followed by the record title.  Each factor listing of record titles below is hyperlinked 
to the appropriate factor number and theme in Figure A3-2.  Thus, clicking on the hyperlinked "1. In 
Vitro Experiments of Repurposed Drug Candidates on Cancer Cell Lines" in Figure A3-2 will link to 
the beginning of the list of record titles in Factor 1. 
 




FACTOR 1. In Vitro Experiments of Repurposed Drug Candidates on Cancer Cell Lines 
1. 4-Acetoxyphenol Prevents RPE Oxidative Stress-Induced Necrosis by Functioning as an NRF2 
Stabilizer 
2. 5-azacytidine inhibits nonsense-mediated decay in a MYC-dependent fashion 
3. A Blockade of IGF Signaling Sensitizes Human Ovarian Cancer Cells to the Anthelmintic 
Niclosamide-Induced Anti-Proliferative and Anticancer Activities 
4. A cellular genetics approach identifies gene-drug interactions and pinpoints drug toxicity pathway 
nodes 
5. A chemical genomics approach to drug reprofiling in oncology: Antipsychotic drug risperidone as a 
potential adenocarcinoma treatment 
6. A chemical-genetic interaction map of small molecules using high-throughput imaging in cancer cells 
7. A Combination of Three Repurposed Drugs Administered at Reperfusion as a Promising Therapy for 
Postischemic Brain Injury 
8. A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor 
9. A comparative study of disease genes and drug targets in the human protein interactome 
10. A comprehensive approach to identifying repurposed drugs to treat SCN8A epilepsy 
11. A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors 
12. A computational method for clinically relevant cancer stratification and driver mutation module 
discovery using personal genomics profiles 
13. A computational method for drug repositioning using publicly available gene expression data 
14. A Computational Systems Biology Approach for Identifying Candidate Drugs for Repositioning for 
Cardiovascular Disease 
15. A Computational Workflow Translates a 58-Gene Signature to a Formalin-Fixed, Paraffin-Embedded 
Sample-Based Companion Diagnostic for Personalized Treatment of the BRAF-Mutation-Like Subtype 
of Colorectal Cancers 
16. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of 
survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated 
Improvement of Glioblastoma Care 
17. A convenient synthesis of lubeluzole and its enantiomer: evaluation as chemosensitizing agents on 
human ovarian adenocarcinoma and lung carcinoma cells 
18. A cross-species analysis method to analyze animal models' similarity to human's disease state 
 




19. A current perspective on the oncopreventive and oncolytic properties of selective serotonin reuptake 
inhibitors 
20. A disease similarity matrix based on the uniqueness of shared genes 
21. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung 
cancer and other neuroendocrine tumors 
22. A drug-repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6-
thioguanine as an effective therapeutic agent for TPMT-low cancer cells 
23. A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase 
Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy 
24. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for 
cryptosporidiosis 
25. A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future 
Research 
26. A network based approach to drug repositioning identifies plausible candidates for breast cancer and 
prostate cancer 
27. A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target 
Therapies in Triple Negative Breast Cancer 
28. A network-based drug repositioning infrastructure for precision cancer medicine through targeting 
significantly mutated genes in the human cancer genomes 
29. A new niclosamide derivatives-B17 can inhibit urological cancers growth through apoptosis-related 
pathway 
30. A novel anti-cancer role of beta-apopicropodophyllin against non-small cell lung cancer cells 
31. A novel application of furazolidone: anti-leukemic activity in acute myeloid leukemia 
32. A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram 
33. A novel computational approach for drug repurposing using systems biology 
34. A Novel High Content Imaging-Based Screen Identifies the Anti-Helminthic Niclosamide as an 
Inhibitor of Lysosome Anterograde Trafficking and Prostate Cancer Cell Invasion 
35. A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy 
36. A novel multi-modal drug repurposing approach for identification of potent ACK1 inhibitors 
37. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer 
treatment 
 




38. A profound computational study to prioritize the disease-causing mutations in PRPS1 gene 
39. A protein folding molecular imaging biosensor monitors the effects of drugs that restore mutant p53 
structure and its downstream function in glioblastoma cells 
40. A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast 
Differentiation In Vitro 
41. A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by 
Combining a Spontaneously Emulsifying Component with a Polymer Carrier 
42. A repurposing strategy for Hsp90 inhibitors demonstrates their potency against filarial nematodes 
43. A review of contemporary options for medical management of hemangiomas, other vascular tumors, 
and vascular malformations 
44. A screen for Fli-1 transcriptional modulators identifies PKC agonists that induce erythroid to 
megakaryocytic differentiation and suppress leukemogenesis 
45. A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection 
46. A screening cascade to identify ERbeta ligands 
47. A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent Cancers 
48. A selective mitochondrial-targeted chlorambucil with remarkable cytotoxicity in breast and pancreatic 
cancers 
49. A Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and 
Repositioning Predictions 
50. A signalome screening approach in the autoinflammatory disease TNF receptor associated periodic 
syndrome (TRAPS) highlights the anti-inflammatory properties of drugs for repurposing 
51. A small molecule screen identifies an inhibitor of DNA repair inducing the degradation of TFIIH and 
the chemosensitization of tumor cells to platinum 
52. A Small-molecule Kinase Inhibitor, CEP-1347, Inhibits Survivin Expression and Sensitizes Ovarian 
Cancer Stem Cells to Paclitaxel 
53. A statin-regulated microRNA represses human c-Myc expression and function 
54. A structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 
ATPase 
55. A survey of current trends in computational drug repositioning 
56. A systematic analysis of FDA-approved anticancer drugs 
 




57. A Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles 
Using Pathway-Drug Network 
58. A systems pharmacology-oriented discovery of a new therapeutic use of the TCM formula 
Liuweiwuling for liver failure 
59. A systems-level analysis of drug-target-disease associations for drug repositioning 
60. A Topical Zinc Ionophore Blocks Tumorigenic Progression in UV-exposed SKH-1 High-risk Mouse 
Skin 
61. A tumor deconstruction platform identifies definitive end points in the evaluation of drug responses 
62. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus 
and Middle East Respiratory Syndrome Coronavirus Fusion 
63. Activity of anti-cancer protein kinase inhibitors against Leishmania spp 
64. Acute oxidant damage promoted on cancer cells by amitriptyline in comparison with some common 
chemotherapeutic drugs 
65. Adaptive mitochondrial reprogramming and resistance to PI3K therapy 
66. ADEPTUS: a discovery tool for disease prediction, enrichment and network analysis based on profiles 
from many diseases 
67. Adjuvant potential of selegiline in attenuating organ dysfunction in septic rats with peritonitis 
68. Advancing cancer drug discovery towards more agile development of targeted combination therapies 
69. Aging-related Repositioned Drugs, Donepezil and Sildenafil Citrate, Increase Apoptosis of Anti-
mitotic Drug-resistant KBV20C Cells Through Different Molecular Mechanisms 
70. Albendazole as a promising molecule for tumor control 
71. Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft 
model 
72. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4 
73. Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review 
74. Alendronate inhalation ameliorates elastase-induced pulmonary emphysema in mice by induction of 
apoptosis of alveolar macrophages 
75. Alternative molecular formats and therapeutic applications for bispecific antibodies 
76. Alternative screening approaches for discovery of Middle East respiratory syndrome coronavirus 
inhibitors 
 




77. An improved approach for predicting drug-target interaction: proteochemometrics to molecular 
docking 
78. An in vitro test system for compounds that modulate human inflammatory macrophage polarization 
79. An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs 
80. An integrated network platform for contextual prioritization of drugs and pathways 
81. An Integrative Drug Repurposing Pipeline: Switching Viral Drugs to Breast Cancer 
82. An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 
83. Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from 
Chemorefractory Neoplasia 
84. Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T-cell 
leukemia cells 
85. Angiotensin II type 1 receptor blockers increase tolerance of cells to copper and cisplatin 
86. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing 
tumour blood vessels 
87. ANTENNA, a Multi-Rank, Multi-Layered Recommender System for Inferring Reliable Drug-Gene-
Disease Associations: Repurposing Diazoxide as a Targeted Anti-Cancer Therapy 
88. Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via 
oxidative stress-mediated mTOR inhibition 
89. Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes 
differentiation of head and neck squamous cell carcinoma (HNSCC 
90. Anti-cancer potential of a novel SERM ormeloxifene 
91. Anti-inflammatory effects of dabrafenib in vitro and in vivo 
92. Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption 
93. Anti-inflammatory effects of methylthiouracil in vitro and in vivo 
94. Anti-malarials are anti-cancers and vice versa - one arrow two sparrows 
95. Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched 
for stem cell-like properties 
96. Antibiotic drug levofloxacin inhibits proliferation and induces apoptosis of lung cancer cells through 
inducing mitochondrial dysfunction and oxidative damage 
97. Antibiotic drug rifabutin is effective against lung cancer cells by targeting the eIF4E-beta-catenin axis 
 




98. Anticancer and Immunogenic Properties of Cardiac Glycosides 
99. Anticancer Drugs as Antibiofilm Agents in Candida albicans: Potential Targets 
100. Anticancer Properties of Fenofibrate: A Repurposing Use 
101. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis 
102. Antifungal application of nonantifungal drugs 
103. Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein 
phosphatase 2A in non-small cell lung cancer cells 
104. Antimalarial activity of novel 4-cyano-3-methylisoquinoline inhibitors against Plasmodium 
falciparum: design, synthesis and biological evaluation 
105. Antimalarial drug mefloquine inhibits nuclear factor kappa B signaling and induces apoptosis in 
colorectal cancer cells 
106. Antischistosomal agents: state of art and perspectives 
107. Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis 
of fatty acids 
108. Antiviral Drug Ribavirin Targets Thyroid Cancer Cells by Inhibiting the eIF4E-beta-Catenin Axis 
109. Application of Atlas of Cancer Signalling Network in preclinical studies 
110. Application of the 4D fingerprint method with a robust scoring function for scaffold-hopping and 
drug repurposing strategies 
111. Appraisal of mechanisms of radioprotection and therapeutic approaches of radiation 
countermeasures 
112. Approved oncology drugs lack in vivo activity against Trichuris muris despite in vitro activity 
113. Aripiprazole, an Antipsychotic and Partial Dopamine Agonist, Inhibits Cancer Stem Cells and 
Reverses Chemoresistance 
114. Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do 
115. Assessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer 
116. Atorvastatin as a promising anticryptococcal agent 
117. Auranofin inactivates Trichomonas vaginalis thioredoxin reductase and is effective against 
trichomonads in vitro and in vivo 
118. Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and 
displayed synergistic lethality with piperlongumine in gastric cancer 
 




119. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical 
activity against chronic lymphocytic leukemia 
120. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell 
lung cancer cells 
121. Auranofin: repurposing an old drug for a golden new age 
122. Autophagy in HIV-induced T cell death 
123. Autophagy Induced by Naftopidil Inhibits Apoptosis of Human Gastric Cancer Cells 
124. Autophagy Modulation in Disease Therapy: Where Do We Stand 
125. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation 
126. Bacoside A Induces Tumor Cell Death in Human Glioblastoma Cell Lines through Catastrophic 
Macropinocytosis 
127. Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake 
128. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy 
129. Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the 
proliferative expansion of stem-like cancer cells (CSCs 
130. Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2 
131. beta-catenin and PI3Kdelta inhibition expands precursor Th17 cells with heightened stemness and 
antitumor activity 
132. Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal 
tumor 
133. Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning 
targets for IBD and other autoimmune diseases 
134. Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of 
interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma 
135. Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer 
resistance to EGFR therapy 
136. Biological basis and clinical study of glycogen synthase kinase- 3beta-targeted therapy by drug 
repositioning for glioblastoma 
137. Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in 
drug development 
 




138. Biotin-targeted Pluronic() P123/F127 mixed micelles delivering niclosamide: A repositioning 
strategy to treat drug-resistant lung cancer cells 
139. Bis-biguanide dihydrochloride inhibits intracellular replication of M. tuberculosis and controls 
infection in mice 
140. Bisphosphonates inactivate human EGFRs to exert antitumor actions 
141. Bithionol inhibits ovarian cancer cell growth in vitro - studies on mechanism(s) of action 
142. Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the 
EIS regimen 
143. Blocking IL-6/GP130 signaling inhibits cell viability/proliferation, glycolysis, and colony forming 
activity in human pancreatic cancer cells 
144. BRCA-Monet: a breast cancer specific drug treatment mode-of-action network for treatment 
effective prediction using large scale microarray database 
145. Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote 
metastasis 
146. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant 
mammary tissues of MMTV-erbB-2 transgenic mice 
147. Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common 
therapies 
148. Cancer based pharmacogenomics network supported with scientific evidences: from the view of drug 
repurposing 
149. Cancer Drug Development Using Drosophila as an in vivo Tool: From Bedside to Bench and Back 
150. Cancer drug discovery by repurposing: teaching new tricks to old dogs 
151. Cancer Drug Response Profile scan (CDRscan): A Deep Learning Model That Predicts Drug 
Effectiveness from Cancer Genomic Signature 
152. Cancer drugs inhibit morphogenesis in the human fungal pathogen, Candida albicans 
153. Cancer Prevention and Interception: A New Era for Chemopreventive Approaches 
154. Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015 
155. Cancer stem cells as the therapeutic target of tomorrow 
156. Cancer: fundamentals behind pH targeting and the double-edged approach 
157. CancerHSP: anticancer herbs database of systems pharmacology 
 




158. Capsaicin: Current Understanding of Its Mechanisms and Therapy of Pain and Other Pre-Clinical 
and Clinical Uses 
159. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer 
160. Carglumic acid promotes apoptosis and suppresses cancer cell proliferation in vitro and in vivo 
161. Case Report: Propranolol increases the therapeutic response to temozolomide in a patient with 
metastatic paraganglioma 
162. Case-specific potentiation of glioblastoma drugs by pterostilbene 
163. CaV channels and cancer: canonical functions indicate benefits of repurposed drugs as cancer 
therapeutics 
164. Cell line modeling for systems medicine in cancers (review 
165. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma 
166. Challenges and perspective of drug repurposing strategies in early phase clinical trials 
167. Characterization of drug-induced transcriptional modules: towards drug repositioning and functional 
understanding 
168. Cheaper faster drug development validated by the repositioning of drugs against neglected tropical 
diseases 
169. Chemical & RNAi screening at MSKCC: a collaborative platform to discover & repurpose drugs to 
fight disease 
170. Chemogenomic Landscape of RUNX1-mutated AML Reveals Importance of RUNX1 Allele Dosage 
in Genetics and Glucocorticoid Sensitivity 
171. Chemoprevention agents for melanoma: a path forward into phase 3 clinical trials 
172. Chemoprevention of colorectal cancer for broad clinical use in the future 
173. Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-kappaB 
signaling 
174. Chk1 as a new therapeutic target in triple-negative breast cancer 
175. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic 
manifestations from malaria to multifarious diseases 
176. Chloroquine upregulates TRAIL/TRAILR2 expression and potentiates doxorubicin anti-tumor 
activity in thioacetamide-induced hepatocellular carcinoma model 
177. Chloroquine-containing compounds: a patent review (2010 - 2014 
 




178. Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances 
179. CK2 inhibition confers functional protection to young and aging axons against ischemia by 
differentially regulating the CDK5 and AKT signaling pathways 
180. Classifying cancer genome aberrations by their mutually exclusive effects on transcription 
181. CLC-Pred: A freely available web-service for in silico prediction of human cell line cytotoxicity for 
drug-like compounds 
182. Clobetasol and Halcinonide Act as Smoothened Agonists to Promote Myelin Gene Expression and 
RxRgamma Receptor Activation 
183. Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in 
South Africa: a retrospective cohort study 
184. Clomipramine kills Trypanosoma brucei by apoptosis 
185. Clustering based drug-drug interaction networks for possible repositioning of drugs against EGFR 
mutations: Clustering based DDI networks for EGFR mutations 
186. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover 
Potentially Targetable Cancer Cell Dependencies 
187. Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive 
melanoma: a strategy for repurposing a phase I clinical trial drug 
188. Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate 
cancer cells 
189. Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell 
carcinoma treatment 
190. Combining automatic table classification and relationship extraction in extracting anticancer drug-
side effect pairs from full-text articles 
191. Combining genomic and network characteristics for extended capability in predicting synergistic 
drugs for cancer 
192. Comparative oncology approach to drug repurposing in osteosarcoma 
193. Comparing treatments for age-related macular degeneration: safety, effectiveness and cost 
194. Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake 
in Lung Cancer 
195. Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3beta and 
Activates WNT Signaling 
 




196. Computational approaches for drug repositioning and combination therapy design 
197. Computational Approaches for Translational Oncology: Concepts and Patents 
198. Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with 
Repurposing Potential 
199. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That 
Reduces Growth of Hepatocellular Carcinoma Cells InVitro and in Mice by Inhibiting Cell Division 
Cycle 37 Signaling 
200. Computational drug repositioning for cancer therapeutics 
201. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent 
pathways among FDA-approved compounds 
202. Computational identification of multi-omic correlates of anticancer therapeutic response 
203. Computational methods and opportunities for phosphorylation network medicine 
204. Computational repositioning and preclinical validation of mifepristone for human vestibular 
schwannoma 
205. Computational repositioning and preclinical validation of pentamidine for renal cell cancer 
206. Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by 
repurposing disulfiram 
207. CONCORD biomarker prediction for novel drug introduction to different cancer types 
208. Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in 
cystic fibrosis 
209. Connectivity mapping using a combined gene signature from multiple colorectal cancer datasets 
identified candidate drugs including existing chemotherapies 
210. Context-specific functional module based drug efficacy prediction 
211. Contributions from emerging transcriptomics technologies and computational strategies for drug 
discovery 
212. Controlling schistosomiasis with praziquantel: How much longer without a viable alternative 
213. Cooperative recognition of T:T mismatch by echinomycin causes structural distortions in DNA 
duplex 
214. Copper Complexes in Cancer Therapy 
215. Copper is required for oncogenic BRAF signalling and tumorigenesis 
 




216. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from 
enhanced docking approach and molecular dynamics analyses 
217. Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 
(TRIB2) pseudokinase in cancer cells 
218. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for 
children and adolescents with cancer 
219. cudaMap: a GPU accelerated program for gene expression connectivity mapping 
220. Current and future immunotherapy targets in autoimmune neurology 
221. Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, 
and Neurological Diseases: A Mini-Review 
222. Current issues concerning drug development for pediatric hematologic malignancies 
223. Cyclic AMP efflux inhibitors as potential therapeutic agents for leukemia 
224. CYP51 as drug targets for fungi and protozoan parasites: past, present and future 
225. Cytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted 
therapeutics 
226. Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in 
ER+ breast cancer 
227. Data integration to prioritize drugs using genomics and curated data 
228. Deciphering cellular biological processes to clinical application: a new perspective for Talpha1 
treatment targeting multiple diseases 
229. DeCoST: A New Approach in Drug Repurposing From Control System Theory 
230. Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug 
Repurposing Using Transcriptomic Data 
231. Delineation of biological and molecular mechanisms underlying the diverse anticancer activities of 
mycophenolic acid 
232. DeSigN: connecting gene expression with therapeutics for drug repurposing and development 
233. Designing Dietary Recommendations Using System Level Interactomics Analysis and Network-
Based Inference 
234. Designing novel therapies against sarcomas in the era of personalized medicine and economic crisis 
235. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly 
Guided Targeted Therapy 
 




236. Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an 
active anticancer agent 
237. Development of a stretch-induced neurotrauma model for medium-throughput screening in vitro: 
identification of rifampicin as a neuroprotectant 
238. Development of Molecular Therapies for Venous Malformations 
239. Developmental toxicity of auranofin in zebrafish embryos 
240. Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells 
241. Diffusion mapping of drug targets on disease signaling network elements reveals drug combination 
strategies 
242. Discovering drugs to overcome chemoresistance in ovarian cancers based on the cancer genome 
atlas tumor transcriptome profile 
243. Discovering gene re-ranking efficiency and conserved gene-gene relationships derived from gene co-
expression network analysis on breast cancer data 
244. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from 
rational design, nature and old drug reposition 
245. Discovery and development of Seliciclib. How systems biology approaches can lead to better drug 
performance 
246. Discovery and validation of the antimetastatic activity of citalopram in colorectal cancer 
247. Discovery of alkyl bis(oxy)dibenzimidamide derivatives as novel protein arginine methyltransferase 
1 (PRMT1) inhibitors 
248. Discovery of drug mode of action and drug repositioning from transcriptional responses 
249. Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues 
250. Discovery of rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer 
251. Discovery of Surface Target Proteins Linking Drugs, Molecular Markers, Gene Regulation, Protein 
Networks, and Disease by Using a Web-Based Platform Targets-search 
252. Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase 
(MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage 
253. Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma invivo 
254. Disulfiram's Anticancer Activity: Evidence and Mechanisms 
255. Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma 
and over-rides resistance to temozolomide 
 




256. Disulfiram/copper causes redox-related proteotoxicity and concomitant heat shock response in 
ovarian cancer cells that is augmented by auranofin-mediated thioredoxin inhibition 
257. Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005 - 2013 
258. Do Cancer Drugs Counteract Neurodegeneration? Repurposing forAlzheimer's Disease 
259. Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma 
260. Docking of a novel DNA methyltransferase inhibitor identified from high-throughput screening: 
insights to unveil inhibitors in chemical databases 
261. Does the oncology community have a rejection bias when it comes to repurposed drugs 
262. Dopaminergic Regulation of Innate Immunity: a Review 
263. Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of 
human African trypanosomiasis 
264. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon 
cancer 
265. Doxycycline and therapeutic targeting of the DNA damage response in cancer cells: old drug, new 
purpose 
266. Doxycycline inhibits proliferation and induces apoptosis of both human papillomavirus positive and 
negative cervical cancer cell lines 
267. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in 
breast cancer 
268. Doxycycline is an NF-kappaB inhibitor that induces apoptotic cell death in malignant T-cells 
269. Doxycycline or how to create new with the old 
270. DPP-4 inhibitors promote proliferation and migration of rat brain microvascular endothelial cells 
under hypoxic/high-glucose conditions, potentially through the SIRT1/HIF-1/VEGF pathway 
271. Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung 
cancer 
272. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking 
(MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-
6/GP130 interface 
273. Drug discovery in academia 
274. Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat 
multi-drug and extensively drug resistant tuberculosis 
 




275. Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer 
cell lines and pathway mechanisms of resistance 
276. Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key 
277. Drug repositioning based on triangularly balanced structure for tissue-specific diseases in incomplete 
interactome 
278. Drug repositioning discovery for early- and late-stage non-small-cell lung cancer 
279. Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional 
Signatures 
280. Drug Repositioning for Effective Prostate Cancer Treatment 
281. Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer 
282. Drug repositioning for non-small cell lung cancer by using machine learning algorithms and 
topological graph theory 
283. Drug repositioning for personalized medicine 
284. Drug repositioning for prostate cancer: using a data-driven approach to gain new insights 
285. Drug repositioning framework by incorporating functional information 
286. Drug Repositioning in Glioblastoma: A Pathway Perspective 
287. Drug Repositioning Meets Precision in Glioblastoma 
288. Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer 
289. Drug Repositioning of Proton Pump Inhibitors for Enhanced Efficacy and Safety of Cancer 
Chemotherapy 
290. Drug repositioning through incomplete bi-cliques in an integrated drug-target-disease network 
291. Drug Repositioning through Systematic Mining of Gene Coexpression Networks in Cancer 
292. Drug repositioning: a machine-learning approach through data integration 
293. Drug Repurposing Approach Identifies a Synergistic Drug Combination of an Antifungal Agent and 
an Experimental Organometallic Drug for Melanoma Treatment 
294. Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections 
295. Drug Repurposing by Simulating Flow Through Protein-Protein Interaction Networks 
296. Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank 
database for allosteric Bcr-Abl inhibitors 
 




297. Drug repurposing for gastrointestinal stromal tumor 
298. Drug repurposing for glioblastoma based on molecular subtypes 
299. Drug repurposing for the treatment of glioblastoma multiforme 
300. Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for 
gastrointestinal stromal tumor 
301. Drug Repurposing in Anticancer Reagent Development 
302. Drug repurposing in cancer 
303. Drug repurposing in malignant pleural mesothelioma: a breath of fresh air 
304. Drug repurposing in oncology--patient and health systems opportunities 
305. Drug Repurposing in the Development of Anticancer Agents 
306. Drug Repurposing of Metabolic Agents in Malignant Glioma 
307. Drug repurposing of quinine as antiviral against dengue virus infection 
308. Drug Repurposing of the Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia 
309. Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) 
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interleukin 6 production and EV-A71 replication 
917. The Concept of Hormesis in Cancer Therapy - Is Less More 
918. The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell 
carcinoma 
919. The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced 
apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes 
920. The Emerging Facets of Non-Cancerous Warburg Effect 
921. The EYA tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromarone 
922. The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate 
cancer 
923. The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer's 
disease amyloid-beta peptides 
924. The heterogeneity of cancer stem-like cells at the invasive front 
925. The Hippo pathway in normal development and cancer 
926. The human disease network in terms of dysfunctional regulatory mechanisms 
927. The human immunodeficiency virus protease inhibitor ritonavir is potentially active against 
urological malignancies 
928. The impact of transcription on metabolism in prostate and breast cancers 
929. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian 
randomisation analysis 
930. The mortality reducing effect of aspirin in colorectal cancer patients: Interpreting the evidence 
931. The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug 
 




932. The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in 
hepatocellular carcinoma 
933. The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo 
934. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute 
lymphoblastic leukemia and synergistically works with dasatinib 
935. The poor design of clinical trials of statins in oncology may explain their failure - Lessons for drug 
repurposing 
936. The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance 
in cancer cell lines 
937. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines 
and discovery of potential new DDK inhibitor scaffolds 
938. The potential of quinoline derivatives for the treatment of Toxoplasma gondii infection 
939. The potential to treat lung cancer via inhalation of repurposed drugs 
940. The prince and the pauper. A tale of anticancer targeted agents 
941. The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-
beta1 
942. The protein kinase 2 inhibitor CX-4945 regulates osteoclast and osteoblast differentiation in vitro 
943. The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the 
treatment of haematologic malignancy 
944. The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory 
NRASQ61K melanoma 
945. The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer 
946. The sodium channel-blocking antiepileptic drug phenytoin inhibits breast tumour growth and 
metastasis 
947. The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in 
hepatocellular carcinoma 
948. The Tissue-Reconstructing Ability of Colon CSCs Is Enhanced by FK506 and Suppressed by GSK3 
Inhibition 
949. The University of New Mexico Center for Molecular Discovery 
950. The wisdom of crowds and the repurposing of artesunate as an anticancer drug 
 




951. Therapeutic Effect of Quinacrine, an Antiprotozoan Drug, by Selective Suppression of p-CHK1/2 in 
p53-Negative Malignant Cancers 
952. Therapeutic Effect of Repurposed Temsirolimus in Lung Adenocarcinoma Model 
953. Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by 
inhibiting Wnt/beta-catenin signaling 
954. Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial 
agent 
955. Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New 
Again 
956. Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review 
(2008-present 
957. Therapeutic potential for phenytoin: targeting Na(v)1.5 sodium channels to reduce migration and 
invasion in metastatic breast cancer 
958. Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from 
pathophysiology to treatment 
959. Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC/BCL2 
double-hit B cell lymphoma 
960. Therapeutical approaches under investigation for treatment of Chagas disease 
961. Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide 
962. Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as 
a Candidate for Treatment of Colorectal Cancer 
963. Tigecycline targets nonsmall cell lung cancer through inhibition of mitochondrial function 
964. Topical delivery of ebselen encapsulated in biopolymeric nanocapsules: drug repurposing enhanced 
antifungal activity 
965. Totally drug-resistant tuberculosis and adjunct therapies 
966. Toward creation of a cancer drug toxicity knowledge base: automatically extracting cancer drug-side 
effect relationships from the literature 
967. Toward drug repurposing in epigenetics: olsalazine as a hypomethylating compound active in a 
cellular context 
968. Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems 
Pharmacology 
 




969. Towards precision medicine-based therapies for glioblastoma: interrogating human disease genomics 
and mouse phenotypes 
970. Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies 
and in vivo effects 
971. Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine 
Approach 
972. Transcriptomic changes induced by mycophenolic acid in gastric cancer cells 
973. Transcriptomic characterization of the novel avian-origin influenza A (H7N9) virus: specific host 
response and responses intermediate between avian (H5N1 and H7N7) and human (H3N2) viruses and 
implications for treatment options 
974. Transforming Cancer Prevention through Precision Medicine and Immune-oncology 
975. Treatment of experimental autoimmune uveoretinitis with peroxisome proliferator-activated receptor 
alpha agonist fenofibrate 
976. Treatment of Schistosoma mansoni with miltefosine in vitro enhances serological recognition of 
defined worm surface antigens 
977. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug 
resistance of lung cancer 
978. Trimodal Therapy: Combining Hyperthermia with Repurposed Bexarotene and Ultrasound for 
Treating Liver Cancer 
979. Tuberculosis: From an incurable scourge to a curable disease - journey over a millennium 
980. Tumor deconstruction as a tool for advanced drug screening and repositioning 
981. Tumor progression: the neuronal input 
982. Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer 
983. TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) 
Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin 
984. Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs 
985. Unveiling anticancer potential of glibenclamide: Its synergistic cytotoxicity with doxorubicin on 
cancer cells 
986. Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic 
987. Use of attenuated paramyxoviruses for cancer therapy 
988. Use of genome-wide association studies for cancer research and drug repositioning 
 




989. Use of metformin and survival of patients with high-grade glioma 
990. Use of monoclonal antibody-IRDye800CW bioconjugates in the resection of breast cancer 
991. Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent 
drug candidates for cancer treatment 
992. Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and 
prostate cancer 
993. Utilizing Cancer - Functional Gene Set - Compound Networks to Identify Putative Drugs for Breast 
Cancer 
994. Validating drug repurposing signals using electronic health records: a case study of metformin 
associated with reduced cancer mortality 
995. Valproic acid in the complex therapy of malignant tumors 
996. Valproic Acid Promotes Apoptosis and Cisplatin Sensitivity Through Downregulation of H19 
Noncoding RNA in Ovarian A2780 Cells 
997. Verteporfin inhibits gastric cancer cell growth by suppressing adhesion molecule FAT1 
998. Viability Screen of LOPAC1280 Reveals Phosphorylation Inhibitor Auranofin as a Potent Inhibitor 
of Blastocystis Subtype 1, 4, and 7 Isolates 
999. Vinorelbine rescue therapy for dogs with primary urinary bladder carcinoma 
1000. Virtual Screening against Phosphoglycerate Kinase 1 in Quest of Novel Apoptosis Inhibitors 
1001. Virtual screening-driven repositioning of etoposide as CD44 antagonist in breast cancer cells 
1002. Vitamin K and hepatocellular carcinoma: The basic and clinic 
1003. Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs 
1004. Voltage-gated sodium channels and metastatic disease 
1005. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial 








FACTOR 2. Gene Expression Signatures for Predicting Repurposed Drugs 
1. 4-Acetoxyphenol Prevents RPE Oxidative Stress-Induced Necrosis by Functioning as an NRF2 
Stabilizer 
2. A Biologically-Based Computational Approach to Drug Repurposing for Anthrax Infection 
3. A cellular genetics approach identifies gene-drug interactions and pinpoints drug toxicity pathway 
nodes 
4. A common rejection module (CRM) for acute rejection across multiple organs identifies novel 
therapeutics for organ transplantation 
5. A comparative study of disease genes and drug targets in the human protein interactome 
6. A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors 
7. A computational method for clinically relevant cancer stratification and driver mutation module 
discovery using personal genomics profiles 
8. A computational method for drug repositioning using publicly available gene expression data 
9. A Computational Systems Biology Approach for Identifying Candidate Drugs for Repositioning for 
Cardiovascular Disease 
10. A Computational Workflow Translates a 58-Gene Signature to a Formalin-Fixed, Paraffin-Embedded 
Sample-Based Companion Diagnostic for Personalized Treatment of the BRAF-Mutation-Like Subtype 
of Colorectal Cancers 
11. A convenient synthesis of lubeluzole and its enantiomer: evaluation as chemosensitizing agents on 
human ovarian adenocarcinoma and lung carcinoma cells 
12. A cross-species analysis method to analyze animal models' similarity to human's disease state 
13. A curated C. difficile strain 630 metabolic network: prediction of essential targets and inhibitors 
14. A disease similarity matrix based on the uniqueness of shared genes 
15. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung 
cancer and other neuroendocrine tumors 
16. A generalizable pre-clinical research approach for orphan disease therapy 
17. A genomics-based systems approach towards drug repositioning for rheumatoid arthritis 
18. A Large-Scale Gene Expression Intensity-Based Similarity Metric for Drug Repositioning 
19. A machine-learned computational functional genomics-based approach to drug classification 
 




20. A meta-analysis of reflux genome-wide association studies in 6750 Northern Europeans from the 
general population 
21. A network based approach to drug repositioning identifies plausible candidates for breast cancer and 
prostate cancer 
22. A network pharmacology approach reveals new candidate caloric restriction mimetics in C. elegans 
23. A network-based drug repositioning infrastructure for precision cancer medicine through targeting 
significantly mutated genes in the human cancer genomes 
24. A novel cell-based high-throughput screen for inhibitors of HIV-1 gene expression and budding 
identifies the cardiac glycosides 
25. A novel computational approach for drug repurposing using systems biology 
26. A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy 
27. A perspective on genomic-guided anthelmintic discovery and repurposing using Haemonchus 
contortus 
28. A profound computational study to prioritize the disease-causing mutations in PRPS1 gene 
29. A protein folding molecular imaging biosensor monitors the effects of drugs that restore mutant p53 
structure and its downstream function in glioblastoma cells 
30. A screen for Fli-1 transcriptional modulators identifies PKC agonists that induce erythroid to 
megakaryocytic differentiation and suppress leukemogenesis 
31. A Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and 
Repositioning Predictions 
32. A structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 
ATPase 
33. A subpathway-based method of drug reposition for polycystic ovary syndrome 
34. A systematic and prospectively validated approach for identifying synergistic drug combinations 
against malaria 
35. A Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles 
Using Pathway-Drug Network 
36. A systems-level analysis of drug-target-disease associations for drug repositioning 
37. A Topical Zinc Ionophore Blocks Tumorigenic Progression in UV-exposed SKH-1 High-risk Mouse 
Skin 
 




38. A two-step drug repositioning method based on a protein-protein interaction network of genes shared 
by two diseases and the similarity of drugs 
39. A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case 
40. ADEPTUS: a discovery tool for disease prediction, enrichment and network analysis based on profiles 
from many diseases 
41. Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus 
42. Advances in epilepsy gene discovery and implications for epilepsy diagnosis and treatment 
43. Advances in intravesical therapy for urinary tract disorders 
44. Albendazole as a promising molecule for tumor control 
45. Alzheimer's disease master regulators analysis: search for potential molecular targets and drug 
repositioning candidates 
46. An in vitro test system for compounds that modulate human inflammatory macrophage polarization 
47. An integrated network platform for contextual prioritization of drugs and pathways 
48. An integrative approach using real-world data to identify alternative therapeutic uses of existing drugs 
49. Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from 
Chemorefractory Neoplasia 
50. Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry 
51. ANTENNA, a Multi-Rank, Multi-Layered Recommender System for Inferring Reliable Drug-Gene-
Disease Associations: Repurposing Diazoxide as a Targeted Anti-Cancer Therapy 
52. Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes 
differentiation of head and neck squamous cell carcinoma (HNSCC 
53. Anticancer Drugs as Antibiofilm Agents in Candida albicans: Potential Targets 
54. Antimalarial drug mefloquine inhibits nuclear factor kappa B signaling and induces apoptosis in 
colorectal cancer cells 
55. Antiviral effects of inhibiting host gene expression 
56. Application of Atlas of Cancer Signalling Network in preclinical studies 
57. Appraisal of mechanisms of radioprotection and therapeutic approaches of radiation countermeasures 
58. Approaches for establishing the function of regulatory genetic variants involved in disease 
59. Ariadne's ChemEffect and Pathway Studio knowledge base 
 




60. Assessment of berberine as a multi-target antimicrobial: a multi-omics study for drug discovery and 
repositioning 
61. Beyond multiple mechanisms and a unique drug: Defective autophagy as pivotal player in cerebral 
cavernous malformation pathogenesis and implications for targeted therapies 
62. Bioinformatic and biological avenues for understanding alcohol use disorder 
63. Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning 
targets for IBD and other autoimmune diseases 
64. Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of 
interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma 
65. Bioinformatics methods in drug repurposing for Alzheimer's disease 
66. Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer 
resistance to EGFR therapy 
67. Blocking IL-6/GP130 signaling inhibits cell viability/proliferation, glycolysis, and colony forming 
activity in human pancreatic cancer cells 
68. BRCA-Monet: a breast cancer specific drug treatment mode-of-action network for treatment effective 
prediction using large scale microarray database 
69. Bromide supplementation exacerbated the renal dysfunction, injury and fibrosis in a mouse model of 
Alport syndrome 
70. Building a drug-target network and its applications 
71. Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common 
therapies 
72. Calcium channel blockers as drug repurposing candidates for gestational diabetes: Mining large scale 
genomic and electronic health records data to repurpose medications 
73. Cancer based pharmacogenomics network supported with scientific evidences: from the view of drug 
repurposing 
74. CANDO and the infinite drug discovery frontier 
75. Carbamazepine alone and in combination with doxycycline attenuates isoproterenol-induced cardiac 
hypertrophy 
76. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer 
77. Cell line modeling for systems medicine in cancers (review 
 




78. Cell specificity dictates similarities in gene expression in multiple sclerosis, Parkinson's disease, and 
Alzheimer's disease 
79. Cell-specific prediction and application of drug-induced gene expression profiles 
80. CellFateScout - a bioinformatics tool for elucidating small molecule signaling pathways that drive 
cells in a specific direction 
81. Chemical signatures and new drug targets for gametocytocidal drug development 
82. Chemogenomic Landscape of RUNX1-mutated AML Reveals Importance of RUNX1 Allele Dosage 
in Genetics and Glucocorticoid Sensitivity 
83. Chemoprevention agents for melanoma: a path forward into phase 3 clinical trials 
84. Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-kappaB 
signaling 
85. Chk1 as a new therapeutic target in triple-negative breast cancer 
86. Chloroquine upregulates TRAIL/TRAILR2 expression and potentiates doxorubicin anti-tumor 
activity in thioacetamide-induced hepatocellular carcinoma model 
87. Classifying cancer genome aberrations by their mutually exclusive effects on transcription 
88. Clobetasol and Halcinonide Act as Smoothened Agonists to Promote Myelin Gene Expression and 
RxRgamma Receptor Activation 
89. Co-expression Network Approach Reveals Functional Similarities among Diseases Affecting Human 
Skeletal Muscle 
90. Cogena, a novel tool for co-expressed gene-set enrichment analysis, applied to drug repositioning and 
drug mode of action discovery 
91. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover 
Potentially Targetable Cancer Cell Dependencies 
92. Combating Ebola with Repurposed Therapeutics Using the CANDO Platform 
93. Combined analysis of gene expression and genome binding profiles identified potential therapeutic 
targets of ciclopirox in Ewing sarcoma 
94. Combining automatic table classification and relationship extraction in extracting anticancer drug-side 
effect pairs from full-text articles 
95. Combining Human Disease Genetics and Mouse Model Phenotypes towards Drug Repositioning for 
Parkinson's disease 
 




96. Comparing structural and transcriptional drug networks reveals signatures of drug activity and toxicity 
in transcriptional responses 
97. Complex-disease networks of trait-associated single-nucleotide polymorphisms (SNPs) unveiled by 
information theory 
98. Computational approaches for drug repositioning and combination therapy design 
99. Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with 
Repurposing Potential 
100. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That 
Reduces Growth of Hepatocellular Carcinoma Cells InVitro and in Mice by Inhibiting Cell Division 
Cycle 37 Signaling 
101. Computational drug repositioning with random walk on a heterogeneous network 
102. Computational Drug Repurposing: Current Trends 
103. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent 
pathways among FDA-approved compounds 
104. Computational functional genomics-based approaches in analgesic drug discovery and repurposing 
105. Computational identification of multi-omic correlates of anticancer therapeutic response 
106. Computational repositioning and preclinical validation of mifepristone for human vestibular 
schwannoma 
107. Computational repositioning and preclinical validation of pentamidine for renal cell cancer 
108. COMPUTING THERAPY FOR PRECISION MEDICINE: COLLABORATIVE FILTERING 
INTEGRATES AND PREDICTS MULTI-ENTITY INTERACTIONS 
109. Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by 
repurposing disulfiram 
110. Connecting genetics and gene expression data for target prioritisation and drug repositioning 
111. Connection Map for Compounds (CMC): A Server for Combinatorial Drug Toxicity and Efficacy 
Analysis 
112. Connections in pharmacology: innovation serving translational medicine 
113. Connectivity mapping using a combined gene signature from multiple colorectal cancer datasets 
identified candidate drugs including existing chemotherapies 
114. Constructing Disease Similarity Networks Based on Disease Module Theory 
 




115. Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for 
myasthenia gravis 
116. Context-specific functional module based drug efficacy prediction 
117. cudaMap: a GPU accelerated program for gene expression connectivity mapping 
118. Cytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted 
therapeutics 
119. Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in 
ER+ breast cancer 
120. Deciphering cellular biological processes to clinical application: a new perspective for Talpha1 
treatment targeting multiple diseases 
121. Deciphering miRNA transcription factor feed-forward loops to identify drug repurposing candidates 
for cystic fibrosis 
122. DeCoST: A New Approach in Drug Repurposing From Control System Theory 
123. Defining the Schistosoma haematobium kinome enables the prediction of essential kinases as anti-
schistosome drug targets 
124. DeSigN: connecting gene expression with therapeutics for drug repurposing and development 
125. Designing Dietary Recommendations Using System Level Interactomics Analysis and Network-
Based Inference 
126. Development of a stretch-induced neurotrauma model for medium-throughput screening in vitro: 
identification of rifampicin as a neuroprotectant 
127. Developmental toxicity of auranofin in zebrafish embryos 
128. Diffusion mapping of drug targets on disease signaling network elements reveals drug combination 
strategies 
129. DIGEP-Pred: web service for in silico prediction of drug-induced gene expression profiles based on 
structural formula 
130. Discovering drugs to overcome chemoresistance in ovarian cancers based on the cancer genome 
atlas tumor transcriptome profile 
131. Discovering gene re-ranking efficiency and conserved gene-gene relationships derived from gene co-
expression network analysis on breast cancer data 
132. Discovery and preclinical validation of drug indications using compendia of public gene expression 
data 
 




133. Discovery and validation of the antimetastatic activity of citalopram in colorectal cancer 
134. Discovery of drug mode of action and drug repositioning from transcriptional responses 
135. Discovery of novel therapeutic properties of drugs from transcriptional responses based on multi-
label classification 
136. Discovery of the neuroprotective effects of alvespimycin by computational prioritization of potential 
anti-Parkinson agents 
137. Disease classification: from phenotypic similarity to integrative genomics and beyond 
138. DiseaseConnect: a comprehensive web server for mechanism-based disease-disease connections 
139. Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma invivo 
140. DMAP: a connectivity map database to enable identification of novel drug repositioning candidates 
141. DNetDB: The human disease network database based on dysfunctional regulation mechanism 
142. Do Cancer Drugs Counteract Neurodegeneration? Repurposing forAlzheimer's Disease 
143. Doxycycline is an NF-kappaB inhibitor that induces apoptotic cell death in malignant T-cells 
144. dRiskKB: a large-scale disease-disease risk relationship knowledge base constructed from 
biomedical text 
145. Drug enrichment and discovery from schizophrenia genome-wide association results: an analysis and 
visualisation approach 
146. Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer 
cell lines and pathway mechanisms of resistance 
147. Drug repositioning based on triangularly balanced structure for tissue-specific diseases in incomplete 
interactome 
148. Drug repositioning by applying 'expression profiles' generated by integrating chemical structure 
similarity and gene semantic similarity 
149. Drug repositioning by integrating target information through a heterogeneous network model 
150. Drug repositioning discovery for early- and late-stage non-small-cell lung cancer 
151. Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional 
Signatures 
152. Drug repositioning for diabetes based on 'omics' data mining 
153. Drug repositioning for non-small cell lung cancer by using machine learning algorithms and 
topological graph theory 
 




154. Drug repositioning for orphan genetic diseases through Conserved Anticoexpressed Gene Clusters 
(CAGCs 
155. Drug repositioning framework by incorporating functional information 
156. Drug repositioning in Alzheimer's disease 
157. Drug Repositioning in Glioblastoma: A Pathway Perspective 
158. Drug Repositioning in Inflammatory Bowel Disease Based on Genetic Information 
159. Drug repositioning in SLE: crowd-sourcing, literature-mining and Big Data analysis 
160. Drug Repositioning through Systematic Mining of Gene Coexpression Networks in Cancer 
161. Drug repositioning: a machine-learning approach through data integration 
162. Drug repurposing and adverse event prediction using high-throughput literature analysis 
163. Drug repurposing and therapeutic anti-microRNA predictions for inhibition of oxidized low-density 
lipoprotein-induced vascular smooth muscle cell-associated diseases 
164. Drug Repurposing Approach Identifies Inhibitors of the Prototypic Viral Transcription Factor IE2 
that Block Human Cytomegalovirus Replication 
165. Drug repurposing for aging research using model organisms 
166. Drug repurposing for glioblastoma based on molecular subtypes 
167. Drug repurposing in idiopathic pulmonary fibrosis filtered by a bioinformatics-derived composite 
score 
168. Drug repurposing of minocycline against dengue virus infection 
169. Drug repurposing of quinine as antiviral against dengue virus infection 
170. Drug Repurposing of the Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia 
171. Drug Repurposing Using Deep Embeddings of Gene Expression Profiles 
172. Drug repurposing: An approach to tackle drug resistance in S. typhimurium 
173. Drug Repurposing: Tolfenamic Acid Inactivates PrbP, a Transcriptional Accessory Protein in 
Liberibacter asiaticus 
174. Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid 
leukemia 
175. Drug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for 
Drug Repositioning in Cancer Therapy 
 




176. Drug Signature-based Finding of Additional Clinical Use of LC28-0126 for Neutrophilic Bronchial 
Asthma 
177. Drug similarity search based on combined signatures in gene expression profiles 
178. Drug Synergy Slows Aging and Improves Healthspan through IGF and SREBP Lipid Signaling 
179. Drug target prediction and repositioning using an integrated network-based approach 
180. Drug target prediction by multi-view low rank embedding 
181. Drug Targeting and Biomarkers in Head and Neck Cancers: Insights from Systems Biology 
Analyses 
182. Drug-Path: a database for drug-induced pathways 
183. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent 
activity against breast cancer 
184. Drug-Repositioning Screens Identify Triamterene as a Selective Drug for the Treatment of DNA 
Mismatch Repair Deficient Cells 
185. Drug-repurposing identified the combination of Trolox C and Cytisine for the treatment of type 2 
diabetes 
186. Drug-target interaction prediction by integrating multiview network data 
187. DrugBank 5.0: a major update to the DrugBank database for 2018 
188. DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-
based drug repurposing 
189. Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of 
dyslipidemia 
190. DrugSig: A resource for computational drug repositioning utilizing gene expression signatures 
191. DSigDB: drug signatures database for gene set analysis 
192. DT-Web: a web-based application for drug-target interaction and drug combination prediction 
through domain-tuned network-based inference 
193. DvD: An R/Cytoscape pipeline for drug repurposing using public repositories of gene expression 
data 
194. Early repositioning through compound set enrichment analysis: a knowledge-recycling strategy 
195. Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol 
and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study 
 




196. EHFPI: a database and analysis resource of essential host factors for pathogenic infection 
197. Elesclomol restores mitochondrial function in genetic models of copper deficiency 
198. Elucidating the modes of action for bioactive compounds in a cell-specific manner by large-scale 
chemically-induced transcriptomics 
199. EMUDRA: Ensemble of Multiple Drug Repositioning Approaches to improve prediction accuracy 
200. Eritoran Suppresses Colon Cancer by Altering a Functional Balance in Toll-like Receptors That 
Bind Lipopolysaccharide 
201. Establishing a Preclinical Multidisciplinary Board for Brain Tumors 
202. Evaluation of a systems biology approach to identify pharmacological correctors of the mutant 
CFTR chloride channel 
203. Expanding the Antimalarial Drug Arsenal-Now, But How 
204. Exploiting the therapeutic potential of ready-to-use drugs: Repurposing antibiotics against amyloid 
aggregation in neurodegenerative diseases 
205. Exploration and analysis of drug modes of action through feature integration 
206. Exploration of the Anti-Inflammatory Drug Space Through Network Pharmacology: Applications 
for Drug Repurposing 
207. Explore Small Molecule-induced Genome-wide Transcriptional Profiles for Novel Inflammatory 
Bowel Disease Drug 
208. Exploring drug-target interaction networks of illicit drugs 
209. Exploring Polypharmacology in Drug Discovery and Repurposing Using the CANDO Platform 
210. Exploring the anti-proliferative activity of Pelargonium sidoides DC with in silico target 
identification and network pharmacology 
211. Exploring the molecular mechanisms of Traditional Chinese Medicine components using gene 
expression signatures and connectivity map 
212. Exploring the potential of adjunct therapy in tuberculosis 
213. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow 
Tumor Growth in Mice 
214. Expression Profiling Identifies Bezafibrate as Potential Therapeutic Drug for Lung Adenocarcinoma 
215. Finding complex biological relationships in recent PubMed articles using Bio-LDA 
 




216. Finding the targets of a drug by integration of gene expression data with a protein interaction 
network 
217. Fine-tuning PERK signaling for neuroprotection 
218. Folic Acid Exerts Post-Ischemic Neuroprotection In Vitro Through HIF-1alpha Stabilization 
219. FoxO3a Mediates the Inhibitory Effects of the Antiepileptic Drug Lamotrigine on Breast Cancer 
Growth 
220. Fragile Histidine Triad (FHIT), a Novel Modifier Gene in Pulmonary Arterial Hypertension 
221. From drug response profiling to target addiction scoring in cancer cell models 
222. From gene networks to drugs: systems pharmacology approaches for AUD 
223. From the era of genome analysis to the era of genomic drug discovery: a pioneering example of 
rheumatoid arthritis 
224. From the Viewpoint of Drug Metabolism Research 
225. Functional genomics of pain in analgesic drug development and therapy 
226. Functional Module Connectivity Map (FMCM): a framework for searching repurposed drug 
compounds for systems treatment of cancer and an application to colorectal adenocarcinoma 
227. Fusing literature and full network data improves disease similarity computation 
228. Future Directions of Genomics Research in Rheumatic Diseases 
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Noncoding RNA in Ovarian A2780 Cells 
547. Verteporfin inhibits gastric cancer cell growth by suppressing adhesion molecule FAT1 
548. Vinorelbine rescue therapy for dogs with primary urinary bladder carcinoma 
549. Virtual screening-driven repositioning of etoposide as CD44 antagonist in breast cancer cells 
550. VisANT 4.0: Integrative network platform to connect genes, drugs, diseases and therapies 
551. Vitamin K and hepatocellular carcinoma: The basic and clinic 
552. What do the genetic association data say about the high risk of suicide in people with depression? A 
novel network-based approach to find common molecular basis for depression and suicidal behavior and 
related therapeutic targets 
553. Zafirlukast inhibits complexation of Lsr2 with DNA and growth of Mycobacterium tuberculosis 
 













FACTOR 3. Antiviral Protease Inhibitors for Cancer Therapy 
1. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival 
paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of 
Glioblastoma Care 
2. A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, West 
Nile and Chikungunya viruses 
3. Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review 
4. Alendronate inhalation ameliorates elastase-induced pulmonary emphysema in mice by induction of 
apoptosis of alveolar macrophages 
5. Anti-inflammatory effects of dabrafenib in vitro and in vivo 
6. Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption 
7. Anti-inflammatory effects of methylthiouracil in vitro and in vivo 
8. Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and displayed 
synergistic lethality with piperlongumine in gastric cancer 
9. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical 
activity against chronic lymphocytic leukemia 
10. Autophagy in HIV-induced T cell death 
11. Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common 
therapies 
12. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer 
13. CK2 inhibition confers functional protection to young and aging axons against ischemia by 
differentially regulating the CDK5 and AKT signaling pathways 
14. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids 
to inhibitors of B-cell receptor signaling 
15. Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake 
in Lung Cancer 
16. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces 
Growth of Hepatocellular Carcinoma Cells InVitro and in Mice by Inhibiting Cell Division Cycle 37 
Signaling 
17. Computer-Aided Structure Based Drug Design Approaches for the Discovery of New Anti-CHIKV 
Agents 
 




18. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from 
enhanced docking approach and molecular dynamics analyses 
19. Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) 
pseudokinase in cancer cells 
20. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for 
children and adolescents with cancer 
21. Current issues concerning drug development for pediatric hematologic malignancies 
22. Direct-acting antivirals and host-targeting strategies to combat enterovirus infections 
23. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational 
design, nature and old drug reposition 
24. Distinct effects of HIV protease inhibitors and ERAD inhibitors on zygote to ookinete transition of 
the malaria parasite 
25. Disulfiram/copper causes redox-related proteotoxicity and concomitant heat shock response in ovarian 
cancer cells that is augmented by auranofin-mediated thioredoxin inhibition 
26. Drug Repurposing of the Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia 
27. Drug repurposing to target Ebola virus replication and virulence using structural systems 
pharmacology 
28. Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination 
with erlotinib in pancreatic cancer cells 
29. Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in 
enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis 
30. Exploiting large-scale drug-protein interaction information for computational drug repurposing 
31. Exploring old drugs for the treatment of hematological malignancies 
32. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow 
Tumor Growth in Mice 
33. Fine-tuning PERK signaling for neuroprotection 
34. From laptop to benchtop to bedside: structure-based drug design on protein targets 
35. Generating Gene Ontology-Disease Inferences to Explore Mechanisms of Human Disease at the 
Comparative Toxicogenomics Database 
36. Genetics of rheumatoid arthritis contributes to biology and drug discovery 
37. Genome-wide association studies of cancer: current insights and future perspectives 
 




38. Glutamate release inhibitor, Riluzole, inhibited proliferation of human hepatocellular carcinoma cells 
by elevated ROS production 
39. High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-
ALL 
40. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer 
41. Identification of an old antibiotic clofoctol as a novel activator of unfolded protein response pathways 
and an inhibitor of prostate cancer 
42. Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new 
potential strategy for identification of anti-cancer therapeutics in B-cell malignancies 
43. In silico drug repurposing of FDA-approved drugs to predict new inhibitors for drug resistant T315I 
mutant and wild-type BCR-ABL1: A virtual screening and molecular dynamics study 
44. In silico identification of novel kinase inhibitors targeting wild-type and T315I mutant ABL1 from 
FDA-approved drugs 
45. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma 
Therapy 
46. LEDGIN-mediated Inhibition of Integrase-LEDGF/p75 Interaction Reduces Reactivation of Residual 
Latent HIV 
47. Linking PharmGKB to phenotype studies and animal models of disease for drug repurposing 
48. Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives 
49. Metformin and epithelial ovarian cancer therapeutics 
50. Metformin use and gynecological cancers: A novel treatment option emerging from drug 
repositioning 
51. Misfolded proteins: from little villains to little helpers in the fight against cancer 
52. Nelfinavir and lopinavir impair Trypanosoma cruzi trypomastigote infection in mammalian host cells 
and show anti-amastigote activity 
53. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces 
endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo 
54. Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy 
55. New derivatives of the antimalarial drug Pyrimethamine in the control of melanoma tumor growth: an 
in vitro and in vivo study 
56. New HSP27 inhibitors efficiently suppress drug resistance development in cancer cells 
 




57. New sources of drugs for hematologic malignancies 
58. Nitazoxanide: a first-in-class broad-spectrum antiviral agent 
59. Old drug, new trick: repurposing metformin for gynecologic cancers 
60. Old-School Chemotherapy in Immunotherapeutic Combination in Cancer, A Low-cost Drug 
Repurposed 
61. Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective 
62. Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines 
63. Pharmacological targeting of p38 MAP-Kinase 6 (MAP2K6) inhibits the growth of esophageal 
adenocarcinoma 
64. Pharmacophore anchor models of flaviviral NS3 proteases lead to drug repurposing for DENV 
infection 
65. Predicting new indications for approved drugs using a proteochemometric method 
66. Prediction of Candidate Drugs for Treating Pancreatic Cancer by Using a Combined Approach 
67. Process Pharmacology: A Pharmacological Data Science Approach to Drug Development and 
Therapy 
68. Recent Developments and Future Opportunities in the Treatment of Tuberculosis in Children 
69. Repositioning approved drugs for the treatment of problematic cancers using a screening approach 
70. Repositioning Drugs for Rare Immune Diseases: Hopes and Challenges for a Precision Medicine 
71. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon 
Cancer Epigenome 
72. Repositioning of amprenavir as a novel extracellular signal-regulated kinase-2 inhibitor and apoptosis 
inducer in MCF-7 human breast cancer 
73. Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot 
investigating propranolol administration in patients receiving hematopoietic cell transplantation 
74. Repurposing itraconazole for the treatment of cancer 
75. Repurposing ospemifene for potentiating an antigen-specific immune response 
76. Repurposing psychiatric drugs as anti-cancer agents 
77. Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian 
cancer cells 
 




78. Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT 
Pathways 
79. Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy 
80. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors 
81. Suppressive effects of methylthiouracil on polyphosphate-mediated vascular inflammatory responses 
82. Sustained Complete Response to Metronomic Chemotherapy in a Child with Refractory Atypical 
Teratoid Rhabdoid Tumor: A Case Report 
83. Targeting the off-targets: a computational bioinformatics approach to understanding the 
polypharmacology of nelfinavir 
84. Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from 
nature and drug repurposing 
85. The Glucose Transporter PfHT1 Is an Antimalarial Target of the HIV Protease Inhibitor Lopinavir 
86. The HIV integrase inhibitor raltegravir inhibits felid alphaherpesvirus 1 (FeHV-1) replication by 
targeting both DNA replication and late gene expression 
87. The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological 
malignancies 
88. The potential to treat lung cancer via inhalation of repurposed drugs 
89. The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the 
treatment of haematologic malignancy 
90. Therapeutic Approaches to Type I Interferonopathies 
91. Therapeutic Effect of Quinacrine, an Antiprotozoan Drug, by Selective Suppression of p-CHK1/2 in 
p53-Negative Malignant Cancers 
92. Totally drug-resistant tuberculosis and adjunct therapies 
93. Tuberculosis: From an incurable scourge to a curable disease - journey over a millennium 
94. Use of minocycline in viral infections 
95. Use of monoclonal antibody-IRDye800CW bioconjugates in the resection of breast cancer 
96. Using HIV drugs to target human papilloma virus 
97. Valproic acid in the complex therapy of malignant tumors 
 
 










FACTOR 4. Neurodegenerative Diseases Biomarkers for Repurposing Targets 
1. 4-Acetoxyphenol Prevents RPE Oxidative Stress-Induced Necrosis by Functioning as an NRF2 
Stabilizer 
2. A bidirectional drug repositioning approach for Parkinson's disease through network-based inference 
3. A Combination of Three Repurposed Drugs Administered at Reperfusion as a Promising Therapy for 
Postischemic Brain Injury 
4. A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors 
5. A Critical Review of Repurposing Apomorphine for Smoking Cessation 
6. A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia 
7. A review of drugs for treatment of Alzheimer's disease in clinical trials: main trends 
8. A screen for Fli-1 transcriptional modulators identifies PKC agonists that induce erythroid to 
megakaryocytic differentiation and suppress leukemogenesis 
9. A structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 
ATPase 
10. A Topical Zinc Ionophore Blocks Tumorigenic Progression in UV-exposed SKH-1 High-risk Mouse 
Skin 
11. Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease 
12. Activation of MyD88-dependent TLR1/2 signaling by misfolded alpha-synuclein, a protein linked to 
neurodegenerative disorders 
13. Activation of RXR/PPARgamma underlies neuroprotection by bexarotene in ischemic stroke 
14. Acute oxidant damage promoted on cancer cells by amitriptyline in comparison with some common 
chemotherapeutic drugs 
15. Adjuvant potential of selegiline in attenuating organ dysfunction in septic rats with peritonitis 
16. Adrenergic regulation of innate immunity: a review 
17. Advanced neuroprotection for brain ischemia: an alternative approach to minimize stroke damage 
18. Advances in drug development for Parkinson's disease: present status 
19. Albendazole as a promising molecule for tumor control 
20. alpha-Methyl-alpha-phenylsuccinimide ameliorates neurodegeneration in a C. elegans model of TDP-
43 proteinopathy 
 




21. AlzhCPI: A knowledge base for predicting chemical-protein interactions towards Alzheimer's disease 
22. Alzheimer's Disease (AD) therapeutics - 1: Repeated clinical failures continue to question the amyloid 
hypothesis of AD and the current understanding of AD causality 
23. Alzheimer's disease master regulators analysis: search for potential molecular targets and drug 
repositioning candidates 
24. Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via 
oxidative stress-mediated mTOR inhibition 
25. Antibiotic drug levofloxacin inhibits proliferation and induces apoptosis of lung cancer cells through 
inducing mitochondrial dysfunction and oxidative damage 
26. Approaches for discovering anti-prion compounds: lessons learned and challenges ahead 
27. Auranofin: repurposing an old drug for a golden new age 
28. Azithromycin protects mice against ischemic stroke injury by promoting macrophage transition 
towards M2 phenotype 
29. Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the 
proliferative expansion of stem-like cancer cells (CSCs 
30. beta-Caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and 
metabolic dysregulation in mice 
31. Biomarker repurposing: Therapeutic drug monitoring of serum theophylline offers a potential 
diagnostic biomarker of Parkinson's disease 
32. Bromide supplementation exacerbated the renal dysfunction, injury and fibrosis in a mouse model of 
Alport syndrome 
33. Can an FDA-Approved Alzheimer's Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika 
Virus 
34. Can commonly prescribed drugs be repurposed for the prevention or treatment of Alzheimer's and 
other neurodegenerative diseases? Protocol for an observational cohort study in the UK Clinical Practice 
Research Datalink 
35. Candesartan stimulates reparative angiogenesis in ischemic retinopathy model: role of 
hemeoxygenase-1 (HO-1 
36. Cell specificity dictates similarities in gene expression in multiple sclerosis, Parkinson's disease, and 
Alzheimer's disease 
37. Checking the STEP-Associated Trafficking and Internalization of Glutamate Receptors for Reduced 
Cognitive Deficits: A Machine Learning Approach-Based Cheminformatics Study and Its Application for 
Drug Repurposing 
 




38. Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances 
39. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug 
development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis 
40. CNS repurposing - Potential new uses for old drugs: Examples of screens for Alzheimer's disease, 
Parkinson's disease and spasticity 
41. Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease 
42. Combining Human Disease Genetics and Mouse Model Phenotypes towards Drug Repositioning for 
Parkinson's disease 
43. Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological 
Proteins Related to the Alzheimer's Disease 
44. Comparing structural and transcriptional drug networks reveals signatures of drug activity and toxicity 
in transcriptional responses 
45. Computational repositioning and experimental validation of approved drugs for HIF-prolyl 
hydroxylase inhibition 
46. Copper Complexes in Cancer Therapy 
47. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease 
48. Cyclin dependent kinase 5: A novel avenue for Alzheimer's disease 
49. Deciphering cellular biological processes to clinical application: a new perspective for Talpha1 
treatment targeting multiple diseases 
50. Developmental toxicity of auranofin in zebrafish embryos 
51. Dexpramipexole improves bioenergetics and outcome in experimental stroke 
52. Discovering new treatments for Alzheimer's disease by repurposing approved medications 
53. Discovery of drug mode of action and drug repositioning from transcriptional responses 
54. Discovery of Surface Target Proteins Linking Drugs, Molecular Markers, Gene Regulation, Protein 
Networks, and Disease by Using a Web-Based Platform Targets-search 
55. Discovery of the neuroprotective effects of alvespimycin by computational prioritization of potential 
anti-Parkinson agents 
56. Do Cancer Drugs Counteract Neurodegeneration? Repurposing forAlzheimer's Disease 
57. Dopamine antagonists for treatment resistance in autism spectrum disorders: review and focus on 
BDNF stimulators loxapine and amitriptyline 
 




58. Dopaminergic Regulation of Innate Immunity: a Review 
59. Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models 
60. Doxycycline is an NF-kappaB inhibitor that induces apoptotic cell death in malignant T-cells 
61. Drug delivery for the treatment of endometriosis and uterine fibroids 
62. Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat 
multi-drug and extensively drug resistant tuberculosis 
63. Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining 
64. Drug Repositioning for Effective Prostate Cancer Treatment 
65. Drug repositioning for treatment of movement disorders: from serendipity to rational discovery 
strategies 
66. Drug Repurposing Approach Identifies Inhibitors of the Prototypic Viral Transcription Factor IE2 that 
Block Human Cytomegalovirus Replication 
67. Drug Repurposing for Duchenne Muscular Dystrophy: The Monoamine Oxidase B Inhibitor 
Safinamide Ameliorates the Pathological Phenotype in mdx Mice and in Myogenic Cultures From DMD 
Patients 
68. Drug repurposing for immune modulation in acute ischemic stroke 
69. Drug repurposing for Leishmania. Molecular basis of the leishmanicidal activity of the antidepressant 
sertraline 
70. Drug Repurposing in Parkinson's Disease 
71. Drug Repurposing Screen Identifies Foxo1-Dependent Angiopoietin-2 Regulation in Sepsis 
72. Drug Repurposing Screening Identifies Novel Compounds That Effectively Inhibit Toxoplasma 
gondii Growth 
73. Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for 
secondary progressive multiple sclerosis 
74. Drug-Repositioning Screening for Keap1-Nrf2 Binding Inhibitors using Fluorescence Correlation 
Spectroscopy 
75. Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends 
76. Emerging amyloid and tau targeting treatments for Alzheimer's disease 
77. Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets 
 




78. Epigenetic Drug Repositioning for Alzheimer's Disease Based on Epigenetic Targets in Human 
Interactome 
79. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and 
synergize with fluconazole in vivo 
80. Examining the potential preventative effects of minocycline prescribed for acne on the incidence of 
severe mental illnesses: A historical cohort study 
81. Exenatide and the treatment of patients with Parkinson's disease 
82. Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats 
83. Exploiting the therapeutic potential of ready-to-use drugs: Repurposing antibiotics against amyloid 
aggregation in neurodegenerative diseases 
84. Exploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A 
convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation 
85. Fast, non-competitive and reversible inhibition of NMDA-activated currents by 2-BFI confers 
neuroprotection 
86. Fibrosis in systemic sclerosis: common and unique pathobiology 
87. Fine-tuning PERK signaling for neuroprotection 
88. Folic Acid Exerts Post-Ischemic Neuroprotection In Vitro Through HIF-1alpha Stabilization 
89. FoxO3a Mediates the Inhibitory Effects of the Antiepileptic Drug Lamotrigine on Breast Cancer 
Growth 
90. From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy 
91. From stroke to neurodegenerative diseases: The multi-target neuroprotective effects of 3-n-
butylphthalide and its derivatives 
92. gene2drug: a computational tool for pathway-based rational drug repositioning 
93. Histamine-2 receptor antagonist famotidine modulates cardiac stem cell characteristics in 
hypertensive heart disease 
94. Identification and Validation of an Antivirulence Agent Targeting HlyU-Regulated Virulence in 
Vibrio vulnificus 
95. Identification of an old antibiotic clofoctol as a novel activator of unfolded protein response pathways 
and an inhibitor of prostate cancer 
96. Identification of common biological pathways and drug targets across multiple respiratory viruses 
based on human host gene expression analysis 
 




97. Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of 
action 
98. Identification of Non-Electrophilic Nrf2 Activators from Approved Drugs 
99. Identifying and Tackling Emergent Vulnerability in Drug-Resistant Mycobacteria 
100. In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-
melanoma drug, for Parkinson's disease 
101. Inferring new indications for approved drugs via random walk on drug-disease heterogenous 
networks 
102. Inhibition of ACE Retards Tau Hyperphosphorylation and Signs of Neuronal Degeneration in Aged 
Rats Subjected to Chronic Mild Stress 
103. Intelligent and effective informatic deconvolution of "Big Data" and its future impact on the 
quantitative nature of neurodegenerative disease therapy 
104. Interactions of Selective Serotonin Reuptake Inhibitors with beta-Amyloid 
105. Lansoprazole Upregulates Polyubiquitination of the TNF Receptor-Associated Factor 6 and 
Facilitates Runx2-mediated Osteoblastogenesis 
106. Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with 
Lewy bodies 
107. Laying in silico pipelines for drug repositioning: a paradigm in ensemble analysis for 
neurodegenerative diseases 
108. Lethal action of the nitrothiazolyl-salicylamide derivative nitazoxanide via induction of oxidative 
stress in Leishmania (L.) infantum 
109. Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using 
screening of multiple prospective new treatments 
110. Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced 
depression model via improving hippocampal neural plasticity 
111. Loxapine add-on for adolescents and adults with autism spectrum disorders and irritability 
112. Mechanistic insights into epigenetic modulation of ethanol consumption 
113. Meta-analysis of human gene expression in response to Mycobacterium tuberculosis infection 
reveals potential therapeutic targets 
114. Metformin as a geroprotector: experimental and clinical evidence 
 




115. Metformin treatment ameliorates diabetes-associated decline in hippocampal neurogenesis and 
memory via phosphorylation of insulin receptor substrate 1 
116. Minocycline repurposing in critical illness: focus on stroke 
117. Mitigation of carbon tetrachloride-induced hepatic injury by methylene blue, a repurposed drug, is 
mediated by dual inhibition of GSK3beta downstream of PKA 
118. Mmp-9 inhibition: a therapeutic strategy in ischemic stroke 
119. Modeling cerebrovascular pathophysiology in amyloid-beta metabolism using neural-crest-derived 
smooth muscle cells 
120. Molecular investigations of protriptyline as a multi-target directed ligand in Alzheimer's disease 
121. Monocyte-macrophage differentiation of acute myeloid leukemia cell lines by small molecules 
identified through interrogation of the Connectivity Map database 
122. Mood, stress and longevity: convergence on ANK3 
123. Mucuna pruriens (L.) DC chemo sensitize human breast cancer cells via downregulation of 
prolactin-mediated JAK2/STAT5A signaling 
124. Myelination induction by a histamine H3 receptor antagonist in a mouse model of preterm white 
matter injury 
125. Neuroprotective and immunomodulatory effects of raloxifene in the myenteric plexus of a mouse 
model of Parkinson's disease 
126. Neuroprotective Drug for Nerve Trauma Revealed Using Artificial Intelligence 
127. Neurotrophin strategies for neuroprotection: are they sufficient 
128. New applications for known drugs: Human glycogen synthase kinase 3 inhibitors as modulators of 
Aspergillus fumigatus growth 
129. New developments in the management of neurogenic orthostatic hypotension 
130. Niclosamide, a Drug with Many (Re)purposes 
131. Nilotinib - Differentiating the Hope fromtheHype 
132. Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-beta 
133. Novel putative drugs and key initiating genes for neurodegenerative disease determined using 
network-based genetic integrative analysis 
134. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-
induced ferroptosis 
 




135. Nutrients, neurogenesis and brain ageing: From disease mechanisms to therapeutic opportunities 
136. Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the 
early phase after heart transplantation in rats 
137. Old Drugs as New Treatments for Neurodegenerative Diseases 
138. Old wines in new bottles: Repurposing opportunities for Parkinson's disease 
139. One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug 
140. Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases 
141. Overcoming obstacles to repurposing for neurodegenerative disease 
142. Oxidative stress during acetaminophen hepatotoxicity: Sources, pathophysiological role and 
therapeutic potential 
143. Parkinson's Disease, Diabetes and Cognitive Impairment 
144. Pharmacological approach for drug repositioning against cardiorenal diseases 
145. Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective 
drugs 
146. Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of 
tauopathy 
147. Pharmacological targeting of p38 MAP-Kinase 6 (MAP2K6) inhibits the growth of esophageal 
adenocarcinoma 
148. Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential 
interventions 
149. Pharmacology and Clinical Drug Candidates in Redox Medicine 
150. Phenotypic screening of the Prestwick library for treatment of Parkinson's tremor symptoms using a 
humanized quantitative systems pharmacology platform 
151. Platelet Hyperreactivity in Diabetes: Focus on GPVI Signaling-Are Useful Drugs Already Available 
152. Poly(ADP-ribose) polymerase is not involved in the neuroprotection exerted by azithromycin against 
ischemic stroke in mice 
153. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-
expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy 
154. Post-ischemic treatment with azithromycin protects ganglion cells against retinal 
ischemia/reperfusion injury in the rat 
 




155. Posttranslational Regulation of O(6)-Methylguanine-DNA Methyltransferase (MGMT) and New 
Opportunities for Treatment of Brain Cancers 
156. Potential repositioning of exemestane as a neuroprotective agent for Parkinson's disease 
157. Potential repurposing of oncology drugs for the treatment of Alzheimer's disease 
158. Preclinical Evidence Supporting Early Initiation of Citalopram Treatment in Machado-Joseph 
Disease 
159. Prediction of structure of human WNT-CRD (FZD) complex for computational drug repurposing 
160. Propofol post-conditioning alleviates hepatic ischaemia reperfusion injury via BRG1-mediated 
Nrf2/HO-1 transcriptional activation in human and mice 
161. Protein Kinases and Parkinson's Disease 
162. Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency 
and with GABAA potentiating activity for use in dementia 
163. Recent Advances in Drug Repurposing for Parkinson's Disease 
164. Reduction of amyloid-beta deposition and attenuation of memory deficits by tolfenamic acid 
165. Repackaging FDA-approved drugs for degenerative diseases: promises and challenges 
166. Repositioning drugs by targeting network modules: a Parkinson's disease case study 
167. Repositioning Microtubule Stabilizing Drugs for Brain Disorders 
168. Repositioning of bromocriptine for treatment of acute myeloid leukemia 
169. Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent 
170. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated 
cellular toxicity 
171. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease 
172. Repurposed drugs targeting eIF2&alpha;-P-mediated translational repression prevent 
neurodegeneration in mice 
173. Repurposing an established drug: an emerging role for methylene blue in L-DOPA-induced 
dyskinesia 
174. Repurposing an orally available drug for the treatment of geographic atrophy 
175. Repurposing and repositioning neurosteroids in the treatment of traumatic brain injury: A report 
from the trenches 
 




176. Repurposing and Rescuing of Mibefradil, an Antihypertensive, for Cancer: A Case Study 
177. Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer 
stem cells 
178. Repurposing auranofin for the treatment of cutaneous staphylococcal infections 
179. Repurposing doxycycline for synucleinopathies: remodelling of alpha-synuclein oligomers towards 
non-toxic parallel beta-sheet structured species 
180. Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent 
181. Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease 
182. Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections 
183. Repurposing of Copper(II)-chelating Drugs for the Treatment of Neurodegenerative Diseases 
184. Repurposing ospemifene for potentiating an antigen-specific immune response 
185. Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease 
186. Repurposing the clinically approved calcium antagonist manidipine dihydrochloride as a new early 
inhibitor of human cytomegalovirus targeting the Immediate-Early 2 (IE2) protein 
187. Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in 
Parkinson's Disease 
188. Repurposing Thioridazine (TDZ) as an anti-inflammatory agent 
189. Research and development of anti-Alzheimer's disease drugs: an update from the perspective of 
technology flows 
190. Retinal Neuroprotective Effects of Flibanserin, an FDA-Approved Dual Serotonin Receptor Agonist-
Antagonist 
191. Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT 
Pathways 
192. Selective human inhibitors of ATR and ATM render Leishmania major promastigotes sensitive to 
oxidative damage 
193. Senicapoc: Repurposing a Drug to Target Microglia KCa3.1 in Stroke 
194. Six psychotropics for pre-symptomatic & early Alzheimer's (MCI), Parkinson's, and Huntington's 
disease modification 
195. Small Molecules in Development for the Treatment of Spinal Muscular Atrophy 
 




196. Structural analysis of protein tyrosine phosphatase 1B reveals potentially druggable allosteric 
binding sites 
197. Sulforaphane Prevents Neuronal Apoptosis and Memory Impairment in Diabetic Rats 
198. SUMOylation in brain ischemia: Patterns, targets, and translational implications 
199. Suppressive effects of methylthiouracil on polyphosphate-mediated vascular inflammatory responses 
200. Systematic dissection of dysregulated transcription factor-miRNA feed-forward loops across tumor 
types 
201. Systems biological understanding of the regulatory network and the possible therapeutic strategies 
for vascular calcification 
202. T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's 
Disease 
203. Tacrine-deferiprone hybrids as multi-target-directed metal chelators against Alzheimer's disease: a 
two-in-one drug 
204. Tamoxifen Provides Structural and Functional Rescue in Murine Models of Photoreceptor 
Degeneration 
205. Targeting cyclin D3/CDK6 activity for treatment of Parkinson's disease 
206. Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins 
207. Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt/mTOR and inducing 
oxidative stress 
208. Targeting STAT1 in Both Cancer and Insulin Resistance Diseases 
209. Tecfidera(): an approach for repurposing 
210. Tetracycline repurposing in neurodegeneration: focus on Parkinson's disease 
211. The Linked Clinical Trials Initiative (LCT) for Parkinson's disease 
212. The polysialic acid mimetics idarubicin and irinotecan stimulate neuronal survival and neurite 
outgrowth and signal via protein kinase C 
213. The possible repositioning of an oral anti-arthritic drug, auranofin, for Nrf2-activating therapy: The 
demonstration of Nrf2-dependent anti-oxidative action using a zebrafish model 
214. The Repurposing of Anti-Psychotic Drugs, Quetiapine and Olanzapine, as Anti-Cryptococcus Drugs 
215. The use of a gene expression signature and connectivity map to repurpose drugs for bipolar disorder 
216. Therapeutic Approaches to Prion Diseases 
 




217. Topical mevastatin promotes wound healing by inhibiting the transcription factor c-Myc via the 
glucocorticoid receptor and the long non-coding RNA Gas5 
218. Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine 
Approach 
219. TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) 
Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin 
220. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities 
221. Understanding organellar protein folding capacities and assessing their pharmacological modulation 
by small molecules 
222. Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease 
223. Using Drugs as Molecular Probes: AComputational Chemical Biology Approach in 
Neurodegenerative Diseases 
224. Utility of Induced Pluripotent Stem Cells for the Study and Treatment of Genetic Diseases: Focus on 
Childhood Neurological Disorders 
225. Validating the Predicted Effect of Astemizole and Ketoconazole Using a Drosophila Model of 
Parkinson's Disease 
226. Valproic acid mediates miR-124 to down-regulate a novel protein target, GNAI1 
227. Virtual Screening against Phosphoglycerate Kinase 1 in Quest of Novel Apoptosis Inhibitors 
228. What do the genetic association data say about the high risk of suicide in people with depression? A 
novel network-based approach to find common molecular basis for depression and suicidal behavior and 








FACTOR 5a. Antifungal Applications of Non-Antifungal Drugs 
1. A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future 
Research 
2. A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common 
structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis 
3. Anticancer Drugs as Antibiofilm Agents in Candida albicans: Potential Targets 
4. Antifungal adjuvants: Preserving and extending the antifungal arsenal 
5. Antifungal amphiphilic kanamycins: new life for an old drug 
6. Antifungal application of nonantifungal drugs 
7. Antifungal Phenothiazines: Optimization, Characterization of Mechanism, and Modulation of 
Neuroreceptor Activity 
8. Antifungal properties of the anti-hypertensive drug: aliskiren 
9. Antifungals 
10. Antiviral activity of micafungin against enterovirus 71 
11. Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of 
bacterial infections: a puzzling paradox or a logical consequence of their mode of action 
12. Artemisinins, new miconazole potentiators resulting in increased activity against Candida albicans 
biofilms 
13. Atorvastatin as a promising anticryptococcal agent 
14. Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the 
EIS regimen 
15. Calcineurin-NFAT signalling in myeloid leucocytes: new prospects and pitfalls in 
immunosuppressive therapy 
16. Cancer drugs inhibit morphogenesis in the human fungal pathogen, Candida albicans 
17. Candidiasis and the impact of flow cytometry on antifungal drug discovery 
18. Combined analysis of gene expression and genome binding profiles identified potential therapeutic 
targets of ciclopirox in Ewing sarcoma 
19. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole 
20. CYP51 as drug targets for fungi and protozoan parasites: past, present and future 
 




21. Development of anti-fungal pesticides from protein kinase inhibitor-based anticancer agents 
22. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning 
in local therapy of lung infections 
23. Drug Repurposing Approach Identifies a Synergistic Drug Combination of an Antifungal Agent and 
an Experimental Organometallic Drug for Melanoma Treatment 
24. Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections 
25. Drug Repurposing Screening Identifies Tioconazole as an ATG4 Inhibitor that Suppresses Autophagy 
and Sensitizes Cancer Cells to Chemotherapy 
26. Drug repurposing to target Ebola virus replication and virulence using structural systems 
pharmacology 
27. Drugs currently under investigation for the treatment of invasive candidiasis 
28. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and 
synergize with fluconazole in vivo 
29. From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic 
Small Cell Lung Cancer (SCLC 
30. Future perspectives for cryptococcosis treatment 
31. Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities 
in schizophrenia 
32. Glybenclamide: an antidiabetic with in vivo antithrombotic activity 
33. High-throughput screening of a collection of known pharmacologically active small compounds for 
identification of Candida albicans biofilm inhibitors 
34. Identification of Small-Molecule Inhibitors of Human Golgi Mannosidase via a Drug Repositioning 
Screen 
35. Imidazole Antifungal Drugs Inhibit the Cell Proliferation and Invasion of Human Breast Cancer Cells 
36. Imidazolium salts as innovative agents against Leishmania amazonensis 
37. In vitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania 
amazonensis 
38. In vitro analysis of finasteride activity against Candida albicans urinary biofilm formation and 
filamentation 
39. In vitro and in vivo studies of the antiparasitic activity of sterol 14alpha-demethylase (CYP51) 
inhibitor VNI against drug-resistant strains of Trypanosoma cruzi 
 




40. Mapping Protein Targets of Bioactive Small Molecules Using Lipid-Based Chemical Proteomics 
41. Molecular docking studies on thirteen fluoroquinolines with human topoisomerase II a and b 
42. New applications for known drugs: Human glycogen synthase kinase 3 inhibitors as modulators of 
Aspergillus fumigatus growth 
43. New pharmacological treatment strategies for relapse prevention 
44. Newer patents in antimycotic therapy 
45. Novel Antifungal Compounds Discovered in Medicines for Malaria Venture's Malaria Box 
46. Pathogenicity phenomena in three model systems: from network mining to emerging system-level 
properties 
47. Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics 
48. Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved 
Therapies and Emerging Concepts 
49. Quinacrine inhibits Candida albicans growth and filamentation at neutral pH 
50. Rapid identification of antifungal compounds against Exserohilum rostratum using high throughput 
drug repurposing screens 
51. Repositioning of Endonuclear Receptors Binders as Potential Antibacterial and Antifungal Agents. 
Eptyloxim: A Potential and Novel Gyrase B and Cytochrome Cyp51 Inhibitor 
52. Repurposing antipsychotic drugs into antifungal agents: Synergistic combinations of azoles and 
bromperidol derivatives in the treatment of various fungal infections 
53. Repurposing Approach Identifies Auranofin with Broad Spectrum Antifungal Activity That Targets 
Mia40-Erv1 Pathway 
54. Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida 
albicans biofilms 
55. Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important 
fungi 
56. Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis 
57. Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans 
58. Repurposing of Aspirin and Ibuprofen as Candidate Anti-Cryptococcus Drugs 
59. Repurposing ospemifene for potentiating an antigen-specific immune response 
 




60. Repurposing Resveratrol and Fluconazole To Modulate Human Cytochrome P450-Mediated 
Arachidonic Acid Metabolism 
61. Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer 
Chemotherapeutic 
62. Reversal of Azole Resistance in Candida albicans by Sulfa Antibacterial Drugs 
63. Role of acid responsive genes in the susceptibility of Escherichia coli to ciclopirox 
64. Screening a Repurposing Library for Inhibitors of Multidrug-Resistant Candida auris Identifies 
Ebselen as a Repositionable Candidate for Antifungal Drug Development 
65. Statins: antimicrobial resistance breakers or makers 
66. Strategies in the discovery of novel antifungal scaffolds 
67. Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans 
68. Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma 
cruzi 
69. Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review 
70. The anti-Aspergillus drug pipeline: Is the glass half full or empty 
71. The Anti-helminthic Compound Mebendazole Has Multiple Antifungal Effects against Cryptococcus 
neoformans 
72. The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-
enhanced platelet function 
73. The Repurposing of Anti-Psychotic Drugs, Quetiapine and Olanzapine, as Anti-Cryptococcus Drugs 
74. The Tissue-Reconstructing Ability of Colon CSCs Is Enhanced by FK506 and Suppressed by GSK3 
Inhibition 
75. The triphenylethylenes, a novel class of antifungals 
76. Topical delivery of ebselen encapsulated in biopolymeric nanocapsules: drug repurposing enhanced 
antifungal activity 
77. Toward improved anti-cryptococcal drugs: Novel molecules and repurposed drugs 
78. Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, 
Escherichia coli, and Klebsiella pneumoniae 
79. Treatment of Disseminated Leishmaniasis With Liposomal Amphotericin B 
80. Tricyclic antidepressants inhibit Candida albicans growth and biofilm formation 
 













FACTOR 5b. Network-Based Approaches to Drug Repositioning 
1. A disease similarity matrix based on the uniqueness of shared genes 
2. A framework for the targeted selection of herbs with similar efficacy by exploiting drug repositioning 
technique and curated biomedical knowledge 
3. A genomics-based systems approach towards drug repositioning for rheumatoid arthritis 
4. A miRNA-driven inference model to construct potential drug-disease associations for drug 
repositioning 
5. A network integration approach for drug-target interaction prediction and computational drug 
repositioning from heterogeneous information 
6. A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target 
Therapies in Triple Negative Breast Cancer 
7. A network-based drug repositioning infrastructure for precision cancer medicine through targeting 
significantly mutated genes in the human cancer genomes 
8. A review of network-based approaches to drug repositioning 
9. A Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles 
Using Pathway-Drug Network 
10. A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case 
11. Advances in epilepsy gene discovery and implications for epilepsy diagnosis and treatment 
12. Application of Atlas of Cancer Signalling Network in preclinical studies 
13. Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the 
proliferative expansion of stem-like cancer cells (CSCs 
14. Cancer Drug Response Profile scan (CDRscan): A Deep Learning Model That Predicts Drug 
Effectiveness from Cancer Genomic Signature 
15. Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological 
Proteins Related to the Alzheimer's Disease 
16. Compensating for literature annotation bias when predicting novel drug-disease relationships through 
Medical Subject Heading Over-representation Profile (MeSHOP) similarity 
17. Computational approaches for innovative antiepileptic drug discovery 
18. Computational drug repositioning for peripheral arterial disease: prediction of anti-inflammatory and 
pro-angiogenic therapeutics 
19. Computational drug repositioning through heterogeneous network clustering 
 




20. Computational drug repositioning using low-rank matrix approximation and randomized algorithms 
21. Computational drug repositioning with random walk on a heterogeneous network 
22. Constructing Disease Similarity Networks Based on Disease Module Theory 
23. Deep-Learning-Based Drug-Target Interaction Prediction 
24. DenguePredict: An Integrated Drug Repositioning Approach towards Drug Discovery for Dengue 
25. Designing Dietary Recommendations Using System Level Interactomics Analysis and Network-
Based Inference 
26. Detecting drug promiscuity using Gaussian ensemble screening 
27. Discovery and preclinical validation of drug indications using compendia of public gene expression 
data 
28. Disease classification: from phenotypic similarity to integrative genomics and beyond 
29. DR2DI: a powerful computational tool for predicting novel drug-disease associations 
30. dRiskKB: a large-scale disease-disease risk relationship knowledge base constructed from biomedical 
text 
31. DrPOCS: Drug repositioning based on projection onto convex sets 
32. Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm 
33. Drug repositioning based on triangularly balanced structure for tissue-specific diseases in incomplete 
interactome 
34. Drug Repositioning by Integrating Known Disease-Gene and Drug-Target Associations in a Semi-
supervised Learning Model 
35. Drug repositioning by integrating target information through a heterogeneous network model 
36. Drug repositioning for enzyme modulator based on human metabolite-likeness 
37. Drug repositioning for orphan genetic diseases through Conserved Anticoexpressed Gene Clusters 
(CAGCs 
38. Drug repositioning for prostate cancer: using a data-driven approach to gain new insights 
39. Drug repurposing based on drug-drug interaction 
40. Drug target prediction and repositioning using an integrated network-based approach 
41. Drug-disease association and drug-repositioning predictions in complex diseases using causal 
inference-probabilistic matrix factorization 
 




42. DrugNet: network-based drug-disease prioritization by integrating heterogeneous data 
43. DT-Web: a web-based application for drug-target interaction and drug combination prediction 
through domain-tuned network-based inference 
44. Elucidating the modes of action for bioactive compounds in a cell-specific manner by large-scale 
chemically-induced transcriptomics 
45. Exploration of the Anti-Inflammatory Drug Space Through Network Pharmacology: Applications for 
Drug Repurposing 
46. Exploring anti-malarial potential of FDA approved drugs: an in silico approach 
47. Finding the targets of a drug by integration of gene expression data with a protein interaction network 
48. From drug response profiling to target addiction scoring in cancer cell models 
49. Functional genetics-directed identification of novel pharmacological inhibitors of FAS- and TNF-
dependent apoptosis that protect mice from acute liver failure 
50. Fusing literature and full network data improves disease similarity computation 
51. Heter-LP: A heterogeneous label propagation algorithm and its application in drug repositioning 
52. Identification of drug candidates and repurposing opportunities through compound-target interaction 
networks 
53. In silico prediction of chemical mechanism of action via an improved network-based inference 
method 
54. Individualized network-based drug repositioning infrastructure for precision oncology in the panomics 
era 
55. Inferring drug-disease associations based on known protein complexes 
56. Inferring drug-disease associations from integration of chemical, genomic and phenotype data using 
network propagation 
57. Inferring new indications for approved drugs via random walk on drug-disease heterogenous networks 
58. Inferring novel indications of approved drugs via a learning method with local and global consistency 
59. Large-scale extraction of accurate drug-disease treatment pairs from biomedical literature for drug 
repurposing 
60. Link prediction in drug-target interactions network using similarity indices 
61. Linking biochemical pathways and networks to adverse drug reactions 
62. Linking PharmGKB to phenotype studies and animal models of disease for drug repurposing 
 




63. LRSSL: predict and interpret drug-disease associations based on data integration using sparse 
subspace learning 
64. Macromolecular target prediction by self-organizing feature maps 
65. Matrix Factorization-Based Prediction of Novel Drug Indications by Integrating Genomic Space 
66. MD-Miner: a network-based approach for personalized drug repositioning 
67. Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-
like cancer cells 
68. Multi-target drug repositioning by bipartite block-wise sparse multi-task learning 
69. Network-based approach to prediction and population-based validation of in silico drug repurposing 
70. Network-based drug ranking and repositioning with respect to DrugBank therapeutic categories 
71. Network-based drug repositioning 
72. Network-based drug repositioning: A novel strategy for discovering potential antidepressants and 
their mode of action 
73. Network-based in silico drug efficacy screening 
74. Network-based inference methods for drug repositioning 
75. Network-based machine learning and graph theory algorithms for precision oncology 
76. Neuroblastoma, a Paradigm for Big Data Science in Pediatric Oncology 
77. New drug candidates for treatment of atypical meningiomas: An integrated approach using gene 
expression signatures for drug repurposing 
78. Novel putative drugs and key initiating genes for neurodegenerative disease determined using 
network-based genetic integrative analysis 
79. Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and 
redox capacity 
80. On the Integration of In Silico Drug Design Methods for Drug Repurposing 
81. One reporter for in-cell activity profiling of majority of protein kinase oncogenes 
82. Pathway and network-based strategies to translate genetic discoveries into effective therapies 
83. PATIENT-SPECIFIC DATA FUSION FOR CANCER STRATIFICATION AND PERSONALISED 
TREATMENT 
84. Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective 
 




85. Predicting drug-disease associations and their therapeutic function based on the drug-disease 
association bipartite network 
86. Predicting drug-disease interactions by semi-supervised graph cut algorithm and three-layer data 
integration 
87. Predicting drug-target interactions using restricted Boltzmann machines 
88. Predicting Drug-Target Interactions With Multi-Information Fusion 
89. Predicting new indications for approved drugs using a proteochemometric method 
90. Predicting Potential Drugs for Breast Cancer based on miRNA and Tissue Specificity 
91. Prediction of chemical-protein interactions network with weighted network-based inference method 
92. Prediction of drug-target interaction by label propagation with mutual interaction information derived 
from heterogeneous network 
93. Prediction of drug-target interactions and drug repositioning via network-based inference 
94. Prediction of drugs having opposite effects on disease genes in a directed network 
95. Prediction of new drug indications based on clinical data and network modularity 
96. Prediction of Novel Drugs and Diseases for Hepatocellular Carcinoma Based on Multi-Source 
Simulated Annealing Based Random Walk 
97. Prediction of Novel Drugs for Hepatocellular Carcinoma Based on Multi-Source Random Walk 
98. PROMISCUOUS: a database for network-based drug-repositioning 
99. ProphTools: general prioritization tools for heterogeneous biological networks 
100. Protein localization vector propagation: a method for improving the accuracy of drug repositioning 
101. RANKS: a flexible tool for node label ranking and classification in biological networks 
102. Recent Advances in the Development of Pharmaceutical Agents for Metabolic Disorders: A 
Computational Perspective 
103. Recent advances in the machine learning-based drug-target interaction prediction 
104. Repurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic medical records 
105. RepurposeVS: A Drug Repurposing-Focused Computational Method for Accurate Drug-Target 
Signature Predictions 
106. Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer 
stem cells 
 




107. Scoring multiple features to predict drug disease associations using information fusion and 
aggregation 
108. SDTNBI: an integrated network and chemoinformatics tool for systematic prediction of drug-target 
interactions and drug repositioning 
109. SemFunSim: a new method for measuring disease similarity by integrating semantic and gene 
functional association 
110. Some Remarks on Prediction of Drug-Target Interaction with Network Models 
111. Sorafenib Impedes Rift Valley Fever Virus Egress by Inhibiting Valosin-Containing Protein 
Function in the Cellular Secretory Pathway 
112. Substrate-driven mapping of the degradome by comparison of sequence logos 
113. Systematic drug repositioning for a wide range of diseases with integrative analyses of phenotypic 
and molecular data 
114. The Amide Local Anesthetic Lidocaine in Cancer Surgery-Potential Antimetastatic Effects and 
Preservation of Immune Cell Function? A Narrative Review 
115. The extraction of drug-disease correlations based on module distance in incomplete human 
interactome 
116. Therapeutic Effect of Repurposed Temsirolimus in Lung Adenocarcinoma Model 
117. Towards drug repositioning: a unified computational framework for integrating multiple aspects of 
drug similarity and disease similarity 
118. Transcriptomic profiling of human hippocampal progenitor cells treated with antidepressants and its 
application in drug repositioning 
119. Updates on drug-target network; facilitating polypharmacology and data integration by growth of 
DrugBank database 
120. Using predicate and provenance information from a knowledge graph for drug efficacy screening 








FACTOR 6. Antimicrobial Applications of Repurposed Drugs 
1. 3, 5, 3'-Triiodothyroacetic acid (TRIAC) is an anti-inflammatory drug that targets toll-like receptor 2 
2. A Biologically-Based Computational Approach to Drug Repurposing for Anthrax Infection 
3. A combined systems and structural modeling approach repositions antibiotics for Mycoplasma 
genitalium 
4. A curated C. difficile strain 630 metabolic network: prediction of essential targets and inhibitors 
5. A Drug Repositioning Approach Reveals that Streptococcus mutans Is Susceptible to a Diverse Range 
of Established Antimicrobials and Nonantibiotics 
6. A drug-repositioning screening identifies pentetic acid as a potential therapeutic agent for suppressing 
the elastase-mediated virulence of Pseudomonas aeruginosa 
7. A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia 
8. A signalome screening approach in the autoinflammatory disease TNF receptor associated periodic 
syndrome (TRAPS) highlights the anti-inflammatory properties of drugs for repurposing 
9. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents 
10. Activity of anti-cancer protein kinase inhibitors against Leishmania spp 
11. Aerosolized gentamicin reduces the burden of tuberculosis in a murine model 
12. Alternative clinical indications for novel antibiotics licensed for skin and soft tissue infection 
13. Alternative screening approaches for discovery of Middle East respiratory syndrome coronavirus 
inhibitors 
14. An FDA-Drug Library Screen for Compounds with Bioactivities against Meticillin-Resistant 
Staphylococcus aureus (MRSA 
15. An invitro and invivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi 
predicted by a computational drug repositioning method 
16. An optimized background regimen for treatment of active tuberculosis with the next-generation 
benzothiazinone Macozinone (PBTZ169 
17. Analysis of drug binding pockets and repurposing opportunities for twelve essential enzymes of 
ESKAPE pathogens 
18. Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant 
Acinetobacter baumannii 
19. Anti-infectious drug repurposing using an integrated chemical genomics and structural systems 
biology approach 
 




20. Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched 
for stem cell-like properties 
21. Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial 
pathogens 
22. Antibacterial effects of antiretrovirals, potential implications for microbiome studies in HIV 
23. Antibiotic drug levofloxacin inhibits proliferation and induces apoptosis of lung cancer cells through 
inducing mitochondrial dysfunction and oxidative damage 
24. Antibiotic drug rifabutin is effective against lung cancer cells by targeting the eIF4E-beta-catenin axis 
25. Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void 
26. Anticancer Drugs as Antibiofilm Agents in Candida albicans: Potential Targets 
27. Antidepressants, antimicrobials or both? Gut microbiota dysbiosis in depression and possible 
implications of the antimicrobial effects of antidepressant drugs for antidepressant effectiveness 
28. Antifungal amphiphilic kanamycins: new life for an old drug 
29. Antifungal application of nonantifungal drugs 
30. Antimicrobial Activity of Gallium Compounds on ESKAPE Pathogens 
31. Antiviral activity of doxycycline against vesicular stomatitis virus in vitro 
32. Antiviral Screening of Multiple Compounds against Ebola Virus 
33. Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of 
bacterial infections: a puzzling paradox or a logical consequence of their mode of action 
34. Assessment of berberine as a multi-target antimicrobial: a multi-omics study for drug discovery and 
repositioning 
35. Auranofin and its Analogues Show Potent Antimicrobial Activity Covering Multiresistant Pathogens: 
Structure-Activity Relationships 
36. Auranofin inactivates Trichomonas vaginalis thioredoxin reductase and is effective against 
trichomonads in vitro and in vivo 
37. Auranofin: repurposing an old drug for a golden new age 
38. Azithromycin protects mice against ischemic stroke injury by promoting macrophage transition 
towards M2 phenotype 
39. beta2-Adrenoceptor agonists as novel, safe and potentially effective therapies for Amyotrophic lateral 
sclerosis (ALS 
 




40. Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the 
EIS regimen 
41. Cancer drug discovery by repurposing: teaching new tricks to old dogs 
42. Cancer drugs inhibit morphogenesis in the human fungal pathogen, Candida albicans 
43. Carbamazepine alone and in combination with doxycycline attenuates isoproterenol-induced cardiac 
hypertrophy 
44. Cascade Ligand- and Structure-Based Virtual Screening to Identify New Trypanocidal Compounds 
Inhibiting Putrescine Uptake 
45. Characterization of a Francisella tularensis-Caenorhabditis elegans Pathosystem for the Evaluation of 
Therapeutic Compounds 
46. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic 
manifestations from malaria to multifarious diseases 
47. Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South 
Africa: a retrospective cohort study 
48. Combating Intracellular Pathogens with Repurposed Host-Targeted Drugs 
49. Combating Multidrug-Resistant Pathogens with Host-Directed Nonantibiotic Therapeutics 
50. Combination therapy: the propitious rationale for drug development 
51. Combined analysis of gene expression and genome binding profiles identified potential therapeutic 
targets of ciclopirox in Ewing sarcoma 
52. Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine 
kinase inhibitors as host-directed antimicrobials 
53. Comparative analysis of methicillin-sensitive and resistant Staphylococcus aureus exposed to emodin 
based on proteomic profiling 
54. Cooperative recognition of T:T mismatch by echinomycin causes structural distortions in DNA 
duplex 
55. Copper Complexes in Cancer Therapy 
56. Cryo-EM structure of the Plasmodium falciparum 80S ribosome bound to the anti-protozoan drug 
emetine 
57. Current treatment options and the role of peptides as potential therapeutic components for Middle East 
Respiratory Syndrome (MERS): A review 
58. Delivering drugs to the lungs: The history of repurposing in the treatment of respiratory diseases 
 




59. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning 
in local therapy of lung infections 
60. Discovery of alkyl bis(oxy)dibenzimidamide derivatives as novel protein arginine methyltransferase 1 
(PRMT1) inhibitors 
61. Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues 
62. Doxycycline and therapeutic targeting of the DNA damage response in cancer cells: old drug, new 
purpose 
63. Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models 
64. Doxycycline inhibits proliferation and induces apoptosis of both human papillomavirus positive and 
negative cervical cancer cell lines 
65. Doxycycline is an NF-kappaB inhibitor that induces apoptotic cell death in malignant T-cells 
66. Doxycycline or how to create new with the old 
67. Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by 
medium-throughput phenotypic screening 
68. Drug Repositioning to Alleviate Systemic Inflammatory Response Syndrome Caused by Gram-
Negative Bacterial Outer Membrane Vesicles 
69. Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe 
staphylococcal infections 
70. Drug Repurposing Approach Identifies a Synergistic Drug Combination of an Antifungal Agent and 
an Experimental Organometallic Drug for Melanoma Treatment 
71. Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections 
72. Drug repurposing for the treatment of staphylococcal infections 
73. Drug repurposing of minocycline against dengue virus infection 
74. Drug repurposing of quinine as antiviral against dengue virus infection 
75. Drug Repurposing Screening Identifies Novel Compounds That Effectively Inhibit Toxoplasma 
gondii Growth 
76. Drug repurposing screens and synergistic drug-combinations for infectious diseases 
77. Drug repurposing strategy against Trypanosoma cruzi infection: In vitro and in vivo assessment of the 
activity of metronidazole in mono- and combined therapy 
78. Drug repurposing: a new front in the war against Staphylococcus aureus 
 




79. Drug repurposing: In-vitro anti-glycation properties of 18 common drugs 
80. Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid 
leukemia 
81. Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment 
82. Effects of Benzothiazolamines on Voltage-Gated Sodium Channels 
83. EMUDRA: Ensemble of Multiple Drug Repositioning Approaches to improve prediction accuracy 
84. Estimated generic prices for novel treatments for drug-resistant tuberculosis 
85. Evaluating New Compounds to Treat Burkholderia pseudomallei Infections 
86. Evaluation of anti-tubercular activity of linolenic acid and conjugated-linoleic acid as effective 
inhibitors against Mycobacterium tuberculosis 
87. Examining the potential preventative effects of minocycline prescribed for acne on the incidence of 
severe mental illnesses: A historical cohort study 
88. Exploiting the therapeutic potential of ready-to-use drugs: Repurposing antibiotics against amyloid 
aggregation in neurodegenerative diseases 
89. Exploring anti-malarial potential of FDA approved drugs: an in silico approach 
90. Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent 
91. Exposure Matching of Pediatric Anti-infective Drugs: Review of Drugs Submitted to the Food and 
Drug Administration for Pediatric Approval 
92. Extensive impact of non-antibiotic drugs on human gut bacteria 
93. From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" 
Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators 
94. Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic 
killing of Mycobacterium tuberculosis through inositol depletion 
95. Host response to respiratory bacterial pathogens as identified by integrated analysis of human gene 
expression data 
96. Host-directed antimicrobial drugs with broad-spectrum efficacy against intracellular bacterial 
pathogens 
97. Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-
Bechamp Debates 
98. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review 
 




99. Identification and Validation of an Antivirulence Agent Targeting HlyU-Regulated Virulence in 
Vibrio vulnificus 
100. Identification of Agents Active against Methicillin-Resistant Staphylococcus aureus USA300 from a 
Clinical Compound Library 
101. Identification of an old antibiotic clofoctol as a novel activator of unfolded protein response 
pathways and an inhibitor of prostate cancer 
102. Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium 
abscessus and Mycobacterium chelonae 
103. Identification of novel drug targets in bovine respiratory disease: an essential step in applying 
biotechnologic techniques to develop more effective therapeutic treatments 
104. Immunomodulatory tetracyclines shape the intestinal inflammatory response inducing mucosal 
healing and resolution 
105. In vitro activity of the antiasthmatic drug zafirlukast against the oral pathogens Porphyromonas 
gingivalis and Streptococcus mutans 
106. In Vitro and Intracellular Activity of Imipenem Combined with Rifabutin and Avibactam against 
Mycobacterium abscessus 
107. In vitro antibacterial effects of statins against bacterial pathogens causing skin infections 
108. In vitro antimicrobial activity of monensin against common clinical isolates associated with canine 
otitis externa 
109. In Vitro Screening of an FDA-Approved Library Against ESKAPE Pathogens 
110. In-house chemical library repurposing: A case example for Pseudomonas aeruginosa antibiofilm 
activity and quorum sensing inhibition 
111. Inhibition of adenovirus infection by mifepristone 
112. Inhibition of Fosfomycin Resistance Protein FosA by Phosphonoformate (Foscarnet) in Multidrug-
Resistant Gram-Negative Pathogens 
113. Inhibitors of Cancer Stem Cells 
114. Innovative approaches to treat Staphylococcus aureus biofilm-related infections 
115. Interaction of Mycobacterium tuberculosis Virulence Factor RipA with Chaperone MoxR1 Is 
Required for Transport through the TAT Secretion System 
116. Is repositioning of drugs a viable alternative in the treatment of tuberculosis 
117. Is There Potential for Repurposing Statins as Novel Antimicrobials 
 




118. L-Captopril and its derivatives as potential inhibitors of microbial enzyme DapE: A combined 
approach of drug repurposing and similarity screening 
119. L-Lysine-alpha-Oxidase: Acidovorax citrulli Bacterium Inhibitor 
120. Laboratory testing of clinically approved drugs against Balamuthia mandrillaris 
121. Loperamide Restricts Intracellular Growth of Mycobacterium tuberculosis in Lung Macrophages 
122. Lytic activity of the staphylolytic Twort phage endolysin CHAP domain is enhanced by the SH3b 
cell wall binding domain 
123. Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase 
Inhibition for Peritoneal Carcinomatosis 
124. Metformin use and gynecological cancers: A novel treatment option emerging from drug 
repositioning 
125. Microbial protein targets: towards understanding and intervention 
126. Minocycline repurposing in critical illness: focus on stroke 
127. Misfolded proteins: from little villains to little helpers in the fight against cancer 
128. Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of 
stem-like cancer cells 
129. Mitochondrial dysfunction and potential anticancer therapy 
130. Mode of action and resistance studies unveil new roles for tropodithietic acid as an anticancer agent 
and the gamma-glutamyl cycle as a proton sink 
131. Molecular docking studies on thirteen fluoroquinolines with human topoisomerase II a and b 
132. Molecular pathways: trafficking of metabolic resources in the tumor microenvironment 
133. Multiple effects of digoxin on subsets of cancer-associated genes through the alternative splicing 
pathway 
134. New antibacterial, non-genotoxic materials, derived from the functionalization of the anti-thyroid 
drug methimazole with silver ions 
135. New Antimicrobial Approaches: Reuse of Old Drugs 
136. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects 
137. New frontiers for anti-biofilm drug development 
138. New perspectives for metformin in cancer therapy 
 




139. New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria 
140. Niclosamide Induces Epiboly Delay During Early Zebrafish Embryogenesis 
141. Non-anti-infective effects of antimicrobials and their clinical applications: a review 
142. Nonantibiotic properties of macrolides and their role in modulation of the inflammatory reaction 
143. Novel Antifungal Compounds Discovered in Medicines for Malaria Venture's Malaria Box 
144. Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing 
Against Polymyxin-Resistant Multidrug-Resistant Gram-Negative Pathogens 
145. Pathogenicity phenomena in three model systems: from network mining to emerging system-level 
properties 
146. Pharmacologically active metabolites, combination screening and target identification-driven drug 
repositioning in antituberculosis drug discovery 
147. Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA 
Efflux Pump Inhibitors 
148. Poly(ADP-ribose) polymerase is not involved in the neuroprotection exerted by azithromycin against 
ischemic stroke in mice 
149. Post-ischemic treatment with azithromycin protects ganglion cells against retinal 
ischemia/reperfusion injury in the rat 
150. Potential repurposing of known drugs as potent bacterial beta-glucuronidase inhibitors 
151. Prospects for Anti-Biofilm Pharmaceuticals 
152. Protein kinase C-delta inhibitor, Rottlerin inhibits growth and survival of mycobacteria exclusively 
through Shikimate kinase 
153. Raloxifene attenuates Pseudomonas aeruginosa pyocyanin production and virulence 
154. Rationale for an experimental treatment of retinitis pigmentosa: 140-month test of hypothesis with 
one patient 
155. Real-Time" High-Throughput Drug and Synergy Testing for Multidrug-Resistant Bacterial Infection: 
A Case Report 
156. Recent advances in technologies for developing drugs against Chlamydia pneumoniae 
157. Recent Drug-Repurposing-Driven Advances in the Discovery of Novel Antibiotics 
158. Reinstating cloxacilin for empiric antibiotic in late-onset sepsis 
 




159. Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual 
Screening, In Vitro and In Vivo Studies 
160. Repositioning of antibiotic levofloxacin as a mitochondrial biogenesis inhibitor to target breast 
cancer 
161. Repositioning of Endonuclear Receptors Binders as Potential Antibacterial and Antifungal Agents. 
Eptyloxim: A Potential and Novel Gyrase B and Cytochrome Cyp51 Inhibitor 
162. Repositioning of Memantine as a Potential Novel Therapeutic Agent against Meningitic E. coli-
Induced Pathogenicities through Disease-Associated Alpha7 Cholinergic Pathway and RNA Sequencing-
Based Transcriptome Analysis of Host Inflammatory Responses 
163. Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent 
164. Repurposed drugs targeting eIF2&alpha;-P-mediated translational repression prevent 
neurodegeneration in mice 
165. Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute 
ischemic stroke: minocycline 
166. Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute 
ischemic stroke: minocycline 
167. Repurposing an old drug: aztreonam as a new treatment strategy for gonorrhoea 
168. Repurposing an orally available drug for the treatment of geographic atrophy 
169. Repurposing and Revival of the Drugs: A New Approach to Combat the Drug Resistant 
Tuberculosis 
170. Repurposing Approach Identifies Auranofin with Broad Spectrum Antifungal Activity That Targets 
Mia40-Erv1 Pathway 
171. Repurposing auranofin for the treatment of cutaneous staphylococcal infections 
172. Repurposing celecoxib as a topical antimicrobial agent 
173. Repurposing cephalosporin antibiotics as pro-senescent radiosensitizers 
174. Repurposing Clinical Molecule Ebselen to Combat Drug Resistant Pathogens 
175. Repurposing drugs for the treatment and control of helminth infections 
176. Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs 
177. Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent 
178. Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis 
 




179. Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections 
180. Repurposing FDA-approved drugs to combat drug-resistant Acinetobacter baumannii 
181. Repurposing Ivacaftor for treatment of Staphylococcus aureus infections 
182. Repurposing niclosamide as a versatile antimicrobial surface coating against device-associated, 
hospital-acquired bacterial infections 
183. Repurposing Non-Antimicrobial Drugs and Clinical Molecules to Treat Bacterial Infections 
184. Repurposing of Anticancer Drugs for the Treatment of Bacterial Infections 
185. Repurposing of approved drugs from the human pharmacopoeia to target Wolbachia endosymbionts 
of onchocerciasis and lymphatic filariasis 
186. Repurposing of Aspirin and Ibuprofen as Candidate Anti-Cryptococcus Drugs 
187. Repurposing of Existing Statin drugs for treatment of Microbial Infections: How much Promising 
188. Repurposing of gallium-based drugs for antibacterial therapy 
189. Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: a crucial 
role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation 
190. Repurposing of nucleoside- and nucleobase-derivative drugs as antibiotics and biofilm inhibitors 
191. Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus 
192. Repurposing screens identify rifamycins as potential broad-spectrum therapy for multidrug-resistant 
Acinetobacter baumannii and select agent microorganisms 
193. Repurposing Strategy of Atorvastatin against Trypanosoma cruzi: In Vitro Monotherapy and 
Combined Therapy with Benznidazole Exhibit Synergistic Trypanocidal Activity 
194. Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori 
195. Repurposing the anticancer drug mitomycin C for the treatment of persistent Acinetobacter 
baumannii infections 
196. Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus 
197. Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa 
pathogenicity 
198. Repurposing the Nonsteroidal Anti-inflammatory Drug Diflunisal as an Osteoprotective, 
Antivirulence Therapy for Staphylococcus aureus Osteomyelitis 
199. Repurposing Toremifene for Treatment of Oral Bacterial Infections 
 




200. Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant 
Enterobacteriaceae infections 
201. Repurposing-a ray of hope in tackling extensively drug resistance in tuberculosis 
202. Resistance-resistant antibiotics 
203. Reversal of Azole Resistance in Candida albicans by Sulfa Antibacterial Drugs 
204. Ribavirin suppresses bacterial virulence by targeting LysR-type transcriptional regulators 
205. Rifampin inhibits Toll-like receptor 4 signaling by targeting myeloid differentiation protein 2 and 
attenuates neuropathic pain 
206. Role of acid responsive genes in the susceptibility of Escherichia coli to ciclopirox 
207. SCMBYK: prediction and characterization of bacterial tyrosine-kinases based on propensity scores 
of dipeptides 
208. Screening a Commercial Library of Pharmacologically Active Small Molecules against 
Staphylococcus aureus Biofilms 
209. Screening a repurposing library for potentiators of antibiotics against Staphylococcus aureus 
biofilms 
210. Screening of a Drug Library Identifies Inhibitors of Cell Intoxication by CNF1 
211. Simvastatin increases the in vivo activity of the first-line tuberculosis regimen 
212. Sphingolipids as targets for inhalation treatment of cystic fibrosis 
213. Statins and Antimicrobial Effects: Simvastatin as a Potential Drug against Staphylococcus aureus 
Biofilm 
214. Statins: antimicrobial resistance breakers or makers 
215. Strategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant 
bacterial infections 
216. Structural Basis of Metallo-beta-Lactamase Inhibition by Captopril Stereoisomers 
217. Synthetic lethality reveals mechanisms of Mycobacterium tuberculosis resistance to beta-lactams 
218. Systematic discovery of drug action mechanisms by an integrated chemical genomics approach: 
identification of functional disparities between azacytidine and decitabine 
219. Tackling tuberculosis: Insights from an international TB Summit in London 
220. Tamoxifen Provides Structural and Functional Rescue in Murine Models of Photoreceptor 
Degeneration 
 




221. Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic 
protease in mycobacteria 
222. Targeting intracellular p-aminobenzoic acid production potentiates the anti-tubercular action of 
antifolates 
223. Tedizolid Activity Against Clinical Mycobacterium abscessus Complex Isolates-An in vitro 
Characterization Study 
224. Teicoplanin inhibits Ebola pseudovirus infection in cell culture 
225. Tetracycline repurposing in neurodegeneration: focus on Parkinson's disease 
226. The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to 
inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy 
227. The combination effects of licl and the active leflunomide metabolite, A771726, on viral-induced 
interleukin 6 production and EV-A71 replication 
228. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, 
extensively drug-resistant, and incurable tuberculosis 
229. The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate 
cancer 
230. The Immunomodulatory Drug Glatiramer Acetate is Also an Effective Antimicrobial Agent that 
Kills Gram-negative Bacteria 
231. The potential role of trimethoprim-sulfamethoxazole in the treatment of drug-resistant tuberculosis 
232. The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the 
treatment of haematologic malignancy 
233. The Repurposing of Anti-Psychotic Drugs, Quetiapine and Olanzapine, as Anti-Cryptococcus Drugs 
234. The role of moxifloxacin in tuberculosis therapy 
235. Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by 
inhibiting Wnt/beta-catenin signaling 
236. Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC/BCL2 
double-hit B cell lymphoma 
237. Tigecycline targets nonsmall cell lung cancer through inhibition of mitochondrial function 
238. Totally drug-resistant tuberculosis and adjunct therapies 
239. Toward Repositioning Niclosamide for Antivirulence Therapy of Pseudomonas aeruginosa Lung 
Infections: Development of Inhalable Formulations through Nanosuspension Technology 
 




240. Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, 
Escherichia coli, and Klebsiella pneumoniae 
241. Transcriptomic Analysis of the Host Response and Innate Resilience to Enterotoxigenic Escherichia 
coli Infection in Humans 
242. Treatment of experimental autoimmune uveoretinitis with peroxisome proliferator-activated receptor 
alpha agonist fenofibrate 
243. Triclosan Is an Aminoglycoside Adjuvant for Eradication of Pseudomonas aeruginosa Biofilms 
244. Tricyclic antidepressants inhibit Candida albicans growth and biofilm formation 
245. Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio 
246. Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, 
and biomarkers 
247. Use of minocycline in viral infections 
248. Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA 
virus infection 








FACTOR 7. Repurposed Drugs or Antifungal Applications 
1. A disease similarity matrix based on the uniqueness of shared genes 
2. A genomics-based systems approach towards drug repositioning for rheumatoid arthritis 
3. A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future 
Research 
4. A miRNA-driven inference model to construct potential drug-disease associations for drug 
repositioning 
5. A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target 
Therapies in Triple Negative Breast Cancer 
6. A network-based drug repositioning infrastructure for precision cancer medicine through targeting 
significantly mutated genes in the human cancer genomes 
7. A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common 
structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis 
8. A review of network-based approaches to drug repositioning 
9. A Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles 
Using Pathway-Drug Network 
10. A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case 
11. Advances in epilepsy gene discovery and implications for epilepsy diagnosis and treatment 
12. Anticancer Drugs as Antibiofilm Agents in Candida albicans: Potential Targets 
13. Antifungal adjuvants: Preserving and extending the antifungal arsenal 
14. Antifungal amphiphilic kanamycins: new life for an old drug 
15. Antifungal application of nonantifungal drugs 
16. Antifungal Phenothiazines: Optimization, Characterization of Mechanism, and Modulation of 
Neuroreceptor Activity 
17. Antifungal properties of the anti-hypertensive drug: aliskiren 
18. Antifungals 
19. Antiviral activity of micafungin against enterovirus 71 
20. Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of 
bacterial infections: a puzzling paradox or a logical consequence of their mode of action 
 




21. Application of Atlas of Cancer Signalling Network in preclinical studies 
22. Artemisinins, new miconazole potentiators resulting in increased activity against Candida albicans 
biofilms 
23. Atorvastatin as a promising anticryptococcal agent 
24. Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the 
proliferative expansion of stem-like cancer cells (CSCs 
25. Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the 
EIS regimen 
26. Calcineurin-NFAT signalling in myeloid leucocytes: new prospects and pitfalls in 
immunosuppressive therapy 
27. Cancer Drug Response Profile scan (CDRscan): A Deep Learning Model That Predicts Drug 
Effectiveness from Cancer Genomic Signature 
28. Cancer drugs inhibit morphogenesis in the human fungal pathogen, Candida albicans 
29. Candidiasis and the impact of flow cytometry on antifungal drug discovery 
30. Combined analysis of gene expression and genome binding profiles identified potential therapeutic 
targets of ciclopirox in Ewing sarcoma 
31. Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological 
Proteins Related to the Alzheimer's Disease 
32. Compensating for literature annotation bias when predicting novel drug-disease relationships through 
Medical Subject Heading Over-representation Profile (MeSHOP) similarity 
33. Computational approaches for innovative antiepileptic drug discovery 
34. Computational drug repositioning for peripheral arterial disease: prediction of anti-inflammatory and 
pro-angiogenic therapeutics 
35. Computational drug repositioning using low-rank matrix approximation and randomized algorithms 
36. Constructing Disease Similarity Networks Based on Disease Module Theory 
37. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole 
38. CYP51 as drug targets for fungi and protozoan parasites: past, present and future 
39. DenguePredict: An Integrated Drug Repositioning Approach towards Drug Discovery for Dengue 
40. Designing Dietary Recommendations Using System Level Interactomics Analysis and Network-
Based Inference 
 




41. Development of anti-fungal pesticides from protein kinase inhibitor-based anticancer agents 
42. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning 
in local therapy of lung infections 
43. Disease classification: from phenotypic similarity to integrative genomics and beyond 
44. DR2DI: a powerful computational tool for predicting novel drug-disease associations 
45. dRiskKB: a large-scale disease-disease risk relationship knowledge base constructed from biomedical 
text 
46. DrPOCS: Drug repositioning based on projection onto convex sets 
47. Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm 
48. Drug repositioning based on triangularly balanced structure for tissue-specific diseases in incomplete 
interactome 
49. Drug Repositioning by Integrating Known Disease-Gene and Drug-Target Associations in a Semi-
supervised Learning Model 
50. Drug repositioning for enzyme modulator based on human metabolite-likeness 
51. Drug repositioning for orphan genetic diseases through Conserved Anticoexpressed Gene Clusters 
(CAGCs 
52. Drug repositioning for prostate cancer: using a data-driven approach to gain new insights 
53. Drug Repurposing Approach Identifies a Synergistic Drug Combination of an Antifungal Agent and 
an Experimental Organometallic Drug for Melanoma Treatment 
54. Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections 
55. Drug Repurposing Screening Identifies Tioconazole as an ATG4 Inhibitor that Suppresses Autophagy 
and Sensitizes Cancer Cells to Chemotherapy 
56. Drug repurposing to target Ebola virus replication and virulence using structural systems 
pharmacology 
57. Drug target prediction and repositioning using an integrated network-based approach 
58. Drug-disease association and drug-repositioning predictions in complex diseases using causal 
inference-probabilistic matrix factorization 
59. DrugNet: network-based drug-disease prioritization by integrating heterogeneous data 
60. Drugs currently under investigation for the treatment of invasive candidiasis 
 




61. DT-Web: a web-based application for drug-target interaction and drug combination prediction 
through domain-tuned network-based inference 
62. Elucidating the modes of action for bioactive compounds in a cell-specific manner by large-scale 
chemically-induced transcriptomics 
63. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and 
synergize with fluconazole in vivo 
64. Exploration of the Anti-Inflammatory Drug Space Through Network Pharmacology: Applications for 
Drug Repurposing 
65. Exploring anti-malarial potential of FDA approved drugs: an in silico approach 
66. Finding the targets of a drug by integration of gene expression data with a protein interaction network 
67. From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic 
Small Cell Lung Cancer (SCLC 
68. From drug response profiling to target addiction scoring in cancer cell models 
69. Functional genetics-directed identification of novel pharmacological inhibitors of FAS- and TNF-
dependent apoptosis that protect mice from acute liver failure 
70. Fusing literature and full network data improves disease similarity computation 
71. Future perspectives for cryptococcosis treatment 
72. Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities 
in schizophrenia 
73. Glybenclamide: an antidiabetic with in vivo antithrombotic activity 
74. Heter-LP: A heterogeneous label propagation algorithm and its application in drug repositioning 
75. High-throughput screening of a collection of known pharmacologically active small compounds for 
identification of Candida albicans biofilm inhibitors 
76. Identification of drug candidates and repurposing opportunities through compound-target interaction 
networks 
77. Identification of Small-Molecule Inhibitors of Human Golgi Mannosidase via a Drug Repositioning 
Screen 
78. Imidazole Antifungal Drugs Inhibit the Cell Proliferation and Invasion of Human Breast Cancer Cells 
79. Imidazolium salts as innovative agents against Leishmania amazonensis 
80. In silico prediction of chemical mechanism of action via an improved network-based inference 
method 
 




81. In vitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania 
amazonensis 
82. In vitro analysis of finasteride activity against Candida albicans urinary biofilm formation and 
filamentation 
83. In vitro and in vivo studies of the antiparasitic activity of sterol 14alpha-demethylase (CYP51) 
inhibitor VNI against drug-resistant strains of Trypanosoma cruzi 
84. Individualized network-based drug repositioning infrastructure for precision oncology in the panomics 
era 
85. Inferring drug-disease associations based on known protein complexes 
86. Inferring drug-disease associations from integration of chemical, genomic and phenotype data using 
network propagation 
87. Inferring new indications for approved drugs via random walk on drug-disease heterogenous networks 
88. Inferring novel indications of approved drugs via a learning method with local and global consistency 
89. Link prediction in drug-target interactions network using similarity indices 
90. Linking biochemical pathways and networks to adverse drug reactions 
91. Linking PharmGKB to phenotype studies and animal models of disease for drug repurposing 
92. LRSSL: predict and interpret drug-disease associations based on data integration using sparse 
subspace learning 
93. Mapping Protein Targets of Bioactive Small Molecules Using Lipid-Based Chemical Proteomics 
94. Matrix Factorization-Based Prediction of Novel Drug Indications by Integrating Genomic Space 
95. MD-Miner: a network-based approach for personalized drug repositioning 
96. Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-
like cancer cells 
97. Molecular docking studies on thirteen fluoroquinolines with human topoisomerase II a and b 
98. Multi-target drug repositioning by bipartite block-wise sparse multi-task learning 
99. Network-based approach to prediction and population-based validation of in silico drug repurposing 
100. Network-based drug repositioning 
101. Network-based drug repositioning: A novel strategy for discovering potential antidepressants and 
their mode of action 
 




102. Network-based in silico drug efficacy screening 
103. Network-based inference methods for drug repositioning 
104. Network-based machine learning and graph theory algorithms for precision oncology 
105. Neuroblastoma, a Paradigm for Big Data Science in Pediatric Oncology 
106. New applications for known drugs: Human glycogen synthase kinase 3 inhibitors as modulators of 
Aspergillus fumigatus growth 
107. New drug candidates for treatment of atypical meningiomas: An integrated approach using gene 
expression signatures for drug repurposing 
108. New pharmacological treatment strategies for relapse prevention 
109. Newer patents in antimycotic therapy 
110. Novel Antifungal Compounds Discovered in Medicines for Malaria Venture's Malaria Box 
111. Novel putative drugs and key initiating genes for neurodegenerative disease determined using 
network-based genetic integrative analysis 
112. Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and 
redox capacity 
113. On the Integration of In Silico Drug Design Methods for Drug Repurposing 
114. One reporter for in-cell activity profiling of majority of protein kinase oncogenes 
115. Pathogenicity phenomena in three model systems: from network mining to emerging system-level 
properties 
116. Pathway and network-based strategies to translate genetic discoveries into effective therapies 
117. PATIENT-SPECIFIC DATA FUSION FOR CANCER STRATIFICATION AND 
PERSONALISED TREATMENT 
118. Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics 
119. Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of 
Approved Therapies and Emerging Concepts 
120. Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective 
121. Predicting drug-disease associations and their therapeutic function based on the drug-disease 
association bipartite network 
122. Predicting drug-disease interactions by semi-supervised graph cut algorithm and three-layer data 
integration 
 




123. Predicting drug-target interactions using restricted Boltzmann machines 
124. Predicting Drug-Target Interactions With Multi-Information Fusion 
125. Predicting new indications for approved drugs using a proteochemometric method 
126. Predicting Potential Drugs for Breast Cancer based on miRNA and Tissue Specificity 
127. Prediction of chemical-protein interactions network with weighted network-based inference method 
128. Prediction of drug-target interaction by label propagation with mutual interaction information 
derived from heterogeneous network 
129. Prediction of drug-target interactions and drug repositioning via network-based inference 
130. Prediction of drugs having opposite effects on disease genes in a directed network 
131. Prediction of new drug indications based on clinical data and network modularity 
132. Prediction of Novel Drugs and Diseases for Hepatocellular Carcinoma Based on Multi-Source 
Simulated Annealing Based Random Walk 
133. Prediction of Novel Drugs for Hepatocellular Carcinoma Based on Multi-Source Random Walk 
134. PROMISCUOUS: a database for network-based drug-repositioning 
135. ProphTools: general prioritization tools for heterogeneous biological networks 
136. Protein localization vector propagation: a method for improving the accuracy of drug repositioning 
137. Quinacrine inhibits Candida albicans growth and filamentation at neutral pH 
138. RANKS: a flexible tool for node label ranking and classification in biological networks 
139. Rapid identification of antifungal compounds against Exserohilum rostratum using high throughput 
drug repurposing screens 
140. Recent Advances in the Development of Pharmaceutical Agents for Metabolic Disorders: A 
Computational Perspective 
141. Recent advances in the machine learning-based drug-target interaction prediction 
142. Repositioning of Endonuclear Receptors Binders as Potential Antibacterial and Antifungal Agents. 
Eptyloxim: A Potential and Novel Gyrase B and Cytochrome Cyp51 Inhibitor 
143. Repurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic medical records 
144. RepurposeVS: A Drug Repurposing-Focused Computational Method for Accurate Drug-Target 
Signature Predictions 
 




145. Repurposing antipsychotic drugs into antifungal agents: Synergistic combinations of azoles and 
bromperidol derivatives in the treatment of various fungal infections 
146. Repurposing Approach Identifies Auranofin with Broad Spectrum Antifungal Activity That Targets 
Mia40-Erv1 Pathway 
147. Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida 
albicans biofilms 
148. Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer 
stem cells 
149. Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important 
fungi 
150. Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis 
151. Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans 
152. Repurposing of Aspirin and Ibuprofen as Candidate Anti-Cryptococcus Drugs 
153. Repurposing ospemifene for potentiating an antigen-specific immune response 
154. Repurposing Resveratrol and Fluconazole To Modulate Human Cytochrome P450-Mediated 
Arachidonic Acid Metabolism 
155. Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer 
Chemotherapeutic 
156. Reversal of Azole Resistance in Candida albicans by Sulfa Antibacterial Drugs 
157. Role of acid responsive genes in the susceptibility of Escherichia coli to ciclopirox 
158. Scoring multiple features to predict drug disease associations using information fusion and 
aggregation 
159. Screening a Repurposing Library for Inhibitors of Multidrug-Resistant Candida auris Identifies 
Ebselen as a Repositionable Candidate for Antifungal Drug Development 
160. SDTNBI: an integrated network and chemoinformatics tool for systematic prediction of drug-target 
interactions and drug repositioning 
161. SemFunSim: a new method for measuring disease similarity by integrating semantic and gene 
functional association 
162. Some Remarks on Prediction of Drug-Target Interaction with Network Models 
163. Sorafenib Impedes Rift Valley Fever Virus Egress by Inhibiting Valosin-Containing Protein 
Function in the Cellular Secretory Pathway 
 




164. Statins: antimicrobial resistance breakers or makers 
165. Strategies in the discovery of novel antifungal scaffolds 
166. Substrate-driven mapping of the degradome by comparison of sequence logos 
167. Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans 
168. Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma 
cruzi 
169. Systematic drug repositioning for a wide range of diseases with integrative analyses of phenotypic 
and molecular data 
170. Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review 
171. The Amide Local Anesthetic Lidocaine in Cancer Surgery-Potential Antimetastatic Effects and 
Preservation of Immune Cell Function? A Narrative Review 
172. The anti-Aspergillus drug pipeline: Is the glass half full or empty 
173. The Anti-helminthic Compound Mebendazole Has Multiple Antifungal Effects against Cryptococcus 
neoformans 
174. The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-
enhanced platelet function 
175. The extraction of drug-disease correlations based on module distance in incomplete human 
interactome 
176. The Repurposing of Anti-Psychotic Drugs, Quetiapine and Olanzapine, as Anti-Cryptococcus Drugs 
177. The Tissue-Reconstructing Ability of Colon CSCs Is Enhanced by FK506 and Suppressed by GSK3 
Inhibition 
178. The triphenylethylenes, a novel class of antifungals 
179. Therapeutic Effect of Repurposed Temsirolimus in Lung Adenocarcinoma Model 
180. Topical delivery of ebselen encapsulated in biopolymeric nanocapsules: drug repurposing enhanced 
antifungal activity 
181. Toward improved anti-cryptococcal drugs: Novel molecules and repurposed drugs 
182. Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, 
Escherichia coli, and Klebsiella pneumoniae 
183. Towards drug repositioning: a unified computational framework for integrating multiple aspects of 
drug similarity and disease similarity 
 




184. Transcriptomic profiling of human hippocampal progenitor cells treated with antidepressants and its 
application in drug repositioning 
185. Treatment of Disseminated Leishmaniasis With Liposomal Amphotericin B 
186. Tricyclic antidepressants inhibit Candida albicans growth and biofilm formation 
187. Updates on drug-target network; facilitating polypharmacology and data integration by growth of 
DrugBank database 
188. Virtual screening and drug repositioning as strategies for the discovery of new antifungal inhibitors 
of oxidosqualene cyclase 








FACTOR 8a. Use of Cellular Signatures Library to Provide Gene Expression Profiles for Drug 
Repurposing Prediction 
1. A comparative study of disease genes and drug targets in the human protein interactome 
2. A Large-Scale Gene Expression Intensity-Based Similarity Metric for Drug Repositioning 
3. Drug repurposing to target Ebola virus replication and virulence using structural systems pharmacology 
4. Drug repurposing: An approach to tackle drug resistance in S. typhimurium 
5. Elucidating the modes of action for bioactive compounds in a cell-specific manner by large-scale 
chemically-induced transcriptomics 
6. Exploration of the Anti-Inflammatory Drug Space Through Network Pharmacology: Applications for 
Drug Repurposing 
7. Exploring the anti-proliferative activity of Pelargonium sidoides DC with in silico target identification 
and network pharmacology 
8. Fenoprofen -- an old drug rediscovered as a biased allosteric enhancer for melanocortin receptors 
9. Human pathway-based disease network 
10. Identification of key pathways and drug repurposing for anaplastic thyroid carcinoma by integrated 
bioinformatics analysis 
11. Identification of Potential Therapeutics to Conquer Drug Resistance in Salmonella typhimurium: 
Drug Repurposing Strategy 
12. Multi-target drug repositioning by bipartite block-wise sparse multi-task learning 
13. Neighbours of cancer-related proteins have key influence on pathogenesis and could increase the drug 
target space for anticancer therapies 
14. Network-based machine learning and graph theory algorithms for precision oncology 
15. New drug candidates for treatment of atypical meningiomas: An integrated approach using gene 
expression signatures for drug repurposing 
16. Novel putative drugs and key initiating genes for neurodegenerative disease determined using 
network-based genetic integrative analysis 
17. Old drugs with new skills: fenoprofen as an allosteric enhancer at melanocortin receptor 3 
18. Repositioning drugs by targeting network modules: a Parkinson's disease case study 
19. The extraction of drug-disease correlations based on module distance in incomplete human 
interactome 
 




20. Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems 
Pharmacology 
21. Transcriptomic profiling of human hippocampal progenitor cells treated with antidepressants and its 
application in drug repositioning 








FACTOR 8b. Ligand-Based Target Inference 
1. Application of drug repositioning strategy to TOFISOPAM 
2. Application of the 4D fingerprint method with a robust scoring function for scaffold-hopping and drug 
repurposing strategies 
3. Cascade Ligand- and Structure-Based Virtual Screening to Identify New Trypanocidal Compounds 
Inhibiting Putrescine Uptake 
4. Chemical-induced disease extraction via recurrent piecewise convolutional neural networks 
5. Computational profiling of bioactive compounds using a target-dependent composite workflow 
6. Disease classification: from phenotypic similarity to integrative genomics and beyond 
7. Docking of a novel DNA methyltransferase inhibitor identified from high-throughput screening: 
insights to unveil inhibitors in chemical databases 
8. Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank 
database for allosteric Bcr-Abl inhibitors 
9. Expediting the Design, Discovery and Development of Anticancer Drugs using Computational 
Approaches 
10. Exploring polypharmacology using a ROCS-based target fishing approach 
11. High-throughput identification of off-targets for the mechanistic study of severe adverse drug 
reactions induced by analgesics 
12. Hit Recycling: Discovery of a Potent Carbonic Anhydrase Inhibitor by in Silico Target Fishing 
13. How good are publicly available web services that predict bioactivity profiles for drug repurposing 
14. In Silico target fishing: addressing a "Big Data" problem by ligand-based similarity rankings with data 
fusion 
15. MOST: most-similar ligand based approach to target prediction 
16. Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA 
Efflux Pump Inhibitors 
17. Polypharmacological Drug-target Inference for Chemogenomics 
18. Predicting targeted polypharmacology for drug repositioning and multi- target drug discovery 
19. Prediction of Human Drug Targets and Their Interactions Using Machine Learning Methods: Current 
and Future Perspectives 
 




20. Protein-ligand-based pharmacophores: generation and utility assessment in computational ligand 
profiling 
21. Research advance in the drug target prediction based on chemoinformatics 
22. Reverse docking: a powerful tool for drug repositioning and drug rescue 
23. Reverse Screening Methods to Search for the Protein Targets of Chemopreventive Compounds 
24. SMAP-WS: a parallel web service for structural proteome-wide ligand-binding site comparison 
25. TargetHunter: an in silico target identification tool for predicting therapeutic potential of small 
organic molecules based on chemogenomic database 
26. TarPred: a web application for predicting therapeutic and side effect targets of chemical compounds 
27. Tools for in silico target fishing 








FACTOR 9. Binding Site Analysis for Drug Repurposing 
1. 2-acylamino-5-nitro-1,3-thiazoles: preparation and in vitro bioevaluation against four neglected 
protozoan parasites 
2. 3, 5, 3'-Triiodothyroacetic acid (TRIAC) is an anti-inflammatory drug that targets toll-like receptor 2 
3. A Biologically-Based Computational Approach to Drug Repurposing for Anthrax Infection 
4. A combined systems and structural modeling approach repositions antibiotics for Mycoplasma 
genitalium 
5. A comparative study of disease genes and drug targets in the human protein interactome 
6. A computational approach to finding novel targets for existing drugs 
7. A cross-species analysis method to analyze animal models' similarity to human's disease state 
8. A curated C. difficile strain 630 metabolic network: prediction of essential targets and inhibitors 
9. A disease similarity matrix based on the uniqueness of shared genes 
10. A Drug Screen using Human iPSC-Derived Hepatocyte-like Cells Reveals Cardiac Glycosides as a 
Potential Treatment for Hypercholesterolemia 
11. A drug target slim: using gene ontology and gene ontology annotations to navigate protein-ligand 
target space in ChEMBL 
12. A dual drug regimen synergistically blocks human parainfluenza virus infection 
13. A framework for the targeted selection of herbs with similar efficacy by exploiting drug repositioning 
technique and curated biomedical knowledge 
14. A large-scale computational approach to drug repositioning 
15. A Large-Scale Gene Expression Intensity-Based Similarity Metric for Drug Repositioning 
16. A machine learning-based method to improve docking scoring functions and its application to drug 
repurposing 
17. A Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases 
18. A network integration approach for drug-target interaction prediction and computational drug 
repositioning from heterogeneous information 
19. A network-based drug repositioning infrastructure for precision cancer medicine through targeting 
significantly mutated genes in the human cancer genomes 
20. A New Method for Computational Drug Repositioning Using Drug Pairwise Similarity 
 




21. A new niclosamide derivatives-B17 can inhibit urological cancers growth through apoptosis-related 
pathway 
22. A novel application of furazolidone: anti-leukemic activity in acute myeloid leukemia 
23. A novel multi-modal drug repurposing approach for identification of potent ACK1 inhibitors 
24. A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, 
West Nile and Chikungunya viruses 
25. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system 
availability of AZD0530 (saracatinib) in Alzheimer's disease 
26. A physarum-inspired prize-collecting steiner tree approach to identify subnetworks for drug 
repositioning 
27. A potential target of Tanshinone IIA for acute promyelocytic leukemia revealed by inverse docking 
and drug repurposing 
28. A profound computational study to prioritize the disease-causing mutations in PRPS1 gene 
29. A protein folding molecular imaging biosensor monitors the effects of drugs that restore mutant p53 
structure and its downstream function in glioblastoma cells 
30. A quality alert and call for improved curation of public chemistry databases 
31. A rapid and affordable screening platform for membrane protein trafficking 
32. A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast 
Differentiation In Vitro 
33. A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia 
34. A review of drugs for treatment of Alzheimer's disease in clinical trials: main trends 
35. A review of MED-SuMo applications 
36. A screen for Fli-1 transcriptional modulators identifies PKC agonists that induce erythroid to 
megakaryocytic differentiation and suppress leukemogenesis 
37. A screening cascade to identify ERbeta ligands 
38. A Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and 
Repositioning Predictions 
39. A signalome screening approach in the autoinflammatory disease TNF receptor associated periodic 
syndrome (TRAPS) highlights the anti-inflammatory properties of drugs for repurposing 
40. A structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 
ATPase 
 




41. A tool to utilize adverse effect profiles to identify brain-active medications for repurposing 
42. A Topical Zinc Ionophore Blocks Tumorigenic Progression in UV-exposed SKH-1 High-risk Mouse 
Skin 
43. A two-step drug repositioning method based on a protein-protein interaction network of genes shared 
by two diseases and the similarity of drugs 
44. A Zebrafish Drug-Repurposing Screen Reveals sGC-Dependent and sGC-Independent Pro-
Inflammatory Activities of Nitric Oxide 
45. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus 
and Middle East Respiratory Syndrome Coronavirus Fusion 
46. Accidental interaction between PDZ domains and diclofenac revealed by NMR-assisted virtual 
screening 
47. Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease 
48. Activity of anti-cancer protein kinase inhibitors against Leishmania spp 
49. Activity-Based Protein Profiling for the Study of Parasite Biology 
50. Adaptive mitochondrial reprogramming and resistance to PI3K therapy 
51. Advanced Assay Monitoring APP-Carboxyl-Terminal Fragments as Markers of APP Processing in 
Alzheimer Disease Mouse Models 
52. Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus 
53. Advances in Developing Therapies to Combat Zika Virus: Current Knowledge and Future 
Perspectives 
54. Advances in intravesical therapy for urinary tract disorders 
55. Advances in the Development of Shape Similarity Methods and Their Application in Drug Discovery 
56. Aging-related Repositioned Drugs, Donepezil and Sildenafil Citrate, Increase Apoptosis of Anti-
mitotic Drug-resistant KBV20C Cells Through Different Molecular Mechanisms 
57. Albendazole as a promising molecule for tumor control 
58. Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft 
model 
59. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4 
60. Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review 
 




61. alpha-Methyl-alpha-phenylsuccinimide ameliorates neurodegeneration in a C. elegans model of TDP-
43 proteinopathy 
62. Alternative molecular formats and therapeutic applications for bispecific antibodies 
63. AlzhCPI: A knowledge base for predicting chemical-protein interactions towards Alzheimer's disease 
64. Ameliorative effect of methylthiouracil on TGFBIp-induced septic responses 
65. An improved approach for predicting drug-target interaction: proteochemometrics to molecular 
docking 
66. An in vitro test system for compounds that modulate human inflammatory macrophage polarization 
67. An integrated structure- and system-based framework to identify new targets of metabolites and 
known drugs 
68. An invitro and invivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi 
predicted by a computational drug repositioning method 
69. Analysis and assay of oseltamivir-resistant mutants of influenza neuraminidase via direct observation 
of drug unbinding and rebinding in simulation 
70. Analysis of drug binding pockets and repurposing opportunities for twelve essential enzymes of 
ESKAPE pathogens 
71. Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T-cell 
leukemia cells 
72. Angiotensin II type 1 receptor blockers increase tolerance of cells to copper and cisplatin 
73. ANTENNA, a Multi-Rank, Multi-Layered Recommender System for Inferring Reliable Drug-Gene-
Disease Associations: Repurposing Diazoxide as a Targeted Anti-Cancer Therapy 
74. Anthelmintics - from discovery to resistance 
75. Anti-infectious drug repurposing using an integrated chemical genomics and structural systems 
biology approach 
76. Anti-inflammatory effects of dabrafenib in vitro and in vivo 
77. Anti-inflammatory effects of methylthiouracil in vitro and in vivo 
78. Anti-obesogenic and hypolipidemic effects of a glucagon-like peptide-1 receptor agonist derived from 
the saliva of the Gila monster 
79. Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched 
for stem cell-like properties 
 




80. Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial 
pathogens 
81. Anticancer and Immunogenic Properties of Cardiac Glycosides 
82. Anticonvulsant activity of artificial sweeteners: a structural link between sweet-taste receptor T1R3 
and brain glutamate receptors 
83. Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein 
phosphatase 2A in non-small cell lung cancer cells 
84. Antimalarial activity of novel 4-cyano-3-methylisoquinoline inhibitors against Plasmodium 
falciparum: design, synthesis and biological evaluation 
85. Antiseptic effects of dabrafenib on TGFBIp-induced septic responses 
86. Antiviral activity of micafungin against enterovirus 71 
87. Application of computer-aided drug repurposing in the search of new cruzipain inhibitors: discovery 
of amiodarone and bromocriptine inhibitory effects 
88. Application of drug repositioning strategy to TOFISOPAM 
89. Application of molecular framework-based data-mining method in the search for beta-secretase 1 
inhibitors through drug repurposing 
90. Application of the 4D fingerprint method with a robust scoring function for scaffold-hopping and 
drug repurposing strategies 
91. Approaches for discovering anti-prion compounds: lessons learned and challenges ahead 
92. Approaches for establishing the function of regulatory genetic variants involved in disease 
93. Approved oncology drugs lack in vivo activity against Trichuris muris despite in vitro activity 
94. Ariadne's ChemEffect and Pathway Studio knowledge base 
95. Assessing protein kinase target similarity: Comparing sequence, structure, and cheminformatics 
approaches 
96. Assessing relative bioactivity of chemical substances using quantitative molecular network topology 
analysis 
97. Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New 
Platform for Computer-Aided Drug Repurposing 
98. Autophagy in HIV-induced T cell death 
99. Autophagy Induced by Naftopidil Inhibits Apoptosis of Human Gastric Cancer Cells 
 




100. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation 
101. Back to the Roots: Prediction of Biologically Active Natural Products from Ayurveda Traditional 
Medicine 
102. Bacoside A Induces Tumor Cell Death in Human Glioblastoma Cell Lines through Catastrophic 
Macropinocytosis 
103. Balance and circumstance: The renin angiotensin system in wound healing and fibrosis 
104. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy 
105. Benchmarking human protein complexes to investigate drug-related systems and evaluate predicted 
protein complexes 
106. Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2 
107. beta-Caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and 
metabolic dysregulation in mice 
108. beta2-Adrenoceptor agonists as novel, safe and potentially effective therapies for Amyotrophic 
lateral sclerosis (ALS 
109. beta3-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in 
a repositioning clinical drug development project 
110. Beyond Channel Activity: Protein-Protein Interactions Involving Viroporins 
111. Binding site matching in rational drug design: algorithms and applications 
112. Biocomputational resources useful for drug discovery against compartmentalized targets 
113. BioGPS: navigating biological space to predict polypharmacology, off-targeting, and selectivity 
114. BioGPS: The Music for the Chemo- and Bioinformatics Walzer 
115. Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning 
targets for IBD and other autoimmune diseases 
116. Bioinformatics and Drug Discovery 
117. Bioinformatics approach to prioritize known drugs towards repurposing for tuberculosis 
118. Bioinformatics methods in drug repurposing for Alzheimer's disease 
119. Biomolecular Network Controllability With Drug Binding Information 
120. Biotin-targeted Pluronic() P123/F127 mixed micelles delivering niclosamide: A repositioning 
strategy to treat drug-resistant lung cancer cells 
 




121. Bisphosphonates inactivate human EGFRs to exert antitumor actions 
122. Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the 
EIS regimen 
123. Blocking IL-6/GP130 signaling inhibits cell viability/proliferation, glycolysis, and colony forming 
activity in human pancreatic cancer cells 
124. Butamben derivatives enhance BMP-2-stimulated commitment of C2C12 cells into osteoblasts with 
induction of voltage-gated potassium channel expression 
125. C-SPADE: a web-tool for interactive analysis and visualization of drug screening experiments 
through compound-specific bioactivity dendrograms 
126. Calcium channel blockers as drug repurposing candidates for gestational diabetes: Mining large scale 
genomic and electronic health records data to repurpose medications 
127. Can sodium/hydrogen exchange inhibitors be repositioned for treating attention deficit hyperactivity 
disorder? An in silico approach 
128. CancerHSP: anticancer herbs database of systems pharmacology 
129. CANDO and the infinite drug discovery frontier 
130. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer 
131. Cascade Ligand- and Structure-Based Virtual Screening to Identify New Trypanocidal Compounds 
Inhibiting Putrescine Uptake 
132. Case-specific potentiation of glioblastoma drugs by pterostilbene 
133. Catecholamine receptors: prototypes for GPCR-based drug discovery 
134. CaV channels and cancer: canonical functions indicate benefits of repurposed drugs as cancer 
therapeutics 
135. Cell line modeling for systems medicine in cancers (review 
136. Cell-based screening identifies paroxetine as an inhibitor of diabetic endothelial dysfunction 
137. CellFateScout - a bioinformatics tool for elucidating small molecule signaling pathways that drive 
cells in a specific direction 
138. Characterization of a Francisella tularensis-Caenorhabditis elegans Pathosystem for the Evaluation 
of Therapeutic Compounds 
139. Characterizing protein domain associations by Small-molecule ligand binding 
140. Characterizing the pocketome of Mycobacterium tuberculosis and application in rationalizing 
polypharmacological target selection 
 




141. Checking the STEP-Associated Trafficking and Internalization of Glutamate Receptors for Reduced 
Cognitive Deficits: A Machine Learning Approach-Based Cheminformatics Study and Its Application for 
Drug Repurposing 
142. Chemical-protein interactome and its application in off-target identification 
143. ChemMapper: a versatile web server for exploring pharmacology and chemical structure association 
based on molecular 3D similarity method 
144. Chk1 as a new therapeutic target in triple-negative breast cancer 
145. Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-
Joseph Disease 
146. CK2 inhibition confers functional protection to young and aging axons against ischemia by 
differentially regulating the CDK5 and AKT signaling pathways 
147. Classifying cancer genome aberrations by their mutually exclusive effects on transcription 
148. Clobetasol and Halcinonide Act as Smoothened Agonists to Promote Myelin Gene Expression and 
RxRgamma Receptor Activation 
149. Clomipramine kills Trypanosoma brucei by apoptosis 
150. Clozapine Improves Memory Impairment and Reduces Abeta Level in the Tg-APPswe/PS1dE9 
Mouse Model of Alzheimer's Disease 
151. Co-expression Network Approach Reveals Functional Similarities among Diseases Affecting Human 
Skeletal Muscle 
152. Combating Ebola with Repurposed Therapeutics Using the CANDO Platform 
153. Combating Intracellular Pathogens with Repurposed Host-Targeted Drugs 
154. Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved 
outcomes in spinal muscular atrophy patient-derived fibroblasts 
155. Combined analysis of gene expression and genome binding profiles identified potential therapeutic 
targets of ciclopirox in Ewing sarcoma 
156. Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the 
Pathological Proteins Related to the Alzheimer's Disease 
157. Comparative analysis of methicillin-sensitive and resistant Staphylococcus aureus exposed to 
emodin based on proteomic profiling 
158. Comparative assessment of strategies to identify similar ligand-binding pockets in proteins 
 




159. Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate 
Synthase Case 
160. Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake 
in Lung Cancer 
161. Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3beta and 
Activates WNT Signaling 
162. Complex-disease networks of trait-associated single-nucleotide polymorphisms (SNPs) unveiled by 
information theory 
163. Comprehensive prediction of drug-protein interactions and side effects for the human proteome 
164. Computational approaches for drug repositioning and combination therapy design 
165. Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with 
Repurposing Potential 
166. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That 
Reduces Growth of Hepatocellular Carcinoma Cells InVitro and in Mice by Inhibiting Cell Division 
Cycle 37 Signaling 
167. Computational Discovery of Putative Leads for Drug Repositioning through Drug-Target Interaction 
Prediction 
168. Computational Drug Repositioning by Target Hopping: A Use Case in Chagas Disease 
169. Computational drug repositioning for peripheral arterial disease: prediction of anti-inflammatory and 
pro-angiogenic therapeutics 
170. Computational drug repositioning through heterogeneous network clustering 
171. Computational drug repurposing to predict approved and novel drug-disease associations 
172. Computational Drug Repurposing: Current Trends 
173. Computational Drug Target Screening through Protein Interaction Profiles 
174. Computational functional genomics-based approaches in analgesic drug discovery and repurposing 
175. Computational methods and opportunities for phosphorylation network medicine 
176. Computational Prediction of Drug?Target Interactions Using Chemical, Biological, and Network 
Features 
177. Computational profiling of bioactive compounds using a target-dependent composite workflow 
178. Computational repositioning and experimental validation of approved drugs for HIF-prolyl 
hydroxylase inhibition 
 




179. Computational Study of Drugs by Integrating Omics Data with Kernel Methods 
180. Computational-experimental approach to drug-target interaction mapping: A case study on kinase 
inhibitors 
181. Computer-Aided Structure Based Drug Design Approaches for the Discovery of New Anti-CHIKV 
Agents 
182. Concept Modeling-based Drug Repositioning 
183. Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by 
repurposing disulfiram 
184. Concise Review: Cell Surface N-Linked Glycoproteins as Potential Stem Cell Markers and Drug 
Targets 
185. Concise Review: Cell Surface N-Linked Glycoproteins as Potential Stem Cell Markers and Drug 
Targets 
186. Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in 
cystic fibrosis 
187. Constructing Disease Similarity Networks Based on Disease Module Theory 
188. Construction of drug network based on side effects and its application for drug repositioning 
189. Convergent downstream candidate mechanisms of independent intergenic polymorphisms between 
co-classified diseases implicate epistasis among noncoding elements 
190. Cooperative recognition of T:T mismatch by echinomycin causes structural distortions in DNA 
duplex 
191. Copper is required for oncogenic BRAF signalling and tumorigenesis 
192. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from 
enhanced docking approach and molecular dynamics analyses 
193. Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 
(TRIB2) pseudokinase in cancer cells 
194. Cryo-EM structure of the Plasmodium falciparum 80S ribosome bound to the anti-protozoan drug 
emetine 
195. Cyclic AMP efflux inhibitors as potential therapeutic agents for leukemia 
196. Cyclin dependent kinase 5: A novel avenue for Alzheimer's disease 
197. Cyclotides as Tools in Chemical Biology 
198. CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM 
 




199. Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in 
ER+ breast cancer 
200. Data integration to prioritize drugs using genomics and curated data 
201. Database of Optimized Proteomic Quantitative Methods for Human Drug Disposition-Related 
Proteins for Applications in Physiologically Based Pharmacokinetic Modeling 
202. Deciphering miRNA transcription factor feed-forward loops to identify drug repurposing candidates 
for cystic fibrosis 
203. Deep-Learning-Based Drug-Target Interaction Prediction 
204. Defining the Schistosoma haematobium kinome enables the prediction of essential kinases as anti-
schistosome drug targets 
205. Delineation of biological and molecular mechanisms underlying the diverse anticancer activities of 
mycophenolic acid 
206. Design of efficient computational workflows for in silico drug repurposing 
207. Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target 
Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment 
of Alzheimer's Disease 
208. Designing Dietary Recommendations Using System Level Interactomics Analysis and Network-
Based Inference 
209. Designing novel therapies against sarcomas in the era of personalized medicine and economic crisis 
210. Detecting drug promiscuity using Gaussian ensemble screening 
211. Detection of Binding Site Molecular Interaction Field Similarities 
212. Development of a Sigma-2 Receptor affinity filter through a Monte Carlo based QSAR analysis 
213. Development of anti-fungal pesticides from protein kinase inhibitor-based anticancer agents 
214. Diclofenac Identified as a Kynurenine 3-Monooxygenase Binder and Inhibitor by Molecular 
Similarity Techniques 
215. DIGEP-Pred: web service for in silico prediction of drug-induced gene expression profiles based on 
structural formula 
216. Discovering L-type calcium channels inhibitors of antihypertensive drugs based on drug 
repositioning 
217. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from 
rational design, nature and old drug reposition 
 




218. Discovery of alkyl bis(oxy)dibenzimidamide derivatives as novel protein arginine methyltransferase 
1 (PRMT1) inhibitors 
219. Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs 
220. Discovery of drug mode of action and drug repositioning from transcriptional responses 
221. Discovery of New Potential Anti-Infective Compounds Based on Carbonic Anhydrase Inhibitors by 
Rational Target-Focused Repurposing Approaches 
222. Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues 
223. Discovery of Novel Liver-Stage Antimalarials through Quantum Similarity 
224. Discovery of novel polyamine analogs with anti-protozoal activity by computer guided drug 
repositioning 
225. Discovery of Novel SPAK Inhibitors That Block WNK Kinase Signaling to Cation Chloride 
Transporters 
226. Discovery of rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer 
227. Discovery of Surface Target Proteins Linking Drugs, Molecular Markers, Gene Regulation, Protein 
Networks, and Disease by Using a Web-Based Platform Targets-search 
228. Disease classification: from phenotypic similarity to integrative genomics and beyond 
229. Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease 
230. Disulfiram as a novel inactivator of Giardia lamblia triosephosphate isomerase with antigiardial 
potential 
231. Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase 
(MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage 
232. Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma invivo 
233. Disulfiram/copper causes redox-related proteotoxicity and concomitant heat shock response in 
ovarian cancer cells that is augmented by auranofin-mediated thioredoxin inhibition 
234. DMAP: a connectivity map database to enable identification of novel drug repositioning candidates 
235. DNetDB: The human disease network database based on dysfunctional regulation mechanism 
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864. Toward drug repurposing in epigenetics: olsalazine as a hypomethylating compound active in a 
cellular context 
865. Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems 
Pharmacology 
866. Towards drug repositioning: a unified computational framework for integrating multiple aspects of 
drug similarity and disease similarity 
867. Transcriptomic Analysis of the Host Response and Innate Resilience to Enterotoxigenic Escherichia 
coli Infection in Humans 
868. Transcriptomic changes induced by mycophenolic acid in gastric cancer cells 
869. Transcriptomic RNAseq drug screen in cerebrocortical cultures: toward novel neurogenetic disease 
therapies 
870. Translating Mendelian and complex inheritance of Alzheimer's disease genes for predicting unique 
personal genome variants 
871. Treating Influenza Infection, From Now and Into the Future 
872. Treatment of Schistosoma mansoni with miltefosine in vitro enhances serological recognition of 
defined worm surface antigens 
873. Trypanocidal Effect of Isotretinoin through the Inhibition of Polyamine and Amino Acid 
Transporters in Trypanosoma cruzi 
874. Uncovering Drug Mechanism of Action by Proteome Wide- Identification of Drug-Binding Proteins 
875. Understanding organellar protein folding capacities and assessing their pharmacological modulation 
by small molecules 
876. Unveiling anticancer potential of glibenclamide: Its synergistic cytotoxicity with doxorubicin on 
cancer cells 
877. Unveiling the role of network and systems biology in drug discovery 
878. Updates on drug-target network; facilitating polypharmacology and data integration by growth of 
DrugBank database 
 




879. Use of monoclonal antibody-IRDye800CW bioconjugates in the resection of breast cancer 
880. Using predicate and provenance information from a knowledge graph for drug efficacy screening 
881. Using reverse docking for target identification and its applications for drug discovery 
882. Valproic acid in the complex therapy of malignant tumors 
883. Valproic acid mediates miR-124 to down-regulate a novel protein target, GNAI1 
884. Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA 
virus infection 
885. Virtual Screening against Phosphoglycerate Kinase 1 in Quest of Novel Apoptosis Inhibitors 
886. Virtual screening and drug repositioning as strategies for the discovery of new antifungal inhibitors 
of oxidosqualene cyclase 
887. Virtual screening-driven repositioning of etoposide as CD44 antagonist in breast cancer cells 
888. Virtual target screening: validation using kinase inhibitors 
889. VisANT 4.0: Integrative network platform to connect genes, drugs, diseases and therapies 
890. Vitamin K and hepatocellular carcinoma: The basic and clinic 
891. Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs 
892. Voltage-gated sodium channels and metastatic disease 
893. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity 
and Metastasis 
894. Web-based drug repurposing tools: a survey 
895. West Nile virus drug discovery 
896. Word-of-Mouth Innovation: Hypothesis Generation for Supplement Repurposing based on 
Consumer Reviews 
897. YAP/TAZ Are Mechanoregulators of TGF-beta-Smad Signaling and Renal Fibrogenesis 
898. Zafirlukast inhibits complexation of Lsr2 with DNA and growth of Mycobacterium tuberculosis 









FACTOR 10. Antiinflammatory Applications for Repurposed Drugs 
1. 3, 5, 3'-Triiodothyroacetic acid (TRIAC) is an anti-inflammatory drug that targets toll-like receptor 2 
2. A Combination of Three Repurposed Drugs Administered at Reperfusion as a Promising Therapy for 
Postischemic Brain Injury 
3. A computational approach to finding novel targets for existing drugs 
4. A current perspective on the oncopreventive and oncolytic properties of selective serotonin reuptake 
inhibitors 
5. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer 
and other neuroendocrine tumors 
6. A drug-repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6-
thioguanine as an effective therapeutic agent for TPMT-low cancer cells 
7. A genomics-based systems approach towards drug repositioning for rheumatoid arthritis 
8. A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor 
Ponatinib for Repurposing in Neuroblastoma Therapy 
9. A meta-analysis of reflux genome-wide association studies in 6750 Northern Europeans from the 
general population 
10. A network integration approach for drug-target interaction prediction and computational drug 
repositioning from heterogeneous information 
11. A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target 
Therapies in Triple Negative Breast Cancer 
12. A novel anti-cancer role of beta-apopicropodophyllin against non-small cell lung cancer cells 
13. A novel application of furazolidone: anti-leukemic activity in acute myeloid leukemia 
14. A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram 
15. A Novel High Content Imaging-Based Screen Identifies the Anti-Helminthic Niclosamide as an 
Inhibitor of Lysosome Anterograde Trafficking and Prostate Cancer Cell Invasion 
16. A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by 
Combining a Spontaneously Emulsifying Component with a Polymer Carrier 
17. A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent Cancers 
18. A selective mitochondrial-targeted chlorambucil with remarkable cytotoxicity in breast and pancreatic 
cancers 
 




19. A signalome screening approach in the autoinflammatory disease TNF receptor associated periodic 
syndrome (TRAPS) highlights the anti-inflammatory properties of drugs for repurposing 
20. A small molecule screen identifies an inhibitor of DNA repair inducing the degradation of TFIIH and 
the chemosensitization of tumor cells to platinum 
21. A statin-regulated microRNA represses human c-Myc expression and function 
22. A systems-level analysis of drug-target-disease associations for drug repositioning 
23. A tumor deconstruction platform identifies definitive end points in the evaluation of drug responses 
24. A Zebrafish Drug-Repurposing Screen Reveals sGC-Dependent and sGC-Independent Pro-
Inflammatory Activities of Nitric Oxide 
25. Accidental interaction between PDZ domains and diclofenac revealed by NMR-assisted virtual 
screening 
26. ACTH: The forgotten therapy 
27. Acute oxidant damage promoted on cancer cells by amitriptyline in comparison with some common 
chemotherapeutic drugs 
28. Adaptive mitochondrial reprogramming and resistance to PI3K therapy 
29. Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas 
30. Adjuvant potential of selegiline in attenuating organ dysfunction in septic rats with peritonitis 
31. Advanced systems biology methods in drug discovery and translational biomedicine 
32. Advances in the development of new tuberculosis drugs and treatment regimens 
33. Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology 
34. Albendazole as a promising molecule for tumor control 
35. Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft 
model 
36. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4 
37. Alendronate inhalation ameliorates elastase-induced pulmonary emphysema in mice by induction of 
apoptosis of alveolar macrophages 
38. Alternative molecular formats and therapeutic applications for bispecific antibodies 
39. Ameliorative effect of methylthiouracil on TGFBIp-induced septic responses 
40. An in vitro test system for compounds that modulate human inflammatory macrophage polarization 
 




41. An integrative approach using real-world data to identify alternative therapeutic uses of existing drugs 
42. An invitro and invivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi 
predicted by a computational drug repositioning method 
43. Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from 
Chemorefractory Neoplasia 
44. Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via 
oxidative stress-mediated mTOR inhibition 
45. Anti-inflammatory effects of dabrafenib in vitro and in vivo 
46. Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption 
47. Anti-inflammatory effects of methylthiouracil in vitro and in vivo 
48. Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched 
for stem cell-like properties 
49. Antibiotic drug levofloxacin inhibits proliferation and induces apoptosis of lung cancer cells through 
inducing mitochondrial dysfunction and oxidative damage 
50. Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void 
51. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis 
52. Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein 
phosphatase 2A in non-small cell lung cancer cells 
53. Antimalarial drug mefloquine inhibits nuclear factor kappa B signaling and induces apoptosis in 
colorectal cancer cells 
54. Antiseptic effects of dabrafenib on TGFBIp-induced septic responses 
55. Antiviral activity of gemcitabine against human rhinovirus invitro and invivo 
56. Antiviral Drug Ribavirin Targets Thyroid Cancer Cells by Inhibiting the eIF4E-beta-Catenin Axis 
57. Are biologic treatments a potential approach to wear- and corrosion-related problems 
58. Ariadne's ChemEffect and Pathway Studio knowledge base 
59. Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do 
60. Assessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer 
61. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical 
activity against chronic lymphocytic leukemia 
 




62. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell 
lung cancer cells 
63. Azithromycin protects mice against ischemic stroke injury by promoting macrophage transition 
towards M2 phenotype 
64. Bacoside A Induces Tumor Cell Death in Human Glioblastoma Cell Lines through Catastrophic 
Macropinocytosis 
65. Balance and circumstance: The renin angiotensin system in wound healing and fibrosis 
66. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy 
67. Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2 
68. Benznidazole/Itraconazole Combination Treatment Enhances Anti-Trypanosoma cruzi Activity in 
Experimental Chagas Disease 
69. beta-Caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and 
metabolic dysregulation in mice 
70. beta-catenin and PI3Kdelta inhibition expands precursor Th17 cells with heightened stemness and 
antitumor activity 
71. Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor 
72. Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning 
targets for IBD and other autoimmune diseases 
73. Bioinformatics in translational drug discovery 
74. Biological basis and clinical study of glycogen synthase kinase- 3beta-targeted therapy by drug 
repositioning for glioblastoma 
75. Biomarker repurposing: Therapeutic drug monitoring of serum theophylline offers a potential 
diagnostic biomarker of Parkinson's disease 
76. Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug 
development 
77. Bisphosphonates inactivate human EGFRs to exert antitumor actions 
78. Bithionol inhibits ovarian cancer cell growth in vitro - studies on mechanism(s) of action 
79. Blocking IL-6/GP130 signaling inhibits cell viability/proliferation, glycolysis, and colony forming 
activity in human pancreatic cancer cells 
80. Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote 
metastasis 
 




81. Bromide supplementation exacerbated the renal dysfunction, injury and fibrosis in a mouse model of 
Alport syndrome 
82. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant 
mammary tissues of MMTV-erbB-2 transgenic mice 
83. Butamben derivatives enhance BMP-2-stimulated commitment of C2C12 cells into osteoblasts with 
induction of voltage-gated potassium channel expression 
84. Calcineurin-NFAT signalling in myeloid leucocytes: new prospects and pitfalls in 
immunosuppressive therapy 
85. Can sodium/hydrogen exchange inhibitors be repositioned for treating attention deficit hyperactivity 
disorder? An in silico approach 
86. Cancer based pharmacogenomics network supported with scientific evidences: from the view of drug 
repurposing 
87. Cancer Prevention and Interception: A New Era for Chemopreventive Approaches 
88. Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015 
89. Cancer: fundamentals behind pH targeting and the double-edged approach 
90. Candesartan stimulates reparative angiogenesis in ischemic retinopathy model: role of 
hemeoxygenase-1 (HO-1 
91. Case-specific potentiation of glioblastoma drugs by pterostilbene 
92. Cell-based screening identifies paroxetine as an inhibitor of diabetic endothelial dysfunction 
93. Characterization of a Francisella tularensis-Caenorhabditis elegans Pathosystem for the Evaluation of 
Therapeutic Compounds 
94. Chemoprevention agents for melanoma: a path forward into phase 3 clinical trials 
95. Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-kappaB 
signaling 
96. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic 
manifestations from malaria to multifarious diseases 
97. Chloroquine upregulates TRAIL/TRAILR2 expression and potentiates doxorubicin anti-tumor 
activity in thioacetamide-induced hepatocellular carcinoma model 
98. Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances 
99. Classifying cancer genome aberrations by their mutually exclusive effects on transcription 
100. Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All 
 




101. Clobetasol promotes remyelination in a mouse model of neuromyelitis optica 
102. Co-expression Network Approach Reveals Functional Similarities among Diseases Affecting Human 
Skeletal Muscle 
103. Colonic delivery of celecoxib is a potential pharmaceutical strategy for repositioning the selective 
COX-2 inhibitor as an anti-colitic agent 
104. Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive 
melanoma: a strategy for repurposing a phase I clinical trial drug 
105. Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate 
cancer cells 
106. Comparative oncology approach to drug repurposing in osteosarcoma 
107. Computational Approaches for Translational Oncology: Concepts and Patents 
108. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That 
Reduces Growth of Hepatocellular Carcinoma Cells InVitro and in Mice by Inhibiting Cell Division 
Cycle 37 Signaling 
109. Computational drug repositioning for peripheral arterial disease: prediction of anti-inflammatory and 
pro-angiogenic therapeutics 
110. Computational identification of multi-omic correlates of anticancer therapeutic response 
111. Computational repositioning and experimental validation of approved drugs for HIF-prolyl 
hydroxylase inhibition 
112. Computational repositioning and preclinical validation of mifepristone for human vestibular 
schwannoma 
113. Computational repositioning and preclinical validation of pentamidine for renal cell cancer 
114. Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by 
repurposing disulfiram 
115. CONCORD biomarker prediction for novel drug introduction to different cancer types 
116. Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in 
cystic fibrosis 
117. Copper is required for oncogenic BRAF signalling and tumorigenesis 
118. Current and future immunotherapy targets in autoimmune neurology 
119. Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, 
and Neurological Diseases: A Mini-Review 
 




120. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease 
121. Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current 
perspectives 
122. Cytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted 
therapeutics 
123. Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in 
ER+ breast cancer 
124. Data integration to prioritize drugs using genomics and curated data 
125. Designing drugs that combat kidney damage 
126. Designing novel therapies against sarcomas in the era of personalized medicine and economic crisis 
127. Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an 
active anticancer agent 
128. Development of therapies for autoimmune disease at Stanford: a tale of multiple shots and one goal 
129. Diclofenac Identified as a Kynurenine 3-Monooxygenase Binder and Inhibitor by Molecular 
Similarity Techniques 
130. Diffusion mapping of drug targets on disease signaling network elements reveals drug combination 
strategies 
131. Discovering drugs to overcome chemoresistance in ovarian cancers based on the cancer genome 
atlas tumor transcriptome profile 
132. Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues 
133. Discovery of Surface Target Proteins Linking Drugs, Molecular Markers, Gene Regulation, Protein 
Networks, and Disease by Using a Web-Based Platform Targets-search 
134. Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase 
(MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage 
135. Disulfiram's Anticancer Activity: Evidence and Mechanisms 
136. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon 
cancer 
137. Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models 
138. Doxycycline is an NF-kappaB inhibitor that induces apoptotic cell death in malignant T-cells 
139. Doxycycline or how to create new with the old 
 




140. DPP-4 inhibitors promote proliferation and migration of rat brain microvascular endothelial cells 
under hypoxic/high-glucose conditions, potentially through the SIRT1/HIF-1/VEGF pathway 
141. Drug discovery and development for rare genetic disorders 
142. Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer 
cell lines and pathway mechanisms of resistance 
143. Drug repositioning and pharmacophore identification in the discovery of hookworm MIF inhibitors 
144. Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining 
145. Drug Repositioning for Preeclampsia Therapeutics by In Vitro Screening: Phosphodiesterase-5 
Inhibitor Vardenafil Restores Endothelial Dysfunction via Induction of Placental Growth Factor 
146. Drug Repositioning in Glioblastoma: A Pathway Perspective 
147. Drug Repositioning in Inflammatory Bowel Disease Based on Genetic Information 
148. Drug Repositioning Meets Precision in Glioblastoma 
149. Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer 
150. Drug Repositioning of Proton Pump Inhibitors for Enhanced Efficacy and Safety of Cancer 
Chemotherapy 
151. Drug Repositioning Strategies for the Identification of Novel Therapies for Rheumatic Autoimmune 
Inflammatory Diseases 
152. Drug Repositioning through Systematic Mining of Gene Coexpression Networks in Cancer 
153. Drug Repositioning to Alleviate Systemic Inflammatory Response Syndrome Caused by Gram-
Negative Bacterial Outer Membrane Vesicles 
154. Drug repurposing and emerging adjunctive treatments for schizophrenia 
155. Drug Repurposing Approach Identifies a Synergistic Drug Combination of an Antifungal Agent and 
an Experimental Organometallic Drug for Melanoma Treatment 
156. Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections 
157. Drug Repurposing by Simulating Flow Through Protein-Protein Interaction Networks 
158. Drug repurposing for gastrointestinal stromal tumor 
159. Drug repurposing for the treatment of glioblastoma multiforme 
160. Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for 
gastrointestinal stromal tumor 
 




161. Drug repurposing may generate novel approaches to treating depression 
162. Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in 
Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and 
Blocking LTB4 Biosynthesis 
163. Drug Repurposing of Metabolic Agents in Malignant Glioma 
164. Drug Repurposing of the Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia 
165. Drug Repurposing Screen Identifies Foxo1-Dependent Angiopoietin-2 Regulation in Sepsis 
166. Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer 
associated fibroblasts (CAFs) by synergistic induction of apoptosis 
167. Drug Repurposing Screening Identifies Tioconazole as an ATG4 Inhibitor that Suppresses 
Autophagy and Sensitizes Cancer Cells to Chemotherapy 
168. Drug repurposing: In-vitro anti-glycation properties of 18 common drugs 
169. Drug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for 
Drug Repositioning in Cancer Therapy 
170. Drug Signature-based Finding of Additional Clinical Use of LC28-0126 for Neutrophilic Bronchial 
Asthma 
171. Drug Synergy Slows Aging and Improves Healthspan through IGF and SREBP Lipid Signaling 
172. Drug Targeting and Biomarkers in Head and Neck Cancers: Insights from Systems Biology 
Analyses 
173. Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian 
tumor cells 
174. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent 
activity against breast cancer 
175. Drug-Repositioning Screens Identify Triamterene as a Selective Drug for the Treatment of DNA 
Mismatch Repair Deficient Cells 
176. DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-
based drug repurposing 
177. Drugs in clinical development for the treatment of amyotrophic lateral sclerosis 
178. Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol 
and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study 
179. Effects of Benzothiazolamines on Voltage-Gated Sodium Channels 
 




180. Effects of digitoxin on cell migration in ovarian cancer inflammatory microenvironment 
181. Emerging amyloid and tau targeting treatments for Alzheimer's disease 
182. Emerging nanotherapeutic strategies in breast cancer 
183. Emerging roles of Myc in stem cell biology and novel tumor therapies 
184. Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets 
185. Eritoran Suppresses Colon Cancer by Altering a Functional Balance in Toll-like Receptors That 
Bind Lipopolysaccharide 
186. Establishing a Preclinical Multidisciplinary Board for Brain Tumors 
187. Evaluating a novel treatment for coronary artery inflammation in acute Kawasaki disease: A Phase 
I/IIa trial of atorvastatin 
188. Evaluation of a systems biology approach to identify pharmacological correctors of the mutant 
CFTR chloride channel 
189. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute 
lymphoblastic leukemia 
190. Ex vivo drug sensitivity testing as a means for drug repurposing in esophageal adenocarcinoma 
191. Existing drugs and their application in drug discovery targeting cancer stem cells 
192. Exploration of the Anti-Inflammatory Drug Space Through Network Pharmacology: Applications 
for Drug Repurposing 
193. Explore Small Molecule-induced Genome-wide Transcriptional Profiles for Novel Inflammatory 
Bowel Disease Drug 
194. Exploring novel pharmacotherapeutic applications and repurposing potential of sodium glucose 
CoTransporter 2 inhibitors 
195. Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent 
196. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow 
Tumor Growth in Mice 
197. Expression Profiling Identifies Bezafibrate as Potential Therapeutic Drug for Lung Adenocarcinoma 
198. Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment 
199. Fenofibrate Attenuates Neutrophilic Inflammation in Airway Epithelia: Potential Drug Repurposing 
for Cystic Fibrosis 
 




200. Fenofibrate Suppresses Oral Tumorigenesis via Reprogramming Metabolic Processes: Potential 
Drug Repurposing for Oral Cancer 
201. Fenoprofen -- an old drug rediscovered as a biased allosteric enhancer for melanocortin receptors 
202. Ferroquine, the next generation antimalarial drug, has antitumor activity 
203. Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy 
204. Finding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-
based systems biology approach 
205. Fishing Anti-Inflammatories from Known Drugs: In Silico Repurposing, Design, Synthesis and 
Biological Evaluation of Bisacodyl Analogues 
206. Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin 
polymerization 
207. Folate Receptor-Targeted Polymeric Micellar Nanocarriers for Delivery of Orlistat as a Repurposed 
Drug against Triple-Negative Breast Cancer 
208. FoxO3a Mediates the Inhibitory Effects of the Antiepileptic Drug Lamotrigine on Breast Cancer 
Growth 
209. From drug response profiling to target addiction scoring in cancer cell models 
210. From the era of genome analysis to the era of genomic drug discovery: a pioneering example of 
rheumatoid arthritis 
211. From the Viewpoint of Drug Metabolism Research 
212. FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model 
213. Future Directions of Genomics Research in Rheumatic Diseases 
214. Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular 
carcinoma 
215. Genetic Mechanisms of Asthma and the Implications for Drug Repositioning 
216. Genomic medicine: a decade of successes, challenges, and opportunities 
217. Glipizide suppresses prostate cancer progression in the TRAMP model by inhibiting angiogenesis 
218. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling 
219. Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality 
220. High-dose methotrexate with leucovorin rescue: For monumentally severe CNS inflammatory 
syndromes 
 




221. High-field MRS in clinical drug development 
222. High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitor 
223. High-throughput screening for the identification of new therapeutic options for metastatic 
pheochromocytoma and paraganglioma 
224. High-Throughput Screening forIdentification of Blood-Brain Barrier Integrity Enhancers: A Drug 
Repurposing Opportunity to Rectify Vascular Amyloid Toxicity 
225. HMG-CoA Reductase Inhibition Delays DNA Repair and Promotes Senescence After Tumor 
Irradiation 
226. How will insights from genetics translate to clinical practice in inflammatory bowel disease 
227. Human CCL3L1 copy number variation, gene expression, and the role of the CCL3L1-CCR5 axis in 
lung function 
228. Human enterovirus 71 protein interaction network prompts antiviral drug repositioning 
229. Hyaluronan-Derived Swelling of Solid Tumors, the Contribution of Collagen and Cancer Cells, and 
Implications for Cancer Therapy 
230. Ibuprofen and diclofenac treatments reduce proliferation of pancreatic acinar cells upon 
inflammatory injury and mitogenic stimulation 
231. Identification and validation of uterine stimulant methylergometrine as a potential inhibitor of 
caspase-1 activation 
232. Identification of a new pharmacological activity of the phenylpiperazine derivative naftopidil: 
tubulin-binding drug 
233. Identification of Chemical Inhibitors of beta-Catenin-Driven Liver Tumorigenesis in Zebrafish 
234. Identification of driver copy number alterations in diverse cancer types and application in drug 
repositioning 
235. Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung 
Cancer 
236. Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of 
sensitivity 
237. Identification of FDA-approved drugs that computationally bind to MDM2 
238. Identification of Iguratimod as an Inhibitor of Macrophage Migration Inhibitory Factor (MIF) with 
Steroid-sparing Potential 
 




239. Identification of key pathways and drug repurposing for anaplastic thyroid carcinoma by integrated 
bioinformatics analysis 
240. Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of 
action 
241. Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme 
242. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma 
243. Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction 
with Dbf4 by the Fragment Complementation and Drug Repositioning Approach 
244. Identification of repaglinide as a therapeutic drug for glioblastoma multiforme 
245. Identification of repurposed small molecule drugs for chordoma therapy 
246. Identification of small molecules enhancing autophagic function from drug network analysis 
247. Identification of Small-Molecule Inhibitors of Human Golgi Mannosidase via a Drug Repositioning 
Screen 
248. Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell 
agent using public gene expression data 
249. Identifying prognostic features by bottom-up approach and correlating to drug repositioning 
250. Immune Cell Metabolism in Tumor Microenvironment 
251. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design 
252. Immunomodulatory tetracyclines shape the intestinal inflammatory response inducing mucosal 
healing and resolution 
253. Improving contrast enhancement in magnetic resonance imaging using 5-aminolevulinic acid-
induced protoporphyrin IX for high-grade gliomas 
254. In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-
melanoma drug, for Parkinson's disease 
255. In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a 
Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug 
256. In silico prediction and in vitro and in vivo validation of acaricide fluazuron as a potential inhibitor 
of FGFR3 and a candidate anticancer drug for bladder carcinoma 
257. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities 
258. In vitro and in vivo study of hydralazine, a potential anti-angiogenic agent 
 




259. In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian 
cancer 
260. Individualized network-based drug repositioning infrastructure for precision oncology in the 
panomics era 
261. Inflammation-dependent cerebrospinal fluid hypersecretion by the choroid plexus epithelium in 
posthemorrhagic hydrocephalus 
262. Inflammatory pathway network-based drug repositioning and molecular phenomics 
263. Informed walks: whispering hints to gene hunters inside networks' jungle 
264. Inhaled mannitol in patients with cystic fibrosis: A randomised open-label dose response trial 
265. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma 
Therapy 
266. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate 
cancer invivo 
267. Inhibition of PI4K IIIalpha radiosensitizes in human tumor xenograft and immune-competent 
syngeneic murine tumor model 
268. Inhibition of Radiation and Temozolomide-Induced Invadopodia Activity in Glioma Cells Using 
FDA-Approved Drugs 
269. Inhibition of the insulin-like growth factor system is a potential therapy for rheumatoid arthritis 
270. Innovations in asthma therapy: is there a role for inhaled statins 
271. Insights from Second-Line Treatments for Idiopathic Dilated Cardiomyopathy 
272. Insights into respiratory disease through bioinformatics 
273. Integrated analysis of numerous heterogeneous gene expression profiles for detecting robust disease-
specific biomarkers and proposing drug targets 
274. Integrative clinical transcriptomics analyses for new therapeutic intervention strategies: a psoriasis 
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and biomarkers 
581. Tuberculosis: From an incurable scourge to a curable disease - journey over a millennium 
582. Tumor deconstruction as a tool for advanced drug screening and repositioning 
583. Tumor progression: the neuronal input 
584. Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer 
585. TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) 
Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin 
586. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities 
587. Use of attenuated paramyxoviruses for cancer therapy 
588. Use of minocycline in viral infections 
589. Use of monoclonal antibody-IRDye800CW bioconjugates in the resection of breast cancer 
590. Validating drug repurposing signals using electronic health records: a case study of metformin 
associated with reduced cancer mortality 
591. Valproic acid in the complex therapy of malignant tumors 
592. Vinorelbine rescue therapy for dogs with primary urinary bladder carcinoma 
593. Vitamin K and hepatocellular carcinoma: The basic and clinic 
594. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity 
and Metastasis 
595. What's new in dermatology 








FACTOR 11a. Biomarkers for Repurposed Drug-Enhanced Apoptosis of Cancer Cells 
1. A Blockade of IGF Signaling Sensitizes Human Ovarian Cancer Cells to the Anthelmintic 
Niclosamide-Induced Anti-Proliferative and Anticancer Activities 
2. A comparative study of disease genes and drug targets in the human protein interactome 
3. A convenient synthesis of lubeluzole and its enantiomer: evaluation as chemosensitizing agents on 
human ovarian adenocarcinoma and lung carcinoma cells 
4. A new niclosamide derivatives-B17 can inhibit urological cancers growth through apoptosis-related 
pathway 
5. A novel anti-cancer role of beta-apopicropodophyllin against non-small cell lung cancer cells 
6. A protein folding molecular imaging biosensor monitors the effects of drugs that restore mutant p53 
structure and its downstream function in glioblastoma cells 
7. A selective mitochondrial-targeted chlorambucil with remarkable cytotoxicity in breast and pancreatic 
cancers 
8. A Small-molecule Kinase Inhibitor, CEP-1347, Inhibits Survivin Expression and Sensitizes Ovarian 
Cancer Stem Cells to Paclitaxel 
9. Adjuvant potential of selegiline in attenuating organ dysfunction in septic rats with peritonitis 
10. Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft 
model 
11. Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T-cell 
leukemia cells 
12. Angiotensin II type 1 receptor blockers increase tolerance of cells to copper and cisplatin 
13. ANTENNA, a Multi-Rank, Multi-Layered Recommender System for Inferring Reliable Drug-Gene-
Disease Associations: Repurposing Diazoxide as a Targeted Anti-Cancer Therapy 
14. Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes 
differentiation of head and neck squamous cell carcinoma (HNSCC 
15. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis 
16. Antimalarial activity of novel 4-cyano-3-methylisoquinoline inhibitors against Plasmodium 
falciparum: design, synthesis and biological evaluation 
17. Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do 
18. Assessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer 
 




19. Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of 
interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma 
20. Bithionol inhibits ovarian cancer cell growth in vitro - studies on mechanism(s) of action 
21. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant 
mammary tissues of MMTV-erbB-2 transgenic mice 
22. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer 
23. Case-specific potentiation of glioblastoma drugs by pterostilbene 
24. Characterization of drug-induced transcriptional modules: towards drug repositioning and functional 
understanding 
25. Chloroquine upregulates TRAIL/TRAILR2 expression and potentiates doxorubicin anti-tumor 
activity in thioacetamide-induced hepatocellular carcinoma model 
26. Clustering based drug-drug interaction networks for possible repositioning of drugs against EGFR 
mutations: Clustering based DDI networks for EGFR mutations 
27. Clustering drug-drug interaction networks with energy model layouts: community analysis and drug 
repurposing 
28. Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive 
melanoma: a strategy for repurposing a phase I clinical trial drug 
29. Comparative oncology approach to drug repurposing in osteosarcoma 
30. Complex-disease networks of trait-associated single-nucleotide polymorphisms (SNPs) unveiled by 
information theory 
31. Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with 
Repurposing Potential 
32. Computational Prediction of Drug?Target Interactions Using Chemical, Biological, and Network 
Features 
33. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole 
34. Cyclic AMP efflux inhibitors as potential therapeutic agents for leukemia 
35. Data integration to prioritize drugs using genomics and curated data 
36. Delineation of biological and molecular mechanisms underlying the diverse anticancer activities of 
mycophenolic acid 
37. DenguePredict: An Integrated Drug Repositioning Approach towards Drug Discovery for Dengue 
 




38. Designing Dietary Recommendations Using System Level Interactomics Analysis and Network-
Based Inference 
39. Discovering drugs to overcome chemoresistance in ovarian cancers based on the cancer genome atlas 
tumor transcriptome profile 
40. Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues 
41. Discovery of rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer 
42. Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase 
(MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage 
43. Disulfiram/copper causes redox-related proteotoxicity and concomitant heat shock response in ovarian 
cancer cells that is augmented by auranofin-mediated thioredoxin inhibition 
44. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer 
45. Drug repositioning based on triangularly balanced structure for tissue-specific diseases in incomplete 
interactome 
46. Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer 
47. Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer 
48. Drug repositioning using disease associated biological processes and network analysis of drug targets 
49. Drug Repurposing by Simulating Flow Through Protein-Protein Interaction Networks 
50. Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) 
polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast 
cancer cells 
51. Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer 
associated fibroblasts (CAFs) by synergistic induction of apoptosis 
52. Drug repurposing: a better approach for infectious disease drug discovery 
53. Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian 
tumor cells 
54. Effects of digitoxin on cell migration in ovarian cancer inflammatory microenvironment 
55. Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination 
with erlotinib in pancreatic cancer cells 
56. eMatchSite: sequence order-independent structure alignments of ligand binding pockets in protein 
models 
57. Emerging roles of Myc in stem cell biology and novel tumor therapies 
 




58. Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells 
59. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute 
lymphoblastic leukemia 
60. Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats 
61. Exploring the anti-proliferative activity of Pelargonium sidoides DC with in silico target identification 
and network pharmacology 
62. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow 
Tumor Growth in Mice 
63. Expression Profiling Identifies Bezafibrate as Potential Therapeutic Drug for Lung Adenocarcinoma 
64. Folate Receptor-Targeted Polymeric Micellar Nanocarriers for Delivery of Orlistat as a Repurposed 
Drug against Triple-Negative Breast Cancer 
65. FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model 
66. Functional genomics of pain in analgesic drug development and therapy 
67. Functional Module Connectivity Map (FMCM): a framework for searching repurposed drug 
compounds for systems treatment of cancer and an application to colorectal adenocarcinoma 
68. Glutamate release inhibitor, Riluzole, inhibited proliferation of human hepatocellular carcinoma cells 
by elevated ROS production 
69. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling 
70. High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitor 
71. Human disease-drug network based on genomic expression profiles 
72. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia 
73. Ibuprofen and diclofenac treatments reduce proliferation of pancreatic acinar cells upon inflammatory 
injury and mitogenic stimulation 
74. Identification of a new pharmacological activity of the phenylpiperazine derivative naftopidil: tubulin-
binding drug 
75. Identification of an old antibiotic clofoctol as a novel activator of unfolded protein response pathways 
and an inhibitor of prostate cancer 
76. Identification of FDA-approved drugs as novel allosteric inhibitors of human executioner caspases 
77. Identification of novel small-molecule inhibitors targeting menin-MLL interaction, repurposing the 
antidiarrheal loperamide 
 




78. Identification of repaglinide as a therapeutic drug for glioblastoma multiforme 
79. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a 
drug repurposing screen 
80. Identification of thiazolo[5,4-d]pyrimidine derivatives as potent antiproliferative agents through the 
drug repurposing strategy 
81. Identifying candidate agents for lung adenocarcinoma by walking the human interactome 
82. Imidazole Antifungal Drugs Inhibit the Cell Proliferation and Invasion of Human Breast Cancer Cells 
83. In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a 
Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug 
84. In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian 
cancer 
85. Integrating systems biology sources illuminates drug action 
86. Interaction and localization diversities of global and local hubs in human protein-protein interaction 
networks 
87. Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, 
lapatinib-derived lead compound for trypanosomiasis 
88. Kinome Profiling Identifies Druggable Targets for Novel Human Cytomegalovirus (HCMV) 
Antivirals 
89. Licofelone Enhances the Efficacy of Paclitaxel in Ovarian Cancer by Reversing Drug Resistance and 
Tumor Stem-like Properties 
90. Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of 
Opportunity for Ovarian Cancer Chemoprevention 
91. Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by 
artesunate 
92. Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase 
Inhibition for Peritoneal Carcinomatosis 
93. Memantine induces apoptosis and inhibits cell cycle progression in LNCaP prostate cancer cells 
94. Metformin and epithelial ovarian cancer therapeutics 
95. Metformin repositioning as antitumoral agent: selective antiproliferative effects in human 
glioblastoma stem cells, via inhibition of CLIC1-mediated ion current 
 




96. Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and 
Ovarian Carcinoma in Mouse Models 
97. Molecular mimicry-based repositioning of nutlin-3 to anti-apoptotic Bcl-2 family proteins 
98. Mucuna pruriens (L.) DC chemo sensitize human breast cancer cells via downregulation of prolactin-
mediated JAK2/STAT5A signaling 
99. Multiple effects of digoxin on subsets of cancer-associated genes through the alternative splicing 
pathway 
100. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces 
endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo 
101. Network approaches to drug discovery 
102. Network insights into the genes regulated by hepatocyte nuclear factor 4 in response to drug induced 
perturbations: a review 
103. Network-based machine learning and graph theory algorithms for precision oncology 
104. New derivatives of the antimalarial drug Pyrimethamine in the control of melanoma tumor growth: 
an in vitro and in vivo study 
105. Niclosamide and its analogs are potent inhibitors of Wnt/beta-catenin, mTOR and STAT3 signaling 
in ovarian cancer 
106. Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal 
Cell Cancer Cells 
107. Niclosamide Induces Epiboly Delay During Early Zebrafish Embryogenesis 
108. Novel strategies of ovarian cancer treatment 
109. Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and 
redox capacity 
110. Olanzapine, an Atypical Antipsychotic, Inhibits Survivin Expression and Sensitizes Cancer Cells to 
Chemotherapeutic Agents 
111. Old drug, new trick: repurposing metformin for gynecologic cancers 
112. Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc 
adenomas are downregulated in response to tumor suppression by Clotam 
113. Ormeloxifene efficiently inhibits ovarian cancer growth 
114. P-gp Inhibition by the Anti-psychotic Drug Pimozide Increases Apoptosis, as well as Expression of 
pRb and pH2AX in Highly Drug-resistant KBV20C Cells 
 




115. Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia 
Patients 
116. PATIENT-SPECIFIC DATA FUSION FOR CANCER STRATIFICATION AND 
PERSONALISED TREATMENT 
117. PEGylated chitosan nanoparticles potentiate repurposing of ormeloxifene in breast cancer therapy 
118. Phosphorylation of Single Stranded RNA Virus Proteins and Potential for Novel Therapeutic 
Strategies 
119. Piperazine-based Alpha-1 AR Blocker, Naftopidil, Selectively Suppresses Malignant Human 
Bladder Cells via Induction of Apoptosis 
120. Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas 
121. Predicting drug-target interactions using probabilistic matrix factorization 
122. Predicting Drug-Target Interactions With Multi-Information Fusion 
123. Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity 
in thyroid cancer cells: opportunities for repurposing 
124. Rationale for an experimental treatment of retinitis pigmentosa: 140-month test of hypothesis with 
one patient 
125. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints 
126. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide 
targeting de novo DNA synthesis, irrespective of molecular subtype 
127. Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of 
cytochrome c oxidase bearing the COX4-1 regulatory subunit 
128. Repositioning of anti-viral drugs as therapy for cervical cancer 
129. Repurposing itraconazole for the treatment of cancer 
130. Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: a crucial 
role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation 
131. Repurposing of phentolamine as a potential anticancer agent against human castration-resistant 
prostate cancer: A central role on microtubule stabilization and mitochondrial apoptosis pathway 
132. Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic 
pontine glioma 
133. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell 
carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis 
 




134. Retinal Neuroprotective Effects of Flibanserin, an FDA-Approved Dual Serotonin Receptor Agonist-
Antagonist 
135. Revisiting old drugs as novel agents for retinoblastoma: in vitro and in vivo antitumor activity of 
cardenolides 
136. Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian 
cancer cells 
137. Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT 
Pathways 
138. Selective human inhibitors of ATR and ATM render Leishmania major promastigotes sensitive to 
oxidative damage 
139. Structural re-positioning, in silico molecular modelling, oxidative degradation, and biological 
screening of linagliptin as adenosine 3 receptor (ADORA3) modulators targeting hepatocellular 
carcinoma 
140. Sulforaphane Prevents Neuronal Apoptosis and Memory Impairment in Diabetic Rats 
141. Systematic discovery of drug action mechanisms by an integrated chemical genomics approach: 
identification of functional disparities between azacytidine and decitabine 
142. Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian 
Cancer 
143. Systems Biology-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap 
Insertional Mutagenesis 
144. Targeting cyclin D3/CDK6 activity for treatment of Parkinson's disease 
145. Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from 
nature and drug repurposing 
146. The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma 
Cells by Targeting Multiple Signal Pathways 
147. The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-
associated fibroblasts 
148. The anti-hypertensive drug prazosin inhibits glioblastoma growth via the PKCdelta-dependent 
inhibition of the AKT pathway 
149. The Antiarrhythmic Drug, Amiodarone, Decreases AKT Activity and Sensitizes Human Acute 
Myeloid Leukemia Cells to Apoptosis by ABT-263 
150. The aryl hydrocarbon receptor is required for induction of p21cip1/waf1 expression and growth 
inhibition by SU5416 in hepatoma cells 
 




151. The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell 
carcinoma 
152. The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate 
cancer 
153. The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in 
hepatocellular carcinoma 
154. The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo 
155. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines 
and discovery of potential new DDK inhibitor scaffolds 
156. The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory 
NRASQ61K melanoma 
157. Therapeutic Effect of Quinacrine, an Antiprotozoan Drug, by Selective Suppression of p-CHK1/2 in 
p53-Negative Malignant Cancers 
158. Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial 
agent 
159. Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from 
pathophysiology to treatment 
160. Transcriptomic changes induced by mycophenolic acid in gastric cancer cells 
161. Transcriptomic characterization of the novel avian-origin influenza A (H7N9) virus: specific host 
response and responses intermediate between avian (H5N1 and H7N7) and human (H3N2) viruses and 
implications for treatment options 
162. Transforming Cancer Prevention through Precision Medicine and Immune-oncology 
163. Trypanocidal Effect of Isotretinoin through the Inhibition of Polyamine and Amino Acid 
Transporters in Trypanosoma cruzi 
164. Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer 
165. Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic 
166. Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent 
drug candidates for cancer treatment 
167. Valproic acid in the complex therapy of malignant tumors 
168. Valproic Acid Promotes Apoptosis and Cisplatin Sensitivity Through Downregulation of H19 
Noncoding RNA in Ovarian A2780 Cells 
 











FACTOR 11b. Repurposed Drugs for Oxidative Stress Reduction 
1. 4-Acetoxyphenol Prevents RPE Oxidative Stress-Induced Necrosis by Functioning as an NRF2 
Stabilizer 
2. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival 
paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of 
Glioblastoma Care 
3. A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia 
4. A Topical Zinc Ionophore Blocks Tumorigenic Progression in UV-exposed SKH-1 High-risk Mouse 
Skin 
5. Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease 
6. Activity of imidazole compounds on Leishmania (L.) infantum chagasi: reactive oxygen species 
induced by econazole 
7. Acute oxidant damage promoted on cancer cells by amitriptyline in comparison with some common 
chemotherapeutic drugs 
8. Adjuvant potential of selegiline in attenuating organ dysfunction in septic rats with peritonitis 
9. Albendazole as a promising molecule for tumor control 
10. Angiotensin II type 1 receptor blockers increase tolerance of cells to copper and cisplatin 
11. Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via 
oxidative stress-mediated mTOR inhibition 
12. Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial 
pathogens 
13. Antibiotic drug levofloxacin inhibits proliferation and induces apoptosis of lung cancer cells through 
inducing mitochondrial dysfunction and oxidative damage 
14. Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein 
phosphatase 2A in non-small cell lung cancer cells 
15. Artemisinin analogues as potent inhibitors of in vitro hepatitis C virus replication 
16. Atorvastatin as a promising anticryptococcal agent 
17. Auranofin and its Analogues Show Potent Antimicrobial Activity Covering Multiresistant Pathogens: 
Structure-Activity Relationships 
18. Auranofin inactivates Trichomonas vaginalis thioredoxin reductase and is effective against 
trichomonads in vitro and in vivo 
 




19. Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and 
displayed synergistic lethality with piperlongumine in gastric cancer 
20. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical 
activity against chronic lymphocytic leukemia 
21. Auranofin is highly efficacious against Toxoplasma gondii in vitro and in an in vivo experimental 
model of acute toxoplasmosis 
22. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell 
lung cancer cells 
23. Auranofin: repurposing an old drug for a golden new age 
24. Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the 
proliferative expansion of stem-like cancer cells (CSCs 
25. beta-Caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and 
metabolic dysregulation in mice 
26. Beyond multiple mechanisms and a unique drug: Defective autophagy as pivotal player in cerebral 
cavernous malformation pathogenesis and implications for targeted therapies 
27. Bithionol inhibits ovarian cancer cell growth in vitro - studies on mechanism(s) of action 
28. Case-specific potentiation of glioblastoma drugs by pterostilbene 
29. Cell-based screening identifies paroxetine as an inhibitor of diabetic endothelial dysfunction 
30. Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease 
31. Comparative oncology approach to drug repurposing in osteosarcoma 
32. Computational repositioning and experimental validation of approved drugs for HIF-prolyl 
hydroxylase inhibition 
33. Copper Complexes in Cancer Therapy 
34. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease 
35. Deciphering cellular biological processes to clinical application: a new perspective for Talpha1 
treatment targeting multiple diseases 
36. Developmental toxicity of auranofin in zebrafish embryos 
37. Discovery of the neuroprotective effects of alvespimycin by computational prioritization of potential 
anti-Parkinson agents 
38. Disulfiram/copper causes redox-related proteotoxicity and concomitant heat shock response in ovarian 
cancer cells that is augmented by auranofin-mediated thioredoxin inhibition 
 




39. Doxycycline is an NF-kappaB inhibitor that induces apoptotic cell death in malignant T-cells 
40. Drug delivery for the treatment of endometriosis and uterine fibroids 
41. Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe 
staphylococcal infections 
42. Drug Repurposing for Duchenne Muscular Dystrophy: The Monoamine Oxidase B Inhibitor 
Safinamide Ameliorates the Pathological Phenotype in mdx Mice and in Myogenic Cultures From DMD 
Patients 
43. Drug repurposing for gastrointestinal stromal tumor 
44. Drug repurposing for Leishmania. Molecular basis of the leishmanicidal activity of the antidepressant 
sertraline 
45. Drug Repurposing of the Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia 
46. Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine 
uptake through system Xc-, leading to glutathione depletion 
47. Drug-Repositioning Screening for Keap1-Nrf2 Binding Inhibitors using Fluorescence Correlation 
Spectroscopy 
48. Drug-Repositioning Screens Identify Triamterene as a Selective Drug for the Treatment of DNA 
Mismatch Repair Deficient Cells 
49. Evaluating New Compounds to Treat Burkholderia pseudomallei Infections 
50. Fibrosis in systemic sclerosis: common and unique pathobiology 
51. From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy 
52. From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" 
Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators 
53. Glutamate release inhibitor, Riluzole, inhibited proliferation of human hepatocellular carcinoma cells 
by elevated ROS production 
54. Histamine-2 receptor antagonist famotidine modulates cardiac stem cell characteristics in 
hypertensive heart disease 
55. Identification of Non-Electrophilic Nrf2 Activators from Approved Drugs 
56. Identifying and Tackling Emergent Vulnerability in Drug-Resistant Mycobacteria 
57. Imidazolium salts as innovative agents against Leishmania amazonensis 
58. In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma 
 




59. In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against 
multiple life stages of Schistosoma mansoni 
60. In vitro and in vivo antischistosomal activity of ferroquine derivatives 
61. In vitro leishmanicidal effects of the anti-fungal drug natamycin are mediated through disruption of 
calcium homeostasis and mitochondrial dysfunction 
62. Inhibition of Peroxidase Activity of Cytochrome c: De Novo Compound Discovery and Validation 
63. Lethal action of the nitrothiazolyl-salicylamide derivative nitazoxanide via induction of oxidative 
stress in Leishmania (L.) infantum 
64. Mitigation of carbon tetrachloride-induced hepatic injury by methylene blue, a repurposed drug, is 
mediated by dual inhibition of GSK3beta downstream of PKA 
65. Mitochondria-targeted metformins: anti-tumour and redox signalling mechanisms 
66. Mode of Action of Clofazimine and Combination Therapy with Benzothiazinones against 
Mycobacterium tuberculosis 
67. Modified Metformin as a More Potent Anticancer Drug: Mitochondrial Inhibition, Redox Signaling, 
Antiproliferative Effects and Future EPR Studies 
68. Mood, stress and longevity: convergence on ANK3 
69. Niclosamide enhances ROS-mediated cell death through c-Jun activation 
70. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-
induced ferroptosis 
71. Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the 
early phase after heart transplantation in rats 
72. Oxidative stress during acetaminophen hepatotoxicity: Sources, pathophysiological role and 
therapeutic potential 
73. Pharmacological approach for drug repositioning against cardiorenal diseases 
74. Pharmacological exploitation of the phenothiazine antipsychotics to develop novel antitumor agents-A 
drug repurposing strategy 
75. Pharmacology and Clinical Drug Candidates in Redox Medicine 
76. Phase I Clinical Trial Results of Auranofin, a Novel Antiparasitic Agent 
77. Platelet Hyperreactivity in Diabetes: Focus on GPVI Signaling-Are Useful Drugs Already Available 
78. Posttranslational Regulation of O(6)-Methylguanine-DNA Methyltransferase (MGMT) and New 
Opportunities for Treatment of Brain Cancers 
 




79. Potential repositioning of exemestane as a neuroprotective agent for Parkinson's disease 
80. Propofol post-conditioning alleviates hepatic ischaemia reperfusion injury via BRG1-mediated 
Nrf2/HO-1 transcriptional activation in human and mice 
81. Rationale for an experimental treatment of retinitis pigmentosa: 140-month test of hypothesis with 
one patient 
82. Reactions of model proteins with aurothiomalate, a clinically established gold(I) drug: The 
comparison with auranofin 
83. Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its 
Anticancer Activity 
84. Repurposing an orally available drug for the treatment of geographic atrophy 
85. Repurposing Approach Identifies Auranofin with Broad Spectrum Antifungal Activity That Targets 
Mia40-Erv1 Pathway 
86. Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem 
cells 
87. Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis 
88. Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important 
fungi 
89. Repurposing auranofin for the treatment of cutaneous staphylococcal infections 
90. Repurposing cephalosporin antibiotics as pro-senescent radiosensitizers 
91. Repurposing of Aspirin and Ibuprofen as Candidate Anti-Cryptococcus Drugs 
92. Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in 
Parkinson's Disease 
93. Retinal Neuroprotective Effects of Flibanserin, an FDA-Approved Dual Serotonin Receptor Agonist-
Antagonist 
94. Screening a Commercial Library of Pharmacologically Active Small Molecules against 
Staphylococcus aureus Biofilms 
95. Selective human inhibitors of ATR and ATM render Leishmania major promastigotes sensitive to 
oxidative damage 
96. Synergic in vitro combinations of artemisinin, pyrimethamine and methylene blue against Neospora 
caninum 
 




97. T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's 
Disease 
98. Tacrine-deferiprone hybrids as multi-target-directed metal chelators against Alzheimer's disease: a 
two-in-one drug 
99. Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt/mTOR and inducing 
oxidative stress 
100. The antifungal compound butenafine eliminates promastigote and amastigote forms of Leishmania 
(Leishmania) amazonensis and Leishmania (Viannia) braziliensis 
101. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal 
melanoma in vitro and in vivo 
102. The heterogeneity of cancer stem-like cells at the invasive front 
103. The Oral Antimalarial Drug Tafenoquine Shows Activity against Trypanosoma brucei 
104. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute 
lymphoblastic leukemia and synergistically works with dasatinib 
105. The polysialic acid mimetics idarubicin and irinotecan stimulate neuronal survival and neurite 
outgrowth and signal via protein kinase C 
106. The possible repositioning of an oral anti-arthritic drug, auranofin, for Nrf2-activating therapy: The 
demonstration of Nrf2-dependent anti-oxidative action using a zebrafish model 
107. Tigecycline targets nonsmall cell lung cancer through inhibition of mitochondrial function 
108. Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine 
Approach 
109. TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) 
Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin 
110. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities 
111. Viability Screen of LOPAC1280 Reveals Phosphorylation Inhibitor Auranofin as a Potent Inhibitor 








FACTOR 12. Repurposed Drugs that Increase or Decrease ROS for Different Applications 
1. 4-Acetoxyphenol Prevents RPE Oxidative Stress-Induced Necrosis by Functioning as an NRF2 
Stabilizer 
2. A Blockade of IGF Signaling Sensitizes Human Ovarian Cancer Cells to the Anthelmintic 
Niclosamide-Induced Anti-Proliferative and Anticancer Activities 
3. A cellular genetics approach identifies gene-drug interactions and pinpoints drug toxicity pathway 
nodes 
4. A chemical-genetic interaction map of small molecules using high-throughput imaging in cancer cells 
5. A Combination of Three Repurposed Drugs Administered at Reperfusion as a Promising Therapy for 
Postischemic Brain Injury 
6. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival 
paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of 
Glioblastoma Care 
7. A cross-species analysis method to analyze animal models' similarity to human's disease state 
8. A current perspective on the oncopreventive and oncolytic properties of selective serotonin reuptake 
inhibitors 
9. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer 
and other neuroendocrine tumors 
10. A drug-repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6-
thioguanine as an effective therapeutic agent for TPMT-low cancer cells 
11. A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase 
Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy 
12. A network based approach to drug repositioning identifies plausible candidates for breast cancer and 
prostate cancer 
13. A new niclosamide derivatives-B17 can inhibit urological cancers growth through apoptosis-related 
pathway 
14. A novel anti-cancer role of beta-apopicropodophyllin against non-small cell lung cancer cells 
15. A novel application of furazolidone: anti-leukemic activity in acute myeloid leukemia 
16. A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram 
17. A Novel High Content Imaging-Based Screen Identifies the Anti-Helminthic Niclosamide as an 
Inhibitor of Lysosome Anterograde Trafficking and Prostate Cancer Cell Invasion 
 




18. A protein folding molecular imaging biosensor monitors the effects of drugs that restore mutant p53 
structure and its downstream function in glioblastoma cells 
19. A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia 
20. A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by 
Combining a Spontaneously Emulsifying Component with a Polymer Carrier 
21. A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection 
22. A selective mitochondrial-targeted chlorambucil with remarkable cytotoxicity in breast and pancreatic 
cancers 
23. A Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and 
Repositioning Predictions 
24. A signalome screening approach in the autoinflammatory disease TNF receptor associated periodic 
syndrome (TRAPS) highlights the anti-inflammatory properties of drugs for repurposing 
25. A Small-molecule Kinase Inhibitor, CEP-1347, Inhibits Survivin Expression and Sensitizes Ovarian 
Cancer Stem Cells to Paclitaxel 
26. A structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 
ATPase 
27. A systems pharmacology-oriented discovery of a new therapeutic use of the TCM formula 
Liuweiwuling for liver failure 
28. A Topical Zinc Ionophore Blocks Tumorigenic Progression in UV-exposed SKH-1 High-risk Mouse 
Skin 
29. Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease 
30. Activity of imidazole compounds on Leishmania (L.) infantum chagasi: reactive oxygen species 
induced by econazole 
31. Acute oxidant damage promoted on cancer cells by amitriptyline in comparison with some common 
chemotherapeutic drugs 
32. Adaptive mitochondrial reprogramming and resistance to PI3K therapy 
33. Adjuvant potential of selegiline in attenuating organ dysfunction in septic rats with peritonitis 
34. Aging-related Repositioned Drugs, Donepezil and Sildenafil Citrate, Increase Apoptosis of Anti-
mitotic Drug-resistant KBV20C Cells Through Different Molecular Mechanisms 
35. Albendazole as a promising molecule for tumor control 
 




36. Alendronate inhalation ameliorates elastase-induced pulmonary emphysema in mice by induction of 
apoptosis of alveolar macrophages 
37. Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T-cell 
leukemia cells 
38. Angiotensin II type 1 receptor blockers increase tolerance of cells to copper and cisplatin 
39. Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via 
oxidative stress-mediated mTOR inhibition 
40. Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes 
differentiation of head and neck squamous cell carcinoma (HNSCC 
41. Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched 
for stem cell-like properties 
42. Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial 
pathogens 
43. Antibiotic drug levofloxacin inhibits proliferation and induces apoptosis of lung cancer cells through 
inducing mitochondrial dysfunction and oxidative damage 
44. Antibiotic drug rifabutin is effective against lung cancer cells by targeting the eIF4E-beta-catenin axis 
45. Anticancer Properties of Fenofibrate: A Repurposing Use 
46. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis 
47. Antifungal application of nonantifungal drugs 
48. Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein 
phosphatase 2A in non-small cell lung cancer cells 
49. Antimalarial activity of novel 4-cyano-3-methylisoquinoline inhibitors against Plasmodium 
falciparum: design, synthesis and biological evaluation 
50. Antimalarial drug mefloquine inhibits nuclear factor kappa B signaling and induces apoptosis in 
colorectal cancer cells 
51. Antiviral Drug Ribavirin Targets Thyroid Cancer Cells by Inhibiting the eIF4E-beta-Catenin Axis 
52. Appraisal of mechanisms of radioprotection and therapeutic approaches of radiation countermeasures 
53. Artemisinin analogues as potent inhibitors of in vitro hepatitis C virus replication 
54. Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do 
55. Assessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer 
 




56. Atorvastatin as a promising anticryptococcal agent 
57. Auranofin and its Analogues Show Potent Antimicrobial Activity Covering Multiresistant Pathogens: 
Structure-Activity Relationships 
58. Auranofin inactivates Trichomonas vaginalis thioredoxin reductase and is effective against 
trichomonads in vitro and in vivo 
59. Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and 
displayed synergistic lethality with piperlongumine in gastric cancer 
60. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical 
activity against chronic lymphocytic leukemia 
61. Auranofin is highly efficacious against Toxoplasma gondii in vitro and in an in vivo experimental 
model of acute toxoplasmosis 
62. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell 
lung cancer cells 
63. Auranofin: repurposing an old drug for a golden new age 
64. Autophagy in HIV-induced T cell death 
65. Autophagy Induced by Naftopidil Inhibits Apoptosis of Human Gastric Cancer Cells 
66. Bacoside A Induces Tumor Cell Death in Human Glioblastoma Cell Lines through Catastrophic 
Macropinocytosis 
67. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy 
68. Bedaquiline Inhibits the ATP Synthase in Mycobacterium abscessus and Is Effective in Infected 
Zebrafish 
69. Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the 
proliferative expansion of stem-like cancer cells (CSCs 
70. Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2 
71. beta-Caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and 
metabolic dysregulation in mice 
72. Beyond multiple mechanisms and a unique drug: Defective autophagy as pivotal player in cerebral 
cavernous malformation pathogenesis and implications for targeted therapies 
73. Biocomputational resources useful for drug discovery against compartmentalized targets 
74. Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of 
interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma 
 




75. Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer 
resistance to EGFR therapy 
76. Biotin-targeted Pluronic() P123/F127 mixed micelles delivering niclosamide: A repositioning strategy 
to treat drug-resistant lung cancer cells 
77. Bithionol inhibits ovarian cancer cell growth in vitro - studies on mechanism(s) of action 
78. BRCA-Monet: a breast cancer specific drug treatment mode-of-action network for treatment effective 
prediction using large scale microarray database 
79. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant 
mammary tissues of MMTV-erbB-2 transgenic mice 
80. Can an FDA-Approved Alzheimer's Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika 
Virus 
81. Cancer Drug Response Profile scan (CDRscan): A Deep Learning Model That Predicts Drug 
Effectiveness from Cancer Genomic Signature 
82. Cancer: fundamentals behind pH targeting and the double-edged approach 
83. CancerHSP: anticancer herbs database of systems pharmacology 
84. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer 
85. Carglumic acid promotes apoptosis and suppresses cancer cell proliferation in vitro and in vivo 
86. Case-specific potentiation of glioblastoma drugs by pterostilbene 
87. CaV channels and cancer: canonical functions indicate benefits of repurposed drugs as cancer 
therapeutics 
88. Cell line modeling for systems medicine in cancers (review 
89. Cell-based screening identifies paroxetine as an inhibitor of diabetic endothelial dysfunction 
90. Characterization of drug-induced transcriptional modules: towards drug repositioning and functional 
understanding 
91. Chk1 as a new therapeutic target in triple-negative breast cancer 
92. Chloroquine upregulates TRAIL/TRAILR2 expression and potentiates doxorubicin anti-tumor 
activity in thioacetamide-induced hepatocellular carcinoma model 
93. CK2 inhibition confers functional protection to young and aging axons against ischemia by 
differentially regulating the CDK5 and AKT signaling pathways 
94. CLC-Pred: A freely available web-service for in silico prediction of human cell line cytotoxicity for 
drug-like compounds 
 




95. Clomipramine kills Trypanosoma brucei by apoptosis 
96. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover 
Potentially Targetable Cancer Cell Dependencies 
97. Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease 
98. Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive 
melanoma: a strategy for repurposing a phase I clinical trial drug 
99. Combined Analysis of Phenotypic and Target-Based Screening in Assay Networks 
100. Comparative oncology approach to drug repurposing in osteosarcoma 
101. Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake 
in Lung Cancer 
102. Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with 
Repurposing Potential 
103. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That 
Reduces Growth of Hepatocellular Carcinoma Cells InVitro and in Mice by Inhibiting Cell Division 
Cycle 37 Signaling 
104. Computational identification of multi-omic correlates of anticancer therapeutic response 
105. Computational methods and opportunities for phosphorylation network medicine 
106. Computational repositioning and experimental validation of approved drugs for HIF-prolyl 
hydroxylase inhibition 
107. Computational repositioning and preclinical validation of pentamidine for renal cell cancer 
108. Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in 
cystic fibrosis 
109. Cooperative recognition of T:T mismatch by echinomycin causes structural distortions in DNA 
duplex 
110. Copper Complexes in Cancer Therapy 
111. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease 
112. Cyclic AMP efflux inhibitors as potential therapeutic agents for leukemia 
113. Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in 
ER+ breast cancer 
114. Deciphering cellular biological processes to clinical application: a new perspective for Talpha1 
treatment targeting multiple diseases 
 




115. Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug 
Repurposing Using Transcriptomic Data 
116. Delineation of biological and molecular mechanisms underlying the diverse anticancer activities of 
mycophenolic acid 
117. DenguePredict: An Integrated Drug Repositioning Approach towards Drug Discovery for Dengue 
118. DeSigN: connecting gene expression with therapeutics for drug repurposing and development 
119. Designing drugs that combat kidney damage 
120. Development of a stretch-induced neurotrauma model for medium-throughput screening in vitro: 
identification of rifampicin as a neuroprotectant 
121. Developmental toxicity of auranofin in zebrafish embryos 
122. Dexpramipexole improves bioenergetics and outcome in experimental stroke 
123. Discovery of alkyl bis(oxy)dibenzimidamide derivatives as novel protein arginine methyltransferase 
1 (PRMT1) inhibitors 
124. Discovery of drug mode of action and drug repositioning from transcriptional responses 
125. Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues 
126. Discovery of rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer 
127. Discovery of the neuroprotective effects of alvespimycin by computational prioritization of potential 
anti-Parkinson agents 
128. Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase 
(MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage 
129. Disulfiram's Anticancer Activity: Evidence and Mechanisms 
130. Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma 
and over-rides resistance to temozolomide 
131. Disulfiram/copper causes redox-related proteotoxicity and concomitant heat shock response in 
ovarian cancer cells that is augmented by auranofin-mediated thioredoxin inhibition 
132. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon 
cancer 
133. Doxycycline inhibits proliferation and induces apoptosis of both human papillomavirus positive and 
negative cervical cancer cell lines 
134. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in 
breast cancer 
 




135. Doxycycline is an NF-kappaB inhibitor that induces apoptotic cell death in malignant T-cells 
136. Doxycycline or how to create new with the old 
137. Drug delivery for the treatment of endometriosis and uterine fibroids 
138. Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer 
cell lines and pathway mechanisms of resistance 
139. Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional 
Signatures 
140. Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer 
141. Drug Repositioning in Glioblastoma: A Pathway Perspective 
142. Drug repositioning: a machine-learning approach through data integration 
143. Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe 
staphylococcal infections 
144. Drug Repurposing Approach Identifies a Synergistic Drug Combination of an Antifungal Agent and 
an Experimental Organometallic Drug for Melanoma Treatment 
145. Drug Repurposing for Duchenne Muscular Dystrophy: The Monoamine Oxidase B Inhibitor 
Safinamide Ameliorates the Pathological Phenotype in mdx Mice and in Myogenic Cultures From DMD 
Patients 
146. Drug repurposing for gastrointestinal stromal tumor 
147. Drug repurposing for Leishmania. Molecular basis of the leishmanicidal activity of the 
antidepressant sertraline 
148. Drug repurposing in cancer 
149. Drug repurposing of quinine as antiviral against dengue virus infection 
150. Drug Repurposing of the Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia 
151. Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) 
polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast 
cancer cells 
152. Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer 
associated fibroblasts (CAFs) by synergistic induction of apoptosis 
153. Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine 
uptake through system Xc-, leading to glutathione depletion 
 




154. Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian 
tumor cells 
155. Drug-Repositioning Screening for Keap1-Nrf2 Binding Inhibitors using Fluorescence Correlation 
Spectroscopy 
156. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent 
activity against breast cancer 
157. Drug-Repositioning Screens Identify Triamterene as a Selective Drug for the Treatment of DNA 
Mismatch Repair Deficient Cells 
158. Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed Drugs Elicits 
Cell-Lethal Autophagy and Therapeutic Benefit 
159. Effects of digitoxin on cell migration in ovarian cancer inflammatory microenvironment 
160. Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination 
with erlotinib in pancreatic cancer cells 
161. Elucidating the modes of action for bioactive compounds in a cell-specific manner by large-scale 
chemically-induced transcriptomics 
162. Emerging roles of Myc in stem cell biology and novel tumor therapies 
163. Eritoran Suppresses Colon Cancer by Altering a Functional Balance in Toll-like Receptors That 
Bind Lipopolysaccharide 
164. Erythropoietin, a novel repurposed drug: an innovative treatment for wound healing in patients with 
diabetes mellitus 
165. Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer 
166. Evaluating New Compounds to Treat Burkholderia pseudomallei Infections 
167. Evaluation of Crimean-Congo hemorrhagic fever virus in vitro inhibition by chloroquine and 
chlorpromazine, two FDA approved molecules 
168. Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells 
169. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute 
lymphoblastic leukemia 
170. Ex vivo drug sensitivity testing as a means for drug repurposing in esophageal adenocarcinoma 
171. Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats 
172. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow 
Tumor Growth in Mice 
 




173. Expression Profiling Identifies Bezafibrate as Potential Therapeutic Drug for Lung Adenocarcinoma 
174. Fenofibrate Suppresses Oral Tumorigenesis via Reprogramming Metabolic Processes: Potential 
Drug Repurposing for Oral Cancer 
175. Ferroquine, the next generation antimalarial drug, has antitumor activity 
176. Fibrosis in systemic sclerosis: common and unique pathobiology 
177. Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice 
with FLT3/ITD leukemia 
178. Folate Receptor-Targeted Polymeric Micellar Nanocarriers for Delivery of Orlistat as a Repurposed 
Drug against Triple-Negative Breast Cancer 
179. Four clinically utilized drugs were identified and validated for treatment of adrenocortical cancer 
using quantitative high-throughput screening 
180. From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy 
181. From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" 
Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators 
182. FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model 
183. Functional genetics-directed identification of novel pharmacological inhibitors of FAS- and TNF-
dependent apoptosis that protect mice from acute liver failure 
184. GDA, a web-based tool for Genomics and Drugs integrated analysis 
185. Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular 
carcinoma 
186. Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivity 
187. Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA 
Metabolic Pathway Regulated by DCPS 
188. Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma 
189. Glutamate release inhibitor, Riluzole, inhibited proliferation of human hepatocellular carcinoma cells 
by elevated ROS production 
190. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling 
191. Harnessing the biological complexity of Big Data from LINCS gene expression signatures 
192. Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells 
193. High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitor 
 




194. High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-
ALL 
195. High-throughput screening for daunorubicin-mediated drug resistance identifies mometasone furoate 
as a novel ABCB1-reversal agent 
196. High-throughput screening for the identification of new therapeutic options for metastatic 
pheochromocytoma and paraganglioma 
197. High-throughput screening of FDA-approved drugs using oxygen biosensor plates reveals secondary 
mitofunctional effects 
198. Highly Halaven-resistant KBV20C Cancer Cells Can Be Sensitized by Co-treatment with 
Fluphenazine 
199. Histamine-2 receptor antagonist famotidine modulates cardiac stem cell characteristics in 
hypertensive heart disease 
200. HMG-CoA Reductase Inhibition Delays DNA Repair and Promotes Senescence After Tumor 
Irradiation 
201. Human disease-drug network based on genomic expression profiles 
202. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia 
203. Ibuprofen and diclofenac treatments reduce proliferation of pancreatic acinar cells upon 
inflammatory injury and mitogenic stimulation 
204. Identification of a new pharmacological activity of the phenylpiperazine derivative naftopidil: 
tubulin-binding drug 
205. Identification of an old antibiotic clofoctol as a novel activator of unfolded protein response 
pathways and an inhibitor of prostate cancer 
206. Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug 
207. Identification of driver copy number alterations in diverse cancer types and application in drug 
repositioning 
208. Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new 
potential strategy for identification of anti-cancer therapeutics in B-cell malignancies 
209. Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung 
Cancer 
210. Identification of FDA-approved drugs as novel allosteric inhibitors of human executioner caspases 
211. Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of 
sensitivity 
 




212. Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of 
action 
213. Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme 
214. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma 
215. Identification of Non-Electrophilic Nrf2 Activators from Approved Drugs 
216. Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction 
with Dbf4 by the Fragment Complementation and Drug Repositioning Approach 
217. Identification of novel small-molecule inhibitors targeting menin-MLL interaction, repurposing the 
antidiarrheal loperamide 
218. Identification of repaglinide as a therapeutic drug for glioblastoma multiforme 
219. Identification of repurposed small molecule drugs for chordoma therapy 
220. Identification of small molecules enhancing autophagic function from drug network analysis 
221. Identification of Small-Molecule Inhibitors of Human Golgi Mannosidase via a Drug Repositioning 
Screen 
222. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a 
drug repurposing screen 
223. Identification of thiazolo[5,4-d]pyrimidine derivatives as potent antiproliferative agents through the 
drug repurposing strategy 
224. Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell 
agent using public gene expression data 
225. Identifying and Tackling Emergent Vulnerability in Drug-Resistant Mycobacteria 
226. Identifying candidate agents for lung adenocarcinoma by walking the human interactome 
227. Imidazole Antifungal Drugs Inhibit the Cell Proliferation and Invasion of Human Breast Cancer 
Cells 
228. Imidazolium salts as innovative agents against Leishmania amazonensis 
229. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design 
230. Improved anticancer drug response prediction in cell lines using matrix factorization with similarity 
regularization 
231. In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma 
 




232. In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-
melanoma drug, for Parkinson's disease 
233. In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a 
Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug 
234. In silico identification of potent small molecule inhibitors targeting epidermal growth factor receptor 
1 
235. In silico prediction and in vitro and in vivo validation of acaricide fluazuron as a potential inhibitor 
of FGFR3 and a candidate anticancer drug for bladder carcinoma 
236. In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against 
multiple life stages of Schistosoma mansoni 
237. In vitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania 
amazonensis 
238. In vitro and in vivo antischistosomal activity of ferroquine derivatives 
239. In vitro leishmanicidal effects of the anti-fungal drug natamycin are mediated through disruption of 
calcium homeostasis and mitochondrial dysfunction 
240. In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian 
cancer 
241. Increasing procaspase 8 expression using repurposed drugs to induce HIV infected cell death in ex 
vivo patient cells 
242. Induction of DNA damage and apoptosis in human leukemia cells by efavirenz 
243. Inhibition of mTOR/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel 
in oral tongue squamous cell carcinoma 
244. Inhibition of Peroxidase Activity of Cytochrome c: De Novo Compound Discovery and Validation 
245. Inhibition of Radiation and Temozolomide-Induced Invadopodia Activity in Glioma Cells Using 
FDA-Approved Drugs 
246. Ketanserin, an antidepressant, exerts its antileishmanial action via inhibition of 3-hydroxy-3-
methylglutaryl coenzyme A reductase (HMGR) enzyme of Leishmania donovani 
247. Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, 
lapatinib-derived lead compound for trypanosomiasis 
248. Kinome Profiling Identifies Druggable Targets for Novel Human Cytomegalovirus (HCMV) 
Antivirals 
 




249. Lethal action of the nitrothiazolyl-salicylamide derivative nitazoxanide via induction of oxidative 
stress in Leishmania (L.) infantum 
250. Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells 
251. Licofelone Enhances the Efficacy of Paclitaxel in Ovarian Cancer by Reversing Drug Resistance and 
Tumor Stem-like Properties 
252. Linking drug target and pathway activation for effective therapy using multi-task learning 
253. Low-dose salinomycin induces anti-leukemic responses in AML and MLL 
254. Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by 
artesunate 
255. Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical 
properties 
256. MATE2 Expression Is Associated with Cancer Cell Response to Metformin 
257. Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing 
258. Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase 
Inhibition for Peritoneal Carcinomatosis 
259. Medications for alcohol use disorders: An overview 
260. Memantine induces apoptosis and inhibits cell cycle progression in LNCaP prostate cancer cells 
261. Metformin and epithelial ovarian cancer therapeutics 
262. Metformin directly acts on mitochondria to alter cellular bioenergetics 
263. Metformin repositioning as antitumoral agent: selective antiproliferative effects in human 
glioblastoma stem cells, via inhibition of CLIC1-mediated ion current 
264. Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of 
retinoblastoma protein in renal cell carcinoma 
265. Mining Exosomal Genes for Pancreatic Cancer Targets 
266. Minocycline repurposing in critical illness: focus on stroke 
267. Mitigation of carbon tetrachloride-induced hepatic injury by methylene blue, a repurposed drug, is 
mediated by dual inhibition of GSK3beta downstream of PKA 
268. Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and 
Radiosensitizing Effects in Pancreatic Cancer Cells 
269. Mitochondria-targeted metformins: anti-tumour and redox signalling mechanisms 
 




270. Mitochondrial dysfunction and potential anticancer therapy 
271. Mitochondrial protein sorting as a therapeutic target for ATP synthase disorders 
272. Mmp-9 inhibition: a therapeutic strategy in ischemic stroke 
273. Mode of Action of Clofazimine and Combination Therapy with Benzothiazinones against 
Mycobacterium tuberculosis 
274. Model-based unsupervised learning informs metformin-induced cell-migration inhibition through an 
AMPK-independent mechanism in breast cancer 
275. Modified Metformin as a More Potent Anticancer Drug: Mitochondrial Inhibition, Redox Signaling, 
Antiproliferative Effects and Future EPR Studies 
276. Molecular mimicry-based repositioning of nutlin-3 to anti-apoptotic Bcl-2 family proteins 
277. Monocyte-macrophage differentiation of acute myeloid leukemia cell lines by small molecules 
identified through interrogation of the Connectivity Map database 
278. Mood, stress and longevity: convergence on ANK3 
279. Mouse hospital and co-clinical trial project--from bench to bedside 
280. MPGraph: multi-view penalised graph clustering for predicting drug-target interactions 
281. Mucuna pruriens (L.) DC chemo sensitize human breast cancer cells via downregulation of 
prolactin-mediated JAK2/STAT5A signaling 
282. Multi-target drug repositioning by bipartite block-wise sparse multi-task learning 
283. Multiple effects of digoxin on subsets of cancer-associated genes through the alternative splicing 
pathway 
284. N-bromotaurine surrogates for loss of antiproliferative response and enhances cisplatin efficacy in 
cancer cells with impaired glucocorticoid receptor 
285. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces 
endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo 
286. Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy 
287. New derivatives of the antimalarial drug Pyrimethamine in the control of melanoma tumor growth: 
an in vitro and in vivo study 
288. New HSP27 inhibitors efficiently suppress drug resistance development in cancer cells 
289. New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale 
cancer cell line panels 
 




290. New perspectives for metformin in cancer therapy 
291. Niclosamide and its analogs are potent inhibitors of Wnt/beta-catenin, mTOR and STAT3 signaling 
in ovarian cancer 
292. Niclosamide enhances ROS-mediated cell death through c-Jun activation 
293. Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal 
Cell Cancer Cells 
294. Niclosamide Induces Epiboly Delay During Early Zebrafish Embryogenesis 
295. Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and 
redox capacity 
296. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-
induced ferroptosis 
297. Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity 
298. Olanzapine, an Atypical Antipsychotic, Inhibits Survivin Expression and Sensitizes Cancer Cells to 
Chemotherapeutic Agents 
299. Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the 
early phase after heart transplantation in rats 
300. Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc 
adenomas are downregulated in response to tumor suppression by Clotam 
301. Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases 
302. Ormeloxifene efficiently inhibits ovarian cancer growth 
303. Oxidative stress during acetaminophen hepatotoxicity: Sources, pathophysiological role and 
therapeutic potential 
304. P-gp Inhibition by the Anti-psychotic Drug Pimozide Increases Apoptosis, as well as Expression of 
pRb and pH2AX in Highly Drug-resistant KBV20C Cells 
305. p73 as a pharmaceutical target for cancer therapy 
306. Parainfluenza Virus Infection Sensitizes Cancer Cells to DNA-Damaging Agents: Implications for 
Oncolytic Virus Therapy 
307. Parkinson's Disease, Diabetes and Cognitive Impairment 
308. Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B 
Virus Infection 
 




309. Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia 
Patients 
310. PEGylated chitosan nanoparticles potentiate repurposing of ormeloxifene in breast cancer therapy 
311. Pharmacological approach for drug repositioning against cardiorenal diseases 
312. Pharmacological exploitation of the phenothiazine antipsychotics to develop novel antitumor agents-
A drug repurposing strategy 
313. Pharmacological targeting of ion channels for cancer therapy: In vivo evidences 
314. Pharmacological targeting of p38 MAP-Kinase 6 (MAP2K6) inhibits the growth of esophageal 
adenocarcinoma 
315. Pharmacology and Clinical Drug Candidates in Redox Medicine 
316. Phase I Clinical Trial Results of Auranofin, a Novel Antiparasitic Agent 
317. Phenotypic identification of the redox dye methylene blue as an antagonist of heat shock response 
gene expression in metastatic melanoma cells 
318. Phosphoproteomics in drug discovery 
319. Phosphorylation of Single Stranded RNA Virus Proteins and Potential for Novel Therapeutic 
Strategies 
320. Piperazine-based Alpha-1 AR Blocker, Naftopidil, Selectively Suppresses Malignant Human 
Bladder Cells via Induction of Apoptosis 
321. Platelet Hyperreactivity in Diabetes: Focus on GPVI Signaling-Are Useful Drugs Already Available 
322. Poly(ADP-ribose) polymerase is not involved in the neuroprotection exerted by azithromycin against 
ischemic stroke in mice 
323. Posttranslational Regulation of O(6)-Methylguanine-DNA Methyltransferase (MGMT) and New 
Opportunities for Treatment of Brain Cancers 
324. Potential repositioning of exemestane as a neuroprotective agent for Parkinson's disease 
325. PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase 
inhibitors by inducing autophagy 
326. Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes 
327. Precision medicine for suicidality: from universality to subtypes and personalization 
328. Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas 
329. Prediction of anti-cancer drug response by kernelized multi-task learning 
 




330. Prediction of Candidate Drugs for Treating Pancreatic Cancer by Using a Combined Approach 
331. Prioritizing therapeutics for lung cancer: an integrative meta-analysis of cancer gene signatures and 
chemogenomic data 
332. Probabilistic drug connectivity mapping 
333. Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through 
Akt/mTOR suppression 
334. Propofol post-conditioning alleviates hepatic ischaemia reperfusion injury via BRG1-mediated 
Nrf2/HO-1 transcriptional activation in human and mice 
335. Proscillaridin A exerts anti-tumor effects through GSK3beta activation and alteration of microtubule 
dynamics in glioblastoma 
336. Pyrvinium Sensitizes Clear Cell Renal Cell Carcinoma Response to Chemotherapy Via Casein 
Kinase 1alpha-Dependent Inhibition of Wnt/beta-Catenin 
337. Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity 
in thyroid cancer cells: opportunities for repurposing 
338. Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple 
opportunities for drug repurposing 
339. Quinacrine in endometrial cancer: Repurposing an old antimalarial drug 
340. Rational drug repositioning guided by an integrated pharmacological network of protein, disease and 
drug 
341. Rationale for an experimental treatment of retinitis pigmentosa: 140-month test of hypothesis with 
one patient 
342. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints 
343. Reactions of model proteins with aurothiomalate, a clinically established gold(I) drug: The 
comparison with auranofin 
344. Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for 
Overcoming Tamoxifen Resistance in ER-positive Breast Cancer 
345. Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its 
Anticancer Activity 
346. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide 
targeting de novo DNA synthesis, irrespective of molecular subtype 
347. Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1 
 




348. Repositioning approved drugs for the treatment of problematic cancers using a screening approach 
349. Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of 
cytochrome c oxidase bearing the COX4-1 regulatory subunit 
350. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon 
Cancer Epigenome 
351. Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery 
352. Repositioning of amprenavir as a novel extracellular signal-regulated kinase-2 inhibitor and 
apoptosis inducer in MCF-7 human breast cancer 
353. Repositioning of anti-viral drugs as therapy for cervical cancer 
354. Repositioning of antibiotic levofloxacin as a mitochondrial biogenesis inhibitor to target breast 
cancer 
355. Repositioning of bromocriptine for treatment of acute myeloid leukemia 
356. Repositioning of difluorinated propanediones as inhibitors of histone methyltransferases and their 
biological evaluation in human leukemic cell lines 
357. Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer 
358. Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of 
human fatty acid synthase 
359. Repurposed drug screen identifies cardiac glycosides as inhibitors of TGF-beta-induced cancer-
associated fibroblast differentiation 
360. Repurposed FDA-approved drugs targeting genes influencing aging can extend lifespan and 
healthspan in rotifers 
361. Repurposing an orally available drug for the treatment of geographic atrophy 
362. Repurposing anticancer drugs for targeting necroptosis 
363. Repurposing antipsychotic drugs into antifungal agents: Synergistic combinations of azoles and 
bromperidol derivatives in the treatment of various fungal infections 
364. Repurposing Approach Identifies Auranofin with Broad Spectrum Antifungal Activity That Targets 
Mia40-Erv1 Pathway 
365. Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer 
stem cells 
366. Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis 
 




367. Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important 
fungi 
368. Repurposing auranofin for the treatment of cutaneous staphylococcal infections 
369. Repurposing Cationic Amphiphilic Antihistamines for Cancer Treatment 
370. Repurposing cephalosporin antibiotics as pro-senescent radiosensitizers 
371. Repurposing drugs to target the malaria parasite unfolding protein response 
372. Repurposing FDA-approved drugs for anti-aging therapies 
373. Repurposing itraconazole for the treatment of cancer 
374. Repurposing itraconazole to the benefit of skin cancer treatment: A combined azole-DDAB 
nanoencapsulation strategy 
375. Repurposing of Aspirin and Ibuprofen as Candidate Anti-Cryptococcus Drugs 
376. Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: a crucial 
role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation 
377. Repurposing of phentolamine as a potential anticancer agent against human castration-resistant 
prostate cancer: A central role on microtubule stabilization and mitochondrial apoptosis pathway 
378. Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma 
379. Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori 
380. Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic 
pontine glioma 
381. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell 
carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis 
382. Repurposing the Nonsteroidal Anti-inflammatory Drug Diflunisal as an Osteoprotective, 
Antivirulence Therapy for Staphylococcus aureus Osteomyelitis 
383. Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in 
Parkinson's Disease 
384. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the 
bone marrow microenvironment 
385. Rescue of cell death and inflammation of a mouse model of complex 1-mediated vision loss by 
repurposed drug molecules 
386. Retinal Neuroprotective Effects of Flibanserin, an FDA-Approved Dual Serotonin Receptor Agonist-
Antagonist 
 




387. Revisiting old drugs as novel agents for retinoblastoma: in vitro and in vivo antitumor activity of 
cardenolides 
388. Ribavirin as a tri-targeted antitumor repositioned drug 
389. Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian 
cancer cells 
390. Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT 
Pathways 
391. Screening a Commercial Library of Pharmacologically Active Small Molecules against 
Staphylococcus aureus Biofilms 
392. Screening of the Open Source Malaria Box Reveals an Early Lead Compound for the Treatment of 
Alveolar Echinococcosis 
393. Selected drugs with reported secondary cell-differentiating capacity prime latent HIV-1 infection for 
reactivation 
394. Selective human inhibitors of ATR and ATM render Leishmania major promastigotes sensitive to 
oxidative damage 
395. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in 
cancer cell lines 
396. Statistically controlled identification of differentially expressed genes in one-to-one cell line 
comparisons of the CMAP database for drug repositioning 
397. Structural basis for inactivation of Giardia lamblia carbamate kinase by disulfiram 
398. Structural re-positioning, in silico molecular modelling, oxidative degradation, and biological 
screening of linagliptin as adenosine 3 receptor (ADORA3) modulators targeting hepatocellular 
carcinoma 
399. Structure based investigation on the binding interaction of transport proteins in leishmaniasis: 
insights from molecular simulation 
400. Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing 
401. Sulforaphane Prevents Neuronal Apoptosis and Memory Impairment in Diabetic Rats 
402. Synergic in vitro combinations of artemisinin, pyrimethamine and methylene blue against Neospora 
caninum 
403. Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in 
adrenocortical carcinoma and has biomarkers of response 
 




404. Synthesis and biological evaluation of thiabendazole derivatives as anti-angiogenesis and vascular 
disrupting agents 
405. Synthesis and in vitro evaluation of Ca2+ channel blockers 1,4-dihydropyridines analogues against 
Trypanosoma cruzi and Leishmania amazonensis: SAR analysis 
406. Systematic discovery of drug action mechanisms by an integrated chemical genomics approach: 
identification of functional disparities between azacytidine and decitabine 
407. Systems Biology-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap 
Insertional Mutagenesis 
408. Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders 
409. T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's 
Disease 
410. Tacrine-deferiprone hybrids as multi-target-directed metal chelators against Alzheimer's disease: a 
two-in-one drug 
411. Tamoxifen Provides Structural and Functional Rescue in Murine Models of Photoreceptor 
Degeneration 
412. Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review 
413. Targeting cyclin D3/CDK6 activity for treatment of Parkinson's disease 
414. Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt/mTOR and inducing 
oxidative stress 
415. Targeting of embryonic annexin A2 expressed on ovarian and breast cancer by the novel monoclonal 
antibody 2448 
416. Targeting Phosphatidylinositol 4-Kinase IIIalpha for Radiosensitization: A Potential Model of Drug 
Repositioning Using an Anti-Hepatitis C Viral Agent 
417. Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from 
nature and drug repurposing 
418. Tetracycline hydrochloride: A potential clinical drug for radioprotection 
419. Tetracycline repurposing in neurodegeneration: focus on Parkinson's disease 
420. The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma 
Cells by Targeting Multiple Signal Pathways 
421. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical 
and noncanonical Wnt signaling pathway 
 




422. The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-
associated fibroblasts 
423. The anti-hypertensive drug prazosin inhibits glioblastoma growth via the PKCdelta-dependent 
inhibition of the AKT pathway 
424. The Antiarrhythmic Drug, Amiodarone, Decreases AKT Activity and Sensitizes Human Acute 
Myeloid Leukemia Cells to Apoptosis by ABT-263 
425. The antifungal compound butenafine eliminates promastigote and amastigote forms of Leishmania 
(Leishmania) amazonensis and Leishmania (Viannia) braziliensis 
426. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal 
melanoma in vitro and in vivo 
427. The antimalarial amodiaquine causes autophagic-lysosomal and proliferative blockade sensitizing 
human melanoma cells to starvation- and chemotherapy-induced cell death 
428. The aryl hydrocarbon receptor is required for induction of p21cip1/waf1 expression and growth 
inhibition by SU5416 in hepatoma cells 
429. The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory 
responses and accelerates wound healing in a murine model of third-degree burn injury 
430. The combination astemizole-gefitinib as a potential therapy for human lung cancer 
431. The combination effects of licl and the active leflunomide metabolite, A771726, on viral-induced 
interleukin 6 production and EV-A71 replication 
432. The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell 
carcinoma 
433. The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced 
apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes 
434. The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate 
cancer 
435. The heterogeneity of cancer stem-like cells at the invasive front 
436. The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in 
hepatocellular carcinoma 
437. The Oral Antimalarial Drug Tafenoquine Shows Activity against Trypanosoma brucei 
438. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute 
lymphoblastic leukemia and synergistically works with dasatinib 
 




439. The polysialic acid mimetics idarubicin and irinotecan stimulate neuronal survival and neurite 
outgrowth and signal via protein kinase C 
440. The possible repositioning of an oral anti-arthritic drug, auranofin, for Nrf2-activating therapy: The 
demonstration of Nrf2-dependent anti-oxidative action using a zebrafish model 
441. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines 
and discovery of potential new DDK inhibitor scaffolds 
442. The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-
beta1 
443. The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory 
NRASQ61K melanoma 
444. The Tissue-Reconstructing Ability of Colon CSCs Is Enhanced by FK506 and Suppressed by GSK3 
Inhibition 
445. Therapeutic Effect of Quinacrine, an Antiprotozoan Drug, by Selective Suppression of p-CHK1/2 in 
p53-Negative Malignant Cancers 
446. Therapeutic Effect of Repurposed Temsirolimus in Lung Adenocarcinoma Model 
447. Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by 
inhibiting Wnt/beta-catenin signaling 
448. Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial 
agent 
449. Therapeutic potential for phenytoin: targeting Na(v)1.5 sodium channels to reduce migration and 
invasion in metastatic breast cancer 
450. Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from 
pathophysiology to treatment 
451. Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC/BCL2 
double-hit B cell lymphoma 
452. Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as 
a Candidate for Treatment of Colorectal Cancer 
453. Tigecycline targets nonsmall cell lung cancer through inhibition of mitochondrial function 
454. Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies 
and in vivo effects 
455. Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine 
Approach 
 




456. Transcriptomic changes induced by mycophenolic acid in gastric cancer cells 
457. Transcriptomic characterization of the novel avian-origin influenza A (H7N9) virus: specific host 
response and responses intermediate between avian (H5N1 and H7N7) and human (H3N2) viruses and 
implications for treatment options 
458. Treating Influenza Infection, From Now and Into the Future 
459. Trypanocidal Effect of Isotretinoin through the Inhibition of Polyamine and Amino Acid 
Transporters in Trypanosoma cruzi 
460. Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer 
461. TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) 
Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin 
462. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities 
463. Understanding organellar protein folding capacities and assessing their pharmacological modulation 
by small molecules 
464. Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease 
465. Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic 
466. Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent 
drug candidates for cancer treatment 
467. Valproic acid in the complex therapy of malignant tumors 
468. Valproic Acid Promotes Apoptosis and Cisplatin Sensitivity Through Downregulation of H19 
Noncoding RNA in Ovarian A2780 Cells 
469. Verteporfin inhibits gastric cancer cell growth by suppressing adhesion molecule FAT1 
470. Viability Screen of LOPAC1280 Reveals Phosphorylation Inhibitor Auranofin as a Potent Inhibitor 
of Blastocystis Subtype 1, 4, and 7 Isolates 
471. Virtual Screening against Phosphoglycerate Kinase 1 in Quest of Novel Apoptosis Inhibitors 









FACTOR 13. Similarity Searching of Ligand-Target Sets for Drug Repurposing 
1. A screening cascade to identify ERbeta ligands 
2. Accidental interaction between PDZ domains and diclofenac revealed by NMR-assisted virtual 
screening 
3. Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review 
4. Alternative molecular formats and therapeutic applications for bispecific antibodies 
5. AlzhCPI: A knowledge base for predicting chemical-protein interactions towards Alzheimer's disease 
6. Anticancer and Immunogenic Properties of Cardiac Glycosides 
7. Application of drug repositioning strategy to TOFISOPAM 
8. Application of the 4D fingerprint method with a robust scoring function for scaffold-hopping and drug 
repurposing strategies 
9. Balance and circumstance: The renin angiotensin system in wound healing and fibrosis 
10. Binding site matching in rational drug design: algorithms and applications 
11. Cascade Ligand- and Structure-Based Virtual Screening to Identify New Trypanocidal Compounds 
Inhibiting Putrescine Uptake 
12. Characterizing protein domain associations by Small-molecule ligand binding 
13. Characterizing the pocketome of Mycobacterium tuberculosis and application in rationalizing 
polypharmacological target selection 
14. Chemical-induced disease extraction via recurrent piecewise convolutional neural networks 
15. Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate 
Synthase Case 
16. Computational Discovery of Putative Leads for Drug Repositioning through Drug-Target Interaction 
Prediction 
17. Computational profiling of bioactive compounds using a target-dependent composite workflow 
18. Designing novel therapies against sarcomas in the era of personalized medicine and economic crisis 
19. Detecting drug promiscuity using Gaussian ensemble screening 
20. Development of a Sigma-2 Receptor affinity filter through a Monte Carlo based QSAR analysis 
21. Disease classification: from phenotypic similarity to integrative genomics and beyond 
 




22. Docking of a novel DNA methyltransferase inhibitor identified from high-throughput screening: 
insights to unveil inhibitors in chemical databases 
23. DockingApp: a user friendly interface for facilitated docking simulations with AutoDock Vina 
24. Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key 
25. Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer 
26. Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank 
database for allosteric Bcr-Abl inhibitors 
27. eModel-BDB: a database of comparative structure models of drug-target interactions from the 
Binding Database 
28. Enhancing the Enrichment of Pharmacophore-Based Target Prediction for the Polypharmacological 
Profiles of Drugs 
29. Estimated generic prices for novel treatments for drug-resistant tuberculosis 
30. Expediting the Design, Discovery and Development of Anticancer Drugs using Computational 
Approaches 
31. Exploring polypharmacology using a ROCS-based target fishing approach 
32. Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy 
33. From stroke to neurodegenerative diseases: The multi-target neuroprotective effects of 3-n-
butylphthalide and its derivatives 
34. GES polypharmacology fingerprints: a novel approach for drug repositioning 
35. Getting the most out of PubChem for virtual screening 
36. High-throughput identification of off-targets for the mechanistic study of severe adverse drug 
reactions induced by analgesics 
37. High-Throughput parallel blind Virtual Screening using BINDSURF 
38. Hit Recycling: Discovery of a Potent Carbonic Anhydrase Inhibitor by in Silico Target Fishing 
39. How good are publicly available web services that predict bioactivity profiles for drug repurposing 
40. Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs 
41. Identification of raloxifene as a novel CB2 inverse agonist 
42. In Silico Chemogenomics Drug Repositioning Strategies for Neglected Tropical Diseases 
 




43. In silico prediction of chemical mechanism of action via an improved network-based inference 
method 
44. In Silico target fishing: addressing a "Big Data" problem by ligand-based similarity rankings with data 
fusion 
45. Leveraging 3D chemical similarity, target and phenotypic data in the identification of drug-protein 
and drug-adverse effect associations 
46. Molecular Connectivity Predefines Polypharmacology: Aliphatic Rings, Chirality, and sp3 Centers 
Enhance Target Selectivity 
47. Molecular investigations of protriptyline as a multi-target directed ligand in Alzheimer's disease 
48. Molecular therapeutic strategies for FGFR3 gene-related skeletal dysplasia 
49. MOST: most-similar ligand based approach to target prediction 
50. Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a 
medicinal chemist perspective 
51. Multivariate analysis in the identification of biological targets for designed molecular structures: the 
BIOTA protocol 
52. Network measures for chemical library design 
53. Network-based drug repositioning: A novel strategy for discovering potential antidepressants and 
their mode of action 
54. Novel Tadalafil Derivatives Ameliorates Scopolamine-Induced Cognitive Impairment in Mice via 
Inhibition of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5 
55. One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug 
56. Orphan receptor ligand discovery by pickpocketing pharmacological neighbors 
57. Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective drugs 
58. Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential 
interventions 
59. Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA 
Efflux Pump Inhibitors 
60. Polypharmacological Drug-target Inference for Chemogenomics 
61. Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective 
62. Polypharmacology rescored: protein-ligand interaction profiles for remote binding site similarity 
assessment 
 




63. Predicting High-Impact Pharmacological Targets by Integrating Transcriptome and Text-Mining 
Features 
64. Predicting new indications for approved drugs using a proteochemometric method 
65. Predicting targeted polypharmacology for drug repositioning and multi- target drug discovery 
66. Prediction of drug-target interactions for drug repositioning only based on genomic expression 
similarity 
67. Prediction of Human Drug Targets and Their Interactions Using Machine Learning Methods: Current 
and Future Perspectives 
68. ProBiS-ligands: a web server for prediction of ligands by examination of protein binding sites 
69. Protein-ligand-based pharmacophores: generation and utility assessment in computational ligand 
profiling 
70. Recent progress in repositioning Alzheimer's disease drugs based on a multitarget strategy 
71. Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer 
72. Repurposing Lesogaberan to Promote Human Islet Cell Survival and beta-Cell Replication 
73. Research advance in the drug target prediction based on chemoinformatics 
74. Reverse docking: a powerful tool for drug repositioning and drug rescue 
75. Reverse Screening Methods to Search for the Protein Targets of Chemopreventive Compounds 
76. SMAP-WS: a parallel web service for structural proteome-wide ligand-binding site comparison 
77. SPIDR: small-molecule peptide-influenced drug repurposing 
78. Steroids-specific target library for steroids target prediction 
79. Structural analysis of protein tyrosine phosphatase 1B reveals potentially druggable allosteric binding 
sites 
80. Structural basis for the hepatoprotective effects of antihypertensive 1,4-dihydropyridine drugs 
81. Structure based investigation on the binding interaction of transport proteins in leishmaniasis: insights 
from molecular simulation 
82. Structure Investigation, Enrichment Analysis and Structure-based Repurposing of FDA-approved 
Drugs as Inhibitors of BET-BRD4 
83. Tacrine-deferiprone hybrids as multi-target-directed metal chelators against Alzheimer's disease: a 
two-in-one drug 
 




84. TargetHunter: an in silico target identification tool for predicting therapeutic potential of small 
organic molecules based on chemogenomic database 
85. TarPred: a web application for predicting therapeutic and side effect targets of chemical compounds 
86. The bitter pill: clinical drugs that activate the human bitter taste receptor TAS2R14 
87. The Hippo pathway in normal development and cancer 
88. Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review 
(2008-present 
89. Thiopurine Drugs Repositioned as Tyrosinase Inhibitors 
90. Tools for in silico target fishing 
91. Topical mevastatin promotes wound healing by inhibiting the transcription factor c-Myc via the 
glucocorticoid receptor and the long non-coding RNA Gas5 








FACTOR 14. AMPK Activation for Cancer Treatment, Emphasizing Anti-Diabetic Drug 
Metformin 
1. A cross-species analysis method to analyze animal models' similarity to human's disease state 
2. A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of 
hydrocephalus 
3. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system 
availability of AZD0530 (saracatinib) in Alzheimer's disease 
4. A phenome-wide association study of a lipoprotein-associated phospholipase A2 loss-of-function 
variant in 90 000 Chinese adults 
5. A therapy for FXS 
6. A two-step drug repositioning method based on a protein-protein interaction network of genes shared 
by two diseases and the similarity of drugs 
7. A two-tiered unsupervised clustering approach for drug repositioning through heterogeneous data 
integration 
8. Advances in epilepsy gene discovery and implications for epilepsy diagnosis and treatment 
9. Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology 
10. Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via 
oxidative stress-mediated mTOR inhibition 
11. Anti-obesogenic and hypolipidemic effects of a glucagon-like peptide-1 receptor agonist derived from 
the saliva of the Gila monster 
12. Application of computer-aided drug repurposing in the search of new cruzipain inhibitors: discovery 
of amiodarone and bromocriptine inhibitory effects 
13. Baseline Regularization for Computational Drug Repositioning with Longitudinal Observational Data 
14. Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2 
15. beta3-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in 
a repositioning clinical drug development project 
16. Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the 
EIS regimen 
17. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant 
mammary tissues of MMTV-erbB-2 transgenic mice 
 




18. Calcium channel blockers as drug repurposing candidates for gestational diabetes: Mining large scale 
genomic and electronic health records data to repurpose medications 
19. Can commonly prescribed drugs be repurposed for the prevention or treatment of Alzheimer's and 
other neurodegenerative diseases? Protocol for an observational cohort study in the UK Clinical Practice 
Research Datalink 
20. Cancer Prevention and Interception: A New Era for Chemopreventive Approaches 
21. Cancer: fundamentals behind pH targeting and the double-edged approach 
22. Capsaicin: Current Understanding of Its Mechanisms and Therapy of Pain and Other Pre-Clinical and 
Clinical Uses 
23. Cell-based screening identifies paroxetine as an inhibitor of diabetic endothelial dysfunction 
24. Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances 
25. CK2 inhibition confers functional protection to young and aging axons against ischemia by 
differentially regulating the CDK5 and AKT signaling pathways 
26. Clozapine Improves Memory Impairment and Reduces Abeta Level in the Tg-APPswe/PS1dE9 
Mouse Model of Alzheimer's Disease 
27. Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease 
28. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces 
Growth of Hepatocellular Carcinoma Cells InVitro and in Mice by Inhibiting Cell Division Cycle 37 
Signaling 
29. Computational Drug Repositioning Using Continuous Self-Controlled Case Series 
30. Construction of drug network based on side effects and its application for drug repositioning 
31. Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in 
ER+ breast cancer 
32. Deciphering cellular biological processes to clinical application: a new perspective for Talpha1 
treatment targeting multiple diseases 
33. Designing novel therapies against sarcomas in the era of personalized medicine and economic crisis 
34. Development of therapies for autoimmune disease at Stanford: a tale of multiple shots and one goal 
35. Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma invivo 
36. Dopamine antagonists for treatment resistance in autism spectrum disorders: review and focus on 
BDNF stimulators loxapine and amitriptyline 
 




37. DPP-4 inhibitors promote proliferation and migration of rat brain microvascular endothelial cells 
under hypoxic/high-glucose conditions, potentially through the SIRT1/HIF-1/VEGF pathway 
38. Drug repositioning for diabetes based on 'omics' data mining 
39. Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer 
40. Drug repurposing for vascular protection after acute ischemic stroke 
41. Drug repurposing in kidney disease 
42. Drug Repurposing of Metabolic Agents in Malignant Glioma 
43. Drug repurposing: In-vitro anti-glycation properties of 18 common drugs 
44. Drug target prediction and repositioning using an integrated network-based approach 
45. Drug-disease association and drug-repositioning predictions in complex diseases using causal 
inference-probabilistic matrix factorization 
46. Drug-repurposing identified the combination of Trolox C and Cytisine for the treatment of type 2 
diabetes 
47. Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells 
48. Exenatide and the treatment of patients with Parkinson's disease 
49. Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats 
50. Exploration of alpha1-antitrypsin treatment protocol for islet transplantation: dosing plan and route of 
administration 
51. Exploring novel pharmacotherapeutic applications and repurposing potential of sodium glucose 
CoTransporter 2 inhibitors 
52. Exploring the potential of adjunct therapy in tuberculosis 
53. Fenofibrate Suppresses Oral Tumorigenesis via Reprogramming Metabolic Processes: Potential Drug 
Repurposing for Oral Cancer 
54. Fluvastatin activates sirtuin 6 to regulate sterol regulatory element-binding proteins and AMP-
activated protein kinase in HepG2 cells 
55. Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin 
polymerization 
56. Folic Acid Exerts Post-Ischemic Neuroprotection In Vitro Through HIF-1alpha Stabilization 
57. From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy 
 




58. Glipizide suppresses prostate cancer progression in the TRAMP model by inhibiting angiogenesis 
59. Glycogen phosphorylase inhibition improves beta cell function 
60. Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality 
61. High-throughput screening of FDA-approved drugs using oxygen biosensor plates reveals secondary 
mitofunctional effects 
62. Histone Deacetylase Inhibitors and Diabetic Kidney Disease 
63. Identification and validation of uterine stimulant methylergometrine as a potential inhibitor of 
caspase-1 activation 
64. Identification of circadian clock modulators from existing drugs 
65. Identification of novel therapeutics for complex diseases from genome-wide association data 
66. Identification of repaglinide as a therapeutic drug for glioblastoma multiforme 
67. Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell 
agent using public gene expression data 
68. Immune Cell Metabolism in Tumor Microenvironment 
69. In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-
melanoma drug, for Parkinson's disease 
70. In vivo phenotypic screening: clinical proof of concept for a drug repositioning approach 
71. Inhibition of effector antigen-specific T cells by intradermal administration of heme oxygenase-1 
inducers 
72. Inhibition of PI4K IIIalpha radiosensitizes in human tumor xenograft and immune-competent 
syngeneic murine tumor model 
73. Inhibition of the insulin-like growth factor system is a potential therapy for rheumatoid arthritis 
74. Insights into the Link Between Obesity and Cancer 
75. Interplay of DDP4 and IP-10 as a Potential Mechanism for Cell Recruitment to Tuberculosis Lesions 
76. Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan 
77. Leveraging Population-Based Clinical Quantitative Phenotyping for Drug Repositioning 
78. Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced 
depression model via improving hippocampal neural plasticity 
79. Liraglutide modulates gut microbiota and reduces NAFLD in obese mice 
 




80. LIRAGUTIDE AT A DOSE OF 3.0 MG (SAXENDA): NEW INDICATION FOR THE 
TREATMENT OF OBESITY 
81. Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-
infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill 
82. MATE2 Expression Is Associated with Cancer Cell Response to Metformin 
83. Memantine induces apoptosis and inhibits cell cycle progression in LNCaP prostate cancer cells 
84. MeSHDD: Literature-based drug-drug similarity for drug repositioning 
85. Metabolic reprogramming in clear cell renal cell carcinoma 
86. Metformin - The Drug for the Treatment of Autoimmune Diseases; A New Use of a Known Anti-
Diabetic Drug 
87. Metformin and epithelial ovarian cancer therapeutics 
88. Metformin and propranolol combination prevents cancer progression and metastasis in different breast 
cancer models 
89. Metformin as a geroprotector: experimental and clinical evidence 
90. Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a 
phase II trial 
91. Metformin directly acts on mitochondria to alter cellular bioenergetics 
92. Metformin for non-small cell lung cancer patients: Opportunities and pitfalls 
93. Metformin for Prevention and Treatment of Colon Cancer: A Reappraisal of Experimental and 
Clinical Data 
94. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-
controlled phase 2 trial 
95. Metformin inhibits hepatitis B virus protein production and replication in human hepatoma cells 
96. Metformin repositioning as antitumoral agent: selective antiproliferative effects in human 
glioblastoma stem cells, via inhibition of CLIC1-mediated ion current 
97. Metformin treatment ameliorates diabetes-associated decline in hippocampal neurogenesis and 
memory via phosphorylation of insulin receptor substrate 1 
98. Metformin use and gynecological cancers: A novel treatment option emerging from drug 
repositioning 
99. Metformin Use in Relation With Survival Outcomes of Patients With Renal Cell Carcinoma 
 




100. Metformin: its emerging role in oncology 
101. METFORMIN: NONGLYCEMIC EFFECTS AND POTENTIAL NOVEL INDICATIONS 
102. Mitigation of carbon tetrachloride-induced hepatic injury by methylene blue, a repurposed drug, is 
mediated by dual inhibition of GSK3beta downstream of PKA 
103. Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and 
Radiosensitizing Effects in Pancreatic Cancer Cells 
104. Mitochondria-targeted metformins: anti-tumour and redox signalling mechanisms 
105. Model-based unsupervised learning informs metformin-induced cell-migration inhibition through an 
AMPK-independent mechanism in breast cancer 
106. Modified Metformin as a More Potent Anticancer Drug: Mitochondrial Inhibition, Redox Signaling, 
Antiproliferative Effects and Future EPR Studies 
107. Modulating the metabolism by trimetazidine enhances myoblast differentiation and promotes 
myogenesis in cachectic tumor-bearing c26 mice 
108. Molecular property diagnostic suite for diabetes mellitus (MPDSDM): An integrated web portal for 
drug discovery and drug repurposing 
109. Neuropathic Pain Creates an Enduring Prefrontal Cortex Dysfunction Corrected by the Type II 
Diabetic Drug Metformin But Not by Gabapentin 
110. New culture medium concepts for cell transplantation 
111. New perspectives for metformin in cancer therapy 
112. Niclosamide, a Drug with Many (Re)purposes 
113. No association between metformin use and survival in patients with pancreatic cancer: An 
observational cohort study 
114. Non-diabetic clinical applications of insulin 
115. Novel strategies of ovarian cancer treatment 
116. Nutraceuticals and "repurposed" drugs of phytochemical origin in prevention and interception of 
chronic degenerative disease and cancer 
117. Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the 
early phase after heart transplantation in rats 
118. Old drug, new trick: repurposing metformin for gynecologic cancers 
119. One-carbon metabolism: an aging-cancer crossroad for the gerosuppressant metformin 
 




120. Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the 
Receptor Activator of NF-kappaB Ligand Pathway 
121. Paradoxical strategy for treating chronic diseases where the therapeutic effect is derived from 
compensatory response rather than drug effect 
122. Parkinson's Disease, Diabetes and Cognitive Impairment 
123. Pharmacological approach for drug repositioning against cardiorenal diseases 
124. Platelet Hyperreactivity in Diabetes: Focus on GPVI Signaling-Are Useful Drugs Already Available 
125. Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as 
adjuncts to therapy 
126. Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes 
127. Precision medicine for suicidality: from universality to subtypes and personalization 
128. Predicting and characterizing selective multiple drug treatments for metabolic diseases and cancer 
129. Proximal Pathway Enrichment Analysis for Targeting Comorbid Diseases via Network 
Endopharmacology 
130. Recent Advances in the Development of Pharmaceutical Agents for Metabolic Disorders: A 
Computational Perspective 
131. Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant 
lesions 
132. Repositioning drugs for inflammatory disease - fishing for new anti-inflammatory agents 
133. Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery 
134. Repositioning of bromocriptine for treatment of acute myeloid leukemia 
135. Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario 
136. Repositioning therapy for thyroid cancer: new insights on established medications 
137. Reprofiling of Troglitazone Towards More Active and Less Toxic Derivatives: A New Hope for 
Cancer Treatment 
138. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease 
139. Repurposing Drugs for Cancer Prevention 
140. Repurposing Drugs to Target the Diabetes Epidemic 
 




141. Repurposing existing drugs for new AMPK activators as a strategy to extend lifespan: a computer-
aided drug discovery study 
142. Repurposing itraconazole as an anticancer agent 
143. Repurposing Lesogaberan to Promote Human Islet Cell Survival and beta-Cell Replication 
144. Repurposing matrine for the treatment of hepatosteatosis and associated disorders in glucose 
homeostasis in mice 
145. Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform 
146. Repurposing metformin for the prevention of cancer and cancer recurrence 
147. Repurposing metformin: an old drug with new tricks in its binding pockets 
148. Repurposing of Copper(II)-chelating Drugs for the Treatment of Neurodegenerative Diseases 
149. Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic 
cancer prevention and treatment 
150. Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: a crucial 
role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation 
151. Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead 
152. Repurposing old drugs to chemoprevention: the case of metformin 
153. Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma 
154. Repurposing the anti-malarial drug dihydroartemisinin suppresses metastasis of non-small-cell lung 
cancer via inhibiting NF-kappaB/GLUT1 axis 
155. Selective human inhibitors of ATR and ATM render Leishmania major promastigotes sensitive to 
oxidative damage 
156. SIRT1 activation by methylene blue, a repurposed drug, leads to AMPK-mediated inhibition of 
steatosis and steatohepatitis 
157. Statistically controlled identification of differentially expressed genes in one-to-one cell line 
comparisons of the CMAP database for drug repositioning 
158. Structural analysis of protein tyrosine phosphatase 1B reveals potentially druggable allosteric 
binding sites 
159. Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-
mutated or IDH2-mutated solid tumours 
160. Support for phosphoinositol 3 kinase and mTOR inhibitors as treatment for lupus using in-silico 
drug-repurposing analysis 
 




161. Symposium 2-1The autoimmunome: Similarities and differences among genetic susceptibility to 
common immune-related diseases 
162. Systematic drug repositioning based on clinical side-effects 
163. Systems approach to the pharmacological actions of HDAC inhibitors reveals EP300 activities and 
convergent mechanisms of regulation in diabetes 
164. Systems pharmacology of adverse event mitigation by drug combinations 
165. T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's 
Disease 
166. Targeting cyclin D3/CDK6 activity for treatment of Parkinson's disease 
167. Targeting Phosphatidylinositol 4-Kinase IIIalpha for Radiosensitization: A Potential Model of Drug 
Repositioning Using an Anti-Hepatitis C Viral Agent 
168. The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to 
inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy 
169. The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced 
apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes 
170. The Glucose Transporter PfHT1 Is an Antimalarial Target of the HIV Protease Inhibitor Lopinavir 
171. The human disease network in terms of dysfunctional regulatory mechanisms 
172. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian 
randomisation analysis 
173. The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer 
174. The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new 
opportunity for drug repurposing 
175. Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New 
Again 
176. Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review 
(2008-present 
177. Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as 
a Candidate for Treatment of Colorectal Cancer 
178. Topical mevastatin promotes wound healing by inhibiting the transcription factor c-Myc via the 
glucocorticoid receptor and the long non-coding RNA Gas5 
179. Totally drug-resistant tuberculosis and adjunct therapies 
 




180. Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems 
Pharmacology 
181. Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine 
Approach 
182. Transforming Cancer Prevention through Precision Medicine and Immune-oncology 
183. Treating the dysfunctional placenta 
184. TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) 
Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin 
185. Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs 
186. Unveiling anticancer potential of glibenclamide: Its synergistic cytotoxicity with doxorubicin on 
cancer cells 
187. Use of metformin and survival of patients with high-grade glioma 
188. Using genetics to inform new therapeutics for diabetes 
189. Validating drug repurposing signals using electronic health records: a case study of metformin 








FACTOR 15. Repurposing of Cholesterol-Lowering Drugs for Chronic and Infectious Diseases 
1. A Biologically-Based Computational Approach to Drug Repurposing for Anthrax Infection 
2. A common rejection module (CRM) for acute rejection across multiple organs identifies novel 
therapeutics for organ transplantation 
3. A Computational Systems Biology Approach for Identifying Candidate Drugs for Repositioning for 
Cardiovascular Disease 
4. A profound computational study to prioritize the disease-causing mutations in PRPS1 gene 
5. Activity of mefloquine and mefloquine derivatives against Echinococcus multilocularis 
6. An optimized background regimen for treatment of active tuberculosis with the next-generation 
benzothiazinone Macozinone (PBTZ169 
7. Anti-obesogenic and hypolipidemic effects of a glucagon-like peptide-1 receptor agonist derived from 
the saliva of the Gila monster 
8. Anticancer Properties of Fenofibrate: A Repurposing Use 
9. Antileishmanial Activity of Ezetimibe: Inhibition of Sterol Biosynthesis, In Vitro Synergy with Azoles, 
and Efficacy in Experimental Cutaneous Leishmaniasis 
10. Atorvastatin as a promising anticryptococcal agent 
11. Balance and circumstance: The renin angiotensin system in wound healing and fibrosis 
12. Bioinformatics approach to prioritize known drugs towards repurposing for tuberculosis 
13. Bisphosphonates inactivate human EGFRs to exert antitumor actions 
14. Characterization of drug-induced transcriptional modules: towards drug repositioning and functional 
understanding 
15. Computational Drug Repositioning by Target Hopping: A Use Case in Chagas Disease 
16. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent 
pathways among FDA-approved compounds 
17. Development of therapies for autoimmune disease at Stanford: a tale of multiple shots and one goal 
18. Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma 
19. Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer 
20. Drug repurposing for drug development in stroke 
21. Drug repurposing for vascular protection after acute ischemic stroke 
 




22. Drug repurposing may generate novel approaches to treating depression 
23. Drug Repurposing of Metabolic Agents in Malignant Glioma 
24. Drug Repurposing Screen Identifies Foxo1-Dependent Angiopoietin-2 Regulation in Sepsis 
25. Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and 
isoprenoid synthesis that block Cryptosporidium parvum growth 
26. Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of 
dyslipidemia 
27. Effects of nutrition intervention for pressure ulcer patients--healing rate and speed of wound size and 
nutrition 
28. Erythropoietin, a novel repurposed drug: an innovative treatment for wound healing in patients with 
diabetes mellitus 
29. Evaluating a novel treatment for coronary artery inflammation in acute Kawasaki disease: A Phase 
I/IIa trial of atorvastatin 
30. Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent 
31. Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism 
32. Fluvastatin activates sirtuin 6 to regulate sterol regulatory element-binding proteins and AMP-
activated protein kinase in HepG2 cells 
33. Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with 
FLT3/ITD leukemia 
34. From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic 
Small Cell Lung Cancer (SCLC 
35. Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality 
36. HMG-CoA Reductase Inhibition Delays DNA Repair and Promotes Senescence After Tumor 
Irradiation 
37. Host-directed antimicrobial drugs with broad-spectrum efficacy against intracellular bacterial 
pathogens 
38. Identification of potential anti-hepatitis C virus agents targeting non structural protein 5B using 
computational techniques 
39. In Silico-Based Repositioning of Phosphinothricin as a Novel Technetium-99m Imaging Probe with 
Potential Anti-Cancer Activity 
40. In vitro antibacterial effects of statins against bacterial pathogens causing skin infections 
 




41. Inhibiting Mycobacterium tuberculosis within and without 
42. Innovations in asthma therapy: is there a role for inhaled statins 
43. Insights from Second-Line Treatments for Idiopathic Dilated Cardiomyopathy 
44. Integrating systems biology sources illuminates drug action 
45. Is There Potential for Repurposing Statins as Novel Antimicrobials 
46. Ketanserin, an antidepressant, exerts its antileishmanial action via inhibition of 3-hydroxy-3-
methylglutaryl coenzyme A reductase (HMGR) enzyme of Leishmania donovani 
47. Metabolic switch during adipogenesis: From branched chain amino acid catabolism to lipid synthesis 
48. Metastasis and chemoresistance in CD133 expressing pancreatic cancer cells are dependent on their 
lipid raft integrity 
49. Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and 
Ovarian Carcinoma in Mouse Models 
50. Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of 
retinoblastoma protein in renal cell carcinoma 
51. Molecular therapies for inherited epidermolysis bullosa 
52. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide 
analogue drug exposure 
53. New drug candidates for depression - a nationwide population-based study 
54. Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients 
55. Non-diabetic clinical applications of insulin 
56. Pharmacogenomic approaches to lipid-regulating trials 
57. Phenytoin repositioned in wound healing: clinical experience spanning 60 years 
58. Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell 
migration and invasion and is inhibited by statins 
59. Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as 
adjuncts to therapy 
60. Prediction of drug-target interactions and drug repositioning via network-based inference 
61. Repositioning "old" drugs for new causes: identifying new inhibitors of prostate cancer cell migration 
and invasion 
 




62. Repositioning of drugs for intervention in tumor progression and metastasis: Old drugs for new 
targets 
63. Repositioning of Tak-475 In Mevalonate Kinase Disease: Translating Theory Into Practice 
64. Repurposing of approved cardiovascular drugs 
65. Repurposing of Existing Statin drugs for treatment of Microbial Infections: How much Promising 
66. Repurposing of statins via inhalation to treat lung inflammatory conditions 
67. Repurposing Strategy of Atorvastatin against Trypanosoma cruzi: In Vitro Monotherapy and 
Combined Therapy with Benznidazole Exhibit Synergistic Trypanocidal Activity 
68. Simvastatin increases the in vivo activity of the first-line tuberculosis regimen 
69. Simvastatin offers new prospects for the treatment of Duchenne muscular dystrophy 
70. Simvastatin Therapy for Drug Repositioning to Reduce the Risk of Prostate Cancer Mortality in 
Patients With Hyperlipidemia 
71. Statins and Antimicrobial Effects: Simvastatin as a Potential Drug against Staphylococcus aureus 
Biofilm 
72. Statins in conditions other than hypocholesterolemic effects for chronic subdural hematoma therapy, 
old drug, new tricks 
73. Statins: antimicrobial resistance breakers or makers 
74. Stromal microenvironment in type VII collagen-deficient skin: The ground for squamous cell 
carcinoma development 
75. Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins 
76. The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory 
responses and accelerates wound healing in a murine model of third-degree burn injury 
77. The Linked Clinical Trials Initiative (LCT) for Parkinson's disease 
78. The poor design of clinical trials of statins in oncology may explain their failure - Lessons for drug 
repurposing 
79. The potential to treat lung cancer via inhalation of repurposed drugs 
80. The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer 
81. The role of statins in inflammatory vasculitides 
82. Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis 
 




83. Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New 
Again 
84. Topical mevastatin promotes wound healing by inhibiting the transcription factor c-Myc via the 
glucocorticoid receptor and the long non-coding RNA Gas5 
85. Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine 
Approach 
86. Treating Influenza Infection, From Now and Into the Future 








FACTOR 16. Similarity-Based Methods for Drug Repurposing 
1. A cross-species analysis method to analyze animal models' similarity to human's disease state 
2. A disease similarity matrix based on the uniqueness of shared genes 
3. A framework for the targeted selection of herbs with similar efficacy by exploiting drug repositioning 
technique and curated biomedical knowledge 
4. A Large-Scale Gene Expression Intensity-Based Similarity Metric for Drug Repositioning 
5. A New Method for Computational Drug Repositioning Using Drug Pairwise Similarity 
6. A novel computational approach for drug repurposing using systems biology 
7. A novel multi-modal drug repurposing approach for identification of potent ACK1 inhibitors 
8. A physarum-inspired prize-collecting steiner tree approach to identify subnetworks for drug 
repositioning 
9. A Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and 
Repositioning Predictions 
10. A tool to utilize adverse effect profiles to identify brain-active medications for repurposing 
11. A two-step drug repositioning method based on a protein-protein interaction network of genes shared 
by two diseases and the similarity of drugs 
12. Advances in the Development of Shape Similarity Methods and Their Application in Drug Discovery 
13. alpha-Methyl-alpha-phenylsuccinimide ameliorates neurodegeneration in a C. elegans model of TDP-
43 proteinopathy 
14. An integrated structure- and system-based framework to identify new targets of metabolites and 
known drugs 
15. Analysis and assay of oseltamivir-resistant mutants of influenza neuraminidase via direct observation 
of drug unbinding and rebinding in simulation 
16. Analysis of drug binding pockets and repurposing opportunities for twelve essential enzymes of 
ESKAPE pathogens 
17. Anti-infectious drug repurposing using an integrated chemical genomics and structural systems 
biology approach 
18. Application of the 4D fingerprint method with a robust scoring function for scaffold-hopping and 
drug repurposing strategies 
19. Assessing protein kinase target similarity: Comparing sequence, structure, and cheminformatics 
approaches 
 




20. Assessing relative bioactivity of chemical substances using quantitative molecular network topology 
analysis 
21. Back to the Roots: Prediction of Biologically Active Natural Products from Ayurveda Traditional 
Medicine 
22. BioGPS: navigating biological space to predict polypharmacology, off-targeting, and selectivity 
23. BioGPS: The Music for the Chemo- and Bioinformatics Walzer 
24. Bioinformatics methods in drug repurposing for Alzheimer's disease 
25. C-SPADE: a web-tool for interactive analysis and visualization of drug screening experiments 
through compound-specific bioactivity dendrograms 
26. Can sodium/hydrogen exchange inhibitors be repositioned for treating attention deficit hyperactivity 
disorder? An in silico approach 
27. CANDO and the infinite drug discovery frontier 
28. CellFateScout - a bioinformatics tool for elucidating small molecule signaling pathways that drive 
cells in a specific direction 
29. Characterizing protein domain associations by Small-molecule ligand binding 
30. Characterizing the pocketome of Mycobacterium tuberculosis and application in rationalizing 
polypharmacological target selection 
31. ChemMapper: a versatile web server for exploring pharmacology and chemical structure association 
based on molecular 3D similarity method 
32. Classifying cancer genome aberrations by their mutually exclusive effects on transcription 
33. Community-driven roadmap for integrated disease maps 
34. Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate 
Synthase Case 
35. Complex-disease networks of trait-associated single-nucleotide polymorphisms (SNPs) unveiled by 
information theory 
36. Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with 
Repurposing Potential 
37. Computational drug repositioning through heterogeneous network clustering 
38. Computational drug repurposing to predict approved and novel drug-disease associations 
39. Computational Drug Target Screening through Protein Interaction Profiles 
 




40. Concept Modeling-based Drug Repositioning 
41. Constructing Disease Similarity Networks Based on Disease Module Theory 
42. Construction of drug network based on side effects and its application for drug repositioning 
43. Convergent downstream candidate mechanisms of independent intergenic polymorphisms between 
co-classified diseases implicate epistasis among noncoding elements 
44. CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM 
45. Designing Dietary Recommendations Using System Level Interactomics Analysis and Network-
Based Inference 
46. Detecting drug promiscuity using Gaussian ensemble screening 
47. Detection of Binding Site Molecular Interaction Field Similarities 
48. Diclofenac Identified as a Kynurenine 3-Monooxygenase Binder and Inhibitor by Molecular 
Similarity Techniques 
49. Diffusion mapping of drug targets on disease signaling network elements reveals drug combination 
strategies 
50. Discovering gene re-ranking efficiency and conserved gene-gene relationships derived from gene co-
expression network analysis on breast cancer data 
51. Discovery of drug mode of action and drug repositioning from transcriptional responses 
52. Discovery of Novel Liver-Stage Antimalarials through Quantum Similarity 
53. Discovery of Novel SPAK Inhibitors That Block WNK Kinase Signaling to Cation Chloride 
Transporters 
54. Disease classification: from phenotypic similarity to integrative genomics and beyond 
55. DiseaseConnect: a comprehensive web server for mechanism-based disease-disease connections 
56. DMAP: a connectivity map database to enable identification of novel drug repositioning candidates 
57. DNetDB: The human disease network database based on dysfunctional regulation mechanism 
58. Docking of a novel DNA methyltransferase inhibitor identified from high-throughput screening: 
insights to unveil inhibitors in chemical databases 
59. DR2DI: a powerful computational tool for predicting novel drug-disease associations 
60. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking 
(MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-
6/GP130 interface 
 




61. Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key 
62. Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm 
63. Drug repositioning based on triangularly balanced structure for tissue-specific diseases in incomplete 
interactome 
64. Drug repositioning by applying 'expression profiles' generated by integrating chemical structure 
similarity and gene semantic similarity 
65. Drug Repositioning by Integrating Known Disease-Gene and Drug-Target Associations in a Semi-
supervised Learning Model 
66. Drug repositioning by kernel-based integration of molecular structure, molecular activity, and 
phenotype data 
67. Drug repositioning for enzyme modulator based on human metabolite-likeness 
68. Drug Repositioning through Systematic Mining of Gene Coexpression Networks in Cancer 
69. Drug repurposing based on drug-drug interaction 
70. Drug Repurposing Using Deep Embeddings of Gene Expression Profiles 
71. Drug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for 
Drug Repositioning in Cancer Therapy 
72. Drug similarity search based on combined signatures in gene expression profiles 
73. Drug target prediction using adverse event report systems: a pharmacogenomic approach 
74. Drug-target interaction prediction by integrating chemical, genomic, functional and pharmacological 
data 
75. Drug-target interaction prediction by integrating multiview network data 
76. DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-
based drug repurposing 
77. Drugs Polypharmacology by In Silico Methods: New Opportunities in Drug Discovery 
78. DSviaDRM: an R package for estimating disease similarity via dysfunctional regulation mechanism 
79. DT-Web: a web-based application for drug-target interaction and drug combination prediction 
through domain-tuned network-based inference 
80. Elucidating the modes of action for bioactive compounds in a cell-specific manner by large-scale 
chemically-induced transcriptomics 
81. Estimated generic prices for novel treatments for drug-resistant tuberculosis 
 




82. Exploring Polypharmacology in Drug Discovery and Repurposing Using the CANDO Platform 
83. Finding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-
based systems biology approach 
84. Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking 
(MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and 
activator of transcription 3 (STAT3 
85. Fusing literature and full network data improves disease similarity computation 
86. Generating Gene Ontology-Disease Inferences to Explore Mechanisms of Human Disease at the 
Comparative Toxicogenomics Database 
87. GES polypharmacology fingerprints: a novel approach for drug repositioning 
88. How good are publicly available web services that predict bioactivity profiles for drug repurposing 
89. Human disease-drug network based on genomic expression profiles 
90. Human pathway-based disease network 
91. Identification of associations between small molecule drugs and miRNAs based on functional 
similarity 
92. Identification of cisapride as new inhibitor of putrescine uptake in Trypanosoma cruzi by combined 
ligand- and structure-based virtual screening 
93. Identification of driver copy number alterations in diverse cancer types and application in drug 
repositioning 
94. Identify drug repurposing candidates by mining the protein data bank 
95. Improved anticancer drug response prediction in cell lines using matrix factorization with similarity 
regularization 
96. In Silico Receptorome Screening of Antipsychotic Drugs 
97. In Silico target fishing: addressing a "Big Data" problem by ligand-based similarity rankings with data 
fusion 
98. In Silico-Based Repositioning of Phosphinothricin as a Novel Technetium-99m Imaging Probe with 
Potential Anti-Cancer Activity 
99. In vitro analysis of finasteride activity against Candida albicans urinary biofilm formation and 
filamentation 
100. In vitro screening for drug repositioning 
 




101. Inferring disease association using clinical factors in a combinatorial manner and their use in drug 
repositioning 
102. Inferring new drug indications using the complementarity between clinical disease signatures and 
drug effects 
103. Inferring new indications for approved drugs via random walk on drug-disease heterogenous 
networks 
104. Integrated Computational Analysis of Genes Associated with Human Hereditary Insensitivity to 
Pain. A Drug Repurposing Perspective 
105. Integrating Clinical Phenotype and Gene Expression Data to Prioritize Novel Drug Uses 
106. Large-scale Direct Targeting for Drug Repositioning and Discovery 
107. Large-scale integration of heterogeneous pharmacogenomic data for identifying drug mechanism of 
action 
108. Leveraging 3D chemical similarity, target and phenotypic data in the identification of drug-protein 
and drug-adverse effect associations 
109. Linking PharmGKB to phenotype studies and animal models of disease for drug repurposing 
110. Literature-based discovery of new candidates for drug repurposing 
111. Logical comparison over RDF resources in bio-informatics 
112. Medical concept normalization in social media posts with recurrent neural networks 
113. MeSHDD: Literature-based drug-drug similarity for drug repositioning 
114. miREFRWR: a novel disease-related microRNA-environmental factor interactions prediction 
method 
115. MOST: most-similar ligand based approach to target prediction 
116. Mouse model phenotypes provide information about human drug targets 
117. MTGO: PPI Network Analysis Via Topological and Functional Module Identification 
118. Multiscale modelling of relationships between protein classes and drug behavior across all diseases 
using the CANDO platform 
119. Network measures for chemical library design 
120. Network medicine in disease analysis and therapeutics 
121. Network predicting drug's anatomical therapeutic chemical code 
 




122. Network-based analysis of transcriptional profiles from chemical perturbations experiments 
123. Network-based drug ranking and repositioning with respect to DrugBank therapeutic categories 
124. Network-based drug repositioning: A novel strategy for discovering potential antidepressants and 
their mode of action 
125. Network-based prediction and knowledge mining of disease genes 
126. NetwoRx: connecting drugs to networks and phenotypes in Saccharomyces cerevisiae 
127. New HSP27 inhibitors efficiently suppress drug resistance development in cancer cells 
128. Old friends in new guise: repositioning of known drugs with structural bioinformatics 
129. Orphan receptor ligand discovery by pickpocketing pharmacological neighbors 
130. Pathway-based Bayesian inference of drug-disease interactions 
131. Personalized drug discovery: HCA approach optimized for rare diseases at Tel Aviv University 
132. Pharmacological use of a novel scaffold, anomeric N,N-diarylamino tetrahydropyran: molecular 
similarity search, chemocentric target profiling, and experimental evidence 
133. Polypharmacological Drug-target Inference for Chemogenomics 
134. Polypharmacology rescored: protein-ligand interaction profiles for remote binding site similarity 
assessment 
135. PREDICT: a method for inferring novel drug indications with application to personalized medicine 
136. Predicting drug-disease associations and their therapeutic function based on the drug-disease 
association bipartite network 
137. Predicting drug-disease interactions by semi-supervised graph cut algorithm and three-layer data 
integration 
138. Predicting drug-target interaction for new drugs using enhanced similarity measures and super-target 
clustering 
139. Predicting drug-target interactions using probabilistic matrix factorization 
140. Predicting Drug-Target Interactions With Multi-Information Fusion 
141. Predicting targeted polypharmacology for drug repositioning and multi- target drug discovery 
142. Prediction of drug-target interaction by label propagation with mutual interaction information 
derived from heterogeneous network 
143. Prediction of drug-target interactions and drug repositioning via network-based inference 
 




144. Prediction of drug-target interactions for drug repositioning only based on genomic expression 
similarity 
145. Prediction of Non-coding RNAs as Drug Targets 
146. Prediction of novel drug indications using network driven biological data prioritization and 
integration 
147. Prediction of Novel Drugs and Diseases for Hepatocellular Carcinoma Based on Multi-Source 
Simulated Annealing Based Random Walk 
148. Prediction of Novel Drugs for Hepatocellular Carcinoma Based on Multi-Source Random Walk 
149. Prediction of off-target drug effects through data fusion 
150. Prediction of polypharmacological profiles of drugs by the integration of chemical, side effect, and 
therapeutic space 
151. PROMISCUOUS: a database for network-based drug-repositioning 
152. Protein-ligand-based pharmacophores: generation and utility assessment in computational ligand 
profiling 
153. Rational drug repurposing using sscMap analysis in a HOX-TALE model of leukemia 
154. Re-positioning protein-kinase inhibitors against schistosomiasis 
155. Recent advances in the machine learning-based drug-target interaction prediction 
156. Relating anatomical therapeutic indications by the ensemble similarity of drug sets 
157. Repositioning of Endonuclear Receptors Binders as Potential Antibacterial and Antifungal Agents. 
Eptyloxim: A Potential and Novel Gyrase B and Cytochrome Cyp51 Inhibitor 
158. Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer 
159. REPRODUCIBLE DRUG REPURPOSING: WHEN SIMILARITY DOES NOT SUFFICE 
160. RepTB: a gene ontology based drug repurposing approach for tuberculosis 
161. Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent 
antitubercular agents 
162. Review and comparative assessment of similarity-based methods for prediction of drug-protein 
interactions in the druggable human proteome 
163. Revisiting Antipsychotic Drug Actions Through Gene Networks Associated With Schizophrenia 
164. Ribavirin as a tri-targeted antitumor repositioned drug 
 




165. SCMBYK: prediction and characterization of bacterial tyrosine-kinases based on propensity scores 
of dipeptides 
166. Scoring multiple features to predict drug disease associations using information fusion and 
aggregation 
167. SELF-BLM: Prediction of drug-target interactions via self-training SVM 
168. SemFunSim: a new method for measuring disease similarity by integrating semantic and gene 
functional association 
169. SMAP-WS: a parallel web service for structural proteome-wide ligand-binding site comparison 
170. Some Remarks on Prediction of Drug-Target Interaction with Network Models 
171. SPIDR: small-molecule peptide-influenced drug repurposing 
172. Steroids-specific target library for steroids target prediction 
173. Structural analysis of dihydrofolate reductases enables rationalization of antifolate binding affinities 
and suggests repurposing possibilities 
174. Substrate-driven mapping of the degradome by comparison of sequence logos 
175. Systematic drug repositioning based on clinical side-effects 
176. Systematic drug repositioning for a wide range of diseases with integrative analyses of phenotypic 
and molecular data 
177. Target-Based Drug Repositioning Using Large-Scale Chemical-Protein Interactome Data 
178. Target-similarity search using Plasmodium falciparum proteome identifies approved drugs with anti-
malarial activity and their possible targets 
179. TargetHunter: an in silico target identification tool for predicting therapeutic potential of small 
organic molecules based on chemogenomic database 
180. The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod 
181. The human disease network in terms of dysfunctional regulatory mechanisms 
182. The role of drug profiles as similarity metrics: applications to repurposing, adverse effects detection 
and drug-drug interactions 
183. Thiopurine Drugs Repositioned as Tyrosinase Inhibitors 
184. Tools for in silico target fishing 
185. Toward a Reasoned Classification of Diseases Using Physico-Chemical Based Phenotypes 
 




186. Toward drug repurposing in epigenetics: olsalazine as a hypomethylating compound active in a 
cellular context 
187. Towards drug repositioning: a unified computational framework for integrating multiple aspects of 
drug similarity and disease similarity 
188. Updates on drug-target network; facilitating polypharmacology and data integration by growth of 
DrugBank database 
189. Virtual Screening against Phosphoglycerate Kinase 1 in Quest of Novel Apoptosis Inhibitors 
190. VisANT 4.0: Integrative network platform to connect genes, drugs, diseases and therapies 









FACTOR 17. Machine Learning-Based Drug Repurposing Prediction 
1. A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target 
Therapies in Triple Negative Breast Cancer 
2. A Network-Biology Informed Computational Drug Repositioning Strategy to Target Disease Risk 
Trajectories and Comorbidities of Peripheral Artery Disease 
3. A profound computational study to prioritize the disease-causing mutations in PRPS1 gene 
4. A Simple Text Mining Approach for Ranking Pairwise Associations in Biomedical Applications 
5. A systematic and prospectively validated approach for identifying synergistic drug combinations 
against malaria 
6. A tool to utilize adverse effect profiles to identify brain-active medications for repurposing 
7. A two-tiered unsupervised clustering approach for drug repositioning through heterogeneous data 
integration 
8. Accidental interaction between PDZ domains and diclofenac revealed by NMR-assisted virtual 
screening 
9. Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease 
10. AlzhCPI: A knowledge base for predicting chemical-protein interactions towards Alzheimer's disease 
11. Alzheimer's Disease (AD) therapeutics - 1: Repeated clinical failures continue to question the amyloid 
hypothesis of AD and the current understanding of AD causality 
12. An improved approach for predicting drug-target interaction: proteochemometrics to molecular 
docking 
13. An integrative approach using real-world data to identify alternative therapeutic uses of existing drugs 
14. Analysis and assay of oseltamivir-resistant mutants of influenza neuraminidase via direct observation 
of drug unbinding and rebinding in simulation 
15. Analysis of A Drug Target-based Classification System using Molecular Descriptors 
16. Anti-infectious drug repurposing using an integrated chemical genomics and structural systems 
biology approach 
17. Automatic construction of a large-scale and accurate drug-side-effect association knowledge base 
from biomedical literature 
18. Binding site matching in rational drug design: algorithms and applications 
19. BioGPS: navigating biological space to predict polypharmacology, off-targeting, and selectivity 
 




20. BioGPS: The Music for the Chemo- and Bioinformatics Walzer 
21. Bioinformatics and Drug Discovery 
22. Bioinformatics approach to prioritize known drugs towards repurposing for tuberculosis 
23. Bioinformatics in translational drug discovery 
24. Characterizing the pocketome of Mycobacterium tuberculosis and application in rationalizing 
polypharmacological target selection 
25. Checking the STEP-Associated Trafficking and Internalization of Glutamate Receptors for Reduced 
Cognitive Deficits: A Machine Learning Approach-Based Cheminformatics Study and Its Application for 
Drug Repurposing 
26. Chemical-induced disease extraction via recurrent piecewise convolutional neural networks 
27. Classifying cancer genome aberrations by their mutually exclusive effects on transcription 
28. Clustering drug-drug interaction networks with energy model layouts: community analysis and drug 
repurposing 
29. Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease 
30. Combining Human Disease Genetics and Mouse Model Phenotypes towards Drug Repositioning for 
Parkinson's disease 
31. Comparative assessment of strategies to identify similar ligand-binding pockets in proteins 
32. Comparing a knowledge-driven approach to a supervised machine learning approach in large-scale 
extraction of drug-side effect relationships from free-text biomedical literature 
33. Comparing structural and transcriptional drug networks reveals signatures of drug activity and toxicity 
in transcriptional responses 
34. Computational Discovery of Putative Leads for Drug Repositioning through Drug-Target Interaction 
Prediction 
35. Computational Drug Repositioning by Target Hopping: A Use Case in Chagas Disease 
36. Computational identification of multi-omic correlates of anticancer therapeutic response 
37. Computational polypharmacology: a new paradigm for drug discovery 
38. Computational Prediction of Drug?Target Interactions Using Chemical, Biological, and Network 
Features 
39. Computational profiling of bioactive compounds using a target-dependent composite workflow 
40. Computational Study of Drugs by Integrating Omics Data with Kernel Methods 
 




41. Computational tools for polypharmacology and repurposing 
42. Computational-experimental approach to drug-target interaction mapping: A case study on kinase 
inhibitors 
43. COMPUTING THERAPY FOR PRECISION MEDICINE: COLLABORATIVE FILTERING 
INTEGRATES AND PREDICTS MULTI-ENTITY INTERACTIONS 
44. Concept-based semi-automatic classification of drugs 
45. Connection Map for Compounds (CMC): A Server for Combinatorial Drug Toxicity and Efficacy 
Analysis 
46. Connectivity mapping using a combined gene signature from multiple colorectal cancer datasets 
identified candidate drugs including existing chemotherapies 
47. Data Sets Representative of the Structures and Experimental Properties of FDA-Approved Drugs 
48. Deciphering miRNA transcription factor feed-forward loops to identify drug repurposing candidates 
for cystic fibrosis 
49. Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug 
Repurposing Using Transcriptomic Data 
50. DenguePredict: An Integrated Drug Repositioning Approach towards Drug Discovery for Dengue 
51. Design of efficient computational workflows for in silico drug repurposing 
52. Designing Dietary Recommendations Using System Level Interactomics Analysis and Network-
Based Inference 
53. Discovery of Novel Liver-Stage Antimalarials through Quantum Similarity 
54. Discovery of novel therapeutic properties of drugs from transcriptional responses based on multi-label 
classification 
55. Docking of a novel DNA methyltransferase inhibitor identified from high-throughput screening: 
insights to unveil inhibitors in chemical databases 
56. Drug repositioning for non-small cell lung cancer by using machine learning algorithms and 
topological graph theory 
57. Drug repositioning for schizophrenia and depression/anxiety disorders: A machine learning approach 
leveraging expression data 
58. Drug repositioning: a machine-learning approach through data integration 
59. Drug Repurposing by Simulating Flow Through Protein-Protein Interaction Networks 
 




60. Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank 
database for allosteric Bcr-Abl inhibitors 
61. Drug Repurposing Screening Identifies Tioconazole as an ATG4 Inhibitor that Suppresses Autophagy 
and Sensitizes Cancer Cells to Chemotherapy 
62. Drug repurposing to target Ebola virus replication and virulence using structural systems 
pharmacology 
63. Drug Repurposing Using Deep Embeddings of Gene Expression Profiles 
64. Drug repurposing: An approach to tackle drug resistance in S. typhimurium 
65. Drug Side Effect Profiles as Molecular Descriptors for Predictive Modeling of Target Bioactivity 
66. Drug target prediction and repositioning using an integrated network-based approach 
67. Drug-target interaction prediction by integrating multiview network data 
68. Drug-target interaction prediction: A Bayesian ranking approach 
69. DT-Web: a web-based application for drug-target interaction and drug combination prediction 
through domain-tuned network-based inference 
70. eMatchSite: sequence order-independent structure alignments of ligand binding pockets in protein 
models 
71. Epigenetic Drug Repositioning for Alzheimer's Disease Based on Epigenetic Targets in Human 
Interactome 
72. Estimated generic prices for novel treatments for drug-resistant tuberculosis 
73. Exploiting drug-disease relationships for computational drug repositioning 
74. Extracting drug-enzyme relation from literature as evidence for drug drug interaction 
75. FDA approved drugs complexed to their targets: evaluating pose prediction accuracy of docking 
protocols 
76. Fishing Anti-Inflammatories from Known Drugs: In Silico Repurposing, Design, Synthesis and 
Biological Evaluation of Bisacodyl Analogues 
77. Folic Acid Exerts Post-Ischemic Neuroprotection In Vitro Through HIF-1alpha Stabilization 
78. Fusing literature and full network data improves disease similarity computation 
79. GeneExpressionSignature: an R package for discovering functional connections using gene expression 
signatures 
80. High-throughput analysis of behavior for drug discovery 
 




81. How good are publicly available web services that predict bioactivity profiles for drug repurposing 
82. IBM Watson: How Cognitive Computing Can Be Applied to Big Data Challenges in Life Sciences 
Research 
83. Identification of drug candidates and repurposing opportunities through compound-target interaction 
networks 
84. Identification of toxin inhibitors using a magnetic nanosensor-based assay 
85. In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-
melanoma drug, for Parkinson's disease 
86. In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a 
Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug 
87. In silico identification of potent small molecule inhibitors targeting epidermal growth factor receptor 
1 
88. In silico prediction and in vitro and in vivo validation of acaricide fluazuron as a potential inhibitor of 
FGFR3 and a candidate anticancer drug for bladder carcinoma 
89. In silico repurposing of antipsychotic drugs for Alzheimer's disease 
90. Incorporating Protein Dynamics Through Ensemble Docking in Machine Learning Models to Predict 
Drug Binding 
91. Inhibitors for the hepatitis C virus RNA polymerase explored by SAR with advanced machine 
learning methods 
92. Insights into the Modulation of Dopamine Transporter Function by Amphetamine, Orphenadrine, and 
Cocaine Binding 
93. Integrated Computational Analysis of Genes Associated with Human Hereditary Insensitivity to Pain. 
A Drug Repurposing Perspective 
94. Intelligent and effective informatic deconvolution of "Big Data" and its future impact on the 
quantitative nature of neurodegenerative disease therapy 
95. Interactions of Selective Serotonin Reuptake Inhibitors with beta-Amyloid 
96. Introduction: Cancer Gene Networks 
97. Large-scale automatic extraction of side effects associated with targeted anticancer drugs from full-
text oncological articles 
98. Large-scale detection of drug off-targets: hypotheses for drug repurposing and understanding side-
effects 
 




99. Large-Scale Off-Target Identification Using Fast and Accurate Dual Regularized One-Class 
Collaborative Filtering and Its Application to Drug Repurposing 
100. Link prediction in drug-target interactions network using similarity indices 
101. Linking drug target and pathway activation for effective therapy using multi-task learning 
102. Machine learning models identify molecules active against the Ebola virus in vitro 
103. Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical 
properties 
104. Medical concept normalization in social media posts with recurrent neural networks 
105. Modern disease-modifying antirheumatic drugs 
106. Molecular investigations of protriptyline as a multi-target directed ligand in Alzheimer's disease 
107. Molecular property diagnostic suite for diabetes mellitus (MPDSDM): An integrated web portal for 
drug discovery and drug repurposing 
108. Molecular Topology and other Promiscuity Determinants as Predictors of Therapeutic Class- A 
Theoretical Framework to guide Drug Repositioning 
109. MOST: most-similar ligand based approach to target prediction 
110. MTGO: PPI Network Analysis Via Topological and Functional Module Identification 
111. Multivariate analysis in the identification of biological targets for designed molecular structures: the 
BIOTA protocol 
112. Network mirroring for drug repositioning 
113. Network-based drug ranking and repositioning with respect to DrugBank therapeutic categories 
114. Network-based machine learning and graph theory algorithms for precision oncology 
115. Neuroprotective Drug for Nerve Trauma Revealed Using Artificial Intelligence 
116. NMR spectroscopy-based metabolic profiling of drug-induced changes in vitro can discriminate 
between pharmacological classes 
117. Open-source chemogenomic data-driven algorithms for predicting drug-target interactions 
118. Parkinson's Disease, Diabetes and Cognitive Impairment 
119. Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia 
Patients 
 




120. PATIENT-SPECIFIC DATA FUSION FOR CANCER STRATIFICATION AND 
PERSONALISED TREATMENT 
121. Polypharmacology rescored: protein-ligand interaction profiles for remote binding site similarity 
assessment 
122. Potential repositioning of exemestane as a neuroprotective agent for Parkinson's disease 
123. Predicting anatomic therapeutic chemical classification codes using tiered learning 
124. Predicting drug-target interaction for new drugs using enhanced similarity measures and super-target 
clustering 
125. Predicting drug-target interactions using restricted Boltzmann machines 
126. Prediction of anti-cancer drug response by kernelized multi-task learning 
127. Prediction of drug-target interaction by label propagation with mutual interaction information 
derived from heterogeneous network 
128. Prediction of Human Drug Targets and Their Interactions Using Machine Learning Methods: 
Current and Future Perspectives 
129. Prioritizing therapeutics for lung cancer: an integrative meta-analysis of cancer gene signatures and 
chemogenomic data 
130. Protein localization vector propagation: a method for improving the accuracy of drug repositioning 
131. Protein-ligand-based pharmacophores: generation and utility assessment in computational ligand 
profiling 
132. Proteome-scale docking: myth and reality 
133. RANKS: a flexible tool for node label ranking and classification in biological networks 
134. Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency 
and with GABAA potentiating activity for use in dementia 
135. Recent advances in the machine learning-based drug-target interaction prediction 
136. Recent progress in repositioning Alzheimer's disease drugs based on a multitarget strategy 
137. Reprint of: Highthroughtput analysis of behavior for drug discovery 
138. REPRODUCIBLE DRUG REPURPOSING: WHEN SIMILARITY DOES NOT SUFFICE 
139. Repurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic medical records 
140. Repurposed drugs for the treatment of schizophrenia and bipolar disorders 
 




141. Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast 
cancer 
142. Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2 
143. Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease 
144. Review and comparative assessment of similarity-based methods for prediction of drug-protein 
interactions in the druggable human proteome 
145. Scoring multiple features to predict drug disease associations using information fusion and 
aggregation 
146. SELF-BLM: Prediction of drug-target interactions via self-training SVM 
147. SMAP-WS: a parallel web service for structural proteome-wide ligand-binding site comparison 
148. Some Remarks on Prediction of Drug-Target Interaction with Network Models 
149. Structural analysis of protein tyrosine phosphatase 1B reveals potentially druggable allosteric 
binding sites 
150. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors 
151. Structure based investigation on the binding interaction of transport proteins in leishmaniasis: 
insights from molecular simulation 
152. Structure Investigation, Enrichment Analysis and Structure-based Repurposing of FDA-approved 
Drugs as Inhibitors of BET-BRD4 
153. Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of 
influenza A virus 
154. Synergistic drug combinations from electronic health records and gene expression 
155. Systematic Prioritization of Druggable Mutations in 5000 Genomes Across 16 Cancer Types Using a 
Structural Genomics-based Approach 
156. Systems chemical biology and the Semantic Web: what they mean for the future of drug discovery 
research 
157. Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of 
Neuroendocrine Prostate Cancer 
158. Tacrine-deferiprone hybrids as multi-target-directed metal chelators against Alzheimer's disease: a 
two-in-one drug 
159. The EYA tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromarone 
 




160. Toward creation of a cancer drug toxicity knowledge base: automatically extracting cancer drug-side 
effect relationships from the literature 
161. Toward more realistic drug-target interaction predictions 
162. Using predicate and provenance information from a knowledge graph for drug efficacy screening 
163. Using reverse docking for target identification and its applications for drug discovery 
164. Using Social Media Data to Identify Potential Candidates for Drug Repurposing: A Feasibility Study 
165. Valproic acid mediates miR-124 to down-regulate a novel protein target, GNAI1 
166. Virtual screening and repositioning of inconclusive molecules of beta-lactamase Bioassays-A data 
mining approach 








FACTOR 18. Tyrosine Kinase Inhibitors Repurposed for Cancer Treatment 
1. A chemical-genetic interaction map of small molecules using high-throughput imaging in cancer cells 
2. A combined systems and structural modeling approach repositions antibiotics for Mycoplasma 
genitalium 
3. A comprehensive approach to identifying repurposed drugs to treat SCN8A epilepsy 
4. A curated C. difficile strain 630 metabolic network: prediction of essential targets and inhibitors 
5. A current perspective on the oncopreventive and oncolytic properties of selective serotonin reuptake 
inhibitors 
6. A Dual Readout Assay Based on Fluorescence Polarization and Time-Resolved Fluorescence 
Resonance Energy Transfer to Screen for RSK1 Inhibitors 
7. A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor 
Ponatinib for Repurposing in Neuroblastoma Therapy 
8. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for 
cryptosporidiosis 
9. A large-scale computational approach to drug repositioning 
10. A Large-Scale Gene Expression Intensity-Based Similarity Metric for Drug Repositioning 
11. A machine learning-based method to improve docking scoring functions and its application to drug 
repurposing 
12. A network integration approach for drug-target interaction prediction and computational drug 
repositioning from heterogeneous information 
13. A novel cell-based high-throughput screen for inhibitors of HIV-1 gene expression and budding 
identifies the cardiac glycosides 
14. A Novel High Content Imaging-Based Screen Identifies the Anti-Helminthic Niclosamide as an 
Inhibitor of Lysosome Anterograde Trafficking and Prostate Cancer Cell Invasion 
15. A novel multi-modal drug repurposing approach for identification of potent ACK1 inhibitors 
16. A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, 
West Nile and Chikungunya viruses 
17. A repurposing strategy for Hsp90 inhibitors demonstrates their potency against filarial nematodes 
18. A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection 
19. A small molecule screen identifies an inhibitor of DNA repair inducing the degradation of TFIIH and 
the chemosensitization of tumor cells to platinum 
 




20. A structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 
ATPase 
21. A systematic analysis of FDA-approved anticancer drugs 
22. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents 
23. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus 
and Middle East Respiratory Syndrome Coronavirus Fusion 
24. Activation of RXR/PPARgamma underlies neuroprotection by bexarotene in ischemic stroke 
25. Activity of anti-cancer protein kinase inhibitors against Leishmania spp 
26. Adaptive mitochondrial reprogramming and resistance to PI3K therapy 
27. Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus 
28. Advances in Developing Therapies to Combat Zika Virus: Current Knowledge and Future 
Perspectives 
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326. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease 
327. Repurposing an established drug: an emerging role for methylene blue in L-DOPA-induced 
dyskinesia 
328. Repurposing an orally available drug for the treatment of geographic atrophy 
329. Repurposing an Osteoporosis Drug for beta Cell Regeneration in Diabetic Patients 
330. Repurposing anticancer drugs for targeting necroptosis 
331. Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents 
332. Repurposing drugs to target the malaria parasite unfolding protein response 
333. Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans 
 




334. Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection 
335. Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the 
human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei 
336. Repurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and 
evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors 
337. Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication 
338. Repurposing N,N'-bis-(arylamidino)-1,4-piperazinedicarboxamidines: An unexpected class of potent 
inhibitors of cholinesterases 
339. Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma mansoni 
340. Repurposing of approved cardiovascular drugs 
341. Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast 
cancer 
342. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome 
coronavirus infection 
343. Repurposing of Human Kinase Inhibitors in Neglected Protozoan Diseases 
344. Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs 
345. Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-beta-N-
acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease 
346. Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease 
347. Repurposing steroidogenesis inhibitors for the therapy of neuropsychiatric disorders: Promises and 
caveats 
348. Repurposing Strategy of Atorvastatin against Trypanosoma cruzi: In Vitro Monotherapy and 
Combined Therapy with Benznidazole Exhibit Synergistic Trypanocidal Activity 
349. Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori 
350. Repurposing the clinically approved calcium antagonist manidipine dihydrochloride as a new early 
inhibitor of human cytomegalovirus targeting the Immediate-Early 2 (IE2) protein 
351. Repurposing Thioridazine (TDZ) as an anti-inflammatory agent 
352. Resistance-resistant antibiotics 
353. Response to hydralazine-valproate in a patient with mycosis fungoides 
 




354. Rho-associated kinase signalling and the cancer microenvironment: novel biological implications 
and therapeutic opportunities 
355. Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian 
cancer cells 
356. Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT 
Pathways 
357. Role of TGFbeta in regulation of the tumor microenvironment and drug delivery (review 
358. Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy 
359. S100A4 in Cancer Metastasis: Wnt Signaling-Driven Interventions for Metastasis Restriction 
360. Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library 
361. Screening of a composite library of clinically used drugs and well-characterized pharmacological 
compounds for cystathionine beta-synthase inhibition identifies benserazide as a drug potentially suitable 
for repurposing for the experimental therapy of colon cancer 
362. Screening of a Drug Library Identifies Inhibitors of Cell Intoxication by CNF1 
363. Screening of FDA-Approved Drugs for Inhibitors of Japanese Encephalitis Virus Infection 
364. Screening of FDA-Approved Drugs for Treatment of Emerging Pathogens 
365. Selective human inhibitors of ATR and ATM render Leishmania major promastigotes sensitive to 
oxidative damage 
366. Sequence Analysis of Drug Target Genes with Suicidal Behavior in Bipolar Disorder Patients 
367. Simvastatin increases the in vivo activity of the first-line tuberculosis regimen 
368. Simvastatin Therapy for Drug Repositioning to Reduce the Risk of Prostate Cancer Mortality in 
Patients With Hyperlipidemia 
369. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in 
cancer cell lines 
370. Small molecule inhibition of apicomplexan FtsH1 disrupts plastid biogenesis in human pathogens 
371. Sphingolipids as targets for inhalation treatment of cystic fibrosis 
372. Stairway to Heaven or Hell? Perspectives and Limitations of Chagas Disease Chemotherapy 
373. Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via 
MACC1 
 




374. Strategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant 
bacterial infections 
375. Structural analysis of dihydrofolate reductases enables rationalization of antifolate binding affinities 
and suggests repurposing possibilities 
376. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 
reverse transcriptase 
377. Structural Basis of Metallo-beta-Lactamase Inhibition by Captopril Stereoisomers 
378. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors 
379. Structural re-positioning, in silico molecular modelling, oxidative degradation, and biological 
screening of linagliptin as adenosine 3 receptor (ADORA3) modulators targeting hepatocellular 
carcinoma 
380. Structure based investigation on the binding interaction of transport proteins in leishmaniasis: 
insights from molecular simulation 
381. Structure Investigation, Enrichment Analysis and Structure-based Repurposing of FDA-approved 
Drugs as Inhibitors of BET-BRD4 
382. Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of 
influenza A virus 
383. Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-
approved phosphodiesterase inhibitors in the mouse model 
384. Support for phosphoinositol 3 kinase and mTOR inhibitors as treatment for lupus using in-silico 
drug-repurposing analysis 
385. Systemic amyloidosis: novel therapies and role of biomarkers 
386. Systems approach to the pharmacological actions of HDAC inhibitors reveals EP300 activities and 
convergent mechanisms of regulation in diabetes 
387. Target Fishing by Cross-Docking to Explain Polypharmacological Effects 
388. Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic 
protease in mycobacteria 
389. Targeting Abl kinases to regulate vascular leak during sepsis and acute respiratory distress syndrome 
390. Targeting ADAM17 Sheddase Activity in Cancer 
391. Targeting cyclin D3/CDK6 activity for treatment of Parkinson's disease 
 




392. Targeting intracellular p-aminobenzoic acid production potentiates the anti-tubercular action of 
antifolates 
393. Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins 
394. Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion 
injury and for treating heart failure 
395. Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from 
nature and drug repurposing 
396. The A-Z of Zika drug discovery 
397. The Antiarrhythmic Drug, Amiodarone, Decreases AKT Activity and Sensitizes Human Acute 
Myeloid Leukemia Cells to Apoptosis by ABT-263 
398. The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell 
carcinoma 
399. The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis 
400. The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced 
apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes 
401. The EYA tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromarone 
402. The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate 
cancer 
403. The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer's 
disease amyloid-beta peptides 
404. The Glucose Transporter PfHT1 Is an Antimalarial Target of the HIV Protease Inhibitor Lopinavir 
405. The Hippo pathway in normal development and cancer 
406. The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug 
discovery via target repurposing 
407. The human immunodeficiency virus protease inhibitor ritonavir is potentially active against 
urological malignancies 
408. The Linked Clinical Trials Initiative (LCT) for Parkinson's disease 
409. The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance 
in cancer cell lines 
410. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines 
and discovery of potential new DDK inhibitor scaffolds 
 




411. The proton-pump inhibitor lansoprazole enhances amyloid beta production 
412. The purchasable chemical space: a detailed picture 
413. The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer 
414. The Significance of Hypothiocyanite Production via the Pendrin/DUOX/Peroxidase Pathway in the 
Pathogenesis of Asthma 
415. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis 
416. The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new 
opportunity for drug repurposing 
417. The Tissue-Reconstructing Ability of Colon CSCs Is Enhanced by FK506 and Suppressed by GSK3 
Inhibition 
418. Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis 
419. Therapeutic Approaches to Type I Interferonopathies 
420. Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial 
agent 
421. Thiopurine Drugs Repositioned as Tyrosinase Inhibitors 
422. Toll-Like Receptor-4 Signaling Drives Persistent Fibroblast Activation and Prevents Fibrosis 
Resolution in Scleroderma 
423. Topical mevastatin promotes wound healing by inhibiting the transcription factor c-Myc via the 
glucocorticoid receptor and the long non-coding RNA Gas5 
424. Toward more realistic drug-target interaction predictions 
425. Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine 
Approach 
426. Transcriptomic changes induced by mycophenolic acid in gastric cancer cells 
427. Transcriptomic characterization of the novel avian-origin influenza A (H7N9) virus: specific host 
response and responses intermediate between avian (H5N1 and H7N7) and human (H3N2) viruses and 
implications for treatment options 
428. Treating Influenza Infection, From Now and Into the Future 
429. Treating the dysfunctional placenta 
430. Treatment of Cryptosporidium: What We Know, Gaps, and the Way Forward 
 




431. Treatment of experimental autoimmune uveoretinitis with peroxisome proliferator-activated receptor 
alpha agonist fenofibrate 
432. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug 
resistance of lung cancer 
433. Tyrosinase inhibitors: a patent review (2011-2015 
434. Using HIV drugs to target human papilloma virus 
435. Valproic acid in the complex therapy of malignant tumors 
436. Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA 
virus infection 
437. Virtual Screening against Phosphoglycerate Kinase 1 in Quest of Novel Apoptosis Inhibitors 
438. Virtual screening and drug repositioning as strategies for the discovery of new antifungal inhibitors 
of oxidosqualene cyclase 
439. Virtual screening and repositioning of inconclusive molecules of beta-lactamase Bioassays-A data 
mining approach 
440. Virtual screening-driven repositioning of etoposide as CD44 antagonist in breast cancer cells 
441. Virtual target screening: validation using kinase inhibitors 
442. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity 
and Metastasis 
443. West Nile virus drug discovery 
444. What do the genetic association data say about the high risk of suicide in people with depression? A 
novel network-based approach to find common molecular basis for depression and suicidal behavior and 








FACTOR 19. Chemical Structure Similarity for Repurposing Prediction 
1. A hybrid method for prediction and repositioning of drug Anatomical Therapeutic Chemical classes 
2. A New Method for Computational Drug Repositioning Using Drug Pairwise Similarity 
3. A potential target of Tanshinone IIA for acute promyelocytic leukemia revealed by inverse docking and 
drug repurposing 
4. A Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles 
Using Pathway-Drug Network 
5. AlzhCPI: A knowledge base for predicting chemical-protein interactions towards Alzheimer's disease 
6. Can sodium/hydrogen exchange inhibitors be repositioned for treating attention deficit hyperactivity 
disorder? An in silico approach 
7. Characterizing protein domain associations by Small-molecule ligand binding 
8. Chemical-protein interactome and its application in off-target identification 
9. ChemMapper: a versatile web server for exploring pharmacology and chemical structure association 
based on molecular 3D similarity method 
10. Concept-based semi-automatic classification of drugs 
11. Docking of a novel DNA methyltransferase inhibitor identified from high-throughput screening: 
insights to unveil inhibitors in chemical databases 
12. DPDR-CPI, a server that predicts Drug Positioning and Drug Repositioning via Chemical-Protein 
Interactome 
13. DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the 
chemical-protein interactome 
14. Drug repositioning by applying 'expression profiles' generated by integrating chemical structure 
similarity and gene semantic similarity 
15. Drug repositioning by kernel-based integration of molecular structure, molecular activity, and 
phenotype data 
16. Drug repurposing based on drug-drug interaction 
17. Drug target prediction by multi-view low rank embedding 
18. Elucidating the modes of action for bioactive compounds in a cell-specific manner by large-scale 
chemically-induced transcriptomics 
19. Exploring the anti-proliferative activity of Pelargonium sidoides DC with in silico target identification 
and network pharmacology 
 




20. Finding the targets of a drug by integration of gene expression data with a protein interaction network 
21. Identify potential drugs for cardiovascular diseases caused by stress-induced genes in vascular smooth 
muscle cells 
22. Identifying Candidates for Breast Cancer Using Interactions of Chemicals and Proteins 
23. IDMap: facilitating the detection of potential leads with therapeutic targets 
24. Individualized network-based drug repositioning infrastructure for precision oncology in the panomics 
era 
25. Inferring new indications for approved drugs via random walk on drug-disease heterogenous networks 
26. Inflammatory pathway network-based drug repositioning and molecular phenomics 
27. Large-scale integration of heterogeneous pharmacogenomic data for identifying drug mechanism of 
action 
28. Large-Scale Prediction of Beneficial Drug Combinations Using Drug Efficacy and Target Profiles 
29. Link prediction in drug-target interactions network using similarity indices 
30. Linking molecular feature space and disease terms for the immunosuppressive drug rapamycin 
31. Network predicting drug's anatomical therapeutic chemical code 
32. Personalizing Chinese medicine by integrating molecular features of diseases and herb ingredient 
information: application to acute myeloid leukemia 
33. Pharmacological use of a novel scaffold, anomeric N,N-diarylamino tetrahydropyran: molecular 
similarity search, chemocentric target profiling, and experimental evidence 
34. Predict drug permeability to blood-brain-barrier from clinical phenotypes: drug side effects and drug 
indications 
35. Prediction of chemical-protein interactions: multitarget-QSAR versus computational chemogenomic 
methods 
36. PubChem applications in drug discovery: a bibliometric analysis 
37. Repositioning of Endonuclear Receptors Binders as Potential Antibacterial and Antifungal Agents. 
Eptyloxim: A Potential and Novel Gyrase B and Cytochrome Cyp51 Inhibitor 
38. RepTB: a gene ontology based drug repurposing approach for tuberculosis 
39. Repurposing High-Throughput Image Assays Enables Biological Activity Prediction for Drug 
Discovery 
 




40. Repurposing of phentolamine as a potential anticancer agent against human castration-resistant 
prostate cancer: A central role on microtubule stabilization and mitochondrial apoptosis pathway 
41. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C 
virus infection 
42. SPIDR: small-molecule peptide-influenced drug repurposing 
43. Systematic drug repositioning for a wide range of diseases with integrative analyses of phenotypic and 
molecular data 
44. Systematic drug safety evaluation based on public genomic expression (Connectivity Map) data: 
myocardial and infectious adverse reactions as application cases 
45. Target-Based Drug Repositioning Using Large-Scale Chemical-Protein Interactome Data 
46. Toward more realistic drug-target interaction predictions 








FACTOR 20. Network-Based Inference for Predicting Drug-Target Interaction 
1. A bidirectional drug repositioning approach for Parkinson's disease through network-based inference 
2. A Biologically-Based Computational Approach to Drug Repurposing for Anthrax Infection 
3. A comparative study of disease genes and drug targets in the human protein interactome 
4. A computational approach to finding novel targets for existing drugs 
5. A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors 
6. A computational method for clinically relevant cancer stratification and driver mutation module 
discovery using personal genomics profiles 
7. A curated C. difficile strain 630 metabolic network: prediction of essential targets and inhibitors 
8. A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth 
muscle relaxation to direct neuroprotection 
9. A framework for the targeted selection of herbs with similar efficacy by exploiting drug repositioning 
technique and curated biomedical knowledge 
10. A genomics-based systems approach towards drug repositioning for rheumatoid arthritis 
11. A machine learning-based method to improve docking scoring functions and its application to drug 
repurposing 
12. A Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases 
13. A network based approach to drug repositioning identifies plausible candidates for breast cancer and 
prostate cancer 
14. A network integration approach for drug-target interaction prediction and computational drug 
repositioning from heterogeneous information 
15. A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target 
Therapies in Triple Negative Breast Cancer 
16. A network-based drug repositioning infrastructure for precision cancer medicine through targeting 
significantly mutated genes in the human cancer genomes 
17. A Network-Biology Informed Computational Drug Repositioning Strategy to Target Disease Risk 
Trajectories and Comorbidities of Peripheral Artery Disease 
18. A novel computational approach for drug repurposing using systems biology 
19. A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy 
 




20. A Practical Guide for Exploring Opportunities of Repurposing Drugs for CNS Diseases in Systems 
Biology 
21. A review of network-based approaches to drug repositioning 
22. A Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and 
Repositioning Predictions 
23. A simple mathematical approach to the analysis of polypharmacology and polyspecificity data 
24. A statin-regulated microRNA represses human c-Myc expression and function 
25. A systematic analysis of FDA-approved anticancer drugs 
26. A Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles 
Using Pathway-Drug Network 
27. A two-step drug repositioning method based on a protein-protein interaction network of genes shared 
by two diseases and the similarity of drugs 
28. A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case 
29. ADEPTUS: a discovery tool for disease prediction, enrichment and network analysis based on profiles 
from many diseases 
30. Advanced systems biology methods in drug discovery and translational biomedicine 
31. Advances in drug development for Parkinson's disease: present status 
32. Advances in epilepsy gene discovery and implications for epilepsy diagnosis and treatment 
33. AlzhCPI: A knowledge base for predicting chemical-protein interactions towards Alzheimer's disease 
34. Alzheimer's disease master regulators analysis: search for potential molecular targets and drug 
repositioning candidates 
35. An improved approach for predicting drug-target interaction: proteochemometrics to molecular 
docking 
36. An Integrated Data Driven Approach to Drug Repositioning Using Gene-Disease Associations 
37. An integrated network platform for contextual prioritization of drugs and pathways 
38. Analysis of A Drug Target-based Classification System using Molecular Descriptors 
39. Anti-infectious drug repurposing using an integrated chemical genomics and structural systems 
biology approach 
40. Application of Atlas of Cancer Signalling Network in preclinical studies 
 




41. Ariadne's ChemEffect and Pathway Studio knowledge base 
42. Assessing relative bioactivity of chemical substances using quantitative molecular network topology 
analysis 
43. Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New 
Platform for Computer-Aided Drug Repurposing 
44. Back to the Roots: Prediction of Biologically Active Natural Products from Ayurveda Traditional 
Medicine 
45. Benchmarking human protein complexes to investigate drug-related systems and evaluate predicted 
protein complexes 
46. Bioinformatics methods in drug repurposing for Alzheimer's disease 
47. Bioinformatics: Novel Insights from Genomic Information 
48. Biomolecular Network Controllability With Drug Binding Information 
49. BRCA-Monet: a breast cancer specific drug treatment mode-of-action network for treatment effective 
prediction using large scale microarray database 
50. Building a drug-target network and its applications 
51. C-SPADE: a web-tool for interactive analysis and visualization of drug screening experiments 
through compound-specific bioactivity dendrograms 
52. Cancer based pharmacogenomics network supported with scientific evidences: from the view of drug 
repurposing 
53. CellFateScout - a bioinformatics tool for elucidating small molecule signaling pathways that drive 
cells in a specific direction 
54. Characterizing protein domain associations by Small-molecule ligand binding 
55. Characterizing the pocketome of Mycobacterium tuberculosis and application in rationalizing 
polypharmacological target selection 
56. Chemoprevention agents for melanoma: a path forward into phase 3 clinical trials 
57. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug 
development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis 
58. Clustering drug-drug interaction networks with energy model layouts: community analysis and drug 
repurposing 
59. Co-expression Network Approach Reveals Functional Similarities among Diseases Affecting Human 
Skeletal Muscle 
 




60. Combined analysis of gene expression and genome binding profiles identified potential therapeutic 
targets of ciclopirox in Ewing sarcoma 
61. Combined Analysis of Phenotypic and Target-Based Screening in Assay Networks 
62. Community-driven roadmap for integrated disease maps 
63. Comparative assessment of strategies to identify similar ligand-binding pockets in proteins 
64. Comparing structural and transcriptional drug networks reveals signatures of drug activity and toxicity 
in transcriptional responses 
65. Complex-disease networks of trait-associated single-nucleotide polymorphisms (SNPs) unveiled by 
information theory 
66. Computational approaches for innovative antiepileptic drug discovery 
67. Computational Approaches for Translational Oncology: Concepts and Patents 
68. Computational Discovery of Putative Leads for Drug Repositioning through Drug-Target Interaction 
Prediction 
69. Computational drug repositioning for peripheral arterial disease: prediction of anti-inflammatory and 
pro-angiogenic therapeutics 
70. Computational drug repositioning through heterogeneous network clustering 
71. Computational drug repositioning using low-rank matrix approximation and randomized algorithms 
72. Computational drug repositioning with random walk on a heterogeneous network 
73. Computational Drug Target Screening through Protein Interaction Profiles 
74. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent 
pathways among FDA-approved compounds 
75. Computational identification of multi-omic correlates of anticancer therapeutic response 
76. Computational methods and opportunities for phosphorylation network medicine 
77. Computational Prediction of Drug?Target Interactions Using Chemical, Biological, and Network 
Features 
78. Computational tools for polypharmacology and repurposing 
79. Computational-experimental approach to drug-target interaction mapping: A case study on kinase 
inhibitors 
80. COMPUTING THERAPY FOR PRECISION MEDICINE: COLLABORATIVE FILTERING 
INTEGRATES AND PREDICTS MULTI-ENTITY INTERACTIONS 
 




81. Constructing Disease Similarity Networks Based on Disease Module Theory 
82. Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for 
myasthenia gravis 
83. Construction of drug network based on side effects and its application for drug repositioning 
84. Context-specific functional module based drug efficacy prediction 
85. Convergent downstream candidate mechanisms of independent intergenic polymorphisms between 
co-classified diseases implicate epistasis among noncoding elements 
86. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for 
children and adolescents with cancer 
87. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole 
88. Deciphering cellular biological processes to clinical application: a new perspective for Talpha1 
treatment targeting multiple diseases 
89. Deciphering miRNA transcription factor feed-forward loops to identify drug repurposing candidates 
for cystic fibrosis 
90. Deep-Learning-Based Drug-Target Interaction Prediction 
91. DenguePredict: An Integrated Drug Repositioning Approach towards Drug Discovery for Dengue 
92. Design of a tripartite network for the prediction of drug targets 
93. Designing Dietary Recommendations Using System Level Interactomics Analysis and Network-
Based Inference 
94. Diffusion mapping of drug targets on disease signaling network elements reveals drug combination 
strategies 
95. Discovering gene re-ranking efficiency and conserved gene-gene relationships derived from gene co-
expression network analysis on breast cancer data 
96. Discovery of drug mode of action and drug repositioning from transcriptional responses 
97. Disease classification: from phenotypic similarity to integrative genomics and beyond 
98. DNetDB: The human disease network database based on dysfunctional regulation mechanism 
99. Docking-based inverse virtual screening: methods, applications, and challenges 
100. DRABAL: novel method to mine large high-throughput screening assays using Bayesian active 
learning 
 




101. Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer 
cell lines and pathway mechanisms of resistance 
102. Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm 
103. Drug repositioning based on triangularly balanced structure for tissue-specific diseases in incomplete 
interactome 
104. Drug repositioning by applying 'expression profiles' generated by integrating chemical structure 
similarity and gene semantic similarity 
105. Drug Repositioning by Integrating Known Disease-Gene and Drug-Target Associations in a Semi-
supervised Learning Model 
106. Drug repositioning by integrating target information through a heterogeneous network model 
107. Drug repositioning by kernel-based integration of molecular structure, molecular activity, and 
phenotype data 
108. Drug repositioning for prostate cancer: using a data-driven approach to gain new insights 
109. Drug repositioning for schizophrenia and depression/anxiety disorders: A machine learning approach 
leveraging expression data 
110. Drug Repositioning in Glioblastoma: A Pathway Perspective 
111. Drug repositioning in SLE: crowd-sourcing, literature-mining and Big Data analysis 
112. Drug Repositioning Strategies for the Identification of Novel Therapies for Rheumatic Autoimmune 
Inflammatory Diseases 
113. Drug repositioning through incomplete bi-cliques in an integrated drug-target-disease network 
114. Drug Repositioning Through Network Pharmacology 
115. Drug Repositioning through Systematic Mining of Gene Coexpression Networks in Cancer 
116. Drug repositioning using disease associated biological processes and network analysis of drug 
targets 
117. Drug repositioning: a machine-learning approach through data integration 
118. Drug repurposing based on drug-drug interaction 
119. Drug repurposing: far beyond new targets for old drugs 
120. Drug repurposing: translational pharmacology, chemistry, computers and the clinic 
121. Drug similarity search based on combined signatures in gene expression profiles 
 




122. Drug Synergy Slows Aging and Improves Healthspan through IGF and SREBP Lipid Signaling 
123. Drug target prediction and repositioning using an integrated network-based approach 
124. Drug target prediction by multi-view low rank embedding 
125. Drug target prediction using adverse event report systems: a pharmacogenomic approach 
126. Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds 
127. Drug-target interaction prediction by integrating chemical, genomic, functional and pharmacological 
data 
128. Drug-target interaction prediction by integrating multiview network data 
129. Drug-target interaction prediction: A Bayesian ranking approach 
130. Drug-Target Interactions: Prediction Methods and Applications 
131. Drug-Target Networks 
132. DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-
based drug repurposing 
133. DrugNet: network-based drug-disease prioritization by integrating heterogeneous data 
134. DT-Web: a web-based application for drug-target interaction and drug combination prediction 
through domain-tuned network-based inference 
135. Ebola virus: A gap in drug design and discovery - experimental and computational perspective 
136. EHFPI: a database and analysis resource of essential host factors for pathogenic infection 
137. Elucidating the modes of action for bioactive compounds in a cell-specific manner by large-scale 
chemically-induced transcriptomics 
138. Epigenetic Drug Repositioning for Alzheimer's Disease Based on Epigenetic Targets in Human 
Interactome 
139. ERK and ROCK functionally interact in a signaling network that is compensationally upregulated in 
Spinal Muscular Atrophy 
140. Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching 
141. Exploration and analysis of drug modes of action through feature integration 
142. Exploration of the Anti-Inflammatory Drug Space Through Network Pharmacology: Applications 
for Drug Repurposing 
143. Exploring drug-target interaction networks of illicit drugs 
 




144. Exploring the anti-proliferative activity of Pelargonium sidoides DC with in silico target 
identification and network pharmacology 
145. Finding the targets of a drug by integration of gene expression data with a protein interaction 
network 
146. From drug response profiling to target addiction scoring in cancer cell models 
147. From gene networks to drugs: systems pharmacology approaches for AUD 
148. From stroke to neurodegenerative diseases: The multi-target neuroprotective effects of 3-n-
butylphthalide and its derivatives 
149. Functional genetics-directed identification of novel pharmacological inhibitors of FAS- and TNF-
dependent apoptosis that protect mice from acute liver failure 
150. Fusing literature and full network data improves disease similarity computation 
151. Generation and application of drug indication inference models using typed network motif 
comparison analysis 
152. Genetic screens for the control of influenza virus replication: from meta-analysis to drug discovery 
153. Global optimization-based inference of chemogenomic features from drug-target interactions 
154. GUILDify: a web server for phenotypic characterization of genes through biological data integration 
and network-based prioritization algorithms 
155. GWAS and drug targets 
156. Heter-LP: A heterogeneous label propagation algorithm and its application in drug repositioning 
157. High-content drug screening for rare diseases 
158. Homopharma: a new concept for exploring the molecular binding mechanisms and drug repurposing 
159. Human disease-drug network based on genomic expression profiles 
160. Human enterovirus 71 protein interaction network prompts antiviral drug repositioning 
161. Human pathway-based disease network 
162. Identification of associations between small molecule drugs and miRNAs based on functional 
similarity 
163. Identification of drug candidates and repurposing opportunities through compound-target interaction 
networks 
164. Identification of key pathways and drug repurposing for anaplastic thyroid carcinoma by integrated 
bioinformatics analysis 
 




165. Identification of small molecules enhancing autophagic function from drug network analysis 
166. Identify potential drugs for cardiovascular diseases caused by stress-induced genes in vascular 
smooth muscle cells 
167. Identifying and Tackling Emergent Vulnerability in Drug-Resistant Mycobacteria 
168. Identifying prognostic features by bottom-up approach and correlating to drug repositioning 
169. Improved prediction of drug-target interactions using regularized least squares integrating with 
kernel fusion technique 
170. In silico frameworks for systematic pre-clinical screening of potential anti-leukemia therapeutics 
171. In silico methods for drug repurposing and pharmacology 
172. In silico prediction of chemical mechanism of action via an improved network-based inference 
method 
173. In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against 
multiple life stages of Schistosoma mansoni 
174. Individualized network-based drug repositioning infrastructure for precision oncology in the 
panomics era 
175. Inferring drug-disease associations based on known protein complexes 
176. Inferring drug-disease associations from integration of chemical, genomic and phenotype data using 
network propagation 
177. Inferring new indications for approved drugs via random walk on drug-disease heterogenous 
networks 
178. Inferring novel disease indications for known drugs by semantically linking drug action and disease 
mechanism relationships 
179. Inferring novel indications of approved drugs via a learning method with local and global 
consistency 
180. Inflammatory pathway network-based drug repositioning and molecular phenomics 
181. Inhibition of EGFR Signaling Protects from Mucormycosis 
182. Integrative Cancer Pharmacogenomics to Infer Large-Scale Drug Taxonomy 
183. Interaction and localization diversities of global and local hubs in human protein-protein interaction 
networks 
184. Introduction: Cancer Gene Networks 
 




185. Large-scale Direct Targeting for Drug Repositioning and Discovery 
186. Large-scale integration of heterogeneous pharmacogenomic data for identifying drug mechanism of 
action 
187. Large-Scale Off-Target Identification Using Fast and Accurate Dual Regularized One-Class 
Collaborative Filtering and Its Application to Drug Repurposing 
188. Large-Scale Prediction of Drug-Target Interaction: a Data-Centric Review 
189. Learning disease relationships from clinical drug trials 
190. Link prediction in drug-target interactions network using similarity indices 
191. Linking biochemical pathways and networks to adverse drug reactions 
192. Linking PharmGKB to phenotype studies and animal models of disease for drug repurposing 
193. Logical comparison over RDF resources in bio-informatics 
194. Macromolecular target prediction by self-organizing feature maps 
195. Mantra 2.0: an online collaborative resource for drug mode of action and repurposing by network 
analysis 
196. Matrix Factorization-Based Prediction of Novel Drug Indications by Integrating Genomic Space 
197. MD-Miner: a network-based approach for personalized drug repositioning 
198. Mining integrated semantic networks for drug repositioning opportunities 
199. Mining significant substructure pairs for interpreting polypharmacology in drug-target network 
200. miREFRWR: a novel disease-related microRNA-environmental factor interactions prediction 
method 
201. Misfolded proteins: from little villains to little helpers in the fight against cancer 
202. Molecular Topology and other Promiscuity Determinants as Predictors of Therapeutic Class- A 
Theoretical Framework to guide Drug Repositioning 
203. MPGraph: multi-view penalised graph clustering for predicting drug-target interactions 
204. MTGO: PPI Network Analysis Via Topological and Functional Module Identification 
205. Multi-target drug repositioning by bipartite block-wise sparse multi-task learning 
206. Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a 
medicinal chemist perspective 
 




207. Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a 
multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of 
three neuroprotective drugs in secondary progressive multiple sclerosis 
208. Neighbours of cancer-related proteins have key influence on pathogenesis and could increase the 
drug target space for anticancer therapies 
209. Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug 
combinations 
210. Network and matrix analysis of the respiratory disease interactome 
211. Network approaches to drug discovery 
212. Network biology concepts in complex disease comorbidities 
213. Network insights into the genes regulated by hepatocyte nuclear factor 4 in response to drug induced 
perturbations: a review 
214. Network measures for chemical library design 
215. Network medicine in disease analysis and therapeutics 
216. Network predicting drug's anatomical therapeutic chemical code 
217. Network-assisted prediction of potential drugs for addiction 
218. Network-based analysis of transcriptional profiles from chemical perturbations experiments 
219. Network-based approach to prediction and population-based validation of in silico drug repurposing 
220. Network-Based Drug Discovery: Coupling Network Pharmacology with Phenotypic Screening for 
Neuronal Excitability 
221. Network-based drug ranking and repositioning with respect to DrugBank therapeutic categories 
222. Network-based drug repositioning 
223. Network-based drug repositioning: A novel strategy for discovering potential antidepressants and 
their mode of action 
224. Network-based in silico drug efficacy screening 
225. Network-based inference methods for drug repositioning 
226. Network-based machine learning and graph theory algorithms for precision oncology 
227. Network-based prediction and knowledge mining of disease genes 
228. Neuroblastoma, a Paradigm for Big Data Science in Pediatric Oncology 
 




229. New drug candidates for treatment of atypical meningiomas: An integrated approach using gene 
expression signatures for drug repurposing 
230. No association between metformin use and survival in patients with pancreatic cancer: An 
observational cohort study 
231. Novel modeling of cancer cell signaling pathways enables systematic drug repositioning for distinct 
breast cancer metastases 
232. Novel putative drugs and key initiating genes for neurodegenerative disease determined using 
network-based genetic integrative analysis 
233. Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and 
redox capacity 
234. Open-source chemogenomic data-driven algorithms for predicting drug-target interactions 
235. Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases 
236. p73 as a pharmaceutical target for cancer therapy 
237. Pathogenesis of thrombosis: cellular and pharmacogenetic contributions 
238. Pathogenicity phenomena in three model systems: from network mining to emerging system-level 
properties 
239. Pathology assessment is necessary to validate translational endpoints in preclinical aging studies 
240. Pathway and network-based strategies to translate genetic discoveries into effective therapies 
241. Pathway-based Bayesian inference of drug-disease interactions 
242. Pathway-based drug repositioning using causal inference 
243. Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia 
Patients 
244. PATIENT-SPECIFIC DATA FUSION FOR CANCER STRATIFICATION AND 
PERSONALISED TREATMENT 
245. Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French 
medical pharmacology 
246. Phenotypic screening of the Prestwick library for treatment of Parkinson's tremor symptoms using a 
humanized quantitative systems pharmacology platform 
247. Polypharmacological Drug-target Inference for Chemogenomics 
248. Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective 
 




249. Polypharmacology: challenges and opportunities in drug discovery 
250. Predicting drug-disease associations and their therapeutic function based on the drug-disease 
association bipartite network 
251. Predicting drug-disease interactions by semi-supervised graph cut algorithm and three-layer data 
integration 
252. Predicting drug-target interaction for new drugs using enhanced similarity measures and super-target 
clustering 
253. Predicting drug-target interactions using probabilistic matrix factorization 
254. Predicting drug-target interactions using restricted Boltzmann machines 
255. Predicting Drug-Target Interactions via Within-Score and Between-Score 
256. Predicting Drug-Target Interactions With Multi-Information Fusion 
257. Predicting new indications for approved drugs using a proteochemometric method 
258. Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang 
Wan as a case study 
259. Predicting Potential Drugs for Breast Cancer based on miRNA and Tissue Specificity 
260. Prediction of chemical-protein interactions network with weighted network-based inference method 
261. Prediction of chemical-protein interactions: multitarget-QSAR versus computational chemogenomic 
methods 
262. Prediction of drug's Anatomical Therapeutic Chemical (ATC) code by integrating drug-domain 
network 
263. Prediction of drug-target interaction by label propagation with mutual interaction information 
derived from heterogeneous network 
264. Prediction of drug-target interactions and drug repositioning via network-based inference 
265. Prediction of drug-target interactions for drug repositioning only based on genomic expression 
similarity 
266. Prediction of drugs having opposite effects on disease genes in a directed network 
267. Prediction of new drug indications based on clinical data and network modularity 
268. Prediction of Non-coding RNAs as Drug Targets 
269. Prediction of Novel Drugs and Diseases for Hepatocellular Carcinoma Based on Multi-Source 
Simulated Annealing Based Random Walk 
 




270. Prediction of Novel Drugs for Hepatocellular Carcinoma Based on Multi-Source Random Walk 
271. Prediction of polypharmacological profiles of drugs by the integration of chemical, side effect, and 
therapeutic space 
272. Predictive methods in drug repurposing: gold mine or just a bigger haystack 
273. PROMISCUOUS: a database for network-based drug-repositioning 
274. ProphTools: general prioritization tools for heterogeneous biological networks 
275. Protein localization vector propagation: a method for improving the accuracy of drug repositioning 
276. Proximal Pathway Enrichment Analysis for Targeting Comorbid Diseases via Network 
Endopharmacology 
277. RANKS: a flexible tool for node label ranking and classification in biological networks 
278. Rational drug repositioning guided by an integrated pharmacological network of protein, disease and 
drug 
279. Recent Advances in the Development of Pharmaceutical Agents for Metabolic Disorders: A 
Computational Perspective 
280. Recent advances in the machine learning-based drug-target interaction prediction 
281. Recommendation Techniques for Drug-Target Interaction Prediction and Drug Repositioning 
282. Rectifying cancer drug discovery through network pharmacology 
283. Relating anatomical therapeutic indications by the ensemble similarity of drug sets 
284. Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant 
lesions 
285. Repositioning drugs by targeting network modules: a Parkinson's disease case study 
286. RepTB: a gene ontology based drug repurposing approach for tuberculosis 
287. Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast 
cancer 
288. Research advance in the drug target prediction based on chemoinformatics 
289. Research and development of anti-Alzheimer's disease drugs: an update from the perspective of 
technology flows 
290. Revisiting Antipsychotic Drug Actions Through Gene Networks Associated With Schizophrenia 
291. Revisiting Connectivity Map from a gene co-expression network analysis 
 




292. Scoring multiple features to predict drug disease associations using information fusion and 
aggregation 
293. Screening drug-target interactions with positive-unlabeled learning 
294. SDTNBI: an integrated network and chemoinformatics tool for systematic prediction of drug-target 
interactions and drug repositioning 
295. SELF-BLM: Prediction of drug-target interactions via self-training SVM 
296. SemFunSim: a new method for measuring disease similarity by integrating semantic and gene 
functional association 
297. Some Remarks on Prediction of Drug-Target Interaction with Network Models 
298. Structural analysis of dihydrofolate reductases enables rationalization of antifolate binding affinities 
and suggests repurposing possibilities 
299. Substrate-driven mapping of the degradome by comparison of sequence logos 
300. Synergistic drug combinations from electronic health records and gene expression 
301. Systematic drug repositioning for a wide range of diseases with integrative analyses of phenotypic 
and molecular data 
302. Systematic integration of biomedical knowledge prioritizes drugs for repurposing 
303. Systematic Prioritization of Druggable Mutations in 5000 Genomes Across 16 Cancer Types Using a 
Structural Genomics-based Approach 
304. Systematical analysis of lncRNA-mRNA competing endogenous RNA network in breast cancer 
subtypes 
305. Systems approach to the pharmacological actions of HDAC inhibitors reveals EP300 activities and 
convergent mechanisms of regulation in diabetes 
306. Systems biological understanding of the regulatory network and the possible therapeutic strategies 
for vascular calcification 
307. Systems Biology-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap 
Insertional Mutagenesis 
308. Systems biology-embedded target validation: improving efficacy in drug discovery 
309. Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of 
Neuroendocrine Prostate Cancer 
310. Systems pharmacology of adverse event mitigation by drug combinations 
 




311. Systems Pharmacology-Based Approach of Connecting Disease Genes in Genome-Wide Association 
Studies with Traditional Chinese Medicine 
312. Target-Based Drug Repositioning Using Large-Scale Chemical-Protein Interactome Data 
313. The extraction of drug-disease correlations based on module distance in incomplete human 
interactome 
314. The human disease network in terms of dysfunctional regulatory mechanisms 
315. The pain interactome: connecting pain-specific protein interactions 
316. The polypharmacology of natural products 
317. Therapeutic compounds for Cushing's syndrome: a patent review (2012-2016 
318. Therapeutic Effect of Repurposed Temsirolimus in Lung Adenocarcinoma Model 
319. Toward more realistic drug-target interaction predictions 
320. Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems 
Pharmacology 
321. Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine 
Approach 
322. Transcriptomic profiling of human hippocampal progenitor cells treated with antidepressants and its 
application in drug repositioning 
323. Transcriptomic-Guided Drug Repositioning Supported by a New Bioinformatics Search Tool: 
geneXpharma 
324. Translating Mendelian and complex inheritance of Alzheimer's disease genes for predicting unique 
personal genome variants 
325. Trends of Clinical Trials for Drug Development in Rare Diseases 
326. Unveiling the role of network and systems biology in drug discovery 
327. Updates on drug-target network; facilitating polypharmacology and data integration by growth of 
DrugBank database 
328. Using Drugs as Molecular Probes: AComputational Chemical Biology Approach in 
Neurodegenerative Diseases 
329. Utilizing Cancer - Functional Gene Set - Compound Networks to Identify Putative Drugs for Breast 
Cancer 
330. VisANT 4.0: Integrative network platform to connect genes, drugs, diseases and therapies 
 











FACTOR 21. Drug Repurposing for Viral Diseases 
1. 2,8-bis(trifluoromethyl)quinoline analogs show improved anti-Zika virus activity, compared to 
mefloquine 
2. A chemical-genetic interaction map of small molecules using high-throughput imaging in cancer cells 
3. A combined systems and structural modeling approach repositions antibiotics for Mycoplasma 
genitalium 
4. A comprehensive approach to identifying repurposed drugs to treat SCN8A epilepsy 
5. A curated C. difficile strain 630 metabolic network: prediction of essential targets and inhibitors 
6. A current perspective on the oncopreventive and oncolytic properties of selective serotonin reuptake 
inhibitors 
7. A dual drug regimen synergistically blocks human parainfluenza virus infection 
8. A Dual Readout Assay Based on Fluorescence Polarization and Time-Resolved Fluorescence 
Resonance Energy Transfer to Screen for RSK1 Inhibitors 
9. A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor 
Ponatinib for Repurposing in Neuroblastoma Therapy 
10. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for 
cryptosporidiosis 
11. A large-scale computational approach to drug repositioning 
12. A Large-Scale Gene Expression Intensity-Based Similarity Metric for Drug Repositioning 
13. A machine learning-based method to improve docking scoring functions and its application to drug 
repurposing 
14. A network integration approach for drug-target interaction prediction and computational drug 
repositioning from heterogeneous information 
15. A novel cell-based high-throughput screen for inhibitors of HIV-1 gene expression and budding 
identifies the cardiac glycosides 
16. A novel multi-modal drug repurposing approach for identification of potent ACK1 inhibitors 
17. A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, 
West Nile and Chikungunya viruses 
18. A repurposing strategy for Hsp90 inhibitors demonstrates their potency against filarial nematodes 
19. A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity 
 




20. A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection 
21. A small molecule screen identifies an inhibitor of DNA repair inducing the degradation of TFIIH and 
the chemosensitization of tumor cells to platinum 
22. A structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 
ATPase 
23. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents 
24. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus 
and Middle East Respiratory Syndrome Coronavirus Fusion 
25. Activity of anti-cancer protein kinase inhibitors against Leishmania spp 
26. Adaptive mitochondrial reprogramming and resistance to PI3K therapy 
27. Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus 
28. Advances in Developing Therapies to Combat Zika Virus: Current Knowledge and Future 
Perspectives 
29. Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology 
30. Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review 
31. Alternative screening approaches for discovery of Middle East respiratory syndrome coronavirus 
inhibitors 
32. Alzheimer's Disease (AD) therapeutics - 1: Repeated clinical failures continue to question the amyloid 
hypothesis of AD and the current understanding of AD causality 
33. An Integrative Drug Repurposing Pipeline: Switching Viral Drugs to Breast Cancer 
34. An invitro and invivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi 
predicted by a computational drug repositioning method 
35. Analysis and assay of oseltamivir-resistant mutants of influenza neuraminidase via direct observation 
of drug unbinding and rebinding in simulation 
36. Analysis of drug binding pockets and repurposing opportunities for twelve essential enzymes of 
ESKAPE pathogens 
37. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing 
tumour blood vessels 
38. Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched 
for stem cell-like properties 
39. Antidepressants in the Treatment of Functional Dyspepsia: A Systematic Review and Meta-Analysis 
 




40. Antifungal properties of the anti-hypertensive drug: aliskiren 
41. Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis of 
fatty acids 
42. Antiviral activity of cationic amphiphilic drugs 
43. Antiviral activity of doxycycline against vesicular stomatitis virus in vitro 
44. Antiviral activity of gemcitabine against human rhinovirus invitro and invivo 
45. Antiviral activity of micafungin against enterovirus 71 
46. Antiviral effects of inhibiting host gene expression 
47. Antiviral Screening of Multiple Compounds against Ebola Virus 
48. Application of computer-aided drug repurposing in the search of new cruzipain inhibitors: discovery 
of amiodarone and bromocriptine inhibitory effects 
49. Application of drug repositioning strategy to TOFISOPAM 
50. Application of molecular framework-based data-mining method in the search for beta-secretase 1 
inhibitors through drug repurposing 
51. Application of the 4D fingerprint method with a robust scoring function for scaffold-hopping and 
drug repurposing strategies 
52. Approved oncology drugs lack in vivo activity against Trichuris muris despite in vitro activity 
53. Artemisinin analogues as potent inhibitors of in vitro hepatitis C virus replication 
54. Assessing protein kinase target similarity: Comparing sequence, structure, and cheminformatics 
approaches 
55. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical 
activity against chronic lymphocytic leukemia 
56. Autophagy in HIV-induced T cell death 
57. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation 
58. Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the 
proliferative expansion of stem-like cancer cells (CSCs 
59. beta-catenin and PI3Kdelta inhibition expands precursor Th17 cells with heightened stemness and 
antitumor activity 
60. Beyond Channel Activity: Protein-Protein Interactions Involving Viroporins 
 




61. Bioinformatics methods in drug repurposing for Alzheimer's disease 
62. Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer 
resistance to EGFR therapy 
63. Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug 
development 
64. Blocking IL-6/GP130 signaling inhibits cell viability/proliferation, glycolysis, and colony forming 
activity in human pancreatic cancer cells 
65. Calcineurin-NFAT signalling in myeloid leucocytes: new prospects and pitfalls in 
immunosuppressive therapy 
66. Can an FDA-Approved Alzheimer's Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika 
Virus 
67. Can sodium/hydrogen exchange inhibitors be repositioned for treating attention deficit hyperactivity 
disorder? An in silico approach 
68. Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015 
69. Cancer stem cells as the therapeutic target of tomorrow 
70. Captopril mitigates splenomegaly and myelofibrosis in the Gata1low murine model of myelofibrosis 
71. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer 
72. Cascade Ligand- and Structure-Based Virtual Screening to Identify New Trypanocidal Compounds 
Inhibiting Putrescine Uptake 
73. Cell-line dependent antiviral activity of sofosbuvir against Zika virus 
74. Characterization of drug-induced transcriptional modules: towards drug repositioning and functional 
understanding 
75. Checking the STEP-Associated Trafficking and Internalization of Glutamate Receptors for Reduced 
Cognitive Deficits: A Machine Learning Approach-Based Cheminformatics Study and Its Application for 
Drug Repurposing 
76. Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-kappaB 
signaling 
77. Chk1 as a new therapeutic target in triple-negative breast cancer 
78. Chloroquine, a FDA-approved Drug, Prevents Zika Virus Infection and its Associated Congenital 
Microcephaly in Mice 
 




79. CK2 inhibition confers functional protection to young and aging axons against ischemia by 
differentially regulating the CDK5 and AKT signaling pathways 
80. Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for 
Drug Repurposing in Infectious Viral Diseases 
81. Clobetasol and Halcinonide Act as Smoothened Agonists to Promote Myelin Gene Expression and 
RxRgamma Receptor Activation 
82. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover 
Potentially Targetable Cancer Cell Dependencies 
83. Combination therapy: the propitious rationale for drug development 
84. Combined Analysis of Phenotypic and Target-Based Screening in Assay Networks 
85. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids 
to inhibitors of B-cell receptor signaling 
86. Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate 
Synthase Case 
87. Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake 
in Lung Cancer 
88. Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3beta and 
Activates WNT Signaling 
89. Computational drug repositioning for peripheral arterial disease: prediction of anti-inflammatory and 
pro-angiogenic therapeutics 
90. Computational Drug Target Screening through Protein Interaction Profiles 
91. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent 
pathways among FDA-approved compounds 
92. Computational methods and opportunities for phosphorylation network medicine 
93. Computational repositioning and experimental validation of approved drugs for HIF-prolyl 
hydroxylase inhibition 
94. Computer-Aided Structure Based Drug Design Approaches for the Discovery of New Anti-CHIKV 
Agents 
95. Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) 
pseudokinase in cancer cells 
96. Cruzain inhibitors: efforts made, current leads and a structural outlook of new hits 
 




97. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease 
98. Current Strategies for Inhibition of Chikungunya Infection 
99. Current treatment options and the role of peptides as potential therapeutic components for Middle East 
Respiratory Syndrome (MERS): A review 
100. Cyclic AMP efflux inhibitors as potential therapeutic agents for leukemia 
101. CYP51 as drug targets for fungi and protozoan parasites: past, present and future 
102. CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM 
103. Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in 
ER+ breast cancer 
104. Data integration to prioritize drugs using genomics and curated data 
105. Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target 
Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment 
of Alzheimer's Disease 
106. Developing a dengue vaccine: progress and future challenges 
107. Development of anti-fungal pesticides from protein kinase inhibitor-based anticancer agents 
108. Development of therapies for autoimmune disease at Stanford: a tale of multiple shots and one goal 
109. Diclofenac Identified as a Kynurenine 3-Monooxygenase Binder and Inhibitor by Molecular 
Similarity Techniques 
110. Direct-acting antivirals and host-targeting strategies to combat enterovirus infections 
111. Discovering L-type calcium channels inhibitors of antihypertensive drugs based on drug 
repositioning 
112. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from 
rational design, nature and old drug reposition 
113. Discovery and development of DNA methyltransferase inhibitors using in silico approaches 
114. Discovery and development of Seliciclib. How systems biology approaches can lead to better drug 
performance 
115. Discovery of alkyl bis(oxy)dibenzimidamide derivatives as novel protein arginine methyltransferase 
1 (PRMT1) inhibitors 
116. Discovery of drug mode of action and drug repositioning from transcriptional responses 
 




117. Discovery of New Potential Anti-Infective Compounds Based on Carbonic Anhydrase Inhibitors by 
Rational Target-Focused Repurposing Approaches 
118. Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues 
119. Discovery of Novel SPAK Inhibitors That Block WNK Kinase Signaling to Cation Chloride 
Transporters 
120. Discovery of rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer 
121. Distinct effects of HIV protease inhibitors and ERAD inhibitors on zygote to ookinete transition of 
the malaria parasite 
122. Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005 - 2013 
123. Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma 
124. Docking of a novel DNA methyltransferase inhibitor identified from high-throughput screening: 
insights to unveil inhibitors in chemical databases 
125. DockingApp: a user friendly interface for facilitated docking simulations with AutoDock Vina 
126. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon 
cancer 
127. Doxycycline and therapeutic targeting of the DNA damage response in cancer cells: old drug, new 
purpose 
128. Doxycycline is an NF-kappaB inhibitor that induces apoptotic cell death in malignant T-cells 
129. DPP-4 inhibitors promote proliferation and migration of rat brain microvascular endothelial cells 
under hypoxic/high-glucose conditions, potentially through the SIRT1/HIF-1/VEGF pathway 
130. Drug delivery for the treatment of endometriosis and uterine fibroids 
131. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking 
(MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-
6/GP130 interface 
132. Drug repositioning and pharmacophore identification in the discovery of hookworm MIF inhibitors 
133. Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer 
134. Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer 
135. Drug Repositioning of Proton Pump Inhibitors for Enhanced Efficacy and Safety of Cancer 
Chemotherapy 
136. Drug repurposing and the prior art patents of competitors 
 




137. Drug Repurposing Approach Identifies Inhibitors of the Prototypic Viral Transcription Factor IE2 
that Block Human Cytomegalovirus Replication 
138. Drug repurposing approaches to fight Dengue virus infection and related diseases 
139. Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections 
140. Drug Repurposing for Viral Infectious Diseases: How Far Are We 
141. Drug Repurposing Identifies Inhibitors of Oseltamivir-Resistant Influenza Viruses 
142. Drug repurposing in kidney disease 
143. Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in 
Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and 
Blocking LTB4 Biosynthesis 
144. Drug repurposing of minocycline against dengue virus infection 
145. Drug repurposing of quinine as antiviral against dengue virus infection 
146. Drug Repurposing Screen Identifies Foxo1-Dependent Angiopoietin-2 Regulation in Sepsis 
147. Drug Repurposing Screening Identifies Novel Compounds That Effectively Inhibit Toxoplasma 
gondii Growth 
148. Drug Repurposing Screening Identifies Tioconazole as an ATG4 Inhibitor that Suppresses 
Autophagy and Sensitizes Cancer Cells to Chemotherapy 
149. Drug repurposing: a better approach for infectious disease drug discovery 
150. Drug repurposing: In-vitro anti-glycation properties of 18 common drugs 
151. Drug repurposing: mining protozoan proteomes for targets of known bioactive compounds 
152. Drug-Repositioning Screening for Keap1-Nrf2 Binding Inhibitors using Fluorescence Correlation 
Spectroscopy 
153. Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human 
Nonsmall Cell Lung Cancer 
154. Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed Drugs Elicits 
Cell-Lethal Autophagy and Therapeutic Benefit 
155. Ebola virus: A gap in drug design and discovery - experimental and computational perspective 
156. Enterovirus replication: go with the (counter)flow 
157. ERK and ROCK functionally interact in a signaling network that is compensationally upregulated in 
Spinal Muscular Atrophy 
 




158. Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in 
enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis 
159. Exploiting drug repositioning for discovery of a novel HIV combination therapy 
160. Exploring novel pharmacotherapeutic applications and repurposing potential of sodium glucose 
CoTransporter 2 inhibitors 
161. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow 
Tumor Growth in Mice 
162. FDA approved drugs as potential Ebola treatments 
163. FDA-approved drugs selected using virtual screening bind specifically to G-quadruplex DNA 
164. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection 
165. Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment 
166. Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism 
167. Finding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-
based systems biology approach 
168. Fluoxetine and thioridazine inhibit efflux and attenuate crystalline biofilm formation by Proteus 
mirabilis 
169. Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice 
with FLT3/ITD leukemia 
170. Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin 
polymerization 
171. Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking 
(MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and 
activator of transcription 3 (STAT3 
172. From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic 
Small Cell Lung Cancer (SCLC 
173. Functional genetics-directed identification of novel pharmacological inhibitors of FAS- and TNF-
dependent apoptosis that protect mice from acute liver failure 
174. Genetic screens for the control of influenza virus replication: from meta-analysis to drug discovery 
175. Glycogen phosphorylase inhibition improves beta cell function 
176. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling 
 




177. H7N9 and other pathogenic avian influenza viruses elicit a three-pronged transcriptomic signature 
that is reminiscent of 1918 influenza virus and is associated with lethal outcome in mice 
178. Heme Oxygenase Database (HemeOxDB) and QSAR Analysis of Isoform?1 Inhibitors 
179. Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells 
180. Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality 
181. High-content assay to identify inhibitors of dengue virus infection 
182. High-throughput drug screening using the Ebola virus transcription- and replication-competent virus-
like particle system 
183. High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-
ALL 
184. High-throughput screening for modulators of ACVR1 transcription: discovery of potential 
therapeutics for fibrodysplasia ossificans progressiva 
185. High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A 
drug repurposing strategy for advanced cancer 
186. High-throughput screening of a collection of known pharmacologically active small compounds for 
identification of Candida albicans biofilm inhibitors 
187. Histone Deacetylase Inhibitors and Diabetic Kidney Disease 
188. HIV reverse transcriptase: structural interpretation of drug resistant genetic variants from India 
189. HMG-CoA Reductase Inhibition Delays DNA Repair and Promotes Senescence After Tumor 
Irradiation 
190. Host-Directed Antivirals: A Realistic Alternative to Fight Zika Virus 
191. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. 
Preliminary results of a phase-II trial 
192. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer 
193. Hydroxyurea inhibits parvovirus B19 replication in erythroid progenitor cells 
194. Hyphenated 3D-QSAR statistical model-drug repurposing analysis for the identification of potent 
neuraminidase inhibitor 
195. Ibandronate metal complexes: solution behavior and antiparasitic activity 
196. Ibuprofen as a template molecule for drug design against Ebola virus 
 




197. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of 
approved drugs 
198. Identification of an old antibiotic clofoctol as a novel activator of unfolded protein response 
pathways and an inhibitor of prostate cancer 
199. Identification of Chemical Inhibitors of beta-Catenin-Driven Liver Tumorigenesis in Zebrafish 
200. Identification of cisapride as new inhibitor of putrescine uptake in Trypanosoma cruzi by combined 
ligand- and structure-based virtual screening 
201. Identification of common biological pathways and drug targets across multiple respiratory viruses 
based on human host gene expression analysis 
202. Identification of Cryptosporidium parvum active chemical series by Repurposing the open access 
malaria box 
203. Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung 
Cancer 
204. Identification of FDA-approved drugs as novel allosteric inhibitors of human executioner caspases 
205. Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of 
sensitivity 
206. Identification of FDA-approved drugs that computationally bind to MDM2 
207. Identification of FDA-approved drugs that target hepatitis B virus transcription 
208. Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in 
Clinical Situations 
209. Identification of Iguratimod as an Inhibitor of Macrophage Migration Inhibitory Factor (MIF) with 
Steroid-sparing Potential 
210. Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of 
action 
211. Identification of KX2-391 as an inhibitor of HBV transcription by a recombinant HBV-based 
screening assay 
212. Identification of levothyroxine antichagasic activity through computer-aided drug repurposing 
213. Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs 
214. Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction 
with Dbf4 by the Fragment Complementation and Drug Repositioning Approach 
 




215. Identification of novel small-molecule inhibitors targeting menin-MLL interaction, repurposing the 
antidiarrheal loperamide 
216. Identification of potential anti-hepatitis C virus agents targeting non structural protein 5B using 
computational techniques 
217. Identification of repurposed small molecule drugs for chordoma therapy 
218. Identification of resveratrol analogs as potent anti-dengue agents using a cell-based assay 
219. Identification of Small-Molecule Inhibitors of Human Golgi Mannosidase via a Drug Repositioning 
Screen 
220. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a 
drug repurposing screen 
221. Identification of toxin inhibitors using a magnetic nanosensor-based assay 
222. In silico drug re-purposing against African sleeping sickness using GlcNAc-PI de-N-acetylase as an 
experimental target 
223. In silico drug repurposing of FDA-approved drugs to predict new inhibitors for drug resistant T315I 
mutant and wild-type BCR-ABL1: A virtual screening and molecular dynamics study 
224. In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a 
Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug 
225. In silico identification of potent small molecule inhibitors targeting epidermal growth factor receptor 
1 
226. In silico model of the human ClC-Kb chloride channel: pore mapping, biostructural pathology and 
drug screening 
227. In silico prediction and in vitro and in vivo validation of acaricide fluazuron as a potential inhibitor 
of FGFR3 and a candidate anticancer drug for bladder carcinoma 
228. In silico repurposing of antipsychotic drugs for Alzheimer's disease 
229. In vitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania 
amazonensis 
230. In vitro biological evaluation of glyburide as potential inhibitor of collagenases 
231. Induction of DNA damage and apoptosis in human leukemia cells by efavirenz 
232. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma 
Therapy 
233. Inhibition of EGFR Signaling Protects from Mucormycosis 
 




234. Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480 
235. Inhibitors for the hepatitis C virus RNA polymerase explored by SAR with advanced machine 
learning methods 
236. Innovations in asthma therapy: is there a role for inhaled statins 
237. Innovative approaches to treat Staphylococcus aureus biofilm-related infections 
238. Insights from pharmacological similarity of epigenetic targets in epipolypharmacology 
239. Interactions of Selective Serotonin Reuptake Inhibitors with beta-Amyloid 
240. Interplay of DDP4 and IP-10 as a Potential Mechanism for Cell Recruitment to Tuberculosis Lesions 
241. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer 
Treatment 
242. JAK Inhibitors for Treatment of AlopeciaAreata 
243. K-Map: connecting kinases with therapeutics for drug repurposing and development 
244. KCa 3.1-a microglial target ready for drug repurposing 
245. Kinase Inhibitor Screening in Myeloid Malignancies 
246. Kinome Profiling Identifies Druggable Targets for Novel Human Cytomegalovirus (HCMV) 
Antivirals 
247. L-Captopril and its derivatives as potential inhibitors of microbial enzyme DapE: A combined 
approach of drug repurposing and similarity screening 
248. LEDGIN-mediated Inhibition of Integrase-LEDGF/p75 Interaction Reduces Reactivation of 
Residual Latent HIV 
249. Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives 
250. Machine learning models identify molecules active against the Ebola virus in vitro 
251. Management and Treatment of Dengue and Chikungunya - Natural Products to the Rescue 
252. Mechanistic insights into epigenetic modulation of ethanol consumption 
253. Medical genetics-based drug repurposing for Alzheimer's disease 
254. Meeting report: 28th International Conference on Antiviral Research in Rome, Italy 
255. Metformin inhibits hepatitis B virus protein production and replication in human hepatoma cells 
256. Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of 
retinoblastoma protein in renal cell carcinoma 
 




257. Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic 
Options and Potential Targets for Novel Therapies 
258. Misfolded proteins: from little villains to little helpers in the fight against cancer 
259. Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of 
stem-like cancer cells 
260. Modeling of Plasmodium falciparum Telomerase Reverse Transcriptase Ternary Complex: 
Repurposing of Nucleoside Analog Inhibitors 
261. Modern disease-modifying antirheumatic drugs 
262. Molecular Basis for the Selective Inhibition of Respiratory Syncytial Virus RNA Polymerase by 2'-
Fluoro-4'-Chloromethyl-Cytidine Triphosphate 
263. Molecular docking studies on thirteen fluoroquinolines with human topoisomerase II a and b 
264. Multi-pathway cellular analysis of compound selectivity 
265. Multivariate analysis in the identification of biological targets for designed molecular structures: the 
BIOTA protocol 
266. N-Desmethylclozapine, Fluoxetine, and Salmeterol Inhibit Postentry Stages of the Dengue Virus 
Life Cycle 
267. Natural Products as Promising Therapeutics for Treatment of Influenza Disease 
268. Nelfinavir and lopinavir impair Trypanosoma cruzi trypomastigote infection in mammalian host 
cells and show anti-amastigote activity 
269. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces 
endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo 
270. Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy 
271. Neuron-specific regulation of class I PI3K catalytic subunits and their dysfunction in brain disorders 
272. New applications for known drugs: Human glycogen synthase kinase 3 inhibitors as modulators of 
Aspergillus fumigatus growth 
273. New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine 
kinase inhibitor drugs 
274. New developments in flavivirus drug discovery 
275. New HSP27 inhibitors efficiently suppress drug resistance development in cancer cells 
276. New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate 
 




277. Nitazoxanide: a first-in-class broad-spectrum antiviral agent 
278. NMR spectroscopy-based metabolic profiling of drug-induced changes in vitro can discriminate 
between pharmacological classes 
279. Novel antiviral activity and mechanism of bromocriptine as a Zika virus NS2B-NS3 protease 
inhibitor 
280. Novel cruzipain inhibitors for the chemotherapy of chronic Chagas disease 
281. Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly 
Accessible Panel of Assays 
282. Novel Tadalafil Derivatives Ameliorates Scopolamine-Induced Cognitive Impairment in Mice via 
Inhibition of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5 
283. Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity 
284. Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the 
early phase after heart transplantation in rats 
285. One reporter for in-cell activity profiling of majority of protein kinase oncogenes 
286. Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases 
287. Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy 
288. Parainfluenza Virus Infection Sensitizes Cancer Cells to DNA-Damaging Agents: Implications for 
Oncolytic Virus Therapy 
289. Parkinson's Disease, Diabetes and Cognitive Impairment 
290. Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B 
Virus Infection 
291. Pharmacokinetic and protein binding profile of peptidomimetic DPP-4 inhibitor - Teneligliptin in 
rats using liquid chromatography-tandem mass spectrometry 
292. Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential 
interventions 
293. Pharmacophore anchor models of flaviviral NS3 proteases lead to drug repurposing for DENV 
infection 
294. Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA 
Efflux Pump Inhibitors 
295. Pharmacophore-based screening and drug repurposing exemplified on glycogen synthase kinase-3 
inhibitors 
 




296. Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of 
Approved Therapies and Emerging Concepts 
297. Phosphorylation of Single Stranded RNA Virus Proteins and Potential for Novel Therapeutic 
Strategies 
298. Polypharmacology in the treatment of Chagas disease 
299. Posttranslational Regulation of O(6)-Methylguanine-DNA Methyltransferase (MGMT) and New 
Opportunities for Treatment of Brain Cancers 
300. Potential repurposing of known drugs as potent bacterial beta-glucuronidase inhibitors 
301. Potential repurposing of oncology drugs for the treatment of Alzheimer's disease 
302. PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase 
inhibitors by inducing autophagy 
303. Prediction of structure of human WNT-CRD (FZD) complex for computational drug repurposing 
304. Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through 
Akt/mTOR suppression 
305. Protein Kinases and Parkinson's Disease 
306. Quantitative structure-activity relationship and molecular docking revealed a potency of anti-
hepatitis C virus drugs against human corona viruses 
307. Re-positioning protein-kinase inhibitors against schistosomiasis 
308. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints 
309. Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for 
Overcoming Tamoxifen Resistance in ER-positive Breast Cancer 
310. Recent progress in repositioning Alzheimer's disease drugs based on a multitarget strategy 
311. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide 
targeting de novo DNA synthesis, irrespective of molecular subtype 
312. Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual 
Screening, In Vitro and In Vivo Studies 
313. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon 
Cancer Epigenome 
314. Repositioning of amprenavir as a novel extracellular signal-regulated kinase-2 inhibitor and 
apoptosis inducer in MCF-7 human breast cancer 
315. Repositioning of anti-viral drugs as therapy for cervical cancer 
 




316. Repositioning of DHFR Inhibitors 
317. Repositioning of difluorinated propanediones as inhibitors of histone methyltransferases and their 
biological evaluation in human leukemic cell lines 
318. Repositioning of Endonuclear Receptors Binders as Potential Antibacterial and Antifungal Agents. 
Eptyloxim: A Potential and Novel Gyrase B and Cytochrome Cyp51 Inhibitor 
319. Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent 
320. Repositioning of proton pump inhibitors in cancer therapy 
321. Repositioning of Thiourea-Containing Drugs as Tyrosinase Inhibitors 
322. Repositioning organohalogen drugs: a case study for identification of potent B-Raf V600E inhibitors 
via docking and bioassay 
323. Repositioning Potential of PAK4 to Osteoclastic Bone Resorption 
324. Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of 
human fatty acid synthase 
325. Repositioning the substrate activity screening (SAS) approach as a fragment-based method for 
identification of weak binders 
326. Reprofiling using a zebrafish melanoma model reveals drugs cooperating with targeted therapeutics 
327. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease 
328. Repurposed FDA-Approved drug sorafenib reduces replication of Venezuelan equine encephalitis 
virus and other alphaviruses 
329. Repurposing an established drug: an emerging role for methylene blue in L-DOPA-induced 
dyskinesia 
330. Repurposing an Osteoporosis Drug for beta Cell Regeneration in Diabetic Patients 
331. Repurposing anticancer drugs for targeting necroptosis 
332. Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents 
333. Repurposing drugs to target the malaria parasite unfolding protein response 
334. Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans 
335. Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection 
336. Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the 
human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei 
 




337. Repurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and 
evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors 
338. Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication 
339. Repurposing N,N'-bis-(arylamidino)-1,4-piperazinedicarboxamidines: An unexpected class of potent 
inhibitors of cholinesterases 
340. Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma mansoni 
341. Repurposing of approved cardiovascular drugs 
342. Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast 
cancer 
343. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome 
coronavirus infection 
344. Repurposing of Human Kinase Inhibitors in Neglected Protozoan Diseases 
345. Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs 
346. Repurposing of prochlorperazine for use against dengue virus infection 
347. Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-beta-N-
acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease 
348. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C 
virus infection 
349. Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease 
350. Repurposing steroidogenesis inhibitors for the therapy of neuropsychiatric disorders: Promises and 
caveats 
351. Repurposing Strategy of Atorvastatin against Trypanosoma cruzi: In Vitro Monotherapy and 
Combined Therapy with Benznidazole Exhibit Synergistic Trypanocidal Activity 
352. Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori 
353. Repurposing the clinically approved calcium antagonist manidipine dihydrochloride as a new early 
inhibitor of human cytomegalovirus targeting the Immediate-Early 2 (IE2) protein 
354. Repurposing Thioridazine (TDZ) as an anti-inflammatory agent 
355. Resistance-resistant antibiotics 
356. Response to hydralazine-valproate in a patient with mycosis fungoides 
 




357. Rho-associated kinase signalling and the cancer microenvironment: novel biological implications 
and therapeutic opportunities 
358. Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian 
cancer cells 
359. Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT 
Pathways 
360. Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy 
361. S100A4 in Cancer Metastasis: Wnt Signaling-Driven Interventions for Metastasis Restriction 
362. Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library 
363. Screening of a composite library of clinically used drugs and well-characterized pharmacological 
compounds for cystathionine beta-synthase inhibition identifies benserazide as a drug potentially suitable 
for repurposing for the experimental therapy of colon cancer 
364. Screening of a Drug Library Identifies Inhibitors of Cell Intoxication by CNF1 
365. Screening of FDA-Approved Drugs for Inhibitors of Japanese Encephalitis Virus Infection 
366. Screening of FDA-Approved Drugs for Treatment of Emerging Pathogens 
367. Selective human inhibitors of ATR and ATM render Leishmania major promastigotes sensitive to 
oxidative damage 
368. Simvastatin increases the in vivo activity of the first-line tuberculosis regimen 
369. Simvastatin Therapy for Drug Repositioning to Reduce the Risk of Prostate Cancer Mortality in 
Patients With Hyperlipidemia 
370. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in 
cancer cell lines 
371. Small molecule inhibition of apicomplexan FtsH1 disrupts plastid biogenesis in human pathogens 
372. Sorafenib Impedes Rift Valley Fever Virus Egress by Inhibiting Valosin-Containing Protein 
Function in the Cellular Secretory Pathway 
373. Sphingolipids as targets for inhalation treatment of cystic fibrosis 
374. Stairway to Heaven or Hell? Perspectives and Limitations of Chagas Disease Chemotherapy 
375. Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via 
MACC1 
376. Stem Cell Hydrogel, Jump-Starting Zika Drug Discovery, and Engineering RNA Recognition 
 




377. Strategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant 
bacterial infections 
378. Structural analysis of dihydrofolate reductases enables rationalization of antifolate binding affinities 
and suggests repurposing possibilities 
379. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 
reverse transcriptase 
380. Structural Basis of Metallo-beta-Lactamase Inhibition by Captopril Stereoisomers 
381. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors 
382. Structural re-positioning, in silico molecular modelling, oxidative degradation, and biological 
screening of linagliptin as adenosine 3 receptor (ADORA3) modulators targeting hepatocellular 
carcinoma 
383. Structure based investigation on the binding interaction of transport proteins in leishmaniasis: 
insights from molecular simulation 
384. Structure Investigation, Enrichment Analysis and Structure-based Repurposing of FDA-approved 
Drugs as Inhibitors of BET-BRD4 
385. Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of 
influenza A virus 
386. Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-
approved phosphodiesterase inhibitors in the mouse model 
387. Support for phosphoinositol 3 kinase and mTOR inhibitors as treatment for lupus using in-silico 
drug-repurposing analysis 
388. Systemic amyloidosis: novel therapies and role of biomarkers 
389. Systems approach to the pharmacological actions of HDAC inhibitors reveals EP300 activities and 
convergent mechanisms of regulation in diabetes 
390. Systems Biology-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap 
Insertional Mutagenesis 
391. Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic 
protease in mycobacteria 
392. Targeting Abl kinases to regulate vascular leak during sepsis and acute respiratory distress syndrome 
393. Targeting ADAM17 Sheddase Activity in Cancer 
394. Targeting cyclin D3/CDK6 activity for treatment of Parkinson's disease 
 




395. Targeting intracellular p-aminobenzoic acid production potentiates the anti-tubercular action of 
antifolates 
396. Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins 
397. Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy 
398. Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion 
injury and for treating heart failure 
399. Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from 
nature and drug repurposing 
400. The A-Z of Zika drug discovery 
401. The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to 
inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy 
402. The Antiarrhythmic Drug, Amiodarone, Decreases AKT Activity and Sensitizes Human Acute 
Myeloid Leukemia Cells to Apoptosis by ABT-263 
403. The antimalarial drug amodiaquine possesses anti-ZIKA virus activities 
404. The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell 
carcinoma 
405. The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis 
406. The EYA tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromarone 
407. The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate 
cancer 
408. The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer's 
disease amyloid-beta peptides 
409. The Glucose Transporter PfHT1 Is an Antimalarial Target of the HIV Protease Inhibitor Lopinavir 
410. The Hippo pathway in normal development and cancer 
411. The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug 
discovery via target repurposing 
412. The human immunodeficiency virus protease inhibitor ritonavir is potentially active against 
urological malignancies 
413. The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance 
in cancer cell lines 
 




414. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines 
and discovery of potential new DDK inhibitor scaffolds 
415. The proton-pump inhibitor lansoprazole enhances amyloid beta production 
416. The purchasable chemical space: a detailed picture 
417. The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer 
418. The Significance of Hypothiocyanite Production via the Pendrin/DUOX/Peroxidase Pathway in the 
Pathogenesis of Asthma 
419. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis 
420. The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new 
opportunity for drug repurposing 
421. The Tissue-Reconstructing Ability of Colon CSCs Is Enhanced by FK506 and Suppressed by GSK3 
Inhibition 
422. Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis 
423. Therapeutic Approaches to Type I Interferonopathies 
424. Thiopurine Drugs Repositioned as Tyrosinase Inhibitors 
425. Toll-Like Receptor-4 Signaling Drives Persistent Fibroblast Activation and Prevents Fibrosis 
Resolution in Scleroderma 
426. Topical mevastatin promotes wound healing by inhibiting the transcription factor c-Myc via the 
glucocorticoid receptor and the long non-coding RNA Gas5 
427. Toward more realistic drug-target interaction predictions 
428. Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine 
Approach 
429. Transcriptomic changes induced by mycophenolic acid in gastric cancer cells 
430. Transcriptomic characterization of the novel avian-origin influenza A (H7N9) virus: specific host 
response and responses intermediate between avian (H5N1 and H7N7) and human (H3N2) viruses and 
implications for treatment options 
431. Treating Influenza Infection, From Now and Into the Future 
432. Treatment of Cryptosporidium: What We Know, Gaps, and the Way Forward 
433. Treatment With Lopinavir/Ritonavir or Interferon-beta1b Improves Outcome of MERS-CoV 
Infection in a Nonhuman Primate Model of Common Marmoset 
 




434. Tyrosinase inhibitors: a patent review (2011-2015 
435. Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic 
436. Use of attenuated paramyxoviruses for cancer therapy 
437. Use of minocycline in viral infections 
438. Using HIV drugs to target human papilloma virus 
439. Valproic acid in the complex therapy of malignant tumors 
440. Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA 
virus infection 
441. Virtual Screening against Phosphoglycerate Kinase 1 in Quest of Novel Apoptosis Inhibitors 
442. Virtual screening and drug repositioning as strategies for the discovery of new antifungal inhibitors 
of oxidosqualene cyclase 
443. Virtual screening and repositioning of inconclusive molecules of beta-lactamase Bioassays-A data 
mining approach 
444. Virtual screening-driven repositioning of etoposide as CD44 antagonist in breast cancer cells 
445. Virtual target screening: validation using kinase inhibitors 
446. West Nile virus drug discovery 
447. What do the genetic association data say about the high risk of suicide in people with depression? A 
novel network-based approach to find common molecular basis for depression and suicidal behavior and 








FACTOR 22. Drug Repurposing for Anti-Parasitic Applications 
1. A Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases 
2. A novel multi-modal drug repurposing approach for identification of potent ACK1 inhibitors 
3. A quality alert and call for improved curation of public chemistry databases 
4. A structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 
ATPase 
5. Advances in the Development of Shape Similarity Methods and Their Application in Drug Discovery 
6. An improved approach for predicting drug-target interaction: proteochemometrics to molecular 
docking 
7. An invitro and invivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi 
predicted by a computational drug repositioning method 
8. Analysis of drug binding pockets and repurposing opportunities for twelve essential enzymes of 
ESKAPE pathogens 
9. Anticancer Drugs as Antibiofilm Agents in Candida albicans: Potential Targets 
10. Anticonvulsant activity of artificial sweeteners: a structural link between sweet-taste receptor T1R3 
and brain glutamate receptors 
11. Application of computer-aided drug repurposing in the search of new cruzipain inhibitors: discovery 
of amiodarone and bromocriptine inhibitory effects 
12. Application of the 4D fingerprint method with a robust scoring function for scaffold-hopping and 
drug repurposing strategies 
13. Assessment of berberine as a multi-target antimicrobial: a multi-omics study for drug discovery and 
repositioning 
14. Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2 
15. Benznidazole/Itraconazole Combination Treatment Enhances Anti-Trypanosoma cruzi Activity in 
Experimental Chagas Disease 
16. BioGPS: The Music for the Chemo- and Bioinformatics Walzer 
17. Bioinformatics and Drug Discovery 
18. Can sodium/hydrogen exchange inhibitors be repositioned for treating attention deficit hyperactivity 
disorder? An in silico approach 
19. Cascade Ligand- and Structure-Based Virtual Screening to Identify New Trypanocidal Compounds 
Inhibiting Putrescine Uptake 
 




20. Characterizing protein domain associations by Small-molecule ligand binding 
21. Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological 
Proteins Related to the Alzheimer's Disease 
22. Comparative assessment of strategies to identify similar ligand-binding pockets in proteins 
23. Computational Drug Repositioning by Target Hopping: A Use Case in Chagas Disease 
24. Computational Drug Target Screening through Protein Interaction Profiles 
25. Computational profiling of bioactive compounds using a target-dependent composite workflow 
26. Computational repositioning and experimental validation of approved drugs for HIF-prolyl 
hydroxylase inhibition 
27. Computer-Aided Structure Based Drug Design Approaches for the Discovery of New Anti-CHIKV 
Agents 
28. Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine 
and saquinavir 
29. Cruzain inhibitors: efforts made, current leads and a structural outlook of new hits 
30. Design of efficient computational workflows for in silico drug repurposing 
31. Detection of Binding Site Molecular Interaction Field Similarities 
32. Discovering L-type calcium channels inhibitors of antihypertensive drugs based on drug repositioning 
33. Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues 
34. Discovery of novel polyamine analogs with anti-protozoal activity by computer guided drug 
repositioning 
35. Discovery of rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer 
36. Docking of a novel DNA methyltransferase inhibitor identified from high-throughput screening: 
insights to unveil inhibitors in chemical databases 
37. Docking-based inverse virtual screening: methods, applications, and challenges 
38. Docking-based virtual screening of known drugs against murE of Mycobacterium tuberculosis 
towards repurposing for TB 
39. DockingApp: a user friendly interface for facilitated docking simulations with AutoDock Vina 
40. DRABAL: novel method to mine large high-throughput screening assays using Bayesian active 
learning 
 




41. Drug repositioning by structure-based virtual screening 
42. Drug repurposing based on drug-drug interaction 
43. Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank 
database for allosteric Bcr-Abl inhibitors 
44. Drug repurposing for Leishmania. Molecular basis of the leishmanicidal activity of the antidepressant 
sertraline 
45. Drug Repurposing Identifies Inhibitors of Oseltamivir-Resistant Influenza Viruses 
46. Drug repurposing strategy against Trypanosoma cruzi infection: In vitro and in vivo assessment of the 
activity of metronidazole in mono- and combined therapy 
47. Drug repurposing: mining protozoan proteomes for targets of known bioactive compounds 
48. Drug Side Effect Profiles as Molecular Descriptors for Predictive Modeling of Target Bioactivity 
49. eModel-BDB: a database of comparative structure models of drug-target interactions from the 
Binding Database 
50. FDA-approved drugs selected using virtual screening bind specifically to G-quadruplex DNA 
51. Folic Acid Exerts Post-Ischemic Neuroprotection In Vitro Through HIF-1alpha Stabilization 
52. From laptop to benchtop to bedside: structure-based drug design on protein targets 
53. Getting the most out of PubChem for virtual screening 
54. High-throughput drug repositioning for the discovery of new treatments for Chagas disease 
55. High-Throughput parallel blind Virtual Screening using BINDSURF 
56. Ibandronate metal complexes: solution behavior and antiparasitic activity 
57. Ibuprofen as a template molecule for drug design against Ebola virus 
58. Identification of cisapride as new inhibitor of putrescine uptake in Trypanosoma cruzi by combined 
ligand- and structure-based virtual screening 
59. Identification of levothyroxine antichagasic activity through computer-aided drug repurposing 
60. Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs 
61. Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma 
cruzi Hit-Discovery Screening Cascade 
62. Improving attrition rates in Ebola virus drug discovery 
63. In Silico Chemogenomics Drug Repositioning Strategies for Neglected Tropical Diseases 
 




64. In silico drug re-purposing against African sleeping sickness using GlcNAc-PI de-N-acetylase as an 
experimental target 
65. In silico drug repurposing of FDA-approved drugs to predict new inhibitors for drug resistant T315I 
mutant and wild-type BCR-ABL1: A virtual screening and molecular dynamics study 
66. In silico identification of potent small molecule inhibitors targeting epidermal growth factor receptor 
1 
67. In silico model of the human ClC-Kb chloride channel: pore mapping, biostructural pathology and 
drug screening 
68. In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against 
multiple life stages of Schistosoma mansoni 
69. In vitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania 
amazonensis 
70. In vitro and in vivo studies of the antiparasitic activity of sterol 14alpha-demethylase (CYP51) 
inhibitor VNI against drug-resistant strains of Trypanosoma cruzi 
71. Inhibition of Peroxidase Activity of Cytochrome c: De Novo Compound Discovery and Validation 
72. Integrative omics analyses broaden treatment targets in human cancer 
73. iPSC-Based Compound Screening and InVitro Trials Identify a Synergistic Anti-amyloid beta 
Combination for Alzheimer's Disease 
74. Is there a relationship between sweet taste and seizures? Anticonvulsant and proconvulsant effects of 
non-nutritive sweeteners 
75. Large-scale computational drug repositioning to find treatments for rare diseases 
76. Mining significant substructure pairs for interpreting polypharmacology in drug-target network 
77. Molecular docking studies on thirteen fluoroquinolines with human topoisomerase II a and b 
78. Molecular property diagnostic suite for diabetes mellitus (MPDSDM): An integrated web portal for 
drug discovery and drug repurposing 
79. Molecular Topology and other Promiscuity Determinants as Predictors of Therapeutic Class- A 
Theoretical Framework to guide Drug Repositioning 
80. Multitasking models for quantitative structure-biological effect relationships: current status and future 
perspectives to speed up drug discovery 
81. Neglected Tropical Protozoan Diseases: Drug Repositioning as a Rational Option 
 




82. Nelfinavir and lopinavir impair Trypanosoma cruzi trypomastigote infection in mammalian host cells 
and show anti-amastigote activity 
83. New developments in the management of neurogenic orthostatic hypotension 
84. Novel cruzipain inhibitors for the chemotherapy of chronic Chagas disease 
85. One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug 
86. Online structure-based screening of purchasable approved drugs and natural compounds: retrospective 
examples of drug repositioning on cancer targets 
87. Optimization of Physicochemical Properties for 4-Anilinoquinoline Inhibitors of Plasmodium 
falciparum Proliferation 
88. PDID: database of molecular-level putative protein-drug interactions in the structural human 
proteome 
89. Pharmacophore anchor models of flaviviral NS3 proteases lead to drug repurposing for DENV 
infection 
90. Pharmacophore-based screening and drug repurposing exemplified on glycogen synthase kinase-3 
inhibitors 
91. POAP: A GNU parallel based multithreaded pipeline of open babel and AutoDock suite for boosted 
high throughput virtual screening 
92. Polypharmacology in the treatment of Chagas disease 
93. Polypharmacology rescored: protein-ligand interaction profiles for remote binding site similarity 
assessment 
94. Predicting targeted polypharmacology for drug repositioning and multi- target drug discovery 
95. Pros and cons of the tuberculosis drugome approach--an empirical analysis 
96. Protein-ligand-based pharmacophores: generation and utility assessment in computational ligand 
profiling 
97. Pyrazinoates as antiparasitic agents against Trypanosoma cruzi 
98. Recent developments in rationally designed multitarget antiprotozoan agents 
99. Recent trends and future prospects in computational GPCR drug discovery: from virtual screening to 
polypharmacology 
100. Repositioning drugs for inflammatory disease - fishing for new anti-inflammatory agents 
101. Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual 
Screening, In Vitro and In Vivo Studies 
 




102. Repositioning of Endonuclear Receptors Binders as Potential Antibacterial and Antifungal Agents. 
Eptyloxim: A Potential and Novel Gyrase B and Cytochrome Cyp51 Inhibitor 
103. Repositioning organohalogen drugs: a case study for identification of potent B-Raf V600E inhibitors 
via docking and bioassay 
104. RepurposeVS: A Drug Repurposing-Focused Computational Method for Accurate Drug-Target 
Signature Predictions 
105. Repurposing anticancer drugs for targeting necroptosis 
106. Repurposing existing drugs for new AMPK activators as a strategy to extend lifespan: a computer-
aided drug discovery study 
107. Repurposing of Human Kinase Inhibitors in Neglected Protozoan Diseases 
108. Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-beta-N-
acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease 
109. Repurposing of the Open Access Malaria Box for Kinetoplastid Diseases Identifies Novel Active 
Scaffolds against Trypanosomatids 
110. Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2 
111. Repurposing Strategy of Atorvastatin against Trypanosoma cruzi: In Vitro Monotherapy and 
Combined Therapy with Benznidazole Exhibit Synergistic Trypanocidal Activity 
112. Resistance-resistant antibiotics 
113. Reverse Screening Methods to Search for the Protein Targets of Chemopreventive Compounds 
114. SPILLO-PBSS: detecting hidden binding sites within protein 3D-structures through a flexible 
structure-based approach 
115. SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for 
colorectal cancer 
116. Stairway to Heaven or Hell? Perspectives and Limitations of Chagas Disease Chemotherapy 
117. Steroids-specific target library for steroids target prediction 
118. Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1 
119. Structure Investigation, Enrichment Analysis and Structure-based Repurposing of FDA-approved 
Drugs as Inhibitors of BET-BRD4 
120. Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of 
influenza A virus 
121. Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing 
 




122. Structure-based repurposing of FDA-approved drugs as inhibitors of NEDD8-activating enzyme 
123. SWEETLEAD: an in silico database of approved drugs, regulated chemicals, and herbal isolates for 
computer-aided drug discovery 
124. Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma 
cruzi 
125. Systemic amyloidosis: novel therapies and role of biomarkers 
126. Target-similarity search using Plasmodium falciparum proteome identifies approved drugs with anti-
malarial activity and their possible targets 
127. Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review 
128. The bitter pill: clinical drugs that activate the human bitter taste receptor TAS2R14 
129. The Importance of Bioactivation in Computer-Guided Drug Repositioning. Why the Parent Drug is 
Not Always Enough 
130. The purchasable chemical space: a detailed picture 
131. The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory 
NRASQ61K melanoma 
132. The thiol-polyamine metabolism of Trypanosoma cruzi: molecular targets and drug repurposing 
strategies 
133. The University of New Mexico Center for Molecular Discovery 
134. Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from 
pathophysiology to treatment 
135. Therapeutical approaches under investigation for treatment of Chagas disease 
136. Thiopurine Drugs Repositioned as Tyrosinase Inhibitors 
137. Trypanocidal Effect of Isotretinoin through the Inhibition of Polyamine and Amino Acid 
Transporters in Trypanosoma cruzi 
138. Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA 
virus infection 
139. Virtual Screening against Phosphoglycerate Kinase 1 in Quest of Novel Apoptosis Inhibitors 
140. Virtual screening and drug repositioning as strategies for the discovery of new antifungal inhibitors 
of oxidosqualene cyclase 
141. Virtual target screening: validation using kinase inhibitors 
 












FACTOR 23. Phosphodiesterase Inhibitors Repurposed from Predicitions of Drug Response 
Signatures 
1. A machine learning-based method to improve docking scoring functions and its application to drug 
repurposing 
2. A multicenter, randomized, placebo-controlled trial for cilostazol in patients with mild cognitive 
impairment: The COMCID study protocol 
3. Aging-related Repositioned Drugs, Donepezil and Sildenafil Citrate, Increase Apoptosis of Anti-
mitotic Drug-resistant KBV20C Cells Through Different Molecular Mechanisms 
4. Application of drug repositioning strategy to TOFISOPAM 
5. Application of the 4D fingerprint method with a robust scoring function for scaffold-hopping and drug 
repurposing strategies 
6. Computational identification of multi-omic correlates of anticancer therapeutic response 
7. Computational profiling of bioactive compounds using a target-dependent composite workflow 
8. Computational-experimental approach to drug-target interaction mapping: A case study on kinase 
inhibitors 
9. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from 
enhanced docking approach and molecular dynamics analyses 
10. Delivering drugs to the lungs: The history of repurposing in the treatment of respiratory diseases 
11. Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target 
Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment 
of Alzheimer's Disease 
12. Docking-based inverse virtual screening: methods, applications, and challenges 
13. Drug Repositioning for Preeclampsia Therapeutics by In Vitro Screening: Phosphodiesterase-5 
Inhibitor Vardenafil Restores Endothelial Dysfunction via Induction of Placental Growth Factor 
14. Drug repositioning for schizophrenia and depression/anxiety disorders: A machine learning approach 
leveraging expression data 
15. Drug repurposing and the prior art patents of competitors 
16. Drug Targeting and Biomarkers in Head and Neck Cancers: Insights from Systems Biology Analyses 
17. Explicit Drug Re-positioning: Predicting Novel Drug-Target Interactions of the Shelved Molecules 
with QM/MM Based Approaches 
18. Formalizing drug indications on the road to therapeutic intent 
 




19. Fragile Histidine Triad (FHIT), a Novel Modifier Gene in Pulmonary Arterial Hypertension 
20. Generation and application of drug indication inference models using typed network motif 
comparison analysis 
21. Homology modelling and molecular docking of MDR1 with chemotherapeutic agents in non-small 
cell lung cancer 
22. Identify drug repurposing candidates by mining the protein data bank 
23. In silico drug repositioning: what we need to know 
24. In silico prediction of chemical mechanism of action via an improved network-based inference 
method 
25. Inhalation of repurposed drugs to treat pulmonary hypertension 
26. Large-Scale Off-Target Identification Using Fast and Accurate Dual Regularized One-Class 
Collaborative Filtering and Its Application to Drug Repurposing 
27. Link prediction in drug-target interactions network using similarity indices 
28. Novel Tadalafil Derivatives Ameliorates Scopolamine-Induced Cognitive Impairment in Mice via 
Inhibition of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5 
29. p73 as a pharmaceutical target for cancer therapy 
30. Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics 
31. Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential 
interventions 
32. Prediction of drugs having opposite effects on disease genes in a directed network 
33. Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for 
Overcoming Tamoxifen Resistance in ER-positive Breast Cancer 
34. Repositioning of molsidomine for its efficacy in diabetes induced erectile dysfunction in rats: In 
silico, in vitro and in vivo approach 
35. Repositioning organohalogen drugs: a case study for identification of potent B-Raf V600E inhibitors 
via docking and bioassay 
36. Repurposing drugs as inhaled therapies in asthma 
37. Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents 
38. Repurposing existing drugs for new AMPK activators as a strategy to extend lifespan: a computer-
aided drug discovery study 
 




39. Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the 
human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei 
40. Repurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and evaluation 
of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors 
41. SPIDR: small-molecule peptide-influenced drug repurposing 
42. Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-
approved phosphodiesterase inhibitors in the mouse model 
43. Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury 
and for treating heart failure 
44. The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell 
carcinoma 
45. The genome of Onchocerca volvulus, agent of river blindness 
46. Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis 
47. Three-dimensional models of Mycobacterium tuberculosis proteins Rv1555, Rv1554 and their 
docking analyses with sildenafil, tadalafil, vardenafil drugs, suggest interference with quinol binding 
likely to affect protein's function 
48. Treating the dysfunctional placenta 








FACTOR 24. Inhibiting NF-KappaB Signaling for Cancer and Inflammation Treatment 
1. 3, 5, 3'-Triiodothyroacetic acid (TRIAC) is an anti-inflammatory drug that targets toll-like receptor 2 
2. A curated C. difficile strain 630 metabolic network: prediction of essential targets and inhibitors 
3. A genomics-based systems approach towards drug repositioning for rheumatoid arthritis 
4. A signalome screening approach in the autoinflammatory disease TNF receptor associated periodic 
syndrome (TRAPS) highlights the anti-inflammatory properties of drugs for repurposing 
5. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents 
6. A Zebrafish Drug-Repurposing Screen Reveals sGC-Dependent and sGC-Independent Pro-
Inflammatory Activities of Nitric Oxide 
7. Activation of MyD88-dependent TLR1/2 signaling by misfolded alpha-synuclein, a protein linked to 
neurodegenerative disorders 
8. Adjuvant potential of selegiline in attenuating organ dysfunction in septic rats with peritonitis 
9. An invitro and invivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi 
predicted by a computational drug repositioning method 
10. Analysis of drug binding pockets and repurposing opportunities for twelve essential enzymes of 
ESKAPE pathogens 
11. Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched 
for stem cell-like properties 
12. Antibiotic drug levofloxacin inhibits proliferation and induces apoptosis of lung cancer cells through 
inducing mitochondrial dysfunction and oxidative damage 
13. Antibiotic drug rifabutin is effective against lung cancer cells by targeting the eIF4E-beta-catenin axis 
14. Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void 
15. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis 
16. Antimalarial drug mefloquine inhibits nuclear factor kappa B signaling and induces apoptosis in 
colorectal cancer cells 
17. Antiviral activity of doxycycline against vesicular stomatitis virus in vitro 
18. Antiviral activity of gemcitabine against human rhinovirus invitro and invivo 
19. Antiviral Drug Ribavirin Targets Thyroid Cancer Cells by Inhibiting the eIF4E-beta-Catenin Axis 
20. Approaches for discovering anti-prion compounds: lessons learned and challenges ahead 
 




21. Auranofin and its Analogues Show Potent Antimicrobial Activity Covering Multiresistant Pathogens: 
Structure-Activity Relationships 
22. Azithromycin protects mice against ischemic stroke injury by promoting macrophage transition 
towards M2 phenotype 
23. Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the 
proliferative expansion of stem-like cancer cells (CSCs 
24. beta-Caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and 
metabolic dysregulation in mice 
25. beta-catenin and PI3Kdelta inhibition expands precursor Th17 cells with heightened stemness and 
antitumor activity 
26. Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning 
targets for IBD and other autoimmune diseases 
27. Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the 
EIS regimen 
28. Bromide supplementation exacerbated the renal dysfunction, injury and fibrosis in a mouse model of 
Alport syndrome 
29. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant 
mammary tissues of MMTV-erbB-2 transgenic mice 
30. Cancer drug discovery by repurposing: teaching new tricks to old dogs 
31. Cancer Prevention and Interception: A New Era for Chemopreventive Approaches 
32. Carbamazepine alone and in combination with doxycycline attenuates isoproterenol-induced cardiac 
hypertrophy 
33. Cascade Ligand- and Structure-Based Virtual Screening to Identify New Trypanocidal Compounds 
Inhibiting Putrescine Uptake 
34. Characterization of a Francisella tularensis-Caenorhabditis elegans Pathosystem for the Evaluation of 
Therapeutic Compounds 
35. Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-kappaB 
signaling 
36. Clobetasol promotes remyelination in a mouse model of neuromyelitis optica 
37. Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine 
kinase inhibitors as host-directed antimicrobials 
 




38. Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3beta and 
Activates WNT Signaling 
39. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces 
Growth of Hepatocellular Carcinoma Cells InVitro and in Mice by Inhibiting Cell Division Cycle 37 
Signaling 
40. Computational repositioning and experimental validation of approved drugs for HIF-prolyl 
hydroxylase inhibition 
41. Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in 
cystic fibrosis 
42. Cooperative recognition of T:T mismatch by echinomycin causes structural distortions in DNA 
duplex 
43. Cryo-EM structure of the Plasmodium falciparum 80S ribosome bound to the anti-protozoan drug 
emetine 
44. Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, 
and Neurological Diseases: A Mini-Review 
45. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease 
46. Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current 
perspectives 
47. Designing drugs that combat kidney damage 
48. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning 
in local therapy of lung infections 
49. Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues 
50. Doxycycline and therapeutic targeting of the DNA damage response in cancer cells: old drug, new 
purpose 
51. Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models 
52. Doxycycline inhibits proliferation and induces apoptosis of both human papillomavirus positive and 
negative cervical cancer cell lines 
53. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in 
breast cancer 
54. Doxycycline is an NF-kappaB inhibitor that induces apoptotic cell death in malignant T-cells 
55. Doxycycline or how to create new with the old 
 




56. Drug Repositioning for Effective Prostate Cancer Treatment 
57. Drug Repositioning through Systematic Mining of Gene Coexpression Networks in Cancer 
58. Drug Repurposing by Simulating Flow Through Protein-Protein Interaction Networks 
59. Drug repurposing may generate novel approaches to treating depression 
60. Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in 
Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and 
Blocking LTB4 Biosynthesis 
61. Drug Repurposing Screen Identifies Foxo1-Dependent Angiopoietin-2 Regulation in Sepsis 
62. Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) 
polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast 
cancer cells 
63. Effects of digitoxin on cell migration in ovarian cancer inflammatory microenvironment 
64. Emerging roles of Myc in stem cell biology and novel tumor therapies 
65. EMUDRA: Ensemble of Multiple Drug Repositioning Approaches to improve prediction accuracy 
66. Evaluating a novel treatment for coronary artery inflammation in acute Kawasaki disease: A Phase 
I/IIa trial of atorvastatin 
67. Evaluating New Compounds to Treat Burkholderia pseudomallei Infections 
68. Evaluation of a systems biology approach to identify pharmacological correctors of the mutant CFTR 
chloride channel 
69. Examining the potential preventative effects of minocycline prescribed for acne on the incidence of 
severe mental illnesses: A historical cohort study 
70. Exploiting the therapeutic potential of ready-to-use drugs: Repurposing antibiotics against amyloid 
aggregation in neurodegenerative diseases 
71. Exploration of the Anti-Inflammatory Drug Space Through Network Pharmacology: Applications for 
Drug Repurposing 
72. Extensive impact of non-antibiotic drugs on human gut bacteria 
73. Fenofibrate Attenuates Neutrophilic Inflammation in Airway Epithelia: Potential Drug Repurposing 
for Cystic Fibrosis 
74. Fenoprofen -- an old drug rediscovered as a biased allosteric enhancer for melanocortin receptors 
75. Finding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-
based systems biology approach 
 




76. From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy 
77. From the era of genome analysis to the era of genomic drug discovery: a pioneering example of 
rheumatoid arthritis 
78. Functional genetics-directed identification of novel pharmacological inhibitors of FAS- and TNF-
dependent apoptosis that protect mice from acute liver failure 
79. Genetic Mechanisms of Asthma and the Implications for Drug Repositioning 
80. Host-directed antimicrobial drugs with broad-spectrum efficacy against intracellular bacterial 
pathogens 
81. Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-
Bechamp Debates 
82. Ibuprofen and diclofenac treatments reduce proliferation of pancreatic acinar cells upon inflammatory 
injury and mitogenic stimulation 
83. Identification and Validation of an Antivirulence Agent Targeting HlyU-Regulated Virulence in 
Vibrio vulnificus 
84. Identification of Chemical Inhibitors of beta-Catenin-Driven Liver Tumorigenesis in Zebrafish 
85. Identification of common biological pathways and drug targets across multiple respiratory viruses 
based on human host gene expression analysis 
86. Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of 
action 
87. Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme 
88. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma 
89. Immunomodulatory tetracyclines shape the intestinal inflammatory response inducing mucosal 
healing and resolution 
90. In vitro activity of the antiasthmatic drug zafirlukast against the oral pathogens Porphyromonas 
gingivalis and Streptococcus mutans 
91. In Vitro and Intracellular Activity of Imipenem Combined with Rifabutin and Avibactam against 
Mycobacterium abscessus 
92. In vitro antimicrobial activity of monensin against common clinical isolates associated with canine 
otitis externa 
93. Increasing procaspase 8 expression using repurposed drugs to induce HIV infected cell death in ex 
vivo patient cells 
 




94. Inflammatory pathway network-based drug repositioning and molecular phenomics 
95. Inhaled mannitol in patients with cystic fibrosis: A randomised open-label dose response trial 
96. Inhibition of Fosfomycin Resistance Protein FosA by Phosphonoformate (Foscarnet) in Multidrug-
Resistant Gram-Negative Pathogens 
97. Inhibition of the insulin-like growth factor system is a potential therapy for rheumatoid arthritis 
98. Inhibitors of Cancer Stem Cells 
99. Innovations in asthma therapy: is there a role for inhaled statins 
100. Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft 
Rejection: Therapeutic Implications of IL-6 Receptor Blockade 
101. Investigating Drug Repositioning Approach to Design Novel Prodrugs for Colon-specific Release of 
Fexofenadine for Ulcerative Colitis 
102. Is There Potential for Repurposing Statins as Novel Antimicrobials 
103. L-Captopril and its derivatives as potential inhibitors of microbial enzyme DapE: A combined 
approach of drug repurposing and similarity screening 
104. Lansoprazole Upregulates Polyubiquitination of the TNF Receptor-Associated Factor 6 and 
Facilitates Runx2-mediated Osteoblastogenesis 
105. Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase 
Inhibition for Peritoneal Carcinomatosis 
106. Metabolic Dysfunction in Alzheimer's Disease: From Basic Neurobiology to Clinical Approaches 
107. Metabolome analysis of effect of aspirin on Drosophila lifespan extension 
108. Metformin - The Drug for the Treatment of Autoimmune Diseases; A New Use of a Known Anti-
Diabetic Drug 
109. Metformin as a geroprotector: experimental and clinical evidence 
110. Minocycline repurposing in critical illness: focus on stroke 
111. Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of 
stem-like cancer cells 
112. Mode of action and resistance studies unveil new roles for tropodithietic acid as an anticancer agent 
and the gamma-glutamyl cycle as a proton sink 
113. Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in 
Cystic Fibrosis 
 




114. N-bromotaurine surrogates for loss of antiproliferative response and enhances cisplatin efficacy in 
cancer cells with impaired glucocorticoid receptor 
115. Nanoliposomal Buparvaquone Immunomodulates Leishmania infantum-Infected Macrophages and 
Is Highly Effective in a Murine Model 
116. Neuroprotective and immunomodulatory effects of raloxifene in the myenteric plexus of a mouse 
model of Parkinson's disease 
117. New Antimicrobial Approaches: Reuse of Old Drugs 
118. New drug candidates for depression - a nationwide population-based study 
119. New frontiers for anti-biofilm drug development 
120. New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria 
121. Niclosamide and its analogs are potent inhibitors of Wnt/beta-catenin, mTOR and STAT3 signaling 
in ovarian cancer 
122. Niclosamide, a Drug with Many (Re)purposes 
123. Nonantibiotic properties of macrolides and their role in modulation of the inflammatory reaction 
124. Novel insight into drug repositioning: Methylthiouracil as a case in point 
125. Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing 
Against Polymyxin-Resistant Multidrug-Resistant Gram-Negative Pathogens 
126. Novel Therapeutics Identification for Fibrosis in Renal Allograft Using Integrative Informatics 
Approach 
127. Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity 
128. Nutraceuticals and "repurposed" drugs of phytochemical origin in prevention and interception of 
chronic degenerative disease and cancer 
129. Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc 
adenomas are downregulated in response to tumor suppression by Clotam 
130. Oral delivery of ivermectin using a fast dissolving oral film: Implications for repurposing ivermectin 
as a pharmacotherapy for alcohol use disorder 
131. Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the 
Receptor Activator of NF-kappaB Ligand Pathway 
132. Pentosan Polysulfate: a Novel Glycosaminoglycan-Like Molecule for Effective Treatment of 
Alphavirus-Induced Cartilage Destruction and Inflammatory Disease 
133. Pharmacogenomic approaches to lipid-regulating trials 
 




134. Pharmacologically active metabolites, combination screening and target identification-driven drug 
repositioning in antituberculosis drug discovery 
135. Poly(ADP-ribose) polymerase is not involved in the neuroprotection exerted by azithromycin against 
ischemic stroke in mice 
136. Post-ischemic treatment with azithromycin protects ganglion cells against retinal 
ischemia/reperfusion injury in the rat 
137. Prediction of structure of human WNT-CRD (FZD) complex for computational drug repurposing 
138. Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine 
for the treatment of malignant glioma 
139. Pyrvinium Sensitizes Clear Cell Renal Cell Carcinoma Response to Chemotherapy Via Casein 
Kinase 1alpha-Dependent Inhibition of Wnt/beta-Catenin 
140. Raloxifene attenuates Pseudomonas aeruginosa pyocyanin production and virulence 
141. Rationale for an experimental treatment of retinitis pigmentosa: 140-month test of hypothesis with 
one patient 
142. Real-Time" High-Throughput Drug and Synergy Testing for Multidrug-Resistant Bacterial Infection: 
A Case Report 
143. Repositioning drugs for inflammatory disease - fishing for new anti-inflammatory agents 
144. Repositioning of antibiotic levofloxacin as a mitochondrial biogenesis inhibitor to target breast 
cancer 
145. Repositioning of Memantine as a Potential Novel Therapeutic Agent against Meningitic E. coli-
Induced Pathogenicities through Disease-Associated Alpha7 Cholinergic Pathway and RNA Sequencing-
Based Transcriptome Analysis of Host Inflammatory Responses 
146. Repositioning of Tak-475 In Mevalonate Kinase Disease: Translating Theory Into Practice 
147. Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute 
ischemic stroke: minocycline 
148. Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute 
ischemic stroke: minocycline 
149. Repurposing an orally available drug for the treatment of geographic atrophy 
150. Repurposing an Osteoporosis Drug for beta Cell Regeneration in Diabetic Patients 
151. Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer 
stem cells 
 




152. Repurposing auranofin for the treatment of cutaneous staphylococcal infections 
153. Repurposing doxycycline for synucleinopathies: remodelling of alpha-synuclein oligomers towards 
non-toxic parallel beta-sheet structured species 
154. Repurposing drugs for the treatment and control of helminth infections 
155. Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs 
156. Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent 
157. Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections 
158. Repurposing FDA-approved drugs to combat drug-resistant Acinetobacter baumannii 
159. Repurposing itraconazole as an anticancer agent 
160. Repurposing niclosamide as a versatile antimicrobial surface coating against device-associated, 
hospital-acquired bacterial infections 
161. Repurposing of Anticancer Drugs for the Treatment of Bacterial Infections 
162. Repurposing of approved drugs from the human pharmacopoeia to target Wolbachia endosymbionts 
of onchocerciasis and lymphatic filariasis 
163. Repurposing of gallium-based drugs for antibacterial therapy 
164. Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic 
cancer prevention and treatment 
165. Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: a crucial 
role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation 
166. Repurposing of nucleoside- and nucleobase-derivative drugs as antibiotics and biofilm inhibitors 
167. Repurposing the anti-malarial drug dihydroartemisinin suppresses metastasis of non-small-cell lung 
cancer via inhibiting NF-kappaB/GLUT1 axis 
168. Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa 
pathogenicity 
169. Repurposing Thioridazine (TDZ) as an anti-inflammatory agent 
170. Repurposing Toremifene for Treatment of Oral Bacterial Infections 
171. Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant 
Enterobacteriaceae infections 
172. Repurposing-a ray of hope in tackling extensively drug resistance in tuberculosis 
 




173. Rescue of cell death and inflammation of a mouse model of complex 1-mediated vision loss by 
repurposed drug molecules 
174. Rifampin inhibits Toll-like receptor 4 signaling by targeting myeloid differentiation protein 2 and 
attenuates neuropathic pain 
175. Role of acid responsive genes in the susceptibility of Escherichia coli to ciclopirox 
176. S100A4 in Cancer Metastasis: Wnt Signaling-Driven Interventions for Metastasis Restriction 
177. SCMBYK: prediction and characterization of bacterial tyrosine-kinases based on propensity scores 
of dipeptides 
178. Screening a Commercial Library of Pharmacologically Active Small Molecules against 
Staphylococcus aureus Biofilms 
179. Screening a repurposing library for potentiators of antibiotics against Staphylococcus aureus 
biofilms 
180. Senicapoc: Repurposing a Drug to Target Microglia KCa3.1 in Stroke 
181. Sphingolipids as targets for inhalation treatment of cystic fibrosis 
182. Statins in conditions other than hypocholesterolemic effects for chronic subdural hematoma therapy, 
old drug, new tricks 
183. Statins: antimicrobial resistance breakers or makers 
184. Strategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant 
bacterial infections 
185. Stromal microenvironment in type VII collagen-deficient skin: The ground for squamous cell 
carcinoma development 
186. Suppressive effects of dabrafenibon endothelial protein C receptor shedding 
187. Symposium 2-1The autoimmunome: Similarities and differences among genetic susceptibility to 
common immune-related diseases 
188. Synthetic lethality reveals mechanisms of Mycobacterium tuberculosis resistance to beta-lactams 
189. Systemic amyloidosis: novel therapies and role of biomarkers 
190. Targeting Abl kinases to regulate vascular leak during sepsis and acute respiratory distress syndrome 
191. Targeting ADAM17 Sheddase Activity in Cancer 
192. Targeting STAT1 in Both Cancer and Insulin Resistance Diseases 
 




193. Tedizolid Activity Against Clinical Mycobacterium abscessus Complex Isolates-An in vitro 
Characterization Study 
194. Teicoplanin inhibits Ebola pseudovirus infection in cell culture 
195. Tetracycline hydrochloride: A potential clinical drug for radioprotection 
196. Tetracycline repurposing in neurodegeneration: focus on Parkinson's disease 
197. Tezosentan inhibits uptake of proinflammatory endothelin-1 in stenotic aortic valves 
198. The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to 
inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy 
199. The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma 
Cells by Targeting Multiple Signal Pathways 
200. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical 
and noncanonical Wnt signaling pathway 
201. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal 
melanoma in vitro and in vivo 
202. The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory 
responses and accelerates wound healing in a murine model of third-degree burn injury 
203. The Concept of Hormesis in Cancer Therapy - Is Less More 
204. The heterogeneity of cancer stem-like cells at the invasive front 
205. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian 
randomisation analysis 
206. The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in 
hepatocellular carcinoma 
207. The Repurposing of Anti-Psychotic Drugs, Quetiapine and Olanzapine, as Anti-Cryptococcus Drugs 
208. The Significance of Hypothiocyanite Production via the Pendrin/DUOX/Peroxidase Pathway in the 
Pathogenesis of Asthma 
209. The Tissue-Reconstructing Ability of Colon CSCs Is Enhanced by FK506 and Suppressed by GSK3 
Inhibition 
210. Therapeutic Effect of Quinacrine, an Antiprotozoan Drug, by Selective Suppression of p-CHK1/2 in 
p53-Negative Malignant Cancers 
211. Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by 
inhibiting Wnt/beta-catenin signaling 
 




212. Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC/BCL2 
double-hit B cell lymphoma 
213. Tigecycline targets nonsmall cell lung cancer through inhibition of mitochondrial function 
214. Toward Repositioning Niclosamide for Antivirulence Therapy of Pseudomonas aeruginosa Lung 
Infections: Development of Inhalable Formulations through Nanosuspension Technology 
215. Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, 
Escherichia coli, and Klebsiella pneumoniae 
216. Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine 
Approach 
217. Treating Influenza Infection, From Now and Into the Future 
218. Treatment of experimental autoimmune uveoretinitis with peroxisome proliferator-activated receptor 
alpha agonist fenofibrate 
219. Triclosan Is an Aminoglycoside Adjuvant for Eradication of Pseudomonas aeruginosa Biofilms 
220. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug 
resistance of lung cancer 
221. Use of minocycline in viral infections 
222. Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent 
drug candidates for cancer treatment 
223. What do the genetic association data say about the high risk of suicide in people with depression? A 
novel network-based approach to find common molecular basis for depression and suicidal behavior and 








FACTOR 25. Repurposing Based on Comprehensive Multi-Metric Similarity Measures 
1. A comparative study of disease genes and drug targets in the human protein interactome 
2. A cross-species analysis method to analyze animal models' similarity to human's disease state 
3. A disease similarity matrix based on the uniqueness of shared genes 
4. A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth 
muscle relaxation to direct neuroprotection 
5. A framework for the targeted selection of herbs with similar efficacy by exploiting drug repositioning 
technique and curated biomedical knowledge 
6. A Large-Scale Gene Expression Intensity-Based Similarity Metric for Drug Repositioning 
7. A machine-learned computational functional genomics-based approach to drug classification 
8. A New Method for Computational Drug Repositioning Using Drug Pairwise Similarity 
9. A novel multi-modal drug repurposing approach for identification of potent ACK1 inhibitors 
10. A physarum-inspired prize-collecting steiner tree approach to identify subnetworks for drug 
repositioning 
11. A Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and 
Repositioning Predictions 
12. A tool to utilize adverse effect profiles to identify brain-active medications for repurposing 
13. A two-step drug repositioning method based on a protein-protein interaction network of genes shared 
by two diseases and the similarity of drugs 
14. A two-tiered unsupervised clustering approach for drug repositioning through heterogeneous data 
integration 
15. Advances in the Development of Shape Similarity Methods and Their Application in Drug Discovery 
16. alpha-Methyl-alpha-phenylsuccinimide ameliorates neurodegeneration in a C. elegans model of TDP-
43 proteinopathy 
17. An integrated structure- and system-based framework to identify new targets of metabolites and 
known drugs 
18. Analysis and assay of oseltamivir-resistant mutants of influenza neuraminidase via direct observation 
of drug unbinding and rebinding in simulation 
19. Analysis of drug binding pockets and repurposing opportunities for twelve essential enzymes of 
ESKAPE pathogens 
 




20. Anti-infectious drug repurposing using an integrated chemical genomics and structural systems 
biology approach 
21. Application of the 4D fingerprint method with a robust scoring function for scaffold-hopping and 
drug repurposing strategies 
22. Assessing protein kinase target similarity: Comparing sequence, structure, and cheminformatics 
approaches 
23. Assessing relative bioactivity of chemical substances using quantitative molecular network topology 
analysis 
24. Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New 
Platform for Computer-Aided Drug Repurposing 
25. Back to the Roots: Prediction of Biologically Active Natural Products from Ayurveda Traditional 
Medicine 
26. Baseline Regularization for Computational Drug Repositioning with Longitudinal Observational Data 
27. BioGPS: navigating biological space to predict polypharmacology, off-targeting, and selectivity 
28. BioGPS: The Music for the Chemo- and Bioinformatics Walzer 
29. Bioinformatics methods in drug repurposing for Alzheimer's disease 
30. Bioinformatics: Novel Insights from Genomic Information 
31. C-SPADE: a web-tool for interactive analysis and visualization of drug screening experiments 
through compound-specific bioactivity dendrograms 
32. Can sodium/hydrogen exchange inhibitors be repositioned for treating attention deficit hyperactivity 
disorder? An in silico approach 
33. CANDO and the infinite drug discovery frontier 
34. CellFateScout - a bioinformatics tool for elucidating small molecule signaling pathways that drive 
cells in a specific direction 
35. Characterizing protein domain associations by Small-molecule ligand binding 
36. Characterizing the pocketome of Mycobacterium tuberculosis and application in rationalizing 
polypharmacological target selection 
37. ChemMapper: a versatile web server for exploring pharmacology and chemical structure association 
based on molecular 3D similarity method 
38. Classifying cancer genome aberrations by their mutually exclusive effects on transcription 
 




39. Clustering based drug-drug interaction networks for possible repositioning of drugs against EGFR 
mutations: Clustering based DDI networks for EGFR mutations 
40. Clustering drug-drug interaction networks with energy model layouts: community analysis and drug 
repurposing 
41. Co-expression Network Approach Reveals Functional Similarities among Diseases Affecting Human 
Skeletal Muscle 
42. Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate 
Synthase Case 
43. Complex-disease networks of trait-associated single-nucleotide polymorphisms (SNPs) unveiled by 
information theory 
44. Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with 
Repurposing Potential 
45. Computational drug repositioning through heterogeneous network clustering 
46. Computational drug repurposing to predict approved and novel drug-disease associations 
47. Computational Drug Target Screening through Protein Interaction Profiles 
48. Computational functional genomics-based approaches in analgesic drug discovery and repurposing 
49. Concept Modeling-based Drug Repositioning 
50. Constructing Disease Similarity Networks Based on Disease Module Theory 
51. Construction of drug network based on side effects and its application for drug repositioning 
52. Context-specific functional module based drug efficacy prediction 
53. Convergent downstream candidate mechanisms of independent intergenic polymorphisms between 
co-classified diseases implicate epistasis among noncoding elements 
54. CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM 
55. Designing Dietary Recommendations Using System Level Interactomics Analysis and Network-
Based Inference 
56. Detecting drug promiscuity using Gaussian ensemble screening 
57. Detection of Binding Site Molecular Interaction Field Similarities 
58. Diclofenac Identified as a Kynurenine 3-Monooxygenase Binder and Inhibitor by Molecular 
Similarity Techniques 
 




59. Diffusion mapping of drug targets on disease signaling network elements reveals drug combination 
strategies 
60. Discovery of drug mode of action and drug repositioning from transcriptional responses 
61. Discovery of Novel Liver-Stage Antimalarials through Quantum Similarity 
62. Discovery of Novel SPAK Inhibitors That Block WNK Kinase Signaling to Cation Chloride 
Transporters 
63. Disease classification: from phenotypic similarity to integrative genomics and beyond 
64. DNetDB: The human disease network database based on dysfunctional regulation mechanism 
65. Do Cancer Drugs Counteract Neurodegeneration? Repurposing forAlzheimer's Disease 
66. Docking of a novel DNA methyltransferase inhibitor identified from high-throughput screening: 
insights to unveil inhibitors in chemical databases 
67. DR2DI: a powerful computational tool for predicting novel drug-disease associations 
68. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking 
(MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-
6/GP130 interface 
69. Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key 
70. Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm 
71. Drug repositioning based on triangularly balanced structure for tissue-specific diseases in incomplete 
interactome 
72. Drug repositioning by applying 'expression profiles' generated by integrating chemical structure 
similarity and gene semantic similarity 
73. Drug Repositioning by Integrating Known Disease-Gene and Drug-Target Associations in a Semi-
supervised Learning Model 
74. Drug repositioning by kernel-based integration of molecular structure, molecular activity, and 
phenotype data 
75. Drug repositioning discovery for early- and late-stage non-small-cell lung cancer 
76. Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining 
77. Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional 
Signatures 
78. Drug repositioning for enzyme modulator based on human metabolite-likeness 
 




79. Drug repositioning for orphan genetic diseases through Conserved Anticoexpressed Gene Clusters 
(CAGCs 
80. Drug repurposing based on drug-drug interaction 
81. Drug Repurposing of the Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia 
82. Drug Repurposing Using Deep Embeddings of Gene Expression Profiles 
83. Drug similarity search based on combined signatures in gene expression profiles 
84. Drug target prediction using adverse event report systems: a pharmacogenomic approach 
85. Drug-target based cross-sectional analysis of olfactory drug effects 
86. Drug-target interaction prediction by integrating chemical, genomic, functional and pharmacological 
data 
87. Drug-target interaction prediction by integrating multiview network data 
88. Drugs Polypharmacology by In Silico Methods: New Opportunities in Drug Discovery 
89. DSviaDRM: an R package for estimating disease similarity via dysfunctional regulation mechanism 
90. DT-Web: a web-based application for drug-target interaction and drug combination prediction 
through domain-tuned network-based inference 
91. Elucidating the modes of action for bioactive compounds in a cell-specific manner by large-scale 
chemically-induced transcriptomics 
92. Estimated generic prices for novel treatments for drug-resistant tuberculosis 
93. Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching 
94. Exploration of the Anti-Inflammatory Drug Space Through Network Pharmacology: Applications for 
Drug Repurposing 
95. Exploring drug-target interaction networks of illicit drugs 
96. Exploring Polypharmacology in Drug Discovery and Repurposing Using the CANDO Platform 
97. Exploring the anti-proliferative activity of Pelargonium sidoides DC with in silico target identification 
and network pharmacology 
98. Exploring the molecular mechanisms of Traditional Chinese Medicine components using gene 
expression signatures and connectivity map 
99. Finding complex biological relationships in recent PubMed articles using Bio-LDA 
 




100. Finding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-
based systems biology approach 
101. Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking 
(MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and 
activator of transcription 3 (STAT3 
102. Fusing literature and full network data improves disease similarity computation 
103. Gene-Set Local Hierarchical Clustering (GSLHC)--A Gene Set-Based Approach for Characterizing 
Bioactive Compounds in Terms of Biological Functional Groups 
104. Generating Gene Ontology-Disease Inferences to Explore Mechanisms of Human Disease at the 
Comparative Toxicogenomics Database 
105. GES polypharmacology fingerprints: a novel approach for drug repositioning 
106. High-throughput drug screening using the Ebola virus transcription- and replication-competent virus-
like particle system 
107. How good are publicly available web services that predict bioactivity profiles for drug repurposing 
108. Human pathway-based disease network 
109. Identification of associations between small molecule drugs and miRNAs based on functional 
similarity 
110. Identification of cisapride as new inhibitor of putrescine uptake in Trypanosoma cruzi by combined 
ligand- and structure-based virtual screening 
111. Identification of driver copy number alterations in diverse cancer types and application in drug 
repositioning 
112. Identification of key pathways and drug repurposing for anaplastic thyroid carcinoma by integrated 
bioinformatics analysis 
113. Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs 
114. Identification of novel therapeutics for complex diseases from genome-wide association data 
115. Identify drug repurposing candidates by mining the protein data bank 
116. Identify potential drugs for cardiovascular diseases caused by stress-induced genes in vascular 
smooth muscle cells 
117. Identifying Candidates for Breast Cancer Using Interactions of Chemicals and Proteins 
118. Identifying the macromolecular targets of de novo-designed chemical entities through self-
organizing map consensus 
 




119. Improved anticancer drug response prediction in cell lines using matrix factorization with similarity 
regularization 
120. In Silico Receptorome Screening of Antipsychotic Drugs 
121. In Silico target fishing: addressing a "Big Data" problem by ligand-based similarity rankings with 
data fusion 
122. In Silico-Based Repositioning of Phosphinothricin as a Novel Technetium-99m Imaging Probe with 
Potential Anti-Cancer Activity 
123. In vitro analysis of finasteride activity against Candida albicans urinary biofilm formation and 
filamentation 
124. Inferring new indications for approved drugs via random walk on drug-disease heterogenous 
networks 
125. Insights from pharmacological similarity of epigenetic targets in epipolypharmacology 
126. Integrated Computational Analysis of Genes Associated with Human Hereditary Insensitivity to 
Pain. A Drug Repurposing Perspective 
127. Integrating Clinical Phenotype and Gene Expression Data to Prioritize Novel Drug Uses 
128. iPSC-Based Compound Screening and InVitro Trials Identify a Synergistic Anti-amyloid beta 
Combination for Alzheimer's Disease 
129. Large-scale Direct Targeting for Drug Repositioning and Discovery 
130. Large-scale integration of heterogeneous pharmacogenomic data for identifying drug mechanism of 
action 
131. Leveraging 3D chemical similarity, target and phenotypic data in the identification of drug-protein 
and drug-adverse effect associations 
132. Linking PharmGKB to phenotype studies and animal models of disease for drug repurposing 
133. Literature-based discovery of new candidates for drug repurposing 
134. Logical comparison over RDF resources in bio-informatics 
135. Macromolecular target prediction by self-organizing feature maps 
136. Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing 
137. Medical concept normalization in social media posts with recurrent neural networks 
138. MeSHDD: Literature-based drug-drug similarity for drug repositioning 
139. Mining significant substructure pairs for interpreting polypharmacology in drug-target network 
 




140. miREFRWR: a novel disease-related microRNA-environmental factor interactions prediction 
method 
141. Model-based unsupervised learning informs metformin-induced cell-migration inhibition through an 
AMPK-independent mechanism in breast cancer 
142. Molecular Connectivity Predefines Polypharmacology: Aliphatic Rings, Chirality, and sp3 Centers 
Enhance Target Selectivity 
143. Molecular Topology and other Promiscuity Determinants as Predictors of Therapeutic Class- A 
Theoretical Framework to guide Drug Repositioning 
144. MOST: most-similar ligand based approach to target prediction 
145. Mouse model phenotypes provide information about human drug targets 
146. MPGraph: multi-view penalised graph clustering for predicting drug-target interactions 
147. MTGO: PPI Network Analysis Via Topological and Functional Module Identification 
148. Multiscale modelling of relationships between protein classes and drug behavior across all diseases 
using the CANDO platform 
149. Neighbours of cancer-related proteins have key influence on pathogenesis and could increase the 
drug target space for anticancer therapies 
150. Network and matrix analysis of the respiratory disease interactome 
151. Network measures for chemical library design 
152. Network predicting drug's anatomical therapeutic chemical code 
153. Network-assisted prediction of potential drugs for addiction 
154. Network-based analysis of transcriptional profiles from chemical perturbations experiments 
155. Network-based drug ranking and repositioning with respect to DrugBank therapeutic categories 
156. Network-based drug repositioning: A novel strategy for discovering potential antidepressants and 
their mode of action 
157. NetwoRx: connecting drugs to networks and phenotypes in Saccharomyces cerevisiae 
158. New HSP27 inhibitors efficiently suppress drug resistance development in cancer cells 
159. New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale 
cancer cell line panels 
160. NMR spectroscopy-based metabolic profiling of drug-induced changes in vitro can discriminate 
between pharmacological classes 
 




161. Novel therapeutics for coronary artery disease from genome-wide association study data 
162. Old friends in new guise: repositioning of known drugs with structural bioinformatics 
163. Open-source chemogenomic data-driven algorithms for predicting drug-target interactions 
164. Orphan receptor ligand discovery by pickpocketing pharmacological neighbors 
165. PATIENT-SPECIFIC DATA FUSION FOR CANCER STRATIFICATION AND 
PERSONALISED TREATMENT 
166. Personalized drug discovery: HCA approach optimized for rare diseases at Tel Aviv University 
167. Personalized Proteomics in Proliferative Vitreoretinopathy Implicate Hematopoietic Cell 
Recruitment and mTOR as a Therapeutic Target 
168. Pharmacological use of a novel scaffold, anomeric N,N-diarylamino tetrahydropyran: molecular 
similarity search, chemocentric target profiling, and experimental evidence 
169. Polypharmacological Drug-target Inference for Chemogenomics 
170. Polypharmacology rescored: protein-ligand interaction profiles for remote binding site similarity 
assessment 
171. PREDICT: a method for inferring novel drug indications with application to personalized medicine 
172. Predicting and characterizing selective multiple drug treatments for metabolic diseases and cancer 
173. Predicting drug-disease associations and their therapeutic function based on the drug-disease 
association bipartite network 
174. Predicting drug-disease interactions by semi-supervised graph cut algorithm and three-layer data 
integration 
175. Predicting drug-target interaction for new drugs using enhanced similarity measures and super-target 
clustering 
176. Predicting drug-target interactions using probabilistic matrix factorization 
177. Predicting Drug-Target Interactions via Within-Score and Between-Score 
178. Predicting Drug-Target Interactions With Multi-Information Fusion 
179. Predicting targeted polypharmacology for drug repositioning and multi- target drug discovery 
180. Prediction of drug-target interaction by label propagation with mutual interaction information 
derived from heterogeneous network 
181. Prediction of drug-target interactions and drug repositioning via network-based inference 
 




182. Prediction of drug-target interactions for drug repositioning only based on genomic expression 
similarity 
183. Prediction of new drug indications based on clinical data and network modularity 
184. Prediction of Non-coding RNAs as Drug Targets 
185. Prediction of Novel Drugs and Diseases for Hepatocellular Carcinoma Based on Multi-Source 
Simulated Annealing Based Random Walk 
186. Prediction of Novel Drugs for Hepatocellular Carcinoma Based on Multi-Source Random Walk 
187. Prediction of off-target drug effects through data fusion 
188. Prediction of polypharmacological profiles of drugs by the integration of chemical, side effect, and 
therapeutic space 
189. Prediction of structure of human WNT-CRD (FZD) complex for computational drug repurposing 
190. Process Pharmacology: A Pharmacological Data Science Approach to Drug Development and 
Therapy 
191. PROMISCUOUS: a database for network-based drug-repositioning 
192. Protein-ligand-based pharmacophores: generation and utility assessment in computational ligand 
profiling 
193. Re-positioning protein-kinase inhibitors against schistosomiasis 
194. Recent advances in the machine learning-based drug-target interaction prediction 
195. Relating anatomical therapeutic indications by the ensemble similarity of drug sets 
196. Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual 
Screening, In Vitro and In Vivo Studies 
197. Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario 
198. Repositioning of Endonuclear Receptors Binders as Potential Antibacterial and Antifungal Agents. 
Eptyloxim: A Potential and Novel Gyrase B and Cytochrome Cyp51 Inhibitor 
199. Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer 
200. REPRODUCIBLE DRUG REPURPOSING: WHEN SIMILARITY DOES NOT SUFFICE 
201. RepTB: a gene ontology based drug repurposing approach for tuberculosis 
202. Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent 
antitubercular agents 
 




203. Review and comparative assessment of similarity-based methods for prediction of drug-protein 
interactions in the druggable human proteome 
204. Revisiting Connectivity Map from a gene co-expression network analysis 
205. Ribavirin as a tri-targeted antitumor repositioned drug 
206. SCMBYK: prediction and characterization of bacterial tyrosine-kinases based on propensity scores 
of dipeptides 
207. Screening drug-target interactions with positive-unlabeled learning 
208. SELF-BLM: Prediction of drug-target interactions via self-training SVM 
209. SemFunSim: a new method for measuring disease similarity by integrating semantic and gene 
functional association 
210. SMAP-WS: a parallel web service for structural proteome-wide ligand-binding site comparison 
211. Some Remarks on Prediction of Drug-Target Interaction with Network Models 
212. SPIDR: small-molecule peptide-influenced drug repurposing 
213. Steroids-specific target library for steroids target prediction 
214. Structural analysis of dihydrofolate reductases enables rationalization of antifolate binding affinities 
and suggests repurposing possibilities 
215. Structural analysis of protein tyrosine phosphatase 1B reveals potentially druggable allosteric 
binding sites 
216. Substrate-driven mapping of the degradome by comparison of sequence logos 
217. Systematic drug repositioning for a wide range of diseases with integrative analyses of phenotypic 
and molecular data 
218. Target-Based Drug Repositioning Using Large-Scale Chemical-Protein Interactome Data 
219. Target-similarity search using Plasmodium falciparum proteome identifies approved drugs with anti-
malarial activity and their possible targets 
220. TargetHunter: an in silico target identification tool for predicting therapeutic potential of small 
organic molecules based on chemogenomic database 
221. The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod 
222. The human disease network in terms of dysfunctional regulatory mechanisms 
223. The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory 
NRASQ61K melanoma 
 




224. The role of drug profiles as similarity metrics: applications to repurposing, adverse effects detection 
and drug-drug interactions 
225. Therapeutic drug repositioning using personalized proteomics of liquid biopsies 
226. Thiopurine Drugs Repositioned as Tyrosinase Inhibitors 
227. Tools for in silico target fishing 
228. Toward drug repurposing in epigenetics: olsalazine as a hypomethylating compound active in a 
cellular context 
229. Towards drug repositioning: a unified computational framework for integrating multiple aspects of 
drug similarity and disease similarity 
230. Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine 
Approach 
231. Updates on drug-target network; facilitating polypharmacology and data integration by growth of 
DrugBank database 
232. Virtual Screening against Phosphoglycerate Kinase 1 in Quest of Novel Apoptosis Inhibitors 
233. Virtual screening and repositioning of inconclusive molecules of beta-lactamase Bioassays-A data 
mining approach 









FACTOR 26. Genome-Wide Association-Based Networks for Repurposing 
1. 4-Acetoxyphenol Prevents RPE Oxidative Stress-Induced Necrosis by Functioning as an NRF2 
Stabilizer 
2. A bidirectional drug repositioning approach for Parkinson's disease through network-based inference 
3. A Biologically-Based Computational Approach to Drug Repurposing for Anthrax Infection 
4. A cellular genetics approach identifies gene-drug interactions and pinpoints drug toxicity pathway 
nodes 
5. A chemo-centric view of human health and disease 
6. A combined systems and structural modeling approach repositions antibiotics for Mycoplasma 
genitalium 
7. A common rejection module (CRM) for acute rejection across multiple organs identifies novel 
therapeutics for organ transplantation 
8. A comparative study of disease genes and drug targets in the human protein interactome 
9. A computational approach to finding novel targets for existing drugs 
10. A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors 
11. A computational method for clinically relevant cancer stratification and driver mutation module 
discovery using personal genomics profiles 
12. A computational method for drug repositioning using publicly available gene expression data 
13. A Computational Systems Biology Approach for Identifying Candidate Drugs for Repositioning for 
Cardiovascular Disease 
14. A curated C. difficile strain 630 metabolic network: prediction of essential targets and inhibitors 
15. A disease similarity matrix based on the uniqueness of shared genes 
16. A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth 
muscle relaxation to direct neuroprotection 
17. A Drug Screen using Human iPSC-Derived Hepatocyte-like Cells Reveals Cardiac Glycosides as a 
Potential Treatment for Hypercholesterolemia 
18. A drug target slim: using gene ontology and gene ontology annotations to navigate protein-ligand 
target space in ChEMBL 
19. A dual drug regimen synergistically blocks human parainfluenza virus infection 
 




20. A framework for the targeted selection of herbs with similar efficacy by exploiting drug repositioning 
technique and curated biomedical knowledge 
21. A generalizable pre-clinical research approach for orphan disease therapy 
22. A genomics-based systems approach towards drug repositioning for rheumatoid arthritis 
23. A large-scale computational approach to drug repositioning 
24. A Large-Scale Gene Expression Intensity-Based Similarity Metric for Drug Repositioning 
25. A machine-learned computational functional genomics-based approach to drug classification 
26. A meta-analysis of reflux genome-wide association studies in 6750 Northern Europeans from the 
general population 
27. A Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases 
28. A network based approach to drug repositioning identifies plausible candidates for breast cancer and 
prostate cancer 
29. A network integration approach for drug-target interaction prediction and computational drug 
repositioning from heterogeneous information 
30. A network pharmacology approach reveals new candidate caloric restriction mimetics in C. elegans 
31. A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target 
Therapies in Triple Negative Breast Cancer 
32. A network-based drug repositioning infrastructure for precision cancer medicine through targeting 
significantly mutated genes in the human cancer genomes 
33. A Network-Biology Informed Computational Drug Repositioning Strategy to Target Disease Risk 
Trajectories and Comorbidities of Peripheral Artery Disease 
34. A New Method for Computational Drug Repositioning Using Drug Pairwise Similarity 
35. A new niclosamide derivatives-B17 can inhibit urological cancers growth through apoptosis-related 
pathway 
36. A novel application of furazolidone: anti-leukemic activity in acute myeloid leukemia 
37. A novel computational approach for drug repurposing using systems biology 
38. A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy 
39. A perspective on genomic-guided anthelmintic discovery and repurposing using Haemonchus 
contortus 
 




40. A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, 
West Nile and Chikungunya viruses 
41. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system 
availability of AZD0530 (saracatinib) in Alzheimer's disease 
42. A physarum-inspired prize-collecting steiner tree approach to identify subnetworks for drug 
repositioning 
43. A potential target of Tanshinone IIA for acute promyelocytic leukemia revealed by inverse docking 
and drug repurposing 
44. A Practical Guide for Exploring Opportunities of Repurposing Drugs for CNS Diseases in Systems 
Biology 
45. A profound computational study to prioritize the disease-causing mutations in PRPS1 gene 
46. A protein folding molecular imaging biosensor monitors the effects of drugs that restore mutant p53 
structure and its downstream function in glioblastoma cells 
47. A quality alert and call for improved curation of public chemistry databases 
48. A rapid and affordable screening platform for membrane protein trafficking 
49. A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast 
Differentiation In Vitro 
50. A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia 
51. A review of drugs for treatment of Alzheimer's disease in clinical trials: main trends 
52. A review of MED-SuMo applications 
53. A review of network-based approaches to drug repositioning 
54. A screen for Fli-1 transcriptional modulators identifies PKC agonists that induce erythroid to 
megakaryocytic differentiation and suppress leukemogenesis 
55. A Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and 
Repositioning Predictions 
56. A signalome screening approach in the autoinflammatory disease TNF receptor associated periodic 
syndrome (TRAPS) highlights the anti-inflammatory properties of drugs for repurposing 
57. A simple mathematical approach to the analysis of polypharmacology and polyspecificity data 
58. A statin-regulated microRNA represses human c-Myc expression and function 
59. A structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 
ATPase 
 




60. A subpathway-based method of drug reposition for polycystic ovary syndrome 
61. A systematic analysis of FDA-approved anticancer drugs 
62. A Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles 
Using Pathway-Drug Network 
63. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents 
64. A systems pharmacology-oriented discovery of a new therapeutic use of the TCM formula 
Liuweiwuling for liver failure 
65. A systems-level analysis of drug-target-disease associations for drug repositioning 
66. A Topical Zinc Ionophore Blocks Tumorigenic Progression in UV-exposed SKH-1 High-risk Mouse 
Skin 
67. A two-step drug repositioning method based on a protein-protein interaction network of genes shared 
by two diseases and the similarity of drugs 
68. A two-tiered unsupervised clustering approach for drug repositioning through heterogeneous data 
integration 
69. A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case 
70. A Zebrafish Drug-Repurposing Screen Reveals sGC-Dependent and sGC-Independent Pro-
Inflammatory Activities of Nitric Oxide 
71. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus 
and Middle East Respiratory Syndrome Coronavirus Fusion 
72. Accidental interaction between PDZ domains and diclofenac revealed by NMR-assisted virtual 
screening 
73. Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease 
74. Activation of RXR/PPARgamma underlies neuroprotection by bexarotene in ischemic stroke 
75. Activity of anti-cancer protein kinase inhibitors against Leishmania spp 
76. Activity-Based Protein Profiling for the Study of Parasite Biology 
77. Adaptive mitochondrial reprogramming and resistance to PI3K therapy 
78. ADEPTUS: a discovery tool for disease prediction, enrichment and network analysis based on profiles 
from many diseases 
79. Advanced Assay Monitoring APP-Carboxyl-Terminal Fragments as Markers of APP Processing in 
Alzheimer Disease Mouse Models 
 




80. Advanced systems biology methods in drug discovery and translational biomedicine 
81. Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus 
82. Advances in Developing Therapies to Combat Zika Virus: Current Knowledge and Future 
Perspectives 
83. Advances in drug development for Parkinson's disease: present status 
84. Advances in epilepsy gene discovery and implications for epilepsy diagnosis and treatment 
85. Advances in intravesical therapy for urinary tract disorders 
86. Advances in the Development of Shape Similarity Methods and Their Application in Drug Discovery 
87. Advancing cancer drug discovery towards more agile development of targeted combination therapies 
88. Aging-related Repositioned Drugs, Donepezil and Sildenafil Citrate, Increase Apoptosis of Anti-
mitotic Drug-resistant KBV20C Cells Through Different Molecular Mechanisms 
89. Albendazole as a promising molecule for tumor control 
90. Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft 
model 
91. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4 
92. Alternative molecular formats and therapeutic applications for bispecific antibodies 
93. AlzhCPI: A knowledge base for predicting chemical-protein interactions towards Alzheimer's disease 
94. Alzheimer's Disease (AD) therapeutics - 1: Repeated clinical failures continue to question the amyloid 
hypothesis of AD and the current understanding of AD causality 
95. Alzheimer's disease master regulators analysis: search for potential molecular targets and drug 
repositioning candidates 
96. Ameliorative effect of methylthiouracil on TGFBIp-induced septic responses 
97. An improved approach for predicting drug-target interaction: proteochemometrics to molecular 
docking 
98. An in vitro test system for compounds that modulate human inflammatory macrophage polarization 
99. An Integrated Data Driven Approach to Drug Repositioning Using Gene-Disease Associations 
100. An integrated dataset for in silico drug discovery 
101. An integrated network platform for contextual prioritization of drugs and pathways 
 




102. An integrated structure- and system-based framework to identify new targets of metabolites and 
known drugs 
103. An integrative approach using real-world data to identify alternative therapeutic uses of existing 
drugs 
104. Analysis of drug binding pockets and repurposing opportunities for twelve essential enzymes of 
ESKAPE pathogens 
105. Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry 
106. Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T-cell 
leukemia cells 
107. Angiotensin II type 1 receptor blockers increase tolerance of cells to copper and cisplatin 
108. ANTENNA, a Multi-Rank, Multi-Layered Recommender System for Inferring Reliable Drug-Gene-
Disease Associations: Repurposing Diazoxide as a Targeted Anti-Cancer Therapy 
109. Anthelmintics - from discovery to resistance 
110. Anti-infectious drug repurposing using an integrated chemical genomics and structural systems 
biology approach 
111. Anti-inflammatory effects of dabrafenib in vitro and in vivo 
112. Anti-inflammatory effects of methylthiouracil in vitro and in vivo 
113. Anti-obesogenic and hypolipidemic effects of a glucagon-like peptide-1 receptor agonist derived 
from the saliva of the Gila monster 
114. Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes 
enriched for stem cell-like properties 
115. Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial 
pathogens 
116. Anticancer Drugs as Antibiofilm Agents in Candida albicans: Potential Targets 
117. Anticonvulsant activity of artificial sweeteners: a structural link between sweet-taste receptor T1R3 
and brain glutamate receptors 
118. Antifungals 
119. Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein 
phosphatase 2A in non-small cell lung cancer cells 
120. Antimalarial activity of novel 4-cyano-3-methylisoquinoline inhibitors against Plasmodium 
falciparum: design, synthesis and biological evaluation 
 




121. Antimalarial drug mefloquine inhibits nuclear factor kappa B signaling and induces apoptosis in 
colorectal cancer cells 
122. Antiseptic effects of dabrafenib on TGFBIp-induced septic responses 
123. Antiviral activity of micafungin against enterovirus 71 
124. Antiviral Drug Ribavirin Targets Thyroid Cancer Cells by Inhibiting the eIF4E-beta-Catenin Axis 
125. Antiviral effects of inhibiting host gene expression 
126. Application of Atlas of Cancer Signalling Network in preclinical studies 
127. Application of molecular framework-based data-mining method in the search for beta-secretase 1 
inhibitors through drug repurposing 
128. Appraisal of mechanisms of radioprotection and therapeutic approaches of radiation 
countermeasures 
129. Approaches for discovering anti-prion compounds: lessons learned and challenges ahead 
130. Approaches for establishing the function of regulatory genetic variants involved in disease 
131. Approved oncology drugs lack in vivo activity against Trichuris muris despite in vitro activity 
132. Ariadne's ChemEffect and Pathway Studio knowledge base 
133. Assessing protein kinase target similarity: Comparing sequence, structure, and cheminformatics 
approaches 
134. Assessing relative bioactivity of chemical substances using quantitative molecular network topology 
analysis 
135. Assessment of berberine as a multi-target antimicrobial: a multi-omics study for drug discovery and 
repositioning 
136. Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New 
Platform for Computer-Aided Drug Repurposing 
137. Auranofin and its Analogues Show Potent Antimicrobial Activity Covering Multiresistant 
Pathogens: Structure-Activity Relationships 
138. Automatic construction of a large-scale and accurate drug-side-effect association knowledge base 
from biomedical literature 
139. Autophagy in HIV-induced T cell death 
140. Autophagy Induced by Naftopidil Inhibits Apoptosis of Human Gastric Cancer Cells 
141. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation 
 




142. Back to the Roots: Prediction of Biologically Active Natural Products from Ayurveda Traditional 
Medicine 
143. Bacoside A Induces Tumor Cell Death in Human Glioblastoma Cell Lines through Catastrophic 
Macropinocytosis 
144. Benchmarking human protein complexes to investigate drug-related systems and evaluate predicted 
protein complexes 
145. Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2 
146. beta-Caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and 
metabolic dysregulation in mice 
147. beta2-Adrenoceptor agonists as novel, safe and potentially effective therapies for Amyotrophic 
lateral sclerosis (ALS 
148. Beyond Channel Activity: Protein-Protein Interactions Involving Viroporins 
149. Beyond multiple mechanisms and a unique drug: Defective autophagy as pivotal player in cerebral 
cavernous malformation pathogenesis and implications for targeted therapies 
150. Binding site matching in rational drug design: algorithms and applications 
151. Biocomputational resources useful for drug discovery against compartmentalized targets 
152. BioGPS: navigating biological space to predict polypharmacology, off-targeting, and selectivity 
153. BioGPS: The Music for the Chemo- and Bioinformatics Walzer 
154. Bioinformatic and biological avenues for understanding alcohol use disorder 
155. Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning 
targets for IBD and other autoimmune diseases 
156. Bioinformatics and Drug Discovery 
157. Bioinformatics in translational drug discovery 
158. Bioinformatics methods in drug repurposing for Alzheimer's disease 
159. Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer 
resistance to EGFR therapy 
160. Bioinformatics: Novel Insights from Genomic Information 
161. Biomolecular Network Controllability With Drug Binding Information 
162. Biotin-targeted Pluronic() P123/F127 mixed micelles delivering niclosamide: A repositioning 
strategy to treat drug-resistant lung cancer cells 
 




163. Bisphosphonates inactivate human EGFRs to exert antitumor actions 
164. Blocking IL-6/GP130 signaling inhibits cell viability/proliferation, glycolysis, and colony forming 
activity in human pancreatic cancer cells 
165. BRCA-Monet: a breast cancer specific drug treatment mode-of-action network for treatment 
effective prediction using large scale microarray database 
166. Bromide supplementation exacerbated the renal dysfunction, injury and fibrosis in a mouse model of 
Alport syndrome 
167. Building a drug-target network and its applications 
168. Butamben derivatives enhance BMP-2-stimulated commitment of C2C12 cells into osteoblasts with 
induction of voltage-gated potassium channel expression 
169. Calcium channel blockers as drug repurposing candidates for gestational diabetes: Mining large scale 
genomic and electronic health records data to repurpose medications 
170. Cancer based pharmacogenomics network supported with scientific evidences: from the view of drug 
repurposing 
171. CancerHSP: anticancer herbs database of systems pharmacology 
172. CANDO and the infinite drug discovery frontier 
173. Carbamazepine alone and in combination with doxycycline attenuates isoproterenol-induced cardiac 
hypertrophy 
174. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer 
175. Cascade Ligand- and Structure-Based Virtual Screening to Identify New Trypanocidal Compounds 
Inhibiting Putrescine Uptake 
176. Case-specific potentiation of glioblastoma drugs by pterostilbene 
177. Catecholamine receptors: prototypes for GPCR-based drug discovery 
178. CaV channels and cancer: canonical functions indicate benefits of repurposed drugs as cancer 
therapeutics 
179. Cell line modeling for systems medicine in cancers (review 
180. Cell specificity dictates similarities in gene expression in multiple sclerosis, Parkinson's disease, and 
Alzheimer's disease 
181. Cell-based screening identifies paroxetine as an inhibitor of diabetic endothelial dysfunction 
182. Cell-specific prediction and application of drug-induced gene expression profiles 
 




183. CellFateScout - a bioinformatics tool for elucidating small molecule signaling pathways that drive 
cells in a specific direction 
184. Chapter 7: Pharmacogenomics 
185. Characterization of a Francisella tularensis-Caenorhabditis elegans Pathosystem for the Evaluation 
of Therapeutic Compounds 
186. Characterizing protein domain associations by Small-molecule ligand binding 
187. Characterizing the pocketome of Mycobacterium tuberculosis and application in rationalizing 
polypharmacological target selection 
188. Checking the STEP-Associated Trafficking and Internalization of Glutamate Receptors for Reduced 
Cognitive Deficits: A Machine Learning Approach-Based Cheminformatics Study and Its Application for 
Drug Repurposing 
189. Chemical-induced disease extraction via recurrent piecewise convolutional neural networks 
190. Chemical-protein interactome and its application in off-target identification 
191. Chemoprevention agents for melanoma: a path forward into phase 3 clinical trials 
192. Chk1 as a new therapeutic target in triple-negative breast cancer 
193. Chloroquine upregulates TRAIL/TRAILR2 expression and potentiates doxorubicin anti-tumor 
activity in thioacetamide-induced hepatocellular carcinoma model 
194. Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-
Joseph Disease 
195. CK2 inhibition confers functional protection to young and aging axons against ischemia by 
differentially regulating the CDK5 and AKT signaling pathways 
196. Classifying cancer genome aberrations by their mutually exclusive effects on transcription 
197. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug 
development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis 
198. Clobetasol and Halcinonide Act as Smoothened Agonists to Promote Myelin Gene Expression and 
RxRgamma Receptor Activation 
199. Clozapine Improves Memory Impairment and Reduces Abeta Level in the Tg-APPswe/PS1dE9 
Mouse Model of Alzheimer's Disease 
200. Clustering based drug-drug interaction networks for possible repositioning of drugs against EGFR 
mutations: Clustering based DDI networks for EGFR mutations 
 




201. Clustering drug-drug interaction networks with energy model layouts: community analysis and drug 
repurposing 
202. Co-expression Network Approach Reveals Functional Similarities among Diseases Affecting Human 
Skeletal Muscle 
203. Cogena, a novel tool for co-expressed gene-set enrichment analysis, applied to drug repositioning 
and drug mode of action discovery 
204. Collaboration for rare disease drug discovery research 
205. Combating Ebola with Repurposed Therapeutics Using the CANDO Platform 
206. Combating Intracellular Pathogens with Repurposed Host-Targeted Drugs 
207. Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved 
outcomes in spinal muscular atrophy patient-derived fibroblasts 
208. Combined analysis of gene expression and genome binding profiles identified potential therapeutic 
targets of ciclopirox in Ewing sarcoma 
209. Combined Analysis of Phenotypic and Target-Based Screening in Assay Networks 
210. Combining automatic table classification and relationship extraction in extracting anticancer drug-
side effect pairs from full-text articles 
211. Combining genomic and network characteristics for extended capability in predicting synergistic 
drugs for cancer 
212. Combining Human Disease Genetics and Mouse Model Phenotypes towards Drug Repositioning for 
Parkinson's disease 
213. Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the 
Pathological Proteins Related to the Alzheimer's Disease 
214. Community-driven roadmap for integrated disease maps 
215. Comparative analysis of methicillin-sensitive and resistant Staphylococcus aureus exposed to 
emodin based on proteomic profiling 
216. Comparative assessment of strategies to identify similar ligand-binding pockets in proteins 
217. Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate 
Synthase Case 
218. Comparing structural and transcriptional drug networks reveals signatures of drug activity and 
toxicity in transcriptional responses 
 




219. Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake 
in Lung Cancer 
220. Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3beta and 
Activates WNT Signaling 
221. Complex-disease networks of trait-associated single-nucleotide polymorphisms (SNPs) unveiled by 
information theory 
222. Comprehensive prediction of drug-protein interactions and side effects for the human proteome 
223. Computational approaches for drug repositioning and combination therapy design 
224. Computational approaches for innovative antiepileptic drug discovery 
225. Computational Approaches for Translational Oncology: Concepts and Patents 
226. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That 
Reduces Growth of Hepatocellular Carcinoma Cells InVitro and in Mice by Inhibiting Cell Division 
Cycle 37 Signaling 
227. Computational Discovery of Putative Leads for Drug Repositioning through Drug-Target Interaction 
Prediction 
228. Computational Drug Repositioning by Target Hopping: A Use Case in Chagas Disease 
229. Computational drug repositioning for peripheral arterial disease: prediction of anti-inflammatory and 
pro-angiogenic therapeutics 
230. Computational drug repositioning through heterogeneous network clustering 
231. Computational drug repositioning using low-rank matrix approximation and randomized algorithms 
232. Computational drug repositioning with random walk on a heterogeneous network 
233. Computational drug repurposing to predict approved and novel drug-disease associations 
234. Computational Drug Repurposing: Current Trends 
235. Computational Drug Target Screening through Protein Interaction Profiles 
236. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent 
pathways among FDA-approved compounds 
237. Computational functional genomics-based approaches in analgesic drug discovery and repurposing 
238. Computational methods and opportunities for phosphorylation network medicine 
239. Computational Prediction of Drug?Target Interactions Using Chemical, Biological, and Network 
Features 
 




240. Computational repositioning and preclinical validation of pentamidine for renal cell cancer 
241. Computational Study of Drugs by Integrating Omics Data with Kernel Methods 
242. Computational tools for polypharmacology and repurposing 
243. COMPUTING THERAPY FOR PRECISION MEDICINE: COLLABORATIVE FILTERING 
INTEGRATES AND PREDICTS MULTI-ENTITY INTERACTIONS 
244. Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by 
repurposing disulfiram 
245. Concise Review: Cell Surface N-Linked Glycoproteins as Potential Stem Cell Markers and Drug 
Targets 
246. Concise Review: Cell Surface N-Linked Glycoproteins as Potential Stem Cell Markers and Drug 
Targets 
247. Connecting genetics and gene expression data for target prioritisation and drug repositioning 
248. Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in 
cystic fibrosis 
249. Connectivity mapping using a combined gene signature from multiple colorectal cancer datasets 
identified candidate drugs including existing chemotherapies 
250. Constructing Disease Similarity Networks Based on Disease Module Theory 
251. Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for 
myasthenia gravis 
252. Construction of drug network based on side effects and its application for drug repositioning 
253. Context-specific functional module based drug efficacy prediction 
254. Contributions from emerging transcriptomics technologies and computational strategies for drug 
discovery 
255. Convergent downstream candidate mechanisms of independent intergenic polymorphisms between 
co-classified diseases implicate epistasis among noncoding elements 
256. Copper is required for oncogenic BRAF signalling and tumorigenesis 
257. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from 
enhanced docking approach and molecular dynamics analyses 
258. Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 
(TRIB2) pseudokinase in cancer cells 
 




259. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for 
children and adolescents with cancer 
260. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole 
261. Cryo-EM structure of the Plasmodium falciparum 80S ribosome bound to the anti-protozoan drug 
emetine 
262. Cyclic AMP efflux inhibitors as potential therapeutic agents for leukemia 
263. Cyclin dependent kinase 5: A novel avenue for Alzheimer's disease 
264. Cytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted 
therapeutics 
265. Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in 
ER+ breast cancer 
266. Data integration to prioritize drugs using genomics and curated data 
267. Database of Optimized Proteomic Quantitative Methods for Human Drug Disposition-Related 
Proteins for Applications in Physiologically Based Pharmacokinetic Modeling 
268. Deciphering cellular biological processes to clinical application: a new perspective for Talpha1 
treatment targeting multiple diseases 
269. Deciphering miRNA transcription factor feed-forward loops to identify drug repurposing candidates 
for cystic fibrosis 
270. DeCoST: A New Approach in Drug Repurposing From Control System Theory 
271. Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug 
Repurposing Using Transcriptomic Data 
272. Deep-Learning-Based Drug-Target Interaction Prediction 
273. Defining the Schistosoma haematobium kinome enables the prediction of essential kinases as anti-
schistosome drug targets 
274. Delineation of biological and molecular mechanisms underlying the diverse anticancer activities of 
mycophenolic acid 
275. DenguePredict: An Integrated Drug Repositioning Approach towards Drug Discovery for Dengue 
276. Design of a tripartite network for the prediction of drug targets 
277. Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target 
Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment 
of Alzheimer's Disease 
 




278. DeSigN: connecting gene expression with therapeutics for drug repurposing and development 
279. Designing Dietary Recommendations Using System Level Interactomics Analysis and Network-
Based Inference 
280. DESM: portal for microbial knowledge exploration systems 
281. Detecting drug promiscuity using Gaussian ensemble screening 
282. Detection of Binding Site Molecular Interaction Field Similarities 
283. Development of anti-fungal pesticides from protein kinase inhibitor-based anticancer agents 
284. Developmental toxicity of auranofin in zebrafish embryos 
285. Diclofenac Identified as a Kynurenine 3-Monooxygenase Binder and Inhibitor by Molecular 
Similarity Techniques 
286. Diffusion mapping of drug targets on disease signaling network elements reveals drug combination 
strategies 
287. DIGEP-Pred: web service for in silico prediction of drug-induced gene expression profiles based on 
structural formula 
288. Discovering drugs to overcome chemoresistance in ovarian cancers based on the cancer genome 
atlas tumor transcriptome profile 
289. Discovering gene re-ranking efficiency and conserved gene-gene relationships derived from gene co-
expression network analysis on breast cancer data 
290. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from 
rational design, nature and old drug reposition 
291. Discovery and development of Seliciclib. How systems biology approaches can lead to better drug 
performance 
292. Discovery of alkyl bis(oxy)dibenzimidamide derivatives as novel protein arginine methyltransferase 
1 (PRMT1) inhibitors 
293. Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs 
294. Discovery of drug mode of action and drug repositioning from transcriptional responses 
295. Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues 
296. Discovery of novel polyamine analogs with anti-protozoal activity by computer guided drug 
repositioning 
297. Discovery of Novel SPAK Inhibitors That Block WNK Kinase Signaling to Cation Chloride 
Transporters 
 




298. Discovery of rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer 
299. Discovery of Surface Target Proteins Linking Drugs, Molecular Markers, Gene Regulation, Protein 
Networks, and Disease by Using a Web-Based Platform Targets-search 
300. Discovery of the neuroprotective effects of alvespimycin by computational prioritization of potential 
anti-Parkinson agents 
301. Disease classification: from phenotypic similarity to integrative genomics and beyond 
302. Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease 
303. DiseaseConnect: a comprehensive web server for mechanism-based disease-disease connections 
304. Disulfiram as a novel inactivator of Giardia lamblia triosephosphate isomerase with antigiardial 
potential 
305. Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase 
(MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage 
306. Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma invivo 
307. Disulfiram's Anticancer Activity: Evidence and Mechanisms 
308. Disulfiram/copper causes redox-related proteotoxicity and concomitant heat shock response in 
ovarian cancer cells that is augmented by auranofin-mediated thioredoxin inhibition 
309. DMAP: a connectivity map database to enable identification of novel drug repositioning candidates 
310. DNetDB: The human disease network database based on dysfunctional regulation mechanism 
311. Do Cancer Drugs Counteract Neurodegeneration? Repurposing forAlzheimer's Disease 
312. Docking-based inverse virtual screening: methods, applications, and challenges 
313. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon 
cancer 
314. Doxycycline is an NF-kappaB inhibitor that induces apoptotic cell death in malignant T-cells 
315. Doxycycline or how to create new with the old 
316. DPDR-CPI, a server that predicts Drug Positioning and Drug Repositioning via Chemical-Protein 
Interactome 
317. DPP-4 inhibitors promote proliferation and migration of rat brain microvascular endothelial cells 
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Cancer 
972. Systematic integration of biomedical knowledge prioritizes drugs for repurposing 
973. Systematic Prioritization of Druggable Mutations in 5000 Genomes Across 16 Cancer Types Using a 
Structural Genomics-based Approach 
974. Systematical analysis of lncRNA-mRNA competing endogenous RNA network in breast cancer 
subtypes 
975. Systemic amyloidosis: novel therapies and role of biomarkers 
976. Systems approach to the pharmacological actions of HDAC inhibitors reveals EP300 activities and 
convergent mechanisms of regulation in diabetes 
977. Systems biological understanding of the regulatory network and the possible therapeutic strategies 
for vascular calcification 
978. Systems Biology-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap 
Insertional Mutagenesis 
979. Systems biology-embedded target validation: improving efficacy in drug discovery 
980. Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of 
Neuroendocrine Prostate Cancer 
981. Systems medicine: evolution of systems biology from bench to bedside 
982. Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders 
983. Systems pharmacology of adverse event mitigation by drug combinations 
984. Systems Pharmacology-Based Approach of Connecting Disease Genes in Genome-Wide Association 
Studies with Traditional Chinese Medicine 
985. Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic 
protease in mycobacteria 
986. Target-Based Drug Repositioning Using Large-Scale Chemical-Protein Interactome Data 
987. Target-similarity search using Plasmodium falciparum proteome identifies approved drugs with anti-
malarial activity and their possible targets 
988. Targeting ADAM17 Sheddase Activity in Cancer 
989. Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review 
990. Targeting cyclin D3/CDK6 activity for treatment of Parkinson's disease 
 




991. Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference 
992. Targeting STAT1 in Both Cancer and Insulin Resistance Diseases 
993. Targeting the off-targets: a computational bioinformatics approach to understanding the 
polypharmacology of nelfinavir 
994. Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic 
995. Tegaserod mimics the neurostimulatory glycan polysialic acid and promotes nervous system repair 
996. Tetracycline hydrochloride: A potential clinical drug for radioprotection 
997. Tetracycline repurposing in neurodegeneration: focus on Parkinson's disease 
998. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical 
and noncanonical Wnt signaling pathway 
999. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal 
melanoma in vitro and in vivo 
1000. The antimalarial amodiaquine causes autophagic-lysosomal and proliferative blockade sensitizing 
human melanoma cells to starvation- and chemotherapy-induced cell death 
1001. The aryl hydrocarbon receptor is required for induction of p21cip1/waf1 expression and growth 
inhibition by SU5416 in hepatoma cells 
1002. The CARLSBAD database: a confederated database of chemical bioactivities 
1003. The combination astemizole-gefitinib as a potential therapy for human lung cancer 
1004. The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell 
carcinoma 
1005. The druggable genome and support for target identification and validation in drug development 
1006. The extraction of drug-disease correlations based on module distance in incomplete human 
interactome 
1007. The EYA tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromarone 
1008. The genome of Onchocerca volvulus, agent of river blindness 
1009. The Hippo pathway in normal development and cancer 
1010. The HIV integrase inhibitor raltegravir inhibits felid alphaherpesvirus 1 (FeHV-1) replication by 
targeting both DNA replication and late gene expression 
1011. The Horizon of a Therapy for Rare Genetic Diseases: A "Druggable" Future for Fibrodysplasia 
Ossificans Progressiva 
 




1012. The human disease network in terms of dysfunctional regulatory mechanisms 
1013. The human immunodeficiency virus protease inhibitor ritonavir is potentially active against 
urological malignancies 
1014. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian 
randomisation analysis 
1015. The Molecular Revolution in Cutaneous Biology: Emerging Landscape in Genomic Dermatology: 
New Mechanistic Ideas, Gene Editing, and Therapeutic Breakthroughs 
1016. The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug 
1017. The neuroimmune transcriptome and alcohol dependence: potential for targeted therapies 
1018. The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in 
hepatocellular carcinoma 
1019. The pain interactome: connecting pain-specific protein interactions 
1020. The polypharmacology of natural products 
1021. The polysialic acid mimetics idarubicin and irinotecan stimulate neuronal survival and neurite 
outgrowth and signal via protein kinase C 
1022. The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug 
resistance in cancer cell lines 
1023. The prescribable drugs with efficacy in experimental epilepsies (PDE3) database for drug 
repurposing research in epilepsy 
1024. The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-
beta1 
1025. The protein kinase 2 inhibitor CX-4945 regulates osteoclast and osteoblast differentiation in vitro 
1026. The proton-pump inhibitor lansoprazole enhances amyloid beta production 
1027. The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory 
NRASQ61K melanoma 
1028. The role of drug profiles as similarity metrics: applications to repurposing, adverse effects detection 
and drug-drug interactions 
1029. The sodium channel-blocking antiepileptic drug phenytoin inhibits breast tumour growth and 
metastasis 
1030. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis 
 




1031. The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new 
opportunity for drug repurposing 
1032. The use of a gene expression signature and connectivity map to repurpose drugs for bipolar 
disorder 
1033. Therapeutic Approaches to Prion Diseases 
1034. Therapeutic compositions and uses of alpha1-antitrypsin: a patent review (2012 - 2015 
1035. Therapeutic compounds for Cushing's syndrome: a patent review (2012-2016 
1036. Therapeutic drug repositioning using personalized proteomics of liquid biopsies 
1037. Therapeutic Effect of Repurposed Temsirolimus in Lung Adenocarcinoma Model 
1038. Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by 
inhibiting Wnt/beta-catenin signaling 
1039. Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial 
agent 
1040. Therapeutic potential for phenytoin: targeting Na(v)1.5 sodium channels to reduce migration and 
invasion in metastatic breast cancer 
1041. Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from 
pathophysiology to treatment 
1042. Three-dimensional models of Mycobacterium tuberculosis proteins Rv1555, Rv1554 and their 
docking analyses with sildenafil, tadalafil, vardenafil drugs, suggest interference with quinol binding 
likely to affect protein's function 
1043. Toll-Like Receptor-4 Signaling Drives Persistent Fibroblast Activation and Prevents Fibrosis 
Resolution in Scleroderma 
1044. Toward more realistic drug-target interaction predictions 
1045. Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, 
Escherichia coli, and Klebsiella pneumoniae 
1046. Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems 
Pharmacology 
1047. Towards building a disease-phenotype knowledge base: extracting disease-manifestation 
relationship from literature 
1048. Towards drug repositioning: a unified computational framework for integrating multiple aspects of 
drug similarity and disease similarity 
 




1049. Towards precision medicine-based therapies for glioblastoma: interrogating human disease 
genomics and mouse phenotypes 
1050. Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine 
Approach 
1051. Transcriptional data: a new gateway to drug repositioning 
1052. Transcriptomic Analysis of the Host Response and Innate Resilience to Enterotoxigenic 
Escherichia coli Infection in Humans 
1053. Transcriptomic changes induced by mycophenolic acid in gastric cancer cells 
1054. Transcriptomic characterization of the novel avian-origin influenza A (H7N9) virus: specific host 
response and responses intermediate between avian (H5N1 and H7N7) and human (H3N2) viruses and 
implications for treatment options 
1055. Transcriptomic profiling of human hippocampal progenitor cells treated with antidepressants and 
its application in drug repositioning 
1056. Transcriptomic RNAseq drug screen in cerebrocortical cultures: toward novel neurogenetic disease 
therapies 
1057. Transcriptomic-Guided Drug Repositioning Supported by a New Bioinformatics Search Tool: 
geneXpharma 
1058. Translating Mendelian and complex inheritance of Alzheimer's disease genes for predicting unique 
personal genome variants 
1059. Treating Influenza Infection, From Now and Into the Future 
1060. Treating the dysfunctional placenta 
1061. Treatment of Schistosoma mansoni with miltefosine in vitro enhances serological recognition of 
defined worm surface antigens 
1062. Trends of Clinical Trials for Drug Development in Rare Diseases 
1063. Trypanocidal Effect of Isotretinoin through the Inhibition of Polyamine and Amino Acid 
Transporters in Trypanosoma cruzi 
1064. Uncovering Drug Mechanism of Action by Proteome Wide- Identification of Drug-Binding 
Proteins 
1065. Uncovering novel repositioning opportunities using the Open Targets platform 
1066. Understanding organellar protein folding capacities and assessing their pharmacological 
modulation by small molecules 
 




1067. Unveiling the role of network and systems biology in drug discovery 
1068. Updates on drug-target network; facilitating polypharmacology and data integration by growth of 
DrugBank database 
1069. Use of genome-wide association studies for cancer research and drug repositioning 
1070. Using Big Data to Discover Diagnostics and Therapeutics forGastrointestinal and Liver Diseases 
1071. Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and 
prostate cancer 
1072. Using gene expression signatures to identify novel treatment strategies in gulf war illness 
1073. Using predicate and provenance information from a knowledge graph for drug efficacy screening 
1074. Utilizing Cancer - Functional Gene Set - Compound Networks to Identify Putative Drugs for Breast 
Cancer 
1075. Valproic acid in the complex therapy of malignant tumors 
1076. Valproic acid mediates miR-124 to down-regulate a novel protein target, GNAI1 
1077. Verteporfin inhibits gastric cancer cell growth by suppressing adhesion molecule FAT1 
1078. Virtual screening and repositioning of inconclusive molecules of beta-lactamase Bioassays-A data 
mining approach 
1079. Virtual screening-driven repositioning of etoposide as CD44 antagonist in breast cancer cells 
1080. Virtual target screening: validation using kinase inhibitors 
1081. VisANT 4.0: Integrative network platform to connect genes, drugs, diseases and therapies 
1082. Vitamin K and hepatocellular carcinoma: The basic and clinic 
1083. Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs 
1084. Voltage-gated sodium channels and metastatic disease 
1085. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial 
Plasticity and Metastasis 
1086. What do the genetic association data say about the high risk of suicide in people with depression? A 
novel network-based approach to find common molecular basis for depression and suicidal behavior and 
related therapeutic targets 
1087. YAP/TAZ Are Mechanoregulators of TGF-beta-Smad Signaling and Renal Fibrogenesis 
1088. Zafirlukast inhibits complexation of Lsr2 with DNA and growth of Mycobacterium tuberculosis 
 













FACTOR 27. Drug Repurposing for Brain Cancer 
1. A chemical-genetic interaction map of small molecules using high-throughput imaging in cancer cells 
2. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival 
paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of 
Glioblastoma Care 
3. A current perspective on the oncopreventive and oncolytic properties of selective serotonin reuptake 
inhibitors 
4. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer 
and other neuroendocrine tumors 
5. A Drug Screen using Human iPSC-Derived Hepatocyte-like Cells Reveals Cardiac Glycosides as a 
Potential Treatment for Hypercholesterolemia 
6. A drug-repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6-
thioguanine as an effective therapeutic agent for TPMT-low cancer cells 
7. A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor 
Ponatinib for Repurposing in Neuroblastoma Therapy 
8. A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future 
Research 
9. A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target 
Therapies in Triple Negative Breast Cancer 
10. A novel anti-cancer role of beta-apopicropodophyllin against non-small cell lung cancer cells 
11. A novel application of furazolidone: anti-leukemic activity in acute myeloid leukemia 
12. A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram 
13. A Novel High Content Imaging-Based Screen Identifies the Anti-Helminthic Niclosamide as an 
Inhibitor of Lysosome Anterograde Trafficking and Prostate Cancer Cell Invasion 
14. A protein folding molecular imaging biosensor monitors the effects of drugs that restore mutant p53 
structure and its downstream function in glioblastoma cells 
15. A rapid and affordable screening platform for membrane protein trafficking 
16. A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by 
Combining a Spontaneously Emulsifying Component with a Polymer Carrier 
17. A repurposing strategy for Hsp90 inhibitors demonstrates their potency against filarial nematodes 
 




18. A selective mitochondrial-targeted chlorambucil with remarkable cytotoxicity in breast and pancreatic 
cancers 
19. A small molecule screen identifies an inhibitor of DNA repair inducing the degradation of TFIIH and 
the chemosensitization of tumor cells to platinum 
20. A Small-molecule Kinase Inhibitor, CEP-1347, Inhibits Survivin Expression and Sensitizes Ovarian 
Cancer Stem Cells to Paclitaxel 
21. A systems-level analysis of drug-target-disease associations for drug repositioning 
22. A tumor deconstruction platform identifies definitive end points in the evaluation of drug responses 
23. Activity of anti-cancer protein kinase inhibitors against Leishmania spp 
24. Acute oxidant damage promoted on cancer cells by amitriptyline in comparison with some common 
chemotherapeutic drugs 
25. Adaptive mitochondrial reprogramming and resistance to PI3K therapy 
26. Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft 
model 
27. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4 
28. Alternative molecular formats and therapeutic applications for bispecific antibodies 
29. Alternative screening approaches for discovery of Middle East respiratory syndrome coronavirus 
inhibitors 
30. An in vitro test system for compounds that modulate human inflammatory macrophage polarization 
31. Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from 
Chemorefractory Neoplasia 
32. Angiotensin II type 1 receptor blockers increase tolerance of cells to copper and cisplatin 
33. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing 
tumour blood vessels 
34. Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via 
oxidative stress-mediated mTOR inhibition 
35. Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes 
differentiation of head and neck squamous cell carcinoma (HNSCC 
36. Anti-inflammatory effects of dabrafenib in vitro and in vivo 
37. Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption 
 




38. Anti-inflammatory effects of methylthiouracil in vitro and in vivo 
39. Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched 
for stem cell-like properties 
40. Antibiotic drug levofloxacin inhibits proliferation and induces apoptosis of lung cancer cells through 
inducing mitochondrial dysfunction and oxidative damage 
41. Anticancer Properties of Fenofibrate: A Repurposing Use 
42. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis 
43. Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein 
phosphatase 2A in non-small cell lung cancer cells 
44. Antimalarial drug mefloquine inhibits nuclear factor kappa B signaling and induces apoptosis in 
colorectal cancer cells 
45. Antischistosomal agents: state of art and perspectives 
46. Antitubercular activity of disulfiram, an antialcoholism drug, against multidrug- and extensively drug-
resistant Mycobacterium tuberculosis isolates 
47. Antiviral Drug Ribavirin Targets Thyroid Cancer Cells by Inhibiting the eIF4E-beta-Catenin Axis 
48. Aripiprazole, an Antipsychotic and Partial Dopamine Agonist, Inhibits Cancer Stem Cells and 
Reverses Chemoresistance 
49. Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do 
50. Assessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer 
51. Atorvastatin as a promising anticryptococcal agent 
52. Auranofin inactivates Trichomonas vaginalis thioredoxin reductase and is effective against 
trichomonads in vitro and in vivo 
53. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical 
activity against chronic lymphocytic leukemia 
54. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell 
lung cancer cells 
55. Bacoside A Induces Tumor Cell Death in Human Glioblastoma Cell Lines through Catastrophic 
Macropinocytosis 
56. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy 
57. Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2 
 




58. beta-catenin and PI3Kdelta inhibition expands precursor Th17 cells with heightened stemness and 
antitumor activity 
59. Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor 
60. Biological basis and clinical study of glycogen synthase kinase- 3beta-targeted therapy by drug 
repositioning for glioblastoma 
61. Biotin-targeted Pluronic() P123/F127 mixed micelles delivering niclosamide: A repositioning strategy 
to treat drug-resistant lung cancer cells 
62. Bisphosphonates inactivate human EGFRs to exert antitumor actions 
63. Bithionol inhibits ovarian cancer cell growth in vitro - studies on mechanism(s) of action 
64. Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the 
EIS regimen 
65. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant 
mammary tissues of MMTV-erbB-2 transgenic mice 
66. Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common 
therapies 
67. Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015 
68. Cancer stem cells as the therapeutic target of tomorrow 
69. Cancer: fundamentals behind pH targeting and the double-edged approach 
70. Case Report: Propranolol increases the therapeutic response to temozolomide in a patient with 
metastatic paraganglioma 
71. Case-specific potentiation of glioblastoma drugs by pterostilbene 
72. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma 
73. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic 
manifestations from malaria to multifarious diseases 
74. Chloroquine-containing compounds: a patent review (2010 - 2014 
75. Classifying cancer genome aberrations by their mutually exclusive effects on transcription 
76. Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South 
Africa: a retrospective cohort study 
77. Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive 
melanoma: a strategy for repurposing a phase I clinical trial drug 
 




78. Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate 
cancer cells 
79. Comparative oncology approach to drug repurposing in osteosarcoma 
80. Computational approaches for drug repositioning and combination therapy design 
81. Computational Approaches for Translational Oncology: Concepts and Patents 
82. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces 
Growth of Hepatocellular Carcinoma Cells InVitro and in Mice by Inhibiting Cell Division Cycle 37 
Signaling 
83. Computational identification of multi-omic correlates of anticancer therapeutic response 
84. Computational repositioning and preclinical validation of mifepristone for human vestibular 
schwannoma 
85. Computational repositioning and preclinical validation of pentamidine for renal cell cancer 
86. Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by 
repurposing disulfiram 
87. Concise Review: Cell Surface N-Linked Glycoproteins as Potential Stem Cell Markers and Drug 
Targets 
88. Concise Review: Cell Surface N-Linked Glycoproteins as Potential Stem Cell Markers and Drug 
Targets 
89. Connectivity mapping using a combined gene signature from multiple colorectal cancer datasets 
identified candidate drugs including existing chemotherapies 
90. Controlling schistosomiasis with praziquantel: How much longer without a viable alternative 
91. Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, 
and Neurological Diseases: A Mini-Review 
92. Current issues concerning drug development for pediatric hematologic malignancies 
93. Cytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted 
therapeutics 
94. Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in 
ER+ breast cancer 
95. Data integration to prioritize drugs using genomics and curated data 
96. Designing novel therapies against sarcomas in the era of personalized medicine and economic crisis 
 




97. Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an 
active anticancer agent 
98. Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells 
99. Diffusion mapping of drug targets on disease signaling network elements reveals drug combination 
strategies 
100. Discovering drugs to overcome chemoresistance in ovarian cancers based on the cancer genome 
atlas tumor transcriptome profile 
101. Disulfiram as a novel inactivator of Giardia lamblia triosephosphate isomerase with antigiardial 
potential 
102. Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase 
(MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage 
103. Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma invivo 
104. Disulfiram's Anticancer Activity: Evidence and Mechanisms 
105. Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma 
and over-rides resistance to temozolomide 
106. Disulfiram/copper causes redox-related proteotoxicity and concomitant heat shock response in 
ovarian cancer cells that is augmented by auranofin-mediated thioredoxin inhibition 
107. Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma 
108. Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of 
human African trypanosomiasis 
109. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon 
cancer 
110. Doxycycline and therapeutic targeting of the DNA damage response in cancer cells: old drug, new 
purpose 
111. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in 
breast cancer 
112. Drug discovery and development for rare genetic disorders 
113. Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer 
cell lines and pathway mechanisms of resistance 
114. Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional 
Signatures 
 




115. Drug Repositioning in Glioblastoma: A Pathway Perspective 
116. Drug Repositioning Meets Precision in Glioblastoma 
117. Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer 
118. Drug Repositioning of Proton Pump Inhibitors for Enhanced Efficacy and Safety of Cancer 
Chemotherapy 
119. Drug Repositioning through Systematic Mining of Gene Coexpression Networks in Cancer 
120. Drug Repurposing Approach Identifies a Synergistic Drug Combination of an Antifungal Agent and 
an Experimental Organometallic Drug for Melanoma Treatment 
121. Drug Repurposing by Simulating Flow Through Protein-Protein Interaction Networks 
122. Drug repurposing for gastrointestinal stromal tumor 
123. Drug repurposing for glioblastoma based on molecular subtypes 
124. Drug repurposing for the treatment of glioblastoma multiforme 
125. Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for 
gastrointestinal stromal tumor 
126. Drug Repurposing in Anticancer Reagent Development 
127. Drug Repurposing of Metabolic Agents in Malignant Glioma 
128. Drug Repurposing of the Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia 
129. Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer 
associated fibroblasts (CAFs) by synergistic induction of apoptosis 
130. Drug Repurposing Screening Identifies Tioconazole as an ATG4 Inhibitor that Suppresses 
Autophagy and Sensitizes Cancer Cells to Chemotherapy 
131. Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine 
uptake through system Xc-, leading to glutathione depletion 
132. Drug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for 
Drug Repositioning in Cancer Therapy 
133. Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian 
tumor cells 
134. Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds 
135. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent 
activity against breast cancer 
 




136. Drug-Repositioning Screens Identify Triamterene as a Selective Drug for the Treatment of DNA 
Mismatch Repair Deficient Cells 
137. Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed Drugs Elicits 
Cell-Lethal Autophagy and Therapeutic Benefit 
138. Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol 
and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study 
139. Effects of digitoxin on cell migration in ovarian cancer inflammatory microenvironment 
140. Emerging nanotherapeutic strategies in breast cancer 
141. Emerging roles of Myc in stem cell biology and novel tumor therapies 
142. Eritoran Suppresses Colon Cancer by Altering a Functional Balance in Toll-like Receptors That 
Bind Lipopolysaccharide 
143. Establishing a Preclinical Multidisciplinary Board for Brain Tumors 
144. Estimated generic prices for novel treatments for drug-resistant tuberculosis 
145. Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells 
146. Evaluation of methylene blue, pyrimethamine and its combination on an in vitro Neospora caninum 
model 
147. Evidence for the efficacy of disulfiram and copper combination in glioblastoma multiforme - A 
propos of a case 
148. Existing drugs and their application in drug discovery targeting cancer stem cells 
149. Expanding the Antimalarial Drug Arsenal-Now, But How 
150. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow 
Tumor Growth in Mice 
151. Expression Profiling Identifies Bezafibrate as Potential Therapeutic Drug for Lung Adenocarcinoma 
152. Fenofibrate Attenuates Neutrophilic Inflammation in Airway Epithelia: Potential Drug Repurposing 
for Cystic Fibrosis 
153. Fenofibrate Suppresses Oral Tumorigenesis via Reprogramming Metabolic Processes: Potential 
Drug Repurposing for Oral Cancer 
154. Ferroquine, the next generation antimalarial drug, has antitumor activity 
155. Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin 
polymerization 
 




156. Folate Receptor-Targeted Polymeric Micellar Nanocarriers for Delivery of Orlistat as a Repurposed 
Drug against Triple-Negative Breast Cancer 
157. FoxO3a Mediates the Inhibitory Effects of the Antiepileptic Drug Lamotrigine on Breast Cancer 
Growth 
158. Fragmin/protamine microparticle carriers as a drug repositioning strategy for cell transplantation 
159. From drug response profiling to target addiction scoring in cancer cell models 
160. FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model 
161. Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular 
carcinoma 
162. Glipizide suppresses prostate cancer progression in the TRAMP model by inhibiting angiogenesis 
163. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling 
164. Has the time come for metronomics in low-income and middle-income countries 
165. High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-
ALL 
166. High-throughput screening for daunorubicin-mediated drug resistance identifies mometasone furoate 
as a novel ABCB1-reversal agent 
167. High-throughput screening for the identification of new therapeutic options for metastatic 
pheochromocytoma and paraganglioma 
168. Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug 
repositioning in oncology, 27-28 May, 2016, Rosario, Argentina 
169. Histamine-2 receptor antagonist famotidine modulates cardiac stem cell characteristics in 
hypertensive heart disease 
170. HMG-CoA Reductase Inhibition Delays DNA Repair and Promotes Senescence After Tumor 
Irradiation 
171. Human Pluripotent Stem Cell-derived Cortical Neurons for High Throughput Medication Screening 
in Autism: A Proof of Concept Study in SHANK3 Haploinsufficiency Syndrome 
172. Hyaluronan-Derived Swelling of Solid Tumors, the Contribution of Collagen and Cancer Cells, and 
Implications for Cancer Therapy 
173. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer 
174. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia 
175. Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug 
 




176. Identification of Chemical Inhibitors of beta-Catenin-Driven Liver Tumorigenesis in Zebrafish 
177. Identification of driver copy number alterations in diverse cancer types and application in drug 
repositioning 
178. Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung 
Cancer 
179. Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of 
sensitivity 
180. Identification of FDA-approved drugs that computationally bind to MDM2 
181. Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme 
182. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma 
183. Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction 
with Dbf4 by the Fragment Complementation and Drug Repositioning Approach 
184. Identification of repaglinide as a therapeutic drug for glioblastoma multiforme 
185. Identification of repurposed small molecule drugs for chordoma therapy 
186. Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell 
agent using public gene expression data 
187. Identifying prognostic features by bottom-up approach and correlating to drug repositioning 
188. Immune Cell Metabolism in Tumor Microenvironment 
189. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design 
190. Improving contrast enhancement in magnetic resonance imaging using 5-aminolevulinic acid-
induced protoporphyrin IX for high-grade gliomas 
191. In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma 
192. In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a 
Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug 
193. In silico prediction and in vitro and in vivo validation of acaricide fluazuron as a potential inhibitor 
of FGFR3 and a candidate anticancer drug for bladder carcinoma 
194. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities 
195. In vitro and in vivo study of hydralazine, a potential anti-angiogenic agent 
196. In vitro effects of new artemisinin derivatives in Neospora caninum-infected human fibroblasts 
 




197. In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian 
cancer 
198. Individualized network-based drug repositioning infrastructure for precision oncology in the 
panomics era 
199. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate 
cancer invivo 
200. Inhibition of PI4K IIIalpha radiosensitizes in human tumor xenograft and immune-competent 
syngeneic murine tumor model 
201. Inhibition of Radiation and Temozolomide-Induced Invadopodia Activity in Glioma Cells Using 
FDA-Approved Drugs 
202. Inhibition of the insulin-like growth factor system is a potential therapy for rheumatoid arthritis 
203. Inhibitors of Cancer Stem Cells 
204. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer 
Treatment 
205. Isogenic FUS-eGFP iPSC Reporter Lines Enable Quantification of FUS Stress Granule Pathology 
that Is Rescued by Drugs Inducing Autophagy 
206. Ketanserin, an antidepressant, exerts its antileishmanial action via inhibition of 3-hydroxy-3-
methylglutaryl coenzyme A reductase (HMGR) enzyme of Leishmania donovani 
207. Lansoprazole Upregulates Polyubiquitination of the TNF Receptor-Associated Factor 6 and 
Facilitates Runx2-mediated Osteoblastogenesis 
208. Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, 
Milan 
209. Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells 
210. Licofelone Enhances the Efficacy of Paclitaxel in Ovarian Cancer by Reversing Drug Resistance and 
Tumor Stem-like Properties 
211. Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of 
Opportunity for Ovarian Cancer Chemoprevention 
212. MATE2 Expression Is Associated with Cancer Cell Response to Metformin 
213. Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing 
214. Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical 
reports 
 




215. MediSyn: uncertainty-aware visualization of multiple biomedical datasets to support drug treatment 
selection 
216. Mefloquine and its oxazolidine derivative compound are active against drug-resistant 
Mycobacterium tuberculosis strains and in a murine model of tuberculosis infection 
217. Metabolic Competition in Tumor Microenvironment 
218. Metabolic reprogramming: the emerging concept and associated therapeutic strategies 
219. Metastasis and chemoresistance in CD133 expressing pancreatic cancer cells are dependent on their 
lipid raft integrity 
220. Metformin and epithelial ovarian cancer therapeutics 
221. Metformin and propranolol combination prevents cancer progression and metastasis in different 
breast cancer models 
222. Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a 
phase II trial 
223. Metformin for non-small cell lung cancer patients: Opportunities and pitfalls 
224. Metformin repositioning as antitumoral agent: selective antiproliferative effects in human 
glioblastoma stem cells, via inhibition of CLIC1-mediated ion current 
225. Metformin treatment ameliorates diabetes-associated decline in hippocampal neurogenesis and 
memory via phosphorylation of insulin receptor substrate 1 
226. Metformin use and gynecological cancers: A novel treatment option emerging from drug 
repositioning 
227. Metformin: its emerging role in oncology 
228. Methylene blue inhibits lumefantrine-resistant Plasmodium berghei 
229. Metronomics: towards personalized chemotherapy 
230. Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma 
and Ovarian Carcinoma in Mouse Models 
231. Miltefosine lipid nanocapsules: Intersection of drug repurposing and nanotechnology for single dose 
oral treatment of pre-patent schistosomiasis mansoni 
232. Misfolded proteins: from little villains to little helpers in the fight against cancer 
233. Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and 
Radiosensitizing Effects in Pancreatic Cancer Cells 
 




234. Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of 
stem-like cancer cells 
235. Modeling cerebrovascular pathophysiology in amyloid-beta metabolism using neural-crest-derived 
smooth muscle cells 
236. Modeling Niemann Pick type C1 using human embryonic and induced pluripotent stem cells 
237. Modified Metformin as a More Potent Anticancer Drug: Mitochondrial Inhibition, Redox Signaling, 
Antiproliferative Effects and Future EPR Studies 
238. Molecular pathways: trafficking of metabolic resources in the tumor microenvironment 
239. Molecular-targeted nanotherapies in cancer: enabling treatment specificity 
240. Nanoliposomal Buparvaquone Immunomodulates Leishmania infantum-Infected Macrophages and 
Is Highly Effective in a Murine Model 
241. Nanoscale Reaction Vessels Designed for Synthesis of Copper-Drug Complexes Suitable for 
Preclinical Development 
242. Nelfinavir and lopinavir impair Trypanosoma cruzi trypomastigote infection in mammalian host 
cells and show anti-amastigote activity 
243. Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy 
244. Neural Crossroads in the Hematopoietic Stem Cell Niche 
245. Neuroblastoma, a Paradigm for Big Data Science in Pediatric Oncology 
246. New culture medium concepts for cell transplantation 
247. New derivatives of the antimalarial drug Pyrimethamine in the control of melanoma tumor growth: 
an in vitro and in vivo study 
248. New pharmacological treatment strategies for relapse prevention 
249. New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate 
250. Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic 
and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai 
251. Niclosamide and its analogs are potent inhibitors of Wnt/beta-catenin, mTOR and STAT3 signaling 
in ovarian cancer 
252. Niclosamide enhances ROS-mediated cell death through c-Jun activation 
253. Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal 
Cell Cancer Cells 
 




254. Novel cruzipain inhibitors for the chemotherapy of chronic Chagas disease 
255. Novel drug candidates for the treatment of metastatic colorectal cancer through global inverse gene-
expression profiling 
256. Novel modeling of cancer cell signaling pathways enables systematic drug repositioning for distinct 
breast cancer metastases 
257. Novel spirobicyclic artemisinin analogues (artemalogues): Synthesis and antitumor activities 
258. Novel strategies of ovarian cancer treatment 
259. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-
induced ferroptosis 
260. Old-School Chemotherapy in Immunotherapeutic Combination in Cancer, A Low-cost Drug 
Repurposed 
261. Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc 
adenomas are downregulated in response to tumor suppression by Clotam 
262. Oral treatments of Echinococcus multilocularis-infected mice with the antimalarial drug mefloquine 
that potentially interacts with parasite ferritin and cystatin 
263. Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy 
264. p73 as a pharmaceutical target for cancer therapy 
265. PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness 
266. Parainfluenza Virus Infection Sensitizes Cancer Cells to DNA-Damaging Agents: Implications for 
Oncolytic Virus Therapy 
267. Patient derived organoids to model rare prostate cancer phenotypes 
268. Pediatric psychopharmacology: too much or too little 
269. PEGylated chitosan nanoparticles potentiate repurposing of ormeloxifene in breast cancer therapy 
270. Pharmacological targeting of ion channels for cancer therapy: In vivo evidences 
271. Pharmacological targeting of p38 MAP-Kinase 6 (MAP2K6) inhibits the growth of esophageal 
adenocarcinoma 
272. Phenotypic identification of the redox dye methylene blue as an antagonist of heat shock response 
gene expression in metastatic melanoma cells 
273. Piperazine-based Alpha-1 AR Blocker, Naftopidil, Selectively Suppresses Malignant Human 
Bladder Cells via Induction of Apoptosis 
 




274. Pluripotent Stem Cell Platforms for Drug Discovery 
275. Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells 
276. Polypharmacology in Precision Oncology: Current Applications and Future Prospects 
277. Possible targets on carcinoma for bMAb retargeting of lymphocyte or drug cytotoxicity 
278. Posttranslational Regulation of O(6)-Methylguanine-DNA Methyltransferase (MGMT) and New 
Opportunities for Treatment of Brain Cancers 
279. Potential anti-cancer drugs commonly used for other indications 
280. Potential repurposing of known drugs as potent bacterial beta-glucuronidase inhibitors 
281. PPARgamma agonists promote differentiation of cancer stem cells by restraining YAP 
transcriptional activity 
282. Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang 
Wan as a case study 
283. Prediction of anti-cancer drug response by kernelized multi-task learning 
284. Prediction of Novel Drugs and Diseases for Hepatocellular Carcinoma Based on Multi-Source 
Simulated Annealing Based Random Walk 
285. Preliminary evaluation of children treated with metronomic chemotherapy and valproic acid in a 
low-income country: Metro-Mali-02 
286. Prevention of skin carcinogenesis by the beta-blocker carvedilol 
287. Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine 
for the treatment of malignant glioma 
288. Proscillaridin A exerts anti-tumor effects through GSK3beta activation and alteration of microtubule 
dynamics in glioblastoma 
289. Proton pump inhibitor ilaprazole suppresses cancer growth by targeting T-cell-originated protein 
kinase 
290. Pyrvinium Sensitizes Clear Cell Renal Cell Carcinoma Response to Chemotherapy Via Casein 
Kinase 1alpha-Dependent Inhibition of Wnt/beta-Catenin 
291. Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity 
in thyroid cancer cells: opportunities for repurposing 
292. Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple 
opportunities for drug repurposing 
293. Quinacrine in endometrial cancer: Repurposing an old antimalarial drug 
 




294. Raloxifene attenuates Pseudomonas aeruginosa pyocyanin production and virulence 
295. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints 
296. Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for 
Overcoming Tamoxifen Resistance in ER-positive Breast Cancer 
297. Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its 
Anticancer Activity 
298. Recent developments in rationally designed multitarget antiprotozoan agents 
299. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide 
targeting de novo DNA synthesis, irrespective of molecular subtype 
300. Redox modulation of adjacent thiols in VLA-4 by AS101 converts myeloid leukemia cells from a 
drug-resistant to drug-sensitive state 
301. Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in 
colorectal cancer: Invitro and invivo study 
302. Replication Study: Discovery and preclinical validation of drug indications using compendia of 
public gene expression data 
303. Repositioning "old" drugs for new causes: identifying new inhibitors of prostate cancer cell 
migration and invasion 
304. Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1 
305. Repositioning approved drugs for the treatment of problematic cancers using a screening approach 
306. Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant 
lesions 
307. Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of 
cytochrome c oxidase bearing the COX4-1 regulatory subunit 
308. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon 
Cancer Epigenome 
309. Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery 
310. Repositioning of amprenavir as a novel extracellular signal-regulated kinase-2 inhibitor and 
apoptosis inducer in MCF-7 human breast cancer 
311. Repositioning of anti-viral drugs as therapy for cervical cancer 
312. Repositioning of bromocriptine for treatment of acute myeloid leukemia 
313. Repositioning of DHFR Inhibitors 
 




314. Repositioning of difluorinated propanediones as inhibitors of histone methyltransferases and their 
biological evaluation in human leukemic cell lines 
315. Repositioning of proton pump inhibitors in cancer therapy 
316. Repositioning of the antipsychotic trifluoperazine: Synthesis, biological evaluation and in silico 
study of trifluoperazine analogs as anti-glioblastoma agents 
317. Reprofiling using a zebrafish melanoma model reveals drugs cooperating with targeted therapeutics 
318. Repurposed drug screen identifies cardiac glycosides as inhibitors of TGF-beta-induced cancer-
associated fibroblast differentiation 
319. Repurposing an old drug: aztreonam as a new treatment strategy for gonorrhoea 
320. Repurposing an orally available drug for the treatment of geographic atrophy 
321. Repurposing and Rescuing of Mibefradil, an Antihypertensive, for Cancer: A Case Study 
322. Repurposing and Revival of the Drugs: A New Approach to Combat the Drug Resistant 
Tuberculosis 
323. Repurposing auranofin for the treatment of cutaneous staphylococcal infections 
324. Repurposing Cationic Amphiphilic Antihistamines for Cancer Treatment 
325. Repurposing celecoxib as a topical antimicrobial agent 
326. Repurposing cephalosporin antibiotics as pro-senescent radiosensitizers 
327. Repurposing disulfiram for cancer therapy via targeted nanotechnology through enhanced tumor 
mass penetration and disassembly 
328. Repurposing drugs for glioblastoma: From bench to bedside 
329. Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections 
330. Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs 
331. Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot 
investigating propranolol administration in patients receiving hematopoietic cell transplantation 
332. Repurposing HAMI3379 to Block GPR17 and Promote Rodent and Human Oligodendrocyte 
Differentiation 
333. Repurposing itraconazole as an anticancer agent 
334. Repurposing Ivacaftor for treatment of Staphylococcus aureus infections 
 




335. Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast 
cancer 
336. Repurposing of gallium-based drugs for antibacterial therapy 
337. Repurposing of nucleoside- and nucleobase-derivative drugs as antibiotics and biofilm inhibitors 
338. Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma 
339. Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer 
activity to provide new treatment options for glioblastoma 
340. Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic 
pontine glioma 
341. Repurposing the anticancer drug mitomycin C for the treatment of persistent Acinetobacter 
baumannii infections 
342. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the 
bone marrow microenvironment 
343. Repurposing Treprostinil for Enhancing Hematopoietic Progenitor Cell Transplantation 
344. Repurposing-a ray of hope in tackling extensively drug resistance in tuberculosis 
345. Revisiting nomenclature for the description of prostate cancer androgen-responsiveness 
346. Revisiting old drugs as novel agents for retinoblastoma: in vitro and in vivo antitumor activity of 
cardenolides 
347. Rho-associated kinase signalling and the cancer microenvironment: novel biological implications 
and therapeutic opportunities 
348. Rifampin inhibits Toll-like receptor 4 signaling by targeting myeloid differentiation protein 2 and 
attenuates neuropathic pain 
349. Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian 
cancer cells 
350. Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT 
Pathways 
351. Role of TGFbeta in regulation of the tumor microenvironment and drug delivery (review 
352. S100A4 in Cancer Metastasis: Wnt Signaling-Driven Interventions for Metastasis Restriction 
353. Screening a repurposing library for potentiators of antibiotics against Staphylococcus aureus 
biofilms 
 




354. Screening of a composite library of clinically used drugs and well-characterized pharmacological 
compounds for cystathionine beta-synthase inhibition identifies benserazide as a drug potentially suitable 
for repurposing for the experimental therapy of colon cancer 
355. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative 
breast cancer growth and metastasis 
356. Simvastatin increases the in vivo activity of the first-line tuberculosis regimen 
357. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in 
cancer cell lines 
358. Stairway to Heaven or Hell? Perspectives and Limitations of Chagas Disease Chemotherapy 
359. Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via 
MACC1 
360. Stem cells in pediatric cardiology 
361. Structural basis for inactivation of Giardia lamblia carbamate kinase by disulfiram 
362. Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1 
363. Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-
mutated or IDH2-mutated solid tumours 
364. Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-
approved phosphodiesterase inhibitors in the mouse model 
365. Suppressive effects of dabrafenibon endothelial protein C receptor shedding 
366. Sustained Complete Response to Metronomic Chemotherapy in a Child with Refractory Atypical 
Teratoid Rhabdoid Tumor: A Case Report 
367. Synergic in vitro combinations of artemisinin, pyrimethamine and methylene blue against Neospora 
caninum 
368. Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in 
adrenocortical carcinoma and has biomarkers of response 
369. Systematic dissection of dysregulated transcription factor-miRNA feed-forward loops across tumor 
types 
370. Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian 
Cancer 
371. Systematic Prioritization of Druggable Mutations in 5000 Genomes Across 16 Cancer Types Using a 
Structural Genomics-based Approach 
 




372. Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-
cancer activity 
373. Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-
induced lytic activation 
374. Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete 
response of a relapsing metastatic angiosarcoma 
375. Targeting ADAM17 Sheddase Activity in Cancer 
376. Targeting cancer stem cells with dietary phytochemical - Repositioned drug combinations 
377. Targeting epithelial-mesenchymal plasticity in cancer: clinical and preclinical advances in therapy 
and monitoring 
378. Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference 
379. Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy 
380. Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins 
381. Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt/mTOR and inducing 
oxidative stress 
382. Targeting of embryonic annexin A2 expressed on ovarian and breast cancer by the novel monoclonal 
antibody 2448 
383. Targeting Phosphatidylinositol 4-Kinase IIIalpha for Radiosensitization: A Potential Model of Drug 
Repositioning Using an Anti-Hepatitis C Viral Agent 
384. Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from 
nature and drug repurposing 
385. The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to 
inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy 
386. The Amide Local Anesthetic Lidocaine in Cancer Surgery-Potential Antimetastatic Effects and 
Preservation of Immune Cell Function? A Narrative Review 
387. The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma 
Cells by Targeting Multiple Signal Pathways 
388. The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-
associated fibroblasts 
389. The anti-hypertensive drug prazosin inhibits glioblastoma growth via the PKCdelta-dependent 
inhibition of the AKT pathway 
 




390. The Antiarrhythmic Drug, Amiodarone, Decreases AKT Activity and Sensitizes Human Acute 
Myeloid Leukemia Cells to Apoptosis by ABT-263 
391. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal 
melanoma in vitro and in vivo 
392. The antiparasitic drug, potassium antimony tartrate, inhibits tumor angiogenesis and tumor growth in 
nonsmall-cell lung cancer 
393. The Architecture and Function of Monoclonal Antibody-Functionalized Mesoporous Silica 
Nanoparticles Loaded with Mifepristone: Repurposing Abortifacient for Cancer Metastatic 
Chemoprevention 
394. The CARMA3-Bcl10-MALT1 Signalosome Drives NFkappaB Activation and Promotes 
Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer 
395. The Concept of Hormesis in Cancer Therapy - Is Less More 
396. The EYA tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromarone 
397. The heterogeneity of cancer stem-like cells at the invasive front 
398. The Hippo pathway in normal development and cancer 
399. The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in 
hepatocellular carcinoma 
400. The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo 
401. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute 
lymphoblastic leukemia and synergistically works with dasatinib 
402. The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance 
in cancer cell lines 
403. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines 
and discovery of potential new DDK inhibitor scaffolds 
404. The potential of quinoline derivatives for the treatment of Toxoplasma gondii infection 
405. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis 
406. The Tissue-Reconstructing Ability of Colon CSCs Is Enhanced by FK506 and Suppressed by GSK3 
Inhibition 
407. Therapeutic Effect of Repurposed Temsirolimus in Lung Adenocarcinoma Model 
408. Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by 
inhibiting Wnt/beta-catenin signaling 
 




409. Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial 
agent 
410. Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from 
pathophysiology to treatment 
411. Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC/BCL2 
double-hit B cell lymphoma 
412. Therapeutical approaches under investigation for treatment of Chagas disease 
413. Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide 
414. Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as 
a Candidate for Treatment of Colorectal Cancer 
415. Tigecycline targets nonsmall cell lung cancer through inhibition of mitochondrial function 
416. Totally drug-resistant tuberculosis and adjunct therapies 
417. Towards precision medicine-based therapies for glioblastoma: interrogating human disease genomics 
and mouse phenotypes 
418. Transforming Cancer Prevention through Precision Medicine and Immune-oncology 
419. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug 
resistance of lung cancer 
420. Trimodal Therapy: Combining Hyperthermia with Repurposed Bexarotene and Ultrasound for 
Treating Liver Cancer 
421. Tuberculosis: From an incurable scourge to a curable disease - journey over a millennium 
422. Tumor deconstruction as a tool for advanced drug screening and repositioning 
423. Tumor progression: the neuronal input 
424. Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer 
425. TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) 
Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin 
426. Unveiling anticancer potential of glibenclamide: Its synergistic cytotoxicity with doxorubicin on 
cancer cells 
427. Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic 
428. Use of attenuated paramyxoviruses for cancer therapy 
429. Use of metformin and survival of patients with high-grade glioma 
 




430. Use of monoclonal antibody-IRDye800CW bioconjugates in the resection of breast cancer 
431. Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent 
drug candidates for cancer treatment 
432. Utility of Induced Pluripotent Stem Cells for the Study and Treatment of Genetic Diseases: Focus on 
Childhood Neurological Disorders 
433. Validating drug repurposing signals using electronic health records: a case study of metformin 
associated with reduced cancer mortality 
434. Valproic acid in the complex therapy of malignant tumors 
435. Vitamin K and hepatocellular carcinoma: The basic and clinic 









FACTOR 28. Repurposing Anthelmintic Drugs for Cancer Treatment 
1. A Blockade of IGF Signaling Sensitizes Human Ovarian Cancer Cells to the Anthelmintic 
Niclosamide-Induced Anti-Proliferative and Anticancer Activities 
2. A chemical-genetic interaction map of small molecules using high-throughput imaging in cancer cells 
3. A convenient synthesis of lubeluzole and its enantiomer: evaluation as chemosensitizing agents on 
human ovarian adenocarcinoma and lung carcinoma cells 
4. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer 
and other neuroendocrine tumors 
5. A network-based drug repositioning infrastructure for precision cancer medicine through targeting 
significantly mutated genes in the human cancer genomes 
6. A new niclosamide derivatives-B17 can inhibit urological cancers growth through apoptosis-related 
pathway 
7. A novel computational approach for drug repurposing using systems biology 
8. A Novel High Content Imaging-Based Screen Identifies the Anti-Helminthic Niclosamide as an 
Inhibitor of Lysosome Anterograde Trafficking and Prostate Cancer Cell Invasion 
9. A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy 
10. A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent Cancers 
11. A Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and 
Repositioning Predictions 
12. A signalome screening approach in the autoinflammatory disease TNF receptor associated periodic 
syndrome (TRAPS) highlights the anti-inflammatory properties of drugs for repurposing 
13. Adaptive mitochondrial reprogramming and resistance to PI3K therapy 
14. Advancing host-directed therapy for tuberculosis 
15. Albendazole as a promising molecule for tumor control 
16. Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from 
Chemorefractory Neoplasia 
17. Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via 
oxidative stress-mediated mTOR inhibition 
18. Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes 
differentiation of head and neck squamous cell carcinoma (HNSCC 
19. Anti-malarials are anti-cancers and vice versa - one arrow two sparrows 
 




20. Antibiotic drug rifabutin is effective against lung cancer cells by targeting the eIF4E-beta-catenin axis 
21. Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein 
phosphatase 2A in non-small cell lung cancer cells 
22. Antiviral Drug Ribavirin Targets Thyroid Cancer Cells by Inhibiting the eIF4E-beta-Catenin Axis 
23. Applications and implications of heparin and protamine in tissue engineering and regenerative 
medicine 
24. Artemisinins, new miconazole potentiators resulting in increased activity against Candida albicans 
biofilms 
25. Arylpyrrole and fipronil analogues that inhibit the motility and/or development of Haemonchus 
contortus in vitro 
26. beta-catenin and PI3Kdelta inhibition expands precursor Th17 cells with heightened stemness and 
antitumor activity 
27. Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of 
interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma 
28. Biotin-targeted Pluronic() P123/F127 mixed micelles delivering niclosamide: A repositioning strategy 
to treat drug-resistant lung cancer cells 
29. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant 
mammary tissues of MMTV-erbB-2 transgenic mice 
30. Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common 
therapies 
31. Cancer Drug Development Using Drosophila as an in vivo Tool: From Bedside to Bench and Back 
32. Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015 
33. CellFateScout - a bioinformatics tool for elucidating small molecule signaling pathways that drive 
cells in a specific direction 
34. Chemoprevention agents for melanoma: a path forward into phase 3 clinical trials 
35. Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-kappaB 
signaling 
36. Chloroquine upregulates TRAIL/TRAILR2 expression and potentiates doxorubicin anti-tumor 
activity in thioacetamide-induced hepatocellular carcinoma model 
37. Chloroquine-containing compounds: a patent review (2010 - 2014 
 




38. CK2 inhibition confers functional protection to young and aging axons against ischemia by 
differentially regulating the CDK5 and AKT signaling pathways 
39. Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3beta and 
Activates WNT Signaling 
40. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces 
Growth of Hepatocellular Carcinoma Cells InVitro and in Mice by Inhibiting Cell Division Cycle 37 
Signaling 
41. Computational Drug Repurposing: Current Trends 
42. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent 
pathways among FDA-approved compounds 
43. Computational repositioning and preclinical validation of pentamidine for renal cell cancer 
44. Data integration to prioritize drugs using genomics and curated data 
45. DeSigN: connecting gene expression with therapeutics for drug repurposing and development 
46. Development of Molecular Therapies for Venous Malformations 
47. Diffusion mapping of drug targets on disease signaling network elements reveals drug combination 
strategies 
48. Discovery of drug mode of action and drug repositioning from transcriptional responses 
49. Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma invivo 
50. Disulfiram's Anticancer Activity: Evidence and Mechanisms 
51. Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by 
medium-throughput phenotypic screening 
52. Drug repositioning based on triangularly balanced structure for tissue-specific diseases in incomplete 
interactome 
53. Drug Repositioning for Effective Prostate Cancer Treatment 
54. Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer 
55. Drug Repositioning through Systematic Mining of Gene Coexpression Networks in Cancer 
56. Drug repurposing and adverse event prediction using high-throughput literature analysis 
57. Drug Repurposing for Schistosomiasis: Combinations of Drugs or Biomolecules 
58. Drug Repurposing of the Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia 
 




59. Drug Targeting and Biomarkers in Head and Neck Cancers: Insights from Systems Biology Analyses 
60. DrugMap Central: an on-line query and visualization tool to facilitate drug repositioning studies 
61. Eritoran Suppresses Colon Cancer by Altering a Functional Balance in Toll-like Receptors That Bind 
Lipopolysaccharide 
62. Establishing a Preclinical Multidisciplinary Board for Brain Tumors 
63. Exploring the anti-proliferative activity of Pelargonium sidoides DC with in silico target identification 
and network pharmacology 
64. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow 
Tumor Growth in Mice 
65. Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism 
66. Fibrosis in systemic sclerosis: common and unique pathobiology 
67. Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy 
68. From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy 
69. Functional genetics-directed identification of novel pharmacological inhibitors of FAS- and TNF-
dependent apoptosis that protect mice from acute liver failure 
70. Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular 
carcinoma 
71. Glutamate release inhibitor, Riluzole, inhibited proliferation of human hepatocellular carcinoma cells 
by elevated ROS production 
72. High-content assay to identify inhibitors of dengue virus infection 
73. High-throughput screening for the identification of new therapeutic options for metastatic 
pheochromocytoma and paraganglioma 
74. Identification of Chemical Inhibitors of beta-Catenin-Driven Liver Tumorigenesis in Zebrafish 
75. Identification of driver copy number alterations in diverse cancer types and application in drug 
repositioning 
76. Identification of key pathways and drug repurposing for anaplastic thyroid carcinoma by integrated 
bioinformatics analysis 
77. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma 
78. Identification of small molecules enhancing autophagic function from drug network analysis 
 




79. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a 
drug repurposing screen 
80. Identifying prognostic features by bottom-up approach and correlating to drug repositioning 
81. Idiopathic pulmonary fibrosis and cancer: do they really look similar 
82. In search for geroprotectors: in silico screening and in vitro validation of signalome-level mimetics of 
young healthy state 
83. In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a 
Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug 
84. In silico prediction and in vitro and in vivo validation of acaricide fluazuron as a potential inhibitor of 
FGFR3 and a candidate anticancer drug for bladder carcinoma 
85. In vitro and in vivo study of hydralazine, a potential anti-angiogenic agent 
86. Informed walks: whispering hints to gene hunters inside networks' jungle 
87. Inhibition of mTOR/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in 
oral tongue squamous cell carcinoma 
88. Integrated Computational Analysis of Genes Associated with Human Hereditary Insensitivity to Pain. 
A Drug Repurposing Perspective 
89. Integrative bioinformatic analyses of an oncogenomic profile reveal the biology of endometrial cancer 
and guide drug discovery 
90. Integrative Cancer Pharmacogenomics to Infer Large-Scale Drug Taxonomy 
91. Ion channels and drug transporters as targets for anthelmintics 
92. Lansoprazole Upregulates Polyubiquitination of the TNF Receptor-Associated Factor 6 and Facilitates 
Runx2-mediated Osteoblastogenesis 
93. Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan 
94. Linking drug target and pathway activation for effective therapy using multi-task learning 
95. Linking molecular feature space and disease terms for the immunosuppressive drug rapamycin 
96. Liraglutide modulates gut microbiota and reduces NAFLD in obese mice 
97. Luteolin Impacts on the DNA Damage Pathway in Oral Squamous Cell Carcinoma 
98. MD-Miner: a network-based approach for personalized drug repositioning 
99. Metabolic reprogramming in clear cell renal cell carcinoma 
 




100. Metformin Use in Relation With Survival Outcomes of Patients With Renal Cell Carcinoma 
101. Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma 
and Ovarian Carcinoma in Mouse Models 
102. Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of 
retinoblastoma protein in renal cell carcinoma 
103. Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of 
stem-like cancer cells 
104. Multi-pathway cellular analysis of compound selectivity 
105. Multiple effects of digoxin on subsets of cancer-associated genes through the alternative splicing 
pathway 
106. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces 
endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo 
107. Neuron-specific regulation of class I PI3K catalytic subunits and their dysfunction in brain disorders 
108. Niclosamide and its analogs are potent inhibitors of Wnt/beta-catenin, mTOR and STAT3 signaling 
in ovarian cancer 
109. Niclosamide enhances ROS-mediated cell death through c-Jun activation 
110. Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal 
Cell Cancer Cells 
111. Niclosamide Induces Epiboly Delay During Early Zebrafish Embryogenesis 
112. Niclosamide, a Drug with Many (Re)purposes 
113. Novel modeling of cancer cell signaling pathways enables systematic drug repositioning for distinct 
breast cancer metastases 
114. Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and 
redox capacity 
115. Novel Therapeutics Identification for Fibrosis in Renal Allograft Using Integrative Informatics 
Approach 
116. Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc 
adenomas are downregulated in response to tumor suppression by Clotam 
117. Parainfluenza Virus Infection Sensitizes Cancer Cells to DNA-Damaging Agents: Implications for 
Oncolytic Virus Therapy 
118. Personalised drug repositioning for Clear Cell Renal Cell Carcinoma using gene expression 
 




119. Pharmacological exploitation of the phenothiazine antipsychotics to develop novel antitumor agents-
A drug repurposing strategy 
120. Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of 
tauopathy 
121. Platelet Hyperreactivity in Diabetes: Focus on GPVI Signaling-Are Useful Drugs Already Available 
122. Possible targets on carcinoma for bMAb retargeting of lymphocyte or drug cytotoxicity 
123. Potential anti-cancer drugs commonly used for other indications 
124. PPARgamma agonists promote differentiation of cancer stem cells by restraining YAP 
transcriptional activity 
125. PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase 
inhibitors by inducing autophagy 
126. Prediction of new drug indications based on clinical data and network modularity 
127. Prediction of Novel Drugs and Diseases for Hepatocellular Carcinoma Based on Multi-Source 
Simulated Annealing Based Random Walk 
128. Prediction of Novel Drugs for Hepatocellular Carcinoma Based on Multi-Source Random Walk 
129. Prediction of structure of human WNT-CRD (FZD) complex for computational drug repurposing 
130. Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine 
for the treatment of malignant glioma 
131. Pyrvinium Sensitizes Clear Cell Renal Cell Carcinoma Response to Chemotherapy Via Casein 
Kinase 1alpha-Dependent Inhibition of Wnt/beta-Catenin 
132. Recent trends in ZikV research: A step away from cure 
133. Registered report: Discovery and preclinical validation of drug indications using compendia of 
public gene expression data 
134. Replication Study: Discovery and preclinical validation of drug indications using compendia of 
public gene expression data 
135. Repositioning drugs by targeting network modules: a Parkinson's disease case study 
136. Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery 
137. Repurposed FDA-Approved drug sorafenib reduces replication of Venezuelan equine encephalitis 
virus and other alphaviruses 
138. Repurposing drugs for the treatment and control of helminth infections 
 




139. Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent 
140. Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection 
141. Repurposing itraconazole as an anticancer agent 
142. Repurposing niclosamide as a versatile antimicrobial surface coating against device-associated, 
hospital-acquired bacterial infections 
143. Repurposing of Drugs Targeting YAP-TEAD Functions 
144. Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic 
cancer prevention and treatment 
145. Repurposing of phentolamine as a potential anticancer agent against human castration-resistant 
prostate cancer: A central role on microtubule stabilization and mitochondrial apoptosis pathway 
146. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C 
virus infection 
147. Repurposing ospemifene for potentiating an antigen-specific immune response 
148. Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-
Lindau disease 
149. Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus 
150. Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori 
151. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell 
carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis 
152. Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer 
Chemotherapeutic 
153. Reverse Screening Methods to Search for the Protein Targets of Chemopreventive Compounds 
154. Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy 
155. S100A4 in Cancer Metastasis: Wnt Signaling-Driven Interventions for Metastasis Restriction 
156. Screening a Commercial Library of Pharmacologically Active Small Molecules against 
Staphylococcus aureus Biofilms 
157. Screening and personalizing nootropic drugs and cognitive modulator regimens in silico 
158. Selective human inhibitors of ATR and ATM render Leishmania major promastigotes sensitive to 
oxidative damage 
 




159. Sertraline, Paroxetine, and Chlorpromazine Are Rapidly Acting Anthelmintic Drugs Capable of 
Clinical Repurposing 
160. Simvastatin offers new prospects for the treatment of Duchenne muscular dystrophy 
161. Sorafenib Impedes Rift Valley Fever Virus Egress by Inhibiting Valosin-Containing Protein 
Function in the Cellular Secretory Pathway 
162. Statistically controlled identification of differentially expressed genes in one-to-one cell line 
comparisons of the CMAP database for drug repositioning 
163. Structural re-positioning, in silico molecular modelling, oxidative degradation, and biological 
screening of linagliptin as adenosine 3 receptor (ADORA3) modulators targeting hepatocellular 
carcinoma 
164. Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders 
165. Targeting Abl kinases to regulate vascular leak during sepsis and acute respiratory distress syndrome 
166. Targeting cancer stem cells with dietary phytochemical - Repositioned drug combinations 
167. Targeting epithelial-mesenchymal plasticity in cancer: clinical and preclinical advances in therapy 
and monitoring 
168. Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins 
169. Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt/mTOR and inducing 
oxidative stress 
170. Targeting Phosphatidylinositol 4-Kinase IIIalpha for Radiosensitization: A Potential Model of Drug 
Repositioning Using an Anti-Hepatitis C Viral Agent 
171. The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to 
inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy 
172. The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma 
Cells by Targeting Multiple Signal Pathways 
173. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical 
and noncanonical Wnt signaling pathway 
174. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal 
melanoma in vitro and in vivo 
175. The aryl hydrocarbon receptor is required for induction of p21cip1/waf1 expression and growth 
inhibition by SU5416 in hepatoma cells 
176. The CARMA3-Bcl10-MALT1 Signalosome Drives NFkappaB Activation and Promotes 
Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer 
 




177. The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell 
carcinoma 
178. The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced 
apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes 
179. The heterogeneity of cancer stem-like cells at the invasive front 
180. The human immunodeficiency virus protease inhibitor ritonavir is potentially active against 
urological malignancies 
181. The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in 
hepatocellular carcinoma 
182. The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in 
hepatocellular carcinoma 
183. The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new 
opportunity for drug repurposing 
184. The Tissue-Reconstructing Ability of Colon CSCs Is Enhanced by FK506 and Suppressed by GSK3 
Inhibition 
185. Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by 
inhibiting Wnt/beta-catenin signaling 
186. Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial 
agent 
187. Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as 
a Candidate for Treatment of Colorectal Cancer 
188. Tigecycline targets nonsmall cell lung cancer through inhibition of mitochondrial function 
189. Toll-Like Receptor-4 Signaling Drives Persistent Fibroblast Activation and Prevents Fibrosis 
Resolution in Scleroderma 
190. Toward Repositioning Niclosamide for Antivirulence Therapy of Pseudomonas aeruginosa Lung 
Infections: Development of Inhalable Formulations through Nanosuspension Technology 
191. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug 
resistance of lung cancer 
192. Trimodal Therapy: Combining Hyperthermia with Repurposed Bexarotene and Ultrasound for 
Treating Liver Cancer 
193. Uncovering Drug Mechanism of Action by Proteome Wide- Identification of Drug-Binding Proteins 
194. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities 
 




195. Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent 
drug candidates for cancer treatment 
196. Vinorelbine rescue therapy for dogs with primary urinary bladder carcinoma 








FACTOR 29. Drug Repurposing for Neurodegenerative Diseases 
1. A bidirectional drug repositioning approach for Parkinson's disease through network-based inference 
2. A Biologically-Based Computational Approach to Drug Repurposing for Anthrax Infection 
3. A computational approach to finding novel targets for existing drugs 
4. A Drug Repositioning Approach Reveals that Streptococcus mutans Is Susceptible to a Diverse Range 
of Established Antimicrobials and Nonantibiotics 
5. A Drug Screen using Human iPSC-Derived Hepatocyte-like Cells Reveals Cardiac Glycosides as a 
Potential Treatment for Hypercholesterolemia 
6. A drug target slim: using gene ontology and gene ontology annotations to navigate protein-ligand 
target space in ChEMBL 
7. A dual drug regimen synergistically blocks human parainfluenza virus infection 
8. A large-scale computational approach to drug repositioning 
9. A multicenter, randomized, placebo-controlled trial for cilostazol in patients with mild cognitive 
impairment: The COMCID study protocol 
10. A Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases 
11. A network-based drug repositioning infrastructure for precision cancer medicine through targeting 
significantly mutated genes in the human cancer genomes 
12. A novel application of furazolidone: anti-leukemic activity in acute myeloid leukemia 
13. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system 
availability of AZD0530 (saracatinib) in Alzheimer's disease 
14. A physarum-inspired prize-collecting steiner tree approach to identify subnetworks for drug 
repositioning 
15. A potential target of Tanshinone IIA for acute promyelocytic leukemia revealed by inverse docking 
and drug repurposing 
16. A profound computational study to prioritize the disease-causing mutations in PRPS1 gene 
17. A protein folding molecular imaging biosensor monitors the effects of drugs that restore mutant p53 
structure and its downstream function in glioblastoma cells 
18. A rapid and affordable screening platform for membrane protein trafficking 
19. A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast 
Differentiation In Vitro 
 




20. A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia 
21. A review of drugs for treatment of Alzheimer's disease in clinical trials: main trends 
22. A review of MED-SuMo applications 
23. A review: treatment of Alzheimer's disease discovered in repurposed agents 
24. A screen for Fli-1 transcriptional modulators identifies PKC agonists that induce erythroid to 
megakaryocytic differentiation and suppress leukemogenesis 
25. A signalome screening approach in the autoinflammatory disease TNF receptor associated periodic 
syndrome (TRAPS) highlights the anti-inflammatory properties of drugs for repurposing 
26. A structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 
ATPase 
27. A Topical Zinc Ionophore Blocks Tumorigenic Progression in UV-exposed SKH-1 High-risk Mouse 
Skin 
28. A Zebrafish Drug-Repurposing Screen Reveals sGC-Dependent and sGC-Independent Pro-
Inflammatory Activities of Nitric Oxide 
29. Accidental interaction between PDZ domains and diclofenac revealed by NMR-assisted virtual 
screening 
30. Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease 
31. Activation of MyD88-dependent TLR1/2 signaling by misfolded alpha-synuclein, a protein linked to 
neurodegenerative disorders 
32. Activity of anti-cancer protein kinase inhibitors against Leishmania spp 
33. Activity-Based Protein Profiling for the Study of Parasite Biology 
34. Adaptive mitochondrial reprogramming and resistance to PI3K therapy 
35. Adrenergic regulation of innate immunity: a review 
36. Advanced Assay Monitoring APP-Carboxyl-Terminal Fragments as Markers of APP Processing in 
Alzheimer Disease Mouse Models 
37. Advances in Developing Therapies to Combat Zika Virus: Current Knowledge and Future 
Perspectives 
38. Advances in intravesical therapy for urinary tract disorders 
39. Advances in the Development of Shape Similarity Methods and Their Application in Drug Discovery 
 




40. Aging-related Repositioned Drugs, Donepezil and Sildenafil Citrate, Increase Apoptosis of Anti-
mitotic Drug-resistant KBV20C Cells Through Different Molecular Mechanisms 
41. Albendazole as a promising molecule for tumor control 
42. Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft 
model 
43. alpha-Methyl-alpha-phenylsuccinimide ameliorates neurodegeneration in a C. elegans model of TDP-
43 proteinopathy 
44. AlzhCPI: A knowledge base for predicting chemical-protein interactions towards Alzheimer's disease 
45. Alzheimer's Disease (AD) therapeutics - 1: Repeated clinical failures continue to question the amyloid 
hypothesis of AD and the current understanding of AD causality 
46. Alzheimer's disease master regulators analysis: search for potential molecular targets and drug 
repositioning candidates 
47. Ameliorative effect of methylthiouracil on TGFBIp-induced septic responses 
48. Amino acid conjugated chitosan nanoparticles for the brain targeting of a model dipeptidyl peptidase-
4 inhibitor 
49. An improved approach for predicting drug-target interaction: proteochemometrics to molecular 
docking 
50. An in vitro test system for compounds that modulate human inflammatory macrophage polarization 
51. An integrated structure- and system-based framework to identify new targets of metabolites and 
known drugs 
52. Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T-cell 
leukemia cells 
53. Anthelmintics - from discovery to resistance 
54. Anti-inflammatory effects of methylthiouracil in vitro and in vivo 
55. Anti-obesogenic and hypolipidemic effects of a glucagon-like peptide-1 receptor agonist derived from 
the saliva of the Gila monster 
56. Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched 
for stem cell-like properties 
57. Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial 
pathogens 
 




58. Anticonvulsant activity of artificial sweeteners: a structural link between sweet-taste receptor T1R3 
and brain glutamate receptors 
59. Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein 
phosphatase 2A in non-small cell lung cancer cells 
60. Antimalarial activity of novel 4-cyano-3-methylisoquinoline inhibitors against Plasmodium 
falciparum: design, synthesis and biological evaluation 
61. Antiseptic effects of dabrafenib on TGFBIp-induced septic responses 
62. Application of molecular framework-based data-mining method in the search for beta-secretase 1 
inhibitors through drug repurposing 
63. Approaches for discovering anti-prion compounds: lessons learned and challenges ahead 
64. Approaches for establishing the function of regulatory genetic variants involved in disease 
65. Approved oncology drugs lack in vivo activity against Trichuris muris despite in vitro activity 
66. Ariadne's ChemEffect and Pathway Studio knowledge base 
67. Assessing protein kinase target similarity: Comparing sequence, structure, and cheminformatics 
approaches 
68. Assessing relative bioactivity of chemical substances using quantitative molecular network topology 
analysis 
69. Auranofin: repurposing an old drug for a golden new age 
70. Autophagy Induced by Naftopidil Inhibits Apoptosis of Human Gastric Cancer Cells 
71. Bacoside A Induces Tumor Cell Death in Human Glioblastoma Cell Lines through Catastrophic 
Macropinocytosis 
72. Benchmarking human protein complexes to investigate drug-related systems and evaluate predicted 
protein complexes 
73. Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2 
74. beta-Caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and 
metabolic dysregulation in mice 
75. beta2-Adrenoceptor agonists as novel, safe and potentially effective therapies for Amyotrophic lateral 
sclerosis (ALS 
76. Binding site matching in rational drug design: algorithms and applications 
77. BioGPS: navigating biological space to predict polypharmacology, off-targeting, and selectivity 
 




78. BioGPS: The Music for the Chemo- and Bioinformatics Walzer 
79. Bioinformatics and Drug Discovery 
80. Bioinformatics methods in drug repurposing for Alzheimer's disease 
81. Biomarker repurposing: Therapeutic drug monitoring of serum theophylline offers a potential 
diagnostic biomarker of Parkinson's disease 
82. Biotin-targeted Pluronic() P123/F127 mixed micelles delivering niclosamide: A repositioning strategy 
to treat drug-resistant lung cancer cells 
83. Bisphosphonates inactivate human EGFRs to exert antitumor actions 
84. Blocking IL-6/GP130 signaling inhibits cell viability/proliferation, glycolysis, and colony forming 
activity in human pancreatic cancer cells 
85. Buspirone Counteracts MK-801-Induced Schizophrenia-Like Phenotypes through Dopamine D3 
Receptor Blockade 
86. Butamben derivatives enhance BMP-2-stimulated commitment of C2C12 cells into osteoblasts with 
induction of voltage-gated potassium channel expression 
87. Can an FDA-Approved Alzheimer's Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika 
Virus 
88. Can commonly prescribed drugs be repurposed for the prevention or treatment of Alzheimer's and 
other neurodegenerative diseases? Protocol for an observational cohort study in the UK Clinical Practice 
Research Datalink 
89. CancerHSP: anticancer herbs database of systems pharmacology 
90. CANDO and the infinite drug discovery frontier 
91. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer 
92. Cascade Ligand- and Structure-Based Virtual Screening to Identify New Trypanocidal Compounds 
Inhibiting Putrescine Uptake 
93. Case-specific potentiation of glioblastoma drugs by pterostilbene 
94. CaV channels and cancer: canonical functions indicate benefits of repurposed drugs as cancer 
therapeutics 
95. Cell line modeling for systems medicine in cancers (review 
96. Cell specificity dictates similarities in gene expression in multiple sclerosis, Parkinson's disease, and 
Alzheimer's disease 
97. Cell-based screening identifies paroxetine as an inhibitor of diabetic endothelial dysfunction 
 




98. Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory 
Defects 
99. Characterization of a Francisella tularensis-Caenorhabditis elegans Pathosystem for the Evaluation of 
Therapeutic Compounds 
100. Characterizing protein domain associations by Small-molecule ligand binding 
101. Checking the STEP-Associated Trafficking and Internalization of Glutamate Receptors for Reduced 
Cognitive Deficits: A Machine Learning Approach-Based Cheminformatics Study and Its Application for 
Drug Repurposing 
102. Chk1 as a new therapeutic target in triple-negative breast cancer 
103. Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances 
104. Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-
Joseph Disease 
105. CK2 inhibition confers functional protection to young and aging axons against ischemia by 
differentially regulating the CDK5 and AKT signaling pathways 
106. Clobetasol and Halcinonide Act as Smoothened Agonists to Promote Myelin Gene Expression and 
RxRgamma Receptor Activation 
107. Clozapine Improves Memory Impairment and Reduces Abeta Level in the Tg-APPswe/PS1dE9 
Mouse Model of Alzheimer's Disease 
108. CNS repurposing - Potential new uses for old drugs: Examples of screens for Alzheimer's disease, 
Parkinson's disease and spasticity 
109. Co-expression Network Approach Reveals Functional Similarities among Diseases Affecting Human 
Skeletal Muscle 
110. Combating Ebola with Repurposed Therapeutics Using the CANDO Platform 
111. Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's 
disease 
112. Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved 
outcomes in spinal muscular atrophy patient-derived fibroblasts 
113. Combined analysis of gene expression and genome binding profiles identified potential therapeutic 
targets of ciclopirox in Ewing sarcoma 
114. Combining Human Disease Genetics and Mouse Model Phenotypes towards Drug Repositioning for 
Parkinson's disease 
 




115. Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the 
Pathological Proteins Related to the Alzheimer's Disease 
116. Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy 
117. Comparative analysis of methicillin-sensitive and resistant Staphylococcus aureus exposed to 
emodin based on proteomic profiling 
118. Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate 
Synthase Case 
119. Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake 
in Lung Cancer 
120. Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3beta and 
Activates WNT Signaling 
121. Complex-disease networks of trait-associated single-nucleotide polymorphisms (SNPs) unveiled by 
information theory 
122. Comprehensive prediction of drug-protein interactions and side effects for the human proteome 
123. Computational approaches for drug repositioning and combination therapy design 
124. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That 
Reduces Growth of Hepatocellular Carcinoma Cells InVitro and in Mice by Inhibiting Cell Division 
Cycle 37 Signaling 
125. Computational Discovery of Putative Leads for Drug Repositioning through Drug-Target Interaction 
Prediction 
126. Computational Drug Repurposing: Current Trends 
127. Computational Drug Target Screening through Protein Interaction Profiles 
128. Computational functional genomics-based approaches in analgesic drug discovery and repurposing 
129. Computational methods and opportunities for phosphorylation network medicine 
130. Computational Prediction of Drug?Target Interactions Using Chemical, Biological, and Network 
Features 
131. Concise Review: Cell Surface N-Linked Glycoproteins as Potential Stem Cell Markers and Drug 
Targets 
132. Concise Review: Cell Surface N-Linked Glycoproteins as Potential Stem Cell Markers and Drug 
Targets 
 




133. Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in 
cystic fibrosis 
134. Convergent downstream candidate mechanisms of independent intergenic polymorphisms between 
co-classified diseases implicate epistasis among noncoding elements 
135. Copper Complexes in Cancer Therapy 
136. Copper is required for oncogenic BRAF signalling and tumorigenesis 
137. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from 
enhanced docking approach and molecular dynamics analyses 
138. Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 
(TRIB2) pseudokinase in cancer cells 
139. Cryo-EM structure of the Plasmodium falciparum 80S ribosome bound to the anti-protozoan drug 
emetine 
140. Cyclic AMP efflux inhibitors as potential therapeutic agents for leukemia 
141. Cyclin dependent kinase 5: A novel avenue for Alzheimer's disease 
142. Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in 
ER+ breast cancer 
143. Deciphering cellular biological processes to clinical application: a new perspective for Talpha1 
treatment targeting multiple diseases 
144. Deciphering miRNA transcription factor feed-forward loops to identify drug repurposing candidates 
for cystic fibrosis 
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465. Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: a crucial 
role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation 
466. Repurposing of phentolamine as a potential anticancer agent against human castration-resistant 
prostate cancer: A central role on microtubule stabilization and mitochondrial apoptosis pathway 
467. Repurposing of Potent Drug Candidates for Multiparasite Targeting 
468. Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-beta-N-
acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease 
469. Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease 
470. Repurposing the clinically approved calcium antagonist manidipine dihydrochloride as a new early 
inhibitor of human cytomegalovirus targeting the Immediate-Early 2 (IE2) protein 
471. Repurposing Thioridazine (TDZ) as an anti-inflammatory agent 
472. Repurposing Toremifene for Treatment of Oral Bacterial Infections 
473. Research and development of anti-Alzheimer's disease drugs: an update from the perspective of 
technology flows 
474. Reverse Screening Methods to Search for the Protein Targets of Chemopreventive Compounds 
 




475. Review and comparative assessment of similarity-based methods for prediction of drug-protein 
interactions in the druggable human proteome 
476. Revisiting Antipsychotic Drug Actions Through Gene Networks Associated With Schizophrenia 
477. Revisiting Connectivity Map from a gene co-expression network analysis 
478. Rho-associated kinase signalling and the cancer microenvironment: novel biological implications 
and therapeutic opportunities 
479. Rifampin inhibits Toll-like receptor 4 signaling by targeting myeloid differentiation protein 2 and 
attenuates neuropathic pain 
480. Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT 
Pathways 
481. Schizophrenia interactome with 504 novel protein-protein interactions 
482. Screening a repurposing library, the Medicines for Malaria Venture Stasis Box, against Schistosoma 
mansoni 
483. Screening of FDA-Approved Drugs for Inhibitors of Japanese Encephalitis Virus Infection 
484. SELF-BLM: Prediction of drug-target interactions via self-training SVM 
485. Sequence Analysis of Drug Target Genes with Suicidal Behavior in Bipolar Disorder Patients 
486. Simvastatin offers new prospects for the treatment of Duchenne muscular dystrophy 
487. Six psychotropics for pre-symptomatic & early Alzheimer's (MCI), Parkinson's, and Huntington's 
disease modification 
488. Small Molecules in Development for the Treatment of Spinal Muscular Atrophy 
489. SMAP-WS: a parallel web service for structural proteome-wide ligand-binding site comparison 
490. Sorafenib Impedes Rift Valley Fever Virus Egress by Inhibiting Valosin-Containing Protein 
Function in the Cellular Secretory Pathway 
491. SPILLO-PBSS: detecting hidden binding sites within protein 3D-structures through a flexible 
structure-based approach 
492. Steroids-specific target library for steroids target prediction 
493. Structural analysis of protein tyrosine phosphatase 1B reveals potentially druggable allosteric 
binding sites 
494. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 
reverse transcriptase 
 




495. Structural re-positioning, in silico molecular modelling, oxidative degradation, and biological 
screening of linagliptin as adenosine 3 receptor (ADORA3) modulators targeting hepatocellular 
carcinoma 
496. Structure based investigation on the binding interaction of transport proteins in leishmaniasis: 
insights from molecular simulation 
497. Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing 
498. Structure-based repurposing of FDA-approved drugs as inhibitors of NEDD8-activating enzyme 
499. Substrate-driven mapping of the degradome by comparison of sequence logos 
500. Sulforaphane Prevents Neuronal Apoptosis and Memory Impairment in Diabetic Rats 
501. SUMOylation in brain ischemia: Patterns, targets, and translational implications 
502. Suppressive effects of dabrafenibon endothelial protein C receptor shedding 
503. Symposium 2-1The autoimmunome: Similarities and differences among genetic susceptibility to 
common immune-related diseases 
504. Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in 
adrenocortical carcinoma and has biomarkers of response 
505. Systematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, 
biological and epidemiological factors influencing drug repositioning 
506. Systematic discovery of drug action mechanisms by an integrated chemical genomics approach: 
identification of functional disparities between azacytidine and decitabine 
507. Systematic dissection of dysregulated transcription factor-miRNA feed-forward loops across tumor 
types 
508. Systematic Prioritization of Druggable Mutations in 5000 Genomes Across 16 Cancer Types Using a 
Structural Genomics-based Approach 
509. T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's 
Disease 
510. Tacrine-deferiprone hybrids as multi-target-directed metal chelators against Alzheimer's disease: a 
two-in-one drug 
511. Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review 
512. Targeting cyclin D3/CDK6 activity for treatment of Parkinson's disease 
513. Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion 
injury and for treating heart failure 
 




514. Targeting the off-targets: a computational bioinformatics approach to understanding the 
polypharmacology of nelfinavir 
515. Tetracycline hydrochloride: A potential clinical drug for radioprotection 
516. Tetracycline repurposing in neurodegeneration: focus on Parkinson's disease 
517. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal 
melanoma in vitro and in vivo 
518. The antimalarial amodiaquine causes autophagic-lysosomal and proliferative blockade sensitizing 
human melanoma cells to starvation- and chemotherapy-induced cell death 
519. The aryl hydrocarbon receptor is required for induction of p21cip1/waf1 expression and growth 
inhibition by SU5416 in hepatoma cells 
520. The CARLSBAD database: a confederated database of chemical bioactivities 
521. The case of galantamine: repurposing and late blooming of a cholinergic drug 
522. The combination astemizole-gefitinib as a potential therapy for human lung cancer 
523. The Coming of Age of the Angiotensin Hypothesis in Alzheimer's Disease: Progress Toward 
Disease Prevention and Treatment 
524. The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell 
carcinoma 
525. The extraction of drug-disease correlations based on module distance in incomplete human 
interactome 
526. The EYA tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromarone 
527. The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer's 
disease amyloid-beta peptides 
528. The human immunodeficiency virus protease inhibitor ritonavir is potentially active against 
urological malignancies 
529. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian 
randomisation analysis 
530. The Molecular Revolution in Cutaneous Biology: Emerging Landscape in Genomic Dermatology: 
New Mechanistic Ideas, Gene Editing, and Therapeutic Breakthroughs 
531. The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug 
532. The polysialic acid mimetics idarubicin and irinotecan stimulate neuronal survival and neurite 
outgrowth and signal via protein kinase C 
 




533. The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance 
in cancer cell lines 
534. The protein kinase 2 inhibitor CX-4945 regulates osteoclast and osteoblast differentiation in vitro 
535. The proton-pump inhibitor lansoprazole enhances amyloid beta production 
536. The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory 
NRASQ61K melanoma 
537. The role of drug profiles as similarity metrics: applications to repurposing, adverse effects detection 
and drug-drug interactions 
538. The sodium channel-blocking antiepileptic drug phenytoin inhibits breast tumour growth and 
metastasis 
539. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis 
540. The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new 
opportunity for drug repurposing 
541. Therapeutic Approaches to Prion Diseases 
542. Therapeutic compositions and uses of alpha1-antitrypsin: a patent review (2012 - 2015 
543. Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial 
agent 
544. Therapeutic potential for phenytoin: targeting Na(v)1.5 sodium channels to reduce migration and 
invasion in metastatic breast cancer 
545. Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from 
pathophysiology to treatment 
546. Three-dimensional models of Mycobacterium tuberculosis proteins Rv1555, Rv1554 and their 
docking analyses with sildenafil, tadalafil, vardenafil drugs, suggest interference with quinol binding 
likely to affect protein's function 
547. Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine 
Approach 
548. Transcriptomic Analysis of the Host Response and Innate Resilience to Enterotoxigenic Escherichia 
coli Infection in Humans 
549. Transcriptomic changes induced by mycophenolic acid in gastric cancer cells 
550. Transcriptomic RNAseq drug screen in cerebrocortical cultures: toward novel neurogenetic disease 
therapies 
 




551. Translating Mendelian and complex inheritance of Alzheimer's disease genes for predicting unique 
personal genome variants 
552. Trypanocidal Effect of Isotretinoin through the Inhibition of Polyamine and Amino Acid 
Transporters in Trypanosoma cruzi 
553. Uncovering Drug Mechanism of Action by Proteome Wide- Identification of Drug-Binding Proteins 
554. Understanding organellar protein folding capacities and assessing their pharmacological modulation 
by small molecules 
555. Unveiling the role of network and systems biology in drug discovery 
556. Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease 
557. Using Drugs as Molecular Probes: AComputational Chemical Biology Approach in 
Neurodegenerative Diseases 
558. Using predicate and provenance information from a knowledge graph for drug efficacy screening 
559. Validating the Predicted Effect of Astemizole and Ketoconazole Using a Drosophila Model of 
Parkinson's Disease 
560. Valproic acid in the complex therapy of malignant tumors 
561. Valproic acid mediates miR-124 to down-regulate a novel protein target, GNAI1 
562. Virtual Screening against Phosphoglycerate Kinase 1 in Quest of Novel Apoptosis Inhibitors 
563. Virtual target screening: validation using kinase inhibitors 
564. Vitamin K and hepatocellular carcinoma: The basic and clinic 
565. Voltage-gated sodium channels and metastatic disease 
566. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity 
and Metastasis 
567. YAP/TAZ Are Mechanoregulators of TGF-beta-Smad Signaling and Renal Fibrogenesis 








FACTOR 30. Repurposed Drugs Targeting Glutamate Receptors 
1. A current perspective on the oncopreventive and oncolytic properties of selective serotonin reuptake 
inhibitors 
2. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer 
and other neuroendocrine tumors 
3. A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity 
4. ADEPTUS: a discovery tool for disease prediction, enrichment and network analysis based on profiles 
from many diseases 
5. Advances in epilepsy gene discovery and implications for epilepsy diagnosis and treatment 
6. Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology 
7. Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry 
8. Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via 
oxidative stress-mediated mTOR inhibition 
9. Anticonvulsant activity of artificial sweeteners: a structural link between sweet-taste receptor T1R3 and 
brain glutamate receptors 
10. Antidepressants in the Treatment of Functional Dyspepsia: A Systematic Review and Meta-Analysis 
11. Antidepressants, antimicrobials or both? Gut microbiota dysbiosis in depression and possible 
implications of the antimicrobial effects of antidepressant drugs for antidepressant effectiveness 
12. Butamben derivatives enhance BMP-2-stimulated commitment of C2C12 cells into osteoblasts with 
induction of voltage-gated potassium channel expression 
13. Case-specific potentiation of glioblastoma drugs by pterostilbene 
14. CaV channels and cancer: canonical functions indicate benefits of repurposed drugs as cancer 
therapeutics 
15. Cell-based screening identifies paroxetine as an inhibitor of diabetic endothelial dysfunction 
16. Clinical validation of blood/brain glutamate grabbing in acute ischemic stroke 
17. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces 
Growth of Hepatocellular Carcinoma Cells InVitro and in Mice by Inhibiting Cell Division Cycle 37 
Signaling 
18. Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in 
ER+ breast cancer 
 




19. Discovering gene re-ranking efficiency and conserved gene-gene relationships derived from gene co-
expression network analysis on breast cancer data 
20. Drug discovery for the treatment of substance use disorders: novel targets, repurposing, and the need 
for new paradigms 
21. Drug repurposing for Leishmania. Molecular basis of the leishmanicidal activity of the antidepressant 
sertraline 
22. Drug repurposing may generate novel approaches to treating depression 
23. Drug similarity search based on combined signatures in gene expression profiles 
24. Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed Drugs Elicits 
Cell-Lethal Autophagy and Therapeutic Benefit 
25. Effects of the nicotinic agonist varenicline on the performance of tasks of cognition in aged and 
middle-aged rhesus and pigtail monkeys 
26. Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats 
27. Fast, non-competitive and reversible inhibition of NMDA-activated currents by 2-BFI confers 
neuroprotection 
28. Finding the targets of a drug by integration of gene expression data with a protein interaction network 
29. Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin 
polymerization 
30. From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic 
Small Cell Lung Cancer (SCLC 
31. Glutamate release inhibitor, Riluzole, inhibited proliferation of human hepatocellular carcinoma cells 
by elevated ROS production 
32. High-content drug screening for rare diseases 
33. Identification of Chemical Inhibitors of beta-Catenin-Driven Liver Tumorigenesis in Zebrafish 
34. In Silico-Based Repositioning of Phosphinothricin as a Novel Technetium-99m Imaging Probe with 
Potential Anti-Cancer Activity 
35. Inhibition of ACE Retards Tau Hyperphosphorylation and Signs of Neuronal Degeneration in Aged 
Rats Subjected to Chronic Mild Stress 
36. Insights into the Modulation of Dopamine Transporter Function by Amphetamine, Orphenadrine, and 
Cocaine Binding 
 




37. Is there a relationship between sweet taste and seizures? Anticonvulsant and proconvulsant effects of 
non-nutritive sweeteners 
38. KCa 3.1-a microglial target ready for drug repurposing 
39. Ketamine for treatment-resistant unipolar depression: current evidence 
40. Ketamine: repurposing and redefining a multifaceted drug 
41. Ketanserin, an antidepressant, exerts its antileishmanial action via inhibition of 3-hydroxy-3-
methylglutaryl coenzyme A reductase (HMGR) enzyme of Leishmania donovani 
42. Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced 
depression model via improving hippocampal neural plasticity 
43. MD-Miner: a network-based approach for personalized drug repositioning 
44. Medications for alcohol use disorders: An overview 
45. Metformin use and gynecological cancers: A novel treatment option emerging from drug 
repositioning 
46. Metformin: its emerging role in oncology 
47. Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's Disease 
48. Mining mouse behavior for patterns predicting psychiatric drug classification 
49. Molecular investigations of protriptyline as a multi-target directed ligand in Alzheimer's disease 
50. Mood, stress and longevity: convergence on ANK3 
51. N-acetylcysteine prevents stress-induced anxiety behavior in zebrafish 
52. Network-assisted prediction of potential drugs for addiction 
53. Network-based drug repositioning 
54. Network-based drug repositioning: A novel strategy for discovering potential antidepressants and 
their mode of action 
55. New drug candidates for depression - a nationwide population-based study 
56. New indications for existing drugs; repurposing in psychiatry and addiction medicine 
57. New perspectives for metformin in cancer therapy 
58. New pharmacological treatment strategies for relapse prevention 
59. New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate 
 




60. Pharmacological targeting of ion channels for cancer therapy: In vivo evidences 
61. Potential repurposing of known drugs as potent bacterial beta-glucuronidase inhibitors 
62. Predicting Potential Drugs for Breast Cancer based on miRNA and Tissue Specificity 
63. Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and 
with GABAA potentiating activity for use in dementia 
64. Repurposing itraconazole as an anticancer agent 
65. Repurposing Lesogaberan to Promote Human Islet Cell Survival and beta-Cell Replication 
66. Repurposing potential of 1st generation H1-specific antihistamines as anti-filovirus therapeutics 
67. Senicapoc: Repurposing a Drug to Target Microglia KCa3.1 in Stroke 
68. Sertraline, Paroxetine, and Chlorpromazine Are Rapidly Acting Anthelmintic Drugs Capable of 
Clinical Repurposing 
69. Sphingolipids as targets for inhalation treatment of cystic fibrosis 
70. SPIDR: small-molecule peptide-influenced drug repurposing 
71. SPILLO-PBSS: detecting hidden binding sites within protein 3D-structures through a flexible 
structure-based approach 
72. Stress-Activated Kinase Mitogen-Activated Kinase Kinase-7 Governs Epigenetics of Cardiac 
Repolarization for Arrhythmia Prevention 
73. Subanaesthetic dose of ketamine in intractable asthma 
74. Support for phosphoinositol 3 kinase and mTOR inhibitors as treatment for lupus using in-silico drug-
repurposing analysis 
75. Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of 
Neuroendocrine Prostate Cancer 
76. Targeting cyclin D3/CDK6 activity for treatment of Parkinson's disease 
77. Teaching an old dog new tricks: drug repositioning in small cell lung cancer 
78. The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit 
epithelial-to-mesenchymal transition and augment capecitabine efficacy 
79. The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-
enhanced platelet function 
80. The antiparasitic drug, potassium antimony tartrate, inhibits tumor angiogenesis and tumor growth in 
nonsmall-cell lung cancer 
 




81. The bitter pill: clinical drugs that activate the human bitter taste receptor TAS2R14 
82. The case of galantamine: repurposing and late blooming of a cholinergic drug 
83. The combination astemizole-gefitinib as a potential therapy for human lung cancer 
84. The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new 
opportunity for drug repurposing 
85. Topical phenytoin for the treatment of neuropathic pain 
86. Transcriptomic profiling of human hippocampal progenitor cells treated with antidepressants and its 
application in drug repositioning 
87. Tricyclic antidepressants inhibit Candida albicans growth and biofilm formation 
88. What do the genetic association data say about the high risk of suicide in people with depression? A 
novel network-based approach to find common molecular basis for depression and suicidal behavior and 
related therapeutic targets 








FACTOR 31. Repurposing Drugs that Target Oxidative and Inflammation Biomarkers VEGF, 
HO-1, iNOS, Nrf2 
1. 4-Acetoxyphenol Prevents RPE Oxidative Stress-Induced Necrosis by Functioning as an NRF2 
Stabilizer 
2. A Novel High Content Imaging-Based Screen Identifies the Anti-Helminthic Niclosamide as an 
Inhibitor of Lysosome Anterograde Trafficking and Prostate Cancer Cell Invasion 
3. A Topical Zinc Ionophore Blocks Tumorigenic Progression in UV-exposed SKH-1 High-risk Mouse 
Skin 
4. A Zebrafish Drug-Repurposing Screen Reveals sGC-Dependent and sGC-Independent Pro-
Inflammatory Activities of Nitric Oxide 
5. Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease 
6. Acute oxidant damage promoted on cancer cells by amitriptyline in comparison with some common 
chemotherapeutic drugs 
7. Adjuvant potential of selegiline in attenuating organ dysfunction in septic rats with peritonitis 
8. Advances in intravesical therapy for urinary tract disorders 
9. Albendazole as a promising molecule for tumor control 
10. Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft 
model 
11. Ameliorative effect of methylthiouracil on TGFBIp-induced septic responses 
12. Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via 
oxidative stress-mediated mTOR inhibition 
13. Antibiotic drug levofloxacin inhibits proliferation and induces apoptosis of lung cancer cells through 
inducing mitochondrial dysfunction and oxidative damage 
14. Antiviral effects of inhibiting host gene expression 
15. Auranofin: repurposing an old drug for a golden new age 
16. Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the 
proliferative expansion of stem-like cancer cells (CSCs 
17. beta-Caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and 
metabolic dysregulation in mice 
18. Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor 
19. Bioinformatics methods in drug repurposing for Alzheimer's disease 
 




20. Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer 
resistance to EGFR therapy 
21. Bisphosphonates inactivate human EGFRs to exert antitumor actions 
22. Blocking IL-6/GP130 signaling inhibits cell viability/proliferation, glycolysis, and colony forming 
activity in human pancreatic cancer cells 
23. Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote 
metastasis 
24. Candesartan stimulates reparative angiogenesis in ischemic retinopathy model: role of 
hemeoxygenase-1 (HO-1 
25. Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-kappaB 
signaling 
26. CK2 inhibition confers functional protection to young and aging axons against ischemia by 
differentially regulating the CDK5 and AKT signaling pathways 
27. Clinical dosage of meclozine promotes longitudinal bone growth, bone volume, and trabecular bone 
quality in transgenic mice with achondroplasia 
28. Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease 
29. Combined analysis of gene expression and genome binding profiles identified potential therapeutic 
targets of ciclopirox in Ewing sarcoma 
30. Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine 
kinase inhibitors as host-directed antimicrobials 
31. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces 
Growth of Hepatocellular Carcinoma Cells InVitro and in Mice by Inhibiting Cell Division Cycle 37 
Signaling 
32. Computational repositioning and experimental validation of approved drugs for HIF-prolyl 
hydroxylase inhibition 
33. Computational-experimental approach to drug-target interaction mapping: A case study on kinase 
inhibitors 
34. Copper Complexes in Cancer Therapy 
35. Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) 
pseudokinase in cancer cells 
36. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease 
 




37. Deciphering cellular biological processes to clinical application: a new perspective for Talpha1 
treatment targeting multiple diseases 
38. Designing novel therapies against sarcomas in the era of personalized medicine and economic crisis 
39. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly 
Guided Targeted Therapy 
40. Developmental toxicity of auranofin in zebrafish embryos 
41. Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and 
over-rides resistance to temozolomide 
42. DPP-4 inhibitors promote proliferation and migration of rat brain microvascular endothelial cells 
under hypoxic/high-glucose conditions, potentially through the SIRT1/HIF-1/VEGF pathway 
43. Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer 
44. Drug delivery for the treatment of endometriosis and uterine fibroids 
45. Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer 
46. Drug Repositioning for Preeclampsia Therapeutics by In Vitro Screening: Phosphodiesterase-5 
Inhibitor Vardenafil Restores Endothelial Dysfunction via Induction of Placental Growth Factor 
47. Drug Repurposing for Duchenne Muscular Dystrophy: The Monoamine Oxidase B Inhibitor 
Safinamide Ameliorates the Pathological Phenotype in mdx Mice and in Myogenic Cultures From DMD 
Patients 
48. Drug repurposing for Leishmania. Molecular basis of the leishmanicidal activity of the antidepressant 
sertraline 
49. Drug Repurposing Screen Identifies Foxo1-Dependent Angiopoietin-2 Regulation in Sepsis 
50. Drug-Repositioning Screening for Keap1-Nrf2 Binding Inhibitors using Fluorescence Correlation 
Spectroscopy 
51. Fibrosis in systemic sclerosis: common and unique pathobiology 
52. Folic Acid Exerts Post-Ischemic Neuroprotection In Vitro Through HIF-1alpha Stabilization 
53. Fragile Histidine Triad (FHIT), a Novel Modifier Gene in Pulmonary Arterial Hypertension 
54. From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy 
55. Heme Oxygenase Database (HemeOxDB) and QSAR Analysis of Isoform?1 Inhibitors 
56. Histamine-2 receptor antagonist famotidine modulates cardiac stem cell characteristics in 
hypertensive heart disease 
 




57. Identification of KX2-391 as an inhibitor of HBV transcription by a recombinant HBV-based 
screening assay 
58. Identification of Non-Electrophilic Nrf2 Activators from Approved Drugs 
59. Identifying and Tackling Emergent Vulnerability in Drug-Resistant Mycobacteria 
60. Imidazolium salts as innovative agents against Leishmania amazonensis 
61. In silico identification of potent small molecule inhibitors targeting epidermal growth factor receptor 
1 
62. In silico prediction and in vitro and in vivo validation of acaricide fluazuron as a potential inhibitor of 
FGFR3 and a candidate anticancer drug for bladder carcinoma 
63. In vitro and in vivo study of hydralazine, a potential anti-angiogenic agent 
64. Inhibition of effector antigen-specific T cells by intradermal administration of heme oxygenase-1 
inducers 
65. Inhibition of EGFR Signaling Protects from Mucormycosis 
66. Inhibition of the insulin-like growth factor system is a potential therapy for rheumatoid arthritis 
67. KCa 3.1-a microglial target ready for drug repurposing 
68. Lethal action of the nitrothiazolyl-salicylamide derivative nitazoxanide via induction of oxidative 
stress in Leishmania (L.) infantum 
69. Luteolin Impacts on the DNA Damage Pathway in Oral Squamous Cell Carcinoma 
70. Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase 
Inhibition for Peritoneal Carcinomatosis 
71. Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally 
activated FGFR3 signaling in achondroplasia 
72. Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical 
reports 
73. Metformin use and gynecological cancers: A novel treatment option emerging from drug 
repositioning 
74. Microglial role in the development of chronic pain 
75. Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related 
Macular Degeneration 
76. Mitigation of carbon tetrachloride-induced hepatic injury by methylene blue, a repurposed drug, is 
mediated by dual inhibition of GSK3beta downstream of PKA 
 




77. Molecular therapeutic strategies for FGFR3 gene-related skeletal dysplasia 
78. Mood, stress and longevity: convergence on ANK3 
79. Nelfinavir and lopinavir impair Trypanosoma cruzi trypomastigote infection in mammalian host cells 
and show anti-amastigote activity 
80. Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy 
81. Neuroprotective and immunomodulatory effects of raloxifene in the myenteric plexus of a mouse 
model of Parkinson's disease 
82. Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-beta 
83. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-
induced ferroptosis 
84. Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the 
early phase after heart transplantation in rats 
85. Oxidative stress during acetaminophen hepatotoxicity: Sources, pathophysiological role and 
therapeutic potential 
86. Parkinson's Disease, Diabetes and Cognitive Impairment 
87. Pharmacological approach for drug repositioning against cardiorenal diseases 
88. Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of 
tauopathy 
89. Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential 
interventions 
90. Pharmacological use of a novel scaffold, anomeric N,N-diarylamino tetrahydropyran: molecular 
similarity search, chemocentric target profiling, and experimental evidence 
91. Pharmacology and Clinical Drug Candidates in Redox Medicine 
92. Platelet Hyperreactivity in Diabetes: Focus on GPVI Signaling-Are Useful Drugs Already Available 
93. Posttranslational Regulation of O(6)-Methylguanine-DNA Methyltransferase (MGMT) and New 
Opportunities for Treatment of Brain Cancers 
94. Potential repositioning of exemestane as a neuroprotective agent for Parkinson's disease 
95. PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase 
inhibitors by inducing autophagy 
96. Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes 
 




97. Promethazine Hydrochloride Inhibits Ectopic Fat Cell Formation in Skeletal Muscle 
98. Propofol post-conditioning alleviates hepatic ischaemia reperfusion injury via BRG1-mediated 
Nrf2/HO-1 transcriptional activation in human and mice 
99. Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and 
with GABAA potentiating activity for use in dementia 
100. Repositioning of molsidomine for its efficacy in diabetes induced erectile dysfunction in rats: In 
silico, in vitro and in vivo approach 
101. Repurposing an established drug: an emerging role for methylene blue in L-DOPA-induced 
dyskinesia 
102. Repurposing an orally available drug for the treatment of geographic atrophy 
103. Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer 
stem cells 
104. Repurposing cationic amphiphilic drugs as adjuvants to induce lysosomal siRNA escape in nanogel 
transfected cells 
105. Repurposing Drugs in Oncology (ReDO)-nitroglycerin as an anti-cancer agent 
106. Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection 
107. Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast 
cancer 
108. Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-
Lindau disease 
109. Repurposing the anti-malarial drug, quinacrine: new anti-colitis properties 
110. Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in 
Parkinson's Disease 
111. Retinal Neuroprotective Effects of Flibanserin, an FDA-Approved Dual Serotonin Receptor Agonist-
Antagonist 
112. Ribavirin as a tri-targeted antitumor repositioned drug 
113. Rifampin inhibits Toll-like receptor 4 signaling by targeting myeloid differentiation protein 2 and 
attenuates neuropathic pain 
114. Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian 
cancer cells 
115. Role of TGFbeta in regulation of the tumor microenvironment and drug delivery (review 
 




116. Sequence Analysis of Drug Target Genes with Suicidal Behavior in Bipolar Disorder Patients 
117. Sorafenib Impedes Rift Valley Fever Virus Egress by Inhibiting Valosin-Containing Protein 
Function in the Cellular Secretory Pathway 
118. Systemic hemin therapy attenuates blood-brain barrier disruption after intracerebral hemorrhage 
119. T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's 
Disease 
120. Tacrine-deferiprone hybrids as multi-target-directed metal chelators against Alzheimer's disease: a 
two-in-one drug 
121. Targeting ADAM17 Sheddase Activity in Cancer 
122. Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt/mTOR and inducing 
oxidative stress 
123. Targeting transcriptional control of soluble guanylyl cyclase via NOTCH for prevention of 
cardiovascular disease 
124. The antifungal compound butenafine eliminates promastigote and amastigote forms of Leishmania 
(Leishmania) amazonensis and Leishmania (Viannia) braziliensis 
125. The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced 
apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes 
126. The neuroimmune transcriptome and alcohol dependence: potential for targeted therapies 
127. The polysialic acid mimetics idarubicin and irinotecan stimulate neuronal survival and neurite 
outgrowth and signal via protein kinase C 
128. The possible repositioning of an oral anti-arthritic drug, auranofin, for Nrf2-activating therapy: The 
demonstration of Nrf2-dependent anti-oxidative action using a zebrafish model 
129. Therapeutic Effect of Quinacrine, an Antiprotozoan Drug, by Selective Suppression of p-CHK1/2 in 
p53-Negative Malignant Cancers 
130. Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial 
agent 
131. Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine 
Approach 
132. Treating the dysfunctional placenta 
133. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug 
resistance of lung cancer 
 




134. TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) 
Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin 
135. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities 
136. Valproic Acid Promotes Apoptosis and Cisplatin Sensitivity Through Downregulation of H19 








FACTOR 32. Computational Drug Repositioning Based on Similarity Networks 
1. A bidirectional drug repositioning approach for Parkinson's disease through network-based inference 
2. A Biologically-Based Computational Approach to Drug Repurposing for Anthrax Infection 
3. A chemo-centric view of human health and disease 
4. A comparative study of disease genes and drug targets in the human protein interactome 
5. A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors 
6. A computational method for clinically relevant cancer stratification and driver mutation module 
discovery using personal genomics profiles 
7. A convenient synthesis of lubeluzole and its enantiomer: evaluation as chemosensitizing agents on 
human ovarian adenocarcinoma and lung carcinoma cells 
8. A cross-species analysis method to analyze animal models' similarity to human's disease state 
9. A curated C. difficile strain 630 metabolic network: prediction of essential targets and inhibitors 
10. A disease similarity matrix based on the uniqueness of shared genes 
11. A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth 
muscle relaxation to direct neuroprotection 
12. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung 
cancer and other neuroendocrine tumors 
13. A framework for the targeted selection of herbs with similar efficacy by exploiting drug repositioning 
technique and curated biomedical knowledge 
14. A genomics-based systems approach towards drug repositioning for rheumatoid arthritis 
15. A Large-Scale Gene Expression Intensity-Based Similarity Metric for Drug Repositioning 
16. A miRNA-driven inference model to construct potential drug-disease associations for drug 
repositioning 
17. A Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases 
18. A network based approach to drug repositioning identifies plausible candidates for breast cancer and 
prostate cancer 
19. A network integration approach for drug-target interaction prediction and computational drug 
repositioning from heterogeneous information 
20. A network pharmacology approach reveals new candidate caloric restriction mimetics in C. elegans 
 




21. A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target 
Therapies in Triple Negative Breast Cancer 
22. A network-based drug repositioning infrastructure for precision cancer medicine through targeting 
significantly mutated genes in the human cancer genomes 
23. A Network-Biology Informed Computational Drug Repositioning Strategy to Target Disease Risk 
Trajectories and Comorbidities of Peripheral Artery Disease 
24. A New Method for Computational Drug Repositioning Using Drug Pairwise Similarity 
25. A novel computational approach for drug repurposing using systems biology 
26. A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy 
27. A novel multi-modal drug repurposing approach for identification of potent ACK1 inhibitors 
28. A physarum-inspired prize-collecting steiner tree approach to identify subnetworks for drug 
repositioning 
29. A Practical Guide for Exploring Opportunities of Repurposing Drugs for CNS Diseases in Systems 
Biology 
30. A review of network-based approaches to drug repositioning 
31. A Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and 
Repositioning Predictions 
32. A simple mathematical approach to the analysis of polypharmacology and polyspecificity data 
33. A statin-regulated microRNA represses human c-Myc expression and function 
34. A systematic analysis of FDA-approved anticancer drugs 
35. A Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles 
Using Pathway-Drug Network 
36. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents 
37. A systems pharmacology-oriented discovery of a new therapeutic use of the TCM formula 
Liuweiwuling for liver failure 
38. A tool to utilize adverse effect profiles to identify brain-active medications for repurposing 
39. A two-step drug repositioning method based on a protein-protein interaction network of genes shared 
by two diseases and the similarity of drugs 
40. A two-tiered unsupervised clustering approach for drug repositioning through heterogeneous data 
integration 
 




41. ADEPTUS: a discovery tool for disease prediction, enrichment and network analysis based on profiles 
from many diseases 
42. Advanced systems biology methods in drug discovery and translational biomedicine 
43. Advances in drug development for Parkinson's disease: present status 
44. Advances in epilepsy gene discovery and implications for epilepsy diagnosis and treatment 
45. Advances in the Development of Shape Similarity Methods and Their Application in Drug Discovery 
46. Advancing cancer drug discovery towards more agile development of targeted combination therapies 
47. Albendazole as a promising molecule for tumor control 
48. alpha-Methyl-alpha-phenylsuccinimide ameliorates neurodegeneration in a C. elegans model of TDP-
43 proteinopathy 
49. AlzhCPI: A knowledge base for predicting chemical-protein interactions towards Alzheimer's disease 
50. Alzheimer's disease master regulators analysis: search for potential molecular targets and drug 
repositioning candidates 
51. An Integrated Data Driven Approach to Drug Repositioning Using Gene-Disease Associations 
52. An integrated network platform for contextual prioritization of drugs and pathways 
53. An integrated structure- and system-based framework to identify new targets of metabolites and 
known drugs 
54. Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from 
Chemorefractory Neoplasia 
55. Analysis and assay of oseltamivir-resistant mutants of influenza neuraminidase via direct observation 
of drug unbinding and rebinding in simulation 
56. Analysis of drug binding pockets and repurposing opportunities for twelve essential enzymes of 
ESKAPE pathogens 
57. ANTENNA, a Multi-Rank, Multi-Layered Recommender System for Inferring Reliable Drug-Gene-
Disease Associations: Repurposing Diazoxide as a Targeted Anti-Cancer Therapy 
58. Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes 
differentiation of head and neck squamous cell carcinoma (HNSCC 
59. Anti-infectious drug repurposing using an integrated chemical genomics and structural systems 
biology approach 
60. Application of Atlas of Cancer Signalling Network in preclinical studies 
 




61. Application of the 4D fingerprint method with a robust scoring function for scaffold-hopping and 
drug repurposing strategies 
62. Ariadne's ChemEffect and Pathway Studio knowledge base 
63. Assessing protein kinase target similarity: Comparing sequence, structure, and cheminformatics 
approaches 
64. Assessing relative bioactivity of chemical substances using quantitative molecular network topology 
analysis 
65. Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New 
Platform for Computer-Aided Drug Repurposing 
66. Back to the Roots: Prediction of Biologically Active Natural Products from Ayurveda Traditional 
Medicine 
67. Bacoside A Induces Tumor Cell Death in Human Glioblastoma Cell Lines through Catastrophic 
Macropinocytosis 
68. Benchmarking human protein complexes to investigate drug-related systems and evaluate predicted 
protein complexes 
69. BioGPS: navigating biological space to predict polypharmacology, off-targeting, and selectivity 
70. BioGPS: The Music for the Chemo- and Bioinformatics Walzer 
71. Bioinformatic and biological avenues for understanding alcohol use disorder 
72. Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of 
interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma 
73. Bioinformatics methods in drug repurposing for Alzheimer's disease 
74. Bioinformatics: Novel Insights from Genomic Information 
75. Biomolecular Network Controllability With Drug Binding Information 
76. BRCA-Monet: a breast cancer specific drug treatment mode-of-action network for treatment effective 
prediction using large scale microarray database 
77. Building a drug-target network and its applications 
78. C-SPADE: a web-tool for interactive analysis and visualization of drug screening experiments 
through compound-specific bioactivity dendrograms 
79. Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common 
therapies 
 




80. Can sodium/hydrogen exchange inhibitors be repositioned for treating attention deficit hyperactivity 
disorder? An in silico approach 
81. Cancer based pharmacogenomics network supported with scientific evidences: from the view of drug 
repurposing 
82. CANDO and the infinite drug discovery frontier 
83. CellFateScout - a bioinformatics tool for elucidating small molecule signaling pathways that drive 
cells in a specific direction 
84. Characterizing protein domain associations by Small-molecule ligand binding 
85. Characterizing the pocketome of Mycobacterium tuberculosis and application in rationalizing 
polypharmacological target selection 
86. Chemical-induced disease extraction via recurrent piecewise convolutional neural networks 
87. ChemMapper: a versatile web server for exploring pharmacology and chemical structure association 
based on molecular 3D similarity method 
88. Chemoprevention agents for melanoma: a path forward into phase 3 clinical trials 
89. Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-kappaB 
signaling 
90. Chloroquine upregulates TRAIL/TRAILR2 expression and potentiates doxorubicin anti-tumor 
activity in thioacetamide-induced hepatocellular carcinoma model 
91. Classifying cancer genome aberrations by their mutually exclusive effects on transcription 
92. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug 
development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis 
93. Clustering based drug-drug interaction networks for possible repositioning of drugs against EGFR 
mutations: Clustering based DDI networks for EGFR mutations 
94. Clustering drug-drug interaction networks with energy model layouts: community analysis and drug 
repurposing 
95. Co-expression Network Approach Reveals Functional Similarities among Diseases Affecting Human 
Skeletal Muscle 
96. Collaboration for rare disease drug discovery research 
97. Combined analysis of gene expression and genome binding profiles identified potential therapeutic 
targets of ciclopirox in Ewing sarcoma 
98. Combined Analysis of Phenotypic and Target-Based Screening in Assay Networks 
 




99. Combining genomic and network characteristics for extended capability in predicting synergistic 
drugs for cancer 
100. Community-driven roadmap for integrated disease maps 
101. Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate 
Synthase Case 
102. Comparing structural and transcriptional drug networks reveals signatures of drug activity and 
toxicity in transcriptional responses 
103. Compensating for literature annotation bias when predicting novel drug-disease relationships 
through Medical Subject Heading Over-representation Profile (MeSHOP) similarity 
104. Complex-disease networks of trait-associated single-nucleotide polymorphisms (SNPs) unveiled by 
information theory 
105. Computational approaches for innovative antiepileptic drug discovery 
106. Computational Approaches for Translational Oncology: Concepts and Patents 
107. Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with 
Repurposing Potential 
108. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That 
Reduces Growth of Hepatocellular Carcinoma Cells InVitro and in Mice by Inhibiting Cell Division 
Cycle 37 Signaling 
109. Computational Discovery of Putative Leads for Drug Repositioning through Drug-Target Interaction 
Prediction 
110. Computational drug repositioning for peripheral arterial disease: prediction of anti-inflammatory and 
pro-angiogenic therapeutics 
111. Computational drug repositioning through heterogeneous network clustering 
112. Computational drug repositioning using low-rank matrix approximation and randomized algorithms 
113. Computational drug repositioning with random walk on a heterogeneous network 
114. Computational drug repurposing to predict approved and novel drug-disease associations 
115. Computational Drug Target Screening through Protein Interaction Profiles 
116. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent 
pathways among FDA-approved compounds 
117. Computational methods and opportunities for phosphorylation network medicine 
 




118. Computational Prediction of Drug?Target Interactions Using Chemical, Biological, and Network 
Features 
119. Computational repositioning and preclinical validation of pentamidine for renal cell cancer 
120. Computational tools for polypharmacology and repurposing 
121. COMPUTING THERAPY FOR PRECISION MEDICINE: COLLABORATIVE FILTERING 
INTEGRATES AND PREDICTS MULTI-ENTITY INTERACTIONS 
122. Concept Modeling-based Drug Repositioning 
123. Constructing Disease Similarity Networks Based on Disease Module Theory 
124. Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for 
myasthenia gravis 
125. Construction of drug network based on side effects and its application for drug repositioning 
126. Context-specific functional module based drug efficacy prediction 
127. Convergent downstream candidate mechanisms of independent intergenic polymorphisms between 
co-classified diseases implicate epistasis among noncoding elements 
128. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for 
children and adolescents with cancer 
129. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole 
130. CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM 
131. Deciphering cellular biological processes to clinical application: a new perspective for Talpha1 
treatment targeting multiple diseases 
132. Deciphering miRNA transcription factor feed-forward loops to identify drug repurposing candidates 
for cystic fibrosis 
133. Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug 
Repurposing Using Transcriptomic Data 
134. Deep-Learning-Based Drug-Target Interaction Prediction 
135. DenguePredict: An Integrated Drug Repositioning Approach towards Drug Discovery for Dengue 
136. Design of a tripartite network for the prediction of drug targets 
137. DeSigN: connecting gene expression with therapeutics for drug repurposing and development 
138. Designing Dietary Recommendations Using System Level Interactomics Analysis and Network-
Based Inference 
 




139. DESM: portal for microbial knowledge exploration systems 
140. Detecting drug promiscuity using Gaussian ensemble screening 
141. Detection of Binding Site Molecular Interaction Field Similarities 
142. Diclofenac Identified as a Kynurenine 3-Monooxygenase Binder and Inhibitor by Molecular 
Similarity Techniques 
143. Diffusion mapping of drug targets on disease signaling network elements reveals drug combination 
strategies 
144. DIGEP-Pred: web service for in silico prediction of drug-induced gene expression profiles based on 
structural formula 
145. Discovering gene re-ranking efficiency and conserved gene-gene relationships derived from gene co-
expression network analysis on breast cancer data 
146. Discovery of drug mode of action and drug repositioning from transcriptional responses 
147. Discovery of Novel Liver-Stage Antimalarials through Quantum Similarity 
148. Discovery of Novel SPAK Inhibitors That Block WNK Kinase Signaling to Cation Chloride 
Transporters 
149. Discovery of Surface Target Proteins Linking Drugs, Molecular Markers, Gene Regulation, Protein 
Networks, and Disease by Using a Web-Based Platform Targets-search 
150. Discovery of the neuroprotective effects of alvespimycin by computational prioritization of potential 
anti-Parkinson agents 
151. Disease classification: from phenotypic similarity to integrative genomics and beyond 
152. DiseaseConnect: a comprehensive web server for mechanism-based disease-disease connections 
153. Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma invivo 
154. DNetDB: The human disease network database based on dysfunctional regulation mechanism 
155. Docking of a novel DNA methyltransferase inhibitor identified from high-throughput screening: 
insights to unveil inhibitors in chemical databases 
156. Docking-based inverse virtual screening: methods, applications, and challenges 
157. DR2DI: a powerful computational tool for predicting novel drug-disease associations 
158. DRABAL: novel method to mine large high-throughput screening assays using Bayesian active 
learning 
 




159. DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the 
chemical-protein interactome 
160. DrPOCS: Drug repositioning based on projection onto convex sets 
161. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking 
(MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-
6/GP130 interface 
162. Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer 
cell lines and pathway mechanisms of resistance 
163. Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key 
164. Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm 
165. Drug repositioning based on triangularly balanced structure for tissue-specific diseases in incomplete 
interactome 
166. Drug repositioning by applying 'expression profiles' generated by integrating chemical structure 
similarity and gene semantic similarity 
167. Drug Repositioning by Integrating Known Disease-Gene and Drug-Target Associations in a Semi-
supervised Learning Model 
168. Drug repositioning by integrating target information through a heterogeneous network model 
169. Drug repositioning by kernel-based integration of molecular structure, molecular activity, and 
phenotype data 
170. Drug repositioning for enzyme modulator based on human metabolite-likeness 
171. Drug repositioning for orphan genetic diseases through Conserved Anticoexpressed Gene Clusters 
(CAGCs 
172. Drug repositioning for prostate cancer: using a data-driven approach to gain new insights 
173. Drug repositioning for schizophrenia and depression/anxiety disorders: A machine learning approach 
leveraging expression data 
174. Drug Repositioning in Glioblastoma: A Pathway Perspective 
175. Drug repositioning in SLE: crowd-sourcing, literature-mining and Big Data analysis 
176. Drug repositioning through incomplete bi-cliques in an integrated drug-target-disease network 
177. Drug Repositioning Through Network Pharmacology 
178. Drug Repositioning through Systematic Mining of Gene Coexpression Networks in Cancer 
 




179. Drug repositioning using disease associated biological processes and network analysis of drug 
targets 
180. Drug repositioning: a machine-learning approach through data integration 
181. Drug repurposing and adverse event prediction using high-throughput literature analysis 
182. Drug repurposing based on drug-drug interaction 
183. Drug Repurposing by Simulating Flow Through Protein-Protein Interaction Networks 
184. Drug Repurposing Using Deep Embeddings of Gene Expression Profiles 
185. Drug repurposing: a better approach for infectious disease drug discovery 
186. Drug repurposing: translational pharmacology, chemistry, computers and the clinic 
187. Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid 
leukemia 
188. Drug similarity search based on combined signatures in gene expression profiles 
189. Drug Synergy Slows Aging and Improves Healthspan through IGF and SREBP Lipid Signaling 
190. Drug target prediction and repositioning using an integrated network-based approach 
191. Drug target prediction using adverse event report systems: a pharmacogenomic approach 
192. Drug Targeting and Biomarkers in Head and Neck Cancers: Insights from Systems Biology 
Analyses 
193. Drug voyager: a computational platform for exploring unintended drug action 
194. Drug-disease association and drug-repositioning predictions in complex diseases using causal 
inference-probabilistic matrix factorization 
195. Drug-target interaction prediction by integrating chemical, genomic, functional and pharmacological 
data 
196. Drug-target interaction prediction by integrating multiview network data 
197. Drug-Target Networks 
198. DrugBank 5.0: a major update to the DrugBank database for 2018 
199. DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-
based drug repurposing 
200. DrugNet: network-based drug-disease prioritization by integrating heterogeneous data 
201. Drugs Polypharmacology by In Silico Methods: New Opportunities in Drug Discovery 
 




202. DSviaDRM: an R package for estimating disease similarity via dysfunctional regulation mechanism 
203. DT-Web: a web-based application for drug-target interaction and drug combination prediction 
through domain-tuned network-based inference 
204. EHFPI: a database and analysis resource of essential host factors for pathogenic infection 
205. Elucidating the modes of action for bioactive compounds in a cell-specific manner by large-scale 
chemically-induced transcriptomics 
206. eMatchSite: sequence order-independent structure alignments of ligand binding pockets in protein 
models 
207. Epigenetic Drug Repositioning for Alzheimer's Disease Based on Epigenetic Targets in Human 
Interactome 
208. Eritoran Suppresses Colon Cancer by Altering a Functional Balance in Toll-like Receptors That 
Bind Lipopolysaccharide 
209. ERK and ROCK functionally interact in a signaling network that is compensationally upregulated in 
Spinal Muscular Atrophy 
210. Establishing a Preclinical Multidisciplinary Board for Brain Tumors 
211. Estimated generic prices for novel treatments for drug-resistant tuberculosis 
212. Exploration and analysis of drug modes of action through feature integration 
213. Exploration of the Anti-Inflammatory Drug Space Through Network Pharmacology: Applications 
for Drug Repurposing 
214. Exploring drug-target interaction networks of illicit drugs 
215. Exploring Polypharmacology in Drug Discovery and Repurposing Using the CANDO Platform 
216. Exploring the anti-proliferative activity of Pelargonium sidoides DC with in silico target 
identification and network pharmacology 
217. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow 
Tumor Growth in Mice 
218. Extracting drug-enzyme relation from literature as evidence for drug drug interaction 
219. Finding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-
based systems biology approach 
220. Finding the targets of a drug by integration of gene expression data with a protein interaction 
network 
 




221. Folate Receptor-Targeted Polymeric Micellar Nanocarriers for Delivery of Orlistat as a Repurposed 
Drug against Triple-Negative Breast Cancer 
222. Folic Acid Exerts Post-Ischemic Neuroprotection In Vitro Through HIF-1alpha Stabilization 
223. Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking 
(MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and 
activator of transcription 3 (STAT3 
224. From gene networks to drugs: systems pharmacology approaches for AUD 
225. From stroke to neurodegenerative diseases: The multi-target neuroprotective effects of 3-n-
butylphthalide and its derivatives 
226. From the Viewpoint of Drug Metabolism Research 
227. Functional genomics of pain in analgesic drug development and therapy 
228. Functional Module Connectivity Map (FMCM): a framework for searching repurposed drug 
compounds for systems treatment of cancer and an application to colorectal adenocarcinoma 
229. Fusing literature and full network data improves disease similarity computation 
230. Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular 
carcinoma 
231. Generating Gene Ontology-Disease Inferences to Explore Mechanisms of Human Disease at the 
Comparative Toxicogenomics Database 
232. Generation and application of drug indication inference models using typed network motif 
comparison analysis 
233. Genetic screens for the control of influenza virus replication: from meta-analysis to drug discovery 
234. Genetics and pharmacology of longevity: the road to therapeutics for healthy aging 
235. GES polypharmacology fingerprints: a novel approach for drug repositioning 
236. Glutamate release inhibitor, Riluzole, inhibited proliferation of human hepatocellular carcinoma cells 
by elevated ROS production 
237. GUILDify: a web server for phenotypic characterization of genes through biological data integration 
and network-based prioritization algorithms 
238. GWAS and drug targets 
239. Harnessing Polypharmacology with Computer-Aided Drug Design and Systems Biology 
240. Heter-LP: A heterogeneous label propagation algorithm and its application in drug repositioning 
 




241. High-content drug screening for rare diseases 
242. Homology modelling and molecular docking of MDR1 with chemotherapeutic agents in non-small 
cell lung cancer 
243. How good are publicly available web services that predict bioactivity profiles for drug repurposing 
244. Human disease-drug network based on genomic expression profiles 
245. Human enterovirus 71 protein interaction network prompts antiviral drug repositioning 
246. Human pathway-based disease network 
247. Human Pluripotent Stem Cell-derived Cortical Neurons for High Throughput Medication Screening 
in Autism: A Proof of Concept Study in SHANK3 Haploinsufficiency Syndrome 
248. Identification of associations between small molecule drugs and miRNAs based on functional 
similarity 
249. Identification of Chemical Inhibitors of beta-Catenin-Driven Liver Tumorigenesis in Zebrafish 
250. Identification of cisapride as new inhibitor of putrescine uptake in Trypanosoma cruzi by combined 
ligand- and structure-based virtual screening 
251. Identification of driver copy number alterations in diverse cancer types and application in drug 
repositioning 
252. Identification of drug candidates and repurposing opportunities through compound-target interaction 
networks 
253. Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in 
Clinical Situations 
254. Identification of key pathways and drug repurposing for anaplastic thyroid carcinoma by integrated 
bioinformatics analysis 
255. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma 
256. Identification of repaglinide as a therapeutic drug for glioblastoma multiforme 
257. Identification of small molecules enhancing autophagic function from drug network analysis 
258. Identify drug repurposing candidates by mining the protein data bank 
259. Identify potential drugs for cardiovascular diseases caused by stress-induced genes in vascular 
smooth muscle cells 
260. Identifying and Tackling Emergent Vulnerability in Drug-Resistant Mycobacteria 
261. Identifying candidate agents for lung adenocarcinoma by walking the human interactome 
 




262. Identifying prognostic features by bottom-up approach and correlating to drug repositioning 
263. Improved anticancer drug response prediction in cell lines using matrix factorization with similarity 
regularization 
264. In silico frameworks for systematic pre-clinical screening of potential anti-leukemia therapeutics 
265. In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a 
Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug 
266. In silico prediction and in vitro and in vivo validation of acaricide fluazuron as a potential inhibitor 
of FGFR3 and a candidate anticancer drug for bladder carcinoma 
267. In silico prediction of chemical mechanism of action via an improved network-based inference 
method 
268. In Silico Receptorome Screening of Antipsychotic Drugs 
269. In Silico target fishing: addressing a "Big Data" problem by ligand-based similarity rankings with 
data fusion 
270. In Silico-Based Repositioning of Phosphinothricin as a Novel Technetium-99m Imaging Probe with 
Potential Anti-Cancer Activity 
271. In vitro analysis of finasteride activity against Candida albicans urinary biofilm formation and 
filamentation 
272. In vitro and in vivo study of hydralazine, a potential anti-angiogenic agent 
273. Incorporating Protein Dynamics Through Ensemble Docking in Machine Learning Models to Predict 
Drug Binding 
274. Inferring disease association using clinical factors in a combinatorial manner and their use in drug 
repositioning 
275. Inferring drug-disease associations based on known protein complexes 
276. Inferring drug-disease associations from integration of chemical, genomic and phenotype data using 
network propagation 
277. Inferring new drug indications using the complementarity between clinical disease signatures and 
drug effects 
278. Inferring new indications for approved drugs via random walk on drug-disease heterogenous 
networks 
279. Inferring novel disease indications for known drugs by semantically linking drug action and disease 
mechanism relationships 
 




280. Inferring novel indications of approved drugs via a learning method with local and global 
consistency 
281. Inflammatory pathway network-based drug repositioning and molecular phenomics 
282. Information exploration system for sickle cell disease and repurposing of hydroxyfasudil 
283. Informed walks: whispering hints to gene hunters inside networks' jungle 
284. Inhibition of EGFR Signaling Protects from Mucormycosis 
285. Inhibition of mTOR/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel 
in oral tongue squamous cell carcinoma 
286. Integrated Computational Analysis of Genes Associated with Human Hereditary Insensitivity to 
Pain. A Drug Repurposing Perspective 
287. Integrating Clinical Phenotype and Gene Expression Data to Prioritize Novel Drug Uses 
288. Integrating systems biology sources illuminates drug action 
289. Integrative bioinformatic analyses of an oncogenomic profile reveal the biology of endometrial 
cancer and guide drug discovery 
290. Integrative Cancer Pharmacogenomics to Infer Large-Scale Drug Taxonomy 
291. Interaction and localization diversities of global and local hubs in human protein-protein interaction 
networks 
292. Introduction: Cancer Gene Networks 
293. ksRepo: a generalized platform for computational drug repositioning 
294. Large-scale Direct Targeting for Drug Repositioning and Discovery 
295. Large-scale integration of heterogeneous pharmacogenomic data for identifying drug mechanism of 
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296. Large-Scale Prediction of Beneficial Drug Combinations Using Drug Efficacy and Target Profiles 
297. Large-Scale Prediction of Drug-Target Interaction: a Data-Centric Review 
298. Learning disease relationships from clinical drug trials 
299. Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, 
Milan 
300. Leveraging 3D chemical similarity, target and phenotypic data in the identification of drug-protein 
and drug-adverse effect associations 
 




301. Link prediction in drug-target interactions network using similarity indices 
302. Linking PharmGKB to phenotype studies and animal models of disease for drug repurposing 
303. Liraglutide modulates gut microbiota and reduces NAFLD in obese mice 
304. Literature-based discovery of new candidates for drug repurposing 
305. Logical comparison over RDF resources in bio-informatics 
306. LRSSL: predict and interpret drug-disease associations based on data integration using sparse 
subspace learning 
307. Luteolin Impacts on the DNA Damage Pathway in Oral Squamous Cell Carcinoma 
308. Macromolecular target prediction by self-organizing feature maps 
309. Management of drug-resistant TB in patients with HIV co-infection 
310. Mantra 2.0: an online collaborative resource for drug mode of action and repurposing by network 
analysis 
311. Master Regulators Connectivity Map: A Transcription Factors-Centered Approach to Drug 
Repositioning 
312. Matrix Factorization-Based Prediction of Novel Drug Indications by Integrating Genomic Space 
313. MD-Miner: a network-based approach for personalized drug repositioning 
314. Medical concept normalization in social media posts with recurrent neural networks 
315. MeSHDD: Literature-based drug-drug similarity for drug repositioning 
316. Metabolic reprogramming in clear cell renal cell carcinoma 
317. Metformin treatment ameliorates diabetes-associated decline in hippocampal neurogenesis and 
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318. Metformin Use in Relation With Survival Outcomes of Patients With Renal Cell Carcinoma 
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320. Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of 
retinoblastoma protein in renal cell carcinoma 
321. Mining integrated semantic networks for drug repositioning opportunities 
322. Mining significant substructure pairs for interpreting polypharmacology in drug-target network 
 




323. miREFRWR: a novel disease-related microRNA-environmental factor interactions prediction 
method 
324. Misfolded proteins: from little villains to little helpers in the fight against cancer 
325. MOST: most-similar ligand based approach to target prediction 
326. Mouse model phenotypes provide information about human drug targets 
327. MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that 
Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia 
328. MTGO: PPI Network Analysis Via Topological and Functional Module Identification 
329. Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a 
multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of 
three neuroprotective drugs in secondary progressive multiple sclerosis 
330. Multiscale modelling of relationships between protein classes and drug behavior across all diseases 
using the CANDO platform 
331. Neighbours of cancer-related proteins have key influence on pathogenesis and could increase the 
drug target space for anticancer therapies 
332. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces 
endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo 
333. Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug 
combinations 
334. Network and matrix analysis of the respiratory disease interactome 
335. Network approaches to drug discovery 
336. Network biology concepts in complex disease comorbidities 
337. Network insights into the genes regulated by hepatocyte nuclear factor 4 in response to drug induced 
perturbations: a review 
338. Network measures for chemical library design 
339. Network medicine in disease analysis and therapeutics 
340. Network mirroring for drug repositioning 
341. Network predicting drug's anatomical therapeutic chemical code 
342. Network-assisted prediction of potential drugs for addiction 
343. Network-based analysis of transcriptional profiles from chemical perturbations experiments 
 




344. Network-based approach to prediction and population-based validation of in silico drug repurposing 
345. Network-Based Drug Discovery: Coupling Network Pharmacology with Phenotypic Screening for 
Neuronal Excitability 
346. Network-based drug ranking and repositioning with respect to DrugBank therapeutic categories 
347. Network-based drug repositioning 
348. Network-based drug repositioning: A novel strategy for discovering potential antidepressants and 
their mode of action 
349. Network-based in silico drug efficacy screening 
350. Network-based inference methods for drug repositioning 
351. Network-based machine learning and graph theory algorithms for precision oncology 
352. Network-based prediction and knowledge mining of disease genes 
353. NetwoRx: connecting drugs to networks and phenotypes in Saccharomyces cerevisiae 
354. Neuroprotective Drug for Nerve Trauma Revealed Using Artificial Intelligence 
355. New drugs and perspectives for new anti-tuberculosis regimens 
356. New HSP27 inhibitors efficiently suppress drug resistance development in cancer cells 
357. Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal 
Cell Cancer Cells 
358. No association between metformin use and survival in patients with pancreatic cancer: An 
observational cohort study 
359. Novel modeling of cancer cell signaling pathways enables systematic drug repositioning for distinct 
breast cancer metastases 
360. Novel putative drugs and key initiating genes for neurodegenerative disease determined using 
network-based genetic integrative analysis 
361. Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and 
redox capacity 
362. Nutrients, neurogenesis and brain ageing: From disease mechanisms to therapeutic opportunities 
363. Old friends in new guise: repositioning of known drugs with structural bioinformatics 
364. On the Integration of In Silico Drug Design Methods for Drug Repurposing 
365. One reporter for in-cell activity profiling of majority of protein kinase oncogenes 
 




366. Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases 
367. Orphan receptor ligand discovery by pickpocketing pharmacological neighbors 
368. p73 as a pharmaceutical target for cancer therapy 
369. Pathogenesis of thrombosis: cellular and pharmacogenetic contributions 
370. Pathogenicity phenomena in three model systems: from network mining to emerging system-level 
properties 
371. Pathology assessment is necessary to validate translational endpoints in preclinical aging studies 
372. Pathway and network-based strategies to translate genetic discoveries into effective therapies 
373. Pathway-based Bayesian inference of drug-disease interactions 
374. Pathway-based drug repositioning using causal inference 
375. Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia 
Patients 
376. Personalised drug repositioning for Clear Cell Renal Cell Carcinoma using gene expression 
377. Personalization of cancer treatment using predictive simulation 
378. Personalized drug discovery: HCA approach optimized for rare diseases at Tel Aviv University 
379. Pharmacological use of a novel scaffold, anomeric N,N-diarylamino tetrahydropyran: molecular 
similarity search, chemocentric target profiling, and experimental evidence 
380. Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French 
medical pharmacology 
381. Phenotypic screening of the Prestwick library for treatment of Parkinson's tremor symptoms using a 
humanized quantitative systems pharmacology platform 
382. Polypharmacological Drug-target Inference for Chemogenomics 
383. Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective 
384. Polypharmacology rescored: protein-ligand interaction profiles for remote binding site similarity 
assessment 
385. Polypharmacology: challenges and opportunities in drug discovery 
386. Possible targets on carcinoma for bMAb retargeting of lymphocyte or drug cytotoxicity 
387. PREDICT: a method for inferring novel drug indications with application to personalized medicine 
388. Predicting and characterizing selective multiple drug treatments for metabolic diseases and cancer 
 




389. Predicting drug-disease associations and their therapeutic function based on the drug-disease 
association bipartite network 
390. Predicting drug-disease interactions by semi-supervised graph cut algorithm and three-layer data 
integration 
391. Predicting drug-target interaction for new drugs using enhanced similarity measures and super-target 
clustering 
392. Predicting drug-target interactions using probabilistic matrix factorization 
393. Predicting drug-target interactions using restricted Boltzmann machines 
394. Predicting Drug-Target Interactions via Within-Score and Between-Score 
395. Predicting Drug-Target Interactions With Multi-Information Fusion 
396. Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang 
Wan as a case study 
397. Predicting Potential Drugs for Breast Cancer based on miRNA and Tissue Specificity 
398. Predicting targeted polypharmacology for drug repositioning and multi- target drug discovery 
399. Prediction of chemical-protein interactions network with weighted network-based inference method 
400. Prediction of chemical-protein interactions: multitarget-QSAR versus computational chemogenomic 
methods 
401. Prediction of drug's Anatomical Therapeutic Chemical (ATC) code by integrating drug-domain 
network 
402. Prediction of drug-target interaction by label propagation with mutual interaction information 
derived from heterogeneous network 
403. Prediction of drug-target interactions and drug repositioning via network-based inference 
404. Prediction of drug-target interactions for drug repositioning only based on genomic expression 
similarity 
405. Prediction of drugs having opposite effects on disease genes in a directed network 
406. Prediction of new drug indications based on clinical data and network modularity 
407. Prediction of Non-coding RNAs as Drug Targets 
408. Prediction of novel drug indications using network driven biological data prioritization and 
integration 
 




409. Prediction of Novel Drugs and Diseases for Hepatocellular Carcinoma Based on Multi-Source 
Simulated Annealing Based Random Walk 
410. Prediction of Novel Drugs for Hepatocellular Carcinoma Based on Multi-Source Random Walk 
411. Prediction of off-target drug effects through data fusion 
412. Prediction of polypharmacological profiles of drugs by the integration of chemical, side effect, and 
therapeutic space 
413. Prediction of structure of human WNT-CRD (FZD) complex for computational drug repurposing 
414. PROMISCUOUS: a database for network-based drug-repositioning 
415. ProphTools: general prioritization tools for heterogeneous biological networks 
416. Protein localization vector propagation: a method for improving the accuracy of drug repositioning 
417. Protein-ligand-based pharmacophores: generation and utility assessment in computational ligand 
profiling 
418. Proximal Pathway Enrichment Analysis for Targeting Comorbid Diseases via Network 
Endopharmacology 
419. Pyrvinium Sensitizes Clear Cell Renal Cell Carcinoma Response to Chemotherapy Via Casein 
Kinase 1alpha-Dependent Inhibition of Wnt/beta-Catenin 
420. RANKS: a flexible tool for node label ranking and classification in biological networks 
421. Rare Diseases: Drug Discovery and Informatics Resource 
422. Rational drug repositioning guided by an integrated pharmacological network of protein, disease and 
drug 
423. Re-positioning protein-kinase inhibitors against schistosomiasis 
424. Recent Advances in the Development of Pharmaceutical Agents for Metabolic Disorders: A 
Computational Perspective 
425. Recent advances in the machine learning-based drug-target interaction prediction 
426. Recommendation Techniques for Drug-Target Interaction Prediction and Drug Repositioning 
427. Rectifying cancer drug discovery through network pharmacology 
428. Registered report: Discovery and preclinical validation of drug indications using compendia of 
public gene expression data 
429. Relating anatomical therapeutic indications by the ensemble similarity of drug sets 
 




430. Replication Study: Discovery and preclinical validation of drug indications using compendia of 
public gene expression data 
431. Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant 
lesions 
432. Repositioning drugs by targeting network modules: a Parkinson's disease case study 
433. Repositioning of DHFR Inhibitors 
434. Repositioning of Endonuclear Receptors Binders as Potential Antibacterial and Antifungal Agents. 
Eptyloxim: A Potential and Novel Gyrase B and Cytochrome Cyp51 Inhibitor 
435. Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer 
436. REPRODUCIBLE DRUG REPURPOSING: WHEN SIMILARITY DOES NOT SUFFICE 
437. RepTB: a gene ontology based drug repurposing approach for tuberculosis 
438. Repurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic medical records 
439. Repurposed FDA-Approved drug sorafenib reduces replication of Venezuelan equine encephalitis 
virus and other alphaviruses 
440. Repurposing and Rescuing of Mibefradil, an Antihypertensive, for Cancer: A Case Study 
441. Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent 
442. Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection 
443. Repurposing itraconazole as an anticancer agent 
444. Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent 
antitubercular agents 
445. Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast 
cancer 
446. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C 
virus infection 
447. Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-
Lindau disease 
448. Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus 
449. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell 
carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis 
450. Research advance in the drug target prediction based on chemoinformatics 
 




451. Research and development of anti-Alzheimer's disease drugs: an update from the perspective of 
technology flows 
452. Review and comparative assessment of similarity-based methods for prediction of drug-protein 
interactions in the druggable human proteome 
453. Revisiting Antipsychotic Drug Actions Through Gene Networks Associated With Schizophrenia 
454. Revisiting Connectivity Map from a gene co-expression network analysis 
455. Ribavirin as a tri-targeted antitumor repositioned drug 
456. Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy 
457. SCMBYK: prediction and characterization of bacterial tyrosine-kinases based on propensity scores 
of dipeptides 
458. Scoring multiple features to predict drug disease associations using information fusion and 
aggregation 
459. SDTNBI: an integrated network and chemoinformatics tool for systematic prediction of drug-target 
interactions and drug repositioning 
460. SELF-BLM: Prediction of drug-target interactions via self-training SVM 
461. SemFunSim: a new method for measuring disease similarity by integrating semantic and gene 
functional association 
462. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in 
cancer cell lines 
463. SMAP-WS: a parallel web service for structural proteome-wide ligand-binding site comparison 
464. Some Remarks on Prediction of Drug-Target Interaction with Network Models 
465. Sorafenib Impedes Rift Valley Fever Virus Egress by Inhibiting Valosin-Containing Protein 
Function in the Cellular Secretory Pathway 
466. SPIDR: small-molecule peptide-influenced drug repurposing 
467. Statistically controlled identification of differentially expressed genes in one-to-one cell line 
comparisons of the CMAP database for drug repositioning 
468. Steroids-specific target library for steroids target prediction 
469. Structural analysis of dihydrofolate reductases enables rationalization of antifolate binding affinities 
and suggests repurposing possibilities 
 




470. Structural re-positioning, in silico molecular modelling, oxidative degradation, and biological 
screening of linagliptin as adenosine 3 receptor (ADORA3) modulators targeting hepatocellular 
carcinoma 
471. Substrate-driven mapping of the degradome by comparison of sequence logos 
472. Synergistic drug combinations from electronic health records and gene expression 
473. Systematic drug repositioning for a wide range of diseases with integrative analyses of phenotypic 
and molecular data 
474. Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian 
Cancer 
475. Systematic integration of biomedical knowledge prioritizes drugs for repurposing 
476. Systematic Prioritization of Druggable Mutations in 5000 Genomes Across 16 Cancer Types Using a 
Structural Genomics-based Approach 
477. Systematical analysis of lncRNA-mRNA competing endogenous RNA network in breast cancer 
subtypes 
478. Systems approach to the pharmacological actions of HDAC inhibitors reveals EP300 activities and 
convergent mechanisms of regulation in diabetes 
479. Systems biological understanding of the regulatory network and the possible therapeutic strategies 
for vascular calcification 
480. Systems Biology-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap 
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486. Target-Based Drug Repositioning Using Large-Scale Chemical-Protein Interactome Data 
487. Target-similarity search using Plasmodium falciparum proteome identifies approved drugs with anti-
malarial activity and their possible targets 
 




488. TargetHunter: an in silico target identification tool for predicting therapeutic potential of small 
organic molecules based on chemogenomic database 
489. Targeting epithelial-mesenchymal plasticity in cancer: clinical and preclinical advances in therapy 
and monitoring 
490. Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt/mTOR and inducing 
oxidative stress 
491. Targeting Phosphatidylinositol 4-Kinase IIIalpha for Radiosensitization: A Potential Model of Drug 
Repositioning Using an Anti-Hepatitis C Viral Agent 
492. The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod 
493. The aryl hydrocarbon receptor is required for induction of p21cip1/waf1 expression and growth 
inhibition by SU5416 in hepatoma cells 
494. The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell 
carcinoma 
495. The extraction of drug-disease correlations based on module distance in incomplete human 
interactome 
496. The human disease network in terms of dysfunctional regulatory mechanisms 
497. The neuroimmune transcriptome and alcohol dependence: potential for targeted therapies 
498. The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in 
hepatocellular carcinoma 
499. The pain interactome: connecting pain-specific protein interactions 
500. The polypharmacology of natural products 
501. The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance 
in cancer cell lines 
502. The role of drug profiles as similarity metrics: applications to repurposing, adverse effects detection 
and drug-drug interactions 
503. The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in 
hepatocellular carcinoma 
504. Therapeutic compounds for Cushing's syndrome: a patent review (2012-2016 
505. Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by 
inhibiting Wnt/beta-catenin signaling 
 




506. Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial 
agent 
507. Thiopurine Drugs Repositioned as Tyrosinase Inhibitors 
508. Tigecycline targets nonsmall cell lung cancer through inhibition of mitochondrial function 
509. Tools for in silico target fishing 
510. Toward drug repurposing in epigenetics: olsalazine as a hypomethylating compound active in a 
cellular context 
511. Toward more realistic drug-target interaction predictions 
512. Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems 
Pharmacology 
513. Towards drug repositioning: a unified computational framework for integrating multiple aspects of 
drug similarity and disease similarity 
514. Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine 
Approach 
515. Transcriptional data: a new gateway to drug repositioning 
516. Transcriptomic-Guided Drug Repositioning Supported by a New Bioinformatics Search Tool: 
geneXpharma 
517. Translating Mendelian and complex inheritance of Alzheimer's disease genes for predicting unique 
personal genome variants 
518. Trends of Clinical Trials for Drug Development in Rare Diseases 
519. Trimodal Therapy: Combining Hyperthermia with Repurposed Bexarotene and Ultrasound for 
Treating Liver Cancer 
520. Tuberculosis: From an incurable scourge to a curable disease - journey over a millennium 
521. Unveiling the role of network and systems biology in drug discovery 
522. Updates on drug-target network; facilitating polypharmacology and data integration by growth of 
DrugBank database 
523. Utilizing Cancer - Functional Gene Set - Compound Networks to Identify Putative Drugs for Breast 
Cancer 
524. Vinorelbine rescue therapy for dogs with primary urinary bladder carcinoma 
525. Virtual Screening against Phosphoglycerate Kinase 1 in Quest of Novel Apoptosis Inhibitors 
 




526. Virtual screening and repositioning of inconclusive molecules of beta-lactamase Bioassays-A data 
mining approach 
527. VisANT 4.0: Integrative network platform to connect genes, drugs, diseases and therapies 
528. Vitamin K and hepatocellular carcinoma: The basic and clinic 
529. What do the genetic association data say about the high risk of suicide in people with depression? A 
novel network-based approach to find common molecular basis for depression and suicidal behavior and 
related therapeutic targets 









FACTOR 33. Repurposing Antipsychotic Drugs 
1. A chemical genomics approach to drug reprofiling in oncology: Antipsychotic drug risperidone as a 
potential adenocarcinoma treatment 
2. A comparative study of disease genes and drug targets in the human protein interactome 
3. A Critical Review of Repurposing Apomorphine for Smoking Cessation 
4. A current perspective on the oncopreventive and oncolytic properties of selective serotonin reuptake 
inhibitors 
5. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer 
and other neuroendocrine tumors 
6. A genomics-based systems approach towards drug repositioning for rheumatoid arthritis 
7. A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future 
Research 
8. A rapid and affordable screening platform for membrane protein trafficking 
9. A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity 
10. A systems-level analysis of drug-target-disease associations for drug repositioning 
11. A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case 
12. Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease 
13. Activation of PP2A by perphenazine induces apoptosis in T-ALL 
14. Acute oxidant damage promoted on cancer cells by amitriptyline in comparison with some common 
chemotherapeutic drugs 
15. Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas 
16. Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry 
17. Antidepressants in the Treatment of Functional Dyspepsia: A Systematic Review and Meta-Analysis 
18. Antidepressants, antimicrobials or both? Gut microbiota dysbiosis in depression and possible 
implications of the antimicrobial effects of antidepressant drugs for antidepressant effectiveness 
19. Antifungal Phenothiazines: Optimization, Characterization of Mechanism, and Modulation of 
Neuroreceptor Activity 
20. Approaches for establishing the function of regulatory genetic variants involved in disease 
 




21. Aripiprazole, an Antipsychotic and Partial Dopamine Agonist, Inhibits Cancer Stem Cells and 
Reverses Chemoresistance 
22. Buspirone Counteracts MK-801-Induced Schizophrenia-Like Phenotypes through Dopamine D3 
Receptor Blockade 
23. Calcium channel blockers as drug repurposing candidates for gestational diabetes: Mining large scale 
genomic and electronic health records data to repurpose medications 
24. Cancer based pharmacogenomics network supported with scientific evidences: from the view of drug 
repurposing 
25. Case-specific potentiation of glioblastoma drugs by pterostilbene 
26. Cell-based screening identifies paroxetine as an inhibitor of diabetic endothelial dysfunction 
27. Chapter 7: Pharmacogenomics 
28. Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-Joseph 
Disease 
29. Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia 
30. Clomipramine kills Trypanosoma brucei by apoptosis 
31. Combating Multidrug-Resistant Pathogens with Host-Directed Nonantibiotic Therapeutics 
32. Complex-disease networks of trait-associated single-nucleotide polymorphisms (SNPs) unveiled by 
information theory 
33. Connecting genetics and gene expression data for target prioritisation and drug repositioning 
34. Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs 
35. Discovery of novel polyamine analogs with anti-protozoal activity by computer guided drug 
repositioning 
36. DiseaseConnect: a comprehensive web server for mechanism-based disease-disease connections 
37. Dopamine antagonists for treatment resistance in autism spectrum disorders: review and focus on 
BDNF stimulators loxapine and amitriptyline 
38. Dopaminergic Regulation of Innate Immunity: a Review 
39. Drug enrichment and discovery from schizophrenia genome-wide association results: an analysis and 
visualisation approach 
40. Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease 
 




41. Drug repositioning for schizophrenia and depression/anxiety disorders: A machine learning approach 
leveraging expression data 
42. Drug repurposing and emerging adjunctive treatments for schizophrenia 
43. Drug repurposing for Leishmania. Molecular basis of the leishmanicidal activity of the antidepressant 
sertraline 
44. Drug repurposing may generate novel approaches to treating depression 
45. Drug Repurposing Screening Identifies Novel Compounds That Effectively Inhibit Toxoplasma 
gondii Growth 
46. Drug Side Effect Profiles as Molecular Descriptors for Predictive Modeling of Target Bioactivity 
47. Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed Drugs Elicits 
Cell-Lethal Autophagy and Therapeutic Benefit 
48. Effects of lorcaserin and buspirone, administered alone and as a mixture, on cocaine self-
administration in male and female rhesus monkeys 
49. Enhancing the Promise of Drug Repositioning through Genetics 
50. Evaluation of Crimean-Congo hemorrhagic fever virus in vitro inhibition by chloroquine and 
chlorpromazine, two FDA approved molecules 
51. Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching 
52. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow 
Tumor Growth in Mice 
53. FDA-approved drugs selected using virtual screening bind specifically to G-quadruplex DNA 
54. Filling the gap in CNS drug development: evaluation of the role of drug repurposing 
55. Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin 
polymerization 
56. From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic 
Small Cell Lung Cancer (SCLC 
57. From the era of genome analysis to the era of genomic drug discovery: a pioneering example of 
rheumatoid arthritis 
58. Future Directions of Genomics Research in Rheumatic Diseases 
59. Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular 
carcinoma 
 




60. Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities 
in schizophrenia 
61. Genetic and molecular aspects of hypertension 
62. Genetics of rheumatoid arthritis contributes to biology and drug discovery 
63. Genome-wide association analyses for lung function and chronic obstructive pulmonary disease 
identify new loci and potential druggable targets 
64. Genome-wide association studies of cancer: current insights and future perspectives 
65. GWAS of Rheumatoid Arthritis and Drug Discovery 
66. High-throughput screen of drug repurposing library identifies inhibitors of Sarcocystis neurona 
growth 
67. Histamine H1-receptor antagonists against Leishmania (L.) infantum: an in vitro and in vivo 
evaluation using phosphatidylserine-liposomes 
68. Human Pluripotent Stem Cell-derived Cortical Neurons for High Throughput Medication Screening in 
Autism: A Proof of Concept Study in SHANK3 Haploinsufficiency Syndrome 
69. Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug 
70. Identification of Chemical Inhibitors of beta-Catenin-Driven Liver Tumorigenesis in Zebrafish 
71. Identification of novel therapeutics for complex diseases from genome-wide association data 
72. Identification of ST3AGL4, MFHAS1, CSNK2A2 and CD226 as loci associated with systemic lupus 
erythematosus (SLE) and evaluation of SLE genetics in drug repositioning 
73. Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell 
agent using public gene expression data 
74. In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-
melanoma drug, for Parkinson's disease 
75. In Silico Receptorome Screening of Antipsychotic Drugs 
76. In silico repurposing of antipsychotic drugs for Alzheimer's disease 
77. Insights into the Modulation of Dopamine Transporter Function by Amphetamine, Orphenadrine, and 
Cocaine Binding 
78. Integrating systems biology sources illuminates drug action 
79. Interactions of Selective Serotonin Reuptake Inhibitors with beta-Amyloid 
80. Ketamine for treatment-resistant unipolar depression: current evidence 
 




81. Ketamine: repurposing and redefining a multifaceted drug 
82. Ketanserin, an antidepressant, exerts its antileishmanial action via inhibition of 3-hydroxy-3-
methylglutaryl coenzyme A reductase (HMGR) enzyme of Leishmania donovani 
83. Learning Opportunities for Drug Repositioning via GWAS and PheWAS Findings 
84. Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced 
depression model via improving hippocampal neural plasticity 
85. Low Dose Loxapine: Neuromotor Side Effects and Tolerability in Autism Spectrum Disorders 
86. Loxapine add-on for adolescents and adults with autism spectrum disorders and irritability 
87. Medication discovery for addiction: translating the dopamine D3 receptor hypothesis 
88. Medications for alcohol use disorders: An overview 
89. Meta-analysis of human gene expression in response to Mycobacterium tuberculosis infection reveals 
potential therapeutic targets 
90. Mining mouse behavior for patterns predicting psychiatric drug classification 
91. Molecular investigations of protriptyline as a multi-target directed ligand in Alzheimer's disease 
92. Molecular mechanisms underlying variations in lung function: a systems genetics analysis 
93. Mood, stress and longevity: convergence on ANK3 
94. Mucuna pruriens (L.) DC chemo sensitize human breast cancer cells via downregulation of prolactin-
mediated JAK2/STAT5A signaling 
95. Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm 
phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three 
neuroprotective drugs in secondary progressive multiple sclerosis 
96. Network-based drug repositioning: A novel strategy for discovering potential antidepressants and 
their mode of action 
97. Neuroleptic drugs in the treatment of tuberculosis: Minimal inhibitory concentrations of different 
phenothiazines against Mycobacterium tuberculosis 
98. Neuron-specific regulation of class I PI3K catalytic subunits and their dysfunction in brain disorders 
99. New Antimicrobial Approaches: Reuse of Old Drugs 
100. New developments in the management of neurogenic orthostatic hypotension 
101. New drug candidates for depression - a nationwide population-based study 
 




102. New HSP27 inhibitors efficiently suppress drug resistance development in cancer cells 
103. New indications for existing drugs; repurposing in psychiatry and addiction medicine 
104. New pathogenic insights into rheumatoid arthritis 
105. New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria 
106. New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate 
107. Novel putative drugs and key initiating genes for neurodegenerative disease determined using 
network-based genetic integrative analysis 
108. Novel therapeutics for coronary artery disease from genome-wide association study data 
109. Olanzapine, an Atypical Antipsychotic, Inhibits Survivin Expression and Sensitizes Cancer Cells to 
Chemotherapeutic Agents 
110. Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial 
infarction 
111. Pharmacological exploitation of the phenothiazine antipsychotics to develop novel antitumor agents-
A drug repurposing strategy 
112. Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective 
drugs 
113. Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of 
tauopathy 
114. PhenoPredict: A disease phenome-wide drug repositioning approach towards schizophrenia drug 
discovery 
115. Potential repurposing of known drugs as potent bacterial beta-glucuronidase inhibitors 
116. Preclinical Evidence Supporting Early Initiation of Citalopram Treatment in Machado-Joseph 
Disease 
117. Prediction of polypharmacological profiles of drugs by the integration of chemical, side effect, and 
therapeutic space 
118. Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine 
for the treatment of malignant glioma 
119. Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine 
tuberculosis 
120. Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1 
 




121. Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of 
cytochrome c oxidase bearing the COX4-1 regulatory subunit 
122. Repositioning drugs by targeting network modules: a Parkinson's disease case study 
123. Repositioning Microtubule Stabilizing Drugs for Brain Disorders 
124. Repositioning of the antipsychotic trifluoperazine: Synthesis, biological evaluation and in silico 
study of trifluoperazine analogs as anti-glioblastoma agents 
125. Repurposed drugs for the treatment of schizophrenia and bipolar disorders 
126. Repurposing Drugs for Cognition in Schizophrenia 
127. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome 
coronavirus infection 
128. Repurposing of prochlorperazine for use against dengue virus infection 
129. Repurposing psychiatric drugs as anti-cancer agents 
130. Repurposing Thioridazine (TDZ) as an anti-inflammatory agent 
131. Revisiting Antipsychotic Drug Actions Through Gene Networks Associated With Schizophrenia 
132. Schizophrenia interactome with 504 novel protein-protein interactions 
133. Sequence Analysis of Drug Target Genes with Suicidal Behavior in Bipolar Disorder Patients 
134. Sertraline, Paroxetine, and Chlorpromazine Are Rapidly Acting Anthelmintic Drugs Capable of 
Clinical Repurposing 
135. Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology 
136. Sphingolipids as targets for inhalation treatment of cystic fibrosis 
137. Spironolactone is an antagonist of NRG1-ERBB4 signaling and schizophrenia-relevant 
endophenotypes in mice 
138. Sulforaphane Prevents Neuronal Apoptosis and Memory Impairment in Diabetic Rats 
139. Sympathoadrenergic modulation of hematopoiesis: a review of available evidence and of therapeutic 
perspectives 
140. Symposium 2-1The autoimmunome: Similarities and differences among genetic susceptibility to 
common immune-related diseases 
141. Symptomatic thinking: the current state of Phase III and IV clinical trials for cognition in 
schizophrenia 
 




142. Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma 
cruzi 
143. Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic 
144. Teaching an old dog new tricks: drug repositioning in small cell lung cancer 
145. Tegaserod mimics the neurostimulatory glycan polysialic acid and promotes nervous system repair 
146. The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to 
inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy 
147. The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-
enhanced platelet function 
148. The druggable genome and support for target identification and validation in drug development 
149. The effects of buspirone on occupancy of dopamine receptors and the rat gambling task 
150. Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis 
151. Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide 
152. Topical phenytoin for the treatment of neuropathic pain 
153. Transcriptomic profiling of human hippocampal progenitor cells treated with antidepressants and its 
application in drug repositioning 
154. Translating Mendelian and complex inheritance of Alzheimer's disease genes for predicting unique 
personal genome variants 
155. Tricyclic antidepressants inhibit Candida albicans growth and biofilm formation 
156. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug 
resistance of lung cancer 
157. Use of genome-wide association studies for cancer research and drug repositioning 
158. Valproic acid mediates miR-124 to down-regulate a novel protein target, GNAI1 
159. What do the genetic association data say about the high risk of suicide in people with depression? A 
novel network-based approach to find common molecular basis for depression and suicidal behavior and 








FACTOR 34. Multiple Ligand Simultaneous Docking and Drug Repositioning for Cancer Therapy 
1. 2-acylamino-5-nitro-1,3-thiazoles: preparation and in vitro bioevaluation against four neglected 
protozoan parasites 
2. 3, 5, 3'-Triiodothyroacetic acid (TRIAC) is an anti-inflammatory drug that targets toll-like receptor 2 
3. 4-Acetoxyphenol Prevents RPE Oxidative Stress-Induced Necrosis by Functioning as an NRF2 
Stabilizer 
4. A Blockade of IGF Signaling Sensitizes Human Ovarian Cancer Cells to the Anthelmintic 
Niclosamide-Induced Anti-Proliferative and Anticancer Activities 
5. A cellular genetics approach identifies gene-drug interactions and pinpoints drug toxicity pathway 
nodes 
6. A Combination of Three Repurposed Drugs Administered at Reperfusion as a Promising Therapy for 
Postischemic Brain Injury 
7. A current perspective on the oncopreventive and oncolytic properties of selective serotonin reuptake 
inhibitors 
8. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer 
and other neuroendocrine tumors 
9. A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor 
Ponatinib for Repurposing in Neuroblastoma Therapy 
10. A machine learning-based method to improve docking scoring functions and its application to drug 
repurposing 
11. A new niclosamide derivatives-B17 can inhibit urological cancers growth through apoptosis-related 
pathway 
12. A novel anti-cancer role of beta-apopicropodophyllin against non-small cell lung cancer cells 
13. A novel application of furazolidone: anti-leukemic activity in acute myeloid leukemia 
14. A screening cascade to identify ERbeta ligands 
15. A statin-regulated microRNA represses human c-Myc expression and function 
16. A systems pharmacology-oriented discovery of a new therapeutic use of the TCM formula 
Liuweiwuling for liver failure 
17. A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case 
18. Accidental interaction between PDZ domains and diclofenac revealed by NMR-assisted virtual 
screening 
 




19. Acute oxidant damage promoted on cancer cells by amitriptyline in comparison with some common 
chemotherapeutic drugs 
20. Adaptive mitochondrial reprogramming and resistance to PI3K therapy 
21. Adjuvant potential of selegiline in attenuating organ dysfunction in septic rats with peritonitis 
22. Advances in Developing Therapies to Combat Zika Virus: Current Knowledge and Future 
Perspectives 
23. Aging-related Repositioned Drugs, Donepezil and Sildenafil Citrate, Increase Apoptosis of Anti-
mitotic Drug-resistant KBV20C Cells Through Different Molecular Mechanisms 
24. Albendazole as a promising molecule for tumor control 
25. Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft 
model 
26. Alendronate inhalation ameliorates elastase-induced pulmonary emphysema in mice by induction of 
apoptosis of alveolar macrophages 
27. An in vitro test system for compounds that modulate human inflammatory macrophage polarization 
28. Analysis of drug binding pockets and repurposing opportunities for twelve essential enzymes of 
ESKAPE pathogens 
29. Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T-cell 
leukemia cells 
30. Angiotensin II type 1 receptor blockers increase tolerance of cells to copper and cisplatin 
31. Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via 
oxidative stress-mediated mTOR inhibition 
32. Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes 
differentiation of head and neck squamous cell carcinoma (HNSCC 
33. Anti-infectious drug repurposing using an integrated chemical genomics and structural systems 
biology approach 
34. Antibiotic drug levofloxacin inhibits proliferation and induces apoptosis of lung cancer cells through 
inducing mitochondrial dysfunction and oxidative damage 
35. Antibiotic drug rifabutin is effective against lung cancer cells by targeting the eIF4E-beta-catenin axis 
36. Anticancer Properties of Fenofibrate: A Repurposing Use 
37. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis 
 




38. Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein 
phosphatase 2A in non-small cell lung cancer cells 
39. Antimalarial drug mefloquine inhibits nuclear factor kappa B signaling and induces apoptosis in 
colorectal cancer cells 
40. Antiviral Drug Ribavirin Targets Thyroid Cancer Cells by Inhibiting the eIF4E-beta-Catenin Axis 
41. Application of the 4D fingerprint method with a robust scoring function for scaffold-hopping and 
drug repurposing strategies 
42. Appraisal of mechanisms of radioprotection and therapeutic approaches of radiation countermeasures 
43. Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do 
44. Assessing protein kinase target similarity: Comparing sequence, structure, and cheminformatics 
approaches 
45. Assessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer 
46. Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and 
displayed synergistic lethality with piperlongumine in gastric cancer 
47. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical 
activity against chronic lymphocytic leukemia 
48. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell 
lung cancer cells 
49. Auranofin: repurposing an old drug for a golden new age 
50. Autophagy in HIV-induced T cell death 
51. Autophagy Induced by Naftopidil Inhibits Apoptosis of Human Gastric Cancer Cells 
52. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy 
53. Benchmarking human protein complexes to investigate drug-related systems and evaluate predicted 
protein complexes 
54. Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2 
55. beta3-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in 
a repositioning clinical drug development project 
56. Beyond Channel Activity: Protein-Protein Interactions Involving Viroporins 
57. BioGPS: The Music for the Chemo- and Bioinformatics Walzer 
 




58. Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of 
interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma 
59. Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer 
resistance to EGFR therapy 
60. Bithionol inhibits ovarian cancer cell growth in vitro - studies on mechanism(s) of action 
61. Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the 
EIS regimen 
62. Blocking IL-6/GP130 signaling inhibits cell viability/proliferation, glycolysis, and colony forming 
activity in human pancreatic cancer cells 
63. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant 
mammary tissues of MMTV-erbB-2 transgenic mice 
64. Cancer: fundamentals behind pH targeting and the double-edged approach 
65. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer 
66. Carglumic acid promotes apoptosis and suppresses cancer cell proliferation in vitro and in vivo 
67. CaV channels and cancer: canonical functions indicate benefits of repurposed drugs as cancer 
therapeutics 
68. Chemogenomic Landscape of RUNX1-mutated AML Reveals Importance of RUNX1 Allele Dosage 
in Genetics and Glucocorticoid Sensitivity 
69. Chk1 as a new therapeutic target in triple-negative breast cancer 
70. Chloroquine upregulates TRAIL/TRAILR2 expression and potentiates doxorubicin anti-tumor 
activity in thioacetamide-induced hepatocellular carcinoma model 
71. Chloroquine-containing compounds: a patent review (2010 - 2014 
72. Clomipramine kills Trypanosoma brucei by apoptosis 
73. Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive 
melanoma: a strategy for repurposing a phase I clinical trial drug 
74. Comparative oncology approach to drug repurposing in osteosarcoma 
75. Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate 
Synthase Case 
76. Computational profiling of bioactive compounds using a target-dependent composite workflow 
77. Computational repositioning and preclinical validation of pentamidine for renal cell cancer 
 




78. Computer-Aided Structure Based Drug Design Approaches for the Discovery of New Anti-CHIKV 
Agents 
79. COMPUTING THERAPY FOR PRECISION MEDICINE: COLLABORATIVE FILTERING 
INTEGRATES AND PREDICTS MULTI-ENTITY INTERACTIONS 
80. Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in 
cystic fibrosis 
81. Cyclic AMP efflux inhibitors as potential therapeutic agents for leukemia 
82. Cyclotides as Tools in Chemical Biology 
83. Deciphering miRNA transcription factor feed-forward loops to identify drug repurposing candidates 
for cystic fibrosis 
84. Delineation of biological and molecular mechanisms underlying the diverse anticancer activities of 
mycophenolic acid 
85. Detecting drug promiscuity using Gaussian ensemble screening 
86. Development of a stretch-induced neurotrauma model for medium-throughput screening in vitro: 
identification of rifampicin as a neuroprotectant 
87. Discovering gene re-ranking efficiency and conserved gene-gene relationships derived from gene co-
expression network analysis on breast cancer data 
88. Discovery of alkyl bis(oxy)dibenzimidamide derivatives as novel protein arginine methyltransferase 1 
(PRMT1) inhibitors 
89. Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues 
90. Disulfiram's Anticancer Activity: Evidence and Mechanisms 
91. Do Cancer Drugs Counteract Neurodegeneration? Repurposing forAlzheimer's Disease 
92. Docking-based inverse virtual screening: methods, applications, and challenges 
93. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer 
94. Doxycycline inhibits proliferation and induces apoptosis of both human papillomavirus positive and 
negative cervical cancer cell lines 
95. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in 
breast cancer 
96. Doxycycline is an NF-kappaB inhibitor that induces apoptotic cell death in malignant T-cells 
97. Doxycycline or how to create new with the old 
 




98. DPP-4 inhibitors promote proliferation and migration of rat brain microvascular endothelial cells 
under hypoxic/high-glucose conditions, potentially through the SIRT1/HIF-1/VEGF pathway 
99. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking 
(MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-
6/GP130 interface 
100. Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key 
101. Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer 
102. Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank 
database for allosteric Bcr-Abl inhibitors 
103. Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for 
gastrointestinal stromal tumor 
104. Drug repurposing of minocycline against dengue virus infection 
105. Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) 
polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast 
cancer cells 
106. Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer 
associated fibroblasts (CAFs) by synergistic induction of apoptosis 
107. Drug repurposing to target Ebola virus replication and virulence using structural systems 
pharmacology 
108. Drug-Repositioning Screening for Keap1-Nrf2 Binding Inhibitors using Fluorescence Correlation 
Spectroscopy 
109. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent 
activity against breast cancer 
110. DrugBank 5.0: a major update to the DrugBank database for 2018 
111. DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-
based drug repurposing 
112. Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination 
with erlotinib in pancreatic cancer cells 
113. eMatchSite: sequence order-independent structure alignments of ligand binding pockets in protein 
models 
114. eModel-BDB: a database of comparative structure models of drug-target interactions from the 
Binding Database 
 




115. Eritoran Suppresses Colon Cancer by Altering a Functional Balance in Toll-like Receptors That 
Bind Lipopolysaccharide 
116. Erythropoietin, a novel repurposed drug: an innovative treatment for wound healing in patients with 
diabetes mellitus 
117. Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer 
118. Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells 
119. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute 
lymphoblastic leukemia 
120. Explicit Drug Re-positioning: Predicting Novel Drug-Target Interactions of the Shelved Molecules 
with QM/MM Based Approaches 
121. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow 
Tumor Growth in Mice 
122. Fast, non-competitive and reversible inhibition of NMDA-activated currents by 2-BFI confers 
neuroprotection 
123. FDA approved drugs complexed to their targets: evaluating pose prediction accuracy of docking 
protocols 
124. Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism 
125. Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice 
with FLT3/ITD leukemia 
126. Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin 
polymerization 
127. Folate Receptor-Targeted Polymeric Micellar Nanocarriers for Delivery of Orlistat as a Repurposed 
Drug against Triple-Negative Breast Cancer 
128. From laptop to benchtop to bedside: structure-based drug design on protein targets 
129. FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model 
130. Functional genetics-directed identification of novel pharmacological inhibitors of FAS- and TNF-
dependent apoptosis that protect mice from acute liver failure 
131. GES polypharmacology fingerprints: a novel approach for drug repositioning 
132. Glipizide suppresses prostate cancer progression in the TRAMP model by inhibiting angiogenesis 
133. Glutamate release inhibitor, Riluzole, inhibited proliferation of human hepatocellular carcinoma cells 
by elevated ROS production 
 




134. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling 
135. Heme Oxygenase Database (HemeOxDB) and QSAR Analysis of Isoform?1 Inhibitors 
136. High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitor 
137. High-Throughput parallel blind Virtual Screening using BINDSURF 
138. Highly Halaven-resistant KBV20C Cancer Cells Can Be Sensitized by Co-treatment with 
Fluphenazine 
139. HMG-CoA Reductase Inhibition Delays DNA Repair and Promotes Senescence After Tumor 
Irradiation 
140. Ibuprofen and diclofenac treatments reduce proliferation of pancreatic acinar cells upon 
inflammatory injury and mitogenic stimulation 
141. Identification of a new pharmacological activity of the phenylpiperazine derivative naftopidil: 
tubulin-binding drug 
142. Identification of an old antibiotic clofoctol as a novel activator of unfolded protein response 
pathways and an inhibitor of prostate cancer 
143. Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug 
144. Identification of FDA-approved drugs as novel allosteric inhibitors of human executioner caspases 
145. Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of 
sensitivity 
146. Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of 
action 
147. Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme 
148. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma 
149. Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction 
with Dbf4 by the Fragment Complementation and Drug Repositioning Approach 
150. Identification of novel small-molecule inhibitors targeting menin-MLL interaction, repurposing the 
antidiarrheal loperamide 
151. Identification of repaglinide as a therapeutic drug for glioblastoma multiforme 
152. Identification of Small-Molecule Inhibitors of Human Golgi Mannosidase via a Drug Repositioning 
Screen 
153. Identification of thiazolo[5,4-d]pyrimidine derivatives as potent antiproliferative agents through the 
drug repurposing strategy 
 




154. Identify drug repurposing candidates by mining the protein data bank 
155. Identifying candidate agents for lung adenocarcinoma by walking the human interactome 
156. Imidazole Antifungal Drugs Inhibit the Cell Proliferation and Invasion of Human Breast Cancer 
Cells 
157. Implications of the small number of distinct ligand binding pockets in proteins for drug discovery, 
evolution and biochemical function 
158. In silico drug re-purposing against African sleeping sickness using GlcNAc-PI de-N-acetylase as an 
experimental target 
159. In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-
melanoma drug, for Parkinson's disease 
160. In silico identification of potent small molecule inhibitors targeting epidermal growth factor receptor 
1 
161. In silico prediction and in vitro and in vivo validation of acaricide fluazuron as a potential inhibitor 
of FGFR3 and a candidate anticancer drug for bladder carcinoma 
162. In Silico target fishing: addressing a "Big Data" problem by ligand-based similarity rankings with 
data fusion 
163. In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian 
cancer 
164. Induction of DNA damage and apoptosis in human leukemia cells by efavirenz 
165. Inhibition of mTOR/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel 
in oral tongue squamous cell carcinoma 
166. Inhibition of Peroxidase Activity of Cytochrome c: De Novo Compound Discovery and Validation 
167. Inhibition of the insulin-like growth factor system is a potential therapy for rheumatoid arthritis 
168. Insights into the Modulation of Dopamine Transporter Function by Amphetamine, Orphenadrine, 
and Cocaine Binding 
169. Large-scale Direct Targeting for Drug Repositioning and Discovery 
170. Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells 
171. Looking Back, Looking Forward at Halogen Bonding in Drug Discovery 
172. Low-dose salinomycin induces anti-leukemic responses in AML and MLL 
173. Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by 
artesunate 
 




174. Macromolecular target prediction by self-organizing feature maps 
175. Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing 
176. Memantine induces apoptosis and inhibits cell cycle progression in LNCaP prostate cancer cells 
177. Metformin and epithelial ovarian cancer therapeutics 
178. Metformin repositioning as antitumoral agent: selective antiproliferative effects in human 
glioblastoma stem cells, via inhibition of CLIC1-mediated ion current 
179. Metformin treatment ameliorates diabetes-associated decline in hippocampal neurogenesis and 
memory via phosphorylation of insulin receptor substrate 1 
180. Metformin: its emerging role in oncology 
181. Mining Exosomal Genes for Pancreatic Cancer Targets 
182. Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related 
Macular Degeneration 
183. Minocycline repurposing in critical illness: focus on stroke 
184. Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and 
Radiosensitizing Effects in Pancreatic Cancer Cells 
185. Mmp-9 inhibition: a therapeutic strategy in ischemic stroke 
186. Model-based unsupervised learning informs metformin-induced cell-migration inhibition through an 
AMPK-independent mechanism in breast cancer 
187. Molecular investigations of protriptyline as a multi-target directed ligand in Alzheimer's disease 
188. Molecular mimicry-based repositioning of nutlin-3 to anti-apoptotic Bcl-2 family proteins 
189. MOST: most-similar ligand based approach to target prediction 
190. Mucuna pruriens (L.) DC chemo sensitize human breast cancer cells via downregulation of 
prolactin-mediated JAK2/STAT5A signaling 
191. Multiple effects of digoxin on subsets of cancer-associated genes through the alternative splicing 
pathway 
192. Myelination induction by a histamine H3 receptor antagonist in a mouse model of preterm white 
matter injury 
193. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces 
endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo 
194. Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy 
 




195. Network measures for chemical library design 
196. Network-based drug ranking and repositioning with respect to DrugBank therapeutic categories 
197. Network-based drug repositioning: A novel strategy for discovering potential antidepressants and 
their mode of action 
198. New derivatives of the antimalarial drug Pyrimethamine in the control of melanoma tumor growth: 
an in vitro and in vivo study 
199. New HSP27 inhibitors efficiently suppress drug resistance development in cancer cells 
200. New perspectives for metformin in cancer therapy 
201. Niclosamide enhances ROS-mediated cell death through c-Jun activation 
202. Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal 
Cell Cancer Cells 
203. Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and 
redox capacity 
204. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-
induced ferroptosis 
205. Nuclear matrix, nuclear envelope and premature aging syndromes in a translational research 
perspective 
206. Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc 
adenomas are downregulated in response to tumor suppression by Clotam 
207. Ormeloxifene efficiently inhibits ovarian cancer growth 
208. Orphan receptor ligand discovery by pickpocketing pharmacological neighbors 
209. Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the 
Receptor Activator of NF-kappaB Ligand Pathway 
210. P-gp Inhibition by the Anti-psychotic Drug Pimozide Increases Apoptosis, as well as Expression of 
pRb and pH2AX in Highly Drug-resistant KBV20C Cells 
211. p73 as a pharmaceutical target for cancer therapy 
212. Parainfluenza Virus Infection Sensitizes Cancer Cells to DNA-Damaging Agents: Implications for 
Oncolytic Virus Therapy 
213. Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B 
Virus Infection 
 




214. Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia 
Patients 
215. PEGylated chitosan nanoparticles potentiate repurposing of ormeloxifene in breast cancer therapy 
216. Pharmacological targeting of ion channels for cancer therapy: In vivo evidences 
217. Phenotypic identification of the redox dye methylene blue as an antagonist of heat shock response 
gene expression in metastatic melanoma cells 
218. Phosphorylation of Single Stranded RNA Virus Proteins and Potential for Novel Therapeutic 
Strategies 
219. POAP: A GNU parallel based multithreaded pipeline of open babel and AutoDock suite for boosted 
high throughput virtual screening 
220. Polypharmacology rescored: protein-ligand interaction profiles for remote binding site similarity 
assessment 
221. PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase 
inhibitors by inducing autophagy 
222. Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas 
223. Predicting new indications for approved drugs using a proteochemometric method 
224. ProBiS-ligands: a web server for prediction of ligands by examination of protein binding sites 
225. PROMISCUOUS: a database for network-based drug-repositioning 
226. Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through 
Akt/mTOR suppression 
227. Propofol post-conditioning alleviates hepatic ischaemia reperfusion injury via BRG1-mediated 
Nrf2/HO-1 transcriptional activation in human and mice 
228. Proscillaridin A exerts anti-tumor effects through GSK3beta activation and alteration of microtubule 
dynamics in glioblastoma 
229. Protein-ligand-based pharmacophores: generation and utility assessment in computational ligand 
profiling 
230. Proteome-scale docking: myth and reality 
231. Pyrvinium Sensitizes Clear Cell Renal Cell Carcinoma Response to Chemotherapy Via Casein 
Kinase 1alpha-Dependent Inhibition of Wnt/beta-Catenin 
232. Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity 
in thyroid cancer cells: opportunities for repurposing 
 




233. Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple 
opportunities for drug repurposing 
234. Rationale for an experimental treatment of retinitis pigmentosa: 140-month test of hypothesis with 
one patient 
235. Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for 
Overcoming Tamoxifen Resistance in ER-positive Breast Cancer 
236. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide 
targeting de novo DNA synthesis, irrespective of molecular subtype 
237. Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1 
238. Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual 
Screening, In Vitro and In Vivo Studies 
239. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon 
Cancer Epigenome 
240. Repositioning of amprenavir as a novel extracellular signal-regulated kinase-2 inhibitor and 
apoptosis inducer in MCF-7 human breast cancer 
241. Repositioning of anti-viral drugs as therapy for cervical cancer 
242. Repositioning of antibiotic levofloxacin as a mitochondrial biogenesis inhibitor to target breast 
cancer 
243. Repositioning of bromocriptine for treatment of acute myeloid leukemia 
244. Repositioning of difluorinated propanediones as inhibitors of histone methyltransferases and their 
biological evaluation in human leukemic cell lines 
245. Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of 
human fatty acid synthase 
246. Repurposed FDA-approved drugs targeting genes influencing aging can extend lifespan and 
healthspan in rotifers 
247. Repurposing a novel parathyroid hormone analogue to treat hypoparathyroidism 
248. Repurposing an orally available drug for the treatment of geographic atrophy 
249. Repurposing an Osteoporosis Drug for beta Cell Regeneration in Diabetic Patients 
250. Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer 
stem cells 
 




251. Repurposing disulfiram for cancer therapy via targeted nanotechnology through enhanced tumor 
mass penetration and disassembly 
252. Repurposing FDA-approved drugs for anti-aging therapies 
253. Repurposing itraconazole for the treatment of cancer 
254. Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: a crucial 
role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation 
255. Repurposing of phentolamine as a potential anticancer agent against human castration-resistant 
prostate cancer: A central role on microtubule stabilization and mitochondrial apoptosis pathway 
256. Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma 
257. Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2 
258. Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic 
pontine glioma 
259. Retinal Neuroprotective Effects of Flibanserin, an FDA-Approved Dual Serotonin Receptor Agonist-
Antagonist 
260. Revisiting Antipsychotic Drug Actions Through Gene Networks Associated With Schizophrenia 
261. Revisiting old drugs as novel agents for retinoblastoma: in vitro and in vivo antitumor activity of 
cardenolides 
262. Ribavirin suppresses bacterial virulence by targeting LysR-type transcriptional regulators 
263. Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian 
cancer cells 
264. Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy 
265. Schizophrenia interactome with 504 novel protein-protein interactions 
266. Screening of a composite library of clinically used drugs and well-characterized pharmacological 
compounds for cystathionine beta-synthase inhibition identifies benserazide as a drug potentially suitable 
for repurposing for the experimental therapy of colon cancer 
267. Selective human inhibitors of ATR and ATM render Leishmania major promastigotes sensitive to 
oxidative damage 
268. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative 
breast cancer growth and metastasis 
269. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in 
cancer cell lines 
 




270. SPIDR: small-molecule peptide-influenced drug repurposing 
271. Structural re-positioning, in silico molecular modelling, oxidative degradation, and biological 
screening of linagliptin as adenosine 3 receptor (ADORA3) modulators targeting hepatocellular 
carcinoma 
272. Structure based drug discovery for designing leads for the non-toxic metabolic targets in multi drug 
resistant Mycobacterium tuberculosis 
273. Structure Investigation, Enrichment Analysis and Structure-based Repurposing of FDA-approved 
Drugs as Inhibitors of BET-BRD4 
274. Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing 
275. Sulforaphane Prevents Neuronal Apoptosis and Memory Impairment in Diabetic Rats 
276. Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in 
adrenocortical carcinoma and has biomarkers of response 
277. Synthesis and biological evaluation of thiabendazole derivatives as anti-angiogenesis and vascular 
disrupting agents 
278. Tamoxifen Provides Structural and Functional Rescue in Murine Models of Photoreceptor 
Degeneration 
279. Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review 
280. Targeting cyclin D3/CDK6 activity for treatment of Parkinson's disease 
281. Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference 
282. Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt/mTOR and inducing 
oxidative stress 
283. Targeting Phosphatidylinositol 4-Kinase IIIalpha for Radiosensitization: A Potential Model of Drug 
Repositioning Using an Anti-Hepatitis C Viral Agent 
284. The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma 
Cells by Targeting Multiple Signal Pathways 
285. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical 
and noncanonical Wnt signaling pathway 
286. The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-
associated fibroblasts 
287. The anti-hypertensive drug prazosin inhibits glioblastoma growth via the PKCdelta-dependent 
inhibition of the AKT pathway 
 




288. The Antiarrhythmic Drug, Amiodarone, Decreases AKT Activity and Sensitizes Human Acute 
Myeloid Leukemia Cells to Apoptosis by ABT-263 
289. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal 
melanoma in vitro and in vivo 
290. The aryl hydrocarbon receptor is required for induction of p21cip1/waf1 expression and growth 
inhibition by SU5416 in hepatoma cells 
291. The combination astemizole-gefitinib as a potential therapy for human lung cancer 
292. The combination effects of licl and the active leflunomide metabolite, A771726, on viral-induced 
interleukin 6 production and EV-A71 replication 
293. The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell 
carcinoma 
294. The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced 
apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes 
295. The Horizon of a Therapy for Rare Genetic Diseases: A "Druggable" Future for Fibrodysplasia 
Ossificans Progressiva 
296. The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in 
hepatocellular carcinoma 
297. The pain interactome: connecting pain-specific protein interactions 
298. The polysialic acid mimetics idarubicin and irinotecan stimulate neuronal survival and neurite 
outgrowth and signal via protein kinase C 
299. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines 
and discovery of potential new DDK inhibitor scaffolds 
300. The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-
beta1 
301. The purchasable chemical space: a detailed picture 
302. The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory 
NRASQ61K melanoma 
303. The Repurposing of Old Drugs or Unsuccessful Lead Compounds by in Silico Approaches: New 
Advances and Perspectives 
304. The sodium channel-blocking antiepileptic drug phenytoin inhibits breast tumour growth and 
metastasis 
 




305. Therapeutic Effect of Quinacrine, an Antiprotozoan Drug, by Selective Suppression of p-CHK1/2 in 
p53-Negative Malignant Cancers 
306. Therapeutic Effect of Repurposed Temsirolimus in Lung Adenocarcinoma Model 
307. Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by 
inhibiting Wnt/beta-catenin signaling 
308. Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review 
(2008-present 
309. Tigecycline targets nonsmall cell lung cancer through inhibition of mitochondrial function 
310. Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems 
Pharmacology 
311. Transcriptomic changes induced by mycophenolic acid in gastric cancer cells 
312. Translating Mendelian and complex inheritance of Alzheimer's disease genes for predicting unique 
personal genome variants 
313. Treatment of experimental autoimmune uveoretinitis with peroxisome proliferator-activated receptor 
alpha agonist fenofibrate 
314. Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer 
315. TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) 
Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin 
316. Updates on drug-target network; facilitating polypharmacology and data integration by growth of 
DrugBank database 
317. Using reverse docking for target identification and its applications for drug discovery 
318. Valproic acid in the complex therapy of malignant tumors 
319. Valproic Acid Promotes Apoptosis and Cisplatin Sensitivity Through Downregulation of H19 
Noncoding RNA in Ovarian A2780 Cells 
320. Verteporfin inhibits gastric cancer cell growth by suppressing adhesion molecule FAT1 
321. Viability Screen of LOPAC1280 Reveals Phosphorylation Inhibitor Auranofin as a Potent Inhibitor 
of Blastocystis Subtype 1, 4, and 7 Isolates 
322. Virtual Screening against Phosphoglycerate Kinase 1 in Quest of Novel Apoptosis Inhibitors 
323. Virtual screening-driven repositioning of etoposide as CD44 antagonist in breast cancer cells 
324. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity 
and Metastasis  
 




Appendix 4: Markers from the AD Study 
 Four tables adapted from the AD study will be presented to show the breadth of markers 
included, and the directions in which they change in the presence of AD contributing factors (causes) or 
AD treatments. 
 Table A4-1 presents the impact of AD causes (contributing factors) identified in the AD study on 
the myriad markers identified in the study.  Because these impact phrases are arranged by frequency of 
the AD marker, the list starts with the higher-level markers, and then proceeds to address the detailed 
biomarkers. 
Table A4-1: IMPACTS OF AD CAUSES ON MARKERS 
(arranged by # records; abbreviations as shown in software) 
# RECORDS AD CAUSES IMPACTS 
80759 AD enhance 
26726 ABETA incr 
25423 DEMENTIA incr 
24065 COGNITION degrad 
12234 MEMORY degrad 
7388 METABOLISM decr 
6879 APOPTOSIS incr 
6732 CHOLINERGIC decr 
6307 BEHAVIOR degrad 
5946 NEUROTOXICITY incr 
5582 PLASTICITY reduc 
5358 INFLAMM incr 
5075 NFT incr 
5011 ANTIBOD reduc 
4418 OXIDATIVE STRESS incr 
4403 DEPRESSION incr 
3992 MMSE decr 
3701 LEARNING reduc 
3687 HYPERPHOSPHORYLATION incr 
3652 NEURON degrad 
2835 ASTROGLIOSIS incr 
2669 MICROGLIAL ACTIV incr 
2663 TAU PATHOLOGY incr 
2610 MITOCHONDRIA degrad 
2437 ANTIOXIDANT DEFENSE reduc 
2328 ROS incr 
2300 ALPHA-SECRETASE decr 
1623 NEURODEGENERAT incr 
1213 EXCITOTOXICITY incr glut 
1194 NMDA enhanc 
1132 NEUROGENESIS incr 
1121 PHF enhanc 
 




1081 MISFOLD incr 
1062 ANXIETY incr 
988 ESTROGEN reduc 
979 CEREB BLOOD FLOW decr 
971 CASPASE incr 
856 SLEEP decr 
820 NGF decr 
809 AGITATION incr 
770 SEROTONIN decr 
761 DENDR SPINE degrad 
736 BACE-1 incr 
732 IL-1 incr 
700 STRESS incr 
683 GLUTATHIONE decr 
667 TNF-alpha incr 
666 AGGRESSION incr 
652 COPPER incr 
632 GSK-3 incr 
615 NEUR NET degen 
607 LTP decr 
588 AGEs incr 
567 APATHY incr 
567 BRAIN ATROPHY incr 
536 ATP decr 
520 BDNF decr 
497 HOMOCYSTEINE incr 
487 IL-6 incr 
433 PS1 incr 
423 MAPK enhanc 
388 NF-kappaB incr 
360 Akt decr 
358 Cdk5 enhanc 
344 NONAMYLOIDOGENIC decr 
333 ATAXIA incr 
330 CALCIUM incr 
327 ATTENTION decr 
322 INSULIN SIGNAL reduc 
317 CHOLESTEROL incr 
316 MELATONIN decr 
309 MAO enhanc 
307 Bcl-2 decr 
305 NEP decr 
276 PHAGOCYTOSIS reduc 
275 FOLATE degrad 
273 cAMP decr 
269 MULTIPLE PATHWAYS reduc 
261 IDE decr 
254 MOBILITY reduc 
 




253 JNK incr 
250 AXONAL DYSTROPHY incr 
248 DHA decr 
236 CORTISOL incr 
231 NOREPINEPHRINE decr 
223 iNOS incr 
223 PGE2 incr 
222 NAA decr 
213 VIT B12 decr 
211 GPX decr 
204 Bax incr 
196 HISTAMINE decr 
194 TTR decr 
185 IADL reduc 
173 INSOMNIA incr 
162 DOPAMINE decr 
160 TESTOSTERONE decr 
155 ADAM10 decr 
137 PP2A decr 
136 ENDOTHEL FUNCT decr 
135 Hsp70 decr 
134 HDAC incr 
133 DNA METHYLAT decr 
132 CREB decr 
127 BRAIN ACTIVAT decr 
122 CALCINEURIN incr 
122 VEGF decr 
118 ANDROGEN decr 
117 BBB degrad 
116 TYROSINE HYDROXYLASE decr 
109 MDA incr 
108 COX-1 stimulat 
105 DHEA decr 
104 Pgp decr 
101 PROGESTERONE decr 
100 HYPERLIPIDEMIA incr 
96 HYPERGLYCEMIA incr 
96 LRP1 decr 
96 MoCA decr 
96 MTOR incr 
96 PGRN decr 
95 IGF-1 decr 
93 LEPTIN decr 
93 NITROTYROSINE incr 
92 CATHEPSIN-B enhanc 
91 VIT B6 decr 
90 LXR decr 
85 ABCA1 decr 
 




85 CMRglc decr 
84 GLP-1 decr 
83 Nrf2 decr 
82 c-fos decr 
81 LDL incr 
81 SIRT1 decr 
80 TrkB reduc 
76 s100B incr 
75 LH incr 
71 CEREBROVASC DYSFUNCT incr 
71 IL-4 decr 
69 PPAR-gamma decr 
67 MAC enhanc 
63 METAL HOMEOSTAS decr 
59 HMGCoAr decr 
57 PICALM incr 
56 O-GlcNAc decr 
54 MUSCAR M1 decr 
53 BrdU decr 
50 QUALITY OF LIFE reduc 
49 ADDL stimulat 
49 AUTOPHAGY reduc 
48 GELSOLIN decr 
47 AMPK decr 
44 SNAP-25 decr 
41 HISTONE ACETYL decr 
40 27-OHC incr 
40 ECE decr 
38 ALLOPREGNANOLONE decr 
34 Beclin-1 incr 
33 DCX degrad 
33 Drp1 incr 
32 25-OHD decr 
32 PSD95 decr 
31 EAAT2 decr 
31 PGC-1alpha decr 
31 Seladin-1 decr 
30 IRS-1 incr 
30 MYOINOSITOL incr 
30 sAPP decr 
29 PAI-1 enhanc 
26 NFAT incr 
26 PREGNENOLONE decr 
25 ADIPONECTIN decr 
25 MENOPAUSAL worsen 
23 SLAI reduc 
22 ABCA7 decr 
22 LDH incr 
 




20 p38MAPK incr 
19 ADAM9 decr 
19 LR11 decr 
19 MAP1B decr 
18 24-OHC incr 
17 CD33 enhanc 
17 GABA decr 
17 HDL decr 
17 Ngb decr 
17 PCNA decr 
17 UCH-L1 decr 
16 ATF4 incr 
16 HSF1 decr 
16 PAK incr 
15 GLUT4 decr 
15 MEGALIN reduc 
15 miRNA-146a incr 
15 TLR-4 incr 
14 CRP decr 
14 Egr-1 decr 
13 BH4 degrad 
13 PLASMA VITAMIN E decr 
12 ADMA incr 
12 CLAUDIN-5 decr 
12 CNPase decr 
12 CX3CR1 incr 
11 LYSOSOMAL ACIDIFICATION reduc 
11 NAAG decr 
10 CXCR2 incr 
10 GSAP incr 
10 Wnt3 decr 
9 EphB2 decr 
8 PI(4,5)P(2) decr 
7 Ras ACTIVITY decr 
7 SOCE incr 
6 GEPHYRIN decr 
6 TPI decr 
5 EXCESSIVE NO incr 
5 GCSF decr 
5 GLYMPHATIC DRAINAGE reduc 
5 iPLA2 decr 
5 NEUROTROPHIN decr 
5 p16 incr 
5 TUBULIN reduc 
4 BAG3 decr 
4 C3 CONVERTASE incr 
4 CXCL1 decr 
4 IGFBP3 decr 
 




4 RESOLVIN D1 decr 
4 Synj1 incr 
4 TERT reduc 
3 B1R decr 
3 CHROM MIS-SEGR incr 
3 cyclinD1 decr 
3 MAGNESIUM decr 
3 mir-206 incr 
3 Pr-SSG incr 
3 SIR1 decr 
3 TRPM2 incr 
2 B2R decr 
2 DYSPHAGIA incr 
2 HSV REP prevent 
2 HYPERVASCULARITY incr 
2 PALMITOLEIC ACID incr 
2 RLT decr 
2 SREBP2 incr 
2 T-MEHA decr 
2 WT1 incr 
1 BRN-4 decr 
1 IL-12p40/p70 incr 
1 METHIONONE decr 
1 miR-30a-5p incr 
1 miR-339-5p decr 
1 S6K1 incr 
1 TOMOSYN incr 
 
 




 Because of the chronology of conducting the AD study, identification of the AD markers and 
their directions of change was driven by the treatment identification process.  The contributing factors 
identification process served to complete the identification of remaining biomarkers and their directions 
of change.  Table A4-2 reflects the depth of the taxonomy and process used to identify the myriad AD 
existing markers changes resulting from the existing AD treatments identified.  
  
Table A4-2: TAXONOMY OF BENEFITS FROM AD TREATMENT 
AD TREATMENT BENEFITS 
IMPROVE MAINLINE BIOMARKER 
DEFICITS 
1. Neurotransmission modulation 
1.1 Enhance cholinergic neurotransmission 
1.15 Improve synapse plasticity 
1.2 Antagonize NMDA receptors 
1.3 GABAergic modulation 
1.4 Serotonin receptor modulation 
1.5 Histamine receptor modulation 
1.6 Adenosine receptor modulation 
1.7 Other neurotransmitter modulation 
2. Tau modulation 
2.1 Tau phosphorylation inhibition 
2.2 Microtubule stabilization 
2.3 Reducing Tau oligomerization/pathology 
3. Abeta modulation 
3.1 Reduce Abeta 
3.2 Modulate amyloid transport 
3.3 Prevent amyloid aggregation 
3.4 Promote amyloid clearance 
3.5 Amyloid based immunotherapy 
3.6 Secretase enzymes modulation 
3.7 Improve structural deficits 
3.8 Other 
 
IMPROVE METABOLISM BIOMARKERS 
4. Insulin and energy metabolism 
4.1 Insulin metabolism 
4.2 Energy metabolism 
5. Oxidative stress reduction 
5.1 Augment endogenous defense 
5.2 AGEs reduction 
6. Mitochondrial function improvement 
7. Modulation of cellular calcium homeostasis 
 




8. Inflammation alleviation 
9. Others 
9.1 Hormone dyshomeostasis improvement 
9.2 Lipid dyshomeostasis improvement 
9.3 Growth factor restoration 
9.4 Metal homeostasis improvement 
9.5 Epigenetic modification 
9.6 Caspase inhibition 
9.7 Nitric oxide synthase modulation 
9.8 Combinatorial improvements 
  






IMPROVE BEHAVIORAL DEFICITS 
11. Behavioral problems 
11.1 Behavior 









IMPROVE NEUROPATHOLOGY AND 
AD/DEMENTIA 
12. Prevent and reverse neuropathology 
12.1 ameliorate neurodegeneration 
12.2 attenuate neurotoxicity 
12.3 prevent apoptosis 
12.4 protect neurons 
12.5 promote neurogenesis 
13. Prevent and reverse AD/dementia 
13.1 prevent and reverse AD 
13.2 prevent and reverse dementia 
 
 Table A4-3 provides the next level of detail in populating the previous taxonomy of Table A4-2.  
 




Table A4-3: DETAILED TAXONOMY OF AD TREATMENT BENEFITS 
BENEFITS FROM AD TREATMENT 
IMPROVE MAINLINE BIOMARKER DEFICITS 
1. Neurotransmission modulation 
1.101 incr cholinergic 
1.102 restor SLAI 
1.15 Improve synapse plasticity 
1.1501 improv PLASTICITY 
1.1502 reduc SREBP2 
1.1503 regen neural network 
1.1504 incr PSD95 
1.1505 incr Ras activity 
1.1506 incr CMRglc 
1.1507 incr MAP1B 
1.1508 reduc TOMOSYN 
1.1509 reduc myoinositol 
1.151 reduc S6K1 
1.1511 rescu PI(4,5)P(2) 
1.1512 restor SNAP-25 
1.1513 decr PAK 
1.1514 amelior excessive NO 
1.1515 incr magnesium 
1.1516 incr EAAT2 
1.1517 reduc glut excitotoxicity 
1.1518 decr calcineurin 
1.2 Antagonize NMDA receptors 
1.201 antag NMDA 
1.3 GABAergic modulation 
1.301 incr GABA 
1.302 restor gephyrin 
1.4 Serotonin receptor modulation 
1.401 incr SEROTONIN 
1.402 inhibit MAO 
1.5 Histamine receptor modulation 
1.501 incr histamine 
1.502 incr T-MEHA 
1.6 Adenosine receptor modulation 
1.601 incr ATP 
1.7 Other neurotransmitter modulation 
1.701 incr norepinephrine 
1.702 activat M1 
1.703 incr N-acetylaspartate 
1.704 incr NAAG 
 




1.705 incr brain activation 
2. Tau modulation 
2.1 Tau phosphorylation inhibition 
2.101 reduc hyperphosphorylation 
2.2 Microtubule stabilization   
2.201 restor tubulin 
2.202 decr NFT 
2.203 incr glutathione 
2.3 Reducing Tau oligomerization/pathology 
2.301 reduc tau pathology 
2.302 decr paired helical filament 
2.303 inhibit Hsp90alpha 
2.304 prevent hsv 
2.305 incr anti-tau antibod 
3. Abeta modulation 
3.1 Reduce Abeta 
3.101 reduc Abeta 
3.102 reduc mTOR 
3.103 incr AMPK 
3.104 incr Brn-4 
3.105 incr p75ECD 
3.106 incr LR11 
3.107 inhibit CatB 
3.108 reduc PRAS40 phosphorylation 
3.109 restor glymphatic drainage 
3.2 Amyloid transport 
3.201 restor BBB 
3.202 incr Claudin-5 
3.3 Preventing amyloid aggregation 
3.302 incr iPLA2 
3.303 inhibit ADDL 
3.304 reduc C3 convertase 
3.305 incr TTR 
3.306 incr LRP1 
3.307 incr NEP 
3.308 incr ECE-2 
3.309 incr tyrosine hydroxylase 
3.4 Promoting amyloid clearance 
3.401 enhanc phagocytosis 
3.402 restor lysosomal acidification 
3.403 incr ABCA1 
3.404 incr ABCA7 
3.405 inhibit CD33 
3.406 incr LXR 
 




3.407 enhanc megalin 
3.408 incr gelsolin 
3.409 restor Pgp 
3.5 Amyloid based immunotherapy 
3.501 enhanc antibod 
3.6 Secretase enzymes modulation 
3.601 incr alpha-secretase 
3.602 incr sAPP 
3.603 incr nonamyloidogenic 
3.604 reduc GSAP 
3.605 reduc PS1 
3.606 incr ADAM10 
3.607 incr ADAM9 
3.608 reduc BACE1 
3.609 incr SIRT1 
3.61 decr PICALM 
3.7 Improve structural deficits 
3.701 decr brain atrophy 
3.8 Other 
3.801 decr homocysteine 
3.802 incr methionone 
IMPROVE METABOLISM BIOMARKERS 
4. Insulin and Energy metabolism 
4.1 Insulin metabolism 
4.101 allev diabet 
4.102 reduc IRS-1 
4.103 improv hyperglycemia 
4.104 incr IDE 
4.105 incr GLP-1 
4.106 incr Akt 
4.107 incr BAG3 
4.108 incr GLUT4 
4.2 Neuronal metabolism 
4.201 improv metabol 
4.202 incr O-GlcNAc 
5. Oxidative stress reduction 
5.1 Augmenting endogenous defense 
5.101 improv antioxidant defense 
5.102 reduc oxidative stress 
5.103 incr glutathione peroxidase 
5.104 decr nitrotyrosine 
5.105 incr plasma Vitamin E 
5.106 reduc Pr-SSG 
5.107 decr ROS 
 




5.108 incr Nrf2 
5.109 incr IGF-1 
5.11 reduc ADMA 
5.111 decr GSK-3 
5.112 improv endotheli 
5.113 restor BH4 
5.114 incr cerebral blood flow 
5.2 AGEs reduction 
5.201 reduc AGEs 
6. Mitochondrial function improvement 
6.101 protect mitochondria 
6.102 incr SIR1 
6.103 incr PGC-1alpha 
6.104 decr Drp1 
7. Modulation of cellular calcium homeostasis 
7.101 decr calcium 
7.102 reduc SOCE 
8. Inflammation alleviation 
8.101 reduc inflamm 
8.102 decr TNF-alpha 
8.103 decr CRP 
8.104 incr cAMP 
8.105 decr IL-1 
8.106 decr IL-6 
8.107 incr IL-4 
8.108 reduc NF-kappaB 
8.109 decr p16 
8.11 incr cyclinD1 
8.111 incr PPAR-gamma 
8.112 inhib cyclooxygenase-1 
8.113 incr resolvin D1 
8.114 reduc CXCR2 
8.115 reduc TLR-4 
8.116 reduc MKL1 
8.117 reduc s100B 
9. Others 
9.1 Hormone dyshomeostasis 
9.101 incr progesterone 
9.102 incr testosterone 
9.103 replace estrogen 
9.104 incr androgen 
9.105 reduc luteinizing hormone 
9.106 incr DHEA 
9.107 incr Allopregnanolone 
 




9.108 incr pregnenolone 
9.2 Lipid dyshomeostasis 
9.201 reduc cholesterol level 
9.202 decr 24-hydroxycholesterol 
9.203 decr 27-hydroxycholesterol 
9.204 incr HDL 
9.205 decr LDL 
9.206 incr HMGCoAr 
9.207 reduc chromosome mis-segregation 
9.208 ameliorat hyperlipidemia 
9.209 incr leptin 
9.3 Growth factor restoration 
9.301 incr NGF 
9.302 incr VEGF 
9.4 Metal homeostasis improvement 
9.401 restor metal homeostasis 
9.402 decr copper 
9.403 inhib MAPK 
9.5 Epigenetic modification 
9.501 incr DNA methylation 
9.502 amelior B6 
9.503 amelior B12 
9.504 amelior folate 
9.511 inhib HDAC 
9.512 incr histone acetylation 
9.513 incr histone H3K9 
9.521 incr miR-339-5p  
9.522 decr miR-30a-5p 
9.523 decr mir-206 
9.524 decr miRNA-146a 
9.6 Caspase inhibition  
9.601 reduc caspase 
9.602 reduc JNK 
9.603 restor IGFBP3 
9.7 Nitric oxide synthase modulation 
9.701 reduc iNOS 
9.8 Combinatorial improvements 
9.801 activat multiple pathways 
IMPROVE PERFORMANCE DEFICITS 
10. Cognition/Memory/Learning 
10.1 Cognition 
10.101 improv cogniti 
10.102 amelior cerebrovascular dysfunction 
10.103 revers hypervascularity 
 




10.104 incr CXCL1 
10.105 improv MoCA 
10.106 improv MMSE 
10.107 reduc palmitoleic acid 
10.108 incr DHA 
10.109 incr c-fos 
10.11 incr Egr-1 
10.111 incr adiponectin 
10.112 incr TPI 
10.2 Memory 
10.201 improv memory 
10.202 incr B2R 
10.203 incr B1R 
10.204 incr GCSF 
10.205 incr LTP 
10.206 incr RLT 
10.207 inhib Cdk5 
10.208 inhib MAC 
10.209 restor TrkB 
10.21 restor melatonin 
10.211 reduc CX3CR1 
10.212 decr ATF4 
10.213 incr dopamine 
10.214 incr EphB2 
10.3 Learning 
10.301 improv learning 
10.302 decr RORgammat 
IMPROVE BEHAVIORAL DEFICITS 
11. Behavioral problems 
11.1 Behavior  
11.101 improv behavior 
11.2 Quality of Life 
11.201 prevent nutritional deficien 
11.201 improv quality of life 
11.201 improv quality-of-life 
11.202 allev menopausal 
11.203 amelior dysphagia 
11.204 restor IADL 
11.205 allev ataxia 
11.206 improv mobility 
11.207 incr 25-OHD 
11.208 reduc reduce stress 
11.3 Agitation 
11.301 reduc agitat 
 




11.302 decr cortisol 
11.4 Aggression 
11.401 decr aggressi 
11.5 Anxiety 
11.501 reduc anxiety 
11.6 Depression 
11.601 reduc depression 
11.7 Attention 
11.701 improv attention 
11.8 Apathy 
11.801 reduc apathy 
11.9 Sleep 
11.901 improv sleep 
11.902 reduc insomnia 
REVERSE NEUROPATHOLOGY AND AD/DEMENTIA 
12. Prevent and reverse neuropathology  
12.1 Ameliorate neurodegeneration 
12.101 reduc neuro degenerat 
12.102 reduc astrogli 
12.103 suppress activation microgli 
12.104 attenuat NFAT 
12.105 incr CNPase 
12.106 incr Bcl-2 
12.107 decr Bax 
12.108 decr MDA 
12.109 incr BDNF 
12.11 incr neurotrophin 
12.111 incr UCH-L1 
12.112 inhibit PAI-1 
12.113 rescu TGF-beta1 
12.114 decr axonal dystrophy 
12.115 incr PP2A 
12.116 reduc LDH 
12.117 incr PGRN 
12.2 Attenuate neurotoxicity  
12.201 alleviat neurotoxic 
12.202 incr Ngb 
12.3 Prevent apoptosis 
12.301 inhib apopto 
12.302 rescu dendritic spine 
12.303 reduc Ephexin5 
12.304 incr seladin-1 
12.305 incr Hsp70 
12.306 reduc TRPM2 
 




12.307 reduc WT1 
12.308 restor TERT 
12.309 reduc p38MAPK 
12.4 Protect neurons  
12.401 protect neuron 
12.402 enhanc autophagy 
12.403 decr Beclin-1 
12.404 decr SQSTM1 
12.405 reduc synj1 
12.406 incr CREB 
12.407 decr IL-12p40/p70 
12.5 Promote neurogenesis  
12.501 incr neurogenesis 
12.502 restor DCX 
12.503 incr PCNA 
12.504 incr 5-bromo-2'-deoxyuridine 
12.505 incr heat shock transcription factor 
12.506 incr Wnt3 
PREVENT AND REVERSE AD/DEMENTIA 
13. AD and Dementia 
13.1 AD/Dementia 
13.101 prevent AD 
13.102 reduc prostaglandin 
13.103 prevent dementia 
 
 




 Table A4-4 offers a non-taxonomic view of markers and their directions of change resulting from 
AD treatments. 
Table A4-4: AD TREATMENT BENEFITS 
(ordered by # records; abbreviations as shown in software) 
# RECORDS AD TREATMENT BENEFIT 
15766 AD prevent 
8299 DEMENTIA prevent 
8245 COGNITION improv 
6592 ABETA reduc 
3697 MEMORY improv 
3557 CHOLINERGIC enhanc 
2765 BEHAVIOR improv 
2220 INFLAMM reduc 
2053 NEURON protect 
2048 NEUROTOXICITY allev 
1644 METABOLISM improv 
1612 APOPTOSIS inhibit 
1467 OXIDATIVE STRESS reduc 
1456 MMSE improv 
1455 DEPRESSION reduc 
1335 LEARNING improv 
1331 PLASTICITY improv 
1190 NEURODEGENERAT reduc 
1152 ANTIBOD enhanc 
924 HYPERPHOSPHORYLATION reduc 
800 NFT decr 
759 AGITATION reduc 
752 ALPHA-SECRETASE incr 
720 ROS decr 
715 MICROGLIAL ACTIV suppress 
648 INSULIN SIGNAL restor 
562 MITOCHONDRIA protect 
545 TAU PATHOLOGY reduc 
532 NMDA antagon 
526 ESTROGEN replac 
480 ASTROGLIOSIS reduc 
471 ANXIETY reduc 
439 AGGRESSION decr 
390 SLEEP improv 
376 SEROTONIN incr 
364 NEUROGENESIS incr 
322 BACE-1 reduc 
306 NGF incr 
305 GLUTATHIONE incr 
297 BDNF incr 
 




256 CASPASE reduc 
250 GSK-3 decr 
239 TNF-alpha decr 
237 MULTIPLE PATHWAYS activat 
212 IL-1 decr 
211 EXCITOTOXICITY reduc glut 
207 APATHY improv 
195 MELATONIN restor 
190 LTP incr 
190 MAO inhibit 
185 CEREB BLOOD FLOW incr 
185 DHA incr 
163 FOLATE amelior 
160 VIT B12 amelior 
159 HOMOCYSTEINE decr 
153 COPPER decr 
152 MOBILITY improv 
145 Akt incr 
143 AGEs reduc 
139 Bcl-2 incr 
138 ATTENTION improv 
134 DENDR SPINE rescu 
134 NF-kappaB reduc 
123 IL-6 decr 
122 MDA decr 
121 CHOLESTEROL lower 
119 MAPK inhibit 
117 INSOMNIA reduc 
112 GPX incr 
109 Bax decr 
109 NONAMYLOIDOGENIC incr 
107 NEUR NET regen 
106 MISFOLD prevent 
106 NEP incr 
100 IADL restor 
96 ATP incr 
96 PHAGOCYTOSIS enhanc 
93 IDE incr 
93 iNOS reduc 
91 QUALITY OF LIFE improv 
85 TESTOSTERONE incr 
80 ANTIOXIDANT DEFENSE improv 
79 cAMP incr 
76 CREB incr 
74 JNK reduc 
74 PHF inhibit 
69 MUSCAR M1 activat 
66 PGE2 reduc 
 




65 VIT B6 amelior 
64 HDAC inhibit 
62 NOREPINEPHRINE incr 
61 MTOR reduc 
60 ANTI-TAU ANTIBOD incr 
59 HISTAMINE incr 
57 BRAIN ATROPHY reduc 
56 Cdk5 inhibit 
56 HMGCoAr incr 
53 ADAM10 incr 
51 CORTISOL decr 
51 GLP-1 incr 
51 sAPP incr 
49 LEPTIN incr 
47 COX-1 inhib 
46 DHEA incr 
46 PPAR-gamma incr 
46 PROGESTERONE incr 
42 SIRT1 incr 
41 Nrf2 incr 
40 IL-4 incr 
39 ANDROGEN incr 
39 VEGF incr 
36 HYPERLIPIDEMIA ameliorat 
35 Pgp restor 
34 IGF-1 incr 
34 NAA incr 
34 TrkB restor 
33 MoCA improv 
31 NITROTYROSINE decr 
31 PP2A incr 
30 BRAIN ACTIVAT incr 
29 ATAXIA allev 
28 CALCIUM decr 
28 TTR incr 
27 DNA METHYLAT incr 
27 DOPAMINE incr 
27 LRP1 incr 
26 AMPK incr 
26 BrdU incr 
25 LXR incr 
23 LDL decr 
22 HISTONE ACETYL incr 
21 CALCINEURIN decr 
21 Hsp70 incr 
21 HYPERGLYCEMIA improv 
21 STRESS reduc 
20 ABCA1 incr 
 




20 ENDOTHEL FUNCT improv 
19 ADDL inhibit 
19 CATHEPSIN-B inhibit 
19 MAC inhibit 
19 PS1 reduc 
18 ALLOPREGNANOLONE incr 
18 AUTOPHAGY enhanc 
18 DCX restor 
18 METAL HOMEOSTAS restore 
18 PSD95 incr 
17 Seladin-1 incr 
17 SLAI restor 
16 25-OHD incr 
16 GELSOLIN incr 
16 LH reduc 
15 c-fos incr 
15 LDH reduc 
15 PGRN incr 
14 IRS-1 reduc 
14 PGC-1alpha incr 
14 s100B reduc 
13 CMRglc incr 
12 AXONAL DYSTROPHY decr 
12 Beclin-1 decr 
11 ADIPONECTIN incr 
11 PAI-1 inhibit 
11 SNAP-25 restor 
10 GABA incr 
10 p38MAPK reduc 
10 PREGNENOLONE incr 
10 TYROSINE HYDROXYLASE incr 
9 ADAM9 incr 
9 Drp1 decr 
8 HDL incr 
7 BBB restor 
7 ECE incr 
7 Egr-1 incr 
7 NFAT attenuat 
7 PICALM decr 
7 TLR-4 reduc 
6 NEUROTROPHIN incr 
6 Ngb incr 
6 PLASMA VITAMIN E incr 
5 27-OHC decr 
5 GCSF incr 
5 HSF1 incr 
5 MENOPAUSAL allev 
5 O-GlcNAc incr 
 




5 PCNA incr 
5 Ras ACTIVITY incr 
5 RESOLVIN D1 incr 
4 ATF4 decr 
4 CD33 inhibit 
4 EAAT2 incr 
4 GSAP reduc 
4 iPLA2 incr 
4 LR11 incr 
4 MEGALIN enhanc 
4 PAK decr 
3 24-OHC decr 
3 ABCA7 incr 
3 ADMA reduc 
3 CNPase incr 
3 HSV REP prevent 
3 IGFBP3 restor 
3 LYSOSOMAL ACIDIFICATION restor 
3 miR-339-5p incr 
3 miRNA-146a decr 
3 MYOINOSITOL reduc 
3 SIR1 incr 
3 Synj1 decr 
3 TERT restor 
3 TUBULIN restor 
3 Wnt3 incr 
2 BH4 restor 
2 CHROM MIS-SEGR reduc 
2 CLAUDIN-5 incr 
2 CRP decr 
2 CXCR2 reduc 
2 cyclinD1 incr 
2 DYSPHAGIA amelior 
2 EphB2 incr 
2 GLYMPHATIC DRAINAGE restor 
2 MAGNESIUM incr 
2 mir-206 decr 
2 NAAG incr 
2 p75ECD incr 
2 PI(4,5)P(2) rescu 
2 PRAS40 reduc 
2 S6K1 reduc 
2 SOCE reduc 
2 TGF-beta1 rescu 
2 UCH-L1 incr 
1 B1R incr 
1 B2R incr 
1 BAG3 incr 
 




1 BRN-4 incr 
1 C3 CONVERTASE reduc 
1 CEREBROVASC DYSFUNCT amelior 
1 CX3CR1 reduc 
1 CXCL1 incr 
1 Ephexin5 reduc 
1 EXCESSIVE NO amelior 
1 GEPHYRIN restor 
1 GLUT4 incr 
1 HISTONE H3K9 incr 
1 HSP90ALPHA inhibit 
1 HYPERVASCULARITY revers 
1 IL-12p40/p70 decr 
1 MAP1B incr 
1 METHIONONE incr 
1 miR-30a-5p decr 
1 MKL1 reduc 
1 p16 decr 
1 PALMITOLEIC ACID reduc 
1 Pr-SSG reduc 
1 RLT incr 
1 RORgammat decr 
1 SQSTM1 decr 
1 SREBP2 reduc 
1 T-MEHA incr 
1 TOMOSYN reduc 
1 TPI incr 
1 TRPM2 reduc 
1 WT1 reduc 
 
 The present TR approach has the benefit that TR discovery can be generated from searching the 
e.g. Medline database alone.  Any combination of the myriad classes of markers (illustrated above for 
AD) can be used for the query.  However, the present TR approach is not restricted to stand-alone.  It can 
be used as part of a hybrid approach that would impose additional conditions on TR candidates, perhaps 
requiring additional types of information from additional databases.  
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